source_id@collection_memberships.#1@collection_memberships.#2@collection_memberships.#3@collection_memberships.#4@collection_memberships.#5@subscription.#1@subscription.#2@subscription.#3@subscription.#4@subscription.#5@Acronym@Administration@Asset_Classification@ONCO_ATC_Code@ATC_Level3@Black_Box@Company_HQ@Completion_Date@Current_Status@Drug_Description@Drug_Type@DynamicObjectID@ONCO_Full_Indication@Gender@ONCO_Hospital_Status@HTA_Decision_Date.RawValue@HTA_Decision_Date.Value@ICER_QALYs@Intervention@Intervention_Type@Length_Of_Trial@Level_Of_Reimbursement@Licensing_Status@Line_Of_Therapy@NCT_Code@No_Of_Patients@Official_Dosage@ONCO_Approval_Date.RawValue@ONCO_Approval_Date.Value@ONCO_Marketing_Date@ONCO_Orphan_Drug@Breakthrough_Therapy@ONCO_Start_Date@ONCO_Warnings@Other_IDs@ONCO_Parallel_Import@Patent_Expiration@Patient_Description@Patient_Profile@Patient_Profile_Age_Groups@Phase_Of_Trial@Portfolio_Pipeline_Status@ONCO_Regulatory_Submission_Date@Reimbursement_Guidance@Reimbursement_Plan@Results_Efficacy@Results_Safety_and_Adverse_Events@Sponsors@Study_Funded_By@ONCO_Therapeutic_Class@Type_Of_Therapy@API.#1@API.#2@API.#3@API.#4@API.#5@API_KEY@ONCO_Company.#1@ONCO_Company.#2@ONCO_Company.#3@ONCO_Company.#4@ONCO_Company.#5@ONCO_Company_KEY@Country_Clinical_Trial.#1@Country_Clinical_Trial.#2@Country_Clinical_Trial.#3@Country_Clinical_Trial.#4@Country_Clinical_Trial.#5@Country_Clinical_Trial_KEY@Disease_Area.#1@Disease_Area.#2@Disease_Area.#3@Disease_Area.#4@Disease_Area.#5@Disease_Area_KEY@Drug.#1@Drug.#2@Drug.#3@Drug.#4@Drug.#5@Drug_KEY@Drug_Class.#1@Drug_Class.#2@Drug_Class.#3@Drug_Class.#4@Drug_Class.#5@Drug_Class_KEY@Primary_Endpoint.#1@Primary_Endpoint.#2@Primary_Endpoint.#3@Primary_Endpoint.#4@Primary_Endpoint.#5@Secondary_Endpoints.#1@Secondary_Endpoints.#2@Secondary_Endpoints.#3@Secondary_Endpoints.#4@Secondary_Endpoints.#5@Stage_Of_Disease.#1@Stage_Of_Disease.#2@Stage_Of_Disease.#3@Stage_Of_Disease.#4@Stage_Of_Disease.#5@Trial_Design.#1@Trial_Design.#2@Trial_Design.#3@Trial_Design.#4@Trial_Design.#5@Assumption_value@Assumption_unit@ATC_Calculation_attempt@Average_Annual_Cost@Average_Cost_Per_Treatment_Cycle@Average_Duration_of_Use.Value@Average_Duration_of_Use.Unit@Average_Duration_of_Use.Comment@Average_Treatment_Cost.RawValue@Average_Treatment_Cost.Value@Cost_Per_Day@Number_of_Units@ONCO_Exchange_Rate@Factory_Price@Retail_Price@Wholesale_Price@PriceTimestamps.ManufacturerPriceDelta.TimeStamp@PriceTimestamps.ManufacturerPriceDelta.ValueChange@PriceTimestamps.ManufacturerPriceDelta.PercentageChange@PriceTimestamps.WholesalerPriceDelta.TimeStamp@PriceTimestamps.WholesalerPriceDelta.ValueChange@PriceTimestamps.WholesalerPriceDelta.PercentageChange@PriceTimestamps.RetailerPriceDelta.TimeStamp@PriceTimestamps.RetailerPriceDelta.ValueChange@PriceTimestamps.RetailerPriceDelta.PercentageChange@Price_Per_MG@Treatment_Phase_1.Cycle_Duration@Treatment_Phase_1.Cycle_Repetition@Treatment_Phase_1.Dosage_Unit@Treatment_Phase_1.Dosage_Value@Treatment_Phase_1.Treatment_Duration@Treatment_Phase_2.Cycle_Duration@Treatment_Phase_2.Cycle_Repetition@Treatment_Phase_2.Dosage_Unit@Treatment_Phase_2.Dosage_Value@Treatment_Phase_2.Treatment_Duration@Treatment_Phase_3.Cycle_Duration@Treatment_Phase_3.Cycle_Repetition@Treatment_Phase_3.Dosage_Unit@Treatment_Phase_3.Dosage_Value@Treatment_Phase_3.Treatment_Duration@Price_Date@ONCO_Price_per_Unit.RawValue@ONCO_Price_per_Unit.Value@Import_Id@Form@Currency@Active_Ingredients.Original.Active_Ingredient@Active_Ingredients.Original.Input_Language@Active_Ingredients.Original.Active_Ingredient_Translated@Active_Ingredients.Original.Volume@Active_Ingredients.Original.Volume_Unit@Active_Ingredients.Original.Dose@Active_Ingredients.Original.Dose_Unit@Active_Ingredients.Original.Strength@Active_Ingredients.Original.Strength_Unit@Active_Ingredients.Original.Strength_Comment@Active_Ingredients.Original.DDD@Active_Ingredients.Original.DDD_Unit@Active_Ingredients.Original.DDD_Comment@Active_Ingredients.Extracted.Active_Ingredient_Item.#1@Active_Ingredients.Extracted.Active_Ingredient_Item.#2@Active_Ingredients.Extracted.Active_Ingredient_Item.#3@Active_Ingredients.Extracted.Active_Ingredient_Item.#4@Active_Ingredients.Extracted.Active_Ingredient_Item.#5@Active_Ingredients.Extracted.Active_Ingredient_Item_Translated.#1@Active_Ingredients.Extracted.Active_Ingredient_Item_Translated.#2@Active_Ingredients.Extracted.Active_Ingredient_Item_Translated.#3@Active_Ingredients.Extracted.Active_Ingredient_Item_Translated.#4@Active_Ingredients.Extracted.Active_Ingredient_Item_Translated.#5@Active_Ingredients.Extracted.Strength_Item.#1@Active_Ingredients.Extracted.Strength_Item.#2@Active_Ingredients.Extracted.Strength_Item.#3@Active_Ingredients.Extracted.Strength_Item.#4@Active_Ingredients.Extracted.Strength_Item.#5@Active_Ingredients.Extracted.Strength_CALC@Active_Ingredients.Extracted.Strength_unit@Active_Ingredients.Extracted.Strength_value@Active_Ingredients.Extracted.DDD@TimeStamp@geographic_location.#1.row_id@geographic_location.#1.name@geographic_location.#2.row_id@geographic_location.#2.name@geographic_location.#3.row_id@geographic_location.#3.name@geographic_location.#4.row_id@geographic_location.#4.name@geographic_location.#5.row_id@geographic_location.#5.name
16384270@Onco@@@@@@@@@@@"SGN-CD123A, Experimental, SGN-CD123A every 3 weeks"@@@@@SEATTLE, WASHINGTON@1/1/2019@@@@16384270@A Phase 1 Study of SGN-CD123A in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)@Both@@@@@Intravenous infusion in 3-week cycles@@@@@THIRD-LINE@NCT02848248@102@@@@@@@8/1/2016@@SGN123-001@@@-  Relapsed/refractory acute myeloid leukemia following at least 2 but no more than 3 prior regimens  -  Patients may be eligible after only 1 previous regimen if in a high risk category  -  Adequate baseline renal and hepatic function  -  Eastern Coopera@@ADULTS@Phase 1@I@@@@@@@@@MONO@-@@@@@-||||@SEATTLE GENETICS@@@@@SEATTLE GENETICS||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@SGN-CD123A@@@@@SGN-CD123A||||@Other@@@@@Other||||@Type, incidence, severity, seriousness, and relatedness of adverse events@Type, incidence, and severity of laboratory abnormalities@Incidence of dose-limiting toxicity@@@Blood concentrations of SGN-CD123A, total antibodies, and metabolites@Incidence of antitherapeutic antibodies@@@@RELAPSED@REFRACTORY@@@@Safety Study@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916771@Onco@@@@@300f1014ntsdm@300f1813ntsdm@@@@@Two doses of 6 mg/kg with or without standard chemotherapy. [clinicaltrials.gov]@@-@-@-@MONTREAL, CANADA@@@-@@14916771@Pentamidine in Patients With Locally Advanced or Metastatic Pancreatic Cancer Undergoing Standard Therapy@@-@-@@NO REVIEW@@@@-@-@-@NCT00810953@15@-@-@@@-@@1/1/2009@-@OP-103-P@@-@Histologically or cytologically proven diagnosis of advanced pancreatic adenocarcinoma that is unresectable or metastatic. At least one uni-dimensionally measurable lesion (on spiral CT scan) @@@I/II@II@@-@-@Trial registered. [Oncozyme, 16.12.2008]@-@@@@BOTH@PENTAMIDINE@@@@@PENTAMIDINE||||@ONCOZYME PHARMA@@@@@ONCOZYME PHARMA||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@-@@@@@-||||@Other@@@@@Other||||@SEVERE ADVERSE EVENTS@CA19-9 MARKER@@@@TIME TO PROGRESSION@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@C$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14924100@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14924100@Lung adenocarcinoma@@-@-@@NO REVIEW@@@@-@>> Merck & Co and Schering-Plough have announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. Based on the closing price of Merck stock on March 6, 2009, the consideration to be received by Schering-Plough shareholders is valued at $23.61 per share, or $41.1 billion in the aggregate. [Merck & Co, 9 March 2009]>> Schering-Plough holds an option for world-wide license of the Biphasix technology containing interferon alpha-2b- this can be exercised up to end of Phase III trials@-@-@-@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@Clinical trial to commence in 2008@-@@@@MONO@L-DOS47@@@@@L-DOS47||||@HELIX BIOPHARMA@SCHERING-PLOUGH@@@@HELIX BIOPHARMA|SCHERING-PLOUGH|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@-@@@@@-||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920194@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01DB07@L01D@@NEW DELHI, INDIA@@@Although its mechanism of action has not been determined, mitoxantrone is a DNA-reactive agent. It has a cytocidal effect on proliferating and non-proliferating cultured human cells, suggesting activity against rapidly proliferating and slow-growing neoplasms.@@14920194@@@@@@NO REVIEW@@@@@Dabur Pharma will change its name to Fresenius Kabi Oncology. [Dabur, 29.10.2008]@@@@@FDA, 19 May 2008@5/19/2008@@@@@@@No@@@@@@APPROVED@@@@@@@@@COMBO@MITOXANTRONE@@@@@MITOXANTRONE||||@DABUR PHARMA@FRESENIUS KABI ONCOLOGY@@@@DABUR PHARMA|FRESENIUS KABI ONCOLOGY|||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@GENERIC@@@@@GENERIC||||@Cytotoxic Antibiotic@Anthracycline@Topoisomerase II Inhibitor@@@Cytotoxic Antibiotic|Anthracycline|Topoisomerase II Inhibitor||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@US$@@@@@@@@20@MG@2 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924273@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@WESTMINSTER, COLORADO@@@@@14924273@Recurrent malignant glioma; discontinued in Phase II trials in June 2007.@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@DISCONTINUED IN JUNE 2007 AFTER ENRICH TRIAL FAILED STATISTICAL SIGNIFICANCE.@@@-@@@-@-@@-@-@@@II@DISCONTINUED@@-@-@Discontinued in June 2007 after ENRICH trial failed to demonstrate a statistically significant improvement in overall survival in patients receiving efaproxyn plus WBRT, compared to patients receiving WBRT alone. SOURCE: Allos, 19 June 2007@-@@@@-@EFAPROXIRAL@@@@@EFAPROXIRAL||||@ALLOS THERAPEUTICS@@@@@ALLOS THERAPEUTICS||||@@@@@@|||||||||@Brain Cancer@@@@@Brain Cancer|||||||||@EFAPROXYN@@@@@EFAPROXYN||||@Radiolabeled@@@@@Radiolabeled||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918934@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@BETHESA, MARYLAND@@@DCVax products are being developed to activate all aspects of the immune response, both cellular and antibody, thus potentially providing a broader and longer lasting immune and clinical response. Northwest Biotherapeutics' products are deigned as pure, activated DC loaded with the immunogen as would naturally occur, and that are capable of migrating to lymph nodes. The intended result is a very robust, and full immune response consisting of both a specific cellular T cell response and a specific antibody response against the cancer associated antigen.@@14918934@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@-@FDA cleared for this trial. SOURCE: Northwest@-@@@@-@-@@@@@-||||@NORTHWEST BIOTHERAPEUTICS@@@@@NORTHWEST BIOTHERAPEUTICS||||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@DCVAX@@@@@DCVAX||||@Immunotherapy@Vaccine@@@@Immunotherapy|Vaccine|||@RESPONSE RATE@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916079@Onco@@@@@@@@@@@Gardasil at day 1, month 2 and month 6 versus placebo@@-@-@-@WHITEHOUSE STATION, NEW JERSEY@12/1/2008@@Gardasil is an adjuvanted non-infectious recombinant quadrivalent vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid L1 protein of HPV types 6, 11, 16 and 18. The VLPs contain no viral DNA, they cannot infect cells, reproduce or cause disease. HPV only infects humans, but animal studies with analogous papillomaviruses suggest that the efficacy of LI VLP vaccines is mediated by the development of a humoral immune response. HPV 16 and HPV 18 are estimated to be responsible for approximately 70% of cervical cancers; 80% of adenocarcinoma in situ (AIS); 45-70% of high-grade cervical intraepithelial neoplasia (CIN 2/3); 25% of low grade cervical intraepithelial neoplasia (CIN 1); approximately 70% of HPV related high-grade vulvar (VIN 2/3) and vaginal (VaIN 2/3) intraepithelial neoplasia. HPV 6 and 11 are responsible for approximately 90% of genital warts and 10% of low grade cervical intraepithelial neoplasia (CIN 1). CIN 3 and AIS have been accepted as immediate precursors of invasive cervical cancer.@@14916079@Registrational China trial@@-@-@@NO REVIEW@@@@-@extra-Australia rights licensed from CSL@-@NCT00496626@300@-@-@@@-@@3/1/2008@-@V501-030@@-@-@@@III@III@@-@-@RESULTS PENDING@-@@@@MONO@HUMAN PAPILLOMAVIRUS@@@@@HUMAN PAPILLOMAVIRUS||||@MERCK & CO@@@@@MERCK & CO||||@China@@@@@China|||||||||@Cervical Cancer@@@@@Cervical Cancer|||||||||@GARDASIL@@@@@GARDASIL||||@Vaccine@@@@@Vaccine||||@IMMUNE RESPONSE@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922675@Onco@@@@@@@@@@@Maintenance enzastaurin following whole brain radiation therapy versus placebo@@-@-@-@INDIANAPOLIS, INDIANA@@@Enzastaurin is an oral, serine threonine kinase inhibitor which selectively targets the PKCBeta and PI3/AKTsignaling pathways. By blocking these key pathways frequently over-expressed in a wide variety of cancers, enzastaurin suppresses tumor cell proliferation, induces tumor cell death and inhibits tumor-induced angiogenesis. Treatment has been well tolerated with minimal drug-related toxicity. Enzastaurin administration is associated with fatigue, diarrhea, nausea, decreased platelets, cough, vomiting, transaminase elevation, dyspnea, peripheral edema, and dizziness. Further testing in Phase III versus a placebo will provide us with a more complete look at the side effect profile for enzastaurin. In addition to DLBCL, enzastaurin is also being studied in other tumor types including breast, colon, lung, ovarian and prostate cancers@@14922675@Brain metastases of lung cancer after whole brain radiation therapy@@-@-@@NO REVIEW@@@2 YEARS@-@-@-@NCT00415363@108@-@-@@@-@@@-@10710H6Q-MC-S020  @@-@-@@@II@II@@-@-@Completion expected December 2008.@-@@@@MONO@ENZASTAURIN@@@@@ENZASTAURIN||||@LILLY@@@@@LILLY||||@@@@@@|||||||||@Brain Cancer@NSCLC@SCLC@@@Brain Cancer|NSCLC|SCLC|||||||@LY-317615@@@@@LY-317615||||@Angiogenesis Inhibitor@@@@@Angiogenesis Inhibitor||||@TIME TO DISEASE PROGRESSION@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921325@Onco@@@@@@@@@@@>ARM1: AMG 479 12 mg/kg dose + gemcitabine arm: AMG 479 12 mg/kg administered intravenously on days 1 and 15 of a 28 day cycle; gemcitabine 1000mg/m2 administered intravenously on days 1, 8 and 15 of a 28 day cycle>ARM2: Placebo + gemcitabine: Placebo administered intravenously on days 1 and 15 of a 28 day cycle; gemcitabine 1000mg/m2 administered intravenously on days 1, 8 and 15 of a 28 day cycle>ARM3: AMG 479 20 mg/kg + gemcitabine: AMG 479 20mg/kg administered intravenously on days 1 and 15 of a 28 day cycle; gemcitabine 1000mg/m2 administered intravenously on days 1, 8 and 15 of a 28 day cycle@@@@@@12/1/2014@@@@14921325@A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Trial of AMG 479 or Placebo in Combination With Gemcitabine as First Line Therapy for Metastatic Adenocarcinoma of the Pancreas@@@@@@@@@@Takeda and Amgen signed a deal in February 2008 through which, in its first part, Takeda acquired Japanese rights for up to 13 molecules in Amgen's pipeline, including Vectibix (panitumumab), AMG-108, AMG-317, AMG-386, AMG-479 and AMG-655, for US$200 mil.@@NCT01231347@825@@@@@@@4/1/2011@@GAMMA@@@@@@III@III@@@@Trial registered [Amgen 14 October 2010]@@@@@COMBO@GEMCITABINE@@@@@GEMCITABINE||||@AMGEN@TAKEDA PHARMACEUTICAL@@@@AMGEN|TAKEDA PHARMACEUTICAL|||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@AMG-479@GEMZAR@@@@AMG-479|GEMZAR|||@mAb@Human@@@@mAb|Human|||@OVERALL SURVIVAL@@@@@PROGRESSION-FREE SURVIVAL@RESPONSE@@@@METASTATIC@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO CONTROLLED@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14919080@Onco@@@@@@@@@@@N/A@@L01XA03@L01X@-@PARIS, FRANCE@@@Eloxatin is an antineoplastic agent which is an organoplatinum complex in which the platinum atom is complexed with 1,2-DACH and with an oxalate ligand as a leaving group. It undergoes non-enzymatic conversion in physiologic solutions to active derivatives via displacement of the labil oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.@@14919080@Eloxatin in patients with colorectal cancer following surgery@@-@-@@NO REVIEW@@@@-@sanofi-aventis licensed U.S. and European rights from Debiopharm.@-@-@N/A@-@FDA priority review granted. Approval expected within 6 months of filing. SOURCE: sanofi-aventis, 21 February 2008@2/21/2008@@-@@@-@MOSAIC@@-@-@@@III@FILED@@-@-@Eloxatin demonstrated significant improvement in 6-year overall survival in patients who had surgery to remove the tumour.@-@@@@MONO@OXALIPLATIN@@@@@OXALIPLATIN||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ELOXATIN@@@@@ELOXATIN||||@Platinum@@@@@Platinum||||@OVERALL SURVIVAL@@@@@@@@@@-@@@@@RANDOMISED@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@
14918925@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@CEP-701 alone@@-@-@-@FRAZER, PENNSYLVANIA@@@@@14918925@-@@-@-@@NO REVIEW@@@@-@Licensed from Kyowa Hakko; supplied by Abbott/TAP. Original licensing agreement with Schwarz Pharma terminated.@-@-@N/A@-@-@@@-@@11/1/2006@-@N/A@@-@-@@@III@III@@-@-@Little is as yet known about this trial.@-@@@@-@LESTAURTINIB@@@@@LESTAURTINIB||||@CEPHALON@@@@@CEPHALON||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@CEP-701@@@@@CEP-701||||@TK Inhibitor@@@@@TK Inhibitor||||@N/A@@@@@@@@@@-@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919106@Onco@@@@@@@@@@@Part 1: MK1775 capsules will be given on day 1 of a 14 day cycle: starting dose of MK1775 is 325mg and will escalate up to 1300mg or until MTD achieved Part 2-1: Starting dose of MK1775, 100mg with gemcitabine IV infusion dosage ranging from1000 mg/m2 to 600 mg/m2 in a 28 day cyclePart 2-2: Starting dose of MK1775, 100mg with cisplatin IV infusion dosage ranging from 75 mg/m2 to 50 mg/m2in a 21 day cycle. SOURCE: clinicaltrials.gov@@-@-@-@WHITEHOUSE STATION, NEW JERSEY@8/1/2010@@@@14919106@MK-1775 as monotherapy and combination with either Gemzar, cisplatin or carboplatin@@-@-@@NO REVIEW@@@@-@-@-@NCT00648648@155@-@NDA filing expected within 2 years. SOURCE: CMS, 17 January 2008@1/17/2008@@-@@3/1/2008@-@MK1775-001@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@BOTH@-@GEMCITABINE@CISPLATIN@CARBOPLATIN@@-|GEMCITABINE|CISPLATIN|CARBOPLATIN|@MERCK & CO@@@@@MERCK & CO||||@Netherlands@@@@@Netherlands|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@MK-1775@GEMZAR@@@@MK-1775|GEMZAR|||@Other@@@@@Other||||@DOSE-LIMITING TOXICITY@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14923715@Onco@@@@@300f1008ntsdm@@@@@@-@@-@-@-@-@@@Bendamustine is an alkylating that is a bifunctional mechlorethamine derivative. Mechlorethamine and its derivatives dissociate into electrophilic alkyl groups. These groups form covalent bonds with electron-rich nucleophilic moieties. The bifunctional covalent linkage can lead to cell death via several pathways. The exact mechanism of action of bendamustine remains unknown. Bendamustine is active against both quiescent and dividing cells.@@14923715@-@@-@-@@NO REVIEW@@@@-@Eisai licenses Japanese/selected Asian rights friom Symbio. SOURCE: Eisai, 19 August 2008@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@@RESULTS PENDING@-@@@@-@BENDAMUSTINE@RITUXIMAB@@@@BENDAMUSTINE|RITUXIMAB|||@EISAI@SYMBIO@@@@EISAI|SYMBIO|||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@TREANDA@SYB-L-5010@@@@TREANDA|SYB-L-5010|||@Alkylating Agent@Nitrogen Mustard Analogue@@@@Alkylating Agent|Nitrogen Mustard Analogue|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14924826@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14924826@Stage III/IV metastatic melanoma; Phase I/II trial to commence early 2008.@@-@-@@NO REVIEW@@@@-@Co-development deal signed with Life Therapeutics in August 2006; amended October 2007 to make the latter company a non-exclusive rather than exclusive supplier. GammaCan has signed a second plasma supply agreement with DCI Biologicals. The financial term@-@-@-@-@ORPHAN DRUG DESIGNATION GRANTED IN AUGUST 2007@@@ORPHAN DRUG DESIGNATION GRANTED IN AUGUST 2007@@@-@-@@-@-@@@I/II@II@@-@-@-@-@@@@-@-@@@@@-||||@GAMMACAN@@@@@GAMMACAN||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@VITIGAM@@@@@VITIGAM||||@Immunotherapy@@@@@Immunotherapy||||@-@@@@@@@@@@METASTATIC@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916740@Onco@@@@@300f1015ntsdm@@@@@@Four IMP321 dose levels, 50 µg, 250 µg, 1,250 µg and 6,250 µg will be evaluated in successive cohorts of patients. At any given dose level 3 patients will be administered one subcutaneous dose every 2 weeks for a total of 12 weeks (6 injections in total), separated by 13-day administration-free intervals. SOURCE: clinical.trials.gov@@-@-@-@-@4/1/2008@@@@14916740@-@@YES@-@@NO REVIEW@@@@-@-@-@NCT00351949@18@-@-@@@-@@9/1/2005@-@P003@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@COMBO@-@@@@@-||||@IMMUTEP@@@@@IMMUTEP||||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@IMP-321@@@@@IMP-321||||@Immunotherapy@@@@@Immunotherapy||||@SAFETY@PHARMACODYNAMICS@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14919281@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Dose escalation of ABT-888 and Temodal@@-@-@-@UNITED STATES@2/1/2009@@ABT-888 is a potent inhibitor of both PARP-1 and PARP-2 with Kis of 5.2 and 2.9 nmol/L, respectively. The compound has good oral bioavailability and crosses the blood-brain barrier. ABT-888 strongly potentiated temozolomide in the B16F10 s.c. murine melanoma model. PARP inhibition dramatically increased the efficacy of temozolomide at ABT-888 doses as low as 3.1 mg/kg/d and a maximal efficacy achieved at 25 mg/kg/d. @@14919281@Combo with Temodal@@YES@-@@NO REVIEW@@@@-@-@-@NCT00526617@36@-@-@@@-@@8/1/2007@-@M06-862@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@COMBO@-@TEMOZOLOMIDE@@@@-|TEMOZOLOMIDE|||@ABBOTT@@@@@ABBOTT||||@@@@@@|||||||||@Melanoma / Skin Cancer@Solid Tumours@@@@Melanoma / Skin Cancer|Solid Tumours||||||||@ABT-888@TEMODAL@@@@ABT-888|TEMODAL|||@Other@@@@@Other||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921703@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Weekly infusion for 3 week-cycles until disease progression or unacceptable toxicity: 3.2, 4.8, 7.2, 10.8 or 15MG/KG@@-@-@-@MENLO PARK, CALIFORNIA@12/1/2008@@@@14921703@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00594126@36@-@-@@@-@@11/1/2007@-@CP14A004@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@GERON@@@@@GERON||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@GRN-163L@@@@@GRN-163L||||@Telomerase Inhibitor@@@@@Telomerase Inhibitor||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922481@Onco@@@@@300f1010ntsdm@@@@@@500mg Faslodex plus Arimidex versus 500mg Faslodex alone and Arimidex alone@@L02BA03@L02B@-@LONDON, UNITED KINGDOM@@@Fulvestrant is an oestrogen receptor antagonist and binds to oestrogen receptors in a competitive manner with an affinity comparable with that of oestradiol. Fulvestrant blocks the trophic actions of oestrogens without itself having any partial agonist (oestrogen-like) activity. The mode of action is associated with down-regulation of oestrogen receptor (ER) protein. Clinical trials in postmenopausal women with primary breast cancer have shown that fulvestrant significantly down-regulates ER protein in ER positive tumours compared with placebo. There was also a significant decrease in progesterone receptor expression consistent with a lack of intrinsic oestrogen agonist effects.@@14922481@Primary breast cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00259090@120@-@-@@@-@@4/1/2004@-@9238IL0057D6997C00057  @@-@-@@@II@II@@-@-@RESULTS PENDING (recruiting)@-@@@@BOTH@FULVESTRANT@@@@@FULVESTRANT||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@FASLODEX@@@@@FASLODEX||||@Hormone Antagonist@@@@@Hormone Antagonist||||@RESPONSE RATE@@@@@@@@@@EARLY@@@@@RANDOMISED@DOUBLE-BLIND@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@GB£@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
16062569@Onco@@@@@@@@@@@Icotinib 375mg Tid, Experimental, The human subject gets icotinib 375mg, Tid until intracranial PD or intolerable toxicity reaction.@@@@@@3/1/2018@@@@16062569@A Phase II Study to Determine the Efficacy and Safety of Icotinib For NSCLC Patients Harboring EGFR Mutation With Brain Metastases@Both@@@@@375 mg Tid (1125 mg per day)@@@@@@NCT02726568@30@@@@@@@3/1/2016@@BD-IC-IV-65@@@Histological or cytological confirmation of non-small cell lung cancer (NSCLC);  -  Diagnosis of brain metastases on a Gadolinium-enhanced MRI.  -  More than 3 sites of intracranial metastases, or the longest diameter of the intracranial lesion is more than 3cm.  -  Positive EGFR mutation.  -  Life expectancy ≥3months.  -  Have one or more measurable encephalic lesions according to RECIST.  -  Adequate hematological function: Absolute neutrophil count (ANC) ≥1.5 x 109/L, and Platelet count ≥100 x 109/L.  -  Adequate renal function: Serum creatinine ≤1.5 x ULN, or ≥ 50 ml/min.  -  Adequate liver function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN) and Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) < 2.5 x ULN in the absence of liver metastases, or < 5 x ULN in case of liver metastases.  -  Female subjects should not be pregnant.  -  All human subjects should able to comply with the required protocol and follow-up procedures, and able to receive oral medications.  -  Written informed consent provided.@EGFR MUTATION@ADULTS@Phase 2@II@@@@@@@@@MONO@ICOTINIB@@@@@ICOTINIB||||@BETTA PHARMACEUTICALS@@@@@BETTA PHARMACEUTICALS||||@China@@@@@China|||||||||@NSCLC@@@@@NSCLC|||||||||@-@@@@@-||||@Other@@@@@Other||||@iPFS@@@@@Progress-free survival (PFS)@Quality of life measured by FACT-L/LCS 4.0 and FACT-Br@@@@@@@@@Efficacy Study@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14957525@Onco@@@@@@@@@@@E-7389 given as an IV bolus infusion Day and Day 8 every 3 weeks@@L01XX41@L01X@-@TOKYO, JAPAN@@@The mesylate salt of a synthetic analogue of halichondrin B, a substance derived from a marine sponge (Lissodendoryx sp.) with antineoplastic activity. Eribulin binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at G2/M phase, and, potentially, tumor regression@@14957525@Advanced and/or metastatic soft tissue sarcoma@@-@-@@NO REVIEW@@@Started in January 2007@-@Acquired through takeover of Morphotek in April 2007; Ludwig Institute@-@NCT00413192@150@-@-@@@-@@@-@E044-207@@-@-@@@II@II@@-@-@Trial registered [Eisai, 15 December 2006]@-@@@@MONO@ERIBULIN MESYLATE@@@@@ERIBULIN MESYLATE||||@EISAI@@@@@EISAI||||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@HALAVEN@@@@@HALAVEN||||@Plant Alkaloid@Vinca Alkaloids@@@@Plant Alkaloid|Vinca Alkaloids|||@PROGRESSION-FREE SURVIVAL@RECIST@@@@@@@@@METASTATIC@ADVANCED@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
16387714@Onco@@@@@@@@@@@Nivolumab for population A, Experimental, Specified dose on specified days for population with PCNSL.Nivolumab for population B, Experimental, Specified dose on specified days for population with PTL.@@L01XC17@L01X@@NEW YORK, NEW YORK@7/1/2018@@Nivolumab is an investigational, fully-human IgG4 anti-PD-1 receptor blocking monoclonal antibody that binds to the checkpoint receptor PD-1 (programmed death-1) expressed on activated T cells. Nivolumab inhibits the binding of PD-1 with its tumor-express@@16387714@A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)@Both@@@@@@@@@@FIRST-LINE@NCT02857426@65@@@@@@@9/1/2016@@CA209-647@@@For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com   -  Pathologically confirmed PCNSL or PTL who failed or did not respond to at least 1 line of systemic therapy  -  Measurable disease requirements on scans:  PCNSL subjects should have at least one measurable extranodal brain lesion; PTL subjects should have at least 1 measurable extranodal lesion.  -  Have tumor tissue for PD-L1 expression testing  -  Must have a Karnofsky performance status of 70-100@PD-L1@ADULTS@Phase 2@II@@@@@@@@@MONO@NIVOLUMAB@@@@@NIVOLUMAB||||@BRISTOL-MYERS SQUIBB@@@@@BRISTOL-MYERS SQUIBB||||@@@@@@|||||||||@Other@@@@@Other|||||||||@OPDIVO@@@@@OPDIVO||||@PD-1 Inhibitor@@@@@PD-1 Inhibitor||||@Objective Response Rate (ORR)@@@@@Progression-Free Survival (PFS)@Objective Response Rate (ORR)@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMIZED@Efficacy Study@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924677@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@LONDON, UNITED KINGDOM@@@Cediranib (Recentin AZD2171) is a highly potent inhibitor of the tyrosine kinase activity associated with all three vascular endothelial growth factor (VEGF) receptors and is currently in Phase II/III clinical trials. Preclinically, cediranib inhibits VEGF signaling and angiogenesis in vivo and impedes solid tumor growth significantly. @@14924677@Recurrent GBM@@-@-@@NO REVIEW@@@@-@-@-@-@31@-@-@@@-@@@-@-@@-@31 PATIENTS@@@II@II@@-@-@ASCO 2007; PFS noted in 8 patients (26%).@-@@@@MONO@CEDIRANIB@@@@@CEDIRANIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Brain Cancer@Glioblastoma Multiforme@@@@Brain Cancer|Glioblastoma Multiforme||||||||@RECENTIN@AZD-2171@@@@RECENTIN|AZD-2171|||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@RELAPSED@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16160501@Onco@@@@@@@@@@@Pancreatic cancer, Experimental, Triple Negative Breast cancer, Experimental, Endometrial Carcinoma, Experimental, Melanoma, Experimental,@@@@@BASEL, SWITZERLAND@3/1/2019@@@@16160501@A Phase Ib/II, Open Label, Multicenter Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies@Both@@@@@@@@@@SECOND-LINE@NCT02807844@95@@@@@@@5/1/2016@@CMCS110Z2102@@@#NAME?@@ADULTS@Phase 1/Phase 2@I/II@@@@@@@@@COMBO@-@-@@@@-|-|||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Breast Cancer@Endometrial Cancer@Melanoma / Skin Cancer@Pancreatic Cancer@@Breast Cancer|Endometrial Cancer|Melanoma / Skin Cancer|Pancreatic Cancer||||||@MCS110@PDR001@@@@MCS110|PDR001|||@Other@@@@@Other||||@(phase 1) Number of patients with adverse events, as a measure of safety@(phase 2) : Overall Response rate (ORR)@@@@Phase 1: Overall Response Rate (ORR)@Phase 1: progression free survival (PFS)@@@@ADVANCED@@@@@NON-RANDOMIZED@SAFETY/EFFICACY STUDY@PARALLEL ASSIGNMENT@OPEN LABEL@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14920912@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Karenitecin versus topotecan administered for 5 consecutive days every 3 weeks@@-@-@-@SAN ANTONIO, TEXAS@@@@@14920912@Advanced epithelial ovarian cancer@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00477282@500@-@SPA agreed with FDA@@@-@@8/1/2007@-@KTN32313R@@-@-@@@III@III@@-@-@First-patient in February 2008. SOURCE: Bionumerik, 7 February 2008@-@@@@MONO@KARENITECIN@@@@@KARENITECIN||||@BIONUMERIK@@@@@BIONUMERIK||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@BNP-1350@@@@@BNP-1350||||@Camptothecin@Topoisomerase I Inhibitor@@@@Camptothecin|Topoisomerase I Inhibitor|||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924194@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@WOBURN, MASSACHUSSETTS@@@ARQ 501 is an intravenously administered drug that has completed Phase 2 clinical trials consisting of monotherapy trials in leiomyosarcoma and head and neck cancer, and a combination therapy trial in pancreatic cancer with gemcitabine. Further development of compounds working via the same mechanism as ARQ 501, activation of the E2F biological pathway, is currently under consideration. @@14924194@Monotheray; leiyomyosarcoma@@-@-@@NO REVIEW@@@@-@Further development of the compound is subject to a decision by Roche regarding its option to license rights to the E2F-1 programme.@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@ARQULE@@@@@ARQULE||||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@ARQ-501@R-1668@@@@ARQ-501|R-1668|||@E2F1 Pathway Activator@@@@@E2F1 Pathway Activator||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRAVENOUS@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924785@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@AMSTERDAM, NETHERLANDS@@@@@14924785@Eliminating cancer cells from autologous transplants@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@FDA orphan drug designation for immune reconstitution and prevention of GvHD following allogenic bone marrow transplantation. SOURCE: Kiadis, 7 November 2007@11/7/2007@@>> EMEA orphan drug. [Kiadis, 19.09.2008]>> FDA orphan drug designation for immune reconstitution and prevention of GvHD following allogenic bone marrow transplantation. [Kiadis, 7 November 2007]@@@-@-@@-@-@@@-@II@@-@-@"Initial results are ""promising"", with no acute GVHD observed in the patients treated and early immune reconstitution. Full results to be presented at EBMT. SOURCE: Kiadis, 25 March 2008"@-@@@@-@ATIR@@@@@ATIR||||@KIADIS PHARMA@@@@@KIADIS PHARMA||||@@@@@@|||||||||@Other@@@@@Other|||||||||@THERALUX@ATIR@@@@THERALUX|ATIR|||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922278@Onco@@@@@@@@@@@APO866 is administered by intravenous infusion continuously for 96 hours that is repeated every 4 weeks. Patients will receive 3 cycles of treatment and the primary efficacy endpoint will be assessed at Week 16. Patients will be follow-up for 12 months.@@-@-@-@COPENHAGEN, DENMARK@@@@@14922278@Advanced cutaneous melanoma@@-@-@@NO REVIEW@@@AUGUST 2006-SEPTEMBER 2008@-@Topotarget completes takeover of Apoxis. SOURCE: Apoxis, 27 June 2007@-@NCT00432107@43@-@EMEA issued positive opinion on Orphan Drug designation for alvocidib@@@EMEA issued positive opinion on Orphan Drug designation for alvocidib@@@-@AP3003@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@TOPOTARGET@APOXIS SA@@@@TOPOTARGET|APOXIS SA|||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@APO-866@@@@@APO-866||||@TK Inhibitor@@@@@TK Inhibitor||||@RECIST@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924114@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@120mg oral atriprimod given once daily for 14 days.@@-@-@-@NEW YORK, NEW YORK@@@@@14924114@Advanced carcinoid cancer@@-@-@@NO REVIEW@@@@-@Genzyme and Callisto amended their licensing agreement for the drug in January 2008; all milestone payments owed to Genzyme were exchanged for an upfront payment; Genzyme is eligibly for a reduced royalty rate of single digits. Callisto originally license@-@-@40@120mg of oral atiprimod@-@@@-@@@-@-@@-@-@@@II@II@@-@-@Enrollment completed@-@@@@MONO@ATIPRIMOD@@@@@ATIPRIMOD||||@CALLISTO@@@@@CALLISTO||||@@@@@@|||||||||@Carcinoid / Neuroendocrine Tumour@@@@@Carcinoid / Neuroendocrine Tumour|||||||||@-@@@@@-||||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@RESPONSE RATE@TIME TO PROGRESSION@SAFETY@@@SAFETY@@@@@ADVANCED@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@120@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921667@Onco@@@@@300f1012ntsdm@@@@@@N/A@@-@-@-@BASEL, SWITZERLAND@@@The active substance in Afinitor, everolimus, is an anticancer medicine, which acts by blocking a protein called ‘mammalian target of rapamycin' (mTOR). In the body, everolimus attaches to a protein that is found inside cells to make a ‘complex'. This complex then blocks mTOR. Since mTOR is involved in the control of cell division and the growth of blood vessels, Afinitor prevents the division of cancer cells and reduces their blood supply. This slows down the growth and spread of kidney cancer.@@14921667@Resistant to imatinib@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00510354@53@-@-@@@EMEA issued positive opinion to grant Orphan Drug status for everolimus to treat neuroendocrine gastroenteropancreatic tumours@@10/1/2006@-@CRAD001C2454@@-@-@@@II/III@III@@-@-@RESULTS PENDING@-@@@@COMBO@EVEROLIMUS@IMATINIB@@@@EVEROLIMUS|IMATINIB|||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Sarcoma@GIST@@@@Sarcoma|GIST||||||||@AFINITOR@RAD-001@GLEEVEC@GLIVEC@@AFINITOR|RAD-001|GLEEVEC|GLIVEC|@Immunotherapy@Immunosuppressive@mTOR Inhibitor@@@Immunotherapy|Immunosuppressive|mTOR Inhibitor||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14924876@Onco@@@@@@@@@@@All patients will receive Avastin (10mg/kg IV every 2 weeks, or 15 mg/kg IV every 3 weeks) plus taxane-based chemotherapy@@L01XC07@L01X@-@BASEL, SWITZERLAND@@@Avastin (Bevacizumab) is a recombinant humanized monoclonalIgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems. Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF (1). Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models ofangiogenesis. Administration of Bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.@@14924876@Avastin plus a taxane, with or without additional chemotherapy, as first-line treatment in patients with locally recurrent or metastatic breast cancer@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00448591@>500@-@-@@@-@@9/1/2006@-@-@@NOT YET AVAILABLE; POTENTIALLY 2018.@-@@@III@III@@-@-@RESULTS PENDING@-@@@@-@BEVACIZUMAB@@@@@BEVACIZUMAB||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@AVASTIN@@@@@AVASTIN||||@mAb@Humanised@TK Inhibitor@VEGF@@mAb|Humanised|TK Inhibitor|VEGF|@-@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@1@@@@@@@@@@@@@7.26@@@@@@@@@@@@@@@@@725.53@725.53@@INJECTION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922241@Onco@@@@@@@@@@@Telcyta plus PLD versus PLD alone@@L01AA@L01A@-@-@@@@@14922241@Phase III resumed after clinical hold from failures of ASSIST 1 and 2 in June 2007.@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00350948@-@-@PARTIAL HOLD ON TELCYTA ARMS IMPOSED IN JUNE 2007; ASSIST-3 AND ASSIST-5 PATIENTS WILL CONTINUE TO RECEIVE TREATMENT.@@@-@@5/1/2006@-@ASSIST-5, @@-@PATIENTS (244) ALREADY ENROLLED ALLOWED TO CONTINUE AFTER PARTIAL HOLD. @@@III, SUSPENDED@CLINICAL HOLD@@-@-@RESULTS PENDING@-@@@@COMBO@CANFOSFAMIDE@@@@@CANFOSFAMIDE||||@TELIK@@@@@TELIK||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@TELCYTA@PLD@@@@TELCYTA|PLD|||@Alkylating Agent@Nitrogen Mustard Analogue@@@@Alkylating Agent|Nitrogen Mustard Analogue|||@-@@@@@@@@@@REFRACTORY@REFRACTORY@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924464@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14924464@Treatment of chemotherapy-induced anemia@@-@-@@NO REVIEW@@@@-@Neose is selling substantially all of its assets to BioGeneriX and Novo Nordisk. [Neose, 18.09.2008]@-@-@45@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@Results pending; Phase II data delayed until Q1 2008@-@@@@-@-@@@@@-||||@BIOGENERIX@NEOSE TECHNOLOGIES@@@@BIOGENERIX|NEOSE TECHNOLOGIES|||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@GLYCO-PEG-EPO@NE-180@@@@GLYCO-PEG-EPO|NE-180|||@EPO@@@@@EPO||||@-@@@@@@@@@@-@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924225@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@PASADENA, CALIFORNIA@@@CALAA-02 is a HIF-2 targeting RNA molecule.@@14924225@-@@YES@-@@NO REVIEW@@@@-@Arrowhead merged its two subsidiaries Calando and Insert Therapeutics in February 2008; now known as Calando Pharmaceuticals.@-@-@-@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@Target selected. [Calando, 22.09.2008]@-@@@@MONO@-@@@@@-||||@CALANDO PHARMACEUTICALS@INSERT THERAPEUTICS@@@@CALANDO PHARMACEUTICALS|INSERT THERAPEUTICS|||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@CALAA-02@@@@@CALAA-02||||@RNA@HIF-targeting@@@@RNA|HIF-targeting|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16671597@Onco@@@@@300f1008ntsdm@@@@@@@@L01XE36@L01X@@@@@Alectinib is a tyrosine kinase inhibitor that targets ALK and RET.@@16671597@Treatment of unresectable advanced/relapsed ALK fusion gene-positive non-small-cell lung cancer.@@NA@@@@@@@@@@@46@@MHLW, 20 June 2014@6/20/2014@9/2/2014@Yes@@@@@No@@@ALK POSITIVE@@II@APPROVED@@@NHI@@@@@@MONO@ALECTINIB@@@@@ALECTINIB||||@CHUGAI PHARMACEUTICAL@@@@@CHUGAI PHARMACEUTICAL||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@ALECENSA@@@@@ALECENSA||||@TK Inhibitor@@@@@TK Inhibitor||||@@@@@@@@@@@UNRESECTABLE@ADVANCED@@@@@@@@@1@1@7814449.521@@@11.2@month@11.2 month@7814449.52@7814449.52@22939.2@1@0.0091@764.64@901.7@@@@@@@@@@@38.23@1@@mg@600@1@@@@@@@@@@@8/30/2017@764.64@764.64@4291032M1029@CAPSULE@YEN@@@@@@@@20@MG@20 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14921803@Onco@@@@@@@@@@@Once weekly for four weeks@@-@-@-@BASEL, SWITZERLAND@10/1/2008@@HCD122 is a fully human anti-CD40 antibody intended as a treatment for B-cell mediated diseases, including malignancies and autoimmune diseases.  The antibody has a dual mechanism of action that involves blocking tumor cell growth and survival signals while recruiting immune effector cells to kill tumor cells through a process known as antibody-dependent cellular cytotoxicity (ADCC). @@14921803@Patients with advanced NHL or Hodgkin's lymphoma who have progressed after at least two prior therapies@@-@-@@NO REVIEW@@@@-@>> XOMA and Novartis restructure their 2004 co-development deal; Novartis will pay US$6.2 million upfront and fund all future R&D plus additional milestones/royalties - Novartis receives control of the programme and expand into therapeutic areas beyond oncology. [Novartis, 11.11.2008]             >> HCD122 is the first product candidate selected under the multi-product antibody development and commercialization agreement for the treatment of cancer announced by Chiron (now Novartis) and Xoma, and initiated in March of 2004.@-@NCT00670592@50@-@-@@@-@@4/1/2008@-@CHCD122A2103@@-@-@@@I/II@II@@-@-@Trial registered [Novartis, 30.04.2008]@-@@@@-@-@@@@@-||||@NOVARTIS@XOMA@@@@NOVARTIS|XOMA|||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@Hodgkin's Lymphoma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|Hodgkin's Lymphoma|||||||@HCD-122@@@@@HCD-122||||@mAb@CD40@@@@mAb|CD40|||@DOSE-LIMITING TOXICITY@ADVERSE EVENTS@@@@@@@@@RELAPSED@@@@@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRAVENOUS@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922460@Onco@@@@@@@@@@@Patients will receive intravenous administration of CP-675,206 at a dose of 15 mg/kg on Day 1 of every 90-day cycle for up to 4 cycles. For purposes of treatment visits and scheduling, each cycle is defined as a 90 (± 4 day) period. Patients who discontinue treatment after 4 doses of CP-675,206 without disease progression and who subsequently experience disease progression more than 3 months after the last dose may receive 2 additional doses of CP-675,206 provided that they have not received other systemic therapy for their melanoma. Survival in this study will be monitored on all patients for up to 5 years from the date of first dose of CP-675,206. SOURCE: clinicaltrials.gov@@-@-@-@NEW YORK, NEW YORK@@@Tremelimumab is a fully human anti-CTLA4 (cytotoxic T-lymphocyte antigen 4) IgG2 monoclonal antibody developed by Pfizer for its potential therapeutic application in melanoma, non-small cell lung cancer (NSCLC) and colorectal cancer. CTLA4 is a CD28-family receptor expressed mainly on T-lymphocyte that acts to inhibit T-lymphocyte function.@@14922460@Advanced unresectable melanoma@@-@-@@NO REVIEW@@@@-@Medarex entitled to royalties@-@NCT00584493@N/A@-@-@@@-@@5/1/2008@-@A3671028@@-@-@@@III; SINGLE-ARM, EXPANDED ACCESS@III@@-@-@RESULTS PENDING@-@@@@MONO@TREMELIMUMAB@TICILIMUMAB@@@@TREMELIMUMAB|TICILIMUMAB|||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@CP-675206@@@@@CP-675206||||@mAb@CTLA4 Receptor Antagonist@@@@mAb|CTLA4 Receptor Antagonist|||@OVERALL SURVIVAL@@@@@@@@@@ADVANCED@@@@@SINGLE-ARM@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14925031@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@N02AA01@N02A@NO@READING, UNITED KINGDOM@@@@@14925031@Severe chronic pain and/or pain resistant to other analgesics, in particular pain associated with cancer.@@NO@@@NO REVIEW@@@@100%@Acquired through takeover of Link Holdings in November 2006@@@@Adults: Recommended dosage is one capsule twice daily, at 12-hourly intervals.@EMA, May 1995@@@@@@Caution should be exercised in elderly subjects, in patients with impaired hepatic and/or renal functions, in patients with hypothyroidism or hypoadrenalism, in patients in a state of shock or with asthma. The dose of Zomorph should be reduced, or its use should be avoided in cases of hepatic or renal failure.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@MORPHINE SULPHATE@@@@@MORPHINE SULPHATE||||@ARCHIMEDES PHARMA@@@@@ARCHIMEDES PHARMA||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@ZOMORPH@@@@@ZOMORPH||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@60@1.299@8.3@@@@@@@@@@@@@@@@@@@@@@@@@@@@7/28/2017@0.14@0.14@3.65E+15@CAPSULE MODIFIED RELEASE@GB£@@@@@@@@30@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14924142@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@ABT-751 in combination with Taxotere versus Taxotere alone@@-@-@-@UNITED STATES@@@An orally bioavailable antimitotic sulfonamide. ABT-751 binds to the colchicine-binding site on beta-tubulin and inhibits the polymerization of microtubules, thereby preventing tumor cell replication. This agent also disrupts tumor neovascularization, reducing tumor blood flow and so inducing a cytotoxic effect@@14924142@with Taxotere@@-@-@@NO REVIEW@@@@-@-@-@NCT00354562@180@-@-@@@-@@6/1/2006@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@DOCETAXEL@@@@-|DOCETAXEL|||@ABBOTT@@@@@ABBOTT||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@ABT-751@TAXOTERE@@@@ABT-751|TAXOTERE|||@Plant Alkaloid@Vascular Disrupting Agent@@@@Plant Alkaloid|Vascular Disrupting Agent|||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@ADVANCED@@@@@RANDOMISED@DOUBLE-BLIND@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920979@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@IPI-504 alone@@-@-@-@LONDON, UNITED KINGDOM@@@Heat shock protein 90 (Hsp90) serves a chaperone function by supporting and stabilizing numerous cancer-causing proteins such as c-Kit, EGFR, and HER2. Inhibition of the Hsp90 chaperone knocks out a critical source of support for cancer cells, leading to cancer cell death. IPI-504 (retaspimycin hydrochloride) is a novel, targeted anti-chaperone agent that shows potent and selective inhibition of Hsp90 in preclinical studies. @@14920979@Stage III or IV NSCLC@@-@-@@NO REVIEW@@@@-@AstraZeneca acquired through takeover of MedImmune.@-@NCT00431015@60@-@-@@@-@@1/1/2007@-@IPI-504-03@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@RETASPIMYCIN@@@@@RETASPIMYCIN||||@ASTRAZENECA@MEDIMMUNE@INFINITY PHARMACEUTICALS@@@ASTRAZENECA|MEDIMMUNE|INFINITY PHARMACEUTICALS||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@IPI-504@@@@@IPI-504||||@HSP90 Inhibitor@@@@@HSP90 Inhibitor||||@SAFETY@RESPONSE RATE@@@@@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924195@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@WOBURN, MASSACHUSSETTS@@@ARQ 501 is an intravenously administered drug that has completed Phase 2 clinical trials consisting of monotherapy trials in leiomyosarcoma and head and neck cancer, and a combination therapy trial in pancreatic cancer with gemcitabine. Further development of compounds working via the same mechanism as ARQ 501, activation of the E2F biological pathway, is currently under consideration. @@14924195@Monotherapy@@-@-@@NO REVIEW@@@@-@Further development of the compound is subject to a decision by Roche regarding its option to license rights to the E2F-1 programme.@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@ARQULE@@@@@ARQULE||||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@ARQ-501@R-1668@@@@ARQ-501|R-1668|||@E2F1 Pathway Activator@@@@@E2F1 Pathway Activator||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRAVENOUS@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14923012@Onco@@@@@@@@@@@Patients will be treated with Symadex via intravenous administration weekly for 3 weeks followed by a week of rest for a minimum of two four-week cycles. After two cycle rounds, those with stable disease will continue for two further cycles. Additional cycles are planned for responding patients along with tumour assessments every eight weeks until progressive disease or death. @@-@-@-@CAMBRIDGE, MASSACHUSSETTS@@@@@14923012@Second-line therapy @@-@-@@NO REVIEW@@@STARTED IN JANUARY 2006.@-@Antisoma acquired Xanthus in an all-share deal of GB£26.8 mil. SOURCE: Antisoma, 16 May 2008@SECOND-LINE@-@49@-@-@@@-@@@-@-@@-@49 PATIENTS WITH METASTATIC BREAST CANCER WHO RELAPSED AFTER PRIOR TREATMENT WITH AN ANTHRACYCLINE AND A TAXANE REGIMEN.  @@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@XANTHUS PHARMACEUTICALS@ANTISOMA@@@@XANTHUS PHARMACEUTICALS|ANTISOMA|||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@SYMADEX@C-1311@@@@SYMADEX|C-1311|||@TK Inhibitor@@@@@TK Inhibitor||||@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@OPEN-LABEL@MULTI-CENTRE@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14919013@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@SGN-40 plus gemcitabine and Rituxan@@-@-@-@SEATTLE, WASHINGTON@@@@@14919013@Diffuse large B-cell lymphoma@@-@-@@NO REVIEW@@@@-@Roche announces US$43.7 billion proposal to assume full control of Genentech. SOURCE: Roche, 21 July 2008Genentech licensed the drug from Seattle Genetics in January 2007@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@IB@I@@-@-@Trial to start in Q1 08. SOURCE: Genentech January 2008.@-@@@@COMBO@DACETUZUMAB@GEMCITABINE@@@@DACETUZUMAB|GEMCITABINE|||@SEATTLE GENETICS@GENENTECH@@@@SEATTLE GENETICS|GENENTECH|||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@B-Cell Lymphoma@DLBCL@@Haematological Malignancy|Non-Hodgkin's Lymphoma|B-Cell Lymphoma|DLBCL||||||@SGN-40@ANTI-CD40@GEMZAR@@@SGN-40|ANTI-CD40|GEMZAR||@mAb@Humanised@CD40@@@mAb|Humanised|CD40||@RESPONSE RATE@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16406126@Onco@@@@@@@@@@@"BPI-9016M, Experimental, "@@@@@CHINA@4/1/2018@@@@16406126@Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC: A Phase Ib Study,Open-label,Dose-expansion Study@Both@@@@@@@@@@FIRST-LINE@NCT02929290@50@@@@@@@10/1/2016@@BD-CM-I02@@@-  Histologically or cytologically confirmed, locally advanced or metastatic NSCLC patients, who is not suitable for surgery or radiotherapy  -  Evaluable or measurable disease per Response Evaluation Criteria in Solid Tumors(RECIST1.1)  -  Eastern Cooper@c-Met- Dysregulated @ADULTS@Phase 1/Phase 2@I/II@@@@@@@@@MONO@-@@@@@-||||@BETTA PHARMACEUTICALS@@@@@BETTA PHARMACEUTICALS||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@BPI-9016M@@@@@BPI-9016M||||@Other@@@@@Other||||@Participants with Adverse Events@Objective Response Rate@Disease Control Rate@@@AUCss@Css-min@@@@ADVANCED@METASTATIC@@@@Safety/Efficacy Study@Single Group Assignment@Open Label@Treatment@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916082@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Patients undergo bone marrow harvest. The bone marrow is treated with c-myb antisense oligodeoxynucleotide and cryopreserved. A portion of the marrow is cryopreserved untreated in case of engraftment failure. Patients receive oral busulfan every 6 hours on days -7 to -4 for a total of 16 doses. Patients receive cyclophosphamide IV over 1 hour on days -3 and -2. Bone marrow is reinfused on day 0. Patients receive filgrastim (G-CSF) subcutaneously daily beginning on day 0 and continuing until blood counts recover. Patients are followed every 2-3 months for 2 years. SOURCE: clinicaltrials.gov@@-@-@-@BERKELEY HEIGHTS, NEW JERSEY@@@@@14916082@UPCC-3492, NCI-H94-0532; NCT00002592@@-@-@@NO REVIEW@@@@-@-@-@NCT00002592@40@-@-@@@-@@6/1/1993@-@UPCC-3492, NCI-H94-0532@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@GENTA@@@@@GENTA||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@G-4460@@@@@G-4460||||@Antisense@@@@@Antisense||||@RESPONSE RATE@@@@@@@@@@-@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918963@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Starting dose of 650MG/M2 administered as weekly 1-hour IV infusions@@-@-@-@MADRID, SPAIN@@@Kahalalide F is a depsipeptide derived from the sea slug Elysia rufescens. Kahalalide F alters the function of the lysosomal membranes inducing cell death by oncosis. Antitumour-activity independent of MDR (Multi Drug Resistance) and p53 status and to correlate with basal ErbB3 expression. @@14918963@-@@-@-@@NO REVIEW@@@@-@PharmaMar is part of the Zeltia Group.@-@-@24@-@-@@@-@@@-@N/A@@-@-@@@II@II@@-@-@Stable disease lasting more than three months was reported in five patients. SOURCE: PharmaMar/ESMO, 29 September 2006@-@@@@-@-@@@@@-||||@PHARMAMAR@ZELTIA GROUP@@@@PHARMAMAR|ZELTIA GROUP|||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@KAHALALIDE F@@@@@KAHALALIDE F||||@Depsipeptide@@@@@Depsipeptide||||@RESPONSE RATE@@@@@@@@@@ADVANCED@MALIGNANT@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924128@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@ABI-008 every three weeks@@L01CD02@L01C@-@UNITED STATES@@@ABI-008 (nab-docetaxel) is a microtubule stabilizer and an albumin-bound chemotherapeutic, for the treatment of hormone refractory prostate and metastatic breast cancer.@@14924128@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00477529@77@-@-@@@-@@4/1/2007@-@-@@-@-@@@I/II@II@@-@-@RESULTS PENDING (recruiting).@-@@@@MONO@DOCETAXEL NANOPARTICLE ALBUMIN-BOUND@@@@@DOCETAXEL NANOPARTICLE ALBUMIN-BOUND||||@ABRAXIS@@@@@ABRAXIS||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@ABI-008@@@@@ABI-008||||@Plant Alkaloid@Vinca Alkaloids@@@@Plant Alkaloid|Vinca Alkaloids|||@MAXIMUM TOLERATED DOSE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924958@Onco@@@@@300f1008ntsdm@@@@@@Cohort of 3 patients receive escalating doses of Z-208 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 1 of 3 patients experience dose-limiting toxicity. PhaseII Treatments repeats for 28 days for 6 courses until absence of disease progression or unacceptable toxicity. [clinicaltrials.gov]@@-@-@-@JAPAN@3/1/2010@@-@@14924958@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00731445@43@-@-@@@-@@7/1/2008@-@7010101@@-@-@@@I/II@II@@-@@Trial registered. [08.08.2008]@-@@@@-@-@@@@@-||||@ZERIA@@@@@ZERIA||||@@@@@@|||||||||@Liver Cancer@Hepatocellular Carcinoma@@@@Liver Cancer|Hepatocellular Carcinoma||||||||@Z-208@@@@@Z-208||||@Immunotherapy@@@@@Immunotherapy||||@MAXIMUM TOLERATED DOSE@RECIST@@@@PHARMACOKINETICS@@@@@ADVANCED@@@@@OPEN-LABEL@SINGLE-ARM@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14920911@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Oral AZD-2281 with Gemzar IV injection@@-@-@-@LONDON, UNITED KINGDOM@11/1/2008@@A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. PARP inhibitor AZD2281 selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.@@14920911@-@@-@-@@NO REVIEW@@@@-@Acquired through takeover of KuDOS in January 2007@-@NCT00515866@69@-@-@@@-@@8/1/2007@-@KU36-29@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@COMBO@-@GEMCITABINE@@@@-|GEMCITABINE|||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@AZD-2281@GEMZAR@@@@AZD-2281|GEMZAR|||@PARP Inhibitor@@@@@PARP Inhibitor||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@CAPSULE@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922435@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@125 mg, oral, Days 1-21 of a 28-day cycle @@-@-@-@NEW YORK, NEW YORK@5/1/2009@@@@14922435@In patients who have received prior treatment@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00420056@16@-@-@@@-@@5/1/2007@-@A5481002@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@Mantle Cell Lymphoma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma|||||||@SU-11248@@@@@SU-11248||||@Other@@@@@Other||||@SAFETY@PET@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924285@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients will receive Oxaliplatin + Docetaxel + Capecitabine + Radiation therapy@@L01XA03@L01X@-@PARIS, FRANCE@@@Eloxatin is an antineoplastic agent which is an organoplatinum complex in which the platinum atom is complexed with 1,2-DACH and with an oxalate ligand as a leaving group. It undergoes non-enzymatic conversion in physiologic solutions to active derivatives via displacement of the labil oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.@@14924285@Resectable esophagus cancer@@-@-@@NO REVIEW@@@@-@sanofi-aventis licensed U.S. and European rights from Debiopharm.@-@NCT00193128@60@-@-@@@-@@4/1/2004@-@-@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@COMBO@OXALIPLATIN@@@@@OXALIPLATIN||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Oesophageal Cancer@@@@@Oesophageal Cancer|||||||||@ELOXATIN@@@@@ELOXATIN||||@Platinum@@@@@Platinum||||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922651@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Dosing of BIIB-021 with frequency and duration@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@2/1/2010@@@@14922651@GIST refractory to or intolerant of imatinib/sunitib therapy@@-@-@@NO REVIEW@@@@-@-@-@NCT00618319@60@-@-@@@-@@2/1/2008@-@120GS201@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@BIOGEN IDEC@@@@@BIOGEN IDEC||||@@@@@@|||||||||@Sarcoma@GIST@@@@Sarcoma|GIST||||||||@BIIB-021@@@@@BIIB-021||||@HSP90 Inhibitor@HER2@@@@HSP90 Inhibitor|HER2|||@FDG-PET@@@@@@@@@@RELAPSED@REFRACTORY@@@@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922700@Onco@@@@@300f1008ntsdm@@@@@@N/A@@-@-@-@-@12/1/2009@@@@14922700@CCR4-positive adult T-cell leukaemia-lymphoma and peripheral T-cell lymphoma@@-@-@@NO REVIEW@@@@-@Amgen licensed the non-oncology indications (outside Japan, South Korea, China and Taiwan) for the drug for US$100 mil upfront and up to US$420 in milestones; Kyowa Hakko will continue development until the end of Phase II, when Amgen can license the onco@-@NCT00355472@20@-@-@@@-@@7/1/2006@-@0761-0501@@-@-@@@I@I@@-@@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@KYOWA HAKKO KOGYO@AMGEN@@@@KYOWA HAKKO KOGYO|AMGEN|||@@@@@@|||||||||@Haematological Malignancy@T-Cell Lymphoma@@@@Haematological Malignancy|T-Cell Lymphoma||||||||@KW-761@@@@@KW-761||||@mAb@Humanised@@@@mAb|Humanised|||@SAFETY@TOLERABILITY@PHARMACOKINETICS@@@PHARMACOKINETICS@@@@@RELAPSED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14921347@Onco@@@@@@@@@@@Faslodex labelled dosing@@L02BA03@L02B@-@LONDON, UNITED KINGDOM@@@Fulvestrant is an oestrogen receptor antagonist and binds to oestrogen receptors in a competitive manner with an affinity comparable with that of oestradiol. Fulvestrant blocks the trophic actions of oestrogens without itself having any partial agonist (oestrogen-like) activity. The mode of action is associated with down-regulation of oestrogen receptor (ER) protein. Clinical trials in postmenopausal women with primary breast cancer have shown that fulvestrant significantly down-regulates ER protein in ER positive tumours compared with placebo. There was also a significant decrease in progesterone receptor expression consistent with a lack of intrinsic oestrogen agonist effects.@@14921347@Mammacarcinoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00241462@150@-@-@@@-@@6/1/2005@-@FORUM@@-@-@@@D6997-NL-001 / @IV@@-@-@RESULTS PENDING; studying which patients currently on Faslodex benefit most from the drug.@-@@@@MONO@FULVESTRANT@@@@@FULVESTRANT||||@ASTRAZENECA@@@@@ASTRAZENECA||||@Netherlands@@@@@Netherlands|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@FASLODEX@@@@@FASLODEX||||@Hormone Antagonist@@@@@Hormone Antagonist||||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@PROSPECTIVE@HISTORICAL CONTROL@LONGITUDINAL@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922490@Onco@@@@@@@@@@@Biweekly Gemzar/paclitaxel versys biweekly Gemzar/carboplatin versus biweekly Gemzar/cisplatin@@L01BC05@L01B@-@INDIANAPOLIS, INDIANA@@@Gemcitabine exhibits significant cytotoxicity activity against a variety of cultured murine and human tumour cells. It exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and under certain conditions blocking the progression of cells through the G1/S-phase boundary. In vitro the cytotoxic action of gemcitabine is both concentration and time dependent.@@14922490@-@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00191854@150@-@-@@@-@@3/1/2005@-@7451B9E-AA-S355  @@NOVEMBER 2007 (PAEDIATRIC); JULY 2009 (OVARIAN CANCER); EXTENSIONS TO 2013. Lilly sued Teva//Sicor over its ANDA in February 2006, and the case goes to trial in July 2009.@-@@@II@II@@-@-@Completion expected in May 2008.@-@@@@COMBO@GEMCITABINE HYDROCHLORIDE@PACLITAXEL@CARBOPLATIN@@@GEMCITABINE HYDROCHLORIDE|PACLITAXEL|CARBOPLATIN||@LILLY@@@@@LILLY||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GEMZAR@@@@@GEMZAR||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921330@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients receive placebo, Ostarine 1mg or Ostarine 3mg for 4 months.@@-@-@-@-@11/1/2008@@@@14921330@Cancer cachexia, ESRD muscle wasting and frailty / osteoporosis@@-@-@@NO REVIEW@@@@-@-@-@NCT00467844@150@-@-@@@-@@5/1/2007@-@G200502@@-@150 PATIENTS WITH NSCLC, COLORECTAL CANCER, NHL OR CLL.@@@IIB@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@GTX@@@@@GTX||||@@@@@@|||||||||@Supportive Care@Cachexia@@@@Supportive Care|Cachexia||||||||@OSTARINE@GTX-024@@@@OSTARINE|GTX-024|||@Hormone Antagonist@Anti-androgen@@@@Hormone Antagonist|Anti-androgen|||@TOTAL LEAN BODY MASS@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924836@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@A group of patients will receive a specific dose of Xeloda, whilst another will be administered a lower dose of Xeloda plus Taxotere. @@L01BC06 @L01B@-@BASEL, SWITZERLAND@@@Xeloda is a fluoropyrimidine carbamate with antineoplastic activity. It is an orally administered prodrug of 5'dexoxy-5-fluorouridine which is converted to 5-FU.@@14924836@Patients with locally advanced or metastatic breast cancer after failure of chemotherapy with anthracycline@@-@-@@NO REVIEW@@@@-@-@-@NCT00077857@100-500 @-@-@@@-@@7/1/2003@-@-@@-@-@@@II@II@@-@-@Not yet available.@-@@@@MONO@CAPECITABINE@@@@@CAPECITABINE||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@XELODA@@@@@XELODA||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@TIME TO PROGRESSION@@@@@@@@@@ADVANCED@METASTATIC@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921587@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients receive DX-8951f IV over 30 minutes daily for 5 days. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for survival.@@-@-@-@TOKYO, JAPAN@@@@@14921587@Advanced or recurrent cancer of the cervix@@-@-@@NO REVIEW@@@@-@-@-@NCT00004866@37@-@-@@@-@@1/1/2000@-@DAIICHI-8951A-PRT015, @@-@-@@@MDA-DM-99247; @II@@-@-@RESULTS PENDING@-@@@@MONO@EXATECAN MESYLATE@@@@@EXATECAN MESYLATE||||@DAIICHI SANKYO@@@@@DAIICHI SANKYO||||@@@@@@|||||||||@Cervical Cancer@@@@@Cervical Cancer|||||||||@DX-8951F@@@@@DX-8951F||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@TUMOUR RESPONSE@PHARMACOKINETICS@@@@@@@@@ADVANCED@RELAPSED@@@@INTERVENTIONAL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919287@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@ABT-510 given to subjects with advanced renal cell carcinoma@@-@-@-@UNITED STATES@@@A synthetic peptide that mimics the anti-angiogenic activity of the endogenous protein thrombospondin-1 (TSP-1). ABT-510 inhibits the actions of several pro-angiogenic growth factors important to tumor neovascularization; these pro-angiogenic growth factors include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF)), hepatocyte growth factor (HGF), and interleukin 8 (IL-8). @@14919287@Advanced renal cell carcinoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00073125@103@-@-@@@-@@5/1/2003@-@M02-428@@-@-@@@II@II@@-@-@Trial registered [Abbott, 17.11.2003]@-@@@@COMBO@THROMBOSPONDIN@@@@@THROMBOSPONDIN||||@ABBOTT@@@@@ABBOTT||||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@ABT-510@@@@@ABT-510||||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@ADVANCED@@@@@RANDOMISED@SINGLE-BLIND@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919017@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Continuous twice-daily dose for 28 days@@-@-@-@SAN DIEGO, CALIFORNIA@@@@@14919017@Patients who have failed standard therapy or no standard therapy exists@@-@-@@NO REVIEW@@@@-@Lilly completes US$64 million acquisition of SGX. SOURCE: SGX, 21 August 2008@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@-@SGX observed dose limiting toxicity earlier than anticipated. The toxicity is of a nature that was not anticipated based on the preclinical profile of SGX523. In the continuous dosing trial, patients are continuing to be treated at a lower dose level, and the Company is evaluating the safety and efficacy of treatment at that dose level. SOURCE: SGX, 27 March 2008Trial has started. SOURCE: SGX, January 2008.@-@@@@MONO@-@@@@@-||||@SGX PHARMACEUTICALS@LILLY@@@@SGX PHARMACEUTICALS|LILLY|||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@SGX-523@@@@@SGX-523||||@TK Inhibitor@@@@@TK Inhibitor||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@ADVANCED@REFRACTORY@@@@OPEN-LABEL@DOSE ESCALATION@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916603@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Zarnestra with letrozole or letrozole with placebo@@-@-@-@NEW BRUNSWICK, NEW JERSEY@@@A nonpeptidomimetic quinolinone with potential antineoplastic activity. Tipifarnib binds to and inhibits the enzyme farnesyl protein transferase, an enzyme involved in protein processing (farnesylation) for signal transduction. By inhibiting the farnesylation of proteins, this agent prevents the activation of Ras oncogenes, inhibits cell growth, induces apoptosis, and inhibits angiogenesis.@@14916603@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00050141@120@-@-@@@-@@@-@R115777-INT-22@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@TIPIFARNIB@LETROZOLE@@@@TIPIFARNIB|LETROZOLE|||@JOHNSON & JOHNSON@@@@@JOHNSON & JOHNSON||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@ZARNESTRA@FEMARA@@@@ZARNESTRA|FEMARA|||@Farnesyltransferase Inhibitor@@@@@Farnesyltransferase Inhibitor||||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@RANDOMISED@DOUBLE-BLIND@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924103@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients received defibrotide plus melphalan, prednisone and thalidomide@@-@-@-@-@@@@@14924103@Combo with melphalan, prednisone, thalidomide and defibrotide (MPTD)@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@-@19 EVALUABLE @-@-@@@-@@@-@-@@-@-@@@I/II@II@@-@-@IMW June 2007; 7 PRs, 1 near-CR and 1 CR. Haematological toxicities (greater than/equal to Grade 3) included neutropaenia (47%), thrombocytopaenia (10%), anaemia (21%), non-haematological toxicities greater than/equal to grade 3 were observed in less than 5% of patients. Only one DVT has been seen to date and no significant peripheral neuropathy has been reported. @-@@@@COMBO@DEFRIBOTIDE@THALIDOMIDE@MELPHALAN@PREDNISONE@@DEFRIBOTIDE|THALIDOMIDE|MELPHALAN|PREDNISONE|@GENTIUM@@@@@GENTIUM||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@-@THALOMID@@@@-|THALOMID|||@Other@@@@@Other||||@PARTIAL RESPONSE@COMPLETE RESPONSE@@@@@@@@@RELAPSED@REFRACTORY@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924817@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@VEGF Trap dose of 4.0mg/kg every two weeks@@-@-@-@PARIS, FRANCE@@@Aflibercept (VEGF Trap) is a unique fusion protein that binds all forms of Vascular Endothelial Growth Factor-A (called VEGF-A). VEGF-A is required for the growth of new blood vessels that are needed for tumors to grow and is a potent regulator of vascular permeability and leakage. In addition, aflibercept binds Placental Growth Factor (PLGF), which has also been implicated in tumor angiogenesis. @@14924817@Platinum-resistant and Tarceva-resistant adenocarcinoma of the lung.@@-@-@@NO REVIEW@@@@-@sanofi-aventis holds worldwide licensed including (since January 2006) Japan. Bayer Schering holds eye disease rights.@THIRD-LINE@-@-@-@REGULATORY SUBSMISSION DUE IN 2008@@@-@@@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING available.@-@@@@MONO@AFLIBERCEPT@@@@@AFLIBERCEPT||||@SANOFI-AVENTIS@REGENERON PHARMACEUTICALS@@@@SANOFI-AVENTIS|REGENERON PHARMACEUTICALS|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@VEGF-TRAP@@@@@VEGF-TRAP||||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@RESPONSE RATE@@@@@@@@@@-@@@@@SINGLE-ARM@MULTI-CENTRE@OPEN-LABEL@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919199@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01XA03@L01X@YES@CANONSBURG, PENNSYLVANIA@@@Eloxatin is an antineoplastic agent which is an organoplatinum complex in which the platinum atom is complexed with 1,2-DACH and with an oxalate ligand as a leaving group. It undergoes non-enzymatic conversion in physiologic solutions to active derivatives via displacement of the labil oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.@@14919199@Oxaliplatin in combination with 5-fluorouracil (5-FU) and folinic acid (FA) is indicated for: • Adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of primary tumor. • Treatment of metastatic colorectal cancer.@@YES@@@No ASMR rating.@@@@@@@@@The recommended dose for oxaliplatin in adjuvant setting is 85 mg/m² intravenously repeated every two weeks for 12 cycles (6 months).@@@@@@@Hypersensitivity and anaphylactic / anaphylactoid reactions to Eloxatin have been reported. Eloxatin may cause fetal harm when administered to a pregnant woman.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@ADJUVANT@OXALIPLATIN@@@@@OXALIPLATIN||||@ACTAVIS@@@@@ACTAVIS||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@GENERIC@@@@@GENERIC||||@Platinum@@@@@Platinum||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@9319737T@POWDER FOR SOLUTION FOR PERFUSION, 10 ML@EURO@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14924839@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Administration of Xeloda before surgery  @@L01BC06 @L01B@-@BASEL, SWITZERLAND@@@Xeloda is a fluoropyrimidine carbamate with antineoplastic activity. It is an orally administered prodrug of 5'dexoxy-5-fluorouridine which is converted to 5-FU.@@14924839@Operable breast cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00148720@80@-@-@@@-@@12/1/2004@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@CAPECITABINE@@@@@CAPECITABINE||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@XELODA@@@@@XELODA||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918757@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Irinotecan and vincristine with 1-31 MIBG@@-@-@-@-@@@@@14918757@Young patients with resistant or relapsed high-risk neuroblastoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00509353@30@-@-@@@-@@1/1/2007@-@NANT-2004-06@@-@-@@@I/II, NANT-N04-06, NANT-Draximage-2007-01; @II@@-@-@RESULTS PENDING@-@@@@COMBO@IOBEGUANE I-131@IRINOTECAN@VINCRISTINE@@@IOBEGUANE I-131|IRINOTECAN|VINCRISTINE||@DRAXIMAGE@@@@@DRAXIMAGE||||@@@@@@|||||||||@Carcinoid / Neuroendocrine Tumour@@@@@Carcinoid / Neuroendocrine Tumour|||||||||@I-131 MIBG@CAMPTOSAR@@@@I-131 MIBG|CAMPTOSAR|||@Other@@@@@Other||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@RELAPSED@REFRACTORY@@@@INTERVENTIONAL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918979@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@PRINCETON, NEW JERSEY@@@@@14918979@-@@-@-@@NO REVIEW@@@@-@>>BMS acquires Medarex in July 2009>>Kyowa Hakko and Kirin announced merger in October 2007.@SECOND-LINE@-@36@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@MEDAREX@BIOWA@KYOWA HAKKO KOGYO@KIRIN PHARMA@@MEDAREX|BIOWA|KYOWA HAKKO KOGYO|KIRIN PHARMA|@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@@@@Haematological Malignancy|Hodgkin's Lymphoma||||||||@MDX-1401@@@@@MDX-1401||||@mAb@Human@CD30@@@mAb|Human|CD30||@SAFETY@@@@@@@@@@RELAPSED@REFRACTORY@@@@DOSE ESCALATION@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921137@Onco@@@@@@@@@@@Recentin added to FOLFOX/XELOX versus FOLFOX/XELOX/placebo@@-@-@-@LONDON, UNITED KINGDOM@@@Cediranib (Recentin AZD2171) is a highly potent inhibitor of the tyrosine kinase activity associated with all three vascular endothelial growth factor (VEGF) receptors and is currently in Phase II/III clinical trials. Preclinically, cediranib inhibits VEGF signaling and angiogenesis in vivo and impedes solid tumor growth significantly. @@14921137@First-line mCRC@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00399035@1050@-@-@@@-@@10/1/2006@-@HORIZON II@@-@-@@@III; D8480C00051; EUDRACT NO 2006-001194-14@III@@-@-@Patients will continue to be recruited at 20MG. IDMC recommended HORIZON I, II and III continue. SOURCE: AstraZeneca, 27 February 2008@-@@@@COMBO@CEDIRANIB@@@@@CEDIRANIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@RECENTIN@AZD-2171@@@@RECENTIN|AZD-2171|||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@OVERALL SURVIVAL@@@@@@@@@@METASTATIC@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921311@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Zalutumumab cobo with chemoradiation@@-@-@-@COPENHAGEN, DENMARK@@@Zalutumumab is a fully human, high-affinity antibody targeted at the Epidermal Growth Factor receptor (EGFr) and is in clinical development to treat head and neck cancer, non small cell lung cancer (NSCLC) and colorectal cancer. EGFr is a receptor molecule found on the surface of many cancer cells. Activation of EGFr by the appropriate growth factor molecule promotes the growth of tumor cells. @@14921311@-@@-@-@@NO REVIEW@@@@-@No licensing partner@-@NCT00460551@270@-@-@@@-@@4/1/2007@-@GEN204@@-@PATIENTS WITH STAGE IIIA/IIIB NSCLC@@@II@DISCONTINUED@@-@-@Trial discontinued as part of Genmab's strategic review of its portfolio; the chemotherapy regimen in this trial was considered outdated. [Genmab, 7.10.2008]@-@@@@COMBO@ZALUTUMUMAB@@@@@ZALUTUMUMAB||||@GENMAB@MEDAREX@@@@GENMAB|MEDAREX|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@HUMAX-EGFR@@@@@HUMAX-EGFR||||@mAb@Human@TK Inhibitor@EGFR@@mAb|Human|TK Inhibitor|EGFR|@PROGRESSION-FREE SURVIVAL@@@@@@@@@@-@@@@@OPEN-LABEL@RANDOMISED@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924793@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Stage I: 22 patients will be treated with IV TPI 287 once every 21 days. Stage II to continue with 18 more patients if >=2 patients show a response in previous stage.Drug dropped for HRPC if =< 4 patients show a response in stages 1 and 2 combined.. @@-@-@-@-@5/1/2008@@@@14924793@Hormone refractory@@-@-@@NO REVIEW@@@@-@-@-@NCT00479635@40@-@-@@@-@@1/1/2007@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@TAPESTRY@@@@@TAPESTRY||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@TPI-287@@@@@TPI-287||||@Taxane@@@@@Taxane||||@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919012@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@The phase I study will initially evaluate escalating single-agent doses of SGN-35 administered weekly to patients with relapsed or refractory CD30-positive hematologic malignancies, including Hodgkin lymphoma. Following the monotherapy portion of the study, the trial will continue with an investigation of SGN-35 in combination with Gemzar (gemcitabine). SOURCE: Seattle, 28 March 2008@@L01XC12@L01X@-@SEATTLE, WASHINGTON@@@@@14919012@Hodgkin's lymphoma and other CD30-positive haematological malignancies@@@@@NO REVIEW@@@@@@@-@40@-@@@@@@3/1/2008@-@N/A@@@-@@@I@I@@@@RESULTS PENDING@@@@@BOTH@BRENTUXIMAB@GEMCITABINE@@@@BRENTUXIMAB|GEMCITABINE|||@SEATTLE GENETICS@@@@@SEATTLE GENETICS||||@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@@@@Haematological Malignancy|Hodgkin's Lymphoma||||||||@ADCETRIS@GEMZAR@@@@ADCETRIS|GEMZAR|||@Other@CD30@@@@Other|CD30|||@SAFETY@TOLERABILITY@@@@@@@@@@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INTRAVENOUS@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921677@Onco@@@@@@@@@@@N/A@@-@-@-@BASEL, SWITZERLAND@@@The active substance in Afinitor, everolimus, is an anticancer medicine, which acts by blocking a protein called ‘mammalian target of rapamycin' (mTOR). In the body, everolimus attaches to a protein that is found inside cells to make a ‘complex'. This complex then blocks mTOR. Since mTOR is involved in the control of cell division and the growth of blood vessels, Afinitor prevents the division of cancer cells and reduces their blood supply. This slows down the growth and spread of kidney cancer.@@14921677@Combo with Alimta@@-@-@@NO REVIEW@@@DECEMBER 2006-@-@-@SECOND-LINE@NCT00434174@60@-@-@@@EMEA issued positive opinion to grant Orphan Drug status for everolimus to treat neuroendocrine gastroenteropancreatic tumours@@@-@CRAD001C2112@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@COMBO@EVEROLIMUS@PEMETREXED@@@@EVEROLIMUS|PEMETREXED|||@NOVARTIS@LILLY@@@@NOVARTIS|LILLY|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@AFINITOR@RAD-001@ALIMTA@@@AFINITOR|RAD-001|ALIMTA||@Immunotherapy@Immunosuppressive@mTOR Inhibitor@@@Immunotherapy|Immunosuppressive|mTOR Inhibitor||@DOSE-LIMITING TOXICITY@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924164@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@THOUSAND OAKS, CALIFORNIA@@@Denosumab is a fully human monoclonal antibody that specifically targets the receptor activator of nuclear factor kappa B ligand (“RANKL”), a key mediator of the cells responsible for bone breakdown. Denosumab is being studied across a range of conditions, including osteoporosis, treatment-induced bone loss, bone metastases, rheumatoid arthritis, and multiple myeloma. @@14924164@Prevention of bone metastases@@-@-@@NO REVIEW@@@@-@Japanese rights licensed to Daiichi Sankyo for US$20 mil upfront and royalties in July 2007, and Daiichi Sankyo will pay US$150 mil of expected worldwide development costs through 2009.@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@III@@-@-@RESULTS PENDING; expected in early 2009.@-@@@@-@DENOSUMAB@@@@@DENOSUMAB||||@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Bone Metastases@@@@@Bone Metastases|||||||||@AMG-162@@@@@AMG-162||||@mAb@Human@RANK Ligand@@@mAb|Human|RANK Ligand||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924845@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Xinlay 10mg@@-@-@-@UNITED STATES@@@@@14924845@HRPC@@-@-@@NO REVIEW@@@@-@-@-@NCT-00036543@1000@-@NDA FILED IN DECEMBER 2004; ODAC RECOMMENDED AGAINST APPROVAL IN SEPTEMBER 2005 CITING LACK OF EFFICACY DATA; DEVELOPMENT DISCONTINUED IN EARLY 2007.@@@-@@5/1/2001@-@-@@-@1,000 PATIENTS WITH HRPC@@@III@DISCONTINUED@@-@-@Phase III trials halted in February 2003 due to failure to stop disease progression; but lack of interaction with testosterone led to mitigated side-effects.@-@@@@MONO@ATRASENTAN@@@@@ATRASENTAN||||@ABBOTT@@@@@ABBOTT||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@XINLAY@@@@@XINLAY||||@Endothelin A Receptor Antagonist@@@@@Endothelin A Receptor Antagonist||||@TIME TO PROGRESSION@@@@@@@@@@REFRACTORY@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924647@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@KING OF PRUSSIA, PENNSYLVANIA@@@@@14924647@Xerostomia associated with radiotherapy for head and neck cancer@@-@-@@NO REVIEW@@@@-@Marillion purchased exclusive global rights to the drug; financial rights not disclosed. SOURCE: Cytokine/Marillion, 25 February, 2008@-@-@-@-@EMEA COMP recommended for orphan drug status for multiple myeloma; early granted orphan drug designation for CLL and Hodgkin's lymphoma. SOURCE: GPC Biotech, 14 February 2006@2/14/2006@@EMEA COMP recommended for orphan drug status for multiple myeloma; early granted orphan drug designation for CLL and Hodgkin's lymphoma. SOURCE: GPC Biotech, 14 February 2006@@@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@CYTOKINE PHARMASCIENCES@MARILLION PHARMACEUTICALS@@@@CYTOKINE PHARMASCIENCES|MARILLION PHARMACEUTICALS|||@@@@@@|||||||||@Supportive Care@Head & Neck Cancer@@@@Supportive Care|Head & Neck Cancer||||||||@PILOBUC@@@@@PILOBUC||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14923694@Onco@@@@@300f1008ntsdm@@@@@@-@@-@-@-@KAMAKURA, JAPAN@@@RecQL1-siRNA induces selective apoptosis of cancer cells by inhibiting RecQL1 helicase, an enzyme that plays an important role when cancer cells are divided, with siRNA. The candidate is being combined with Nippon Shunyaku's LIC-101 liposome technology for drug administration.@@14923694@-@@-@-@@NO REVIEW@@@@-@Base technology for RNAi-related patents licensed from Alnylam Pharmaceuticals. [Alnylam, 2005]@-@-@-@-@-@@@-@@@-@-@@-@-@@@I@I@@-@@Trial to start in 2009. [GeneCare, 29.07.2008]@-@@@@MONO@-@@@@@-||||@GENECARE RESEARCH INSTITUTE@NOVARTIS@@@@GENECARE RESEARCH INSTITUTE|NOVARTIS|||@@@@@@|||||||||@Liver Cancer@@@@@Liver Cancer|||||||||@RECQL1-SIRNA@@@@@RECQL1-SIRNA||||@Gene Therapy@@@@@Gene Therapy||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14916428@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Troxatyl continuous infusion@@-@-@-@SAN DIEGO, CALIFORNIA@10/1/2007@@@@14916428@Second salvage AML@@-@-@@NO REVIEW@@@@-@Lilly completes US$64 million acquisition of SGX. SOURCE: SGX, 21 August 2008@SECOND-LINE@NCT00129948@211@-@-@@@-@@7/1/2005@-@SPD758-216@@-@-@@@II@DISCONTINUED@@-@-@RESULTS PENDING@-@@@@MONO@TROXACITABINE@@@@@TROXACITABINE||||@SGX PHARMACEUTICALS@LILLY@@@@SGX PHARMACEUTICALS|LILLY|||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@TROXATYL@@@@@TROXATYL||||@Nucleoside Analogue@@@@@Nucleoside Analogue||||@COMPLETE RESPONSE@@@@@@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919089@Onco@@@@@@@@@@@Lenalidomide in Combination With Melphalan and Prednisone Versus Placebo Plus Melphalan and Prednisone@@L04AX04@L04A@@SUMMIT, NEW JERSEY@12/1/2012@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@14919089@Newly diagnosed MM patients who are not candidates for stem cell transplants; patients who are 65 years or older@@@-@@NO REVIEW@@@@@-@@NCT00405756@450@@-@@@@@1/1/2007@@MM015@@@@@@III@III@@@@Not available yet; due in 2008@-@@@@COMBO@LENALIDOMIDE@MELPHALAN@PREDNISONE@@@LENALIDOMIDE|MELPHALAN|PREDNISONE||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@REVLIMID@@@@@REVLIMID||||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@RESPONSE RATE@SAFETY@@@@@@@@@EARLY@@@@@PLACEBO-CONTROLLED@@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924512@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Irvalec will be administered as an intravenous infusion for 30 minutes every 3 weeks. [PharmaMar]@@-@-@-@MADRID, SPAIN@@@PM02734 is a novel chemical entity resulting from PharmaMar's internal research program for derivatives of marine natural compounds. Produced synthetically in-house by PharmaMar, PM02734 is a new depsipeptide of the kahalalides family. Preliminary in vitro in-house studies identified PM02734 as a new antiproliferative drug demonstrating activity against a broad spectrum of tumor types: breast, colon, pancreas, lung and prostate, among others. PM02734 has been selected for clinical development based on its in vivo activity in xenografted human tumors, as well as an acceptable non-clinical toxicology profile. @@14924512@Patients with non-microcitic lung cancer @@-@-@@NO REVIEW@@@@-@PharmaMar is part of the Zeltia Group.@-@-@-@-@-@@@-@@12/1/2008@-@-@@-@-@@@II@II@@-@-@Trial commenced. [PharmaMar, 18.12.2008]@-@@@@MONO@-@@@@@-||||@PHARMAMAR@ZELTIA GROUP@@@@PHARMAMAR|ZELTIA GROUP|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@IRVALEC@PM-02734@@@@IRVALEC|PM-02734|||@Depsipeptide@@@@@Depsipeptide||||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@NON-MICROCITIC@@@@@MULTI-CENTRE@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16791369@Onco@@@@@300f1015ntsdm@@@@@@@@L01XE12@L01X@@LONDON, UNITED KINGDOM@@@An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGF2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis.@@16791369@Paediatric patients aged 5 to 18 with unresectable locally advanced or metastatic medullary thyroid carcinoma (MTC)@Both@NO@@@NO REVIEW@@@@NA@@@@16@@EMA, 16 December 2016@12/16/2016@8/1/2013@Yes@@@@@No@@@PAEDIATRIC@PAEDIATRIC@I/II@APPROVED@@@NA@@@@@@MONO@VANDETANIB@@@@@VANDETANIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Thyroid Cancer@@@@@Thyroid Cancer|||||||||@CAPRELSA@@@@@CAPRELSA||||@TK Inhibitor@VEGF@EGFR@Angiogenesis Inhibitor@@TK Inhibitor|VEGF|EGFR|Angiogenesis Inhibitor|@@@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@@@@@@1.2@m²@3136@@@8@week@8 week@3136@3136@56@30@1.1511@4200@4418.37@4230@@@@@@@@@@0.47@1@@mg/m²@100@1@@@@@@@@@@@8/1/2017@140@140@3.40E+12@FILM-COATED TABLET@EURO@@@@@@@@300@MG@300 MG@@@@@@@@@@@@@@@@@@@@@@@@85@France
14924603@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@The investigators will collect from each patient's blood a white blood cell population called Dendritic Cells (DC).  These cells are then exposed in vitro to replicated iLRP, cultured, and reintroduced into the patient via subdermal injection. SOURCE: Quantum@@-@-@-@-@@@@@14924603@Patients who have previously failed to respond to conventional therapy consisting of surgery, radiation and/or chemotherapy.  @@-@-@@NO REVIEW@@@@-@-@-@-@-@-@FDA HAS GRANTED ORPHAN DRUG AND FAST-TRACK DESIGNATIONS FOR GBM AND ANAPLASTIC ASTROCYTOMA@@@-@@@-@-@@-@-@@@I/II SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION@II@@-@-@Trial start. SOURCE: Quantum, 29 April 2008@-@@@@MONO@-@@@@@-||||@QUANTUM IMMUNOLOGICS@@@@@QUANTUM IMMUNOLOGICS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@NO NAME@@@@@NO NAME||||@Immunotherapy@Vaccine@@@@Immunotherapy|Vaccine|||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16398915@Onco@@@@@300f1008ntsdm@@@@@@@@L01AA09@L01A@@@@@@@16398915@@@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@@@264@@MHLW, 1 August 2016@8/1/2016@12/1/2010@@@@@@No@@@@@III@APPROVED@@@NHI@@@@@@MONO@BENDAMUSTINE@@@@@BENDAMUSTINE||||@SYMBIO PHARMACEUTICALS@@@@@SYMBIO PHARMACEUTICALS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@TREAKISYM@@@@@TREAKISYM||||@Alkylating Agent@Nitrogen Mustard Analogue@@@@Alkylating Agent|Nitrogen Mustard Analogue|||@@@@@@@@@@@@@@@@@@@@@1.75@m²@1691670.96@@@168@day@168 day@1691670.96@1691670.96@10069.47@1@0.0091@80555.76@94995@@@@@@@@@@@805.56@28@@mg/m²@100@2@@@@@@@@@@@8/30/2017@80555.76@80555.76@4219405D1021@INJECTION@YEN@@@@@@@@100@MG@100 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14918951@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@SAN FRANCISCO, CALIFORNIA@@@@@14918951@-@@-@-@@NO REVIEW@@@@-@">> Roche reaches a friendly agreement to purchase the latter's outstanding shares at a price of US$95 per share. The transaction will be valued at US$46.8 billion. [Genentech, 12 March 2009]>> Roche has made a formal announcement of cash tender offer for all outstanding shares of Genentech at US$86.50 per share for the 44.2% of Genentech not already held by Roche. Genentech's special committee, on the other hand, has responded to the offer by urging its shareholders ""to take no action at this time"". [Genentech, 10.02.2009]          >> Genentech rejects the acquisition bid. [Genentech, 14.08.2008]        >> Roche announces US$43.7 billion proposal to assume full control of Genentech. SOURCE: Roche, 21 July 2008"@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@GENENTECH@@@@@GENENTECH||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@IAP ANTAGONIST@@@@@IAP ANTAGONIST||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16423195@Onco@@@@@300f1010ntsdm@@@@@@@@L01XE29@L01X@@TOKYO, JAPAN@@@@@16423195@Indicated in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy.@Both@NO@@@NO REVIEW@@@@100%@@SECOND-LINE@@153@The recommended daily dose of lenvatinib is 18 mg (one 10 mg capsule and two 4 mg capsules) once daily in combination with 5 mg of everolimus once daily. The daily doses of lenvatinib and, if necessary, everolimus are to be modified as needed according to the dose/toxicity management plan.Treatment should continue as long as there is clinical benefit or until unacceptable toxicity occurs@EMA, 25 August 2016@8/25/2016@@@@@@@No@@@@ADULTS@@APPROVED@@@NHS@@@@@@COMBO@LENVATINIB@EVEROLIMUS@@@@LENVATINIB|EVEROLIMUS|||@EISAI@@@@@EISAI||||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@KISPLYX@AFINITOR@@@@KISPLYX|AFINITOR|||@TK Inhibitor@@@@@TK Inhibitor||||@@@@@@@@@@@ADVANCED@@@@@MULTICENTER@RANDOMIZED@Open Label@@@1@1@38288.02579@@@14.6@month@14.6 month@38288.03@38288.03@86.22@30@1.299@1437@@@@@@@@@@@@4.79@1@@mg@18@1@@@@@@@@@@@7/28/2017@47.9@47.9@3.36E+16@CAPSULE@GB£@@@@@@@@10@MG@10 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14922244@Onco@@@@@@@@@@@232 on Telcyta, 229 on pegylated liposomal doxorubicin or Hycamtin (depending on second-line treatment).@@L01AA@L01A@-@-@@@@@14922244@-@@-@-@@NO REVIEW@@@@-@-@THIRD-LINE@NCT00057720@462@-@PARTIAL HOLD ON TELCYTA ARMS IMPOSED IN JUNE 2007; ASSIST-3 AND ASSIST-5 PATIENTS WILL CONTINUE TO RECEIVE TREATMENT.@@@-@@4/1/2003@-@ASSIST-1, @@-@461 WOMEN WITH ADVANCED, PLATINUM-REFRACTORY OR RESISTANT OVARIAN CANCER@@@III@CLINICAL HOLD@@-@-@ASCO 2007; OS worse in Telcyta arm over control, did not meet primary or secondary endpoint. Median survival was 8.5 months in Telcyta arm and 13.6 months in control arm. PFS was 2.3 months in Telcyta arm and 4.3 months in control arm.@-@@@@MONO@CANFOSFAMIDE@@@@@CANFOSFAMIDE||||@TELIK@@@@@TELIK||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@TELCYTA@@@@@TELCYTA||||@Alkylating Agent@Nitrogen Mustard Analogue@@@@Alkylating Agent|Nitrogen Mustard Analogue|||@OVERALL SURVIVAL@PROGRESSION-FREE SURVIVAL@@@@@@@@@ADVANCED@REFRACTORY@@@@INTERNATIONAL@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924740@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Targretin with tretinoin and chemotherapy (carboplatin, cisplatin, docetaxel)@@L01XX25@L01X@-@TOKYO, JAPAN@@@@@14924740@Stage III or IV NSCLC@@-@-@@NO REVIEW@@@@-@Global rights licensed by Eisai from Ligand in September 2006. Cephalon acquired European rights through takeover of Zeneus in December 2005.@-@NCT00514293@39@-@-@@@-@@1/1/2007@-@-@@2016@-@@@II@II@@-@-@RESULTS PENDING (recruiting).@-@@@@COMBO@BEXAROTENE@DOCETAXEL@CARBOPLATIN@CISPLATIN@@BEXAROTENE|DOCETAXEL|CARBOPLATIN|CISPLATIN|@EISAI@@@@@EISAI||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@TARGRETIN@TAXOTERE@@@@TARGRETIN|TAXOTERE|||@Retinoid@@@@@Retinoid||||@RESPONSE RATE@RECIST@TIME TO PROGRESSION@@@TIME TO PROGRESSION@@@@@-@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924861@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@WHITEHOUSE STATION, NEW JERSEY@@@Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (ClassI) and HDAC6 (Class II) at nanomolar concentrations (IC50<86 nM). These enzymes catalyze the removalof acetyl groups from the lysine residues of proteins, including histones and transcription factors. In somecancer cells, there is an overexpression of HDACs, or an aberrant recruitment of HDACs to oncogenictranscription factors causing hypoacetylation of core nucleosomal histones. Hypoacetylation of histones isassociated with a condensed chromatin structure and repression of gene transcription. Inhibition ofHDAC activity allows for the accumulation of acetyl groups on the histone lysine residues resulting in anopen chromatin structure and transcriptional activation. In vitro, vorinostat causes the accumulation ofacetylated histones and induces cell cycle arrest and/or apoptosis of some transformed cells. Themechanism of the antineoplastic effect of vorinostat has not been fully characterized.@@14924861@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@-@VORINOSTAT@@@@@VORINOSTAT||||@MERCK & CO@@@@@MERCK & CO||||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@ZOLINZA@@@@@ZOLINZA||||@HDAC@@@@@HDAC||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924275@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@L02AE02@L02A@-@PARIS, FRANCE@@@Leuprolide acetate, an LH-RH agonist, acts as a potent inhibitor of gonadotropin secretion when given continuously in therapeutic doses. Animal and human studies indicate that after an initial stimulation, chronic administration of leuprolide acetate results in suppression of ovarian and testicular steroidogenesis. This effect is reversible upon discontinuation of drug therapy. Eligard is a sterile polymeric matrix formulation of leuprolide acetate for subcutaneous injection. It is designed to deliver 7.5 mg of leuprolide acetate at a controlled rate over a one month therapeutic period.@@14924275@-@@NO@-@@NO REVIEW@@@@-@Sanofi-Synthelabo licensed North American rights from pre-merger Atrix in 2001@-@-@-@-@-@@@-@@@-@-@@8-Oct@-@@@-@FILED@@-@-@RESULTS PENDING@-@@@@-@LEUPROLIDE ACETATE@@@@@LEUPROLIDE ACETATE||||@SANOFI-AVENTIS@QLT@@@@SANOFI-AVENTIS|QLT|||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@ELIGARD@@@@@ELIGARD||||@LH-RH Analog@@@@@LH-RH Analog||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916435@Onco@@@@@@@@@@@Weekly Tocosol@@-@-@-@-@@@Tocosol Paclitaxel was previously developed by Sonus Pharmaceuticals prior to the combination of Sonus and OncoGenex Technologies to form the Company on August 21, 2008. They were evaluating alternative strategies for the program, including out-licensing, ahead of the Eagle partnership.@@14916435@Second-line colorectal adenocarcinoma@@-@-@@NO REVIEW@@@@-@>OncoGenex grants Eagle exclusive rights to develop and commercialise Tocosol in exchange for royalties and a percentage of sub-licensing royalty and milestones payments. All development expenses will be held by Eagle; no upfront payments were made. [OncoGenex, 02.09.2008]>Sonus and OncoGenex to merge, with the combined company operating as OncoGenex Pharmaceuticals. [OncoGenex/Sonus, 28.05.2008]>Sonus signed an agreement with Schering AG granting it an exclusive worldwide license to Tocosol. Schering made approximately a 15% equity investment in Sonus, which also received an upfront fee, milestone payments and royalties. [Sonus, October 2005]@SECOND-LINE@NCT00034190@-@-@-@@@-@@3/1/2002@-@SON-8184-1066@@-@-@@@II@DISCONTINUED@@-@-@Discontinued in September 2007 after failure of pivotal breast cancer trial.@-@@@@MONO@PACLITAXEL, VITAMIN E-BASED @@@@@PACLITAXEL, VITAMIN E-BASED ||||@EAGLE PHARMACEUTICALS@@@@@EAGLE PHARMACEUTICALS||||@Russia@@@@@Russia|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@TOCOSOL@@@@@TOCOSOL||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@RESPONSE RATE@SAFETY@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924149@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@TORONTO, CANADA@@@AE37 is designed to stimulate an immune response against the tumor-causing gene HER-2/neu, which occurs in a significant percentage of patients with breast cancer as well as other cancers. A robust immune response against HER-2/neu has the potential to destroy tumor cells even at sites in the body distant from the primary tumor.@@14924149@-@@-@-@@NO REVIEW@@@@-@Antigen Express is a subsidiary of Generex.@-@-@30@-@-@@@-@@11/1/2007@-@-@@-@-@@@I@I@@-@-@First-patient in (FPI) in November 2007. SOURCE: Generex, 5 November 2007@-@@@@MONO@-@@@@@-||||@GENEREX@ANTIGEN EXPRESS@@@@GENEREX|ANTIGEN EXPRESS|||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@AE-37@@@@@AE-37||||@Immunotherapy@Vaccine@@@@Immunotherapy|Vaccine|||@RESPONSE RATE@@@@@@@@@@-@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919588@Onco@@@@@300f1015ntsdm@@@@@@@@N02AB03@N02A@@CANONSBURG, PENNSYLVANIA@@@Fentanyl is a synthetic opiate with a clinical potency of 50 to 100 times that of morphine. Its onset of action is rapid and its duration of action is short. In man, a single iv dose of 0.5-1 mg/70 kg body weight immediately produces a pronounced state of surgical analgesia, respiratory depression, bradycardia and other typical morphine-like effects. The duration of action of the peak effects is about 30 minutes. All potent morphine-like drugs produce relief from pain, ventilatory depression, emesis, constipation, physical dependence, certain vagal effects and varying degrees of sedation. Fentanyl, however, differs from morphine not only by its short duration of action but also by its lack of emetic effect and minimal hypotensive activity in animals.@@14919588@Management of breakthrough cancer pain in patients with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain@@NO@@@NO REVIEW@@@@@Acquired via takeover of generics unit of Merck KGaA@@@@@Oct-92@@@@@@@@No@@@@@@APPROVED@@FREE PRICE IN HOSPITAL@HAUTE AUTORITÉ DE SANTÉ@RESULTS PENDING@@@@@@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@MYLAN@@@@@MYLAN||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@GENERIC@@@@@GENERIC||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14924511@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@MADRID, SPAIN@@@PM02734 is a novel chemical entity resulting from PharmaMar's internal research program for derivatives of marine natural compounds. Produced synthetically in-house by PharmaMar, PM02734 is a new depsipeptide of the kahalalides family. Preliminary in vitro in-house studies identified PM02734 as a new antiproliferative drug demonstrating activity against a broad spectrum of tumor types: breast, colon, pancreas, lung and prostate, among others. PM02734 has been selected for clinical development based on its in vivo activity in xenografted human tumors, as well as an acceptable non-clinical toxicology profile. @@14924511@Irvalec in combination with Tarceva (erlotinib) in solid tumors@@-@-@@NO REVIEW@@@@-@PharmaMar is part of the Zeltia Group.@-@-@-@-@-@@@-@@12/1/2008@-@-@@-@-@@@I/II@II@@-@-@Trial commenced. [PharmaMar, 30.12.2008]@-@@@@COMBO@-@ERLOTINIB@@@@-|ERLOTINIB|||@PHARMAMAR@ZELTIA GROUP@@@@PHARMAMAR|ZELTIA GROUP|||@@@@@@|||||||||@Solid Tumours@NSCLC@@@@Solid Tumours|NSCLC||||||||@IRVALEC@PM-02734@TARCEVA@@@IRVALEC|PM-02734|TARCEVA||@Depsipeptide@@@@@Depsipeptide||||@SAFETY@DOSE-LIMITING TOXICITY@@@@@@@@@RELAPSED@@@@@MULTI-CENTRE@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916077@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Gemzar plus etoposide@@L01BC05@L01B@-@INDIANAPOLIS, INDIANA@@@Gemcitabine exhibits significant cytotoxicity activity against a variety of cultured murine and human tumour cells. It exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and under certain conditions blocking the progression of cells through the G1/S-phase boundary. In vitro the cytotoxic action of gemcitabine is both concentration and time dependent.@@14916077@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00202800@40@-@-@@@-@@@-@VARI-002-1  @@NOVEMBER 2007 (PAEDIATRIC); JULY 2009 (OVARIAN CANCER); EXTENSIONS TO 2013. Lilly sued Teva//Sicor over its ANDA in February 2006, and the case goes to trial in July 2009.@-@@@II@II@@-@-@Completion expected in December 2007.@-@@@@COMBO@GEMCITABINE HYDROCHLORIDE@ETOPOSIDE@@@@GEMCITABINE HYDROCHLORIDE|ETOPOSIDE|||@LILLY@@@@@LILLY||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@GEMZAR@@@@@GEMZAR||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@RESPONSE RATE@@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@NON-RANDOMISED@SINGLE-ARM@UNCONTROLLED@SINGLE-BLIND@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917983@Onco@@@@@300f1015ntsdm@@@@@@@@J06BA02@J06B@@DEERFIELD, ILLINOIS@@@@@14917983@Indicated for prevention of bacterial infections in patients with hypogammaglobulinemia and/or recurrent bacterial infections associated with B-cell Chronic Lymphocytic Leukemia (CCL), for the prevention of coronary artery aneurysms associated with Kawasaki Syndrome and to induce rapid rise in platelet count when needed to prevent and/or to control bleeding in a patient with Idiopathic Thrombocytopenic Purpura (ITP).@@YES@4-Dec@@NO REVIEW@@@@100%@@@@@@Jul-99@@7/1/1999@@@@@@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@RESULTS PENDING@@@@@@IMMUNOGLOBULIN (HUMAN)@@@@@IMMUNOGLOBULIN (HUMAN)||||@BAXTER HEALTHCARE@@@@@BAXTER HEALTHCARE||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@B-Cell Lymphoma@Supportive Care@@Haematological Malignancy|Chronic Lymphocytic Leukaemia|B-Cell Lymphoma|Supportive Care||||||@GAMMAGARD@@@@@GAMMAGARD||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@112.5@@@@@@@@@@@@0.05@@@@@@@@@@@@@@@@8/2/2017@112.5@112.5@9199061R@POWDER AND SOLVANT FOR SOLUTION FOR PERFUSION@EURO@@@@@@@@2500@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14922563@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@CEP-701 alone@@-@-@-@FRAZER, PENNSYLVANIA@@@@@14922563@Myelofibrosis (PH-negative)@@-@-@@NO REVIEW@@@@-@Licensed from Kyowa Hakko; supplied by Abbott/TAP. Original licensing agreement with Schwarz Pharma terminated.@-@NCT00494585@41@-@-@@@-@@6/1/2007@-@2007-0070  @@-@-@@@II@II@@-@-@RESULTS PENDING (recruiting).@-@@@@MONO@LESTAURTINIB@@@@@LESTAURTINIB||||@CEPHALON@@@@@CEPHALON||||@@@@@@|||||||||@Haematological Malignancy@@@@@Haematological Malignancy|||||||||@CEP-701@@@@@CEP-701||||@TK Inhibitor@@@@@TK Inhibitor||||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922359@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Dose esclation of the drug@@-@-@-@NEW YORK, NEW YORK@7/1/2008@@This is an irreversible pan-ERBB inhibitor. PF00299804 is a potent inhibitor of EGFR-activating mutations as well as the EGFR T790M resistance mutation both in vitro and in vivo. Additionally, PF00299804 is a highly effective inhibitor of both the wild-type ERBB2 and the gefitinib-resistant oncogenic ERBB2 mutation identified in lung cancers. @@14922359@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00225121@100@-@-@@@-@@10/1/2005@-@A7471001@@-@-@@@I@I@@-@-@Endpoint over six months.@-@@@@MONO@DACOMITINIB@@@@@DACOMITINIB||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@PF-299804@@@@@PF-299804||||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@SAFETY@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15051150@Onco@@@@@300f1012ntsdm@@@@@@BIBW-2992 daily oral dose of 50MG in two cohorts@@-@-@-@INGELHEIM, GERMANY@6/1/2008@@This is an orally bioavailable dual receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. EGFR/HER2 tyrosine kinase inhibitor BIBW 2992 irreversibly binds to and inhibits human epidermal growth factor receptors 1 and 2 (EGFR-1; HER2), which may result in the inhibition of tumor growth and angiogenesis. EGFR/HER2 are RTKs that belong to the EGFR superfamily; both play major roles in tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types. @@15051150@HER2-negative metastatic breast cancer@@-@-@@NO REVIEW@@@@-@-@THIRD-LINE@NCT00425854@80@-@-@@@-@@11/1/2006@-@1200.1@@-@-@@@II@II@@-@-@Endpoint is assessed at 19 months.@-@@@@MONO@AFATINIB@@@@@AFATINIB||||@BOEHRINGER INGELHEIM@@@@@BOEHRINGER INGELHEIM||||@@@@@@|||||||||@Breast Cancer@HER2-@@@@Breast Cancer|HER2-||||||||@BIBW-2992@TOVOK@@@@BIBW-2992|TOVOK|||@TK Inhibitor@EGFR@HER2@@@TK Inhibitor|EGFR|HER2||@COMPLETE RESPONSE@PARTIAL RESPONSE@RECIST@@@RECIST@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14922420@Onco@@@@@300f1015ntsdm@@@@@@@@@@@DEERFIELD, ILLINOIS@@@Calcium folinate is the calcium salt of 5-formyl tetrahydrofolic acid. It is an active metabolite of folinic acid and an essential coenzyme for nucleic acid synthesis in cytotoxic therapy. Calcium folinate is frequently used to diminish the toxicity and counteract the action of folate antagonists, such as methotrexate. Calcium folinate and folate antagonists share the same membrane transport carrier and compete for transport into cells, stimulating folate antagonist efflux. It also protects cells from the effects of folate antagonist by repletion of the reduce folate pool. Calcium folinate serves as a pre-reduced source of H4 folate; it can therefore bypass folate antagonist blockage and provide a source for the various coenzyme forms of folic acid.@@14922420@Calcium folinate is indicated to diminish the toxicity and counteract the action of folic acid antagonists such as methotrexate in cytotoxic therapy and overdose in adults and children. In cytotoxic therapy, this procedure is commonly known as “Calcium Folinate Rescue”; also, in combination with 5-fluorouracil in cytotoxic therapy.@@NO@@@NO REVIEW@@@@@@@@@@@@@@@@@@No@@@@@@APPROVED@@@@RESULTS PENDING@@@@@@LEUCOVORIN CALCIUM@@@@@LEUCOVORIN CALCIUM||||@BAXTER HEALTHCARE@@@@@BAXTER HEALTHCARE||||@@@@@@|||||||||@Sarcoma@Supportive Care@Colorectal Cancer@@@Sarcoma|Supportive Care|Colorectal Cancer|||||||@PERFOLATE@@@@@PERFOLATE||||@Detoxifying Agent@@@@@Detoxifying Agent||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@3.40E+23@@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14918948@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@OXFORD, UNITED KINGDOM@@@@@14918948@Stage II-IV with no evidence of disease@@-@-@@NO REVIEW@@@@-@Commercial partners sought to co-develop and market the drug. Acquired through takeover of Oxxon in March 2007@-@-@N/A@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@-@Melanoma-specific CD8T-cell immune response seen in 50% of patients; drug was well-tolerated. SOURCE: Oxford BioMedica@-@@@@MONO@-@@@@@-||||@OXFORD BIOMEDICA@@@@@OXFORD BIOMEDICA||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@HI-8 MEL@@@@@HI-8 MEL||||@Vaccine@@@@@Vaccine||||@IMMUNE RESPONSE@@@@@@@@@@METASTATIC@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916037@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Oral daily escalating dose@@-@-@-@-@1/1/2007@@@@14916037@Adults with solid tumours@@-@-@@NO REVIEW@@@@-@Helsinn licensed XL-119 in June 2005@-@NCT00090025@600@-@ORPHAN DRUG IN U.S. AND EU.@@@ORPHAN DRUG IN U.S. AND EU.@@9/1/2004@-@XL119-001@@-@-@@@III@CLINICAL HOLD@@-@-@RESULTS PENDING@-@@@@MONO@BECATECARIN / REBECCAMYCIN@@@@@BECATECARIN / REBECCAMYCIN||||@HELSINN@EXELIXIS@@@@HELSINN|EXELIXIS|||@@@@@@|||||||||@Liver Cancer@@@@@Liver Cancer|||||||||@XL-119@@@@@XL-119||||@Plant Alkaloid@Topoisomerase II Inhibitor@@@@Plant Alkaloid|Topoisomerase II Inhibitor|||@OVERALL SURVIVAL@@@@@@@@@@ADVANCED@@@@@RANDOMISED@SINGLE-BLIND@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918765@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Single agent at doses of 500-600mg/m2 weekly for 3-week cycles@@-@-@-@DURHAM, NORTH CAROLINA@@@@@14918765@Hepatocellular carcinoma and renal cancer@@-@-@@NO REVIEW@@@@-@-@-@-@40@-@-@@@-@@@-@NA@@-@-@@@IIA@II@@-@-@ASCO June 2007;  ADH-1 was well-tolerated and prolonged stable disease@-@@@@MONO@-@@@@@-||||@ADHEREX TECHNOLOGIES@@@@@ADHEREX TECHNOLOGIES||||@@@@@@|||||||||@Liver Cancer@Kidney Cancer@@@@Liver Cancer|Kidney Cancer||||||||@EXHERIN@ADH-1@@@@EXHERIN|ADH-1|||@Vascular Disrupting Agent@@@@@Vascular Disrupting Agent||||@SAFETY@MAXIMUM TOLERATED DOSE@@@@@@@@@-@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922976@Onco@@@@@@@@@@@-@@-@-@-@-@@@Ondansetron thin film formulation is a new oral formulation for the prevention of chemotherapyinduced nausea and vomiting, prevention of nausea and vomiting associated with radiotherapy, and post-operative nausea and vomiting. APR/Labtec's proprietary RapidFilm technology is a novel, non- mucoadhesive, fast dissolving oral dosage form. It features a thin film based on a water-soluble polymer. The film disintegrates rapidly within seconds in contact with water or saliva, releases the drug in the mouth and promotes gastrointestinal absorption. The RapidFilm dosage form was especially designed for high patient compliance. The application is easy. The patient does not have any swallowing difficulty. The fact that no water intake after administration is needed is very well accepted by patients with nausea. SOURCE: APR, 4 August 2008@@14922976@-@@-@-@@NO REVIEW@@@-@-@Labtec and APR Applied Pharma Research entered into an exclusive licensing agreement with BioAlliance under which BioAlliance has acquired the commercialization rights in Europe to the thin film formulation of ondansetron from APR/Labtec using the oral thin film technology named RapidFilm.@-@-@-@-@BioAlliance is preparing restration in Europe. SOURCE: APR, 4 August 2008@8/4/2008@@-@@@-@-@@-@-@@@-@I@@-@-@RESULTS PENDING@-@@@@MONO@ONDANSETRON HYDROCHLORIDE@@@@@ONDANSETRON HYDROCHLORIDE||||@BIOALLIANCE PHARMA@@@@@BIOALLIANCE PHARMA||||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@-@@@@@-||||@5-HT3 Receptor Antagonist@@@@@5-HT3 Receptor Antagonist||||@BIOEQUIVALENCE@@@@@@@@@@-@@@@@PIVOTAL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@THIN FILM@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922991@Onco@@@@@@@@@@@Docetaxel in combinatin with oxaliplatin with or without 5-FU or Capecitabine@@L01XA03@L01X@-@PARIS, FRANCE@@@Eloxatin is an antineoplastic agent which is an organoplatinum complex in which the platinum atom is complexed with 1,2-DACH and with an oxalate ligand as a leaving group. It undergoes non-enzymatic conversion in physiologic solutions to active derivatives via displacement of the labil oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.@@14922991@Oxaliplatin in combination with 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease @@-@-@@NO REVIEW@@@Started in September 2006@-@sanofi-aventis licensed U.S. and European rights from Debiopharm.@-@NCT00382720@270@-@-@@@-@@@-@-@@-@270 patients aged 18 and above@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@OXALIPLATIN@DOCETAXEL@@@@OXALIPLATIN|DOCETAXEL|||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Stomach Cancer@@@@@Stomach Cancer|||||||||@ELOXATIN@TAXOTERE@@@@ELOXATIN|TAXOTERE|||@Platinum@@@@@Platinum||||@TIME TO PROGRESSION@@@@@@@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@
14924744@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@1mg/day TASQ versus placebo@@-@-@-@LUND, SWEDEN@@@@@14924744@Metastatic, castrate-resistant, hormone-refractory prostate cancer@@-@-@@NO REVIEW@@@@-@-@-@-@200@-@-@@@-@@8/1/2007@-@-@@-@-@@@III@III@@-@-@Phase III started November 2007. Efficacy data expected in 2009.@-@@@@MONO@-@@@@@-||||@ACTIVE BIOTECH@@@@@ACTIVE BIOTECH||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@TASQ@ABR-215050@@@@TASQ|ABR-215050|||@Other@@@@@Other||||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@METASTATIC@@@@@RANDOMISED@PLACEBO-CONTROLLED@DOUBLE-BLIND@MULTI-CENTRE@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924098@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Ferumoxytol with or without ESA treatment@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@11/1/2006@@@@14924098@Chemotherapy-induced anaemia with or without concurrent ESA treatment`@@-@-@@NO REVIEW@@@@-@-@-@NCT00255437@303@-@-@@@-@@6/1/2004@-@-@@-@303  WITH CKD.@@@III@FILED@@-@-@Trial to start mid-2008.@-@@@@MONO@FERUMOXYTOL@@@@@FERUMOXYTOL||||@AMAG PHARMACEUTICALS@@@@@AMAG PHARMACEUTICALS||||@@@@@@|||||||||@Supportive Care@Anaemia@@@@Supportive Care|Anaemia||||||||@-@@@@@-||||@Imaging@Iron Therapy@@@@Imaging|Iron Therapy|||@HAEMOGLOBIN@@@@@@@@@@-@@@@@OPEN-LABEL@RANDOMISED@CONTROLLED@MULTI-CENTRE@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@510@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16078283@Onco@@@@@@@@@@@@@@@@CAMBRIDGE, MASSACHUSETTS@@@@@16078283@@Both@@@@@Brigatinib will be administered orally to eligible patients with locally advanced or metastatic ALK+ NSCLC who are resistant or intolerant to a prior ALK inhibitor at a dose of 180 mg QD with a 7 day lead-in at 90 mg QD, continuously, with or without food.@@@@@@NCT02784158@@@@@@@@@@AP26113-16-901@@@Have histologically or cytologically confirmed locally advanced or metastatic NSCLC that is determined to have an ALK-rearrangement detected according to local standard procedure.  - Resistant to or intolerant of at least 1 prior ALK TKI.  - Recovered from toxicities related to prior anticancer therapy to NCI CTCAE, v4.0) grade ≤2.  - Are a male or female patient ≥18 years old. - Have adequate organ and hematologic function, as defined by the study protocol. - Have Eastern Cooperative Oncology Group (ECOG) performance status ≤2.  - Have normal QT interval on screening electrocardiogram (ECG) evaluation, defined as QT interval corrected (Fridericia) (QTcF) of ≤450 ms in males or ≤470 ms in females.  - For female patients of childbearing potential, a negative pregnancy test must be documented prior to enrollment (<7 days prior to the first dose).  - Female and male patients who are fertile must agree to use a highly effective form of contraception as defined by the study protocol.  -  Must provide a signed and dated informed consent indicating that the patient has been informed of all pertinent aspects of the study, including the potential risks, and is willingly participating.@@Adult@N/A@-@@@@@@@@@@BRIGATINIB@@@@@BRIGATINIB||||@ARIAD PHARMACEUTICALS@@@@@ARIAD PHARMACEUTICALS||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@ALUNBRIG@@@@@ALUNBRIG||||@Other@@@@@Other||||@@@@@@@@@@@ADVANCED@@@@@N/A@@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916729@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Patients are stratified according to disease stage (IIIA vs IIIB or IV), response to prior treatment with front-line chemotherapy (stable disease vs partial response or complete response), prior treatment with front-line chemotherapy and radiotherapy (front-line chemotherapy with radiotherapy vs front-line chemotherapy alone), and prior treatment with front-line chemotherapy and other anticancer therapy (front-line chemotherapy with bevacizumab vs front-line chemotherapy alone or in combination with another anticancer agent). Patients are randomized to 1 of 2 treatment arms.Arm I: Patients receive belagenpumatucel-L (Lucanix™) intradermally (ID) once monthly for 18 months and then once at 21 and 24 months in the absence of disease progression or unacceptable toxicity. Arm II: Patients receive placebo ID once monthly for 18 months and then once at 21 and 24 months in the absence of disease progression or unacceptable toxicity. SOURCE: clinicaltrials.gov@@-@-@-@-@2/1/2010@@@@14916729@Stage III or IV NSCLC@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00641966@700@-@-@@@-@@3/1/2008@-@P07298@@-@-@@@III@III@@-@-@RESULTS PENDING@-@@@@MONO@BELEGENPUMATUCEL-L@@@@@BELEGENPUMATUCEL-L||||@NOVARX@@@@@NOVARX||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@LUCANIX@@@@@LUCANIX||||@Vaccine@@@@@Vaccine||||@OVERALL SURVIVAL@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916617@Onco@@@@@@@@@@@Treatment will be administered on an inpatient basis. An initial cohort of 3 patients will receive a tracer dose of 188Re-PTI-6D2 without any preceding unlabeled antibody. The tracer dose will consist of 10 mCi of rhenium-labeled antibody; the amount of antibody (in mg) will depend on specific activity and is estimated to range from 2 to 10 mg. Additional cohorts of three patients each will receive 10 mg, 20 mg, and 50 mg of unlabeled PTI-6D2 immediately preceding administration of the tracer dose. Patients will undergo serial gamma scans and SPECT/CT imaging at specified time points. Blood samples will be obtained prior to dosing and at specified intervals for PK measurements of the mAb as well as for measurement of serum radioactivity. Urine will also be collected for all patients to measure excreted radioactivity. Patients will be closely monitored for safety throughout the duration of the study.@@-@-@-@-@@@@@14916617@-@@YES@-@@NO REVIEW@@@@-@-@-@NCT00399113@12@-@-@@@-@@@-@PTI-6D2-A@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@PAIN THERAPEUTICS@@@@@PAIN THERAPEUTICS||||@Israel@@@@@Israel|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@188RE-PTI-6D2@@@@@188RE-PTI-6D2||||@mAb@@@@@mAb||||@MAXIMUM TOLERATED DOSE@PHARMACOKINETICS@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14918995@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@PD-332991 was administered daily for 21 days in 28-day cycles (schedule 3/1) to patients at doses ranging from 25 mg to 150 mg qd. Another schedule was 14 days dosing in 21-day cycles (schedule 2/1) was tested at doses ranging from 100 to 225 mg qd. SOURCE: Pfizer@@-@-@-@NEW YORK, NEW YORK@@@@@14918995@-@@-@-@@NO REVIEW@@@@-@-@-@-@57@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@-@The recommended phase II dose was identified as 125 mg qd for schedule 3/1 and 200 mg qd for schedule 2/1. Results from 57 patients with solid tumors showed that stable disease was observed in 6 patients on schedule 3/1 and one patient on schedule 2/1. The most common adverse events were neutropaenia, anemia, fatigue, nausea, constipation, vomiting and diarrhoea. SOURCE: Pfizer/ASCO, 5 June 2007@-@@@@MONO@-@@@@@-||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@PD-332991@@@@@PD-332991||||@Other@@@@@Other||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@-@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921596@Onco@@@@@300f1010ntsdm@@@@@@Recentin alone@@-@-@-@LONDON, UNITED KINGDOM@@@Cediranib (Recentin AZD2171) is a highly potent inhibitor of the tyrosine kinase activity associated with all three vascular endothelial growth factor (VEGF) receptors and is currently in Phase II/III clinical trials. Preclinically, cediranib inhibits VEGF signaling and angiogenesis in vivo and impedes solid tumor growth significantly. @@14921596@Patients who failed or are intolerant to imatinib@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00385203@25@-@-@@@-@@9/1/2006@-@D8480C00046  @@-@-@@@II@II@@-@-@RESULTS PENDING (recruiting)@-@@@@MONO@CEDIRANIB@@@@@CEDIRANIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Sarcoma@GIST@@@@Sarcoma|GIST||||||||@RECENTIN@AZD-2171@@@@RECENTIN|AZD-2171|||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@FDG-PET@@@@@@@@@@METASTATIC@RELAPSED@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@GB£@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14922688@Onco@@@@@300f1008ntsdm@@@@@@Gemzar/cisplatin versus Gemzar alone@@L01BC05@L01B@-@INDIANAPOLIS, INDIANA@@@Gemcitabine exhibits significant cytotoxicity activity against a variety of cultured murine and human tumour cells. It exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and under certain conditions blocking the progression of cells through the G1/S-phase boundary. In vitro the cytotoxic action of gemcitabine is both concentration and time dependent.@@14922688@Biliary tract cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00380588@84@-@-@@@-@@@-@10298B9E-JE-BT22  @@-@-@@@II@II@@-@@Completion expected October 2008.@-@@@@BOTH@GEMCITABINE HYDROCHLORIDE@@@@@GEMCITABINE HYDROCHLORIDE||||@LILLY@@@@@LILLY||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@GEMZAR@@@@@GEMZAR||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@OVERALL SURVIVAL@@@@@@@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@YEN@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14918892@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@ABT-751 200MG oral qd for 21 days followed by a 7 day break@@-@-@-@UNITED STATES@@@An orally bioavailable antimitotic sulfonamide. ABT-751 binds to the colchicine-binding site on beta-tubulin and inhibits the polymerization of microtubules, thereby preventing tumor cell replication. This agent also disrupts tumor neovascularization, reducing tumor blood flow and so inducing a cytotoxic effect@@14918892@Taxane-refractory@@-@-@@NO REVIEW@@@@-@-@-@-@35@-@-@@@-@@@-@N/A@@-@-@@@II@II@@-@-@ASCO 2005; ABT-751 was well-tolerated with no grade 3 or 4 alopecia, neutropaenia or significant neuropathies. Median PFS was 9.6 weeks and OS was 36.3 weeks. There was one confirmed PR.@-@@@@MONO@-@@@@@-||||@ABBOTT@@@@@ABBOTT||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@ABT-751@@@@@ABT-751||||@Plant Alkaloid@Vascular Disrupting Agent@@@@Plant Alkaloid|Vascular Disrupting Agent|||@RESPONSE RATE@TIME TO PROGRESSION@@@@@@@@@ADVANCED@REFRACTORY@@@@MULTI-CENTRE@OPEN-LABEL@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924830@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@NEW HAVEN, CONNECTICUT@@@Cloretazine (VNP40101M) is a small molecule that works by damaging DNA. Cloretazine releases the DNA chloroethylating agent 90CE after entering the blood stream. 90CE chloroethylates the O6 position of guanine residues, ultimately resulting in an interstrand DNA cross-link. Interstrand DNA cross-links are difficult to repair and are toxic to cells. Cloretazine demonstrated a broad spectrum of anticancer activity in preclinical studies, including activity in selected cell lines resistant to other alkylating agents such as BCNU, cyclophosphamide and melphalan. In preclinical studies, Cloretazine has been combined with other anticancer agents such as cytarabine (Ara-C). In addition, Cloretazine or its metabolite, has been shown to be capable of crossing the blood brain barrier in preclinical models.@@14924830@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@7/1/2005@-@-@@-@-@@@III@III@@-@-@RESULTS PENDING@-@@@@COMBO@CLORETAZINE@@@@@CLORETAZINE||||@VION PHARMACEUTICALS@@@@@VION PHARMACEUTICALS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@VNP-40101M@@@@@VNP-40101M||||@Alkylating Agent@@@@@Alkylating Agent||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919283@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@ABT-510 given to subjects with refractory lymphoma.@@-@-@-@UNITED STATES@@@A synthetic peptide that mimics the anti-angiogenic activity of the endogenous protein thrombospondin-1 (TSP-1). ABT-510 inhibits the actions of several pro-angiogenic growth factors important to tumor neovascularization; these pro-angiogenic growth factors include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF)), hepatocyte growth factor (HGF), and interleukin 8 (IL-8). @@14919283@Patients with refractory lymphoma@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00061672@67@-@-@@@-@@4/1/2003@-@M02-457@@-@-@@@II@II@@-@-@Trial registered [Abbott, 2.06.2003]@-@@@@MONO@THROMBOSPONDIN@@@@@THROMBOSPONDIN||||@ABBOTT@@@@@ABBOTT||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@Hodgkin's Lymphoma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|Hodgkin's Lymphoma|||||||@ABT-510@@@@@ABT-510||||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@RESPONSE RATE@@@@@@@@@@REFRACTORY@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916802@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@NOV-002 60MG/mL/day for 20-23 days plus carboplatin@@-@-@-@-@5/1/2008@@@@14916802@Platinum-resistant ovarian cancer@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00345540@25@-@Approved in Russia.@@@-@@6/1/2006@-@NOV002- IS21 -OC@@-@-@@@II@II@@-@-@Over half of the 15 patients have experienced slowed disease progression. SOURCE: Novelos/ASCO, 2 June 2008Fifteen patients have now been enrolled and, to date, 60% (9) have had slower than expected disease progression. NOV-002 was well-tolerated, further extending the excellent safety profile NOV-002 has demonstrated in previous studies. Detailed results of this trial will be presented at ASCO 2008. SOURCE: Novelos, 31 March 2008June 2007 interim data; 1 partial response and 5 stable disease from 10 evaluable patients.@-@@@@COMBO@-@@@@@-||||@NOVELOS THERAPEUTICS@@@@@NOVELOS THERAPEUTICS||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@NOV-002@GLUTOXIM@@@@NOV-002|GLUTOXIM|||@Interleukin@Immunotherapy@@@@Interleukin|Immunotherapy|||@RESPONSE RATE@SAFETY@@@@@@@@@REFRACTORY@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924743@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@15 patients enrolled in a 14-day IV infusion schedule and 14 in a weekly IV infusion schedule@@-@-@-@-@@@Deoxycytidine analogue@@14924743@Advanced or metastatic solid tumours@@-@-@@NO REVIEW@@@@-@-@-@-@29@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@Recommended dosage was 2mg/m2 per day on the 14-day schedule and 3mg/m2 on the weekly schedule. 5 patients had stable disease for 12 weeks (4 with colorectal cancer, 1 with NSCLC). Phase II trial to start in H2 2008. SOURCE: Taiho/ASCO, 2 June 2008@Dose-limiting toxicity was febrile neutropaenia in 2 patients and thrombocytopaenia in one patient. @@@@MONO@-@@@@@-||||@TAIHO@@@@@TAIHO||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@TAS-109@@@@@TAS-109||||@Other@@@@@Other||||@MAXIMUM TOLERATED DOSE@DOSE-LIMITING TOXICITY@@@@SAFETY@@@@@ADVANCED@METASTATIC@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916094@Onco@@@@@300f1012ntsdm@@@@@@-@@-@-@-@-@12/1/2009@@The target of U3-1287 is a membrane-bound receptor tyrosine kinase (RTK) that controls a specific signal transduction pathway and has shown involvement in multiple cancer types of epithelial origin, including breast, lung and colorectal cancers, among others. Partnered with Abgenix, now Amgen, U3 Pharma is advancing fully human therapeutic antibodies against this target. @@14916094@-@@-@-@@NO REVIEW@@@@-@Daiichi Sankyo acquires U3 for US$235 million. SOURCE: Daiichi Sankyo, 21 May 2008@-@NCT00730470@60@-@-@@@-@@8/1/2008@-@U3P1287/01@@-@Pathologically or cytologically documented advanced solid tumor that is refractory to standard treatment, for which no standard therapy is available, or the patient refuses standard therapy. @@@I@I@@-@-@>> Trial registered. [U3, 07.08.2008] >> Due to enter Phase I in 2008. [U3, 19 February 2008]@-@@@@-@-@@@@@-||||@U3 PHARMA@DAIICHI SANKYO@@@@U3 PHARMA|DAIICHI SANKYO|||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@U3-1287@@@@@U3-1287||||@TK Inhibitor@@@@@TK Inhibitor||||@SAFETY@MAXIMUM TOLERATED DOSE@@@@PHARMACOKINETICS@PHARMACODYNAMICS@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14923485@Onco@@@@@300f1012ntsdm@@@@@@In the standard arm, patients were administered gemcitabine plus erlotinib, whereas an experimental arm patients received capecitabine plus erlotinib.Patients who fail on first-line therapy are switched to the comparator chemotherapy without erlotinib.@@L01BC06 @L01B@-@BASEL, SWITZERLAND@@@Xeloda is a fluoropyrimidine carbamate with antineoplastic activity. It is an orally administered prodrug of 5'dexoxy-5-fluorouridine which is converted to 5-FU.@@14923485@-@@-@6-Dec@@NO REVIEW@@@@-@-@-@NCT00440167@-@-@-@@@-@@6/1/2006@-@-@@-@-@@@III@III@@-@-@Not yet available.@-@@@@COMBO@CAPECITABINE@@@@@CAPECITABINE||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@XELODA@@@@@XELODA||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@-@@@@@@@@@@ADVANCED@METASTATIC@@@@RANDOMISED@UNCONTROLLED@CROSSOVER@OPEN-LABEL@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14924156@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@FRAZER, PENNSYLVANIA@@@@@14924156@-@@-@-@@NO REVIEW@@@@-@Acusphere signed an agreement to license the intellectual property rights to its Hydrophobic Drug Delivery System (HDDS) for oncology applications, along with the rights to AI-850, its formulation of paclitaxel, to Cephalon, in exchange for a cash payment@-@-@-@-@Approved in Russia.@@@-@@@-@-@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@-@PACLITAXEL, HDDS@@@@@PACLITAXEL, HDDS||||@CEPHALON@ACUSPHERE@@@@CEPHALON|ACUSPHERE|||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@AI-850@@@@@AI-850||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918917@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@PARIS, FRANCE@@@@@14918917@-@@-@-@@NO REVIEW@@@@-@Licensing agreement with Roche terminated in May 2005@-@-@N/A@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@-@ELOMOTECAN@@@@@ELOMOTECAN||||@IPSEN@@@@@IPSEN||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@BN-80927@@@@@BN-80927||||@Plant Alkaloid@Topoisomerase I Inhibitor@Topoisomerase II Inhibitor@Camptothecin@@Plant Alkaloid|Topoisomerase I Inhibitor|Topoisomerase II Inhibitor|Camptothecin|@N/A@@@@@@@@@@-@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919590@Onco@@@@@300f1015ntsdm@@@@@@@@N02AB03@N02A@@BEERSE, BELGIUM@@@Fentanyl is a synthetic opiate with a clinical potency of 50 to 100 times that of morphine. Its onset of action is rapid and its duration of action is short. In man, a single iv dose of 0.5-1 mg/70 kg body weight immediately produces a pronounced state of surgical analgesia, respiratory depression, bradycardia and other typical morphine-like effects. The duration of action of the peak effects is about 30 minutes. All potent morphine-like drugs produce relief from pain, ventilatory depression, emesis, constipation, physical dependence, certain vagal effects and varying degrees of sedation. Fentanyl, however, differs from morphine not only by its short duration of action but also by its lack of emetic effect and minimal hypotensive activity in animals.@@14919590@Management of breakthrough cancer pain in patients with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain@@NO@@@NO REVIEW@@@@@@@@@@October 2006 (renewal)@@@@@@@@No@@@@@@APPROVED@@FREE PRICE IN HOSPITAL@HAUTE AUTORITÉ DE SANTÉ@RESULTS PENDING@@@@@@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@JANSSEN CILAG@@@@@JANSSEN CILAG||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@GENERIC@@@@@GENERIC||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14921653@Onco@@@@@@@@@@@N/A@@L01XE01@L01X@-@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@14921653@Long-term prognosis of imatinib in newly diagnoised chronic phase CML; previously untreated@@NO@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00237120@100@-@-@@@-@@11/1/2002@-@CSTI571AJP02@@NOVEMBER 2008 (PAEDIATRIC); OCTOBER 2013 (PAEDIATRIC)@-@@@III@III@@-@-@Endpoint voer 3 years.@-@@@@MONO@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@GLEEVEC@GLIVEC@@@@GLEEVEC|GLIVEC|||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@OVERALL SURVIVAL@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TABLET@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
15874579@Onco@@@@@@@@@@@Dinutuximab administered for 5 cyclesHigh-risk neuroblastoma patient treated with Unituxin as standard of care@@L01XC16@L01X@@@3/1/2018@@@@15874579@A Post-Marketing Study to Further Assess the Immunogenicity and Safety of Unituxin™ in High-Risk Neuroblastoma Patients@Both@@@@@Unituxin will be administered along with cytokines according to the prescribing information (see FDA-approved Unituxin Package Insert, March 2015; SmPC, August 2015).@@@@@@NCT02693171@100@@@@@@@3/1/2016@@DIV-NB-401@@@Patient has been diagnosed with high-risk neuroblastoma/Patient has been prescribed Unituxin and plans to start Unituxin therapy within 30 days of study entry/Patient must start Unituxin therapy no later than 200 days after Autologous Stem Cell Transplantation (ASCT).  -  Written informed consent / assent must be obtained in accordance with institutional and ICH guidelines.@@PAEDIATRIC@Phase 4@IV@@@@@@@@@@DINUTUXIMAB@@@@@DINUTUXIMAB||||@UNITED THERAPEUTICS@@@@@UNITED THERAPEUTICS||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@UNITUXIN@@@@@UNITUXIN||||@mAb@@@@@mAb||||@Incidence of human anti-chimeric antibody (HACA) in high-risk neuroblastoma patients treated with Unituxin combination therapy.@@@@@Incidence of neutralizing antibody (NAb) in patients with human anti-chimeric antibody (HACA) positive samples.@@@@@@@@@@Cohort@PROSPECTIVE@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921662@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Single-agent RAF-265@@-@-@-@BASEL, SWITZERLAND@@@@@14921662@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00304525@198@-@-@@@-@@@-@CRAF265A2101@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@RAF-265@@@@@RAF-265||||@TK Inhibitor@FGF@VEGF@@@TK Inhibitor|FGF|VEGF||@MAXIMUM TOLERATED DOSE@DOSE-LIMITING TOXICITY@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@OPEN-LABEL@DOSE ESCALATION@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919291@Onco@@@@@300f1018ntsdm@@@@@@ARM1 (100 µg of NY-ESO-1 protein formulated with 120 µg of Iscomatrix adjuvant) Each patient will receive four intramuscular injections of either NY-ESO-1 Iscomatrix vaccine or Iscomatrix adjuvant alone. The first three doses will be given at four-week intervals, days 1, 29, and 57, (± 3 days of scheduled date). The fourth injection will be given at month 6 (day 183 ± 3 days). ARM2 (120 µg of NY-ESO-1 protein formulated with 120 µg of Iscomatrix adjuvant); Each patient will receive four intramuscular injections of either NY-ESO-1 Iscomatrxi vaccine or Iscomatrix adjuvant alone. The first three doses will be given at four-week intervals, days 1, 29, and 57, (± 3 days of scheduled date). The fourth injection will be given at month 6 (day 183 ± 3 days).@@-@-@-@VICTORIA, AUSTRALIA@7/1/2008@@@@14919291@High-risk, resected melanoma@@-@-@@NO REVIEW@@@@-@-@-@-@110@-@-@@@-@@9/1/2005@-@LUD2003-009@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@CSL@@@@@CSL||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@ISCOMATRIX ADJUVANT@@@@@ISCOMATRIX ADJUVANT||||@Immunotherapy@@@@@Immunotherapy||||@-@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14921639@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Topical cream 3% application in the evening and morning@@-@-@-@NORTH ZEALAND, DENMARK@8/1/2008@@@@14921639@In Situ cutaneous squamous cell carcinoma (SCCIS)@@-@-@@NO REVIEW@@@@-@-@-@NCT00652080@30@-@-@@@-@@4/1/2008@-@CTL0408@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@CYTOTECH LABS@@@@@CYTOTECH LABS||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@API-31510@@@@@API-31510||||@Other@@@@@Other||||@SAFETY@@@@@@@@@@-@@@@@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TOPICAL CREAM@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922531@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Diflomotecan (7mg) as 20-minute IV once every 3 weeks@@-@-@-@PARIS, FRANCE@@@@@14922531@Sensitive SCLC@@-@-@@NO REVIEW@@@@-@Licensing agreement with Roche terminated in May 2005@SECOND-LINE@NCT00080015@40@-@-@@@-@@@-@2-91-52990-708  @@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@DIFLOMOTECAN@@@@@DIFLOMOTECAN||||@IPSEN@@@@@IPSEN||||@@@@@@|||||||||@SCLC@@@@@SCLC|||||||||@BN-80915@@@@@BN-80915||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924198@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@WOBURN, MASSACHUSSETTS@@@ARQ 621 is a selective inhibitor of the Eg5 kinesin motor protein. ARQ 621 has been shown pre-clinically to potently and selectively inhibit Eg5 and to induce cell death across multiple human cancer cell lines in vitro and in vivo, while being non-toxic to bone marrow cells in animal models. @@14924198@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@FDA accepts IND for ARQ-621. ArQule plans to commence Phase I trial in 2009. [ArQule, 19.12.2008]@-@@@@-@-@@@@@-||||@ARQULE@@@@@ARQULE||||@@@@@@|||||||||@Solid Tumours@Haematological Malignancy@@@@Solid Tumours|Haematological Malignancy||||||||@ARQ-621@@@@@ARQ-621||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRAVENOUS@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16398917@Onco@@@@@300f1008ntsdm@@@@@@@@L01AA09@L01A@@@@@@@16398917@@@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@@@11@@@@12/1/2010@@@@@@No@@@@@@APPROVED@@@NHI@@@@@@MONO@BENDAMUSTINE@@@@@BENDAMUSTINE||||@SYMBIO PHARMACEUTICALS@@@@@SYMBIO PHARMACEUTICALS||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@Mantle Cell Lymphoma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma|||||||@TREAKISYM@@@@@TREAKISYM||||@Alkylating Agent@Nitrogen Mustard Analogue@@@@Alkylating Agent|Nitrogen Mustard Analogue|||@@@@@@@@@@@@@@@@@@@@@1.75@m²@2030005.152@@@126@day@126 day@2030005.15@2030005.15@16111.15@1@0.0091@80555.76@94995@@@@@@@@@@@805.56@21@@mg/m²@120@2@@@@@@@@@@@8/30/2017@80555.76@80555.76@4219405D1021@INJECTION@YEN@@@@@@@@100@MG@100 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14920970@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@TP-38 alone@@-@-@-@PETACH TIKVA, ISRAEL@@@@@14920970@-@@-@-@@NO REVIEW@@@@-@Via Sicor unit@SECOND-LINE@NCT00104091@56@-@-@@@-@@12/1/2004@-@IXR-202-22-188@@-@-@@@II@II@@-@-@RESULTS PENDING (recruiting)@-@@@@MONO@TALAMPANEL@@@@@TALAMPANEL||||@TEVA PHARMACEUTICAL@@@@@TEVA PHARMACEUTICAL||||@@@@@@|||||||||@Brain Cancer@Glioblastoma Multiforme@@@@Brain Cancer|Glioblastoma Multiforme||||||||@CERVENE@TP-38@@@@CERVENE|TP-38|||@mAb@Chimeric@@@@mAb|Chimeric|||@RESPONSE RATE@SAFETY@@@@@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16406114@Onco@@@@@300f1012ntsdm@@@@@@@@L01XE16@L01X@@NEW YORK, NEW YORK@@@@@16406114@XALKORI is indicated for the treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC).@@NA@16-Mar-17@3/16/2017@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Acquired through takeover of Pharmacia Corp., which acquired it from Sugen@@@53@The recommended dose schedule of XALKORI is 250 mg twice daily (500 mg daily) takencontinuously.@EMA, 25 August 2016@8/25/2016@11/15/2012@No@@@@Study 1001@No@@@ROS1-positive@@@APPROVED@@No additional benefit [16 March 2017, G-BA, https://www.g-ba.de/downloads/39-261-2879/2017-03-16_AM-RL-XII_Crizotinib_D-261.pdf]@GKV@@@@@@MONO@CRIZOTINIB@@@@@CRIZOTINIB||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@XALKORI@@@@@XALKORI||||@PDGF@@@@@PDGF||||@OBJECTIVE RESPONSE RATE@DURATION OF RESPONSE@@@@@@@@@ADVANCED@@@@@MULTICENTER@SINGLE-ARM@@@@1@1@96272.96682@@@19.3@month@19.3 month@96272.97@96272.97@164@60@1.1511@3936.01@4881.68@3974.51@@@@@@@@@@0.33@1@@mg@500@1@@@@@@@@@@@8/1/2017@65.6@65.6@9884704@HARD CAPSULE@EURO@@@@@@@@200@MG@200 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14918964@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Starting dose of 650MG/M2 administered as weekly 1-hour IV infusions@@-@-@-@MADRID, SPAIN@@@Kahalalide F is a depsipeptide derived from the sea slug Elysia rufescens. Kahalalide F alters the function of the lysosomal membranes inducing cell death by oncosis. Antitumour-activity independent of MDR (Multi Drug Resistance) and p53 status and to correlate with basal ErbB3 expression. @@14918964@-@@-@-@@NO REVIEW@@@@-@PharmaMar is part of the Zeltia Group.@SECOND-LINE@-@31@-@-@@@-@@@-@N/A@@-@-@@@II@II@@-@-@One partial response was observed and stable disease was reported in eight patients, with the majority of the clinical benefit being seen in patients with squamous cell carcinoma. SOURCE: PharmaMar/ESMA, 29 September 2006@-@@@@MONO@-@@@@@-||||@PHARMAMAR@ZELTIA GROUP@@@@PHARMAMAR|ZELTIA GROUP|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@KAHALALIDE F@@@@@KAHALALIDE F||||@Depsipeptide@@@@@Depsipeptide||||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921629@Onco@@@@@@@@@@@1: Experimental AZD8931 plus Paclitaxel  Drug: AZD8931 Tablet Oral bid Drug: Paclitaxel IV once weekly for 3 weeks followed by a week off (repeated cycles)  2: Active Comparator Paclitaxel  Drug: Paclitaxel IV once weekly for 3 weeks followed by a week off (repeated cycles)@@-@-@-@LONDON, UNITED KINGDOM@7/1/2012@@@@14921629@A Phase I/II Multi-Centre Study of AZD8931 in Combination With Weekly Paclitaxel to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and in a Selected Population With Low HER2-Expressing Locally Recurrent and/or Metastatic Breast Cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00900627@192@-@-@@@-@@5/1/2009@-@D0102C00003@@-@Male/ female with solid, malignant tumour which is unresponsive to standard therapies (Phase I). Female patients with advanced breast cancer with low HER2 expression (Phase II) Suitable for paclitaxel chemotherapy Life expectancy more than 12 weeks@@@II@II@@-@-@Trial registered [AstraZeneca 12 May 2009]@-@@@@MONO@-@@@@@-||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Solid Tumours@Breast Cancer@@@@Solid Tumours|Breast Cancer||||||||@AZD-8931@@@@@AZD-8931||||@TK Inhibitor@@@@@TK Inhibitor||||@MAXIMUM TOLERATED DOSE@PROGRESSION-FREE SURVIVAL@@@@PHARMACOKINETICS@SAFETY@RESPONSE RATE@@@ADVANCED@METASTATIC@@@@RANDOMISED@DOUBLE-BLIND@PARALLEL ASSIGNMENT@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924539@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Up to five dose levels will be studied at up to three investigational sites. NeoPharm anticipates the enrollment of 25 to 30 patients. SOURCE: NeoPharm@@L01CD02@L01C@-@-@@@@@14924539@After failure of prior chemotherapy@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@-@25-30@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@FPI. SOURCE: NeoPharm, 21 May 2008Phase I to start in 2008. SOURCE: NeoPharm, 2 January 2008@-@@@@-@DOCETAXEL, LIPOSOMAL@@@@@DOCETAXEL, LIPOSOMAL||||@NEOPHARM@@@@@NEOPHARM||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@LE-DT@@@@@LE-DT||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@MAXIMUM TOLERATED DOSE@@@@@PHARMACOKINETICS@@@@@LOCALLY ADVANCED@METASTATIC@@@@OPEN-LABEL@DOSE ESCALATION@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRAVENOUS@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921421@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@@@NO@DALLAS, TEXAS@@@@@14921421@Management of oral mucositis@@@@@NO REVIEW@@@@@"Milestone Biosciences licenses rights for Canada for US$10 million. SOURCE: Access, 19 August 2008The company is in ""active discussions"" for licensing and manufacturing of the drug. SOURCE: Access, December 2006"@@@@N/A@FDA, December 2006@@@@@@NONE@N/A@No@@PATIENTS WITH HEAD AND NECK CANCER RECEIVING RADIATION THERAPY@@@N/A@APPROVED@@@@ISMASCC June 2006; 43% of patients had no mucositis, compared historically to 7% with patients on standard of care. Over 40% of patients had severe mucositis in the Mugard group, compared to over 85% in the historical control.@@@@@@N/A@@@@@N/A||||@ACCESS PHARMACEUTICALS@@@@@ACCESS PHARMACEUTICALS||||@@@@@@|||||||||@Supportive Care@Mucositis@@@@Supportive Care|Mucositis||||||||@MUGARD@@@@@MUGARD||||@Other@@@@@Other||||@OMAS@@@@@@@@@@@@@@@HISTORICAL CONTROL@@@@@@@Invalid Factory Price@@@@@@@@@@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@ORAL RINSE (6 units)@US$@@@@@@@@@@240 ML@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919303@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Virulizin plus Gemzar versus placebo plus Gemzar; second-line therapy can include continuation of Virulizin or placebo, alone or in combination with 5-FU@@-@-@-@TORONTO, CANADA@7/1/2005@@@@14919303@-@@-@-@@NO REVIEW@@@@-@Zor licensed exclusive multinational license agreement from Lorus for US$10 million with royalties of 10-20% depending on sales. It initially focuses on development in pancreatic cancer. SOURCE: Lorus, 8 April 2008@MULTIPLE@NCT00040092@400@-@-@@@-@@7/1/2002@-@LORVIRP03002@@-@-@@@III@III@@-@-@Full enrollment was completed in June 2004.  @-@@@@COMBO@-@GEMCITABINE@@@@-|GEMCITABINE|||@LORUS THERAPEUTICS@ZOR PHARMACEUTICALS@@@@LORUS THERAPEUTICS|ZOR PHARMACEUTICALS|||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@VIRULIZIN@GEMZAR@@@@VIRULIZIN|GEMZAR|||@Immunotherapy@@@@@Immunotherapy||||@TIME TO PROGRESSION@@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@RANDOMISED@DOUBLE-BLIND@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922611@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Arcoxia 90MG versus placebo@@-@-@-@WHITEHOUSE STATION, NEW JERSEY@@@Arcoxia is a COX-2 inhibitor.@@14922611@Cancer pain in breast or prostate cancer with a bone neoplasm@@-@-@@NO REVIEW@@@@-@-@-@NCT00095017@80@-@-@@@-@@11/1/2004@-@2004_090@@-@-@@@II@DISCONTINUED@@-@-@Endpoint over 4 weeks.@-@@@@MONO@ETORICOXIB@@@@@ETORICOXIB||||@MERCK & CO@@@@@MERCK & CO||||@@@@@@|||||||||@Supportive Care@Cancer Pain@Breast Cancer@Prostate Cancer@Bone Metastases@Supportive Care|Cancer Pain|Breast Cancer|Prostate Cancer|Bone Metastases|||||@ARCOXIA@@@@@ARCOXIA||||@Other@@@@@Other||||@PAIN RELIEF@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922637@Onco@@@@@@@@@@@Patients receive Iressa and epirubicin-cyclophosphamide@@L01XE02@L01X@-@LONDON, UNITED KINGDOM@@@The mechanism of the clinical antitumor action of gefitinib is not fully characterized. Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinasesassociated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor (EGFR-TK). EGFR isexpressed on the cell surface of many normal cells and cancer cells. No clinical studies have been performed that demonstrate a correlation between EGFRreceptor expression and response to gefitinib@@14922637@Oestrogen-receptor negative breast cancer@@-@-@@NO REVIEW@@@STARTED IN OCTOBER 2004@-@-@-@NCT00239343@160@-@-@@@-@@@-@1839IL0712  @@-@-@@@II@II@@-@-@RESULTS PENDING (recruiting)@-@@@@COMBO@GEFITINIB@@@@@GEFITINIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@IRESSA@ZD-1839@@@@IRESSA|ZD-1839|||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@RESPONSE RATE@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TABLET@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922262@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Single-agent Apomab@@-@-@-@SAN FRANCISCO, CALIFORNIA@5/1/2011@@@@14922262@Advanced chondrosarcoma@@-@-@@NO REVIEW@@@@-@">> Roche reaches a friendly agreement to purchase the latter's outstanding shares at a price of US$95 per share. The transaction will be valued at US$46.8 billion. [Genentech, 12 March 2009]>> Roche has made a formal announcement of cash tender offer for all outstanding shares of Genentech at US$86.50 per share for the 44.2% of Genentech not already held by Roche. Genentech's special committee, on the other hand, has responded to the offer by urging its shareholders ""to take no action at this time"". [Genentech, 10.02.2009]          >> Genentech rejects the acquisition bid. [Genentech, 14.08.2008]        >> Roche announces US$43.7 billion proposal to assume full control of Genentech. SOURCE: Roche, 21 July 2008"@-@NCT00543712@90@-@-@@@-@@6/1/2007@-@APM4171g@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@GENENTECH@@@@@GENENTECH||||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@APOMAB@@@@@APOMAB||||@mAb@Human@@@@mAb|Human|||@RESPONSE RATE@@@@@@@@@@ADVANCED@REFRACTORY@@@@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16078281@Onco@@@@@@@@@@@Olaratumab + Doxorubicin, Experimental, Cycle 1: Olaratumab given intravenously (IV) on day 1 and day 8 (21 day cycle).Cycle 2: Olaratumab given IV on day 1 and day 8 plus doxorubicin given IV on day 1 (21 day cycle).Cycle 3 through Cycle 7: Olaratumab given IV on day 1 and day 8 plus doxorubicin given IV on day 1 (21 day cycles).@@@@@INDIANAPOLIS, INDIANA@3/1/2019@@@@16078281@A Phase 1b Trial to Assess the Modulation of Biological Markers in Patients With Potentially Resectable Soft Tissue Sarcoma Treated With Olaratumab Monotherapy Followed by Olaratumab Plus Doxorubicin Combination Therapy@Both@@@@@Administered IV@@@@@@NCT02783599@40@@@@@@@9/1/2016@@15840@@@Have a histologically confirmed diagnosis of STS for which olaratumab and doxorubicin would be appropriate therapy. Participants with a diagnosis of Grade 1 liposarcoma are eligible if there is histological or radiographic evidence of evolution to more aggressive disease. Participants with Kaposi's sarcoma and gastrointestinal stromal tumors (GIST) will be excluded. Participants must have potentially resectable disease (as assessed by the study investigator) and have a primary tumor lesion deemed amenable to serial biopsy.  -  Have consented to undergo mandatory serial peripheral whole blood and tumor tissue sampling.@BOTH@Adult@Phase 1@I@@@@@@@@@@OLARATUMAB@DOXORUBICIN@@@@OLARATUMAB|DOXORUBICIN|||@LILLY@@@@@LILLY||||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@-@GENERIC@@@@-|GENERIC|||@Other@@@@@Other||||@Change from Baseline in Enumeration of Circulating Tumor Cells in Whole Blood@Change from Baseline in Expression of Platelet-Derived Growth Factor Receptor (PDGFR) Alpha, PDGFR Beta and Canonical Ligands in Tumor Tissue@@@@PROGRESSION FREE SURVIVAL@Objective Response Rate: Percent of Participants with Best Overall Tumor Response of Complete Response or Partial Response@@@@RESECTABLE@@@@@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14919295@Onco@@@@@@@@@@@The first group of patients will receive a dose of 300 µg of each of the MAGE-1.A2, MAGE-3.A2, MAGE-4.A2, MAGE-10.A2, MAGE-C2.A2, NA17.A2, Tyrosinase.A2 and NY-ESO-1.A2 peptides without adjuvant. The peptides will be mixed together and administered by intradermal and superficial subcutaneous injections at two sites every three weeks on 5 occasions (3 months). The second group of patients will receive on 5 occasions a vaccine containing the same 8 peptides mixed together but emulsified in 1 ml of Montanide ISA51. This vaccine will be also administered by intradermal and subcutaneous injections every three weeks. The third cohort of patients will receive at 3 weeks-interval on 5 occasions the mix of 8 peptides and 500 µg of IMP321. These two injections will be done at the same site, first adjuvant IMP321 then the peptides. The last seven patients will receive as vaccine the same mix of peptides emulsified with Montanide ISA 51 VG and IMP321 injected with the same procedure as cohort 3. These vaccines will be administrated every 3 weeks on 5 occasions by intradermal and superficial subcutaneous injections. SOURCE: clinical.trials.gov@@-@-@-@-@8/1/2009@@@@14919295@Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides@@YES@-@@NO REVIEW@@@@-@-@-@NCT00365937@28@-@-@@@-@@8/1/2006@-@LUC 05-003@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@ADJUVANT@-@@@@@-||||@IMMUTEP@@@@@IMMUTEP||||@Belgium@@@@@Belgium|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@IMP-321@@@@@IMP-321||||@Immunotherapy@@@@@Immunotherapy||||@IMMUNE RESPONSE@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921471@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Terameprocol (EM-1421) will be administered as an intravenous infusion over 24 hours, weekly. Dose will commence in the first cohort with 100 mg per hour (2400 mg in a 24 hour period)with escalation in the 5 cohorts of 3 to 6 patients with increments of 25 mg per hour to a maximum of 200 mg/hr (4800 mg/24 hour period) or until MTD is defined. When the MTD has been declared, then 11 additional subjects will be enrolled at the MTD dose level (to total 14 subjects treated in dosage cohort). SOURCE: clinicaltrials.gov@@-@-@-@-@10/1/2008@@@@14921471@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00664586@32@-@-@@@-@@5/1/2007@-@EM-1421 #104@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@TERAMEPROCOL@@@@@TERAMEPROCOL||||@ERIMOS PHARMACEUTICAL@@@@@ERIMOS PHARMACEUTICAL||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@EM-1421@@@@@EM-1421||||@Survivin Suppressant@@@@@Survivin Suppressant||||@MAXIMUM TOLERATED DOSE@DOSE-LIMITING TOXICITY@@@@@@@@@REFRACTORY@@@@@OPEN-LABEL@SINGLE-ARM@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16407033@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@@@@SAN FRANCISCO, CALIFORNIA@@@@@16407033@TECENTRIQ (atezolizumab) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who Have disease progression during or following platinum-containing chemotherapy; have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy@Both@NA@@@NO REVIEW@@@@@@@@310@1200 mg administered as an intravenous infusion over 60 minutes every 3 weeks until disease progression or unacceptable toxicity.@FDA, 18 May 2016@5/18/2016@@No@@@@@No@@@@ADULTS@@APPROVED@@@NA@@@@@@MONO@ATEZOLIZUMAB@@@@@ATEZOLIZUMAB||||@GENENTECH @ROCHE@@@@GENENTECH |ROCHE|||@@@@@@|||||||||@Bladder Cancer@@@@@Bladder Cancer|||||||||@TECENTRIQ@@@@@TECENTRIQ||||@Other@@@@@Other||||@@@@@@@@@@@METASTATIC@LOCALLY ADVANCED@@@@MULTICENTER@OPEN LABEL@TWO-COHORT@@@1@1@Invalid Average Duration of Use@@@@@@@@@1@1@8620@@@@@@@@@@@@7.18@21@@mg@1200@1@@@@@@@@@@@8/2/2017@8620@8620@50242-0917-01@SOLUTION FOR INJECTION - 20 ML@US$@@@@@@@@1200@MG@60 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924849@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@PETACH TIKVA, ISRAEL@@@Paclitaxel is an antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilises microtubules by preventing depolymerisation. This stability inhibits the normal dynamic reorganisation of the microtubule network, which is essential for vital interphase and mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or bundles of microtubules throughout the cell cycle and multiple astersof microtubules during mitosis.@@14924849@-@@-@-@@NO REVIEW@@@@-@Acquired from the takeover of Ivax in February 2006@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@-@-@@@@-@PACLITAXEL@@@@@PACLITAXEL||||@TEVA PHARMACEUTICAL@@@@@TEVA PHARMACEUTICAL||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@XORANE@@@@@XORANE||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924960@Onco@@@@@@@@@@@ABR-217620 10.3, 16.5 or 22 mcg/kg, IV, daily 5 minute bolus injection for 4 consecutive day per cycle; up to 6 cycles with docetaxel 75mg/m^2, IV, single 60 minute infusion, beginning on Day 5 then every third week @@-@-@-@LUND, SWEDEN@12/1/2006@@Naptumomab estafenatox is a monoclonal antibody and which it is used to treat cancers. It has a chelator, estafenatox. It binds to 5T4 Fab.@@14924960@Advanced NSCLC; combo with Taxotere@@-@-@@NO REVIEW@@@@-@-@-@NCT00132379@13@-@ORPHAN DRUG STATUS APPROVED BY EMEA IN JULY 2007.@@@ORPHAN DRUG STATUS APPROVED BY EMEA IN JULY 2007.@@11/1/2005@-@5762003@@-@Patients with histologically or cytologically confirmed advanced NSCLC who have progressed on first line platin-based therapy or have failed on other treatment regimens or declined standard regimen. ECOG performance status 0 or 1.@@@I@I@@-@-@RESULTS PENDING@-@@@@COMBO@NAPTUMOMAB ESTAFENATOX@DOCETAXEL@@@@NAPTUMOMAB ESTAFENATOX|DOCETAXEL|||@ACTIVE BIOTECH@@@@@ACTIVE BIOTECH||||@Russia@@@@@Russia|||||||||@NSCLC@@@@@NSCLC|||||||||@ANYARA@ABR-217620@TAXOTERE@@@ANYARA|ABR-217620|TAXOTERE||@Immunotherapy@@@@@Immunotherapy||||@SAFETY@@@@@PHARMACOKINETICS@SAFETY@ANTI-SEA/E-120 LEVELS@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@SINGLE GROUP@@@@Invalid Factory Price@@@@@6 CYCLES@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922468@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Three doses of OVax will be tested, and each of the three doses will be analyzed for immunological efficacy with the goal of optimizing the dose for treatment of patients in future trials. SOURCE: AVAX, 11 April 2008@@-@-@-@PHILADELPHA, PENNSYLVANIA@@@@@14922468@Chemotherapy-refractive Stage III/IV ovarian cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00660101@42@-@-@@@-@@@-@A1000501@@-@-@@@I/II@II@@-@-@FDA approval for trial. [Avax, 10 April 2008]@-@@@@MONO@-@@@@@-||||@AVAX TECHNOLOGIES@@@@@AVAX TECHNOLOGIES||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@OVAX@@@@@OVAX||||@Vaccine@@@@@Vaccine||||@IMMUNE RESPONSE@@@@@@@@@@REFRACTORY@@@@@RANDOMISED@DOUBLE-BLIND@DOSE COMPARISON@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924212@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Oral solution, single dose on Day 1 Part A, twice daily ascending dosing from day 8 onwards (until maximum tolerated does is reached), cycles of 28 days treatment. Part B patients will receive the maximum tolerated dose determined in Part A for 28 days as twice daily doses. [clinicaltrials.gov]@@-@-@-@LONDON, UNITED KINGDOM@3/1/2010@@AZD-8055 is a tor kinase inhibitor.@@14924212@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00731263@100@-@-@@@-@@7/1/2008@-@-@@-@>> Histological or cytological confirmation of an advanced solid malignant tumour or lymphoma      >> Cancer which is refactory to standard therapies or for which no standard therapy exists, patients with measurable or non-measurable disease (according to RECIST criteria) can be recruited@@@I/II@II@@-@-@Trial registered. [AstraZeneca, 06.08.2008]@-@@@@MONO@-@@@@@-||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@AZD-8055@@@@@AZD-8055||||@TK Inhibitor@@@@@TK Inhibitor||||@SAFETY@PHARMACOKINETICS@@@@@@@@@ADVANCED@REFRACTORY@@@@OPEN-LABEL@NON-RANDOMISED@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918760@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@BRISBANE, CALIFORNIA@@@@@14918760@-@@-@-@@NO REVIEW@@@@-@Sanofi-Aventis acquires Bi-Par [Sanofi-Aventis 15 April 2009 http://en.sanofi-aventis.com/binaries/20090415_bipar_acquisition_en_tcm28-24863.pdf ]@-@-@-@-@-@@@-@@@-@NABTT@@-@-@@@II@II@@-@-@Trial started. SOURCE: BiPar, 10 April 2008@-@@@@-@-@@@@@-||||@BIPAR SCIENCES@SANOFI-AVENTIS@@@@BIPAR SCIENCES|SANOFI-AVENTIS|||@@@@@@|||||||||@Brain Cancer@Glioblastoma Multiforme@@@@Brain Cancer|Glioblastoma Multiforme||||||||@BSI-201@@@@@BSI-201||||@PARP Inhibitor@@@@@PARP Inhibitor||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922687@Onco@@@@@@@@@@@Arimidex alone 1mg daily for 4 months@@L02BG03@L02B@-@LONDON, UNITED KINGDOM@2/1/2007@@Arimidex is a potent and highly selective non-steroidal aromatase inhibitor. In postmenopausal women, estradiol is produced primarily from the conversion of androstenedione to estrone through the aromatase enzyme complex in peripheral tissues. Estrone is subsequently converted to estradiol. Reducing circulating estradiol levels has been shown to produce a beneficial effect in women with breast cancer. In postmenopausal women, Arimidex at a daily dose of 1 mg produced estradiol suppression of greater than 80% using a highly sensitive assay. Arimidex does not possess any progestogenic, androgenic or oestrogenic activity. Daily doses of Arimidex up to 10 mg do not have any effect on cortisol or aldosterone secretion, measured before or after standard ACTH challenge testing. Corticoid supplements are therefore not needed.@@14922687@Post-menopausal women with operable breast cancer; neoadjuvant treatment@@-@-@@NO REVIEW@@@@-@-@-@NCT00437853@30@-@-@@@-@@6/1/2003@-@1033MX0001  @@-@-@-@@IV@IV@@-@-@Trial is finished, but results not available.@-@@@@NEOADJUVANT@ANASTROZOLE@@@@@ANASTROZOLE||||@ASTRAZENECA@@@@@ASTRAZENECA||||@Mexico@@@@@Mexico|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@ARIMIDEX@@@@@ARIMIDEX||||@Hormone Antagonist@Aromatase Inhibitor@@@@Hormone Antagonist|Aromatase Inhibitor|||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@
14921841@Onco@@@@@300f1014ntsdm@@@@@@N/A@@-@-@-@BASEL, SWITZERLAND@@@Nilotinib is an inhibitor of the Bcr-Abl kinase. Nilotinib binds to and stabilizes the inactive conformation of the kinase domain of Abl protein. In vitro, nilotinib inhibited Bcr-Abl mediated proliferation of murine leukemic cell lines and human cell lines derived from Ph+ CML patients. Under the conditions of the assays, nilotinib was able to overcome imatinib resistance resulting from Bcr-Abl kinase mutations, in 32 out of 33 mutations tested. In vivo, nilotinib reduced the tumor size in a murine Bcr-Abl xenograft model. Nilotinib inhibited the autophosphorylation of the following kinases at IC50 values as indicated: Bcr-Abl (20-60 nM), PDGFR (69 nM) and c-Kit (210 nM).@@14921841@Nilotinib in adults in blast crisis who are imatinib-resistant or intolerant@@-@-@@NO REVIEW@@@@-@-@-@NCT00413270@60@-@-@@@-@@12/1/2006@-@CAMN107ACA01@@-@-@@@III@III@@-@-@RESULTS PENDING@-@@@@MONO@NILOTINIB@@@@@NILOTINIB||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@TASIGNA@@@@@TASIGNA||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@RESPONSE RATE@@@@@@@@@@RELAPSED@REFRACTORY@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@C$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14920965@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Given intradermal injection before and after standard adjuvant radiotherapy and 5-FU.@@-@-@-@SOUTH SAN FRANCISCO, CALIFORNIA@@@@@14920965@Resected Stage I or II adenocarcinoma of the pancreas@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00084383@60@-@-@@@-@@@-@JHOC-J9988@@-@60 PATIENTS WITH OPERABLE PANCREATIC CANCER RECEIVING GVAX AFTER SURGICAL RESECTION AND ADJUVANT RADIATION AND CHEMO@@@II@II@@-@-@ASCO 2007; median OS was 26.8 months (compared to 17-22 months historical control). 53 of the 60 patients were considered high risk (cancer spread to regional lymph nodes). Median DFS of 16 months (compared favorably to 13 months for Gemzar adjuvant therapy). Other patients not receiving GVAX (not part of the trial) survived 21 months or nearly six months shorter than the patients in the Phase 2 trial. Dosing did not continue beyond 18 months, and ongoing booster administrations of GVAX are being evaluated. @-@@@@MONO@-@@@@@-||||@CELL GENESYS@@@@@CELL GENESYS||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@GVAX PANCREATIC@@@@@GVAX PANCREATIC||||@Immunotherapy@@@@@Immunotherapy||||@OVERALL SURVIVAL@DISEASE-FREE SURVIVAL@@@@@@@@@-@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924719@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Somatuline Autogel 120mg every 28 days@@-@-@-@PARIS, FRANCE@@@@@14924719@-@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00353496@200@-@-@@@-@@6/1/2006@-@-@@-@200 PATIENTS WHO FAILED ON LANREOTIDE ALONE@@@III@III@@-@-@RESULTS PENDING@-@@@@COMBO@LANREOTIDE@@@@@LANREOTIDE||||@IPSEN@@@@@IPSEN||||@@@@@@|||||||||@Carcinoid / Neuroendocrine Tumour@@@@@Carcinoid / Neuroendocrine Tumour|||||||||@SOMATULINE AUTOGEL@@@@@SOMATULINE AUTOGEL||||@Somatostatin Analogue@@@@@Somatostatin Analogue||||@RESPONSE RATE@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916423@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Patients randomsied in one-to-one ratio to Eoquin or placebo@@-@-@-@IRVINE, CALIFORNIA@@@@@14916423@High-risk superficial bladder cancer@@-@-@@NO REVIEW@@@@-@Allergan has licensed extra-Asia rights to Eoquin in a US$34.5 million deal plus royalties. [Allergan, 30.10.2008]@-@NCT00141531@53@-@EMEA has agreed that data from these two Phase III trials will suffice to make a decision on approval for non-invasive bladder cancer. SOURCE: Spectrum, January 2008@@@-@@8/1/2005@-@SPI 05-003, 503@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@ADJUVANT@APAZIQUONE@@@@@APAZIQUONE||||@SPECTRUM PHARMACEUTICALS@ALLERGAN@@@@SPECTRUM PHARMACEUTICALS|ALLERGAN|||@@@@@@|||||||||@Bladder Cancer@@@@@Bladder Cancer|||||||||@EOQUIN@@@@@EOQUIN||||@Alkylating Agent@@@@@Alkylating Agent||||@TIME TO PROGRESSION@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRAVESICAL INSTILLATION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924516@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@PETACH TIKVA, ISRAEL@@@@@14924516@-@@-@-@@NO REVIEW@@@@-@Licensing agreement (signed with Ivax in September 2004) terminated in March 2007.@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@DISCONTINUED@@-@-@Clinical results were not made available during development.@-@@@@-@-@@@@@-||||@TEVA PHARMACEUTICAL@NIPPON SHINYAKU@@@@TEVA PHARMACEUTICAL|NIPPON SHINYAKU|||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@IVX-214@HMN-214@@@@IVX-214|HMN-214|||@Enzyme@Sulfonamide@@@@Enzyme|Sulfonamide|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16387710@Onco@@@@@@@@@@@"HMPL-523, Experimental, Oral administration, at dose of 100, 200, 400, 600 and 800 mg once daily at Dose-escalation stage At Dose-expansion stage, HMPL-523 will be dose daily and the dose level will be based on result of Dose-escalation stage"@@@@@CHINA@2/1/2020@@@@16387710@A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HMPL-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms@Both@@@@@Oral administration, once daily@@@@@SECOND-LINE@NCT02857998@92@@@@@@@11/1/2016@@2015-523-00CH1@@@-  Age >=18 years -  Histologically relapsed or refractory mature B-cell Neoplasms, have failed at least one prior therapy or patients who are unable to tolerate standard therapy or no curative therapy or therapy of higher priority exists -ECOG performanc@@ADULTS@Phase 1@I@@@@@@@@@MONO@-@@@@@-||||@HUTCHISON MEDIPHARMA LIMITED@@@@@HUTCHISON MEDIPHARMA LIMITED||||@@@@@@|||||||||@B-Cell Lymphoma@@@@@B-Cell Lymphoma|||||||||@HMPL-523@@@@@HMPL-523||||@Other@@@@@Other||||@Dose limited toxicities evaluated with NCI CTCAE v4.03@@@@@Maximum plasma concentration calculated with Blood samples@Time to reach maximum concentration calculated with Blood samples@@@@RELAPSED@REFRACTORY@@@@SAFETY/EFFICACY STUDY@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922683@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@LY-573636 IV on day 1 of 21-day cycle@@-@-@-@INDIANAPOLIS, INDIANA@@@@@14922683@Malignant melanoma@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00383292@50@-@-@@@-@@@-@10409H8K-MC-JZAF  @@-@-@@@II@II@@-@-@Completion expected February 2008.@-@@@@MONO@-@@@@@-||||@LILLY@@@@@LILLY||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@LY-573636@@@@@LY-573636||||@Sulfonamide@@@@@Sulfonamide||||@RESPONSE RATE@COMPLETE RESPONSE@PARTIAL RESPONSE@@@PARTIAL RESPONSE@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924253@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@DB-67 is a novel, third-generation camptothecin analogue that has demonstrated high potency in preclinical studies and improved pharmacokinetic properties in humans as compared with first and second-generation products. Arno believes that this unique profile and the potential for oral administration may translate into superior efficacy and patient convenience in the treatment of brain, lung, and other cancers. @@14924253@Advanced solid tumours@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@RESULTS PENDING@Safety data were qualitatively similar to that of irinotecan and a fluoropyrimidine with neutropenia, diarrhea, nausea, vomiting and fluid loss events (dehydration and hypokalemia) being the most common. The 210 unit/m2 dose produced more toxicities than seen in the CPX-1 Phase 1 clinical trial, resulting in only 40 percent of patients receiving >80 percent of the planned dose intensity. Treatment will be initiated at a lower dose in future studies. @@@@MONO@-@@@@@-||||@ARNO THERAPEUTICS@@@@@ARNO THERAPEUTICS||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@DB-67@AR-67@@@@DB-67|AR-67|||@Camptothecin@@@@@Camptothecin||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@ADVANCED@@@@@DOSE ESCALATION@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919176@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients receive SJG-136 IV over 15 minutes on days 1-5. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression.@@-@-@-@PARIS, FRANCE@8/1/2006@@@@14919176@-@@-@-@@NO REVIEW@@@@-@Licensed from Spirogen in May 2003@-@NCT00301769@25@-@-@@@-@@12/1/2005@-@MDA-2005-0607, @@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@IPSEN@@@@@IPSEN||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@Acute Lymphocytic Leukaemia@Myelodysplastic Syndrome@Chronic Lymphocytic Leukaemia@Haematological Malignancy|Chronic Myeloid Leukaemia|Acute Lymphocytic Leukaemia|Myelodysplastic Syndrome|Chronic Lymphocytic Leukaemia|||||@SJG-136@@@@@SJG-136||||@Other@@@@@Other||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@RELAPSED@REFRACTORY@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918926@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Daily dose of Clomet for 3 consecutive days as a short infusion of 4 cycles@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@@@@@14918926@-@@-@-@@NO REVIEW@@@@-@Acquisition completed. SOURCE: Antisoma, 11 June 2008Antisoma acquired Xanthus in an all-share deal of GB£26.8 mil. SOURCE: Antisoma, 16 May 2008@-@-@25@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@DMPEN@@@@@DMPEN||||@XANTHUS PHARMACEUTICALS@ANTISOMA@@@@XANTHUS PHARMACEUTICALS|ANTISOMA|||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@CLOMET@@@@@CLOMET||||@Other@@@@@Other||||@DOSE-LIMITING TOXICITY@MAXIMUM TOLERATED DOSE@PHARMACOKINETS@@@PHARMACOKINETICS@@@@@-@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922239@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Single-agent AT-101@@-@-@-@MALVERN, PENNSYLVANIA@@@@@14922239@B-Cell malignancies@@-@-@@NO REVIEW@@@@-@Partnering opportunity@-@NCT00275431@82@-@-@@@-@@11/1/2005@-@AT-101-CS-005@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@ASCENTA THERAPEUTICS@@@@@ASCENTA THERAPEUTICS||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@B-Cell Lymphoma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|B-Cell Lymphoma|||||||@AT-101@@@@@AT-101||||@Bcl-2 Inhibitor@@@@@Bcl-2 Inhibitor||||@SAFETY@RESPONSE RATE@@@@@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916653@Onco@@@@@300f1018ntsdm@@@@@@Cohorts of 3-6 patients receive escalating doses of PI-88 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD has been determined in part I, the effect of dose frequency is determined in patients in part II. Part 2: Patients receive PI-88 SC once daily on days 1-4, 8-11, 15-18, and 22-25 at a dose based on the MTD determined in part 1. Cohorts of 3 patients receive escalating doses of PI-88 until the MTD at this frequency is determined. Phase II (patients with metastatic melanoma): Patients receive PI-88 as in phase I, part 2 at the MTD. Treatment in both phases repeats every 28 days in the absence of disease progression or unacceptable toxicity.@@-@-@-@QUEENSLAND, AUSTRALIA@@@@@14916653@Stage IV melanoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00073892@69@-@FDA Orphan Drug@@@FDA Orphan Drug@@6/1/2001@-@PR88201@@-@-@@@I/II, COMIRB-01-207; @II@@-@-@RESULTS PENDING@-@@@@COMBO@-@@@@@-||||@PROGEN PHARMACEUTICALS@@@@@PROGEN PHARMACEUTICALS||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@PI-88@@@@@PI-88||||@Angiogenesis Inhibitor@VEGF@TK Inhibitor@@@Angiogenesis Inhibitor|VEGF|TK Inhibitor||@STABLE DISEASE@RESPONSE RATE@@@@@@@@@METASTATIC@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
16074363@Onco@@@@@@@@@@@All Patients, Experimental, Microgynon alone in Period 1 then with Nintedanib in Period 2@@L01XE31@L01X@@INGELHEIM, GERMANY@2/1/2017@@Nintedanib is an oral triple angiokinase inhibitor that targets three growth factor receptors simultaneously: vascular endothelial growth factor receptors (VEGFR 1-3), platelet-derived growth factor receptors (PDGFR alpha and beta), and fibroblast growth factor receptors (FGFR 1-3). All three receptors are crucially involved in the formation and maintenance of new blood vessels (angiogenesis); their blockade may lead to the inhibition of angiogenesis, which plays a critical role in tumour growth and spread@@16074363@A Phase I Trial to Investigate the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer@Both@@@@@@@@@@@NCT02751385@14@@@@@@@4/1/2016@@1199.238@@@Female and male patients 18 years or older at screening  -  For female patients only: patient is postmenopausal or surgically sterilised  -  Patient with locally advanced, metastatic or locally recurrent non-small cell lung cancer with histology of adenocarcinoma  -  Nintedanib (Vargatef®) is planned to be prescribed in accordance with the marketing authorisation (SmPC)  -  Signed and dated written informed consent in accordance with Good Clinical Practice (GCP) and local legislation prior to admission to the trial@COMBO@ADULTS@Phase 1@I@@@@@@@@@@NINTEDANIB@ETHINYLESTRADIOL, LEVONORGESTREL@@@@NINTEDANIB|ETHINYLESTRADIOL, LEVONORGESTREL|||@BOEHRINGER INGELHEIM@@@@@BOEHRINGER INGELHEIM||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@VARGATEF@MICROGYNON@@@@VARGATEF|MICROGYNON|||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@AUC 0-tz (area under the concentration-time curve of ethinylestradiol before nintedanib administration in plasma over the time interval from 0 to the time of the last quantifiable data point)@AUC 0-tz@@@@AUC0-infinity@@@@@@@@@@PHARMACOKINETICS STUDY@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14923431@Onco@@@@@300f1012ntsdm@@@@@@-@@-@-@-@-@@@Pieris has developed PRS-050 as a next generation VEGF antagonist and as the first Anticalin -based product in its proprietary pipeline. PRS-050 exemplifies many of the favourable characteristics of Anticalins: compact protein structure, high intrinsic stability, broad formulation flexibility and small molecular size improving the likelihood of effective target access. PRS-050 has already demonstrated potent inhibition of VEGF-induced enhanced vascular permeability and angiogenesis, as well as, anti-tumour activity.@@14923431@Target unknown@@-@-@@NO REVIEW@@@@-@Pieris AG and Wacker Biotech GmbH signed a collaborative deal for the production scale-up of PRS-050. Wacker's proprietary E. coli secretion system, including the E. coli K12-strain, developed by Wacker, secrets recombinant proteins in native form. Production of clinically relevant proteins via direct extracellular secretion is designed to offer a more cost effective approach to biopharmaceutical product manufacture than traditional protein refolding technologies.@-@-@-@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@To enter clinic in 2009. SOURCE: Pieris, 17 July 2008@-@@@@-@ANTICALIN@@@@@ANTICALIN||||@PIERIS AG@WACKER BIOTECH@@@@PIERIS AG|WACKER BIOTECH|||@@@@@@|||||||||@Other@@@@@Other|||||||||@PRS-050@@@@@PRS-050||||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14922139@Onco@@@@@@@@@@@At least two injections; 50kBq per kg body weight; or placebo. Administered 4 weeks apart over 12-week period.@@-@-@-@KJELSAS, NORWAY@@@Algeta's lead product based on the alpha emitter technology is Alpharadin, a product being developed as a new treatment for skeletal metastases in patients with late-stage, hormone refractory prostate cancer (HRPC). Alpharadin (radium-223 chloride) is a unique targeted therapeutic in phase III clinical trials for the treatment for HRPC that has metastasized to the skeleton.@@14922139@HRPC@@-@-@@NO REVIEW@@@-@-@-@-@-@64@-@-@@@-@@@-@BCI-02@@-@64 HRPC PATIENTS@@@II@II@@-@-@ASCO June 2007; patients on Alpharadin survived on median nearly 25 weeks (53% longer than those on placebo (71 weeks compared to 46.4 weeks). Follow-up at 18 months in February 2007, 48% of Alpharadin patients were alive compared to 22% on placebo.@-@@@@MONO@-@@@@@-||||@ALGETA@@@@@ALGETA||||@@@@@@|||||||||@Prostate Cancer@HRPC@@@@Prostate Cancer|HRPC||||||||@ALPHARADIN@@@@@ALPHARADIN||||@Other@@@@@Other||||@OVERALL SURVIVAL@@@@@@@@@@REFRACTORY@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916638@Onco@@@@@300f1018ntsdm@@@@@@Arm I: Patients receive docetaxel IV over 1 hour on days 1, 8, and 15. Arm II: Patients receive docetaxel as in arm I. Patients also receive PI-88 subcutaneously once daily on days 1-4, 8-11, and 15-18.@@-@-@-@QUEENSLAND, AUSTRALIA@@@@@14916638@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00103389@100@-@-@@@-@@2/1/2004@-@PROGEN-PR88202, @@-@-@@@II@II@@-@-@PI-88/docetaxel did not meet primary endpoint of significantly improving progression-free rate at 6 months compared to docetaxel alone. Secondary endpoints of TTP, RR, OS and quality of life were also not met. Progen concluded no further investigation was needed. SOURCE: Progen, 24 September 2007@-@@@@COMBO@-@DOCETAXEL@@@@-|DOCETAXEL|||@PROGEN PHARMACEUTICALS@@@@@PROGEN PHARMACEUTICALS||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@PI-88@TAXOTERE@@@@PI-88|TAXOTERE|||@Angiogenesis Inhibitor@VEGF@TK Inhibitor@@@Angiogenesis Inhibitor|VEGF|TK Inhibitor||@PROGRESSION-FREE SURVIVAL@RECIST@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
16639896@Onco@@@@@@@@@@@"alpelisib + fulvestrant, Experimental, Patients who received any CDK 4/6 inhibitor plus aromatase inhibitor as treatment (immediately prior) will receive alpelisib + fulvestrant alpelisib + letrozole, Experimental, Patients who received any CDK 4/6 inhibitor plus fulvestrant as treatment (immediately prior) will receive alpelisib + letrozole"@@@@@BASEL, SWITZERLAND@3/13/2020@@@@16639896@A Phase II, Multicenter, Open-label, Two-cohort, Non-comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After CDK 4/6 Inhibitor Treatment@Both@@@@@300 mg; oral; once daily@@@@@@NCT03056755@160@@@@@@@@@CBYL719X2402@@@Inclusion Criteria:  -  patient is male or female 18 years or older  -  Patient is identified PIK3CA mutant status  -  Patient has confirmed HER2-negative advanced breast cancer (aBC)  -  Patient must be diagnosed with aBC with documented progression on or after CDK 4/6 treatment (adjuvant or metastatic setting)  -  Patient has histological and/or cytological confirmed ER+ and/or PgR+ aBC  -  Patient has either measurable disease per RECIST v1.1 or at least one predominantly lytic bone lesion must be present  -  ECOG function of greater or equal to 2  -  Patient has adequate bone marrow function  -  Patient has adequate liver and renal function@@ADULTS@Phase 2@II@@@@@@@@@COMBO@ALPELISIB@FULVESTRANT OR LETROZOLE@@@@ALPELISIB|FULVESTRANT OR LETROZOLE|||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@-@FASLODEX OR FEMARA@@@@-|FASLODEX OR FEMARA|||@Other@@@@@Other||||@The percentage of patients who are alive without disease progression@@@@@Progression free survival (PFS) for each cohort@Progression free survival (PFS) on next line treatment PFS2) for each cohort@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922519@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@ZK-PRA 25MG and 100MG administered once daily p.o for 6 months or until disease progression@@-@-@-@LEVERKUSEN, GERMANY@@@@@14922519@Postmenopausal women@@-@-@@NO REVIEW@@@@-@Following a modified agreement in January 2005, Novartis and Schering AG co-market vatalanib in Europe, North America and Japan for oncology indications, whilst Schering AG maintains marketing rights for Latin America, Africa, Australia and Novartis for A@SECOND-LINE@NCT00555919@72@-@-@@@-@@11/1/2007@-@309821,@@-@-@@@II EudraCT 2005-005581-36; @DISCONTINUED@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@BAYER HEALTHCARE@NOVARTIS@@@@BAYER HEALTHCARE|NOVARTIS|||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@ZK-230211@@@@@ZK-230211||||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@RANDOMISED@OPEN-LABEL@DOSE COMPARISON@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16067009@Onco@@@@@@@@@@@Arm 1, Experimental, Biomarker-enriched advanced hematological neoplasmsArm 2, Experimental, Other selected advanced hematological neoplasms@@@@@LEVERKUSEN, GERMANY@10/1/2017@@@@16067009@An Open-label, Multicenter Phase I Study to Characterize the Safety, Tolerability, Preliminary Anti-tumor Activity, Pharmacokinetics and Maximum Tolerated Dose of BAY1251152 in Patients With Advanced Hematological Malignancies@Both@@@@@Weekly infusion of BAY1251152 in 21-day cycles@@@@@@NCT02745743@74@@@@@@@5/1/2016@@18117@@@Male or female patients aged ≥18 years  -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 and Life expectancy of at least 12 weeks  -  Patients are able and willing to provide bone marrow biopsies/aspirates as requested by the protocol  -  Patients with confirmed advanced hematological malignancies  -  Negative serum pregnancy test  -  Women and men of reproductive potential must agree to use highly effective contraception when sexually active.  -  Ability to understand and the willingness to sign a written informed consent.  -  Patients must have adequate coagulation (international normalized ratio (INR) or prothrombin time (PT), partial thromboplastin time (PTT) ≤1.5 times ULN)  -  Adequate liver function (total bilirubin ≤ 1.5 times the ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN@MONO@ADULTS@Phase 1@I@@@@@@@@@@-@@@@@-||||@BAYER HEALTHCARE@@@@@BAYER HEALTHCARE||||@Spain@United States@@@@Spain|United States||||||||@Haematological Malignancy@@@@@Haematological Malignancy|||||||||@BAY1251152@@@@@BAY1251152||||@Other@@@@@Other||||@MAXIMUM TOLERATED DOSE@Recommended Phase 2 dose@Number of adverse events (AE)@@@Response assessment@@@@@ADVANCED@@@@@NON-RANDOMIZED@SAFETY/EFFICACY STUDY@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14920922@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Intravenous repeating doses of Kanglaite Injection with Gemzar versus Gemzar alone. [clinicaltrials.gov]@@-@-@-@-@8/1/2010@@KLT is purified from a traditional Chinese medicine called coix seed - it is approved for lung and liver cancer in China.@@14920922@Kanglaite Injection Plus Gemcitabine (G+K) Versus Gemcitabine in Patients With Advanced Pancreatic Cancer@@-@-@@NO REVIEW@@@@-@-@-@-@60@-@-@@@-@@8/1/2008@-@KLT-PANC-001@@-@>> Must be ambulatory and have either a Karnofsky performance status of 60 or higher or ECOG performance status of 0, 1 or 2 >> Must have histologically confirmed pancreatic cancer, either locally invasive or metastatic, and not amenable to potentially curative resection@@@II@II@@-@-@Trial registered. [KangLaiTe, 11.08.2008]@-@@@@-@-@GEMCITABINE@@@@-|GEMCITABINE|||@KANGLAITE@@@@@KANGLAITE||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@KANGLAITE@KLT@KANGLAITE@@@KANGLAITE|KLT|KANGLAITE||@Other@@@@@Other||||@PROGRESSION-FREE SURVIVAL@@@@@RESPONSE RATE@OVERALL SURVIVAL@@@@-@@@@@RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922974@Onco@@@@@@@@@@@Patients were randomly assigned (1:1:1) to S-1 alone (Arm A), S-1plus CDDP (Arm B) or 5-FU plus CDDP (Arm C).@@-@-@-@-@9/1/2006@@S-1 is an oral fluorouracil anticancer product that combines 3 pharmacological agents in a certain ratio: tegafur which is a pro-drug of 5 fluoro-uracil; gimeracil (5-chloro-2,4 dihydropyridine (CDHP)) which inhibits dihydropyrimidine dehydrogenase (DPD) enzyme activity; and oteracil (potassium oxonate (Oxo)) a gastrointestinal side effects corrector.@@14922974@Gastric cancer@@-@-@@NO REVIEW@@@@-@sanofi-aventis returns its territory rights to Taiho Pharmaceutical for the development and commercialization of the oral anti-cancer agent S-1. Taiho will pursue further development of S-1 outside of Japan with gastric cancer included. SOURCE: Taiho, 18 July 2008@-@NCT00202969@180@-@-@@@-@@7/1/2005@-@-@@-@-@@@III@III@@-@-@RESULTS PENDING@-@@@@COMBO@TEGAFUR GIMERACIL OTERACIL POTASSIUM @@@@@TEGAFUR GIMERACIL OTERACIL POTASSIUM ||||@TAIHO@@@@@TAIHO||||@China@@@@@China|||||||||@Stomach Cancer@@@@@Stomach Cancer|||||||||@S-1@@@@@S-1||||@Fluoropyrimidine@@@@@Fluoropyrimidine||||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924189@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@Archexin is a first-in-class, potent Akt protein kinase inhibitor with potential utility to inhibit cancer cell survival and proliferation, angiogenesis and drug resistance. @@14924189@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@FDA orphan drug designation for renal cell carcinoma, pancreatic, glioblastoma, stomach and ovarian cancerss@@5/1/2007@-@-@@-@-@@@II@II@@-@-@FDA approval to commence trial [Rexahn, 29 May 2007]@-@@@@MONO@-@GEMCITABINE@@@@-|GEMCITABINE|||@REXAHN PHARMACEUTICALS@@@@@REXAHN PHARMACEUTICALS||||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@ARCHEXIN@RX-0201@@@@ARCHEXIN|RX-0201|||@AKT inhibitor@@@@@AKT inhibitor||||@SAFETY@MAXIMUM TOLERATED DOSE@OVERALL SURVIVAL@@@-@@@@@-@@@@@OPEN-LABEL@MULTI-CENTRE@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922335@Onco@@@@@@@@@@@Cyclophosphamide (600mg/m2 IV days 1 and 8), methotrexate (40mg/m2 IV days 1 and 8) and 5-FU (600mg/m2 IV days 1 and 8) versus Zoladex 3.6mg depot every 28 days for 3 years plus 20mg tamoxifen every day for 5 years@@L02AE03@L02A@-@LONDON, UNITED KINGDOM@@@Zoladex (D-Ser(But)6 Azgly10 LHRH) is a synthetic analogue of naturally occurring LHRH. On chronic administration Zoladex results in inhibition of pituitary LH secretion leading to a fall in serum testosterone concentrations in males and serum estradiol concentrations in females. This effect is reversible on discontinuation of therapy. Initially, Zoladex, like other LHRH agonists, may transiently increase serum testosterone concentration in men and serum estradiol concentration in women.@@14922335@Premenopausal, hormone receptor-positive, lymph node-positive or -negative patients with operable breast cancer@@-@-@@NO REVIEW@@@@-@-@-@-@660@-@-@@@-@@@-@AC05@@-@-@@@IIIB@III@@-@-@In the primary efficacy population, 80 (14.3%) patients randomised to receive Zoladex + tamoxifen had an event (ie, disease recurrence, contralateral breast cancer or death) compared to 105 (18.7%) patients on CMF. The median follow-up times for the 2 trial treatment groups were 3.8 and 3.7 years, respectively. The results were statistically significant.@-@@@@COMBO@GOSERELIN ACETATE@@@@@GOSERELIN ACETATE||||@ASTRAZENECA@@@@@ASTRAZENECA||||@Austria@@@@@Austria|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@ZOLADEX@@@@@ZOLADEX||||@LH-RH Analog@@@@@LH-RH Analog||||@DISEASE-FREE SURVIVAL@@@@@@@@@@ADVANCED@@@@@OPEN-LABEL@RANDOMISED@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
16418067@Onco@@@@@@@@@@@Man participants should agree to use and utilize an adequate method of contraception throughout treatment and for at least 6 months after study is stopped  -  Patients should participate in the study voluntarily and sign informed consent@@@@@CHINA@10/1/2018@@@@16418067@Phase I Study of Tolerance and Pharmacokinetics of TQ-B3395 in Patients With Advanced Cancer@Both@@@@@TQ-B3395 p.o. qd@@the result of serum or urine pregnancy test should be negative within 7 days prior to study enrollment，and the patients required to be non-lactating@@@FIRST-LINE@NCT02944864@35@@@@@@@11/1/2016@@TQ-B3395-I-0001@@@-  Histological documentation of Advanced solid tumors,lack of the standard treatment or treatment failure.In expanding stage,enroll the Non-small Cell Lung Cancer with EGFR+(except exon 20)  -  18-70 years,ECOG PS:0-1,Life expectancy of more than 3 month@@ADULTS@Phase 1@I@@@@@@@@@MONO@-@@@@@-||||@JIANGSU CHIA-TAI TIANQING@@@@@JIANGSU CHIA-TAI TIANQING||||@China@@@@@China|||||||||@NSCLC@@@@@NSCLC|||||||||@TQ-B3395@@@@@TQ-B3395||||@Other@@@@@Other||||@"TQ-B3395, Experimental, TQ-B3395 QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent"@The maximum tolerated dose (MTD) of TQ-B3395@The type of dose-limiting toxicity(ies) (DLT[s]) of TQ-B3395@@@Objective Response Rate (ORR)@@@@@ADVANCED@@@@@Pharmacokinetics/Dynamics Study@Single Group Assignment@Open Label@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
15413024@Onco@@@@@@@@@@@Cohort 1: V503 in the Base Study, , Participants received the selected dose formulation of V503 (0.5 mL in a 3-dose regimen) from a Denmark, Norway, or Sweden site in the base study (V503-001, NCT00543543). No study vaccination will be administered in study V503-021.Cohort 2: GARDASIL in the Base Study, , Participants received GARDASIL (0.5 mL in a 3-dose regimen) from a Denmark, Norway, or Sweden site in the base study (V503-001, NCT00543543) and were offered the selected dose formulation of V503 (0.5 mL in a 3-dose regimen) at the conclusion of the base study. V503 vaccination was voluntary and not a condition for inclusion in Cohort 2. No study vaccination will be administered in study V503-021.@@@@@WHITEHOUSE STATION, NEW JERSEY@1/1/2024@@@@15413024@A Registry-Based Extension of Protocol V503-001 in Countries With Centralized Cervical Cancer Screening Infrastructures to Evaluate the Long-Term Effectiveness, Immunogenicity, and Safety of Multivalent Human Papillomavirus (HPV) L1 Virus- Like Particle (VLP) Vaccine as Administered to 16- to 26- Year- Old Women@Female@@@@@@@@@@@NCT02653118@4453@@@@@@@1/1/2016@@V503-021@@@Randomized into the V503-001 (NCT00543543) study from a Denmark, Norway, or Sweden site and participated in the study by receiving either the selected dose formulation of V503 or GARDASIL  -  Age 16 to 26 years at the time of enrollment in study V503-001  -  Agrees to allow passive follow-up, analysis of biopsy specimens, future contact from the National Registry Study Centers, and serum collection@MONO@@N/A@-@@@@@@@@@@-@@@@@-||||@MERCK & CO@@@@@MERCK & CO||||@@@@@@|||||||||@Cervical Cancer@@@@@Cervical Cancer|||||||||@V503@@@@@V503||||@Other@@@@@Other||||@Combined Incidence of HPV Type 16, 18, 31, 33, 45, 52, or 58-related Cervical Intraepithelial Neoplasia (CIN) Grades 2 or 3, Adenocarcinoma In Situ (AIS), and Cervical Cancer@@@@@@@@@@@@@@@Cohort@PROSPECTIVE@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921595@Onco@@@@@300f1010ntsdm@@@@@@Recentin with lomustine oral capsule@@-@-@-@LONDON, UNITED KINGDOM@12/1/2008@@Cediranib (Recentin AZD2171) is a highly potent inhibitor of the tyrosine kinase activity associated with all three vascular endothelial growth factor (VEGF) receptors and is currently in Phase II/III clinical trials. Preclinically, cediranib inhibits VEGF signaling and angiogenesis in vivo and impedes solid tumor growth significantly. @@14921595@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00503204@20@-@-@@@-@@9/1/2007@-@D8480C00057, @@-@-@@@EuDract 2007-000909-30; @I@@-@-@RESULTS PENDING@-@@@@COMBO@CEDIRANIB@@@@@CEDIRANIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Brain Cancer@@@@@Brain Cancer|||||||||@RECENTIN@AZD-2171@@@@RECENTIN|AZD-2171|||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@SAFETY@@@@@@@@@@METASTATIC@RELAPSED@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TABLET@GB£@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14921724@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Abiterone alone@@-@-@-@NEW BRUNSWICK, NEW JERSEY@@@@@14921724@-@@-@-@@NO REVIEW@@@@-@J&J acquired Cougar in 2009.[J&J May 21 2009 http://www.jnj.com/connect/news/all/20090521_160000 ]@-@NCT00473512@-@-@-@@@-@@12/1/2005@-@COU-AA-001@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@ABIRATERONE ACETATE@@@@@ABIRATERONE ACETATE||||@JOHNSON & JOHNSON@COUGAR BIOTECHNOLOGY@@@@JOHNSON & JOHNSON|COUGAR BIOTECHNOLOGY|||@@@@@@|||||||||@Prostate Cancer@HRPC@@@@Prostate Cancer|HRPC||||||||@CB-7630@@@@@CB-7630||||@Other@@@@@Other||||@SAFETY@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916251@Onco@@@@@300f1015ntsdm@@@@@@N/A@@N02AA01@N02A@NO@NEW YORK, NEW YORK@@@@@14916251@Severe chronic pain and/or pain resistant to other analgesics, in particular pain associated with cancer.@@NO@Feb-00@@NO REVIEW@@@@65%@@@@N/A@Adults: Recommended dosage is one capsule twice daily, at 12-hourly intervals. Elderly: As with all narcotics, a reduction in dosage may be advisable in the elderly, as appropriate. Children: Not recommended.@@@4/20/2000@@@@Caution should be exercised:- in elderly subjects, in patients with impaired hepatic and/or renal functions, in patients with hypothyroidism or hypoadrenalism, in patients in a state of shock or with asthma. The dose should be reduced, or its use should be avoided in cases of hepatic or renal failure; and - in patients suffering from the following conditions: hypotension, convulsive disorders, dependence (severe withdrawal symptoms if withdrawn abruptly) and prostatic hypertrophy.@N/A@No@@@@@N/A@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@No clinical data on label.@@@@@@MORPHINE SULPHATE@@@@@MORPHINE SULPHATE||||@BMS@@@@@BMS||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@ACTISKENAN@@@@@ACTISKENAN||||@Opioid Analgesic@@@@@Opioid Analgesic||||@N/A@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@14@1.1807@4.72@6.16@5.04@@@@@@@@@@@@@@@@@@@@@@@@@@9/1/2017@0.34@0.34@3.40E+12@CAPSULE@EURO@@@@@@@@30@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14921690@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@L03A C01@L03A@-@BASEL, SWITZERLAND@@@Aldesleukin has been shown to possess the biological activities ofhuman native interleukin-2. In vitro studies performed on human cell linesdemonstrate the immunoregulatory properties including:a) enhancement of lymphocyte mitogenesis and stimulation of long-term growth ofhuman interleukin-2 dependent cell lines; b) enhancement of lymphocytecytotoxicity; c) induction of killer cell (lymphokine-activated (LAK) and natural (NK))activity; and d) induction of interferon-gamma production.@@14921690@-@@-@-@@NO REVIEW@@@@-@Novartis purchases the final 58% stake in Chiron in US$5.1 billion deal. [Novartis, 30.10.2005]@-@NCT00414765@20@-@-@@@-@@6/1/2006@-@CPRL002A2201@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@ALDESLEUKIN@@@@@ALDESLEUKIN||||@NOVARTIS@CHIRON@@@@NOVARTIS|CHIRON|||@@@@@@|||||||||@Melanoma / Skin Cancer@Kidney Cancer@Renal Cell Carcinoma@@@Melanoma / Skin Cancer|Kidney Cancer|Renal Cell Carcinoma|||||||@PROLEUKIN@@@@@PROLEUKIN||||@Immunotherapy@Interleukin@@@@Immunotherapy|Interleukin|||@PHARMACOKINETICS@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRAVENOUS@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922156@Onco@@@@@300f1012ntsdm@@@@@@Patients received Stimuvax with BSC or BSC alone.@@-@-@-@DARMSTADT, GERMANY@@@Stimuvax is an investigational therapeutic cancer vaccine designed to induce an immune response to cancer cells that express MUC1, a glycoprotein antigen widely expressed on common cancers. MUC1 is over expressed on many cancers such as lung cancer, breast cancer, prostate cancer and colorectal cancer. Stimuvax is thought to work by stimulating the body's immune system to identify and destroy cancer cells expressing MUC1.@@14922156@Stage IIIB or IV NSCLC@@-@-@@NO REVIEW@@@@-@Merck holds exclusive worldwide rights after adding Canada to the deal in August 2007, and Biomira relinquished its U.S. co-promotion rights in January 2006 in exchange for royalties. Original deal signed in May 2001.@-@NCT00157209@171@-@FDA SPA AND FAST-TRACK GRANTED.@@@-@@@-@B25-LG-304@@-@-@@@IIB@II@@-@-@Median survival was 30.6 months versus 13.3 months for control group.@-@@@@COMBO@BLP25 LIPOSOMAL VACCINE@@@@@BLP25 LIPOSOMAL VACCINE||||@MERCK SERONO@ONCOTHYREON@@@@MERCK SERONO|ONCOTHYREON|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@STIMUVAX@L-BLP25@@@@STIMUVAX|L-BLP25|||@Vaccine@@@@@Vaccine||||@OVERALL SURVIVAL@SAFETY@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14916716@Onco@@@@@@@@@@@160MG/day PI-88 versus placebo@@-@-@-@QUEENSLAND, AUSTRALIA@@@@@14916716@Following curative resection@@-@-@@NO REVIEW@@@DECEMBER 2007-JULY 2011@-@-@-@NCT00568308@600@-@EMEA Orphan DrugFDA Fast-Track (and SPA subsequently abandoned). SOURCE: Progen, 2 November 2007@11/2/2007@@EMEA Orphan DrugFDA Fast-Track (and SPA subsequently abandoned). SOURCE: Progen, 2 November 2007@@@-@PATHWAY @@-@-@@@PR88302;@III@@-@-@"Trial started. SOURCE: Progen press release, 11 March 2008First-patient-in (FPI) ""early"" in 2008. SOURCE: Progen, 21 December 2007"@-@@@@ADJUVANT@-@@@@@-||||@PROGEN PHARMACEUTICALS@@@@@PROGEN PHARMACEUTICALS||||@@@@@@|||||||||@Liver Cancer@Hepatocellular Carcinoma@@@@Liver Cancer|Hepatocellular Carcinoma||||||||@PI-88@@@@@PI-88||||@Angiogenesis Inhibitor@VEGF@TK Inhibitor@@@Angiogenesis Inhibitor|VEGF|TK Inhibitor||@DISEASE-FREE SURVIVAL@@@@@@@@@@-@@@@@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922742@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@MPC-2130 daily IV infusions for 5 days@@-@-@-@SALT LAKE CITY, UTAH@@@@@14922742@-@@-@-@@NO REVIEW@@@@-@Myriad licensed the MX-90745 series of apoptosis inducing compounds in December 2003 from Maxim Pharmaceuticals (now EpiCept)@-@NCT00387153@30@-@-@@@-@@8/1/2005@-@04-002@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@MYRIAD GENETICS@@@@@MYRIAD GENETICS||||@@@@@@|||||||||@Haematological Malignancy@@@@@Haematological Malignancy|||||||||@MPC-2130@@@@@MPC-2130||||@Other@@@@@Other||||@MAXIMUM TOLERATED DOSE@STABLE DISEASE@@@@@@@@@REFRACTORY@@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921663@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@BASEL, SWITZERLAND@@@Patupilone (EPO906, epothilone B) is a novel non-taxane-related microtubule-stabilizing natural compound that retains full activity in multidrug-resistant tumors and is clinically less toxic than paclitaxel.@@14921663@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00496600@21@-@-@@@-@@7/1/2007@-@CRAD001US16@@-@-@@@050612-0220060307, @I@@-@-@RESULTS PENDING@-@@@@COMBO@PATUPILONE@EVEROLIMUS@@@@PATUPILONE|EVEROLIMUS|||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@EPO-906@RAD-001@@@@EPO-906|RAD-001|||@Epothilone@@@@@Epothilone||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@ADVANCED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924193@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@WOBURN, MASSACHUSSETTS@@@@@14924193@-@@-@-@@NO REVIEW@@@@-@E2F-1 programme is pursuant to collabroation with Roche, which holds a license to these products based on Phase II trials. SOURCE: ArQule@-@-@-@-@-@@@-@@@-@-@@-@-@@@I@DISCONTINUED@@-@-@Trial discontinued after QTc prolongation data. A new entity ARQ-761 is now the second-generation E2F-1 product behind ARQ-501. SOURCE: ArQule, 10 April 2008@-@@@@-@-@@@@@-||||@ARQULE@@@@@ARQULE||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@ARQ-171@@@@@ARQ-171||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@DOSE ESCALATION@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924771@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@One group of 90 patients will receive chemotherapy followed the next day by a starting dose of 4500mg per day in twice daily divided doses until white blood cell count recovery. Another group of 45 patients will be the chemotherapy-alone control group, which will receive standard supportive care following chemotherapy.@@-@-@-@-@@@@@14924771@NSCLC patients receiving standard front-line chemotherapy@@-@-@@NO REVIEW@@@@-@-@-@-@135@-@PARTIAL HOLD ON TELCYTA ARMS IMPOSED IN JUNE 2007; ASSIST-3 AND ASSIST-5 PATIENTS WILL CONTINUE TO RECEIVE TREATMENT.@@@-@@@-@-@@-@-@@@II@II@@-@-@Trial started. SOURCE: Telik, 20 May 2008@-@@@@MONO@-@@@@@-||||@TELIK@@@@@TELIK||||@@@@@@|||||||||@Haematological Malignancy@Supportive Care@Neutropaenia@NSCLC@@Haematological Malignancy|Supportive Care|Neutropaenia|NSCLC||||||@TELINTRA@@@@@TELINTRA||||@Enzyme@@@@@Enzyme||||@HAEMATOLOGIC RESPONSE@@@@@@@@@@-@@@@@RANDOMISED@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919000@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@NEW YORK, NEW YORK@@@@@14919000@-@@-@-@@NO REVIEW@@@@-@In May 2005, Pfizer licensed global rights for NSCLC and breast cancer from Coley; Pfizer subsequently bought Coley in November 2007. @-@-@N/A@-@-@@@-@@@-@N/A@@-@-@@@N/A@I@@-@-@RESULTS PENDING@-@@@@-@TICILIMUMAB@TREMELIMUMAB@@@@TICILIMUMAB|TREMELIMUMAB|||@PFIZER@COLEY PHARMACEUTICAL@@@@PFIZER|COLEY PHARMACEUTICAL|||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@PF-3512676@CPG-7909@CP-675206@@@PF-3512676|CPG-7909|CP-675206||@TLR-targeted@Immunotherapy@Vaccine@@@TLR-targeted|Immunotherapy|Vaccine||@N/A@@@@@@@@@@-@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924988@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@50 mg intrathecal every 14 days for 8 doses, then every 28 days for six doses.@@-@-@-@BRIDGEWATER, NEW JERSEY@6/1/2010@@@@14924988@Lymphomatous or leukaemic meningitis@@-@-@@NO REVIEW@@@@-@Enzon will spin-off its novel biotechnology business from Enzon in a transaction that will result in two independent and highly focused public companies. Enzon will retain the current marketed products of Abelcet, Adagen, DepoCyt and Oncaspar, the rights to current PEG royalty revenues, including PEG-Intron, Cimzia and Hematide, and the manufacturing facility in Indianapolis. SOURCE: Enzon, 7 May 2008Marketed by Enzon in U.S., Mundipharma in Europe@-@NCT00523939@40@-@-@@@-@@6/1/2006@-@9010@@-@-@@@II@II@@-@-@Endpoint is RR over 1 year.@-@@@@MONO@-@@@@@-||||@ENZON@@@@@ENZON||||@@@@@@|||||||||@Lymphomatous Meningitis@@@@@Lymphomatous Meningitis|||||||||@DEPOCYT@@@@@DEPOCYT||||@Anti-metabolite@@@@@Anti-metabolite||||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918766@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@LIQUIDATED@@@@@14918766@Oral mucositis in head and neck cancer patients receiving radiotherapy (as well as post-operative ileus, asthma/COPD and others)@@-@-@@NO REVIEW@@@@-@"The drug is ""for sale""; ActivBiotics has extended the deadline to place bids on this and other assets to 14 March 2008. SOURCE: ActivBiotics, 15 January 2008"@-@-@-@-@FDA orphan drug. SOURCE: ActivBiotics press release, 6 March 2008EMEA COMP orphan drug. SOURCE: ActivBiotics, 5 February 2008@3/6/2008@@-@@@-@NA@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@ACTIVBIOTICS@@@@@ACTIVBIOTICS||||@@@@@@|||||||||@Supportive Care@Mucositis@Head & Neck Cancer@@@Supportive Care|Mucositis|Head & Neck Cancer|||||||@M-40403@@@@@M-40403||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@NOT AVAILABLE@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916760@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Administered once or twice daily until disease progression or toxicity@@-@-@-@MELVILLE, NEW YORK@12/1/2008@@@@14916760@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00513851@60@-@-@@@-@@4/1/2006@-@OSI-930-102@@-@-@@@I@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@OSI PHARMACEUTICAL@@@@@OSI PHARMACEUTICAL||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@OSI-930@@@@@OSI-930||||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@MAXIMUM TOLERATED DOSE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14923730@Onco@@@@@@@@@@@Patients will receive treatment delivered as a 3-week cycle of IV docetaxel 52.5 mg/m2 on day 1, IV oxaliplatin 105 mg/m2 on day 1 and S-1 80 mg/m2 on day 1-14@@L01CD02@L01C@-@PARIS, FRANCE@@@Docetaxel is an antineoplastic agent which acts by promoting the assembly of tubulin into stable microtubules and inhibits their disassembly which leads to a marked decrease of free tubulin. The binding of docetaxel to microtubules does not alter the number of protofilaments. Docetaxel has been shown in vitro to disrupt the microtubular network in cells which is essential for vital mitotic and interphase cellular functions. Docetaxel was found to be cytotoxic in vitro against various murine and human tumour cell lines and against freshly excised human tumour cells in clonogenic assays. Docetaxel achieves high intracellular concentrations with a long cell residence time. In addition, docetaxel was found to be active on some but not all cell lines over expressing the p-glycoprotein which is encoded by the multidrug resistance gene. In vivo, docetaxel is schedule independent and has a broad spectrum of experimental antitumour activity against advanced murine and human grafted tumours.@@14923730@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00525005@44@-@-@@@-@@8/1/2007@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@DOCETAXEL@OXALIPLATIN@@@@DOCETAXEL|OXALIPLATIN|||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@South Korea@@@@@South Korea|||||||||@Stomach Cancer@@@@@Stomach Cancer|||||||||@TAXOTERE@ELOXATIN@@@@TAXOTERE|ELOXATIN|||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924515@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@PETACH TIKVA, ISRAEL@@@@@14924515@-@@-@-@@NO REVIEW@@@@-@Licensing agreement (signed with Ivax in September 2004) terminated in March 2007.@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@DISCONTINUED@@-@-@Clinical results were not made available during development.@-@@@@-@-@@@@@-||||@TEVA PHARMACEUTICAL@NIPPON SHINYAKU@@@@TEVA PHARMACEUTICAL|NIPPON SHINYAKU|||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@IVX-214@HMN-214@@@@IVX-214|HMN-214|||@Enzyme@Sulfonamide@@@@Enzyme|Sulfonamide|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924629@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@SAN ANTONIO, TEXAS@@@A liposomal formulation of a potent thymidylate synthase (TS) inhibitor@@14924629@-@@-@-@@NO REVIEW@@@@-@Obtained through a licensing agreement with OSI Pharmaceuticals in November 2007@-@-@-@-@-@@@-@@@-@-@@Patent protection through 2021@-@@@II@II@@-@-@Phase II clinical trial being planned. SOURCE: OncoVita, 30 July 2008@-@@@@MONO@-@@@@@-||||@ONCOVISTA INNOVATIVE THERAPIES@@@@@ONCOVISTA INNOVATIVE THERAPIES||||@@@@@@|||||||||@Breast Cancer@Stomach Cancer@@@@Breast Cancer|Stomach Cancer||||||||@OVI-237@@@@@OVI-237||||@TS Inhibitor@@@@@TS Inhibitor||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921644@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Combination with second-line chemotherapy@@-@-@-@-@@@@@14921644@Colorectal adenocarcinoma metastatic to the liver@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00149396@27@-@-@@@-@@7/1/2004@-@CT1030@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@@@@@-||||@MEDIGENE@@@@@MEDIGENE||||@@@@@@|||||||||@Liver Cancer@Colorectal Cancer@@@@Liver Cancer|Colorectal Cancer||||||||@NV-1020@@@@@NV-1020||||@Other@@@@@Other||||@ADVERSE EVENTS@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916425@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Ozarelix dose ranges@@-@-@-@IRVINE, CALIFORNIA@@@@@14916425@Hormone-dependent prostate ccancer@@-@-@@NO REVIEW@@@@-@Ozarelix rights for all indications have been licensed by 'terna Zentaris  to Spectrum Pharmaceuticals for North America and India and oncology rights have been licensed to Nippon Kayaku for Japan. 'terna Zentaris has kept the rest of the world rights.@-@-@-@-@-@@@-@@8/1/2005@-@SPECTRUM-LED@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@OZARELIX@@@@@OZARELIX||||@SPECTRUM PHARMACEUTICALS@@@@@SPECTRUM PHARMACEUTICALS||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@SPI-153@@@@@SPI-153||||@LH-RH Analog@@@@@LH-RH Analog||||@RESPONSE RATE@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921485@Onco@@@@@@@@@@@Lapatinib taken every day@@-@-@-@BRENTFORD, UNITED KINGDOM@@@Lapatinib is a 4-anilinoquinazoline kinase inhibitor of the intracellular tyrosine kinase domains of both Epidermal Growth Factor Receptor (EGFR [ErbB1]) and of Human Epidermal Receptor Type 2 (HER2 [ErbB2]) receptors (estimated Kiapp values of 3nM and 13nM, respectively) with a dissociation half-life of =300 minutes. Lapatinib inhibits ErbB-driven tumor cell growth in vitro and in various animal models. An additive effect was demonstrated in an in vitro study when lapatinib and 5-FU (the active metabolite of capecitabine) were used in combination in the 4 tumor cell lines tested. The growth inhibitory effects of lapatinib were evaluated in trastuzumab-conditioned cell lines. Lapatinib retained significant activity against breast cancer cell lines selected for long-term growth in trastuzumab-containing medium in vitro. These in vitro findings suggest non-cross-resistance between these two agents.@@14921485@Brain metastases in ErbB2-positive breast cancer following Herceptin-based systemic therapy and cranial radiotherapy@@-@-@@NO REVIEW@@@@-@-@-@NCT00263588@220@-@Registrational study for refractory setting@@@-@@11/1/2005@-@EGF105084@@17-Jul@-@@@II@III@@-@-@RESULTS PENDING@-@@@@MONO@LAPATINIB@@@@@LAPATINIB||||@GSK@@@@@GSK||||@@@@@@|||||||||@Breast Cancer@Brain Cancer@HER2+@@@Breast Cancer|Brain Cancer|HER2+|||||||@TYKERB@@@@@TYKERB||||@TK Inhibitor@HER2@EGFR@@@TK Inhibitor|HER2|EGFR||@RESPONSE RATE@@@@@@@@@@METASTATIC@REFRACTORY@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@CROSSOVER@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14918928@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Escalating 8 doses of CNDO-101@@-@-@-@SAN DIEGO, CALIFORNIA@@@@@14918928@-@@-@-@@NO REVIEW@@@@-@-@-@-@30@-@-@@@-@@1/1/2008@-@N/A@@-@-@@@I@I@@-@-@First-patient-in, January 2008. SOURCE: Coronado, 7 January 2008@-@@@@MONO@-@@@@@-||||@CORONADO BIOSCIENCES@@@@@CORONADO BIOSCIENCES||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@Breast Cancer@NSCLC@Other@Haematological Malignancy|Myeloma|Breast Cancer|NSCLC|Other|||||@CNDO-101@@@@@CNDO-101||||@Topoisomerase II Inhibitor@@@@@Topoisomerase II Inhibitor||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@-@@@@@DOSE ESCALATION@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921378@Onco@@@@@@@@@@@Faslodex with Arimidex@@L02BA03@L02B@-@LONDON, UNITED KINGDOM@@@Fulvestrant is an oestrogen receptor antagonist and binds to oestrogen receptors in a competitive manner with an affinity comparable with that of oestradiol. Fulvestrant blocks the trophic actions of oestrogens without itself having any partial agonist (oestrogen-like) activity. The mode of action is associated with down-regulation of oestrogen receptor (ER) protein. Clinical trials in postmenopausal women with primary breast cancer have shown that fulvestrant significantly down-regulates ER protein in ER positive tumours compared with placebo. There was also a significant decrease in progesterone receptor expression consistent with a lack of intrinsic oestrogen agonist effects.@@14921378@Hormone receptor positive breast cancer@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00256698@512@-@-@@@-@@1/1/2004@-@FACT@@-@-@@@III@III@@-@-@RESULTS PENDING (recruiting)@-@@@@COMBO@FULVESTRANT@ANASTROZOLE@@@@FULVESTRANT|ANASTROZOLE|||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@FASLODEX@ARIMIDEX@@@@FASLODEX|ARIMIDEX|||@Hormone Antagonist@@@@@Hormone Antagonist||||@TIME TO PROGRESSION@@@@@@@@@@RELAPSED@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14919151@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@I.v. infusion 0.2, 0.4, 0.8, 1.5, 3 and 6 mg/kg/dose every 7 days for a total of 5 infusions ( Days 1, 8, 15, 22, and 29) [clinicaltrials.gov]@@-@-@-@PRINCETON, NEW JERSEY@6/1/2010@@@@14919151@-@@-@-@@NO REVIEW@@@@-@BMS acquires Medarex in July 2009@-@NCT00730652@50@-@-@@@-@@11/1/2008@-@MDX1411-02@@-@Histologically confirmed diagnosis that is not amenable to cure by surgery or other means and has failed at least 1 prior systemic therapy@@@I@I@@-@-@Trial registered. [Medarex, 04.08.2008]@-@@@@-@-@@@@@-||||@MEDAREX@@@@@MEDAREX||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@Mantle Cell Lymphoma@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia|Mantle Cell Lymphoma|||||||@MDX-1411@@@@@MDX-1411||||@mAb@@@@@mAb||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@-@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924926@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Oral Thrombopoietin Receptor Agonist (SB-497115-GR) Administered at 50, 75, and 100 mg@@-@-@-@BRENTFORD, UNITED KINGDOM@2/1/2007@@@@14924926@Chemotherapy-induced thrombocytopaenia@@-@-@@NO REVIEW@@@@-@The GSK-Ligand collaboration began in 1997 to utilize Ligand's expertise and technology to discover small-molecule drugs to control hematopoieses and treat patients with cancer, anemia or platelet deficiencies. The research phase of the collaboration ende@-@NCT00102726@183@-@-@@@-@@4/1/2005@-@497115003@@-@-@@@II@II@@-@-@>> Trial registered. [GSK, 1 February 2005]@-@@@@MONO@ELTROMBOPAG@@@@@ELTROMBOPAG||||@GSK@@@@@GSK||||@@@@@@|||||||||@Supportive Care@Thrombocytopaenia@@@@Supportive Care|Thrombocytopaenia||||||||@PROMACTA@@@@@PROMACTA||||@Thrombopoietin Agonist@@@@@Thrombopoietin Agonist||||@PLATELET COUNT@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TABLET@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918973@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Lenocta in combination with interferon alpha@@-@-@-@BASKING RIDGE, NEW JERSEY@@@@@14918973@Advanced solid tumours@@-@-@@NO REVIEW@@@@-@-@-@-@12@-@-@@@-@@@-@N/A@@-@-@@@IIA@II@@-@-@Lenocta with IFN was well tolerated at 900MG/M2; 13 patients who received this dose or higher demonstrated increased immune response from dendritic and CD4+ T-cells. SOURCE: VioQuest/ASCO, 2 June 2008@-@@@@COMBO@SODIUM STIBOGLUCONATE@INTERFERON ALPHA-2B@@@@SODIUM STIBOGLUCONATE|INTERFERON ALPHA-2B|||@VIOQUEST PHARMACEUTICALS@@@@@VIOQUEST PHARMACEUTICALS||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@LENOCTA@@@@@LENOCTA||||@TK Inhibitor@@@@@TK Inhibitor||||@RESPONSE RATE@MAXIMUM TOLERATED DOSE@@@@@@@@@ADVANCED@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922243@Onco@@@@@@@@@@@265 on Telcyta and 265 on Gemzar@@L01AA@L01A@-@-@@@@@14922243@Advanced NSCLC progressed following first-line platinum therapy and second-line therapy.@@-@-@@NO REVIEW@@@@-@-@THIRD-LINE@-@530@-@PARTIAL HOLD ON TELCYTA ARMS IMPOSED IN JUNE 2007; ASSIST-3 AND ASSIST-5 PATIENTS WILL CONTINUE TO RECEIVE TREATMENT.@@@-@@@-@ASSIST-2@@-@530 PATIENTS WITH PLATINUM-RESISTANT ADVANCED NSCLC.@@@III@CLINICAL HOLD@@-@-@ASCO 2007; OS worse in Telcyta arm over control, did not meet primary or secondary endpoint. Median survival was 4.6 months in the Telcyta arm and 6.1 months in the control arm. PFS was 2.2 months on Telcyta and 2.3 months on Gemzar.@-@@@@MONO@CANFOSFAMIDE@@@@@CANFOSFAMIDE||||@TELIK@@@@@TELIK||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@TELCYTA@@@@@TELCYTA||||@Alkylating Agent@Nitrogen Mustard Analogue@@@@Alkylating Agent|Nitrogen Mustard Analogue|||@OVERALL SURVIVAL@PROGRESSION-FREE SURVIVAL@@@@@@@@@ADVANCED@@@@@INTERNATIONAL@RANDOMISED@ACTIVE CONTROL@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916646@Onco@@@@@@@@@@@Oral enzastaurin (2) alone versus placebo (1).@@-@-@-@INDIANAPOLIS, INDIANA@@@Enzastaurin is an oral, serine threonine kinase inhibitor which selectively targets the PKCBeta and PI3/AKTsignaling pathways. By blocking these key pathways frequently over-expressed in a wide variety of cancers, enzastaurin suppresses tumor cell proliferation, induces tumor cell death and inhibits tumor-induced angiogenesis. Treatment has been well tolerated with minimal drug-related toxicity. Enzastaurin administration is associated with fatigue, diarrhea, nausea, decreased platelets, cough, vomiting, transaminase elevation, dyspnea, peripheral edema, and dizziness. Further testing in Phase III versus a placebo will provide us with a more complete look at the side effect profile for enzastaurin. In addition to DLBCL, enzastaurin is also being studied in other tumor types including breast, colon, lung, ovarian and prostate cancers@@14916646@Diffuse large B-cell lymphoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00332202@459@-@-@@@EMEA GRANTED ORPHAN DRUG STATUS FOR DIFFUSE LARGE B-CELL LYMPHOMA IN MARCH 2007.@@@-@PRELUDE9823@@-@-@@@III@III@@-@-@Completion expected by November 2013.@-@@@@MONO@ENZASTAURIN@@@@@ENZASTAURIN||||@LILLY@@@@@LILLY||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@B-Cell Lymphoma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|B-Cell Lymphoma|||||||@LY-317615@@@@@LY-317615||||@Angiogenesis Inhibitor@@@@@Angiogenesis Inhibitor||||@DISEASE-FREE SURVIVAL@@@@@@@@@@-@@@@@RANDOMISED@PLACEBO-CONTROLLED@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922464@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@CP-675206 IV every 3 months versus best supportive care@@-@-@-@NEW YORK, NEW YORK@1/1/2010@@Tremelimumab is a fully human anti-CTLA4 (cytotoxic T-lymphocyte antigen 4) IgG2 monoclonal antibody developed by Pfizer for its potential therapeutic application in melanoma, non-small cell lung cancer (NSCLC) and colorectal cancer. CTLA4 is a CD28-family receptor expressed mainly on T-lymphocyte that acts to inhibit T-lymphocyte function.@@14922464@Given straight after first-line platinum-based therapy in Stage IIIB or IV that has responded or remained stable@@-@-@@NO REVIEW@@@@-@Medarex entitled to royalties@FIRST-LINE@NCT00312975@80@-@-@@@-@@5/1/2006@-@A3671015@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@TREMELIMUMAB@TICILIMUMAB@@@@TREMELIMUMAB|TICILIMUMAB|||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@CP-675206@@@@@CP-675206||||@mAb@CTLA4 Receptor Antagonist@@@@mAb|CTLA4 Receptor Antagonist|||@TIME TO PROGRESSION@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921071@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@ILX651 IV daily for 5 consecutive days once every 3 weeks@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@6/1/2006@@@@14921071@-@@-@-@@NO REVIEW@@@@-@Acquired through takeover of Ilex in 2004@-@NCT00078455@-@-@-@@@-@@12/1/2003@-@ILX651-231@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@TASIDOTIN@@@@@TASIDOTIN||||@GENZYME@@@@@GENZYME||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@ILX-651@@@@@ILX-651||||@Depsipeptide@@@@@Depsipeptide||||@RESPONSE RATE@@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916187@Onco@@@@@300f1015ntsdm@@@@@@Zarnestra 100 bid continuously administered from one week prior to radiation therapy until last day of radiation therapy@@-@-@-@NEW BRUNSWICK, NEW JERSEY@12/1/2008@@A nonpeptidomimetic quinolinone with potential antineoplastic activity. Tipifarnib binds to and inhibits the enzyme farnesyl protein transferase, an enzyme involved in protein processing (farnesylation) for signal transduction. By inhibiting the farnesylation of proteins, this agent prevents the activation of Ras oncogenes, inhibits cell growth, induces apoptosis, and inhibits angiogenesis.@@14916187@Resectable GBM or non-surgical GBM; combo with radiation therapy@@-@-@@NO REVIEW@@@@-@-@-@NCT00209989@27@-@-@@@-@@10/1/2005@-@TETE 02@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@TIPIFARNIB@@@@@TIPIFARNIB||||@JOHNSON & JOHNSON@@@@@JOHNSON & JOHNSON||||@@@@@@|||||||||@Brain Cancer@Glioblastoma Multiforme@@@@Brain Cancer|Glioblastoma Multiforme||||||||@ZARNESTRA@@@@@ZARNESTRA||||@Farnesyltransferase Inhibitor@@@@@Farnesyltransferase Inhibitor||||@TIME TO PROGRESSION@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14924123@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@L1A@L1A@-@RIDGEFIELD PARK, NEW JERSEY@@@Glufosfamide combines the active part of an approved alkylator, a member of a widely used class of chemotherapy drugs, with a glucose molecule. The linkage between glucose and the alkylator is cleaved to release the active drug. With glucose as the side product, glufosfamide has fewer side effects than other drugs in its class, which are known to cause hemorrhagic cystitis, a serious condition characterized by severe bladder bleeding.@@14924123@Second-line therapy @@-@-@@NO REVIEW@@@@-@-@-@-@300@-@-@@@-@@@-@-@@-@-@@@III@III@@-@-@Threshold Pharmaceuticals reported overall survival in the glufosfamide arm was 18% higher compared to those in best supportive care alone. But as result was not statistically significant, the trial was closed to enrollment.@-@@@@MONO@GLUFOSFAMIDE@@@@@GLUFOSFAMIDE||||@THRESHOLD PHARMACEUTICALS@@@@@THRESHOLD PHARMACEUTICALS||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@-@@@@@-||||@Alkylating Agent@@@@@Alkylating Agent||||@OVERALL SURVIVAL@@@@@@@@@@ADVANCED@@@@@RANDOMISED@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916629@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Ortataxel alone@@-@-@-@LEVERKUSEN, GERMANY@@@@@14916629@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00044564@140@-@-@@@-@@12/1/2001@-@Protocol No. 100386@@-@-@@@II@DISCONTINUED@@-@-@ASCO 2003; results from 50 patients showed it was not active in this patient population; development for this indication is no longer proceeding. @-@@@@MONO@ORTATAXEL@@@@@ORTATAXEL||||@BAYER HEALTHCARE@@@@@BAYER HEALTHCARE||||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@BAY-598862@@@@@BAY-598862||||@Taxane@@@@@Taxane||||@RESPONSE RATE@SAFETY@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16061297@Onco@@@@@300f1008ntsdm@@@@@@@@L01XX17@L01X@@@@@Topoisomerase I relieves torsional strain in DNA by inducing reversible single strand breaks. Topotecan binds to the topoisomerase I-DNA complex and prevents religation of these single strand breaks. The cytotoxicity of topotecan is thought to be due to double strand DNA damage produced during DNA synthesis, when replication enzymes interact with the ternary complex formed by topotecan, topoisomerase I, and DNA. Mammalian cells cannot efficiently repair these double strand breaks.@@16061297@@@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@@@103@1.0mg / m2 (body surface area) was dispensed daily drip infusion for 5 days,  with a 3 week interval between the start of each course.@MHLW, 1 June 2007@6/1/2007@@@@@@@No@@@@@II@APPROVED@@@NHI@@@@@@MONO@TOPOTECAN HYDROCHLORIDE@@@@@TOPOTECAN HYDROCHLORIDE||||@NIPPON KAYAKU@@@@@NIPPON KAYAKU||||@@@@@@|||||||||@SCLC@@@@@SCLC|||||||||@HYCAMTIN@@@@@HYCAMTIN||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@@@@@@@@@@@@@@@@@@@@@1.75@m²@232313.4545@@@84@day@84 day@232313.45@232313.45@2765.64@1@0.0091@7301.28@8610@@@@@@@@@@@6637.53@21@@mg/m²@1@5@@@@@@@@@@@8/30/2017@7301.28@7301.28@4240408D1037@POWDER FOR INJECTION@YEN@@@@@@@@1.1@MG@1.1 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14918952@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@TOKYO, JAPAN@@@@@14918952@-@@-@-@@NO REVIEW@@@@-@Human Monoclonals licensed exclusive worldwide rights to Eisai's Morphotek subsidiary. SOURCE: Morphotek, 10 March 2008@-@-@N/A@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@EISAI@HUMAN MONOCLONAL INTERNATIONAL@@@@EISAI|HUMAN MONOCLONAL INTERNATIONAL|||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@IGM ANTIBODY@@@@@IGM ANTIBODY||||@mAb@Human@@@@mAb|Human|||@N/A@@@@@@@@@@-@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14925005@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@N02AA01@N02A@NO@READING, UNITED KINGDOM@@@@@14925005@Severe chronic pain and/or pain resistant to other analgesics, in particular pain associated with cancer.@@NO@@@NO REVIEW@@@@100%@Acquired through takeover of Link Holdings in November 2006@@@@Adults: Recommended dosage is one capsule twice daily, at 12-hourly intervals.@EMA, May 1995@@@@@@Caution should be exercised in elderly subjects, in patients with impaired hepatic and/or renal functions, in patients with hypothyroidism or hypoadrenalism, in patients in a state of shock or with asthma. The dose of Zomorph should be reduced, or its use should be avoided in cases of hepatic or renal failure.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@MORPHINE SULPHATE@@@@@MORPHINE SULPHATE||||@ARCHIMEDES PHARMA@@@@@ARCHIMEDES PHARMA||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@ZOMORPH@@@@@ZOMORPH||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@60@1.299@21.8@@@@@@@@@@@@@@@@@@@@@@@@@@@@7/28/2017@0.36@0.36@3.88E+15@CAPSULE MODIFIED RELEASE@GB£@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14919584@Onco@@@@@300f1015ntsdm@@@@@@@@N02AB03@N02A@@@@@Fentanyl is a synthetic opiate with a clinical potency of 50 to 100 times that of morphine. Its onset of action is rapid and its duration of action is short. In man, a single iv dose of 0.5-1 mg/70 kg body weight immediately produces a pronounced state of surgical analgesia, respiratory depression, bradycardia and other typical morphine-like effects. The duration of action of the peak effects is about 30 minutes. All potent morphine-like drugs produce relief from pain, ventilatory depression, emesis, constipation, physical dependence, certain vagal effects and varying degrees of sedation. Fentanyl, however, differs from morphine not only by its short duration of action but also by its lack of emetic effect and minimal hypotensive activity in animals.@@14919584@Management of breakthrough cancer pain in patients with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain@@NO@@@NO REVIEW@@@@@Acquired via takeover of generics unit of Merck KGaA@@@@@Apr-98@@@@@@@@No@@@@@@APPROVED@@FREE PRICE IN HOSPITAL@HAUTE AUTORITÉ DE SANTÉ@RESULTS PENDING@@@@@@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@PANPHARMA@@@@@PANPHARMA||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@GENERIC@@@@@GENERIC||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14921416@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Efaproxyn plus WBRT@@-@-@-@WESTMINSTER, COLORADO@@@@@14921416@Women with brain metastases originating from breast cancer; discontinued in June 2007.@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@ENRICH@@-@-@@@PIVOTAL TRIAL@DISCONTINUED@@-@-@June 2007; Patients who received Efaproxyn plus WBRT did not experience a statistically significant improvement in survival compared to WBRT alone (8.5 months vs. 7.5 months; hazard ratio 0.87, p-value = 0.23). All secondary efficacy endpoints also failed to achieve statistical significance. All Efaproxyn trials discontinued. SOURCE: Allosk, 19 June 2007@-@@@@-@EFAPROXIRAL@@@@@EFAPROXIRAL||||@ALLOS THERAPEUTICS@@@@@ALLOS THERAPEUTICS||||@@@@@@|||||||||@Brain Cancer@@@@@Brain Cancer|||||||||@EFAPROXYN@@@@@EFAPROXYN||||@Radiation Sensitiser@@@@@Radiation Sensitiser||||@OVERALL SURVIVAL@@@@@@@@@@METASTATIC@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921838@Onco@@@@@300f1014ntsdm@@@@@@Arm I: Patients receive oral brivanib alaninate once daily and cetuximab IV over 60-120 minutes once weekly. Arm II: Patients receive oral placebo once daily and cetuximab IV over 60-120 minutes once weekly. SOURCE: clinicaltrials.gov@@-@-@-@NEW YORK, NEW YORK@@@@@14921838@Patients who have failed or are intolerant to all recommended therapies@@-@-@@NO REVIEW@@@@-@-@MULTIPLE@NCT00640471@750@-@-@@@-@@5/1/2008@-@CAN-NCIC-CO20@@-@-@@@III; CAN-NCIC-CA182009;@III@@-@-@RESULTS PENDING@-@@@@COMBO@BRIVANIB ALANINATE@CETUXIMAB@IRINOTECAN@@@BRIVANIB ALANINATE|CETUXIMAB|IRINOTECAN||@BMS@@@@@BMS||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@BMS-582664@ERBITUX@CAMPTOSAR@@@BMS-582664|ERBITUX|CAMPTOSAR||@TK Inhibitor@VEGF@Angiogenesis Inhibitor@@@TK Inhibitor|VEGF|Angiogenesis Inhibitor||@OVERALL SURVIVAL@@@@@@@@@@METASTATIC@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL@C$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14916190@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@1-hour IV infusion on day 1 every 3 weeks or on days 1, 8 and 15 every 3 weeks@@-@-@-@PARIS, FRANCE@@@@@14916190@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00547261@48@-@-@@@-@@10/1/2007@-@TED5710@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@SSR-97225@@@@@SSR-97225||||@Other@@@@@Other||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@REFRACTORY@@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921702@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Weekly infusion for 3 week-cycles until disease progression or unacceptable toxicity: 3.2, 4.8, 7.2, 10.8 or 15MG/KG@@-@-@-@MENLO PARK, CALIFORNIA@@@@@14921702@Combo with paclitaxel and carboplatin@@-@-@@NO REVIEW@@@@-@-@-@NCT00510445@48@-@-@@@-@@7/1/2007@-@CP14A005@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@COMBO@-@@@@@-||||@GERON@@@@@GERON||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@GRN-163L@@@@@GRN-163L||||@Telomerase Inhibitor@@@@@Telomerase Inhibitor||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@ADVANCED@METASTATIC@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14923223@Onco@@@@@300f1015ntsdm@@@@@@-@@L01DB01@L01D@-@PARIS, FRANCE@@@The lead product in the BioAlliance nanoparticle program, doxorubicin Transdrug, has completed in 2006 a Phase I/II study in the EU for treatment of primary liver cancer, hepatocellular carcinoma (HCC), via the intra-arterial route of administration. @@14923223@Primary liver cancer@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@"DSMB and Steering Committee recommended suspension of trial; on the basis of the initial data, the two committees observed a clinical benefit but also more frequent and more severepulmonary adverse events than expected and have thus recommended suspension of the trial, given the incidence of this type of effect. SOURCE: BioAlliance, 16 July 2008"@-@@@@-@DOXORUBICIN, NANOPARTICLE@@@@@DOXORUBICIN, NANOPARTICLE||||@BIOALLIANCE PHARMA@@@@@BIOALLIANCE PHARMA||||@@@@@@|||||||||@Liver Cancer@@@@@Liver Cancer|||||||||@TRANSDRUG@@@@@TRANSDRUG||||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14922306@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@GSK690693 dosed daily for 5 consecutive days every 21 days as an IV infusion over 4 h. SOURCE: clinicaltrials.gov@@-@-@-@BRENTFORD, UNITED KINGDOM@12/1/2009@@AKT inhibitor@@14922306@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00666081@61@-@-@@@-@@4/1/2008@-@AKT108169@@-@-@@@I@I@@-@-@RESULTES PENDING@-@@@@MONO@-@@@@@-||||@GSK@@@@@GSK||||@@@@@@|||||||||@Haematological Malignancy@@@@@Haematological Malignancy|||||||||@GSK-690693@@@@@GSK-690693||||@Other@@@@@Other||||@DOSE RANGE@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919019@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@TOKYO, JAPAN@@@@@14919019@Hepatocellular carcinoma@@-@-@@NO REVIEW@@@@-@BMS joined Japanese development in July 2006@-@-@16@-@-@@@-@@@-@N/A@@-@-@@@II@II@@-@-@9 patients (56%) achieved CR. The grade 3 toxicities were neutropaenia (19%), total bilirubin elevation (19%), AST elevation (44%), and ALT elevation (19%). None of the patients showed grade 4 toxicities or episodes of renal dysfunction.@-@@@@MONO@MIRIPLATIN HYDRATE@@@@@MIRIPLATIN HYDRATE||||@DAINIPPON SUMITOMO@@@@@DAINIPPON SUMITOMO||||@@@@@@|||||||||@Liver Cancer@Hepatocellular Carcinoma@@@@Liver Cancer|Hepatocellular Carcinoma||||||||@SM-11355@@@@@SM-11355||||@Platinum@@@@@Platinum||||@RESPONSE RATE@@@@@@@@@@-@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921563@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients receive carmustine in ethanol intratumorally over 5 minutes during stereotactic biopsy or open craniotomy. Cohorts of 3-6 patients receive escalating doses of DTI-015 until the MTD is determined. The MTD is defined as the dose preceding that at which 3 of 6 patients experience dose-limiting toxicity. (Phase I of this study closed to accrual as of 01/15/2002.) Additional patients then receive treatment with DTI-015 at the recommended phase II dose. Patients are followed at 4, 8, and 12 weeks and then every 1-3 months until disease progression.@@-@-@-@REDWOOD CITY, CALIFORNIA@@@@@14921563@Recurrent, inoperable brain cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00009854@15@-@-@@@-@@6/1/2000@-@DTI-0002, @@-@-@@@I/II UCSF-H7858-17520-01, NCI-V00-1642; @II@@-@-@RESULTS PENDING@-@@@@MONO@CARMUSTINE@@@@@CARMUSTINE||||@DIRECT THERAPEUTICS@@@@@DIRECT THERAPEUTICS||||@@@@@@|||||||||@Brain Cancer@@@@@Brain Cancer|||||||||@DTI-015@@@@@DTI-015||||@Alkylating Agent@@@@@Alkylating Agent||||@DNA ADDUCTS@DOSE-LIMITING TOXICITY@@@@@@@@@-@@@@@DOSE ESCALATION@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ETHANOL SOLVENT@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916624@Onco@@@@@300f1018ntsdm@@@@@@Cavatak administered intratumourally@@-@-@-@-@@@Cavatak is the trade name of Coxsackievirus A21 (CVA21). It is a human virus that occurs naturally in the community, and was first isolated over 50 years ago. Infection by CVA21 is often symptomless; when it does produce illness it is associated with a common cold-like illness. In order to infect a cell, CVA21 must first attach to the outside of a cell, using a specific ‘receptor' on the cell's surface (like a key fitting a lock). CVA21 uses two receptors to infect cells, ICAM-1 (Inter cellular adhesion molecule 1) and DAF (decay accelerating factor). These receptors occur in far higher numbers in metastatic melanoma cells than in normal cells. As ICAM-1 is not present to any significant extent on normal tissue cells, this confers a high degree of specificity on the oncolytic action of the viruses (ICAM-1 is also sometimes present in increased amounts in other cancer types, including breast cancer, prostate cancer, colon cancer and multiple myeloma).@@14916624@Two Intratumoural Doses of Coxsackievirus Type A21 in Melanoma Patients@@-@-@@NO REVIEW@@@@-@-@-@NCT00438009@9@-@-@@@-@@2/1/2007@-@PSX-X-03200649@@-@-@@@I@I@@-@-@Trial registered and commenced [Viralytics, 19.02.2007]@-@@@@MONO@-@@@@@-||||@VIRALYTICS@@@@@VIRALYTICS||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@CAVATAK@@@@@CAVATAK||||@Vaccine@@@@@Vaccine||||@SAFETY@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14922452@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Final dose TBD mg/kg (pending on phase 1 escalation portion of the study), IV on Day 1 of each 28 day cycle until either progression or toxicity  [clinicaltrials.gov]@@-@-@-@NEW YORK, NEW YORK@2/1/2011@@CP-751,871, a fully human monoclonal antibody, is a highly specific inhibitor of the IGF-1R pathway. The IGF-1R pathway is one of the key signaling pathways in cancer cells that lead to uncontrolled growth and survival of tumour cells. @@14922452@CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors@@-@-@@NO REVIEW@@@@-@Acquired through takeover of Pharmacia Corp.@-@NCT00560235@130@-@-@@@-@@12/1/2007@-@A4021020@@-@-@@@I/II@II@@-@-@Trial registered. [Pfizer, 15.11.2007]@-@@@@MONO@FIGITUMUMAB@@@@@FIGITUMUMAB||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@CP-751,871@@@@@CP-751,871||||@mAb@Human@@@@mAb|Human|||@SAFETY@RESPONSE RATE@@@@PHARMACOKINETICS@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919299@Onco@@@@@@@@@@@Litx plus chemotherapy (FOLFOX4 or FOLFIRI) versus chemotherapy@@-@-@-@BELLEVUE, WASHINGTON@@@Litx is a targeted treatment. Destruction of tumor tissue with Litx occurs only where light is delivered in sufficient quantity, thereby sparing the patient the debilitating side effects common to therapies such as radiation and chemotherapy. Litx requires a specific amount of light at a specific wavelength to energize the LS11 drug molecules before tissue destruction occurs, and tissue destruction then occurs only in the immediate vicinity of the LED array. Because the Litx system can control the location and amount of light exposure, it can maintain clean boundaries between destroyed and spared tissue. In addition, LS11 has been shown to accumulate preferentially in tumor tissue, which could be important in the treatment of some solid tumors. @@14919299@Colorectal cancer with recurrent liver metastases@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00440310@450@-@-@@@-@@2/1/2007@-@LSO-OL006@@-@-@@@III@III@@-@-@Trial registered. [LSO, 23.02.2007]@-@@@@COMBO@TALAPORFIN SODIUM@@@@@TALAPORFIN SODIUM||||@LIGHT SCIENCES ONCOLOGY@@@@@LIGHT SCIENCES ONCOLOGY||||@Serbia@@@@@Serbia|||||||||@Colorectal Cancer@Liver Cancer@@@@Colorectal Cancer|Liver Cancer||||||||@LS-11@LITX@FOLFIRI@FOLFOX4@@LS-11|LITX|FOLFIRI|FOLFOX4|@Other@@@@@Other||||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@METASTATIC@RELAPSED@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
15408211@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01XE36@L01X@@BASEL, SWITZERLAND@@@Alectinib is a tyrosine kinase inhibitor that targets ALK and RET.@@15408211@ALECENSA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.@@NA@@@@@@@@@@@138@The recommended dose of ALECENSA is 600 mg orally twice daily. Administer ALECENSA until disease progression or unacceptable toxicity.@FDA, 11 December 2015@12/11/2015@@Yes@@@@@No@@@ALK POSITIVE@@@APPROVED@@@NA@@@@@@MONO@ALECTINIB@@@@@ALECTINIB||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@ALECENSA@@@@@ALECENSA||||@TK Inhibitor@@@@@TK Inhibitor||||@@@@@@@@@@@METASTATIC@@@@@@@@@@1@1@151180.1244@@@11.2@month@11.2 month@151180.12@151180.12@443.79@240@1@13313.61@@@@@@@@@@@@0.37@1@@mg@1200@1@@@@@@@@@@@8/2/2017@55.47@55.47@50242-0130-01@CAPSULE (BOTTLE)@US$@@@@@@@@150@MG@150 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924680@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@10/1/2006@@@@14924680@with interferon alpha-2a@@-@-@@NO REVIEW@@@@-@Wilex obtained option to own full marketing rights to Rencarex from Centocor in October 2004. Wilex inked a marketing partnership with Spanish firm Esteve for Southern Europe in April 2004.  @-@-@31@-@-@@@-@@@-@-@@-@31 PATIENTS WITH PROGRESSIVE CLEAR CELL RCC@@@II@II@@-@-@Wilex reported in October 2006 that a clinical response was seen in 42% of the 31 patients with progressive clear RCC with prior kidney removal, who had a median survival of 30 months and a 2-year survival rate of 57%.  Patients that responded after 12 weeks of treatment and were treated for 6 more weeks with Rencarex had a median survival of 45 months and a 2-year survival rate of 79%. Patients whose treatment stopped after 12 weeks median survival reached 10 months and had a 2-year survival of 30%. @-@@@@COMBO@-@@@@@-||||@WILEX@CENTOCOR@JOHNSON & JOHNSON@@@WILEX|CENTOCOR|JOHNSON & JOHNSON||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@RENCAREX@WX-G250@@@@RENCAREX|WX-G250|||@mAb@Chimeric@@@@mAb|Chimeric|||@OVERALL SURVIVAL@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919076@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients will receive GI-4000 for up to 3 years with the goal of delaying disease recurrence and prolonging survival. SOURCE: GlobeImmune, 19 March 2008@@-@-@-@-@@@@@14919076@Consolidation therapy in subjects with NSCLC treated with curative intent, whose tumor is found to contain a mutation in the ras gene and who are disease free at their first post-treatment re-staging assessment (1-4 months after completion of therapy)@@-@-@@NO REVIEW@@@@-@-@-@-@N/A@-@-@@@-@@3/1/2008@-@MSKCC@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@GLOBEIMMUNE@@@@@GLOBEIMMUNE||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@GI-4000@TARMOGEN@@@@GI-4000|TARMOGEN|||@Vaccine@@@@@Vaccine||||@IMMUNE RESPONSE@@@@@@@@@@-@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920974@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Irofulven with prednisone, capecitabine/prednisone or mitoxantrone/prednisone@@-@-@-@TOKYO, JAPAN@@@@@14920974@Irofulven in various combinations in docetaxel-pretreated HRPC@@-@-@@NO REVIEW@@@@-@Eisai acquired through takeover of MGI Pharma.@SECOND-LINE@NCT00124566@35@-@-@@@-@@6/1/2004@-@IROF-018@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@IROFULVEN@PREDNISONE@@@@IROFULVEN|PREDNISONE|||@EISAI@MGI PHARMA@@@@EISAI|MGI PHARMA|||@@@@@@|||||||||@Prostate Cancer@HRPC@@@@Prostate Cancer|HRPC||||||||@MGI-114@@@@@MGI-114||||@Alkylating Agent@@@@@Alkylating Agent||||@TIME TO PROGRESSION@@@@@@@@@@REFRACTORY@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924163@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@AMG-162 + bisphosphonates@@-@-@-@THOUSAND OAKS, CALIFORNIA@@@Denosumab is a fully human monoclonal antibody that specifically targets the receptor activator of nuclear factor kappa B ligand (“RANKL”), a key mediator of the cells responsible for bone breakdown. Denosumab is being studied across a range of conditions, including osteoporosis, treatment-induced bone loss, bone metastases, rheumatoid arthritis, and multiple myeloma. @@14924163@Advanced cancers with bone metastases@@-@-@@NO REVIEW@@@@-@Japanese rights licensed to Daiichi Sankyo for US$20 mil upfront and royalties in July 2007, and Daiichi Sankyo will pay US$150 mil of expected worldwide development costs through 2009.@-@NCT00104650@-@-@-@@@-@@@-@-@@-@PATIENTS WITH ADVANCED CANCER CURRENTLY BEING TREATED WITH IV BISPHOSPHONATES@@@II@II@@-@-@Trial registered. [Amgen, 3.03.2005]@-@@@@COMBO@DENOSUMAB@@@@@DENOSUMAB||||@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Bone Metastases@@@@@Bone Metastases|||||||||@AMG-162@@@@@AMG-162||||@mAb@Human@RANK Ligand@@@mAb|Human|RANK Ligand||@RESPONSE RATE@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921425@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@EN-3285 oral rinse versus placebo@@-@-@-@CHADDS FORD, PENNSYLVANIA@6/1/2009@@@@14921425@Oral mucositis in patients with head and neck cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00574860@240@-@-@@@-@@12/1/2007@-@EN3285-301@@-@-@@@III@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@ENDO PHARMACEUTICALS@@@@@ENDO PHARMACEUTICALS||||@@@@@@|||||||||@Supportive Care@Mucositis@Head & Neck Cancer@@@Supportive Care|Mucositis|Head & Neck Cancer|||||||@EN-3285@@@@@EN-3285||||@Other@@@@@Other||||@MUCOSITIS (SEVERE)@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920193@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01DB07@L01D@@NEW DELHI, INDIA@@@Although its mechanism of action has not been determined, mitoxantrone is a DNA-reactive agent. It has a cytocidal effect on proliferating and non-proliferating cultured human cells, suggesting activity against rapidly proliferating and slow-growing neoplasms.@@14920193@@@@@@NO REVIEW@@@@@Dabur Pharma will change its name to Fresenius Kabi Oncology. [Dabur, 29.10.2008]@@@@@FDA, 19 May 2008@5/19/2008@@@@@@@No@@@@@@APPROVED@@@@@@@@@COMBO@MITOXANTRONE@@@@@MITOXANTRONE||||@DABUR PHARMA@FRESENIUS KABI ONCOLOGY@@@@DABUR PHARMA|FRESENIUS KABI ONCOLOGY|||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@GENERIC@@@@@GENERIC||||@Cytotoxic Antibiotic@Anthracycline@Topoisomerase II Inhibitor@@@Cytotoxic Antibiotic|Anthracycline|Topoisomerase II Inhibitor||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@US$@@@@@@@@30@MG@2 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922309@Onco@@@@@@@@@@@Eniluracil with escalatin doses of 5-FU administered orally once-weekly for 3 out of 4 weeks@@-@-@-@DURHAM, NORTH CAROLINA@@@@@14922309@Locally advanced, recurrent or metastatic hepatocellular carcinoma@@-@-@@NO REVIEW@@@@-@Recycled from GSK, which suspended development of the drug@-@NCT00319683@-@-@ORPHAN DRUG DESIGNATION RECEIVED FROM THE FDA FOR THE USE OF ENILURACIL IN COMBINATION WITH FLUOROPYRIMIDINES (INCLUDING 5-FU) TO TREAT LIVER CANCER.@@@-@@@-@AHX-03-103  @@-@-@@@I/II@DISCONTINUED@@-@-@>> Trial suspended as part of corporate reorganisation to focus on STS. [Adherex, 13.11.2008]              >> Trial registered. Phase I portion of the trial is due to complete in Q3 2007, Phase II is due for completeion in early 2007 [Adherex, 27.04.2006]@-@@@@-@ENILURACIL@@@@@ENILURACIL||||@ADHEREX TECHNOLOGIES@@@@@ADHEREX TECHNOLOGIES||||@Taiwan@@@@@Taiwan|||||||||@Liver Cancer@@@@@Liver Cancer|||||||||@ADH-300004@@@@@ADH-300004||||@Anti-metabolite@@@@@Anti-metabolite||||@SAFETY@MAXIMUM TOLERATED DOSE@@@@@@@@@LOCALLY ADVANCED@RELAPSED@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@
14924591@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Neovastat versus placebo@@-@-@-@QUEBEC, QUEBEC@@@@@14924591@Patients who are refractory to immunotherapy@@-@-@@NO REVIEW@@@@-@-@-@NCT00005995@280@-@-@@@-@@10/1/2001@-@-@@-@-@@@III@III@@-@-@RESULTS PENDING@-@@@@MONO@AE-941@@@@@AE-941||||@AETERNA ZENTARIS@@@@@AETERNA ZENTARIS||||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@NEOVASTAT@@@@@NEOVASTAT||||@Angiogenesis Inhibitor@@@@@Angiogenesis Inhibitor||||@RESPONSE RATE@@@@@@@@@@METASTATIC@REFRACTORY@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924337@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients will receive four weekly doses of FP-1039 by intravenous administration to characterize the safety and tolerability of FP-1039. [FivePrime]@@-@-@-@SAN FRANCISCO, CALIFORNIA@@@FP-1039 is an FGFR1:Fc fusion protein shown in pre-clinical studies to inhibit angiogenesis and slow the growth of tumors.@@14924337@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@Trial started. [FivePrime, 8.09.2008]@-@@@@MONO@-@@@@@-||||@FIVEPRIME THERAPEUTICS@@@@@FIVEPRIME THERAPEUTICS||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@FP-1039@@@@@FP-1039||||@Angiogenesis Inhibitor@@@@@Angiogenesis Inhibitor||||@SAFETY@TOLERABILITY@@@@RESPONSE RATE@@@@@-@@@@@OPEN-LABEL@MULTI-CENTRE@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924113@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@L1A@L1A@-@RIDGEFIELD PARK, NEW JERSEY@@@Glufosfamide combines the active part of an approved alkylator, a member of a widely used class of chemotherapy drugs, with a glucose molecule. The linkage between glucose and the alkylator is cleaved to release the active drug. With glucose as the side product, glufosfamide has fewer side effects than other drugs in its class, which are known to cause hemorrhagic cystitis, a serious condition characterized by severe bladder bleeding.@@14924113@Recurrent, sensitive@@-@-@@NO REVIEW@@@@-@-@-@NCT00435578@50@-@-@@@-@@2/1/2007@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@-@GLUFOSFAMIDE@@@@@GLUFOSFAMIDE||||@THRESHOLD PHARMACEUTICALS@@@@@THRESHOLD PHARMACEUTICALS||||@@@@@@|||||||||@SCLC@@@@@SCLC|||||||||@-@@@@@-||||@Alkylating Agent@@@@@Alkylating Agent||||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921136@Onco@@@@@@@@@@@Recentin with FOLFOX versus Avastin with FOLFOX@@-@-@-@LONDON, UNITED KINGDOM@@@Cediranib (Recentin AZD2171) is a highly potent inhibitor of the tyrosine kinase activity associated with all three vascular endothelial growth factor (VEGF) receptors and is currently in Phase II/III clinical trials. Preclinically, cediranib inhibits VEGF signaling and angiogenesis in vivo and impedes solid tumor growth significantly. @@14921136@Versus Avastin@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00384176@1600@-@-@@@-@@8/1/2006@-@HORIZON III @@-@-@@@II/III; D8480C00013; 2005-003440-66 / @III@@-@-@>> Trial did not meet primary end point of progression-free survival. [AstraZeneca 8 March 2010 http://www.astrazeneca.com/media/latest-press-releases/2010-new/recoentin-horizon?itemId=8748245 ]>>Patients will progress directly into Phase III at 20MG. IDMC recommended that HORIZON I, II and II continue. SOURCE: AstraZeneca, 27 February 2008@-@@@@COMBO@CEDIRANIB@@@@@CEDIRANIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@RECENTIN@AZD-2171@@@@RECENTIN|AZD-2171|||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@METASTATIC@@@@@RANDOMISED@DOUBLE-BLIND@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922445@Onco@@@@@@@@@@@Axitinib 5MG bid starting dose plus FOLFOX versus Avastin 5MG/KG ever 2 weeks plus FOLFOX versus Axitinib 5MG bid plus Avastin 2MG/KG every 2 weeks plus FOLFOX@@-@-@-@NEW YORK, NEW YORK@8/1/2008@@Axitinib is an oral, selective inhibitor of VEGFR 1, 2, 3 (vascular endothelial growth factor receptors 1, 2 and 3), which has been shown to induce tumor regression as a single-agent and in combination with chemotherapy. Inhibiting VEGF binding plays a key role in anti-angiogenesis - or blocking blood vessel formation which starves tumors of the blood and nutrients needed for growth. @@14922445@-@@-@-@@NO REVIEW@@@@-@Developed from Abgenix (now Amgen) mice, double-digit royalties to go to Medarex due to cross-licensing in this area@-@NCT00460603@123@-@-@@@-@@1/1/2006@-@A4061020@@-@-@@@II@II@@-@-@Results expected in June 2009@-@@@@COMBO@AXITINIB@@@@@AXITINIB||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@AG-013736@FOLFOX@@@@AG-013736|FOLFOX|||@TK Inhibitor@VEGF@PDGF@SCF@Angiogenesis Inhibitor@TK Inhibitor|VEGF|PDGF|SCF|Angiogenesis Inhibitor@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14925054@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Arm A: Combination: Experimental: ON 01910.Na, 1800 mg/m2 via 2 hr CIV infusions administered twice weekly for 3 weeks of a 4 week cycle; Gemcitabine 1000 mg/m2 weekly for 3 weeks of a 4 week cycleArm B: Gemcitabine only: Active Comparator: Gemcitabine, 1000 mg/m2 weekly for 3 weeks of a 4 week cycle@@@@@@12/1/2014@@@@14925054@A Phase II/III, Multi-center, Randomized, Controlled Study to Compare the Efficacy and Safety of Gemcitabine Alone vs. ON 01910.Na Combined With Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Cancer@@@@@@@@@@@@NCT01360853@650@@@@@@@5/1/2011@@@@@Patients must have received no prior chemotherapy for pancreatic cancer. Measurable disease, defined as lesions that can be accurately measured in at least 1 dimension with longest diameter (LD) =20 mm using conventional techniques or =10 mm with spiral computed tomography (CT) scan@@@III@III@@@@Trial registered [Onconova 24 May 2011]@@@@@COMBO@RIGOSERTIB@GEMCITABINE@@@@RIGOSERTIB|GEMCITABINE|||@ONCONOVA@@@@@ONCONOVA||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@ON 01910.NA@GEMZAR@@@@ON 01910.NA|GEMZAR|||@Other@@@@@Other||||@OVERALL SURVIVAL@@@@@PROGRESSION-FREE SURVIVAL@TUMOUR RESPONSE RATE@SAFETY@@@METASTATIC@@@@@RANDOMISED@CONTROLLED@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924754@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Taxoprexin 500MG/M2 weekly for first 5 weeks of a 6-week cycle@@L01CD01@L01C@-@TOKYO, JAPAN@@@Taxoprexin is a conjugate of paclitaxel and the fatty acid docosahexaenoic acid (DHA). Preclinical studies have shown increased activity and an improved therapeutic ratio relative to paclitaxel. @@14924754@Advanced eye melanoma@@-@-@@NO REVIEW@@@@-@Luitpold is a subsidiary of Daiichi Sankyo.@FIRST-LINE@NCT00244816@30@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@Study completed in April 2007, results pending.@-@@@@MONO@PACLITAXEL, DHI@@@@@PACLITAXEL, DHI||||@DAIICHI SANKYO@LUITPOLD PHARMACEUTICALS@@@@DAIICHI SANKYO|LUITPOLD PHARMACEUTICALS|||@@@@@@|||||||||@Melanoma / Skin Cancer@Head & Neck Cancer@@@@Melanoma / Skin Cancer|Head & Neck Cancer||||||||@TAXOPREXIN@@@@@TAXOPREXIN||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918838@Onco@@@@@300f1012ntsdm@@@@@@Sabarubicin 80mg/m2 administered as a short (30 min.) IV infusion every 3 weeks.@@-@-@-@FLORENCE, ITALY@@@@@14918838@-@@-@-@@NO REVIEW@@@@-@Drug available for partnering.@SECOND-LINE@-@37@-@-@@@-@@@-@N/A@@-@-@@@II@II@@-@-@EJC April 2006; 9 patients achieved a PSA response (26.5%), 10 patients had SD (29.4%) and 14 patients disease progression (41.2%). 1 patient (2.9%) had a PSA response that was not confirmed by repeat PSA testing. RECIST response was 6.7% in 15 patients with measurable disease. The median duration of PSA responses was 7.1 months. Median OS was 18.7 months.@-@@@@MONO@SABARUBICIN@@@@@SABARUBICIN||||@MENARINI@@@@@MENARINI||||@@@@@@|||||||||@Prostate Cancer@HRPC@@@@Prostate Cancer|HRPC||||||||@MEN-10755@@@@@MEN-10755||||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@RESPONSE RATE@SAFETY@@@@@@@@@REFRACTORY@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14919306@Onco@@@@@@@@@@@Bioequivalence study is designed to compare the pharmacokinetics of LEP-ETU and Taxol in patients with advanced cancer. Patients are randomized to determine which drug is administered first. A single dose of LEP-ETU or Taxol (Cycle A) will be administered, followed 3 weeks later by a single dose of the other drug (Cycle B). Blood samples for PK analysis will be taken before, during, and after the infusion of each drug. Following successful completion of both Cycles in this study, patients may be eligible for additional cycles of treatment with LEP-ETU in the LEP-ETU-102B extension study. SOURCE: clinicaltrials.gov@@-@-@-@-@@@@@14919306@Advanced cancer; versus Taxol@@-@-@@NO REVIEW@@@@-@-@-@NCT00100139@48@-@-@@@-@@11/1/2004@-@LEP-ETU-102A@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@PACLITAXEL, LIPOSOMAL@@@@@PACLITAXEL, LIPOSOMAL||||@NEOPHARM@@@@@NEOPHARM||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@LEP-ETU@@@@@LEP-ETU||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@BIOEQUIVALENCE@@@@@@@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@CROSSOVER@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922676@Onco@@@@@@@@@@@Enzastaurin with paclitaxel and carboplatin followed by maintenance@@-@-@-@INDIANAPOLIS, INDIANA@@@Enzastaurin is an oral, serine threonine kinase inhibitor which selectively targets the PKCBeta and PI3/AKTsignaling pathways. By blocking these key pathways frequently over-expressed in a wide variety of cancers, enzastaurin suppresses tumor cell proliferation, induces tumor cell death and inhibits tumor-induced angiogenesis. Treatment has been well tolerated with minimal drug-related toxicity. Enzastaurin administration is associated with fatigue, diarrhea, nausea, decreased platelets, cough, vomiting, transaminase elevation, dyspnea, peripheral edema, and dizziness. Further testing in Phase III versus a placebo will provide us with a more complete look at the side effect profile for enzastaurin. In addition to DLBCL, enzastaurin is also being studied in other tumor types including breast, colon, lung, ovarian and prostate cancers@@14922676@-@@-@-@@NO REVIEW@@@5 YEARS@-@-@FIRST-LINE@NCT00391118@149@-@-@@@-@@@-@10708H6Q-MC-S019  @@-@-@@@II@II@@-@-@Completion expected in December 2011.@-@@@@COMBO@ENZASTAURIN@PACLITAXEL@CARBOPLATIN@@@ENZASTAURIN|PACLITAXEL|CARBOPLATIN||@LILLY@@@@@LILLY||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@LY-317615@@@@@LY-317615||||@Angiogenesis Inhibitor@@@@@Angiogenesis Inhibitor||||@TUMOUR SIZE@@@@@@@@@@ADVANCED@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916438@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@SN2310 Injectable Emulsion will be administered intravenously every 21 days. @@-@-@-@-@@@@@14916438@-@@-@-@@NO REVIEW@@@@-@Sonus and OncoGenex to merge, with the combined company operating as OncoGenex Pharmaceuticals. SOURCE: OncoGenex/Sonus, 28 May 2008@SECOND-LINE@NCT00385177@61@-@-@@@-@@9/1/2006@-@SON-2310-06-101@@-@-@@@I@I@@-@-@Phase II trial to commence by year-end 2008. SOURCE: Sonus Q4 earnings, 5 March 2008@-@@@@MONO@-@@@@@-||||@SONUS PHARMACEUTICALS@ONCOGENEX@@@@SONUS PHARMACEUTICALS|ONCOGENEX|||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@SN-2310@@@@@SN-2310||||@Camptothecin@Topoisomerase I Inhibitor@@@@Camptothecin|Topoisomerase I Inhibitor|||@MAXIMUM TOLERATED DOSE@DOSE-LIMITING TOXICITY@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924147@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@@@@BRENTFORD, UNITED KINGDOM@@@Calcium folinate is the calcium salt of 5-formyl tetrahydrofolic acid. It is an active metabolite of folinic acid and an essential coenzyme for nucleic acid synthesis in cytotoxic therapy. Calcium folinate is frequently used to diminish the toxicity and counteract the action of folate antagonists, such as methotrexate. Calcium folinate and folate antagonists share the same membrane transport carrier and compete for transport into cells, stimulating folate antagonist efflux. It also protects cells from the effects of folate antagonist by repletion of the reduce folate pool. Calcium folinate serves as a pre-reduced source of H4 folate; it can therefore bypass folate antagonist blockage and provide a source for the various coenzyme forms of folic acid.@@14924147@Osteosarcoma@@@@@NO REVIEW@@@@@@@@@@@@@@@@@@No@@@@@@APPROVED@@@@RESULTS PENDING@@@@@@LEUCOVORIN CALCIUM@@@@@LEUCOVORIN CALCIUM||||@GSK@@@@@GSK||||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@WELLCOVORIN@@@@@WELLCOVORIN||||@Detoxifying Agent@@@@@Detoxifying Agent||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922479@Onco@@@@@@@@@@@Alimta/carboplatin versus etoposide/carboplatin@@L01BA04@L01B@-@INDIANAPOLIS, INDIANA@@@Pemetrexed is an antifolate containing the pyrrolopyrimidine-based nucleus that exerts its antineoplastic activity by disrupting folate-dependent metabolic processes essential for cell replication. In vitro studies have shown that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), all folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is transported into cells by both the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT. Polyglutamation is a time- and concentration-dependent process that occurs in tumor cells and, to a lesser extent, in normal tissues. Polyglutamated metabolites have an increased intracellular half-life resulting in prolonged drug action in malignant c@@14922479@Extensive-stage SCLC@@-@-@@NO REVIEW@@@@-@-@-@NCT00363415@1820@-@-@@@-@@@-@9691H3E-MC-JMHO  @@FEBRUARY 2009 (NCE); FEBRUARY 2011 (ORPHAN)@-@@@III@III@@-@-@Completion expected March 2010.@-@@@@COMBO@PEMETREXED@CARBOPLATIN@@@@PEMETREXED|CARBOPLATIN|||@LILLY@@@@@LILLY||||@@@@@@|||||||||@SCLC@@@@@SCLC|||||||||@ALIMTA@@@@@ALIMTA||||@Anti-metabolite@Folic Acid Analogue@@@@Anti-metabolite|Folic Acid Analogue|||@OVERALL SURVIVAL@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@POWDER FOR INFUSION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922755@Onco@@@@@@@@@@@-@@J07BM01@J07B@-@WHITEHOUSE STATION, NEW JERSEY@@@Gardasil is an adjuvanted non-infectious recombinant quadrivalent vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid L1 protein of HPV types 6, 11, 16 and 18. The VLPs contain no viral DNA, they cannot infect cells, reproduce or cause disease. HPV only infects humans, but animal studies with analogous papillomaviruses suggest that the efficacy of LI VLP vaccines is mediated by the development of a humoral immune response. HPV 16 and HPV 18 are estimated to be responsible for approximately 70% of cervical cancers; 80% of adenocarcinoma in situ (AIS); 45-70% of high-grade cervical intraepithelial neoplasia (CIN 2/3); 25% of low grade cervical intraepithelial neoplasia (CIN 1); approximately 70% of HPV related high-grade vulvar (VIN 2/3) and vaginal (VaIN 2/3) intraepithelial neoplasia. HPV 6 and 11 are responsible for approximately 90% of genital warts and 10% of low grade cervical intraepithelial neoplasia (CIN 1). CIN 3 and AIS have been accepted as immediate precursors of invasive cervical cancer.@@14922755@For girls and women 16-26 years of age @@-@-@@NO REVIEW@@@@-@extra-Australia rights licensed from CSL@-@NCT00520598@-@-@-@@@-@@10/1/2007@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@HUMAN PAPILLOMAVIRUS@@@@@HUMAN PAPILLOMAVIRUS||||@MERCK & CO@SANOFI PASTEUR@SANOFI PASTEUR MSD@@@MERCK & CO|SANOFI PASTEUR|SANOFI PASTEUR MSD||@Asia-Pacific@@@@@Asia-Pacific|||||||||@Cervical Cancer@@@@@Cervical Cancer|||||||||@GARDASIL@@@@@GARDASIL||||@Vaccine@@@@@Vaccine||||@HPV@@@@@@@@@@-@@@@@PREVENTION@RANDOMISED@DOUBLE-BLIND@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@
14917958@Onco@@@@@300f1015ntsdm@@@@@@Foscan alone@@@@NO@EAST LONGMEADOW, MASSACHUSSETTS@@@@@14917958@Foscan is indicated for the palliative treatment of patients with advanced head and neck squamous cell carcinoma failing prior therapies and unsuitable for radiotherapy, surgery or systemic chemotherapy.@@YES@18-Feb-09@2/18/2009@NO REVIEW@@@@100%@@@@147@The dose is 0.15mg/kg body weight.@EMA, 24 October 2001@10/24/2001@@@@@Special care must be taken to prevent extravasation at the injection site. If extravasation occurs, protect the area from light for at least 3 months. There is no known benefit from injecting the extravasation site with another substance.@@No@@@@@III: ADVANCED H&N CANCER@APPROVED@@Foscan does not bring improvement in therapy compared to current standard of care (ASMR level V)@@Median duration of tumour response was 57 days for overall responseand 84 days for complete response.@@@@@MONO@TEMOPORFIN@@@@@TEMOPORFIN||||@BIOLITEC@@@@@BIOLITEC||||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@FOSCAN@@@@@FOSCAN||||@Other@@@@@Other||||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14921642@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@CT-322 administered alone or with irinotecan@@-@-@-@NEW YORK, NEW YORK@@@CT-322 specifically inhibits VEGFR-2 activation by its ligands VEGF-A, VEGF-C, and VEGF-D. In preclinical studies, this cell-surface receptor drives angiogenesis (growth of new blood vessels) in solid tumors, and CT-322 inhibits the tumorgenic effect of VEGFR-2 in preclinical models. CT-322 was designed using the PROfusion System, Adnexus' patented product design engine. @@14921642@-@@-@-@@NO REVIEW@@@@-@Acquired through purchase of Adnexus in September 2007@-@NCT00562419@50@-@-@@@-@@10/1/2007@-@CT-322.002@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@BOTH@-@@@@@-||||@BMS@ADNEXUS@@@@BMS|ADNEXUS|||@@@@@@|||||||||@Brain Cancer@Glioblastoma Multiforme@@@@Brain Cancer|Glioblastoma Multiforme||||||||@ANGIOCEPT@CT-322@@@@ANGIOCEPT|CT-322|||@TK Inhibitor@Angiogenesis Inhibitor@VEGF@@@TK Inhibitor|Angiogenesis Inhibitor|VEGF||@SAFETY@RESPONSE RATE@PROGRESSION-FREE SURVIVAL@@@PROGRESSION-FREE SURVIVAL@@@@@RELAPSED@@@@@RANDOMISED@OPEN-LABEL@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916675@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Escalating doses of GSK-1059615@@-@-@-@BRENTFORD, UNITED KINGDOM@1/1/2010@@Phosphoinoisitide 3-kinase inhibitor@@14916675@Solid tumours or lymphoma that is not responsive to accepted therapies or for which there is no standard or curative therapy@@-@-@@NO REVIEW@@@@-@-@-@NCT00695448@70@-@-@@@-@@9/1/2008@-@PIK111051@@-@Performance Status score of 0 or 1 according to the Eastern Cooperative Oncology Group (ECOG) scale. A life expectancy of > 12 weeks.@@@I@I@@-@-@RESULTES PENDING@-@@@@MONO@-@@@@@-||||@GSK@@@@@GSK||||@@@@@@|||||||||@Solid Tumours@Haematological Malignancy@Non-Hodgkin's Lymphoma@Hodgkin's Lymphoma@@Solid Tumours|Haematological Malignancy|Non-Hodgkin's Lymphoma|Hodgkin's Lymphoma||||||@GSK-1059615@@@@@GSK-1059615||||@TK Inhibitor@@@@@TK Inhibitor||||@TOXICITY@PHARMACOKINETICS@@@@@@@@@-@@@@@OPEN-LABEL@DOSE COMPARISON@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920915@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients are given karenitecin@@-@-@-@SAN ANTONIO, TEXAS@@@@@14920915@Malignant glioma@@-@-@@NO REVIEW@@@@-@-@-@NCT00062478@-@-@-@@@-@@@-@KTN20405@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@KARENITECIN@@@@@KARENITECIN||||@BIONUMERIK@@@@@BIONUMERIK||||@@@@@@|||||||||@Brain Cancer@@@@@Brain Cancer|||||||||@BNP-1350@@@@@BNP-1350||||@Camptothecin@Topoisomerase I Inhibitor@@@@Camptothecin|Topoisomerase I Inhibitor|||@RESPONSE RATE@@@@@@@@@@MALIGNANT@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14923262@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@N01AH01@N01A@@BUFFALO GROVE, ILLINOIS@@@Fentanyl is a synthetic opiate with a clinical potency of 50 to 100 times that of morphine. Its onset of action is rapid and its duration of action is short. In man, a single iv dose of 0.5-1 mg/70 kg body weight immediately produces a pronounced state of surgical analgesia, respiratory depression, bradycardia and other typical morphine-like effects. The duration of action of the peak effects is about 30 minutes. All potent morphine-like drugs produce relief from pain, ventilatory depression, emesis, constipation, physical dependence, certain vagal effects and varying degrees of sedation. Fentanyl, however, differs from morphine not only by its short duration of action but also by its lack of emetic effect and minimal hypotensive activity in animals.@@14923262@Management of breakthrough cancer pain in patients with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain@@@@@NO REVIEW@@@@@@@@@@FDA, 19 February 1968@2/19/1968@@@@@@@No@@@@@@APPROVED@@@MEDICARE@RESULTS PENDING@@@@@@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@AKORN@@@@@AKORN||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@SUBLIMAZE@@@@@SUBLIMAZE||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@10@1@25.36@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/2/2017@2.54@2.54@17478-0030-05@INJECTION - 5 ML@US$@@@@@@@@250@MCG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918982@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14918982@-@@-@-@@NO REVIEW@@@@-@Licensing deal with Case Western Reserve University to develop the drug after Phase I development. SOURCE: Lentigen press release, 20 March 2008@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@-@Trial to begin in 2008. SOURCE: Lentigen press release, 20 March 2008@-@@@@-@-@@@@@-||||@LENTIGEN CORPORATION@@@@@LENTIGEN CORPORATION||||@@@@@@|||||||||@Brain Cancer@Glioblastoma Multiforme@@@@Brain Cancer|Glioblastoma Multiforme||||||||@MGMT@@@@@MGMT||||@Gene Therapy@@@@@Gene Therapy||||@-@@@@@@@@@@METASTATIC@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16425169@Onco@@@@@300f1008ntsdm@@@@@@@@L01XE24@L01X@@@@@Ponatinib is an investigational BCR-ABL inhibitor that also selectively inhibits certain other tyrosine kinases in preclinical studies, including FLT3, RET, KIT, and the members of the FGFR and PDGFR families of kinases.@@16425169@Chronic myeloid leukaemia in patients resistant or intolerant to previous therapies@@NA@18-Nov-16@11/18/2016@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@@@@@MHLW, 18 November 2016@11/18/2016@@@@@@@No@@@@@@APPROVED@@@NHI@@@@@@MONO@PONATINIB@@@@@PONATINIB||||@OTSUKA PHARMACEUTICAL@@@@@OTSUKA PHARMACEUTICAL||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@ICLUSIG@@@@@ICLUSIG||||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@@@@@@@@@@@@@@@@@@@@@1@1@3520153.44@@@219@day@219 day@3520153.44@3520153.44@16073.76@1@0.0091@5357.92@6318.3@@@@@@@@@@@357.19@1@@mg@45@1@@@@@@@@@@@8/30/2017@5357.92@5357.92@4291048F1020@TABLET@YEN@@@@@@@@15@MG@15 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14918884@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Single-dose study@@-@-@-@VERDUN, QUEBEC@@@Octreotide is a synthetic octapeptide analog of naturally occurring somatostatin with similar pharmacological effects, but with a longer duration of action. It inhibits pathologically increased secretion of growth hormone (GH) and of peptides and serotonin produced within the gastroenteropancreatic (GEP) endocrine system, stomach, intestine and pancreas (for example, gastrin, insulin and glucagon). @@14918884@-@@-@-@@NO REVIEW@@@@-@Ambrilia has partnered with Mallinckrodt for the U.S.; Teva for France, Germany, Benelux, Spain and Scandinavia; with Archimedes in the U.K.; with Gerolymatos for Greece and Turkey; with Kwidza Pharma for Austria; with Pharmis for Portugal and Brazil; and@-@-@8@-@-@@@-@@@-@N/A@@-@-@@@II@II@@-@-@IGF-1 normalised, hGH plasma levels suppressed and no serious adverse events. Efficacy and PK data suggest a 42-day dosing interval versus Sandostatin LAR's 28-day dosing interval.@-@@@@MONO@OCTREOTIDE PROLONGED-RELEASE@@@@@OCTREOTIDE PROLONGED-RELEASE||||@AMBRILIA BIOPHARMA@MALLINCKRODT@@@@AMBRILIA BIOPHARMA|MALLINCKRODT|||@@@@@@|||||||||@Acromegaly@@@@@Acromegaly|||||||||@-@@@@@-||||@Somatostatin Analogue@@@@@Somatostatin Analogue||||@RESPONSE RATE@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16667512@Onco@@@@@@@@@@@nivolumab + ipilimumab, Experimental, Specified Dose on Specified Daysnivolumab, Experimental, Specified Dose on Specified Daysipilimumab, Experimental, Specified Dose on Specified Days@@L01XC17@L01X@@NEW YORK, NEW YORK@12/1/2020@@@@16667512@A Phase 3, Randomized Study of Adjuvant Immunotherapy With Nivolumab Combined With Ipilimumab Versus Ipilimumab or Nivolumab Monotherapy After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma@Both@@@@@Specified Dose on Specified Days@@@@@@NCT03068455@1125@@@@@@@4/1/2017@@CA209-915@@@Completely surgically resected stage IIIb/c/d or stage IV melanoma within 12 weeks of participation in study.  -  Must have full activity or, if limited, must be able to walk and carry out activities such as light house work or office work  -  No prior anti-cancer treatment for melanoma (except surgery for the melanoma lesion(s) and/or except for adjuvant radiation therapy (RT) after neurosurgical resection for central nervous system (CNS) lesions)@@ADULTS@Phase 3@III@@@@@@@@@COMBO@NIVOLUMAB@IPILIMUMAB@@@@NIVOLUMAB|IPILIMUMAB|||@BMS@@@@@BMS||||@Australia@Belgium@Czech Republic@Hungary@Italy@Australia|Belgium|Czech Republic|Hungary|Italy|New Zealand|Poland|Romania|Spain|United Kingdom@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@OPDIVO@YERVOY@@@@OPDIVO|YERVOY|||@PD-1 Inhibitor@@@@@PD-1 Inhibitor||||@Recurrence-free survival (RFS)@@@@@Overall Survival (OS)@PD-L1 expression@@@@ADVANCED@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916038@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Patients receive amonafide IV over 1 hour on days 1-5. Treatment repeats every 21 days for at least 5 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease may receive additional courses (beyond 5 courses) at the investigator's discretion. Patients are followed at 30 days and then every 3 months@@-@-@-@GEELONG, AUSTRALIA@@@@@14916038@-@@-@-@@NO REVIEW@@@@-@Available for partnering.@-@NCT00074100@175@-@-@@@-@@8/1/2003@-@XANTHUS-0001A1-200-GL@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@AMONAFIDE DIHYDROCHLORIDE@@@@@AMONAFIDE DIHYDROCHLORIDE||||@CHEMGENEX@@@@@CHEMGENEX||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@QUINAMED@@@@@QUINAMED||||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@TIME TO PROGRESSION@RESPONSE RATE@COMPLETE RESPONSE@PARTIAL RESPONSE@@COMPLETE RESPONSE@PARTIAL RESPONSE@@@@RELAPSED@REFRACTORY@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916166@Onco@@@@@@@@@@@-@@-@-@-@BASEL, SWITZERLAND@3/1/2010@@TKI258 is an oral TKI that has been demonstrated preclinically to target multiple growth-factor receptors: Fibroblast growth-factor receptor (FGFR), which plays a role in cell development, angiogenesis, and tumorigenesis1 VEGFR, which mediates angiogenesis and lymphangiogenesis2 PDGFR, which is associated with tumor progression and metastasis3 KIT, a receptor that induces cell proliferation and inhibits apoptosis4 Fms-like tyrosine kinase 3 (FLT-3), which mediates cell growth and survival and inhibits tumor-cell differentiation and apoptosis5 Due to its target profile, TKI258 exhibits both antitumor and antiangiogenic activity, and induces apoptosis in preclinical models of various cancers (acute myelogenous leukemia [AML], multiple myeloma, prostate, breast, colon, lung, renal, melanoma, bladder, and ovarian).@@14916166@TKI258 in Adult Patients With Advanced Urothelial Cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00790426@150@-@-@@@-@@2/1/2009@-@TKI258A2201@@-@Patients with MSKCC histological confirmation of transitional cell carcinoma of the bladder, urethra, ureter, or renal pelvis @ADULT@@II@I@@-@-@Trial registered. [Novartis, 10.11.2008]@-@@@@MONO@-@@@@@-||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Bladder Cancer@@@@@Bladder Cancer|||||||||@TKI-258@@@@@TKI-258||||@TK Inhibitor@FGF@VEGF@@@TK Inhibitor|FGF|VEGF||@PROGRESSION-FREE SURVIVAL@@@@@SAFETY@@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921736@Onco@@@@@@@@@@@-@@-@-@-@BERKELEY HEIGHTS, NEW JERSEY@@@Genasense (oblimersen sodium) Injection is a drug that inhibits the production of a protein known as Bcl-2. By reducing production of Bcl-2 in cancer cells, it seeks to restore the basic biological process whereby cancer cells can be readily killed by treatment with current methods of anticancer therapy. Genta's clinical trials programs focus on treating cancer patients with Genasense along with the administration of anticancer therapy with the intention of potentiating the cancer-killing effects of treatment. Genta is developing Genasense Injection with the intention of potentiating the cancer-killing activity of standard anticancer therapies. In a typical example, Genasense might be administered for several days and then be immediately followed by regular doses of chemotherapy. This sequence would then be repeated, depending upon the particular type of chemotherapy regimen and indication. In other applications, Genasense might be administered concurrent with or after conventional chemotherapy, again depending on the chemotherapy and indication. Genasense has the potential to be used in combination with most types of anticancer therapy.@@14921736@Named patient access to Genasense outside of the United States@@-@-@@NO REVIEW@@@August 2007-@-@-@-@-@200@-@-@@@-@@@-@COMPASSIONATE ACCESS@@-@Named patients who specificially request Genasense.@@@III@-@@-@-@Named patient/compassionate use programme commenced outside of the United States. [Genta, 13.08.2007]@-@@@@-@OBLIMERSEN SODIUM@@@@@OBLIMERSEN SODIUM||||@GENTA@@@@@GENTA||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@Chronic Lymphocytic Leukaemia@Melanoma / Skin Cancer@@Haematological Malignancy|Myeloma|Chronic Lymphocytic Leukaemia|Melanoma / Skin Cancer||||||@GENASENSE@@@@@GENASENSE||||@Bcl-2 Inhibitor@@@@@Bcl-2 Inhibitor||||@COMPASSIONATE USE@@@@@@@@@@-@-@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922670@Onco@@@@@@@@@@@Alimta (700mg/m2) plus cisplatin (75mg/m2) on Day every 21-day cycle@@L01BA04@L01B@-@INDIANAPOLIS, INDIANA@@@Pemetrexed is an antifolate containing the pyrrolopyrimidine-based nucleus that exerts its antineoplastic activity by disrupting folate-dependent metabolic processes essential for cell replication. In vitro studies have shown that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), all folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is transported into cells by both the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT. Polyglutamation is a time- and concentration-dependent process that occurs in tumor cells and, to a lesser extent, in normal tissues. Polyglutamated metabolites have an increased intracellular half-life resulting in prolonged drug action in malignant c@@14922670@Stage IV gastric cancer@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00415168@50@-@-@@@-@@@-@10874H3E-MW-S108  @@-@-@@@II@II@@-@-@Completion expected in July 2009.@-@@@@COMBO@PEMETREXED@CISPLATIN@@@@PEMETREXED|CISPLATIN|||@LILLY@@@@@LILLY||||@Russia@@@@@Russia|||||||||@Stomach Cancer@@@@@Stomach Cancer|||||||||@ALIMTA@@@@@ALIMTA||||@Anti-metabolite@Folic Acid Analogue@@@@Anti-metabolite|Folic Acid Analogue|||@RESPONSE RATE@@@@@@@@@@RELAPSED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@POWDER FOR INFUSION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921697@Onco@@@@@@@@@@@Elacyt (200mg/m2/day IV) days 1-5 every 3 weeks with Nexavar (400mg b.i.d. twice daily).@@L01BC01@L01B@-@OSLO, NORWAY@10/1/2008@@Elacyt is the elaidic acid ester of the antimetabolite cytarabine (ara-C), an approved and well-established drug for the treatment of haematological cancers. Antimetabolites act by inhibiting DNA synthesis in dividing cells, preventing the cells from undegoing cell division. Despite the fact that cytarabine has shown excellent effect in leukaemia, the treatment response in solid tumours is modest. The lack of effect in solid tumours may be due to inferior cell penetration and rapid inactivation to its metabolite ara-U. Elacyt is designed to target the larger solid tumour market as well as offering an improved therapy for leukaemia.@@14921697@CP-4055 with Nexavar@@-@-@@NO REVIEW@@@@-@-@-@NCT00498836@40@-@-@@@-@@5/1/2007@-@CP4055-203  @@-@Patients with histological or cytological confirmed stage IV or unresectable stage III non-ocular malignant melanoma who have or have not undergone prior chemotherapy for the treatment of melanoma@@@II@II@@-@-@>> Trial completed. [Clavis, 09.10.2008]          >> Trial registered and commenced [Clavis, 9.07.2007]@-@@@@COMBO@CYTARABINE, ELAIDIC ACID ESTER@SORAFENIB@@@@CYTARABINE, ELAIDIC ACID ESTER|SORAFENIB|||@CLAVIS PHARMA@@@@@CLAVIS PHARMA||||@Sweden@@@@@Sweden|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@ELACYT@CP-4055@NEXAVAR@@@ELACYT|CP-4055|NEXAVAR||@Anti-metabolite@@@@@Anti-metabolite||||@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924110@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@L1A@L1A@-@RIDGEFIELD PARK, NEW JERSEY@@@Glufosfamide combines the active part of an approved alkylator, a member of a widely used class of chemotherapy drugs, with a glucose molecule. The linkage between glucose and the alkylator is cleaved to release the active drug. With glucose as the side product, glufosfamide has fewer side effects than other drugs in its class, which are known to cause hemorrhagic cystitis, a serious condition characterized by severe bladder bleeding.@@14924110@First line with gemcitabine@@-@-@@NO REVIEW@@@@-@-@-@-@52@-@-@@@-@@@-@-@@-@52 PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER. @@@I/II@II@@-@-@RESULTS PENDING@-@@@@-@GLUFOSFAMIDE@@@@@GLUFOSFAMIDE||||@THRESHOLD PHARMACEUTICALS@@@@@THRESHOLD PHARMACEUTICALS||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@-@@@@@-||||@Alkylating Agent@@@@@Alkylating Agent||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916684@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Ticilimumab every day for 8 courses@@-@-@-@NEW YORK, NEW YORK@@@Tremelimumab is a fully human anti-CTLA4 (cytotoxic T-lymphocyte antigen 4) IgG2 monoclonal antibody developed by Pfizer for its potential therapeutic application in melanoma, non-small cell lung cancer (NSCLC) and colorectal cancer. CTLA4 is a CD28-family receptor expressed mainly on T-lymphocyte that acts to inhibit T-lymphocyte function.@@14916684@Stage IIIC/IV melanoma@@-@-@@NO REVIEW@@@@-@Medarex entitled to royalties@-@NCT00471887@21@-@-@@@-@@1/1/2007@-@PFIZER-UCLA-0606093-01@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@TREMELIMUMAB@TICILIMUMAB@@@@TREMELIMUMAB|TICILIMUMAB|||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@CP-675206@@@@@CP-675206||||@mAb@CTLA4 Receptor Antagonist@@@@mAb|CTLA4 Receptor Antagonist|||@IMMUNE RESPONSE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921220@Onco@@@@@@@@@@@-@@-@-@-@SAN FRANCISCO, CALIFORNIA@@@@@14921220@-@@-@-@@NO REVIEW@@@@-@">> Roche reaches a friendly agreement to purchase the latter's outstanding shares at a price of US$95 per share. The transaction will be valued at US$46.8 billion. [Genentech, 12 March 2009]>> Roche has made a formal announcement of cash tender offer for all outstanding shares of Genentech at US$86.50 per share for the 44.2% of Genentech not already held by Roche. Genentech's special committee, on the other hand, has responded to the offer by urging its shareholders ""to take no action at this time"". [Genentech, 10.02.2009]          >> Genentech rejects the acquisition bid. [Genentech, 14.08.2008]        >> Roche announces US$43.7 billion proposal to assume full control of Genentech. SOURCE: Roche, 21 July 2008"@SECOND-LINE@-@224@-@-@@@-@@@-@GLOBAL@@-@-@@@II@II@@-@-@FPI Q4 2007@-@@@@MONO@-@@@@@-||||@GENENTECH@@@@@GENENTECH||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@B-Cell Lymphoma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|B-Cell Lymphoma|||||||@ANTI-CD40@@@@@ANTI-CD40||||@mAb@CD40@@@@mAb|CD40|||@-@@@@@@@@@@RELAPSED@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
16522240@Onco@@@@@@@@@@@"INCB054828, Experimental, "@@@@@WILMINGTON, DELAWARE@11/1/2018@@@@16522240@A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement@Both@@@@@INCB054828 at the protocol-defined once-daily dose.@@@@@@NCT03011372@46@@@@@@@1/1/2017@@INCB 54828-203@@@Inclusion Criteria:  -  Documented lymphoid or myeloid neoplasm with 8p11 rearrangement known to lead to FGFR1 activation, based on standard diagnostic cytogenetic evaluation performed locally, before signing informed consent for this study.  -  Subjects must be relapsed/refractory. Prior stem cell transplantation is allowed.  -  Life expectancy ≥ 12 weeks.  -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.@FGFR1 Rearrangement@ADULTS@Phase 2@II@@@@@@@@@MONO@-@@@@@-||||@INCYTE CORP.@@@@@INCYTE CORP.||||@Austria@France@Germany@Italy@Spain@Austria|France|Germany|Italy|Spain|Switzerland|United Kingdom|United States||@Acute Myeloid Leukaemia@Chronic Myeloid Leukaemia@@@@Acute Myeloid Leukaemia|Chronic Myeloid Leukaemia||||||||@INCB054828@@@@@INCB054828||||@Other@@@@@Other||||@Overall clinical benefit rate based on response criteria for myeloid/lymphoid neoplasms with FGFR1 rearrangement@@@@@Duration of response/benefit@Progression-free survival@@@@RELAPSED@REFRACTORY@@@@Single Group Assignment@Open Label@Treatment@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921101@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Dose escalation, daily dosing for 14 days every 3 weeks, for up to 4 months (28-day cycles). SOURCE: Ziopharm@@-@-@-@BOSTON, MASSACHUSSETTS@10/1/2008@@@@14921101@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00591890@20@-@-@@@-@@10/1/2007@-@IBL1003@@-@-@@@IB@I@@-@-@30 cycles of oral indibulin were well-tolerated with no Grade 2 or higher toxicities or neurotoxicities. Neutropaenia and fatigue were observed at Grade I level. PET scan response rates from 8 evaluable patients showed 1 complete and 1 partial response, with 3 stable disease and 3 progressions. SOURCE: Ziopharm/Targeted Anticancer Therapies, 20 March 2008@-@@@@MONO@INDIBULIN@@@@@INDIBULIN||||@ZIOPHARM ONCOLOGY@@@@@ZIOPHARM ONCOLOGY||||@@@@@@|||||||||@Solid Tumours@Sarcoma@Ovarian Cancer@@@Solid Tumours|Sarcoma|Ovarian Cancer|||||||@ZIO-301@@@@@ZIO-301||||@Other@@@@@Other||||@PET SCAN ANTI-TUMOUR EFFECT@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921578@Onco@@@@@@@@@@@6 years adjuvant Arimidex versus 3 years adjuvant Arimidex, subsequent to 2-3 years tamoxifen@@L02BG03@L02B@-@LONDON, UNITED KINGDOM@@@Arimidex is a potent and highly selective non-steroidal aromatase inhibitor. In postmenopausal women, estradiol is produced primarily from the conversion of androstenedione to estrone through the aromatase enzyme complex in peripheral tissues. Estrone is subsequently converted to estradiol. Reducing circulating estradiol levels has been shown to produce a beneficial effect in women with breast cancer. In postmenopausal women, Arimidex at a daily dose of 1 mg produced estradiol suppression of greater than 80% using a highly sensitive assay. Arimidex does not possess any progestogenic, androgenic or oestrogenic activity. Daily doses of Arimidex up to 10 mg do not have any effect on cortisol or aldosterone secretion, measured before or after standard ACTH challenge testing. Corticoid supplements are therefore not needed.@@14921578@Adjuvant Arimidex in postmenopausal hormone-sensitive breast cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00301457@1900@-@-@@@-@@3/1/2006@-@DATA  D5392NL0003@@-@-@-@@EUDRACT NO: 2005-006167-31 / @III@@-@-@RESULTS PENDING (recruiting)@-@@@@ADJUVANT@ANASTROZOLE@@@@@ANASTROZOLE||||@ASTRAZENECA@@@@@ASTRAZENECA||||@Netherlands@@@@@Netherlands|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@ARIMIDEX@@@@@ARIMIDEX||||@Hormone Antagonist@Aromatase Inhibitor@@@@Hormone Antagonist|Aromatase Inhibitor|||@DISEASE-FREE SURVIVAL@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14923908@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Thyrogen alone@@H01AB01@H01A@NO@CAMBRIDGE, MASSACHUSSETTS@@@@@14923908@Use as an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with well-differentiated thyroid cancer; in December 2007, approved in combination with radioiodine to ablate, or destroy, the remaining thyroid tissue in patients who have had their cancerous thyroids removed.@@NO@@@NO REVIEW@@@@@@@@N/A@Thyrogen 0.9 mg intramuscularly may be administered every 24 hours for two doses or every 72 hours for three doses.@FDA, 30 November 1998@11/30/1998@@@@@NONE@@No@15-Nov@@@@III@APPROVED@@@MEDICARE@Treatment with Thyrogen was similar to withdrawal from thyroid hormone in achieving ablation, and that it could significantly reduce the side effects of thyroid hormone withdrawal by allowing patients to remain on hormone replacement therapy.@@@@@ADJUVANT@THYROTROPIN ALFA@@@@@THYROTROPIN ALFA||||@GENZYME@@@@@GENZYME||||@@@@@@|||||||||@Thyroid Cancer@@@@@Thyroid Cancer|||||||||@THYROGEN@@@@@THYROGEN||||@Other@@@@@Other||||@RESPONSE RATE@@@@@@@@@@@@@@@PIVOTAL@@@@@@@Invalid Dosage Value Phase 1@@@@@@2021.28@2021.28@@2@1@3065@@@@@@@@@@@@1393.18@@@@@@@@@@@@@@@@8/2/2017@1532.5@1532.5@58468-0030-02@LYOPHILISATE FOR SOLUTION FOR INJECTION (VIAL)@US$@@@@@@@@1.1@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15412600@Onco@@@@@@@@@@@SHR6390, Experimental, Each subject will receive a single dose of SHR6390 and then repeat doses following a 3 week/1 week off regimen@@@@@@1/1/2017@@@@15412600@A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Solid Tumor Patients@Both@@@@@SHR6390 either 25, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg given orally, QD@@@@@@NCT02684266@40@@@@@@@2/1/2016@@SHR6390-I-101@@@Pathologically confirmed solid tumor and failed from all standard treatment  -  Eastern Cooperative Oncology Group (ECOG) performance status: 0-1  -  Life expectancy ≥ 3 months  -  Adequate function of major organs, meaning the following criteria should be met within 14 days before randomization:  -  Hemoglobin > 110g/L  -  Neutrophils > 2.0×10^9/L  -  Platelets > 100×10^9/L  -  Total bilirubin < 1.5×the upper limit of normal (ULN)  -  ALT and AST ≤ 1.5×ULN (≤ 5×ULN, if existing liver metastases)  -  Creatinine ≤ 1 ULN  -  Left ventricular ejection fraction (LVEF) ≥ 50%  -  QTcF(Fridericia correction) male≤450 ms, female≤470 ms  -  Good compliance of patient by physician's judgement  -  Signed and dated informed consent@@ADULTS@Phase 1@-@@@@@@@@@@-@@@@@-||||@@@@@@||||@China@@@@@China|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@SHR6390@@@@@SHR6390||||@Other@@@@@Other||||@MAXIMUM TOLERATED DOSE@@@@@Number of patients experience adverse events@Evaluation of pharmacokinetic parameter of SHR6390: Cmax@@@@@@@@@Safety Study@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14925015@Onco@@@@@300f1012ntsdm@@@@@@BI-2536 in sensitive-relapse SCLC@@-@-@-@INGELHEIM, GERMANY@3/1/2008@@This is a novel inhibitor of Polo-like kinase 1 (Plk-1), a cell cycle switch essential for cell proliferation. BI 2536 inhibits cell division (mitosis), resulting in cancer cell death by apoptosis. As the first Plk-1 inhibitor being tested in clinical trials, BI 2536 shows efficacy in a broad spectrum of cancers combined with better tolerability than conventional chemotherapeutic agents@@14925015@Second-line, monotherapy@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00412880@19@-@-@@@-@@1/1/2007@-@1216.11@@-@-@@@II@II@@-@-@Trial registered. Endpoint assessed at 2 months [BI, 18.12.2006]@-@@@@MONO@-@@@@@-||||@BOEHRINGER INGELHEIM@@@@@BOEHRINGER INGELHEIM||||@@@@@@|||||||||@SCLC@@@@@SCLC|||||||||@BI-2536@@@@@BI-2536||||@PLK-1 Inhibitor@@@@@PLK-1 Inhibitor||||@COMPLETE RESPONSE@PARTIAL RESPONSE@RECIST@@@RECIST@@@@@-@@@@@OPEN-LABEL@UNCONTROLLED@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRAVENOUS@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14921359@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Systemic antifungal therapy versus micafungin@@-@-@-@TOKYO, JAPAN@12/1/2009@@@@14921359@Patients with HSCT, acute leukaemia or MDS with proven invasive aspergillosis; refractory or intolerant to voriconazole or amphocetricin B@@-@-@@NO REVIEW@@@@-@-@-@NCT00376337@125@-@-@@@-@@6/1/2006@-@FG463-21-20@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@MICAFUNGIN@@@@@MICAFUNGIN||||@ASTELLAS PHARMA@@@@@ASTELLAS PHARMA||||@@@@@@|||||||||@Supportive Care@@@@@Supportive Care|||||||||@MYCAMINE@FUNGUARD@@@@MYCAMINE|FUNGUARD|||@Other@@@@@Other||||@COMPLETE RESPONSE@PARTIAL RESPONSE@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16408070@Onco@@@@@@@@@@@"eFT508 Escalation Cohort, Experimental, This portion of the study will evaluate the safety and pharmacology of a range of eFT508 doses administered daily in subjects with previously treated lymphomas eFT508 Expansion Cohort, Experimental, This portion of the study provides cohort expansion to further explore the safety, pharmacology, and clinical activity of a single dose level of eFT508 monotherapy in subjects with specific previously treated lymphomas"@@@@@SAN DIEGO, CALIFORNIA@10/1/2018@@@@16408070@A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies@Both@@@@@@@@@@SECOND-LINE@NCT02937675@96@@@@@@@10/1/2016@@eFT508-0002@@@1. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.  2. Presence of an active hematological malignancy.  3. Presence of measurable disease.  4. Hematological malignancy has been previously treated, has relapsed after or progressed during prior therapy, and has limited potential for benefit from currently available therapy including hematopoietic stem cell transplantation.  5. At least 2 weeks post any treatments/therapies at the time of first dose.  6. Adequate bone marrow function.  7. Adequate hepatic function.  8. Adequate renal function.  9. Normal coagulation panel.  10. Negative antiviral serology.  11. Willingness to use effective contraception.@@ADULTS@Phase 1/Phase 2@I/II@@@@@@@@@MONO@-@@@@@-||||@EFFECTOR THERAPEUTICS@@@@@EFFECTOR THERAPEUTICS||||@@@@@@|||||||||@Haematological Malignancy@@@@@Haematological Malignancy|||||||||@EFT508@@@@@EFT508||||@Other@@@@@Other||||@Maximum Tolerated Dose and/or Recommended Dose within the tested eFT508 dose range@Overall Response Rate@@@@@@@@@@@@@@Non-Randomized@Parallel Assignment@Open Label@Treatment@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
15041412@Onco@@@@@300f1012ntsdm@@@@@@@@L03AA10@L03A@@@@@Granocyte injection contains the active ingredient lenograstim, which is a type of medicine called a recombinant human granulocyte-colony stimulating factor (G-CSF). G-CSF is a substance produced naturally by the body that stimulates the bone marrow to produce white blood cells known as neutrophils. Lenograstim is a man-made version of G-CSF.@@15041412@@@NA@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@@@@@@@@@@No@@@@@@APPROVED@@@GKV@@@@@@@LENOGRASTIM@@@@@LENOGRASTIM||||@CHUGAI PHARMA@@@@@CHUGAI PHARMA||||@@@@@@|||||||||@Supportive Care@Neutropaenia@@@@Supportive Care|Neutropaenia||||||||@GRANOCYTE@@@@@GRANOCYTE||||@Immunotherapy@G-CSF@@@@Immunotherapy|G-CSF|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@129.51@174.72@134.28@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@129.51@129.51@7253193@DRY POWDER WITH SOLVANT@EURO@@@@@@@@263@MCG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
15413020@Onco@@@@@@@@@@@Cohort 1, Experimental, CPI-444Cohort 2, Experimental, CPI-444Cohort 3, Experimental, CPI-444Cohort 4, Experimental, CPI-444 + atezolizumab@@@@@SAN FRANCISCO, CALIFORNIA@6/1/2018@@@@15413020@A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers@Both@@@@@100 mg orally twice daily for the first 14 days of each 28-day cycle.@@@@@@NCT02655822@534@@@@@@@1/1/2016@@CPI-444-001@@@1. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.  2. Documented incurable cancer with one of the following histologies: non-small cell lung cancer, malignant melanoma, renal cell cancer, triple negative breast cancer, and metastatic castration-resistant prostate cancer, head and neck cancer, colorectal cancer, and bladder cancer.  3. At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST 1.1).  4. At least 1 but not more than 5 prior systemic therapies for advanced/recurrent or progressing disease.@COMBO@ADULTS@Phase 1@I@@@@@@@@@@-@@@@@-||||@GENENTECH@@@@@GENENTECH||||@@@@@@|||||||||@NSCLC@Melanoma / Skin Cancer@Kidney Cancer@Breast Cancer@Prostate Cancer@NSCLC|Melanoma / Skin Cancer|Kidney Cancer|Breast Cancer|Prostate Cancer|||||@CPI-444@@@@@CPI-444||||@Other@@@@@Other||||@Incidence of dose-limiting toxicities (DLTs) of CPI-444 as a single agent and in combination with atezolizumab@Objective response rate per RECIST v1.1 criteria of CPI-444 as a single agent and in combination with atezolizumab@Incidence of treatment-emergent adverse events, as assessed by NCI CTCAE v.4.03, of CPI-444 as a single agent and in combination with atezolizumab@@@@@@@@ADVANCED@@@@@RANDOMIZED@Safety Study@PARALLEL ASSIGNMENT@OPEN LABEL@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14923989@Onco@@@@@300f1020ntsdm@@@@@@Uftoral/calcium folinate versus Mayo regimen/calcium folinate@@-@-@-@DARMSTADT, GERMANY@@@@@14923989@First-line treatment of metastatic colorectal cancer with calcium folinate.@@YES@-@@NO REVIEW@@@@100%@-@-@-@1196@The dose of Uftoral is 300 mg/m2/day tegafur and 672 mg/m2/day uracil combined with 90 mg/day oral calcium folinate, given in three divided doses (preferably every 8 hours). Calcium folinate should be taken at the same time as Uftoral. Doses should be taken at least one hour before or one hour after meals for 28 consecutive days.@N/A@@@-@@@-@LABEL@@-@1196 [METASTATIC COLORECTAL CANCER]@@@III STUDY-011 AND STUDY-012@APPROVED@@1@SSN@The median survival time was 12.4 months (95% CI: 11.2-13.6 months) and 13.4 months in the Uftoral/calcium folinate and the 5FU/calcium folinate treatment groups, respectively (Study-011). The median TTP was 3.4 months and 3.3 months respectively.@-@@@@COMBO@TEGAFUR / URACIL@@@@@TEGAFUR / URACIL||||@MERCK SERONO@@@@@MERCK SERONO||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@UFT@MAYO REGIMEN@@@@UFT|MAYO REGIMEN|||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@OVERALL SURVIVAL@@@@@@@@@@METASTATIC@@@@@RANDOMISED@@@@@@@Invalid Factory Price@@@@@@@@@28@1.1229@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@CAPSULE@EURO@@@@@@@@@@100 MG|224 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14922716@Onco@@@@@300f1012ntsdm@@@@@@ZK219477 intravenously over approximately 3 hours every 3 weeks.@@-@-@-@LEVERKUSEN, GERMANY@7/1/2009@@@@14922716@Breast cancer and brain metastases@@-@-@@NO REVIEW@@@@-@-@-@NCT00496379@37@-@First Phase III trials planned for 2008.@@@-@@7/1/2007@-@06-268@@-@-@@@II@II@@-@-@Completion due in July 2009. First Phase III trials planned for 2008.@-@@@@MONO@SAGOPILONE@@@@@SAGOPILONE||||@BAYER HEALTHCARE@@@@@BAYER HEALTHCARE||||@@@@@@|||||||||@Breast Cancer@Brain Cancer@@@@Breast Cancer|Brain Cancer||||||||@ZK-EPO@ZK-219477@@@@ZK-EPO|ZK-219477|||@Epothilone@@@@@Epothilone||||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16384267@Onco@@@@@@@@@@@Atezolizumab, Experimental, Participants will receive 1200 milligrams (mg) of atezolizumab administered by intravenous infusion every 21 days until disease progression or loss of clinical benefit (up to approximately 28 months).@@@@@BASEL, SWITZERLAND@12/1/2018@@@@16384267@A Phase II Single-arm Study of Atezolizumab Monotherapy in Locally Advanced or Metastatic Non-small Cell Lung Cancer: Clinical Evaluation of Novel Blood-based Diagnostics@Both@@@@@Atezolizumab 1200 mg will be administered by intravenous infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit (up to approximately 28 months).@@@@@FIRST-LINE@NCT02848651@150@@@@@@@8/1/2016@@ML39237@@@-  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1  -  Histologically or cytologically confirmed Stage IIIB-IVB NSCLC  -  Measurable disease per RECIST v1.1  -  Adequate hematologic and end-organ function  -  Agreement to remain abs@@ADULTS@Phase 2@II@@@@@@@@@MONO@ATEZOLIZUMAB@@@@@ATEZOLIZUMAB||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@TECENTRIQ@@@@@TECENTRIQ||||@Other@@@@@Other||||@Percentage of Participants With Objective Response per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Determined by Investigator@Progression-free Survival (PFS) per RECIST v1.1 by Circulating Blood-based Tumor Biomarkers@@@@PFS per RECIST v1.1 as Determined by Investigator@Duration of Response (DOR) per RECIST v1.1 as Determined by Investigator@@@@ADVANCED@METASTATIC@@@@Efficacy Study@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924125@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients randomised in 1:1 ratio to treatment with A-007 or with placebo gel. Women with biopsy confirmed HSIL will apply gel once daily for 5 consecutive daysof a 28-day cycle for 2 cycles. @@-@-@-@-@12/1/2007@@@@14924125@High-grade squamous intraepithelial lesions (HSIL) of the Cervix. @@-@-@@NO REVIEW@@@@-@-@-@NCT00285207@212@-@-@@@-@@1/1/2006@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@TIGRIS PHARMACEUTICALS@@@@@TIGRIS PHARMACEUTICALS||||@@@@@@|||||||||@Cervical Cancer@@@@@Cervical Cancer|||||||||@A-007@@@@@A-007||||@Immunotherapy@@@@@Immunotherapy||||@PATHOLOGICAL RESPONSE@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916652@Onco@@@@@300f1018ntsdm@@@@@@Arm I: Patients receive dacarbazine IV over 1 hour on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease after 6 courses of therapy may continue to receive dacarbazine in the absence of disease progression. Patients who experience unacceptable dacarbazine-related toxicity or disease progression may receive PI-88 alone as second-line therapy at the discretion of the PI. Arm II: Patients receive dacarbazine and PI-88 as in the lead-in phase, part 2. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease after 6 courses of therapy may continue to receive dacarbazine and PI-88 in the absence of disease progression. Patients who experience unacceptable dacarbazine-related toxicity after 6 courses of therapy but who continue to have responding or stable disease may receive PI-88 alone as maintenance therapy at the discretion of the PI.@@-@-@-@QUEENSLAND, AUSTRALIA@12/1/2008@@@@14916652@Melanoma that cannot be removed by surgery@@-@-@@NO REVIEW@@@@-@-@-@NCT00130442@118@-@FDA Orphan Drug@@@FDA Orphan Drug@@6/1/2005@-@PR88205@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@DACARBAZINE@@@@-|DACARBAZINE|||@PROGEN PHARMACEUTICALS@@@@@PROGEN PHARMACEUTICALS||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@PI-88@@@@@PI-88||||@Angiogenesis Inhibitor@VEGF@TK Inhibitor@@@Angiogenesis Inhibitor|VEGF|TK Inhibitor||@STABLE DISEASE@RESPONSE RATE@@@@@@@@@METASTATIC@@@@@RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
16642998@Onco@@@@@300f1037ntsdm@@@@@@@@L01XE16@L01X@@NEW YORK, NEW YORK@@@@@16642998@XALKORI is indicated for the treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC).@@YES@@@NO REVIEW@@@@@Acquired through takeover of Pharmacia Corp., which acquired it from Sugen@@@53@The recommended dose schedule of XALKORI is 250 mg twice daily (500 mg daily) takencontinuously.@EMA, 25 August 2016@8/25/2016@12/1/2013@No@@@@Study 1001@No@@@ROS1-positive@@@APPROVED@@@SNS@@@@@@MONO@CRIZOTINIB@@@@@CRIZOTINIB||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@XALKORI@@@@@XALKORI||||@PDGF@@@@@PDGF||||@OBJECTIVE RESPONSE RATE@DURATION OF RESPONSE@@@@@@@@@ADVANCED@@@@@MULTICENTER@SINGLE-ARM@@@@1@1@102342.601@@@19.3@month@19.3 month@102342.6@102342.6@174.34@60@1.1511@5230.2@5497.55@5237.74@@@@@@@@@@0.35@1@@mg@500@1@@@@@@@@@@@8/4/2017@87.17@87.17@694399@CAPSULE@EURO@@@@@@@@250@MG@250 MG@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14922746@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@AQ4N (400MG/M2) once every 3 weeks for 24 weeks, 8 treatment cycles@@-@-@-@SOUTH SAN FRANCISCO, CALIFORNIA@3/1/2007@@@@14922746@-@@-@-@@NO REVIEW@@@@-@Novacea licensed from KuDOS, which was acquired by AstraZeneca, and BTG.@-@NCT00109356@55@-@-@@@-@@3/1/2005@-@021-002@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@BANOXANTRONE@@@@@BANOXANTRONE||||@NOVACEA@@@@@NOVACEA||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@Chronic Lymphocytic Leukaemia@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|Chronic Lymphocytic Leukaemia|||||||@AQ4N@@@@@AQ4N||||@Topoisomerase II Inhibitor@@@@@Topoisomerase II Inhibitor||||@RESPONSE RATE@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924660@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Two or three cycles of transrectal ultrasound guided intratumoural injections of 5x1011 particles of AdV-tk followed by oral administration of valacyclovir for 14 days per cycle.@@-@-@-@BOSTON, MASSACHUSETTS@@@@@14924660@Newly diagnosed, non-metastatic prostate cancer@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@ProstAtak showed biological activity and clinical efficacy based on biochemical (PSA) and immunological responses.  PSA levels showed an acute (2 week) rise, indicating increased prostate tumour cell death, with a subsequent decrease to low level nadirs.  The percentage of activated T lymphocytes cells in the peripheral blood increased significantly after treatment in this trial, indicating an activation of the immune system. @-@@@@-@ADV-TK@@@@@ADV-TK||||@ADVANTAGENE@@@@@ADVANTAGENE||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@PROSTATAK@@@@@PROSTATAK||||@Immunotherapy@@@@@Immunotherapy||||@PSA@@@@@@@@@@EARLY@@@@@RANDOMISED@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922482@Onco@@@@@300f1012ntsdm@@@@@@250mg monthly Faslodex for three injection@@L02BA03@L02B@-@LONDON, UNITED KINGDOM@@@Fulvestrant is an oestrogen receptor antagonist and binds to oestrogen receptors in a competitive manner with an affinity comparable with that of oestradiol. Fulvestrant blocks the trophic actions of oestrogens without itself having any partial agonist (oestrogen-like) activity. The mode of action is associated with down-regulation of oestrogen receptor (ER) protein. Clinical trials in postmenopausal women with primary breast cancer have shown that fulvestrant significantly down-regulates ER protein in ER positive tumours compared with placebo. There was also a significant decrease in progesterone receptor expression consistent with a lack of intrinsic oestrogen agonist effects.@@14922482@1st line advanced breast cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00334295@35@-@-@@@-@@9/1/2002@-@9238GR0002  @@-@-@@@II@II@@-@-@RESULTS PENDING (recruiting)@-@@@@MONO@FULVESTRANT@@@@@FULVESTRANT||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Endometrial Cancer@@@@@Endometrial Cancer|||||||||@FASLODEX@@@@@FASLODEX||||@Hormone Antagonist@@@@@Hormone Antagonist||||@RESPONSE RATE@@@@@@@@@@RELAPSED@METASTATIC@@@@RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14921589@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@6 weekly doses of 8mg/kg Zalutumumab plus radiotherapy vs radiotherapy alone@@-@-@-@COPENHAGEN, DENMARK@@@Zalutumumab is a fully human, high-affinity antibody targeted at the Epidermal Growth Factor receptor (EGFr) and is in clinical development to treat head and neck cancer, non small cell lung cancer (NSCLC) and colorectal cancer. EGFr is a receptor molecule found on the surface of many cancer cells. Activation of EGFr by the appropriate growth factor molecule promotes the growth of tumor cells. @@14921589@Squamous cell carcinoma of the head and neck.@@-@-@@NO REVIEW@@@@-@No licensing partner@FIRST-LINE@NCT00024440@600@-@-@@@-@@@-@DAHANCAGENMAB@@-@PREVIOUSLY UNTREATED PATIENTS@@@III@III@@-@-@Started in September 2007.@-@@@@MONO@ZALUTUMUMAB@@@@@ZALUTUMUMAB||||@GENMAB@@@@@GENMAB||||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@HUMAX-EGFR@@@@@HUMAX-EGFR||||@mAb@Human@TK Inhibitor@EGFR@@mAb|Human|TK Inhibitor|EGFR|@OVERALL SURVIVAL@DISEASE-FREE SURVIVAL@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14923496@Onco@@@@@@@@@@@Oxaliplatin  in combination with capecitabine@@L01XA03@L01X@-@PARIS, FRANCE@@@Eloxatin is an antineoplastic agent which is an organoplatinum complex in which the platinum atom is complexed with 1,2-DACH and with an oxalate ligand as a leaving group. It undergoes non-enzymatic conversion in physiologic solutions to active derivatives via displacement of the labil oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.@@14923496@Metastatic nasopharyngeal carcinoma@@-@-@@NO REVIEW@@@@-@sanofi-aventis licensed U.S. and European rights from Debiopharm.@FIRST-LINE@NCT00363831@42@-@-@@@-@@7/1/2006@-@-@@-@42 patients with metastatic NPC without prior chemotherapy for relapse. @@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@OXALIPLATIN@CAPECITABINE@@@@OXALIPLATIN|CAPECITABINE|||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@Hong Kong@@@@@Hong Kong|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@ELOXATIN@XELODA@@@@ELOXATIN|XELODA|||@Platinum@@@@@Platinum||||@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@
14924772@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Two dose schedules of Telintra tablets will be evaluated in low-to-intermediate one risk MDS patients. One group of patients will be given a starting dose of 4500mg daily in divided doses for two weeks followed by one week off therapy. The second group of patients will receive the same dose for three weeks followed by one week off therapy. Patients will receive treatment for up to six months, and if patients are continuing to receive clinical benefit after this initial period, the treatment may be extended for an additional six months with continuous daily dosing. SOURCE: Telik@@-@-@-@-@@@@@14924772@-@@-@-@@NO REVIEW@@@@-@-@-@-@86@-@PARTIAL HOLD ON TELCYTA ARMS IMPOSED IN JUNE 2007; ASSIST-3 AND ASSIST-5 PATIENTS WILL CONTINUE TO RECEIVE TREATMENT.@@@-@@@-@-@@-@-@@@II@II@@-@-@Trial started. SOURCE: Telik, 20 May 2008@-@@@@MONO@-@@@@@-||||@TELIK@@@@@TELIK||||@@@@@@|||||||||@Haematological Malignancy@Myelodysplastic Syndrome@@@@Haematological Malignancy|Myelodysplastic Syndrome||||||||@TELINTRA@@@@@TELINTRA||||@Enzyme@@@@@Enzyme||||@HAEMATOLOGIC RESPONSE@@@@@@@@@@-@@@@@RANDOMISED@MULTI-CENTRE@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924469@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@160mg/m2 per week dosing@@-@-@-@MENLO PARK, CALIFORNIA@@@@@14924469@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@I/II@II@@-@-@June 2007; one-third of patients had stable disease. Well-tolerated and maximum tolerated dose has not yet been reached (peak plasma concentrations of the compound stand at 10µg/mL).@-@@@@MONO@-@@@@@-||||@GERON@@@@@GERON||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@GRN-163L@@@@@GRN-163L||||@Telomerase Inhibitor@@@@@Telomerase Inhibitor||||@SAFETY@@@@@@@@@@ADVANCED@@@@@OPEN-LABEL@DOSE ESCALATION@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924108@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@IV administration of MAC-321 to all patients at the same dose every 3 weeks for up to 6 courses of treatment.@@-@-@-@-@@@@@14924108@Second-line or third-line therapy @@-@-@@NO REVIEW@@@@-@Under a July 2001 collaboration, Wyeth acquired exclusive rights to develop, manufacture and commercialise MAC 321.@SECOND-LINE@NCT00063219@96@-@-@@@-@@@-@-@@-@96 PATIENTS WITH NSCLC REFRACTORY TO PLATINUM-BASED THERAPY.@@@II@II@@-@-@RESULTS PENDING@-@@@@-@MILATAXEL ORAL@@@@@MILATAXEL ORAL||||@TAXOLOG@WYETH@@@@TAXOLOG|WYETH|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@-@@@@@-||||@Taxane@@@@@Taxane||||@SAFETY@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916402@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@6mg/m2 oral tamibarotene@@-@-@-@-@@@@@14916402@Treating relapsed or refractory acute promyelocytic leukaemia@@-@-@@NO REVIEW@@@@-@>> Takeover is complete. [CytRx, 22.09.2008]>> CytRx acquires Innovive in US$25 million deal, mainly paid in future milestones. [CytRx, 10 June 2008]@-@-@50@-@FAST-TRACK DESIGNATION IN U.S. FOR RELAPSED/REFRACTORY APL GRANTED IN JUNE 2007; NDA FILING WITH FDA EXPECTED IN EARLY 2008. SPA RECEIVED IN AUGUST 2007. APPROVED IN JAPAN.@@@-@@8/1/2007@-@STAR-I@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@TAMIBAROTENE@@@@@TAMIBAROTENE||||@INNOVIVE PHARMACEUTICAL@CYTRX CORP.@@@@INNOVIVE PHARMACEUTICAL|CYTRX CORP.|||@@@@@@|||||||||@Haematological Malignancy@@@@@Haematological Malignancy|||||||||@AM-80@@@@@AM-80||||@Retinoid@@@@@Retinoid||||@RESPONSE RATE@COMPLETE RESPONSE@PARTIAL RESPONSE@SAFETY@@PARTIAL RESPONSE@SAFETY@@@@RELAPSED@REFRACTORY@@@@OPEN-LABEL@SINGLE-ARM@PIVOTAL@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916169@Onco@@@@@@@@@@@-@@-@-@-@MILAN, ITALY@@@@@14916169@Haplo-HSCT@@-@-@@NO REVIEW@@@-@-@Takara Bio holds the Asian market rights. MolMed is looking to out-license other rights.@-@NCT00423124@30@-@EMEA Orphan drug 2003.FDA orphan drug 2005.@@@EMEA Orphan drug 2003.FDA orphan drug 2005.@@@-@TK007@@-@-@@@I/II@II@@-@-@The treatment with TK resulted in an unprecedented improvement in patients' survival, showing that it promotes rapid and sustained immune reconstitution, thus abating transplant-related mortality, and that TK enhances safety and efficacy of haploidentical HSCT, thus increasing feasibility of transplantation from partially compatible donors. Phase III trial and another Phase I/II trial planned for 2008. SOURCE: MolMed, 15 December 2005@-@@@@MONO@-@@@@@-||||@MOLMED@@@@@MOLMED||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@Acute Lymphocytic Leukaemia@@@Haematological Malignancy|Acute Myeloid Leukaemia|Acute Lymphocytic Leukaemia|||||||@TK@@@@@TK||||@Gene Therapy@@@@@Gene Therapy||||@OVERALL SURVIVAL@SAFETY@@@@@@@@@-@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924565@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Delivery of low-dose bleomycin by electroporation@@L01DC01@L01D@-@-@@@@@14924565@-@@-@-@@NO REVIEW@@@@-@-@-@-@8 EVALUABLE @-@-@@@-@@@-@-@@-@-@@@I/II@IV@@-@-@June 2007 Madrid Breast Cancer conference; interim data; 6 of 8 patients had complete response at 24 weeks or last evaluation.@-@@@@MONO@BLEOMYCIN @@@@@BLEOMYCIN ||||@INOVIO BIOMEDICAL@@@@@INOVIO BIOMEDICAL||||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@MEDPULSER@@@@@MEDPULSER||||@Cytotoxic Antibiotic@@@@@Cytotoxic Antibiotic||||@RESPONSE RATE@SAFETY@@@@@@@@@-@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15409685@Onco@@@@@@@@@@@Degarelix, Experimental, Leuprolide, Active Comparator,@@@@@@10/1/2019@@@@15409685@A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients With Prostate Cancer and Cardiovascular Disease Receiving Degarelix (Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist)@Male@@@@@@@@@@@NCT02663908@900@@@@@@@2/1/2016@@108@@@Advanced prostate cancer ; Indication to initiate androgen deprivation therapy (ADT); Predefined cardiovascular disease@@@Phase 3@III@@@@@@@@@@DEGARELIX@@@@@DEGARELIX||||@FERRING PHARMACEUTICALS@@@@@FERRING PHARMACEUTICALS||||@Canada@United States@@@@Canada|United States||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@-@@@@@-||||@LH-RH Analog@@@@@LH-RH Analog||||@Time from randomization to the first confirmed (adjudicated) occurrence of the composite Major Adverse Cardiovascular Event (MACE) endpoint@@@@@Time from randomization to occurrence of myocardial infarction (fatal, non-fatal)@Time from randomization to occurrence of stroke (fatal, non-fatal)@@@@@@@@@RANDOMIZED@SAFETY/EFFICACY STUDY@PARALLEL ASSIGNMENT@Single Blind (Outcomes Assessor)@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922669@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Enzastaurin versus placebo@@-@-@-@INDIANAPOLIS, INDIANA@@@Enzastaurin is an oral, serine threonine kinase inhibitor which selectively targets the PKCBeta and PI3/AKTsignaling pathways. By blocking these key pathways frequently over-expressed in a wide variety of cancers, enzastaurin suppresses tumor cell proliferation, induces tumor cell death and inhibits tumor-induced angiogenesis. Treatment has been well tolerated with minimal drug-related toxicity. Enzastaurin administration is associated with fatigue, diarrhea, nausea, decreased platelets, cough, vomiting, transaminase elevation, dyspnea, peripheral edema, and dizziness. Further testing in Phase III versus a placebo will provide us with a more complete look at the side effect profile for enzastaurin. In addition to DLBCL, enzastaurin is also being studied in other tumor types including breast, colon, lung, ovarian and prostate cancers@@14922669@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00466440@96@-@-@@@-@@@-@11311H6Q-MC-S032  @@-@-@@@II@II@@-@-@Completion expected in January 2010.@-@@@@MONO@ENZASTAURIN@@@@@ENZASTAURIN||||@LILLY@@@@@LILLY||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@LY-317615@@@@@LY-317615||||@Angiogenesis Inhibitor@@@@@Angiogenesis Inhibitor||||@RESPONSE RATE@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15413041@Onco@@@@@@@@@@@Cohort Docetaxel, , Participants initiated on docetaxel for the treatment of relapsed non-small cell lung cancer (NSCLC)@@@@@BASEL, SWITZERLAND@5/1/2016@@@@15413041@A Retrospective Chart Review to Describe the Rate of Neutropenic Sepsis in Patients With Non-Small Cell Lung Cancer Treated With Single-Agent Docetaxel and Associated Resource Use in the UK@Both@@@@@No intervention administered in this study@@@@@@NCT02658747@120@@@@@@@1/1/2016@@ML30033@@@Diagnosed with locally advanced or metastatic (stage Ill or IV) non-small cell lung cancer (NSCLC)  -  Relapsed disease following, or unable to tolerate, at least one line of prior chemotherapy  -  Initiated on single-agent docetaxel up to a maximum of 6 years prior to date of collection  -  Aged 18 years at date of first docetaxel dose  -  Completed or stopped treatment with docetaxel at least 30 days prior to date of data collection@@ADULTS@N/A@-@@@@@@@@@@-@@@@@-||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@-@@@@@-||||@Other@@@@@Other||||@Percentage of Participants Receiving Single-Agent Docetaxel Chemotherapy for Treatment of Relapsed Non-Small Cell Lung Cancer (NSCLC) with an Episode of Neutropenic Sepsis (NS) with an Absolute Neutrophil Count of Less Than 1.0 x 10^9/L@@@@@Frequency with which Participants Attend Hospital for Management of Specified Hematological Docetaxel-Related Toxicities, Including Anemia, Thrombocytopenia, Neutropenia, Neutropenic Infection and Pancytopenia@Percentage of Participants Receiving Single-Agent Docetaxel Chemotherapy for Treatment of Relapsed Non-Small Cell Lung Cancer (NSCLC) with an Episode of Neutropenic Sepsis (NS) with an Absolute Neutrophil Count of Less Than 0.5 x 10^9/L@@@@@@@@@Cohort@RETROSPECTIVE@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924480@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@OXFORD, UNITED KINGDOM@@@@@14924480@Stage III/IV metastatic melanoma@@-@-@@NO REVIEW@@@@-@Commercial partners sought to co-develop and market the drug. Acquired through takeover of Oxxon in March 2007@FIRST-LINE@-@41@-@-@@@-@@@-@-@@-@41 HLA-A2 POSITIVE PATIENTS WITH NON-RESECTABLE STAGE III/IV MELANOMA@@@II@II@@-@-@All clinical endpoints were achieved; immunological melanoma-specific CD8 T-cell responses were seen in 91% of patients at highest dose; tumour responses in nearly 20% of patients (8); one partial response obeserved (51% reduction in target lesions) durable at 108 weeks follow-up.; overall survival was 100 weeks for immune responders versus 37 weeks for non-responders and 42 weeks for a groupd of control non-HLA A2 patients receiving standard of care@-@@@@MONO@-@@@@@-||||@OXFORD BIOMEDICA@@@@@OXFORD BIOMEDICA||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@HI-8 MEL@@@@@HI-8 MEL||||@Vaccine@@@@@Vaccine||||@RESPONSE RATE@OVERALL SURVIVAL@@@@@@@@@METASTATIC@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924141@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@ABT-751 in combination with Alimta versus Alimta alone@@-@-@-@UNITED STATES@@@An orally bioavailable antimitotic sulfonamide. ABT-751 binds to the colchicine-binding site on beta-tubulin and inhibits the polymerization of microtubules, thereby preventing tumor cell replication. This agent also disrupts tumor neovascularization, reducing tumor blood flow and so inducing a cytotoxic effect@@14924141@with Alimta@@-@-@@NO REVIEW@@@@-@-@-@NCT00297089@180@-@-@@@-@@4/1/2006@-@-@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@PEMETREXED@@@@-|PEMETREXED|||@ABBOTT@@@@@ABBOTT||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@ABT-751@ALIMTA@@@@ABT-751|ALIMTA|||@Plant Alkaloid@Vascular Disrupting Agent@@@@Plant Alkaloid|Vascular Disrupting Agent|||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@ADVANCED@METASTATIC@@@@RANDOMISED@DOUBLE-BLIND@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924221@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@BrachySil in combination with chemotherapy@@-@-@-@-@@@@@14924221@Patients with inoperable pancreatic cancer@@-@-@@NO REVIEW@@@@-@-@-@-@17@-@-@@@-@@@-@-@@-@17 PATIENTS WITH INOPERABLE PANCREATIC CANCER@@@II@II@@-@-@Phase IIA data year-end 2007; preliminary Phase IIA data showed that at 8 weeks of follow-up, BrachySil led to disease stabilisation or reduced primary tumour size without significant adverse events in 9 of 10 evaluable patients. @-@@@@COMBO@-@@@@@-||||@PSIVIDA@@@@@PSIVIDA||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@BRACHYSIL@@@@@BRACHYSIL||||@Other@@@@@Other||||@SAFETY@OVERALL SURVIVAL@@@@@@@@@-@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920892@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@L01AA02@L01A@YES@BRENTFORD, UNITED KINGDOM@@@Leukeran is a bifunctional alkylating agent of the nitrogen mustard type that has been found active against selected human neoplastic diseases.@@14920892@Leukeran is indicated in the treatment of Hodgkin's disease, certain forms of non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, and Waldenstrom's macroglobulinaemia@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@Waldenstrom's Macroglobulinaemia: Leukeran is the treatment of choice in this indication. Starting doses of 6-12 mg daily until leucopenia occurs are recommended followed by 2-8 mg daily indefinitely.@@@@@@@Can severely suppress bone marrow function. Chlorambucil is a carcinogen in humans. Chlorambucil is probably mutagenic and teratogenic in humans. Chlorambucil produces human infertility@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@CHLORAMBUCIL@@@@@CHLORAMBUCIL||||@GSK@@@@@GSK||||@@@@@@|||||||||@Haematological Malignancy@Waldenstrom's Macroglobinaemia@@@@Haematological Malignancy|Waldenstrom's Macroglobinaemia||||||||@LEUKERAN@@@@@LEUKERAN||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@50@1.1511@100@137.42@103.85@@@@@@@@@@1@@@@@@@@@@@@@@@@8/1/2017@2@2@461126@FILM-COATED TABLET@EURO@@@@@@@@2@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14923501@Onco@@@@@@@@@@@-@@J07BM01@J07B@-@WHITEHOUSE STATION, NEW JERSEY@@@Gardasil is an adjuvanted non-infectious recombinant quadrivalent vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid L1 protein of HPV types 6, 11, 16 and 18. The VLPs contain no viral DNA, they cannot infect cells, reproduce or cause disease. HPV only infects humans, but animal studies with analogous papillomaviruses suggest that the efficacy of LI VLP vaccines is mediated by the development of a humoral immune response. HPV 16 and HPV 18 are estimated to be responsible for approximately 70% of cervical cancers; 80% of adenocarcinoma in situ (AIS); 45-70% of high-grade cervical intraepithelial neoplasia (CIN 2/3); 25% of low grade cervical intraepithelial neoplasia (CIN 1); approximately 70% of HPV related high-grade vulvar (VIN 2/3) and vaginal (VaIN 2/3) intraepithelial neoplasia. HPV 6 and 11 are responsible for approximately 90% of genital warts and 10% of low grade cervical intraepithelial neoplasia (CIN 1). CIN 3 and AIS have been accepted as immediate precursors of invasive cervical cancer.@@14923501@For girls 9-15 years of age for the prevention of diseases caused by HPV types 6, 11, 16, and 18. @@-@-@@NO REVIEW@@@@-@extra-Australia rights licensed from CSL@-@NCT00380367@110@-@-@@@-@@4/1/2007@-@-@@-@-@@@III@III@@-@-@RESULTS PENDING@-@@@@MONO@HUMAN PAPILLOMAVIRUS@@@@@HUMAN PAPILLOMAVIRUS||||@MERCK & CO@SANOFI PASTEUR@SANOFI PASTEUR MSD@@@MERCK & CO|SANOFI PASTEUR|SANOFI PASTEUR MSD||@India@@@@@India|||||||||@Cervical Cancer@@@@@Cervical Cancer|||||||||@GARDASIL@@@@@GARDASIL||||@Vaccine@@@@@Vaccine||||@HPV@@@@@@@@@@-@@@@@PREVENTION@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@
14916497@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@CC-4047 combined with Gemzar@@-@-@-@SUMMIT, NEW JERSEY@@@Pomalidomide is a form of the drug thalidomide. It stops the growth of blood vessels, stimulates the immune system, and may kill cancer cells. Pomalidomide is a type of angiogenesis inhibitor and a type of immunomodulatory agent.@@14916497@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00540579@106@-@-@@@-@@11/1/2007@-@SCRI GI 105, PO-PANC-PI-009@@-@-@@@I/II@II@@-@-@Endpoint is to explore anti-tumour activity on days 1-21 for CC-4047 and days 1,8 and 15 every 28 days for Gemzar@-@@@@COMBO@POMALIDOMIDE@@@@@POMALIDOMIDE||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@ACTIMID@CC-4047@@@@ACTIMID|CC-4047|||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@OPEN-LABEL@SINGLE-ARM@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922973@Onco@@@@@@@@@@@-@@J07BM01@J07B@-@WHITEHOUSE STATION, NEW JERSEY@5/1/2008@@Gardasil is an adjuvanted non-infectious recombinant quadrivalent vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid L1 protein of HPV types 6, 11, 16 and 18. The VLPs contain no viral DNA, they cannot infect cells, reproduce or cause disease. HPV only infects humans, but animal studies with analogous papillomaviruses suggest that the efficacy of LI VLP vaccines is mediated by the development of a humoral immune response. HPV 16 and HPV 18 are estimated to be responsible for approximately 70% of cervical cancers; 80% of adenocarcinoma in situ (AIS); 45-70% of high-grade cervical intraepithelial neoplasia (CIN 2/3); 25% of low grade cervical intraepithelial neoplasia (CIN 1); approximately 70% of HPV related high-grade vulvar (VIN 2/3) and vaginal (VaIN 2/3) intraepithelial neoplasia. HPV 6 and 11 are responsible for approximately 90% of genital warts and 10% of low grade cervical intraepithelial neoplasia (CIN 1). CIN 3 and AIS have been accepted as immediate precursors of invasive cervical cancer.@@14922973@For girls and women 9-26 years of age for the prevention of diseases caused by HPV types 6, 11, 16, and 18. @@-@-@@NO REVIEW@@@@-@extra-Australia rights licensed from CSL@-@NCT00496626@600@-@-@@@-@@9/1/2007@-@-@@-@-@@@III@III@@-@-@RESULTS PENDING@-@@@@MONO@HUMAN PAPILLOMAVIRUS@@@@@HUMAN PAPILLOMAVIRUS||||@MERCK & CO@SANOFI PASTEUR@SANOFI PASTEUR MSD@@@MERCK & CO|SANOFI PASTEUR|SANOFI PASTEUR MSD||@China@@@@@China|||||||||@Cervical Cancer@@@@@Cervical Cancer|||||||||@GARDASIL@@@@@GARDASIL||||@Vaccine@@@@@Vaccine||||@HPV@@@@@@@@@@-@@@@@PREVENTION@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@
14923714@Onco@@@@@300f1008ntsdm@@@@@@Comparing ATRA therapy with tamibarotene for the maintenace treatment of APL@@-@-@-@-@@@@@14923714@Comparing ATRA therapy with tamibarotene for the maintenace treatment of APL@@-@-@@NO REVIEW@@@@-@Extra-APL rights for Japan, and all overseas rights, licensed from Nippon Shinyaku. South Korean APL rights licensed to Choongwae Pharma. North American APL rights licensed to Innovive for royalties and payments in December 2006. Innovive also holds optio@-@-@-@-@APPROVAL EXPECTED BY END-2007@@@-@@@-@-@@-@-@@@-@III@@-@@RESULTS PENDING@-@@@@-@TAMIBAROTENE@@@@@TAMIBAROTENE||||@TMRC CO.@NIPPON SHINYAKU@INNOVIVE PHARMACEUTICAL@@@TMRC CO.|NIPPON SHINYAKU|INNOVIVE PHARMACEUTICAL||@@@@@@|||||||||@Haematological Malignancy@@@@@Haematological Malignancy|||||||||@TM-411@AMNOLAKE@@@@TM-411|AMNOLAKE|||@Retinoid@@@@@Retinoid||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14922148@Onco@@@@@@@@@@@In the first stage of the study, patients will be randomised to receive subcutaneous injections of Mircera once every 3 weeks, at doses of 2.0, 3.5 or 5.0 micrograms/kg. Following the administration of 2 doses, an evaluation of hemoglobin increase will be made at week 6. In the second stage, further groups of patients will receive additional doses of Mircera,at doses of 1.0, 6.5 or 8.0 micrograms/kg, depending on efficacy, safety and pharmacokinetic considerations.The anticipated time on treatment is 3-12 months. SOURCE: clinicaltrials.gov@@-@-@-@BASEL, SWITZERLAND@@@@@14922148@Adult anaemic patients with multiple myeloma@@-@-@@NO REVIEW@@@@-@Roche has offered to pay U.S. biotech firm Amgen Inc. a 20% royalty on U.S. sales of Mircera in order to resolve an ongoing patent dispute. The offer comes as part of a motion filing with the U.S. District Court in Boston, in which Roche suggests ways to @FIRST-LINE@NCT00360347@100@-@-@@@-@@@-@BA16558@@-@-@@@II@II@@-@-@Primary endpoint time frame over 5-13 weeks.@-@@@@MONO@CERA@@@@@CERA||||@ROCHE@@@@@ROCHE||||@Poland@@@@@Poland|||||||||@Supportive Care@Anaemia@Haematological Malignancy@Myeloma@@Supportive Care|Anaemia|Haematological Malignancy|Myeloma||||||@MIRCERA@@@@@MIRCERA||||@EPO@@@@@EPO||||@HAEMOGLOBIN@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@UNCONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916773@Onco@@@@@@@@@@@Patients are receiving 15 administrations of vaccine over 12 months to generate and maintain a strong anti-cancer immune response throughout the treatment period. SOURCE: Onyvax@@-@-@-@-@@@@@14916773@Non-metastatic hormone refractory prostate cancer@@-@-@@NO REVIEW@@@MARCH 2007-@-@-@-@NCT00514072@75@-@FDA orphan drug designation for multiple myeloma. SOURCE: Immunomedics press release, 18 March 2008@3/18/2008@@FDA orphan drug designation for multiple myeloma. SOURCE: Immunomedics press release, 18 March 2008@@@-@ONY-P1-07-01@@-@-@@@II@II@@-@-@Enrolment completed. SOURCE: Onyvax, 17 March 2008Previous results: mild side effects - significant slowing of PSA rise in 40% patients (a blood marker for prostate cancer); and - on average, time to disease progression (i.e. clinical deterioration) took 58 weeks compared to historical experience of 29-30 weeks. SOURCE: Onyvax/Clinical Cancer Research, 15 March 2005@-@@@@MONO@-@@@@@-||||@ONYVAX@@@@@ONYVAX||||@@@@@@|||||||||@Prostate Cancer@HRPC@@@@Prostate Cancer|HRPC||||||||@ONYVAX-P@@@@@ONYVAX-P||||@Vaccine@@@@@Vaccine||||@PSA@@@@@@@@@@REFRACTORY@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922220@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@ATN-161 with carboplatin@@-@-@-@SAN DIEGO, CALIFORNIA@12/1/2007@@@@14922220@Recurrent malignant glioma@@-@-@@NO REVIEW@@@@-@-@-@NCT00352313@82@-@-@@@-@@5/1/2006@-@ATN-161-002@@-@-@@@II@CLINICAL HOLD@@-@-@RESULTS PENDING@-@@@@COMBO@-@CARBOPLATIN@@@@-|CARBOPLATIN|||@ATTENUON@@@@@ATTENUON||||@@@@@@|||||||||@Brain Cancer@@@@@Brain Cancer|||||||||@ATN-161@@@@@ATN-161||||@Angiogenesis Inhibitor@@@@@Angiogenesis Inhibitor||||@SAFETY@MAXIMUM TOLERATED DOSE@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@@@RELAPSED@MALIGNANT@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921400@Onco@@@@@@@@@@@Patients are randomised to one of two treatment arms. In Arm I, patients to receive nolatrexed dihydrochloride IV continuously on days 1-5, whereas in Arm II, patients receive doxorubicin IV on day 1. Without unacceptable toxicity or disease progression, treatment continues in both arms every 3 weeks. Patients are monitored every 2 months for survival.@@-@-@-@ONTARIO, CANADA@@@@@14921400@Unresectable or recurrent hepatocellular carcinoma @@-@-@@NO REVIEW@@@@-@Obtained via the acquisition of YM BioSciences in May 2006 of Eximias Pharmaceutical Corporation@-@NCT00012324,@446@-@-@@@-@@@-@ETHECC@@-@446 PATIENTS (223 PER TREATMENT ARM)@@@III@III@@-@-@In August 2005, Eximia, now part of YM BioSciences, revealed nolatrexed failed to achieve its primary endpoint of a survival benefit compared to doxorubicin.@-@@@@MONO@NOLATREXED@@@@@NOLATREXED||||@YM BIOSCIENCES@@@@@YM BIOSCIENCES||||@@@@@@|||||||||@Liver Cancer@Hepatocellular Carcinoma@@@@Liver Cancer|Hepatocellular Carcinoma||||||||@THYMITAQ@@@@@THYMITAQ||||@TS Inhibitor@@@@@TS Inhibitor||||@OVERALL SURVIVAL@@@@@@@@@@RELAPSED@@@@@TWO-ARM@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14923663@Onco@@@@@300f1008ntsdm@@@@@@-@@-@-@-@LONDON, UNITED KINGDOM@@@ASA404 (DMXAA) is a small-molecule Tumour-Vascular Disrupting Agent (Tumour-VDA) that selectively disrupts established tumour blood vessels. It is currently in clinical trials for lung and prostate cancers. Antisoma has licensed the world-wide rights for ASA404 to Novartis AG. Novartis is now responsible for all further development work on the drug. Antisoma has an option to co-commercialise the drug with Novartis in the United States. @@14923663@-@@-@-@@NO REVIEW@@@@-@Novartis licensed global rights in April 2007; Antisoma has an option to co-commercialise the drug with Novartis in the United States. @-@-@-@-@-@@@-@@5/1/2008@-@-@@-@-@@@I@I@@-@@Trial to form basis of Japanese patients joining the ATTRACT 1 trial. SOURCE: Antisoma, 29 April 2008@-@@@@COMBO@-@@@@@-||||@ANTISOMA@NOVARTIS@@@@ANTISOMA|NOVARTIS|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@ASA-404@AS-1404@DMXAA@@@ASA-404|AS-1404|DMXAA||@Vascular Disrupting Agent@@@@@Vascular Disrupting Agent||||@-@@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14919285@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@ABT-751 by mouth daily for 21 days, then off treatment for 7 days before next cycle begins.@@-@-@-@UNITED STATES@@@An orally bioavailable antimitotic sulfonamide. ABT-751 binds to the colchicine-binding site on beta-tubulin and inhibits the polymerization of microtubules, thereby preventing tumor cell replication. This agent also disrupts tumor neovascularization, reducing tumor blood flow and so inducing a cytotoxic effect@@14919285@-@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT0073138@-@-@-@@@-@@@-@M02-446  @@-@PATIENTS RELAPSED AFTER IRINOTECAN AND/OR OXALIPLATIN@@@II@II@@-@-@RESULTS PENDING (recruiting).@-@@@@-@-@@@@@-||||@ABBOTT@@@@@ABBOTT||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ABT-751@@@@@ABT-751||||@Plant Alkaloid@Vascular Disrupting Agent@@@@Plant Alkaloid|Vascular Disrupting Agent|||@-@@@@@@@@@@RELAPSED@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918975@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@TORONTO, CANADA@@@This is an intravesical formulation of LOR-2040 (formerly GTI-2040), which is an antisense drug that specifically targets the R2 component of ribonucleotide reductase, which is required for DNA synthesis and cell proliferation. Through downregulation of R2, LOR-2040 has demonstrated strong antitumor and antimetastatic activity in a variety of tumor types in both in vivo and in vitro models and is under study in a multiple Phase I/II clinical program. R2 has been described as a malignant determinant that is elevated in a wide range of tumors, which can cooperate with a variety of cellular cancer causing genes known as oncogenes to enhance tumor growth and metastatic potential.@@14918975@Intravesical administration of LOR-2040 for superficial or non-invasive bladder cancer@@-@-@@NO REVIEW@@@@-@Global rights available for partnering@-@-@N/A@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@-@IND to be filed in Q3 2008. SOURCE: Lorus, 22 April 2008@-@@@@MONO@-@@@@@-||||@LORUS THERAPEUTICS@@@@@LORUS THERAPEUTICS||||@@@@@@|||||||||@Bladder Cancer@@@@@Bladder Cancer|||||||||@LOR-2040@@@@@LOR-2040||||@Antisense@@@@@Antisense||||@MAXIMUM TOLERATED DOSE@TOXICITY@@@@@@@@@-@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRAVENOUS@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921609@Onco@@@@@@@@@@@Zactima with BSC versus BSC alone @@-@-@-@LONDON, UNITED KINGDOM@@@An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGF2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis. @@14921609@EGFR failure NSCLC@@-@-@@NO REVIEW@@@@-@-@-@NCT00404924@930@-@-@@@-@@11/1/2006@-@D4200C00044@@-@-@@@III; EUDRACT NUMBER 2006-002384-12 / @III@@-@-@RESULTS PENDING@-@@@@COMBO@VANDETANIB@@@@@VANDETANIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@ZACTIMA@@@@@ZACTIMA||||@TK Inhibitor@VEGF@EGFR@Angiogenesis Inhibitor@@TK Inhibitor|VEGF|EGFR|Angiogenesis Inhibitor|@OVERALL SURVIVAL@@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921138@Onco@@@@@@@@@@@Recentin with FOLFOX versus Avastin with FOLFOX@@-@-@-@LONDON, UNITED KINGDOM@@@Cediranib (Recentin AZD2171) is a highly potent inhibitor of the tyrosine kinase activity associated with all three vascular endothelial growth factor (VEGF) receptors and is currently in Phase II/III clinical trials. Preclinically, cediranib inhibits VEGF signaling and angiogenesis in vivo and impedes solid tumor growth significantly. @@14921138@Second-line mCRC@@-@-@@NO REVIEW@@@STARTED IN JANUARY 2006@-@-@SECOND-LINE@NCT00278889@210@-@-@@@-@@@-@HORIZON I@@-@-@@@NCT00278889@II@@-@-@IDMC would not have recommended continuation of trial, but combined with review of HORIZON II and III it decided to go ahead. SOURCE: AstraZeneca, 27 February 2008@-@@@@COMBO@CEDIRANIB@@@@@CEDIRANIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@RECENTIN@AZD-2171@@@@RECENTIN|AZD-2171|||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@METASTATIC@@@@@RANDOMISED@DOUBLE-BLIND@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924994@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@IT-101 every other week.@@-@-@-@PASADENA, CALIFORNIA@6/1/2008@@@@14924994@-@@YES@-@@NO REVIEW@@@@-@Arrowhead merged its two subsidiaries Calando and Insert Therapeutics in February 2008; now known as Calando Pharmaceuticals.@-@NCT00333502@36@-@-@@@-@@5/1/2006@-@5127@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@CALANDO PHARMACEUTICALS@INSERT THERAPEUTICS@@@@CALANDO PHARMACEUTICALS|INSERT THERAPEUTICS|||@@@@@@|||||||||@Ovarian Cancer@NSCLC@Pancreatic Cancer@Melanoma / Skin Cancer@@Ovarian Cancer|NSCLC|Pancreatic Cancer|Melanoma / Skin Cancer||||||@IT-101@@@@@IT-101||||@Camptothecin@@@@@Camptothecin||||@MAXIMUM TOLERATED DOSE@SAFETY@@@@@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921169@Onco@@@@@300f1020ntsdm@@@@@@Zarnestra with multiple ascending doses of Velcade@@-@-@-@NEW BRUNSWICK, NEW JERSEY@@@A nonpeptidomimetic quinolinone with potential antineoplastic activity. Tipifarnib binds to and inhibits the enzyme farnesyl protein transferase, an enzyme involved in protein processing (farnesylation) for signal transduction. By inhibiting the farnesylation of proteins, this agent prevents the activation of Ras oncogenes, inhibits cell growth, induces apoptosis, and inhibits angiogenesis.@@14921169@Newly diagnosed AML@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00510939@10@-@Johnson & Johnson will not file for the AML indication. SOURCE: Johnson & Johnson, 17 July 2007@7/17/2007@@-@@3/1/2007@-@HEMOSAML0106@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@TIPIFARNIB@BORTEZOMIB@@@@TIPIFARNIB|BORTEZOMIB|||@JOHNSON & JOHNSON@@@@@JOHNSON & JOHNSON||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@ZARNESTRA@VELCADE@@@@ZARNESTRA|VELCADE|||@Farnesyltransferase Inhibitor@@@@@Farnesyltransferase Inhibitor||||@-@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@1.0543@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14922511@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@-@10/1/2003@@@@14922511@Colorectal cancer metastatic to the liver@@-@-@@NO REVIEW@@@@-@-@-@NCT00035919@9@-@The drug has been approved in the Philippines for use as a first-line and adjuvant therapy for pancreatic and breast cancer and a second-line therapy for all other solid tumors that are refractory to standard chemotherapy.@@@-@@11/1/2002@-@3C-01-2@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@EPEIUS BIOTECHNOLOGIES@@@@@EPEIUS BIOTECHNOLOGIES||||@@@@@@|||||||||@Colorectal Cancer@Liver Cancer@@@@Colorectal Cancer|Liver Cancer||||||||@REXIN-G@@@@@REXIN-G||||@Gene Therapy@@@@@Gene Therapy||||@SAFETY@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916722@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Decapeptyl 11.25 versus Pamorelin 11.25MG@@L02AE04@L02A@-@PARIS, FRANCE@@@Triptorelin is a decapeptide analogue of GnRH which initially stimulates release of pituitary gonadotrophins. @@14916722@-@@-@-@@NO REVIEW@@@@-@Ipsen exclusively in-licensed from Debiopharm know-how and new patent applications for the commercialisation rights of Decapeptyl in the world excluding North America, and some other countries (Sweden, Israel, Iran and Japan). [Ipsen, 31 October 2007]@FIRST-LINE@NCT00444639@210@-@-@@@-@@3/1/2007@-@PAMOJECT@@2010@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@TRIPTORELIN PAMOATE@@@@@TRIPTORELIN PAMOATE||||@IPSEN@DEBIOPHARM@@@@IPSEN|DEBIOPHARM|||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@PAMORELIN@@@@@PAMORELIN||||@LH-RH Analog@@@@@LH-RH Analog||||@SERUM TESTOSTERONE@@@@@@@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@1@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@POWDER AND SOLVENT FOR INJECTABLE SUSPENSION@US$@@@@@@@@11.25@MG@11.25 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922141@Onco@@@@@@@@@@@-@@-@-@-@JERUSALEM, ISRAEL@7/1/2010@@@@14922141@Phase 1/2a, Dose-Escalation, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Intratumoral Administration of DTA-H19 in Patients With Unresectable Pancreatic Cancer@@-@-@@NO REVIEW@@@@-@Pro-Pharmaceuticals and BioCancell formed partnership to target destruction of H19 genes in cancer cells by delivering siRNA through IV administration of Davanat and BC-819. SOURCE: Pro-Pharmaceuticals, 19 May 2008@-@NCT00711997@12@-@-@@@FDA grants orphan drug designation for pancreatic cancer.[Biocancell 15 August 2010 http://www.biocancell.com/press-releases/95-pancreaticorphandrugapproval ]@@8/1/2009@-@BC-07-01.CTIL@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@BIOCANCELL THERAPEUTICS@@@@@BIOCANCELL THERAPEUTICS||||@Israel@@@@@Israel|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@BC-819@@@@@BC-819||||@Other@@@@@Other||||@TOLERABILITY@@@@@RESPONSE RATE@@@@@ADVANCED@@@@@SINGLE-ARM@OPEN-LABEL@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922494@Onco@@@@@300f1014ntsdm@@@@@@Zactima alone@@-@-@-@LONDON, UNITED KINGDOM@@@An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGF2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis. @@14922494@-@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00047788@30@-@-@@@-@@@-@6474IL0004@@-@-@@@; IND.145 / @II@@-@-@RESULTS PENDING@-@@@@MONO@VANDETANIB@@@@@VANDETANIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@ZACTIMA@@@@@ZACTIMA||||@TK Inhibitor@VEGF@EGFR@Angiogenesis Inhibitor@@TK Inhibitor|VEGF|EGFR|Angiogenesis Inhibitor|@N/A@@@@@@@@@@RELAPSED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@C$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14918904@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@SAN FRANCISCO, CALIFORNIA@@@@@14918904@-@@-@-@@NO REVIEW@@@@-@">> Roche reaches a friendly agreement to purchase the latter's outstanding shares at a price of US$95 per share. The transaction will be valued at US$46.8 billion. [Genentech, 12 March 2009]>> Roche has made a formal announcement of cash tender offer for all outstanding shares of Genentech at US$86.50 per share for the 44.2% of Genentech not already held by Roche. Genentech's special committee, on the other hand, has responded to the offer by urging its shareholders ""to take no action at this time"". [Genentech, 10.02.2009]          >> Genentech rejects the acquisition bid. [Genentech, 14.08.2008]        >> Roche announces US$43.7 billion proposal to assume full control of Genentech. SOURCE: Roche, 21 July 2008"@-@-@30-40@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@-@FPI Q1 08@-@@@@COMBO@-@RITUXIMAB@@@@-|RITUXIMAB|||@GENENTECH@@@@@GENENTECH||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@ANTI-CD40@RITUXAN@MABTHERA@@@ANTI-CD40|RITUXAN|MABTHERA||@mAb@CD40@@@@mAb|CD40|||@-@@@@@@@@@@RELAPSED@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922515@Onco@@@@@@@@@@@HK-272 240MG daily by mouth. Arm A: Progression following over 12 weeks of Tarceva or Iressa treatment and tumour with EGFR-mutation. Arm B: progression following over 12 weeks of Tarceva or Iressa treatment and tumour without EGFR-mutation. Arm C: No prior EGFR TK inhibitor treatment, adenocarcinoma, a history of smoking and current non-smoker.@@-@-@-@MADISON, NEW JERSEY@3/1/2008@@HKI-272 is a potent inhibitor of HER-2 and is highly active against HER-2-overexpressing human breast cancer cell lines in vitro. It also inhibits the epidermal growth factor receptor (EGFR) kinase and the proliferation of EGFR-dependent cells. HKI-272 reduces HER-2 receptor autophosphorylation in cells at doses consistent with inhibition of cell proliferation and functions as an irreversible binding inhibitor, most likely by targeting a cysteine residue in the ATP-binding pocket of the receptor.@@14922515@-@@-@-@@NO REVIEW@@@@-@Pfizer acquired Wyeth on 26 January 2009 in a deal worth U.S $68 billion [Pfizer 26.01.2009]@-@NCT00266877@138@-@-@@@-@@11/1/2005@-@3144A1-200@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@NERATINIB@@@@@NERATINIB||||@WYETH@PFIZER@@@@WYETH|PFIZER|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@HKI-272@@@@@HKI-272||||@TK Inhibitor@HER2@@@@TK Inhibitor|HER2|||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921833@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@7/1/2005@@@@14921833@Extensive stage SCLC relapsed after first-line chemo@@-@-@@NO REVIEW@@@@-@Helsinn licensed XL-119 in June 2005@SECOND-LINE@NCT00084487@39@-@ORPHAN DRUG IN U.S. AND EU.@@@ORPHAN DRUG IN U.S. AND EU.@@4/1/2004@-@CASE-1503@@-@-@@@II@CLINICAL HOLD@@-@-@RESULTS PENDING@-@@@@MONO@BECATECARIN / REBECCAMYCIN@@@@@BECATECARIN / REBECCAMYCIN||||@HELSINN@EXELIXIS@@@@HELSINN|EXELIXIS|||@@@@@@|||||||||@SCLC@@@@@SCLC|||||||||@XL-119@@@@@XL-119||||@Plant Alkaloid@Topoisomerase II Inhibitor@@@@Plant Alkaloid|Topoisomerase II Inhibitor|||@RESPONSE RATE@@@@@@@@@@-@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916475@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@-@@-@-@-@SEATTLE, WASHINGTON@@@@@14916475@-@@-@-@@NO REVIEW@@@@-@Genentech licensed the drug from Seattle Genetics in January 2007@-@NCT00283101@20@-@ORPHAN DRUG (FDA, FEBRUARY 2006)@@@ORPHAN DRUG (FDA, FEBRUARY 2006)@@7/1/2005@-@SG040-0003@@-@-@@@I/II@II@@-@-@-@-@@@@MONO@DACETUZUMAB@@@@@DACETUZUMAB||||@SEATTLE GENETICS@@@@@SEATTLE GENETICS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@SGN-40@ANTI-CD40@@@@SGN-40|ANTI-CD40|||@mAb@Humanised@CD40@@@mAb|Humanised|CD40||@MAXIMUM TOLERATED DOSE@SAFETY@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14923261@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@N01AH01@N01A@@BUFFALO GROVE, ILLINOIS@@@Fentanyl is a synthetic opiate with a clinical potency of 50 to 100 times that of morphine. Its onset of action is rapid and its duration of action is short. In man, a single iv dose of 0.5-1 mg/70 kg body weight immediately produces a pronounced state of surgical analgesia, respiratory depression, bradycardia and other typical morphine-like effects. The duration of action of the peak effects is about 30 minutes. All potent morphine-like drugs produce relief from pain, ventilatory depression, emesis, constipation, physical dependence, certain vagal effects and varying degrees of sedation. Fentanyl, however, differs from morphine not only by its short duration of action but also by its lack of emetic effect and minimal hypotensive activity in animals.@@14923261@Management of breakthrough cancer pain in patients with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain@@@@@NO REVIEW@@@@@@@@@@FDA, 19 February 1968@2/19/1968@@@@@@@No@@@@@@APPROVED@@@MEDICARE@RESULTS PENDING@@@@@@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@AKORN@@@@@AKORN||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@SUBLIMAZE@@@@@SUBLIMAZE||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@10@1@20.42@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/2/2017@2.04@2.04@17478-0030-02@INJECTION - 2 ML@US$@@@@@@@@100@MCG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916796@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@N/A@@-@-@-@SAN DIEGO, CALIFORNIA@@@@@14916796@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00461045@35@-@FDA orphan drug designation for multiple myeloma. SOURCE: Immunomedics press release, 18 March 2008@3/18/2008@@FDA orphan drug designation for multiple myeloma. SOURCE: Immunomedics press release, 18 March 2008@@3/1/2007@-@NPI-0052-101@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@NEREUS PHARMACEUTICALS@@@@@NEREUS PHARMACEUTICALS||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@NPI-0052@@@@@NPI-0052||||@Proteasome Inhibitor@@@@@Proteasome Inhibitor||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16406116@Onco@@@@@300f1010ntsdm@@@@@@@@L01XE16@L01X@@NEW YORK, NEW YORK@@@@@16406116@XALKORI is indicated for the treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC).@@YES@@@NO REVIEW@@@@100%@Acquired through takeover of Pharmacia Corp., which acquired it from Sugen@@@53@The recommended dose schedule of XALKORI is 250 mg twice daily (500 mg daily) takencontinuously.@EMA, 25 August 2016@8/25/2016@@No@@@@Study 1001@No@@@ROS1-positive@@@APPROVED@@@NHS@@@@@@MONO@CRIZOTINIB@@@@@CRIZOTINIB||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@XALKORI@@@@@XALKORI||||@PDGF@@@@@PDGF||||@OBJECTIVE RESPONSE RATE@DURATION OF RESPONSE@@@@@@@@@ADVANCED@@@@@MULTICENTER@SINGLE-ARM@@@@1@1@100354.5293@@@19.3@month@19.3 month@100354.53@100354.53@170.95@60@1.299@4102.88@@4689@@@@@@@@@@0.34@1@@mg@500@1@@@@@@@@@@@7/28/2017@68.38@68.38@2.16E+16@HARD CAPSULE@GB£@@@@@@@@200@MG@200 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14922466@Onco@@@@@@@@@@@ARM 1: CP-675,206 15 mg/kg IV Q 90 days x 4; ARM 2: decarbazine 1000 mg/m2 IV Q 21 days or 12 or temozolomide 200 mg/m2 orally on Days 1-5 every 28 days x 12  SOURCE: clinicaltrials.gov@@-@-@-@NEW YORK, NEW YORK@1/1/2009@@Tremelimumab is a fully human anti-CTLA4 (cytotoxic T-lymphocyte antigen 4) IgG2 monoclonal antibody developed by Pfizer for its potential therapeutic application in melanoma, non-small cell lung cancer (NSCLC) and colorectal cancer. CTLA4 is a CD28-family receptor expressed mainly on T-lymphocyte that acts to inhibit T-lymphocyte function.@@14922466@Previously untreated melanoma; versus dacarbazine or temozolimide@@-@-@@NO REVIEW@@@@-@Medarex entitled to royalties@FIRST-LINE@NCT00257205@665@-@-@@@-@@3/1/2006@-@A3671009@@-@-@@@III@DISCONTINUED@@-@-@Review of interim data showed that the trial would not demonstrate superiority to standard chemotherapy. This trial will be discontinued, with more details to be presented at ASCO 2008. SOURCE: Pfizer, 1 April 2008@-@@@@MONO@TREMELIMUMAB@TICILIMUMAB@@@@TREMELIMUMAB|TICILIMUMAB|||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@CP-675206@@@@@CP-675206||||@mAb@CTLA4 Receptor Antagonist@@@@mAb|CTLA4 Receptor Antagonist|||@OVERALL SURVIVAL@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14918873@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@V03A@V03A@@IRVINE, CALIFORNIA@@@Fusilev is a novel folate analog available in 50-mg vials of freeze-dried powder. It is the pharmacologically active isomer of leucovorin. Fusilev rescue is indicated after high-dose methotrexate therapy in osteosarcoma, and is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists.@@14918873@Combo with 5-FU as a palliative treatment@@@@@NO REVIEW@@@@@Acquired through takeover of oncology assets of Targent, which licensed it from Merck KGaA in 2004, in March 2006.@@@@@FDA, 29 April 2011@4/29/2011@@@@@@@No@@@@@@APPROVED@@@@@@@@@@LEVOLEUCOVORIN@@@@@LEVOLEUCOVORIN||||@SPECTRUM PHARMACEUTICALS@@@@@SPECTRUM PHARMACEUTICALS||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@FUSILEV@(ISO-VORIN)@@@@FUSILEV|(ISO-VORIN)|||@Detoxifying Agent@@@@@Detoxifying Agent||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1@205@@@@@@@@@@@@4.1@@@@@@@@@@@@@@@@8/2/2017@205@205@68152-0101-00@POWDER FOR INJECTION@US$@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919860@Onco@@@@@300f1010ntsdm@@@@@@-@@L02BB03@L02B@NO@REKYAVIK, ICELAND@@@@@14919860@Indicated for use in combination therapy with an LH-RH analogue for the treatment of Stage D2 metastatic carcinoma of the prostate.@@NO@-@@NO REVIEW@@@@100%@-@FIRST-LINE@-@-@Adult males including the elderly: one tablet (50mg) once a day. Treatment with 'Casodex' should be started at least 3 days before commencing treatment with an LHRH analogue, or at the same time as surgical castration.@First-to-market launch. [Actavis, 10.07.2008]@@@-@@@Rare cases of death or hospitalisation due to severe liver injury have been reported in post-marketing in association with Casdoex use.@-@@-@-@@@-@DISCONTINUED@@-@NHS@-@-@@@@COMBO@BICALUTAMIDE@@@@@BICALUTAMIDE||||@ACTAVIS@@@@@ACTAVIS||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@GENERIC@@@@@GENERIC||||@Hormone Antagonist@Anti-androgen@@@@Hormone Antagonist|Anti-androgen|||@-@@@@@@@@@@METASTATIC@@@@@-@-@@@@@@Invalid Factory Price@@@@@-@-@@@28@1.5665@@@@@@@@@@@@@@@@@@@@@@@@@@@@@11/18/2015@@@1.38E+16@TABLET@GB£@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14919015@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@SGN-40 single-agent@@-@-@-@SEATTLE, WASHINGTON@@@@@14919015@-@@-@-@@NO REVIEW@@@@-@Genentech licensed the drug from Seattle Genetics in January 2007@-@-@45@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@-@Enrolment completed in Q4 07. SOURCE: Genentech, January 2008.@-@@@@MONO@DACETUZUMAB@@@@@DACETUZUMAB||||@SEATTLE GENETICS@@@@@SEATTLE GENETICS||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@SGN-40@ANTI-CD40@@@@SGN-40|ANTI-CD40|||@mAb@Humanised@CD40@@@mAb|Humanised|CD40||@RESPONSE RATE@@@@@@@@@@RELAPSED@REFRACTORY@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924541@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients receive SN-38 liposome IV over 90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.@@-@-@-@-@@@@@14924541@-@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00174863@54@-@-@@@-@@2/1/2006@-@-@@-@54 PATIENTS WITH METASTATIC COLORECTAL CANCER AFTER PROGRESSION ON OXALIPLATIN@@@II@DISCONTINUED@@-@-@March 2007; while the interim analysis following completion of treatment of the first 21 patients demonstrated disease stabilisation, the study did not achieve the primary tumor response endpoint. No new patient accrual will be made. Patients currently receiving therapy will continue treatment per protocol until a study endpoint is reached.@-@@@@MONO@-@@@@@-||||@NEOPHARM@@@@@NEOPHARM||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@LE-SN38@@@@@LE-SN38||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@COMPLETE RESPONSE@PARTIAL RESPONSE@RECIST@@@RECIST@@@@@METASTATIC@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921322@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@IV administration at 4 escalating dose levels [Chugai]@@-@-@-@-@1/1/2010@@-@@14921322@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00746317@21@-@-@@@-@@9/1/2008@-@GC-001US@@-@-@@@I@I@@-@-@Trial registered. [Chugai, 01.09.2008]@-@@@@-@-@@@@@-||||@CHUGAI PHARMACEUTICAL@@@@@CHUGAI PHARMACEUTICAL||||@@@@@@|||||||||@Liver Cancer@Hepatocellular Carcinoma@@@@Liver Cancer|Hepatocellular Carcinoma||||||||@GC-33@@@@@GC-33||||@Other@@@@@Other||||@SAFETY@@@@@PHARMACOKINETICS@RESPONSE RATE@@@@ADVANCED@METASTATIC@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919307@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Up to 8 dose levels will be studied. LEP-ETU will be given to patients by intravenous infusion over 90 minutes, once every 21 days, until their disease progresses or side effects occur requiring the treatments to end. SOURCE: clinicaltrials.gov@@-@-@-@-@@@@@14919307@Advanced cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00080418@40@-@-@@@-@@7/1/2003@-@LEP-ETU-101-R03@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@PACLITAXEL, LIPOSOMAL@@@@@PACLITAXEL, LIPOSOMAL||||@NEOPHARM@@@@@NEOPHARM||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@LEP-ETU@@@@@LEP-ETU||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@MAXIMUM TOLERATED DOSE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921356@Onco@@@@@@@@@@@Faslodex 250mg, 250mg with 250mg loading regimen and 500mg@@L02BA03@L02B@-@LONDON, UNITED KINGDOM@@@Fulvestrant is an oestrogen receptor antagonist and binds to oestrogen receptors in a competitive manner with an affinity comparable with that of oestradiol. Fulvestrant blocks the trophic actions of oestrogens without itself having any partial agonist (oestrogen-like) activity. The mode of action is associated with down-regulation of oestrogen receptor (ER) protein. Clinical trials in postmenopausal women with primary breast cancer have shown that fulvestrant significantly down-regulates ER protein in ER positive tumours compared with placebo. There was also a significant decrease in progesterone receptor expression consistent with a lack of intrinsic oestrogen agonist effects.@@14921356@ER-positive advanced breast cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00313170@135@-@-@@@-@@10/1/2005@-@FINDER II@@-@135 PATIENTS WHO ARE RELAPSED OR PROGRESSING AFTER PREVIOUS ENDOCRINE THERAPY@@@II@II@@-@-@RESULTS PENDING (recruiting)@-@@@@MONO@FULVESTRANT@@@@@FULVESTRANT||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@FASLODEX@@@@@FASLODEX||||@Hormone Antagonist@@@@@Hormone Antagonist||||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@RANDOMISED@DOUBLE-BLIND@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924755@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Weekly Taxoprexin@@L01CD01@L01C@-@TOKYO, JAPAN@@@Taxoprexin is a conjugate of paclitaxel and the fatty acid docosahexaenoic acid (DHA). Preclinical studies have shown increased activity and an improved therapeutic ratio relative to paclitaxel. @@14924755@Advanced primary cancers@@-@-@@NO REVIEW@@@@-@Luitpold is a subsidiary of Daiichi Sankyo.@SECOND-LINE@NCT00422877@N/A@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@Study completion due in September 2008.@-@@@@MONO@PACLITAXEL, DHI@@@@@PACLITAXEL, DHI||||@DAIICHI SANKYO@LUITPOLD PHARMACEUTICALS@@@@DAIICHI SANKYO|LUITPOLD PHARMACEUTICALS|||@@@@@@|||||||||@Liver Cancer@Hepatocellular Carcinoma@@@@Liver Cancer|Hepatocellular Carcinoma||||||||@TAXOPREXIN@@@@@TAXOPREXIN||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16398916@Onco@@@@@300f1008ntsdm@@@@@@@@L01AA09@L01A@@@@@@@16398916@Treatment of relapsed or refractory low-grade B-cell non-Hodgkin's lymphoma@@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@@@58@@@@12/1/2010@@@@@@No@@@@@@APPROVED@@@NHI@@@@@@MONO@BENDAMUSTINE@@@@@BENDAMUSTINE||||@SYMBIO PHARMACEUTICALS@@@@@SYMBIO PHARMACEUTICALS||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@B-Cell Lymphoma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|B-Cell Lymphoma|||||||@TREAKISYM@@@@@TREAKISYM||||@Alkylating Agent@Nitrogen Mustard Analogue@@@@Alkylating Agent|Nitrogen Mustard Analogue|||@@@@@@@@@@@RELAPSED@REFRACTORY@@@@@@@@@1.75@m²@2030005.152@@@126@day@126 day@2030005.15@2030005.15@16111.15@1@0.0091@80555.76@94995@@@@@@@@@@@805.56@21@@mg/m²@120@2@@@@@@@@@@@8/30/2017@80555.76@80555.76@4219405D1021@INJECTION@YEN@@@@@@@@100@MG@100 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14917975@Onco@@@@@300f1010ntsdm@@@@@@Foscan alone@@L01XD05@L01X@NO@EAST LONGMEADOW, MASSACHUSSETTS@@@@@14917975@Foscan is indicated for the palliative treatment of patients with advanced head and neck squamous cell carcinoma failing prior therapies and unsuitable for radiotherapy, surgery or systemic chemotherapy.@@NO@@@NO REVIEW@@@@100%@Licensed from QLT@@@147@The dose is 0.15mg/kg body weight.@EMA, 24 October 2001@10/24/2001@@@@@Special care must be taken to prevent extravasation at the injection site. If extravasation occurs, protect the area from light for at least 3 months. There is no known benefit from injecting the extravasation site with another substance.@LABEL@No@@@@@III@APPROVED@@The SMC advised in May 2004 that temoporfin is not recommended for the palliative treatment of advanced head and neck cancer.@NHS@Median duration of tumour response was 57 days for overall responseand 84 days for complete response.@@@@@MONO@TEMOPORFIN@@@@@TEMOPORFIN||||@BIOLITEC@@@@@BIOLITEC||||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@FOSCAN@@@@@FOSCAN||||@Other@@@@@Other||||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.299@1575@@1800@@@@@@@@@@525@@@@@@@@@@@@@@@@7/28/2017@1575@1575@UK_BNF_1074957639@SOLUTION FOR INJECTION - 3 ML@GB£@@@@@@@@3@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14922671@Onco@@@@@@@@@@@Alimta/carboplatin versus Gemzar/vinorelbine in anthracycline and taxane-pretreated cancers.@@L01BC05@L01B@-@INDIANAPOLIS, INDIANA@@@Gemcitabine exhibits significant cytotoxicity activity against a variety of cultured murine and human tumour cells. It exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and under certain conditions blocking the progression of cells through the G1/S-phase boundary. In vitro the cytotoxic action of gemcitabine is both concentration and time dependent.@@14922671@-@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00325234@144@-@-@@@-@@@-@10826H3E-EW-S098  @@NOVEMBER 2007 (PAEDIATRIC); JULY 2009 (OVARIAN CANCER); EXTENSIONS TO 2013. Lilly sued Teva//Sicor over its ANDA in February 2006, and the case goes to trial in July 2009.@-@@@II@II@@-@-@Completion expected in November 2008.@-@@@@COMBO@GEMCITABINE HYDROCHLORIDE@VINORELBINE@@@@GEMCITABINE HYDROCHLORIDE|VINORELBINE|||@LILLY@@@@@LILLY||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GEMZAR@@@@@GEMZAR||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922437@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@PD-325901 given by mouth as a pill twice a day, CT scans done and biopsies of a tumour and a blood sample will be taken before treatment to examine the how genes affect tumour response to the study medication. @@-@-@-@NEW YORK, NEW YORK@@@@@14922437@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00174369@60@-@-@@@-@@11/1/2005@-@A4581002@@-@-@@@II@DISCONTINUED@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@PD-325901@@@@@PD-325901||||@MEK Inhibitor@@@@@MEK Inhibitor||||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924246@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14924246@Platinum-therapy treated patients@@-@-@@NO REVIEW@@@@-@-@-@-@28@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@Results from 21 patients; 4 showed CA125 response or stabilisation; 2 had major resposne; 1 patients with four previous courses of chemo demonstrated a response of over 12 months. 1 patient treated after two courses of chemotherapy has a response with duration of 14 months. One patient had stable disease of 7 months duration which included 10 weeks classified as minor response and the fourth patient, treated after five courses of chemotherapy, had stable disease for 5 months. An additional patient, treated after four courses of chemotherapy had >25% CA125 reduction which was not confirmed by repeat CA125. CT scan results were generally concordant with CA125 status. There were no serious adverse events that were definitely or probably related to CVacTM treatment. SOURCE: Prima, 4 June 2007@-@@@@MONO@-@@@@@-||||@PRIMA BIOMED@@@@@PRIMA BIOMED||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@CVAC@@@@@CVAC||||@Vaccine@@@@@Vaccine||||@CA125 RESPONSE@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15413049@Onco@@@@@@@@@@JANUS 1@Ruxolitinib: 5 mg tablets to be administered by mouth twice daily [BID] 15 mg BIDCapecitabine: 500 mg tablets to be administered by mouth twice daily [BID]@@@@@WILMINGTON, DELAWARE@4/1/2016@@@@15413049@@Both@@@@@Experimental: Ruxolitinib plus capecitabine Active Comparator: Placebo plus capecitabine@@762@@@SECOND-LINE@NCT02117479@318@@@@@@@3/1/2014@@INCB 18424-362@@@Histologically or cytologically confirmed adenocarcinoma of the pancreas.Advanced adenocarcinoma of the pancreas that is inoperable or metastatic.Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2Received 1 prior chemotherapy regimen for advanced or metastatic disease (not including neoadjuvant and/or adjuvant therapy).≥ 2 weeks elapsed from the completion of previous treatment regimen and subjects must have recovered or be at a new stable baseline from any related toxicities.Radiographically measurable or evaluable diseaseAn mGPS of 1 or 2 as defined below: ◦Criteria: ◾C-reactive protein >10 mg/L AND albumin ≥35 g/L; Score = 1◾C-reactive protein >10 mg L AND albumin <35 g/L; Score = 2@@ADULTS@Phase 3@DISCONTINUED@@@@@@@@@COMBO@RUXOLITINIB@CAPECITABINE@@@@RUXOLITINIB|CAPECITABINE|||@INCYTE CORP.@@@@@INCYTE CORP.||||@World@@@@@World|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@JAKAFI@XELODA@@@@JAKAFI|XELODA|||@JAK inhibitor@@@@@JAK inhibitor||||@OVERALL SURVIVAL@@@@@PROGRESSION-FREE SURVIVAL@OBJECTIVE RESPONSE RATE@DURATION OF RESPONSE@@@ADVANCED@METASTATIC@@@@RANDOMIZED@PARALLEL ASSIGNMENT@DOUBLE BLIND@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921186@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@TNFerade combo with radiotherapy, flourouracil and hydroxyurea (TNF-FHX)@@-@-@-@-@@@@@14921186@Unresectable recurrent head and neck cancer@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00496535@N/A@-@-@@@-@@@-@GV-001.011 (TNF-CORE)@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@FLUOROURACIL@HYDROXYUREA@@@-|FLUOROURACIL|HYDROXYUREA||@GENVEC@@@@@GENVEC||||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@TNFERADE@@@@@TNFERADE||||@Gene Therapy@@@@@Gene Therapy||||@RESPONSE RATE@@@@@@@@@@RELAPSED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921811@Onco@@@@@300f1012ntsdm@@@@@@N/A@@L02BG04@L02B@-@BASEL, SWITZERLAND@@@The elimination of oestrogen-mediated stimulatory effects is a prerequisite for tumour response in cases where the growth of tumour tissue depends on the presence of oestrogens. In postmenopausal women, oestrogens are mainly derived from the action of the aromatase enzyme, which converts adrenal androgens - primarily androstenedione and testosterone - to oestrone (E1) and oestradiol (E2). The suppression of oestrogen biosynthesis in peripheral tissues and the cancer tissue itself can therefore be achieved by specifically inhibiting the aromatase enzyme. Letrozole is a non-steroidal aromatase inhibitor. It inhibits the aromatase enzyme by competitively binding to the haem of the cytochrome P450 subunit of the enzyme, resulting in a reduction of oestrogen biosynthesis in all tissues.@@14921811@Hormone receptor-positive endometrial cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00171808@42@-@-@@@-@@4/1/2005@-@CFEM345ADE08@@-@-@@@II@II@@-@-@Trial registered. [Novartis, 18.11.2002]@-@@@@MONO@LETROZOLE@@@@@LETROZOLE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Endometrial Cancer@@@@@Endometrial Cancer|||||||||@FEMARA@@@@@FEMARA||||@Hormone Antagonist@Aromatase Inhibitor@@@@Hormone Antagonist|Aromatase Inhibitor|||@RESPONSE RATE@@@@@@@@@@ADVANCED@RELAPSED@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14921809@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@300 patients randomised to receive either a single dose of 30mcg/kg velafermin or placebo. 100 additional patients will be randomised to receive a single dose of either 10 mcg/kg velafermin or 60 mcg/kg velafermin to explore the activity of these doses for the prevention of severe OM.  @@-@-@-@CURAGEN, CONNECTICUT@6/1/2008@@@@14921809@Prevention of oral mucositis@@-@-@@NO REVIEW@@@@-@-@-@NCT00323518@400@-@-@@@-@@5/1/2006@-@CG53135-CLN-12@@-@UP TO 400  WITH MULTIPLE MYELOMA OR LYMPHOMA THAT REQUIRES AUTOLOGOUS STEM CELL SUPPORT (HIGH-DOSE MELPHALAN 200MG/M2, BEAM OR CYCLOPHOSPHAMIDE WITH TBI).@@@II@DISCONTINUED@@-@-@October 2007; velafermin was safe and well-tolerated but did not meet its primary endpoint. Based on these results, the company is discontinuing the development of velafermin,@-@@@@MONO@VELAFERMIN@@@@@VELAFERMIN||||@CURAGEN@@@@@CURAGEN||||@@@@@@|||||||||@Supportive Care@Mucositis@@@@Supportive Care|Mucositis||||||||@-@@@@@-||||@FGF@@@@@FGF||||@MUCOSITIS (SEVERE)@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919077@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@MPC-6827 at 2.1mg/m2, 2.7mg/m2 or 3.3mg/m2 administered by intravenous infusion over 2 hours once weekly. Temozolomide at 75 mg/m2 administered orally daily. MPC-6827 (once weekly dosing) and temozolomide (daily dosing) will be administered for 6 weeks followed by a 2 week treatment interruption in each 8 week cycle. @@-@-@-@SALT LAKE CITY, UTAH@8/1/2008@@@@14919077@Melanoma metastatic to the brain; combo with Temodal@@-@-@@NO REVIEW@@@@-@Myriad licensed the MX-90745 series of apoptosis inducing compounds in December 2003 from Maxim Pharmaceuticals (now EpiCept)@-@NCT00609011@16@-@-@@@-@@1/1/2008@-@MPC-6827-07-005@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@@@@@-||||@MYRIAD GENETICS@@@@@MYRIAD GENETICS||||@@@@@@|||||||||@Melanoma / Skin Cancer@Brain Cancer@@@@Melanoma / Skin Cancer|Brain Cancer||||||||@AZIXA@MPC-6827@@@@AZIXA|MPC-6827|||@Vascular Disrupting Agent@@@@@Vascular Disrupting Agent||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921918@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Brivanib 800MG once daily until 6-month progression free@@-@-@-@NEW YORK, NEW YORK@5/1/2010@@@@14921918@Unresectable locally advanced or metastatic hepatocellular carcinoma failing one prior angiogenesis regimen or who received no prior regimen@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00355238@100@-@-@@@-@@12/1/2006@-@CA182-006@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@BRIVANIB ALANINATE@@@@@BRIVANIB ALANINATE||||@BMS@@@@@BMS||||@@@@@@|||||||||@Liver Cancer@Hepatocellular Carcinoma@@@@Liver Cancer|Hepatocellular Carcinoma||||||||@BMS-582664@@@@@BMS-582664||||@TK Inhibitor@VEGF@Angiogenesis Inhibitor@@@TK Inhibitor|VEGF|Angiogenesis Inhibitor||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@NON-RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922514@Onco@@@@@@@@@@@HKI-272 240MG PO QD with Herceptin 2MG/KG. Endpoint judged over 28 days in part 1 and 16 weeks in part 2.@@-@-@-@MADISON, NEW JERSEY@12/1/2008@@HKI-272 is a potent inhibitor of HER-2 and is highly active against HER-2-overexpressing human breast cancer cell lines in vitro. It also inhibits the epidermal growth factor receptor (EGFR) kinase and the proliferation of EGFR-dependent cells. HKI-272 reduces HER-2 receptor autophosphorylation in cells at doses consistent with inhibition of cell proliferation and functions as an irreversible binding inhibitor, most likely by targeting a cysteine residue in the ATP-binding pocket of the receptor.@@14922514@-@@-@-@@NO REVIEW@@@@-@Pfizer acquired Wyeth on 26 January 2009 in a deal worth U.S $68 billion [Pfizer 26.01.2009]@-@NCT00300781@45@-@-@@@-@@3/1/2007@-@3144A1-202@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@COMBO@NERATINIB@TRASTUZUMAB@@@@NERATINIB|TRASTUZUMAB|||@WYETH@PFIZER@@@@WYETH|PFIZER|||@@@@@@|||||||||@Breast Cancer@HER2+@@@@Breast Cancer|HER2+||||||||@HKI-272@HERCEPTIN@@@@HKI-272|HERCEPTIN|||@TK Inhibitor@HER2@@@@TK Inhibitor|HER2|||@SAFETY@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14918839@Onco@@@@@300f1012ntsdm@@@@@@Sabarubicin 80mg/m2 every 3 weeks over 30 minutes- escalated to 90mg/m2 after the 1st cycle for grade 0-1 toxicity, and reduced to 60mg/m2 in case of taoxicity.@@-@-@-@FLORENCE, ITALY@@@@@14918839@Locally advanced or metastatic platinum/taxane resistant ovarian cancer@@-@-@@NO REVIEW@@@@-@Drug available for partnering.@SECOND-LINE@-@19@-@-@@@-@@@-@N/A@@-@-@@@II@II@@-@-@January 2005; 1 patient had confirmed PR, 9 patients had SD, 5 patients had disease progression, 3 patients were not evaluable for response, while one patient had an early progressive disease. The duration of response was 88 days. Mean TTP was 125 days (range 56-188). Median survival was 62 days (range 36-202). Grade 3-4 neutropaenia was observed in 25 out of 52 courses at 80 mg/m2, and grade 4 neutropaenia occurred in one out of 12 courses at 90 mg/m2. Other grade 3-4 toxicities were: fatigue (5), nausea (two cases); LVEF fell below 50% in 2 patients, and 3 patients had a >15% decrease of LVEF from baseline, but there were no signs/symptoms of CHF. @-@@@@MONO@SABARUBICIN@@@@@SABARUBICIN||||@MENARINI@@@@@MENARINI||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@MEN-10755@@@@@MEN-10755||||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@RESPONSE RATE@SAFETY@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14916733@Onco@@@@@@@@@@@Temodar in subject population selected for a biomarker@@L01AX03@L01A@-@KENILWORTH, NEW JERSEY@@@Temozolomide is not directly active but undergoes rapid nonenzymatic conversion at physiologic pH to the reactive compound MTIC. The cytotoxicity of MTIC is thought to be primarily due to alkylation of DNA. Alkylation (methylation) occurs mainly at the O6 and N7 positions of guanine.@@14916733@Aerodigestive tract cancer@@-@-@@NO REVIEW@@@@-@Merck & Co and Schering-Plough have announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. Based on the closing price of Merck stock on March 6, 2009, the consideration to be received by Schering-Plough shareholders is valued at $23.61 per share, or $41.1 billion in the aggregate. [Merck & Co, 9 March 2009]@-@NCT00423150@160@-@-@@@-@@11/1/2006@-@P04273  @@-@-@@@II@II@@-@-@RESULTS PENDING (recruiting).@-@@@@MONO@TEMOZOLOMIDE@@@@@TEMOZOLOMIDE||||@SCHERING-PLOUGH@MERCK & CO@@@@SCHERING-PLOUGH|MERCK & CO|||@@@@@@|||||||||@Colorectal Cancer@Head & Neck Cancer@NSCLC@Oesophageal Cancer@@Colorectal Cancer|Head & Neck Cancer|NSCLC|Oesophageal Cancer||||||@TEMODAR@@@@@TEMODAR||||@Alkylating Agent@@@@@Alkylating Agent||||@SAFETY@RESPONSE RATE@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921482@Onco@@@@@@@@@@@Lapatinib 1250Mg/daily po versus hormonal therapy@@-@-@-@BRENTFORD, UNITED KINGDOM@@@Lapatinib is a 4-anilinoquinazoline kinase inhibitor of the intracellular tyrosine kinase domains of both Epidermal Growth Factor Receptor (EGFR [ErbB1]) and of Human Epidermal Receptor Type 2 (HER2 [ErbB2]) receptors (estimated Kiapp values of 3nM and 13nM, respectively) with a dissociation half-life of =300 minutes. Lapatinib inhibits ErbB-driven tumor cell growth in vitro and in various animal models. An additive effect was demonstrated in an in vitro study when lapatinib and 5-FU (the active metabolite of capecitabine) were used in combination in the 4 tumor cell lines tested. The growth inhibitory effects of lapatinib were evaluated in trastuzumab-conditioned cell lines. Lapatinib retained significant activity against breast cancer cell lines selected for long-term growth in trastuzumab-containing medium in vitro. These in vitro findings suggest non-cross-resistance between these two agents.@@14921482@-@@-@-@@NO REVIEW@@@@-@-@-@-@417@-@-@@@-@@@-@EGF20001@@17-Jul@-@@@III@III@@-@-@Final results; no difference was observed in time to progression and in overall survival between lapatinib and hormonal therapy in all patients; however, the overall survival benefit was significant in patients whose tumours over-expressed ErbB1 (p=0.019). SOURCE: ASCO 2006.@-@@@@MONO@LAPATINIB@@@@@LAPATINIB||||@GSK@@@@@GSK||||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@TYKERB@@@@@TYKERB||||@TK Inhibitor@HER2@EGFR@@@TK Inhibitor|HER2|EGFR||@OVERALL SURVIVAL@@@@@@@@@@ADVANCED@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14918929@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@NEW YORK, NEW YORK@@@CP-724,714 is a potent inhibitor of erbB2 receptor autophosphorylation in intact cells. CP-724,714 is selective for inhibiting growth of HER2-driven cell lines. It induces a marked reduction of extracellular signal–regulated kinase and Akt phosphorylation, tumor cell apoptosis, and release of caspase-3. P.o. administration (q.d. or b.i.d.) of CP-724,714 inhibits the growth of erbB2-overexpressing tumors in athymic mice without overt adverse effects.@@14918929@-@@-@-@@NO REVIEW@@@@-@Pfizer acquired major stake in Oncogene (now OSI) to form a collaborative research programme. [Oncogene, 8.07.1986]@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@I@DISCONTINUED@@-@-@Discontinued in 2006; Pfizer returned rights to OSI and OSI chose not to proceed with development. SOURCE: R&D Focus Drug News, 5 November 2007 @-@@@@-@-@@@@@-||||@PFIZER@OSI PHARMACEUTICAL@@@@PFIZER|OSI PHARMACEUTICAL|||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@CP-724714@@@@@CP-724714||||@TK Inhibitor@HER2@AKT inhibitor@@@TK Inhibitor|HER2|AKT inhibitor||@-@@@@@@@@@@ADVANCED@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924578@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14924578@-@@-@-@@NO REVIEW@@@@-@TMRC licensed rights for Japan and other Asian countries in June 2006 from Schering AG.@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@-@-@@@@-@DOFEQUIDAR FUMARATE@@@@@DOFEQUIDAR FUMARATE||||@TMRC CO.@BAYER HEALTHCARE@@@@TMRC CO.|BAYER HEALTHCARE|||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@MS-209@TM-511@@@@MS-209|TM-511|||@Other@@@@@Other||||@-@@@@@@@@@@ADVANCED@RELAPSED@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921615@Onco@@@@@@@@@@@AZD-6244 versus Alimta@@-@-@-@BOULDER, COLORADO@@@This is a small molecule inhibitor that targets a key position in the Ras/Raf/MEK/ERK signaling pathway. This pathway is implicated in the development and progression of cancers. AZD6244 is a novel, orally active, potent, selective, non-ATP-competitive inhibitor of MEK 1 / 2 that has the potential to treat a range of malignant diseases. Oral administration of AZD6244 has demonstrated tumor suppressive or regressive activity in multiple preclinical models of human cancer, including melanoma, pancreatic, colon, lung and breast cancer models. @@14921615@Third-line NSCLC@@-@-@@NO REVIEW@@@@-@In December 2003, Array entered into an out-licensing and collaboration agreement with AstraZeneca to develop the MEK program in the field of oncology. Under the agreement AstraZeneca acquired exclusive worldwide rights to the clinical development candidate ARRY-886, along with ARRY-704 and an additional second-generation compound for oncology indications developed during the collaboration.@MULTIPLE@NCT00372788@64@-@-@@@-@@9/1/2006@-@D1532C00012  @@-@-@@@II@II@@-@-@December 2007; study did not reach primary endpoint of delaying disease progression versus randomised comparator, but some evidence of anti-tumour activity.@-@@@@MONO@-@@@@@-||||@ARRAY BIOPHARMA@ASTRAZENECA@@@@ARRAY BIOPHARMA|ASTRAZENECA|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@ARRY-886@AZD-6244@@@@ARRY-886|AZD-6244|||@MEK Inhibitor@@@@@MEK Inhibitor||||@TIME TO PROGRESSION@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921141@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Phenoxodiol with docetaxel versus docetaxel alone@@-@-@-@-@6/1/2008@@@@14921141@Recurrent advanced ovarian epithelia cancer, fallopian tube cancer or primary peritoneal cavity cancer@@-@-@@NO REVIEW@@@@-@Marshall Edwards is a subsidiary of Novogen.@-@NCT00303888@60@-@-@@@-@@4/1/2006@-@HIC-27640, @@-@-@@@I/II; YALE-012705; @II@@-@-@RESULTS PENDING@-@@@@COMBO@PHENOXODIOL@DOCETAXEL@@@@PHENOXODIOL|DOCETAXEL|||@NOVOGEN@MARSHALL EDWARDS@@@@NOVOGEN|MARSHALL EDWARDS|||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@-@TAXOTERE@@@@-|TAXOTERE|||@MSTR@@@@@MSTR||||@PROGRESSION-FREE SURVIVAL@RECIST@@@@@@@@@RELAPSED@ADVANCED@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921505@Onco@@@@@300f1014ntsdm@@@@@@Continuous IV infusion for 14 days with 7 days recovery (21 day cycle). [Thallion]@@-@-@-@MONTREAL, CANADA@8/1/2007@@TLN-4601 is a proprietary first-in-class small molecule with the potential to treat multiple solid tumours. like the well known chemotherapeutics, doxorubicin and mitomycin C. TLN-4601 is a natural product derived from a non-pathogenic micro-organism. Discovered using Thallion’s DECIPHER technology, TLN-4601 has completed preclinical studies.@@14921505@-@@-@-@@NO REVIEW@@@@-@Thallion was formed from the merger of Ecopia BioSciences and Caprion Pharmaceuticals. [Thallion, 14.03.2007]@-@NCT00338026@26@-@-@@@-@@2/1/2006@-@ECO-4601-101@@-@">> Clinically or radiologically documented advanced solid malignancy for which no standard therapy is available, or which has failed standard therapy >> Patients with the following solid tumors: high grade glioma, colorectal, prostate, pancreatic, lung, ovarian and breast carcinoma "@@@I@I@@-@-@Trial registered. [Thallion, 15.06.2006]@-@@@@-@-@@@@@-||||@THALLION PHARMACEUTICALS@CAPRION@@@@THALLION PHARMACEUTICALS|CAPRION|||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@TLN-4601@ECO-4601@@@@TLN-4601|ECO-4601|||@Other@@@@@Other||||@SAFETY@MAXIMUM TOLERATED DOSE@@@@PHARMACOKINETICS@RECIST@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@C$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14922711@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Oral capsule, 400 mg every 8 hours daily, for 12 weeks - assement to a maximum of 12 months @@-@-@-@-@11/1/2009@@@@14922711@Castrate and non-castrate prostate cancer@@-@-@@NO REVIEW@@@@-@Marshall Edwards is a subsidiary of Novogen.@-@NCT00557037@60@-@-@@@-@@11/1/2007@-@703002467@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@PHENOXODIOL@@@@@PHENOXODIOL||||@NOVOGEN@MARSHALL EDWARDS@@@@NOVOGEN|MARSHALL EDWARDS|||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@-@@@@@-||||@MSTR@@@@@MSTR||||@PSA@@@@@@@@@@-@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924880@Onco@@@@@@@@@@@Panobinostat with docetaxel and prednisone@@-@-@-@BASEL, SWITZERLAND@@@A cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing hyperacetylation of core histone proteins, which may result in modulation of cell cycle protein expression, cell cycle arrest in the G2/M phase and apoptosis. In addition, this agent appears to modulate the expression of angiogenesis-related genes, such as hypoxia-inducible factor-1alpha (HIF-1a) and vascular endothelial growth factor (VEGF), thus impairing endothelial cell chemotaxis and invasion. HDAC is an enzyme that deacetylates chromatin histone proteins. @@14924880@Combo with docetaxel and prednisone@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@2/1/2008@-@-@@-@-@@@IB@I@@-@-@RESULTS PENDING@-@@@@COMBO@PANOBINOSTAT@DOCETAXEL@PREDNISONE@@@PANOBINOSTAT|DOCETAXEL|PREDNISONE||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Prostate Cancer@HRPC@@@@Prostate Cancer|HRPC||||||||@LBH-589@TAXOTERE@@@@LBH-589|TAXOTERE|||@HDAC@@@@@HDAC||||@N/A@@@@@@@@@@REFRACTORY@@@@@OPEN-LABEL@SINGLE-ARM@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921652@Onco@@@@@300f1012ntsdm@@@@@@Gleevec/vinorelbine combo@@L01XE01@L01X@-@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@14921652@Combo with vinorelbine@@-@-@@NO REVIEW@@@@-@-@-@NCT00372476@30@-@-@@@-@@@-@CSTI571BDE28@@-@-@@@II/III@III@@-@-@RESULTS PENDING@-@@@@COMBO@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GLEEVEC@GLIVEC@@@@GLEEVEC|GLIVEC|||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@SAFETY@RESPONSE RATE@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TABLET@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14921191@Onco@@@@@@@@@@@GS-9219 once every three weeks@@-@-@-@FOSTER CITY, CALIFORNIA@@@GS-9219 is a novel prodrug of the nucleotide analogue 9-(2-phosphonylmethoxyethyl)guanine (PMEG) and was designed as a cytotoxic agent that preferentially targets lymphoid cells.@@14921191@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00499239@62@-@-@@@-@@7/1/2007@-@GS-US-193-0101@@-@-@@@I/II@II@@-@-@Trial started. SOURCE: Global Insight, 15 August 2008@-@@@@MONO@-@@@@@-||||@GILEAD SCIENCES@@@@@GILEAD SCIENCES||||@Czech Republic@@@@@Czech Republic|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@Non-Hodgkin's Lymphoma@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia|Non-Hodgkin's Lymphoma|||||||@GS-9219@@@@@GS-9219||||@Other@@@@@Other||||@CTCAE@MAXIMUM TOLERATED DOSE@@@@@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
15412805@Onco@@@@@@@@@@@@@@@@@12/1/2018@@@@15412805@Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma: a Controlled,Multicentre,Randomised, Phase 3 Trial@Both@@@@@Experimental: Donafenib. Dose:200mg,bid,po.Active Comparator: Sorafenib(Nexavar). Dose:400mg,bid,po.@@-  Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less;  -  Patients had not received prior systemic treatments for HCC;  -  Life expectancy at least 3 months;  -  Adequate hepatic and renal function;  -  Adequate hematologic f@@@@NCT02645981@600@@@@@@@2/1/2016@@ZGDH3@@@Above 18 years old;  -  Patients with measurable, histologically or clinical proven, inoperable HCC;  -  Patients wtih measurable lesion and proved by independent radiology committee(IRC);  -  Child-Pugh (CP) score of 7 or less@MONO@ADULTS@Phase 2/Phase 3@II/III@@@@@@@@@@DONAFENIB@@@@@DONAFENIB||||@@@@@@||||@@@@@@|||||||||@Hepatocellular Carcinoma@@@@@Hepatocellular Carcinoma|||||||||@-@@@@@-||||@Other@@@@@Other||||@Donafenib, Experimental, Drug:Donafenib; Dose:200mg,bid,po.Sorafenib(Nexavar), Active Comparator, Drug:Sorafenib; Dose:400mg,bid,po.@OVERALL SURVIVAL@@@@Progress Free Survival@Percentage of adverse events@@@@ADVANCED@@@@@RANDOMIZED@Efficacy Study@PARALLEL ASSIGNMENT@OPEN LABEL@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921093@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@IRVINE, CALIFORNIA@@@@@14921093@Stage III and IV melanoma@@-@-@@NO REVIEW@@@@-@sanofi-aventis returned global rights for Uvidem. SOURCE: IDM Pharma, 31 December 2007.@-@-@33@-@-@@@-@@@-@IDD-3@@-@-@@@DC-MEL-202@II@@-@-@"IDM will ""continue to evaluate the Uvidem clinical program"" despite cancellation of sanofi-aventis partnership. SOURCE: IDM Pharma, 31 December 2007.Updated results, November 2007: 30% had complete response or partial response or stable disease for 7.2-29.7 months. 12-month survival rate was 67%. Of 29 evaluable patients, 62% had significant increase in TAA-specific cytokine-producing cells. Preliminary results; 1 CR (3%), 2 PRs (7%), and 6 cases of stable disease."@-@@@@MONO@-@@@@@-||||@IDM PHARMA@@@@@IDM PHARMA||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@UVIDEM@@@@@UVIDEM||||@Vaccine@@@@@Vaccine||||@COMPLETE RESPONSE@PARTIAL RESPONSE@STABLE DISEASE@SAFETY@@STABLE DISEASE@SAFETY@@@@METASTATIC@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920894@Onco@@@@@300f1020ntsdm@@@@@@NO LABELLED TRIAL@@L01AA02@L01A@YES@BRENTFORD, UNITED KINGDOM@@@Leukeran is a bifunctional alkylating agent of the nitrogen mustard type that has been found active against selected human neoplastic diseases.@@14920894@Leukeran is indicated in the treatment of Hodgkin's disease, certain forms of non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, and Waldenstrom's macroglobulinaemia@@NO@-@@-@@@@100%@-@-@-@-@Waldenstrom's Macroglobulinaemia: Leukeran is the treatment of choice in this indication. Starting doses of 6-12 mg daily until leucopenia occurs are recommended followed by 2-8 mg daily indefinitely.@N/A@@@-@@@Can severely suppress bone marrow function. Chlorambucil is a carcinogen in humans. Chlorambucil is probably mutagenic and teratogenic in humans. Chlorambucil produces human infertility@NO LABELLED TRIAL@No@-@-@@@-@APPROVED@@@SSN@NO LABELLED TRIAL@-@@@@-@CHLORAMBUCIL@@@@@CHLORAMBUCIL||||@GSK@@@@@GSK||||@@@@@@|||||||||@Haematological Malignancy@Waldenstrom's Macroglobinaemia@@@@Haematological Malignancy|Waldenstrom's Macroglobinaemia||||||||@LEUKERAN@@@@@LEUKERAN||||@Alkylating Agent@@@@@Alkylating Agent||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@25@1.1229@54.65@90.2@57.11@@@@@@@@@@1.09@@@@@@@@@@@@@@@@6/7/2017@2.19@2.19@24790026@FILM-COATED TABLET@EURO@@@@@@@@2@MG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14919023@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@MONTREAL, CANADA@@@@@14919023@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@Orphan drug agreement with FDA for gastric cancer. SOURCE: Supratek, 31 March 2008SPA agreement with FDA. SOURCE: Supratek, 28 November 2008@3/31/2008@@-@@@-@N/A@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@SUPRATEK PHARMA@@@@@SUPRATEK PHARMA||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@SP-1049C@@@@@SP-1049C||||@Other@@@@@Other||||@N/A@@@@@@@@@@-@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922638@Onco@@@@@@@@@@@Patients receive Iressa as an adjuvant therapy.@@L01XE02@L01X@-@LONDON, UNITED KINGDOM@@@The mechanism of the clinical antitumor action of gefitinib is not fully characterized. Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinasesassociated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor (EGFR-TK). EGFR isexpressed on the cell surface of many normal cells and cancer cells. No clinical studies have been performed that demonstrate a correlation between EGFRreceptor expression and response to gefitinib@@14922638@Resectable hepatocellular carcinoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00228501@60@-@-@@@-@@@-@1839IL0562  JS0414  @@-@-@@@II@II@@-@-@RESULTS PENDING (recruiting)@-@@@@MONO@GEFITINIB@@@@@GEFITINIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@Singapore@@@@@Singapore|||||||||@Liver Cancer@Hepatocellular Carcinoma@@@@Liver Cancer|Hepatocellular Carcinoma||||||||@IRESSA@ZD-1839@@@@IRESSA|ZD-1839|||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TABLET@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916441@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Patients will receive Brostallicin administered intravenously (IV) over 10 minutes at a dose of 10 mg/m2 on day one of a 21-day cycle. Safety and efficacy will be closely monitored and assessed.@@-@-@-@SEATTLE, WASHINGTON@2/1/2009@@@@14916441@Myxoid liposarcoma@@-@-@@NO REVIEW@@@@-@Inherited from Pharmacia & Upjohn/Pfizer merger@-@NCT00633165@24@-@-@@@-@@8/1/2007@-@SMI-BRS-202@@-@-@@@II@II@@-@-@RESULTS PENDING. PREVIOUSLY DISCONTINUED AT PHARMACIA & UPJOHN.@-@@@@MONO@BROSTALLICIN@@@@@BROSTALLICIN||||@CELL THERAPEUTICS@SYSTEMS MEDICINE@@@@CELL THERAPEUTICS|SYSTEMS MEDICINE|||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@(PNU-166196)@@@@@(PNU-166196)||||@Anthracycline@@@@@Anthracycline||||@RESPONSE RATE@@@@@@@@@@-@@@@@OPEN-LABEL@SINGLE-ARM@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922114@Onco@@@@@@@@@@@The study will be divided into 2 phases: phase I to determine the MTD in our population, starting with 400mg q.d. continuously, with progressive dose decrements in the event of DLT; and phase 2 to determine efficacy of Vorinostat at MTD in 12-37 evaluable patients.@@-@-@-@WHITEHOUSE STATION, NEW JERSEY@@@Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (ClassI) and HDAC6 (Class II) at nanomolar concentrations (IC50<86 nM). These enzymes catalyze the removalof acetyl groups from the lysine residues of proteins, including histones and transcription factors. In somecancer cells, there is an overexpression of HDACs, or an aberrant recruitment of HDACs to oncogenictranscription factors causing hypoacetylation of core nucleosomal histones. Hypoacetylation of histones isassociated with a condensed chromatin structure and repression of gene transcription. Inhibition ofHDAC activity allows for the accumulation of acetyl groups on the histone lysine residues resulting in anopen chromatin structure and transcriptional activation. In vitro, vorinostat causes the accumulation ofacetylated histones and induces cell cycle arrest and/or apoptosis of some transformed cells. Themechanism of the antineoplastic effect of vorinostat has not been fully characterized.@@14922114@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00416130@49@-@-@@@-@@1/1/2007@-@BR032005@@-@-@@@I/II; DSRB Reference Code: B/06/275, HSA No: CTC0600314; @II@@-@-@RESULTS PENDING@-@@@@MONO@VORINOSTAT@@@@@VORINOSTAT||||@MERCK & CO@@@@@MERCK & CO||||@Singapore@@@@@Singapore|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@ZOLINZA@@@@@ZOLINZA||||@HDAC@@@@@HDAC||||@RECIST@DURATION OF RESPONSE@PROGRESSION-FREE SURVIVAL@@@PROGRESSION-FREE SURVIVAL@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14923666@Onco@@@@@300f1008ntsdm@@@@@@E-7070 combo with carboplatin@@-@-@-@TOKYO, JAPAN@@@@@14923666@Newly diagnosed Stage IIIb or IV NSCLC@@-@-@@NO REVIEW@@@@-@Global rights licensed from Ligand in September 2006@FIRST-LINE@-@29@-@-@@@-@@@-@-@@-@-@@@II@II@@-@@ASCO June 2003 update on 15 patients; 6 patients had progressive disease, 5 had SD. Conclsuion was that more frequent administration may be required. World Conference on Lung Cancer July 2005; preliminary results; 3 unconfirmed PRs and 3 had minor responses. @-@@@@COMBO@INDISULAM@CARBOPLATIN@@@@INDISULAM|CARBOPLATIN|||@EISAI@@@@@EISAI||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@E-7070@@@@@E-7070||||@Cytotoxic Antibiotic@Sulfonamide@@@@Cytotoxic Antibiotic|Sulfonamide|||@RESPONSE RATE@STABLE DISEASE@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14924155@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@DURHAM, NORTH CAROLINA@@@@@14924155@B-cell CLL@@-@-@@NO REVIEW@@@@-@Merger between Kyowa Hakko and Kirin announced in October 2007. Co-developing between Argos and Kirin@-@-@22@-@-@@@-@@1/1/2007@-@-@@-@UP TO 22  WITH PREVIOUSLY TREATED B-CELL CLL@@@-@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@ARGOS THERAPEUTICS@KIRIN PHARMA@@@@ARGOS THERAPEUTICS|KIRIN PHARMA|||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@AGS-005@@@@@AGS-005||||@Immunotherapy@@@@@Immunotherapy||||@RESPONSE RATE@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14925004@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@N02AA01@N02A@NO@READING, UNITED KINGDOM@@@@@14925004@Severe chronic pain and/or pain resistant to other analgesics, in particular pain associated with cancer.@@NO@@@NO REVIEW@@@@100%@Acquired through takeover of Link Holdings in November 2006@@@@Adults: Recommended dosage is one capsule twice daily, at 12-hourly intervals.@EMA, May 1995@@@@@@Caution should be exercised in elderly subjects, in patients with impaired hepatic and/or renal functions, in patients with hypothyroidism or hypoadrenalism, in patients in a state of shock or with asthma. The dose of Zomorph should be reduced, or its use should be avoided in cases of hepatic or renal failure.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@MORPHINE SULPHATE@@@@@MORPHINE SULPHATE||||@ARCHIMEDES PHARMA@@@@@ARCHIMEDES PHARMA||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@ZOMORPH@@@@@ZOMORPH||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@60@1.299@3.47@@@@@@@@@@@@@@@@@@@@@@@@@@@@7/28/2017@0.06@0.06@3.65E+15@CAPSULE MODIFIED RELEASE@GB£@@@@@@@@10@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
15874577@Onco@@@@@@@@@@@Lenalidomide/DexamethasoneStandard of Care doses for relapsed/refractory multiple myeloma@@L04AX04@L04A@@SUMMIT, NEW JERSEY@9/1/2023@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@15874577@Prospective Observational Study Evaluating the Safety of Lenalidomide/Dexamethasone Treatment in Patients With Relapsed or Refractory Multiple Myeloma@Both@@@@@Standard of Care doses for relapsed/refractory multiple myeloma: 25 mg/day lenalidomide 21 of 28 days cycle@@@@@@NCT02692339@120@@@@@@@2/1/2016@@CC5013MM028@@@Patients aged 18 years or higher/Patients who have voluntarily given written informed consent to participate in the study and have their data retrieved for the purposes of the study/Patients diagnosed with 1st or 2nd relapsed or refractory multiple myeloma and indicated for 2nd or 3rd line Len/Dex treatment, according with the SmPC (patients who have received at least one prior therapy)@COMBO@ADULTS@N/A@-@@@@@@@@@@LENALIDOMIDE@DEXAMETHASONE@@@@LENALIDOMIDE|DEXAMETHASONE|||@CELGENE@@@@@CELGENE||||@Portugal@@@@@Portugal|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@REVLIMID@GENERIC@@@@REVLIMID|GENERIC|||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@ADVERSE EVENTS@@@@@Incidence (number) of thromboembolism@Duration of Len/Dex treatment over the course of the study@@@@RELAPSED@REFRACTORY@@@@Cohort@PROSPECTIVE@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921770@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Escalated dose every other day@@-@-@-@NEW YORK, NEW YORK@12/1/2008@@@@14921770@-@@-@-@@NO REVIEW@@@@-@Pfizer acquired Serenex for an undisclosed sum. SOURCE: Serenex, 3 March 2008@-@NCT00506805@69@-@-@@@-@@6/1/2007@-@CLN1-001@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@PFIZER@SERENEX@@@@PFIZER|SERENEX|||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@SNX-5422@@@@@SNX-5422||||@HSP90 Inhibitor@@@@@HSP90 Inhibitor||||@ADVERSE EVENTS@@@@@@@@@@REFRACTORY@@@@@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TABLET@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16388212@Onco@@@@@@@@@@@GS-5745+nivolumab, Experimental, GS-5745+nivolumab for up to 2 yearsNivolumab, Experimental, Nivolumab for up to 2 years@@@@@FOSTER CITY, CALIFORNIA@9/1/2018@@@@16388212@A Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of GS-5745 Combined With Nivolumab Versus Nivolumab Alone in Subjects With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma@Both@@@@@800 mg administered via intravenous (IV) infusion every 2 weeks@@@@@-@NCT02864381@120@@@@@@@9/1/2016@@GS-US-296-2013@@@Histologically confirmed inoperable locally advanced or metastatic adenocarcinoma of the stomach or GEJ which have progressed on at least 1 prior systemic therapy or line of treatment for unresectable/metastatic disease  -  Eastern Cooperative Oncology Group (ECOG) performance score of ≤ 1  -  Measurable disease according to RECIST v1.1  -  Tumor sites that can be accessed for repeat biopsies  -  Archival tumor tissue, preferably obtained from the most recent available biopsy; there must be adequate tissue for a PD-L1 stratification test, as assessed by central pathologist  -  Individuals not receiving anticoagulant medication must have an international normalized ratio (INR) ≤ 1.5 and activated partial thromboplastin (aPTT) ≤ 1.5 x upper limit of normal (ULN)  -  Required baseline laboratory data as outlined in protocol@-@ADULTS@Phase 2@II@@@@@@@@@BOTH@GS-5745@NIVOLUMAB@@@@GS-5745|NIVOLUMAB|||@GILEAD SCIENCES@@@@@GILEAD SCIENCES||||@@@@@@|||||||||@Oesophageal Cancer@GIST@@@@Oesophageal Cancer|GIST||||||||@-@OPDIVO@@@@-|OPDIVO|||@Other@@@@@Other||||@Objective response rate@@@@@PROGRESSION FREE SURVIVAL@OVERALL SURVIVAL@@@@UNRESECTABLE@RECURRENT@@@@RANDOMIZED@SAFETY/EFFICACY STUDY@PARALLEL ASSIGNMENT@OPEN LABEL@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
16379387@Onco@@@@@@@@@@@Ceramide NanoLiposome, Experimental, Dose escalation of Ceramide NanoLiposome@@@@@UNITED STATES@9/1/2018@@@@16379387@@Both@@@@@Intravenous administration of Ceramide NanoLiposome@@@@@SECOND-LINE@NCT02834611@24@@@@@@@9/1/2016@@KNAN1001@@@-  Signed informed consent/authorization is obtained prior to conducting any study-specific screening procedures.  -  18 years of age or order  -  Histologic or cytologic diagnosis of cancer  -  Patients without a curative therapy or whose tumor does not @@ADULTS@Phase 1@I@@@@@@@@@MONO@-@@@@@-||||@KEYSTONE NANO@@@@@KEYSTONE NANO||||@World@@@@@World|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@CERAMIDE NANOLIPOSOME@@@@@CERAMIDE NANOLIPOSOME||||@Other@@@@@Other||||@Maximum tolerated dose of Ceramide NanoLiposome in patients with advanced solid tumors.@@@@@Recommended phase II dose@Incidence of treatment-related adverse events as assessed by CTCAE v4.0@@@@ADVANCED@@@@@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922258@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Apricoxib: 100 mg tablets, 400mg/day erlotinib: per package insert versus Tarceva with placebo SOURCE: clinicaltrials.gov@@-@-@-@-@6/1/2009@@@@14922258@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00652340@115@-@-@@@-@@3/1/2008@-@APRiCOT-L@@-@-@@@II; TP2001-201, @II@@-@-@RESULTS PENDING@-@@@@COMBO@APRICOXIB@ERLOTINIB HYDROCHLORIDE@@@@APRICOXIB|ERLOTINIB HYDROCHLORIDE|||@TRAGARA PHARMACEUTICALS@@@@@TRAGARA PHARMACEUTICALS||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@TP-2001@TARCEVA@@@@TP-2001|TARCEVA|||@Other@@@@@Other||||@TIME TO PROGRESSION@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14923991@Onco@@@@@300f1020ntsdm@@@@@@Uftoral/calcium folinate versus Mayo regimen/calcium folinate@@-@-@-@DARMSTADT, GERMANY@@@@@14923991@First-line treatment of metastatic colorectal cancer with calcium folinate.@@YES@-@@NO REVIEW@@@@100%@-@-@-@1196@The dose of Uftoral is 300 mg/m2/day tegafur and 672 mg/m2/day uracil combined with 90 mg/day oral calcium folinate, given in three divided doses (preferably every 8 hours). Calcium folinate should be taken at the same time as Uftoral. Doses should be taken at least one hour before or one hour after meals for 28 consecutive days.@N/A@@@-@@@-@LABEL@@-@1196 [METASTATIC COLORECTAL CANCER]@@@III STUDY-011 AND STUDY-012@APPROVED@@1@SSN@The median survival time was 12.4 months (95% CI: 11.2-13.6 months) and 13.4 months in the Uftoral/calcium folinate and the 5FU/calcium folinate treatment groups, respectively (Study-011). The median TTP was 3.4 months and 3.3 months respectively.@-@@@@COMBO@TEGAFUR / URACIL@@@@@TEGAFUR / URACIL||||@MERCK SERONO@@@@@MERCK SERONO||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@UFT@MAYO REGIMEN@@@@UFT|MAYO REGIMEN|||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@OVERALL SURVIVAL@@@@@@@@@@METASTATIC@@@@@RANDOMISED@@@@@@@Invalid Factory Price@@@@@@@@@42@1.1229@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@CAPSULE@EURO@@@@@@@@@@100 MG|224 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14924707@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@FRAZER, PENNSYLVANIA@@@@@14924707@Trials discontinued in March 2007@@-@-@@NO REVIEW@@@@-@Acquired through US$160 mil takeover of Salmedix@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@DISCONTINUED@@-@-@Trials discontinued in March 2007; no results available.@-@@@@-@-@@@@@-||||@CEPHALON@@@@@CEPHALON||||@@@@@@|||||||||@Mesothelioma@Pancreatic Cancer@Bone Metastases@Sarcoma@Brain Cancer@Mesothelioma|Pancreatic Cancer|Bone Metastases|Sarcoma|Brain Cancer|||||@SDX-102@@@@@SDX-102||||@Anti-metabolite@@@@@Anti-metabolite||||@N/A@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916002@Onco@@@@@@@@@@@Zactima plus Taxotere docetaxel@@-@-@-@LONDON, UNITED KINGDOM@@@An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGF2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis. @@14916002@with Taxotere@@-@-@@NO REVIEW@@@@-@-@-@NCT00312377@N/A@-@Filing due in 2008@@@-@@@-@ZODIAC  @@-@-@@@II; D4200C00032@II@@-@-@Enrolment completed; filing due in 2008. Phase II data showed that Zactima plus doxetacel met the primary endpoint of improved PFS compared with doxetacel alone. SOURCE: AstraZeneca, March 2008@-@@@@COMBO@HUMAN PAPILLOMAVIRUS@DOCETAXEL@@@@HUMAN PAPILLOMAVIRUS|DOCETAXEL|||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@ZACTIMA@TAXOTERE@@@@ZACTIMA|TAXOTERE|||@TK Inhibitor@VEGF@EGFR@Angiogenesis Inhibitor@@TK Inhibitor|VEGF|EGFR|Angiogenesis Inhibitor|@PROGRESSION-FREE SURVIVAL@@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@RANDOMISED@DOUBLE-BLIND@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
16671598@Onco@@@@@300f1008ntsdm@@@@@@@@L01XE36@L01X@@@@@Alectinib is a tyrosine kinase inhibitor that targets ALK and RET.@@16671598@Treatment of unresectable advanced/relapsed ALK fusion gene-positive non-small-cell lung cancer.@@NA@@@@@@@@@@@46@@MHLW, 20 June 2014@6/20/2014@9/2/2014@Yes@@@@@No@@@ALK POSITIVE@@II@APPROVED@@@NHI@@@@@@MONO@ALECTINIB@@@@@ALECTINIB||||@CHUGAI PHARMACEUTICAL@@@@@CHUGAI PHARMACEUTICAL||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@ALECENSA@@@@@ALECENSA||||@TK Inhibitor@@@@@TK Inhibitor||||@@@@@@@@@@@UNRESECTABLE@ADVANCED@@@@@@@@@1@1@7643319.372@@@11.2@month@11.2 month@7643319.37@7643319.37@22436.85@1@0.0091@1495.79@1763.9@@@@@@@@@@@37.39@1@@mg@600@1@@@@@@@@@@@8/30/2017@1495.79@1495.79@4291032M2025@CAPSULE@YEN@@@@@@@@40@MG@40 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14924643@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@VERDUN, QUEBEC@@@@@14924643@-@@-@-@@NO REVIEW@@@@-@Co-development partner to be selected; Ambrilia aims to out-license during the course of 2008. SOURCE: Ambrilia, 24 March 2008@-@-@-@-@-@@@-@@@-@-@@2023@-@@@I/II@II@@-@-@"Safety without toxicity demonstrated; ""significant increase in PSA-doubling times"" observed in some patients across all dose levels; stable disease observed in ""several"" patients."@-@@@@-@-@@@@@-||||@AMBRILIA BIOPHARMA@@@@@AMBRILIA BIOPHARMA||||@@@@@@|||||||||@Prostate Cancer@HRPC@@@@Prostate Cancer|HRPC||||||||@PCK-3145@@@@@PCK-3145||||@Immunotherapy@Synthetic Peptide@@@@Immunotherapy|Synthetic Peptide|||@SAFETY@PSA@RECIST@@@RECIST@@@@@REFRACTORY@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922169@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NO LABELLED TRIAL@@A14AA08@A14A@YES@-@@@@@14922169@Adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infections or severe trauma, and in some patients who withough definite pathophysiologic reasons fail to gain or to maintain normal weight.@@-@-@@NO REVIEW@@@@-@sanofi-aventis holds worldwide licensed including (since January 2006) Japan. Bayer Schering holds eye disease rights.@-@-@-@The daily adult dosage is 2.5MG to 20MG given in 2 to 4 divided doses.@-@@@-@@@Peliosis hepatitis has been reported in patients receiving androgenic anabolic steroid therapy. These cysts are sometimes present with minimal hepatic dysfunction, but at other times they have been associated with liver failure.@NO LABELLED TRIAL@@-@-@@@-@DISCONTINUED@@-@MEDICARE@NO LABELLED TRIAL@-@@@@ADJUVANT@OXANDROLONE@@@@@OXANDROLONE||||@UPSHER SMITH@@@@@UPSHER SMITH||||@@@@@@|||||||||@Supportive Care@@@@@Supportive Care|||||||||@OXANDRIN@@@@@OXANDRIN||||@Anabolic Steroid@@@@@Anabolic Steroid||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@@@@100@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@1/8/2015@@@54396-0111-11@TABLET@US$@@@@@@@@2.5@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922640@Onco@@@@@300f1014ntsdm@@@@@@Patients receive Iressa versus Gemzar and carboplatin @@L01XE02@L01X@-@LONDON, UNITED KINGDOM@@@The mechanism of the clinical antitumor action of gefitinib is not fully characterized. Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinasesassociated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor (EGFR-TK). EGFR isexpressed on the cell surface of many normal cells and cancer cells. No clinical studies have been performed that demonstrate a correlation between EGFRreceptor expression and response to gefitinib@@14922640@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00264498@122@-@-@@@-@@@-@1839IL0551@@-@122 CHEMO-NAÏVE PATIENTS@@@II@II@@-@-@RESULTS PENDING (recruiting)@-@@@@MONO@GEFITINIB@@@@@GEFITINIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@IRESSA@ZD-1839@@@@IRESSA|ZD-1839|||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TABLET@C$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14921648@Onco@@@@@@@@@@@N/A@@L01XE01@L01X@-@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@14921648@Chronic phase; 400MG versus 800mg@@NO@-@@NO REVIEW@@@@-@-@-@NCT00124748@420@-@-@@@-@@6/1/2005@-@CSTI571K2301@@NOVEMBER 2008 (PAEDIATRIC); OCTOBER 2013 (PAEDIATRIC)@-@@@III@III@@-@-@RESULTS PENDING@-@@@@MONO@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@GLEEVEC@GLIVEC@@@@GLEEVEC|GLIVEC|||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@RESPONSE RATE@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@DOSE COMPARISON@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TABLET@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14919585@Onco@@@@@300f1015ntsdm@@@@@@@@N02AB03@N02A@@@@@Fentanyl is a synthetic opiate with a clinical potency of 50 to 100 times that of morphine. Its onset of action is rapid and its duration of action is short. In man, a single iv dose of 0.5-1 mg/70 kg body weight immediately produces a pronounced state of surgical analgesia, respiratory depression, bradycardia and other typical morphine-like effects. The duration of action of the peak effects is about 30 minutes. All potent morphine-like drugs produce relief from pain, ventilatory depression, emesis, constipation, physical dependence, certain vagal effects and varying degrees of sedation. Fentanyl, however, differs from morphine not only by its short duration of action but also by its lack of emetic effect and minimal hypotensive activity in animals.@@14919585@Management of breakthrough cancer pain in patients with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain@@NO@@@NO REVIEW@@@@@Acquired via takeover of generics unit of Merck KGaA@@@@@September 2006 (renewal)@@@@@@@@No@@@@@@APPROVED@@FREE PRICE IN HOSPITAL@HAUTE AUTORITÉ DE SANTÉ@RESULTS PENDING@@@@@@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@RENAUDIN@@@@@RENAUDIN||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@GENERIC@@@@@GENERIC||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14924937@Onco@@@@@@@@@@@Subjects will be randomized at a 1:1:1 ratio to 1 of 3 treatment arms. Subjects in each of the 3 arms will receive up to 6 cycles of paclitaxel/carboplatin (at the same dose and schedule in part 1) in combination with either AMG 655 at the maximum tolerated dose (Arm 1), AMG 655 at a lower dose (Arm 2), or AMG 655 placebo (Arm 3) IV Q3W. Randomization will be stratified by ECOG (0 or 1) and disease stage (IIIb or IV/recurrent). SOURCE: clinicaltrials.gov@@-@-@-@THOUSAND OAKS, CALIFORNIA@@@AMG 655 is a fully human monoclonal antibody agonist directed against Death Receptor 5 (“DR5”). AMG 655 is designed to activate caspases and induces apoptosis in sensitive tumor cells. Phase 1b/2 studies in pancreatic cancer, NSCLC, CRC and soft tissue sarcoma are ongoing. @@14924937@-@@-@-@@NO REVIEW@@@@-@Takeda and Amgen signed a deal in February 2008 through which, in its first part, Takeda acquired Japanese rights for up to 13 molecules in Amgen's pipeline, including Vectibix (panitumumab), AMG-108, AMG-317, AMG-386, AMG-479 and AMG-655, for US$200 mil.@-@NCT00534027@150@-@-@@@-@@4/1/2008@-@20060295@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@PACLITAXEL@CARBOPLATIN@@@-|PACLITAXEL|CARBOPLATIN||@AMGEN@TAKEDA PHARMACEUTICAL@@@@AMGEN|TAKEDA PHARMACEUTICAL|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@AMG-655@@@@@AMG-655||||@Other@@@@@Other||||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@ADVANCED@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924802@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Soblidotin IV on days 1 and 8, repeated every 3 weeks for at least 2 courses@@-@-@-@-@@@@@14924802@Soft tissue sarcomas@@-@-@@NO REVIEW@@@@-@Yakult Honsha joined developmend in March 2007 after dissolution of previous partnership between Teikoku Hormone and Daiichi Sankyo@-@NCT00064220@27@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@SOBLIDOTIN@@@@@SOBLIDOTIN||||@ASKA PHARMACEUTICAL@YAKULT HONSHA@@@@ASKA PHARMACEUTICAL|YAKULT HONSHA|||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@TZT-1027@@@@@TZT-1027||||@Angiogenesis Inhibitor@@@@@Angiogenesis Inhibitor||||@TIME TO PROGRESSION@@@@@@@@@@ADVANCED@METASTATIC@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRAVENOUS@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922985@Onco@@@@@@@@@@@-@@-@-@-@KENILWORTH, NEW JERSEY@@@@@14922985@Cutaneous melanoma@@-@-@@NO REVIEW@@@-@-@Merck & Co and Schering-Plough have announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. Based on the closing price of Merck stock on March 6, 2009, the consideration to be received by Schering-Plough shareholders is valued at $23.61 per share, or $41.1 billion in the aggregate. [Merck & Co, 9 March 2009]@-@-@-@-@>> Schering-Plough has withdrawn its application for marketing authorisation in Europe based on the view that the data submitted was not sufficient to determine a positive benefit-risk balance. [EMEA 16 March 2009]>> Filed with EMEA [EMEA, 7 September 2007]@3/16/2009@@-@@@-@-@@-@-@@@-@WITHDRAWN@@-@-@RESULTS PENDING (recruiting).@-@@@@-@PEG-INTERFERON@@@@@PEG-INTERFERON||||@SCHERING-PLOUGH@MERCK & CO@@@@SCHERING-PLOUGH|MERCK & CO|||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@CYLATRON@@@@@CYLATRON||||@Interferon@@@@@Interferon||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14919068@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@852A administered subcutaneously twice a week for 12 weeks@@-@-@-@NEW YORK, NEW YORK@@@@@14919068@-@@-@-@@NO REVIEW@@@@-@Pfizer has completed acquisition of Coley Pharmaceutical@-@NCT00276159@60@-@-@@@-@@1/1/2006@-@MT2005-20@@-@-@@@05US02IMP-852A [Miller],@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@PFIZER@COLEY PHARMACEUTICAL@@@@PFIZER|COLEY PHARMACEUTICAL|||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@Chronic Myeloid Leukaemia@Acute Myeloid Leukaemia@Acute Lymphocytic Leukaemia@Haematological Malignancy|Chronic Lymphocytic Leukaemia|Chronic Myeloid Leukaemia|Acute Myeloid Leukaemia|Acute Lymphocytic Leukaemia|||||@852A@@@@@852A||||@Other@@@@@Other||||@RECIST@@@@@@@@@@REFRACTORY@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922214@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients receive PHA-739358 IV over 6 hours on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients benefitting from treatment may receive additional courses at the discretion of the investigator.@@-@-@-@-@@@@@14922214@CHRONIC MYELOGENOUS LEUKAEMIA RELAPSED AFTER IMATINIB OR C-ABL THERAPY@@-@-@@NO REVIEW@@@@-@-@-@NCT00335868@16@-@-@@@-@@@-@AURA-6202-005@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@NERVIANO@@@@@NERVIANO||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@PH-739358@@@@@PH-739358||||@Aurora Kinase Inhibitor@@@@@Aurora Kinase Inhibitor||||@RESPONSE RATE@@@@@@@@@@RELAPSED@@@@@PILOT@OPEN-LABEL@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924948@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@AMG-531 in multiple doses@@-@-@-@THOUSAND OAKS, CALIFORNIA@@@AMG 531 is being studied as a way to treat low platelet counts caused by chemotherapy. It binds to the thrombopoietin receptor and causes the bone marrow to make more platelets. @@14924948@Treatment of chemotherapy-induced thrombocytopaenia in subjects with lymphoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00283439@73@-@FDA orphan designation@@@FDA orphan designation@@10/1/2005@-@20050144@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@ROMIPLOSTIM@@@@@ROMIPLOSTIM||||@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Supportive Care@Haematological Malignancy@@@@Supportive Care|Haematological Malignancy||||||||@AMG-531@@@@@AMG-531||||@Other@@@@@Other||||@SAFETY@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922995@Onco@@@@@@@@@@@-@@J07BM01@J07B@-@WHITEHOUSE STATION, NEW JERSEY@@@Gardasil is an adjuvanted non-infectious recombinant quadrivalent vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid L1 protein of HPV types 6, 11, 16 and 18. The VLPs contain no viral DNA, they cannot infect cells, reproduce or cause disease. HPV only infects humans, but animal studies with analogous papillomaviruses suggest that the efficacy of LI VLP vaccines is mediated by the development of a humoral immune response. HPV 16 and HPV 18 are estimated to be responsible for approximately 70% of cervical cancers; 80% of adenocarcinoma in situ (AIS); 45-70% of high-grade cervical intraepithelial neoplasia (CIN 2/3); 25% of low grade cervical intraepithelial neoplasia (CIN 1); approximately 70% of HPV related high-grade vulvar (VIN 2/3) and vaginal (VaIN 2/3) intraepithelial neoplasia. HPV 6 and 11 are responsible for approximately 90% of genital warts and 10% of low grade cervical intraepithelial neoplasia (CIN 1). CIN 3 and AIS have been accepted as immediate precursors of invasive cervical cancer.@@14922995@Vaginal and vulvar cancer@@NO@-@@NO REVIEW@@@-@-@extra-Australia rights licensed from CSL@-@-@-@-@EC CHMP recommends approval for prevention of high-grade vaginal dysplatic lesions. SOURCE: EMEA, 2 June 2008Supplemental MAA filed in April 2007 with FDA. SOURCE: Merck, 25 April 2007@6/2/2008@@-@@@-@-@@FIRST PATENT EXPIRES IN 2017.@-@@@-@FILED@@-@-@RESULTS PENDING@-@@@@-@HUMAN PAPILLOMAVIRUS@@@@@HUMAN PAPILLOMAVIRUS||||@MERCK & CO@@@@@MERCK & CO||||@@@@@@|||||||||@Cervical Cancer@@@@@Cervical Cancer|||||||||@GARDASIL@@@@@GARDASIL||||@Vaccine@@@@@Vaccine||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14919129@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@High-dose interleukin IL-2 with concomitant sargramostim@@-@-@-@LEVERKUSEN, GERMANY@2/1/2010@@@@14919129@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00616564@35@-@First Phase III trials planned for 2008.@@@-@@2/1/2006@-@MEL0105@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@SARGRAMOSTIM@@@@-|SARGRAMOSTIM|||@BAYER HEALTHCARE@@@@@BAYER HEALTHCARE||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@IL-2@@@@@IL-2||||@Interleukin@@@@@Interleukin||||@OVERALL SURVIVAL@@@@@@@@@@ADVANCED@@@@@OPEN-LABEL@SINGLE-ARM@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16423945@Onco@@@@@@@@@@@"Ensartinib, Experimental, Escalating dose of ensartinib was orally given once er day"@@@@@CHINA@11/1/2017@@@@16423945@Phase 1, Dose-escalating, Open-label Study of Ensartinib, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer@Both@@@@@Oral ensartinib was given daily at escalating doses in a 28-day cycle@@@@@@NCT02959619@24@@@@@@@11/1/2016@@BTP-28311@@@- Histologically or cytologically confirmed diagnosis of advanced solid tumor malignancy  -  For the expanded cohort portion of the study, patients must have NSCLC with ALK genomic alterations positive by FISH or IHC  -  Eastern Cooperative Group ECOG) Pe@ALK-positive@ADULTS@Phase 1@I@@@@@@@@@@ENSARTINIB@@@@@ENSARTINIB||||@BETTA PHARMACEUTICALS@@@@@BETTA PHARMACEUTICALS||||@@@@@@|||||||||@Solid Tumours@NSCLC@@@@Solid Tumours|NSCLC||||||||@-@@@@@-||||@Other@@@@@Other||||@Maximum Tolerated Dose@@@@@Peak Plasma Concentration (Cmax)@Area under the plasma concentration versus time curve (AUC)@@@@@@@@@Safety Study@Single Group Assignment@Open Label@Treatment@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921769@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Escalated dose every other day@@-@-@-@NEW YORK, NEW YORK@2/1/2009@@@@14921769@Refractory haematological malignancies@@-@-@@NO REVIEW@@@@-@Pfizer acquired Serenex for an undisclosed sum. SOURCE: Serenex, 3 March 2008@-@NCT00595686@69@-@-@@@-@@1/1/2008@-@CLN1-002@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@PFIZER@SERENEX@@@@PFIZER|SERENEX|||@@@@@@|||||||||@Haematological Malignancy@@@@@Haematological Malignancy|||||||||@SNX-5422@@@@@SNX-5422||||@HSP90 Inhibitor@@@@@HSP90 Inhibitor||||@ADVERSE EVENTS@@@@@@@@@@REFRACTORY@@@@@OPEN-LABEL@SINGLE-ARM@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TABLET@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924807@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@ONTARIO, CANADA@@@@@14924807@Treatment of superficial bladder cancer (SBC)@@-@-@@NO REVIEW@@@@-@-@-@-@800@-@FDA fast-track designation. SOURCE: Bioniche, March 2008@@@-@@@-@-@@-@-@@@III@III@@-@-@Testing Urodicin in patients with non muscle-invasive bladder cancer at high risk of recurrence or progression vs Bacillus Calmette-Guerin (BGC), the current standard-of-care; beginning Q1 2008.@-@@@@MONO@-@@@@@-||||@BIONICHE LIFE SCIENCES@@@@@BIONICHE LIFE SCIENCES||||@@@@@@|||||||||@Bladder Cancer@@@@@Bladder Cancer|||||||||@UROCIDIN@@@@@UROCIDIN||||@Other@@@@@Other||||@DISEASE-FREE SURVIVAL@@@@@@@@@@-@@@@@DOUBLE-BLIND@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916707@Onco@@@@@@@@@@@Xcytrin 15mg/kg plus Taxotere every 21 days; patients with stable disease, CR, or PR will continue dosing up to 12 cycles.@@-@-@-@SUNNYVALE, CALIFORNIA@@@Motexafin gadolinium (MGd) is a small-molecule drug with a novel mechanism of action; it accumulates selectively in cancer cells due to their increased rates of metabolism. Once inside the cell, MGd induces apoptosis (programmed cell death) by disrupting redox-dependent pathways. MGd inhibits the enzyme thioredoxin reductase, which is a tumor growth promoter. This mechanism provides the opportunity to use MGd in a wide range of cancers. MGd is paramagnetic, and therefore is detectable by magnetic resonance imaging (MRI), allowing the visualization of the drug in tumors.@@14916707@Taxotere combination in patients who have failed at least one platinum therapy@@-@-@@NO REVIEW@@@@-@Available for outlicensing.@SECOND-LINE@NCT00373204@61@-@-@@@-@@5/1/2006@-@PCYC-0229@@-@-@@@II@II@@-@-@Data expected in H1 2008. SOURCE: Pharmacyclics, 21 December 2007June 2007 interim data from 14 evaluable patients; median survival and TTP of 8.2 and 8.7 months respectively.@-@@@@COMBO@MOTEXAFIN GADOLINIUM@DOCETAXEL@@@@MOTEXAFIN GADOLINIUM|DOCETAXEL|||@PHARMACYCLICS@@@@@PHARMACYCLICS||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@XCYTRIN@TAXOTERE@@@@XCYTRIN|TAXOTERE|||@Radiation Sensitiser@@@@@Radiation Sensitiser||||@COMPLETE RESPONSE@PARTIAL RESPONSE@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@HISTORICAL CONTROL@OPEN-LABEL@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924096@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients randomised to placebo, 0.03, 0.1 or 0.2mg/kg velafermin delivered with single IV infusion 24-36 hours after stem cell infusion.@@-@-@-@CURAGEN, CONNECTICUT@@@@@14924096@Prevention of oral mucositis@@-@-@@NO REVIEW@@@@-@-@-@-@212@-@-@@@-@@@-@-@@-@212 PATIENTS WITH GRADE 3/4 OM@@@II@DISCONTINUED@@-@-@ASCO June 2006; incidence of severe OM was around 37% for placebo and 0.1 and 0.2mg/kg velafermin; below 20% for 0.03 velafermin. Primary endpoint not met; incidence of grade 3/4 OM was lower than expected; non-dose dependent. Company believes activity will be confirmed in another study.@-@@@@-@VELAFERMIN@@@@@VELAFERMIN||||@CURAGEN@@@@@CURAGEN||||@@@@@@|||||||||@Supportive Care@Mucositis@@@@Supportive Care|Mucositis||||||||@-@@@@@-||||@FGF@@@@@FGF||||@MUCOSITIS (SEVERE)@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916635@Onco@@@@@300f1014ntsdm@300f1813ntsdm@@@@@NO LABELLED TRIAL@@@@NO@NEW YORK, NEW YORK@@@@@14916635@@@@@@NO REVIEW@@@@@@@@@Continuous therapy: Hydrea 20-30mg/kg should be given daily in single doses. Dosage should be based on the patient's actual or ideal weight, whichever is the less. Therapy should be monitored by repeat blood counts. Intermittent therapy: Hydrea 80mg/kg in single doses should be given every third day. Using the intermittent regimes the likelihood of WBC depression is diminished, but if low counts are produced, 1 or more doses of Hydrea should be omitted.@@@@@@@The complete status of the blood, including bone marrow examination, if indicated, as well as kidney function and liver function should be determined prior to, and repeatedly during, treatment. The determination of haemoglobin level, total leukocyte counts, and platelet counts should be performed at least once a week throughout the course of hydroxycarbamide therapy. If WBC falls below 2.5x109/L or platelet count to <100x109/L, therapy should be interrupted. Counts should be rechecked after 3 days and treatment resumed when they rise significantly towards normal. Severe anaemia must be corrected with whole blood replacement before initiating therapy with hydroxycarbamide.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@RAMQ@NO LABELLED TRIAL@@@@@@HYDROXYUREA@@@@@HYDROXYUREA||||@APOTEX@@@@@APOTEX||||@@@@@@|||||||||@Haematological Malignancy@@@@@Haematological Malignancy|||||||||@APO-HYDROXYUREA@GENERIC@@@@APO-HYDROXYUREA|GENERIC|||@Anti-metabolite@@@@@Anti-metabolite||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@100@0.7934@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@CAPSULE@C$@@@@@@@@500@MG@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14924879@Onco@@@@@@@@@@@On the day 1 after catheter placement (2-7 days after resection, 2-4 catheters sterotactically placed), infusion of IL3-PE38QQR will begin if the patient is neurologically stable and will continue for 96 hours. In Phase I, the total flow rate and the concentration of IL3-PE38QQR will be determined by the dose escalation plan. In the Phase II evaluations of safety and efficacy, patients will be treated at the flow rate and concentration identified in Phase I. @@-@-@-@-@@@@@14924879@Glioma@@-@-@@NO REVIEW@@@@-@NeoPharm and Nippon Kayaku terminated an agreement to develop the drug in Japan. SOURCE: Nippon Kayaku, 14 September 2007@-@NCT00378235@50@-@-@@@-@@@-@-@@-@50 PATIENTS; 24 IN PHASE I AND ANOTHER 26 IF SUCCESSFULLY MOVING INTO PHASE II PORTION.@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@CINTREDEKIN BESUDOTOX@@@@@CINTREDEKIN BESUDOTOX||||@NEOPHARM@@@@@NEOPHARM||||@@@@@@|||||||||@Brain Cancer@Glioblastoma Multiforme@@@@Brain Cancer|Glioblastoma Multiforme||||||||@IL13-PE38QQR@@@@@IL13-PE38QQR||||@Interleukin@@@@@Interleukin||||@MAXIMUM TOLERATED DOSE@OVERALL SURVIVAL@SAFETY@@@SAFETY@@@@@MALIGNANT@RELAPSED@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@CONVECTION-ENHANCED DELIVERY@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924808@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients receiving 6 weekly intravesical doses of 8mg Urodicin in the initial induction stage, followed by weekly doses of Urodicin for three weeks given at 3, 6, 12, 18 and 24 during the maintenance stage. Also, a 36-month follow-up stage.@@-@-@-@ONTARIO, CANADA@@@@@14924808@Treatment of superficial bladder cancer (SBC)@@-@-@@NO REVIEW@@@@-@-@-@-@105@-@FDA fast-track designation. SOURCE: Bioniche, March 2008@@@-@@@-@-@@-@-@@@III@III@@-@-@DSMB recommends continuation of trial. SOURCE: Bioniche, 19 August 2008DSMB held third meeting and recommended to continue trial unmodified until next meeting. SOURCE: Bioniche, 13 February 2008Phase III data expected 2009.@-@@@@MONO@-@@@@@-||||@BIONICHE LIFE SCIENCES@@@@@BIONICHE LIFE SCIENCES||||@@@@@@|||||||||@Bladder Cancer@@@@@Bladder Cancer|||||||||@UROCIDIN@@@@@UROCIDIN||||@Other@@@@@Other||||@DISEASE-FREE SURVIVAL@TIME TO PROGRESSION@OVERALL SURVIVAL@@@OVERALL SURVIVAL@@@@@REFRACTORY@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922996@Onco@@@@@@@@@@@-@@-@-@-@BERKELEY HEIGHTS, NEW JERSEY@@@Genasense (oblimersen sodium) Injection is a drug that inhibits the production of a protein known as Bcl-2. By reducing production of Bcl-2 in cancer cells, it seeks to restore the basic biological process whereby cancer cells can be readily killed by treatment with current methods of anticancer therapy. Genta's clinical trials programs focus on treating cancer patients with Genasense along with the administration of anticancer therapy with the intention of potentiating the cancer-killing effects of treatment. Genta is developing Genasense Injection with the intention of potentiating the cancer-killing activity of standard anticancer therapies. In a typical example, Genasense might be administered for several days and then be immediately followed by regular doses of chemotherapy. This sequence would then be repeated, depending upon the particular type of chemotherapy regimen and indication. In other applications, Genasense might be administered concurrent with or after conventional chemotherapy, again depending on the chemotherapy and indication. Genasense has the potential to be used in combination with most types of anticancer therapy.@@14922996@-@@-@-@@NO REVIEW@@@-@-@-@-@-@-@-@MMA filed in January 2006 for advanced malignant melanoma; CHMP negative opinion in April 2007. Genta was accorded the option of requesting re-examination of this opinion, which would delay any formal action by the EU Commission pending its outcome. July 2007; EMEA reaffirms negative opinion for approval and asks for confirmatory trial (ongoing AGENDA trial).@@@-@@@-@-@@-@-@@@-@FILED@@-@-@RESULTS PENDING@-@@@@-@OBLIMERSEN SODIUM@@@@@OBLIMERSEN SODIUM||||@GENTA@@@@@GENTA||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@GENASENSE@@@@@GENASENSE||||@Bcl-2 Inhibitor@@@@@Bcl-2 Inhibitor||||@-@@@@@@@@@@ADVANCED@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922462@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@15 mg/kg. IV (in the vein) over 1 hour on Day 1 of each 90 day cycle. Number of cycles: maximum of 4 cycles unless progression of disease or unacceptable toxicity. @@-@-@-@NEW YORK, NEW YORK@12/1/2009@@Tremelimumab is a fully human anti-CTLA4 (cytotoxic T-lymphocyte antigen 4) IgG2 monoclonal antibody developed by Pfizer for its potential therapeutic application in melanoma, non-small cell lung cancer (NSCLC) and colorectal cancer. CTLA4 is a CD28-family receptor expressed mainly on T-lymphocyte that acts to inhibit T-lymphocyte function.@@14922462@Surgically incurable melanoma@@-@-@@NO REVIEW@@@@-@Medarex entitled to royalties@-@NCT00585000@110@-@-@@@-@@12/1/2007@-@A3671022@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@TREMELIMUMAB@TICILIMUMAB@@@@TREMELIMUMAB|TICILIMUMAB|||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@CP-675206@@@@@CP-675206||||@mAb@CTLA4 Receptor Antagonist@@@@mAb|CTLA4 Receptor Antagonist|||@SAFETY@TOLERABILITY@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919583@Onco@@@@@300f1015ntsdm@@@@@@@@N02AB03@N02A@@@@@Fentanyl is a synthetic opiate with a clinical potency of 50 to 100 times that of morphine. Its onset of action is rapid and its duration of action is short. In man, a single iv dose of 0.5-1 mg/70 kg body weight immediately produces a pronounced state of surgical analgesia, respiratory depression, bradycardia and other typical morphine-like effects. The duration of action of the peak effects is about 30 minutes. All potent morphine-like drugs produce relief from pain, ventilatory depression, emesis, constipation, physical dependence, certain vagal effects and varying degrees of sedation. Fentanyl, however, differs from morphine not only by its short duration of action but also by its lack of emetic effect and minimal hypotensive activity in animals.@@14919583@Management of breakthrough cancer pain in patients with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain@@NO@@@NO REVIEW@@@@@Acquired via takeover of generics unit of Merck KGaA@@@@@September 2006 (renewal)@@@@@@@@No@@@@@@APPROVED@@FREE PRICE IN HOSPITAL@HAUTE AUTORITÉ DE SANTÉ@RESULTS PENDING@@@@@@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@RENAUDIN@@@@@RENAUDIN||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@GENERIC@@@@@GENERIC||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
15413486@Onco@@@@@@@@@@@@@@@@SUMMIT, NEW JERSEY@4/1/2022@@@@15413486@A Phase 1/2, Multicenter, Open-label Study to Determine the Recommended Dose and Regimen of Durvalumab (MEDI4736) in Combination With Lenalidomide (LEN) With and Without Dexamethasone (Dex) in Subjects With Newly Diagnosed Multiple Myeloma (NDMM).@Both@@@@@@@@@@FIRST-LINE@NCT02685826@138@@@@@@@4/1/2016@@MEDI4736-MM-002@@@Subjects must satisfy the following criteria to be enrolled into the study:a.Subject is ≥ 18 years of age at the time of signing the informed consent form (ICF)b.Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conductedc.Subject is willing and able to adhere to the study visit schedule and other protocol requirementsd.Subject must have documented diagnosis with previously untreated (for cohort C, the induction and consolidation treatment along with the first Autologous stem cell transplantation (ASCT) are allowed), symptomatic Multiple Myeloma (MM) as defined by the criteria below:MM diagnostic criteria (all 3 required);Monoclonal protein present in the serum and/or urine@@ADULTS@Phase 1/2@I/II@@@@@@@@@COMBO@DURVALUMAB@LENALIDOMIDE@DEXAMETHASONE@@@DURVALUMAB|LENALIDOMIDE|DEXAMETHASONE||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@MEDI4736@REVLIMID@GENERIC@@@MEDI4736|REVLIMID|GENERIC||@Other@@@@@Other||||@DOSE-LIMITING TOXICITIES@@@@@ADVERSE EVENTS@OVERALL RESPONSE RATE@RESPONSE IMPROVEMENT RATE@@@@@@@@RANDOMIZED@PARALLEL ASSIGNMENT@OPEN LABEL@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922582@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@15 mg/m2 IV Weekly Over 1 Hour On Days 1, 8, and 15. SOURCE: VioQuest@@-@-@-@BASKING RIDGE, NEW JERSEY@8/1/2008@@@@14922582@Advanced haematological malignancies@@-@-@@NO REVIEW@@@@-@-@-@NCT00642031@34@-@FDA orphan designation for multiple myeloma. SOURCE: VioQuest, 4 February 2008@2/4/2008@@FDA orphan designation for multiple myeloma. SOURCE: VioQuest, 4 February 2008@@8/1/2006@-@2006-0249@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@TRICIBRINE PHOSPHATE MONOHYDRATE@@@@@TRICIBRINE PHOSPHATE MONOHYDRATE||||@VIOQUEST PHARMACEUTICALS@@@@@VIOQUEST PHARMACEUTICALS||||@@@@@@|||||||||@Haematological Malignancy@@@@@Haematological Malignancy|||||||||@VQD-002@VD-0002@@@@VQD-002|VD-0002|||@Other@@@@@Other||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918914@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@To evaluate Azixa in multiple doses with or without Temodar temozolomide@@-@-@-@SALT LAKE CITY, UTAH@@@@@14918914@-@@-@-@@NO REVIEW@@@@-@Myriad licensed the MX-90745 series of apoptosis inducing compounds in December 2003 from Maxim Pharmaceuticals (now EpiCept)@-@-@450@Multiple-dose@-@@@-@@@-@N/A@@-@450 patients with NSCLC with brain metastases@@@II@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@MYRIAD GENETICS@@@@@MYRIAD GENETICS||||@@@@@@|||||||||@NSCLC@Brain Cancer@@@@NSCLC|Brain Cancer||||||||@AZIXA@MPC-6827@@@@AZIXA|MPC-6827|||@Vascular Disrupting Agent@@@@@Vascular Disrupting Agent||||@OVERALL SURVIVAL@PROGRESSION-FREE SURVIVAL@QUALITY OF LIFE@@@QUALITY OF LIFE@@@@@-@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922217@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@ATN-224 combined with Temodar or Temodal followed by ATN-224@@-@-@-@SAN DIEGO, CALIFORNIA@9/1/2008@@@@14922217@Advanced melanoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00383851@60@-@-@@@-@@9/1/2006@-@ATN-224-008@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@BOTH@-@@@@@-||||@ATTENUON@@@@@ATTENUON||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@ATN-224@@@@@ATN-224||||@TK Inhibitor@Angiogenesis Inhibitor@VEGF@PDGF@@TK Inhibitor|Angiogenesis Inhibitor|VEGF|PDGF|@PROGRESSION-FREE SURVIVAL@SAFETY@@@@@@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922238@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@AT-101 in combination with Rituxan (80 mg of AT-101 once daily for three days every other week, 375 mg/m2 of rituximab weekly for up to 12 weeks)@@-@-@-@MALVERN, PENNSYLVANIA@11/1/2007@@@@14922238@Combo with Rituxan@@-@-@@NO REVIEW@@@@-@Partnering opportunity@-@NCT00286780@19@-@-@@@-@@1/1/2006@-@AT-101-CS-008@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@RITUXIMAB@@@@-|RITUXIMAB|||@ASCENTA THERAPEUTICS@@@@@ASCENTA THERAPEUTICS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@AT-101@RITUXAN@@@@AT-101|RITUXAN|||@Bcl-2 Inhibitor@@@@@Bcl-2 Inhibitor||||@SAFETY@@@@@@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@HISTORICAL CONTROL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15413591@Onco@@@@@@@@@@@Drug: Belinostat IV Cohort A:  Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.Cohort B:  Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.Cohort C:  Belinostat 750mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.@@@@@IRVINE, CALIFORNIA@3/1/2017@@@@15413591@An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients With Relapsed/Refractory Solid Tumors or Hematological Malignancies Who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes@Both@@@@@@@394@@@@NCT02680795@18@@@@@@@2/1/2016@@@@@Patient is diagnosed with advanced solid tumors or advanced hematological malignancy that is relapsed/refractory, for which no standard salvage therapy exists.Patient must have received at least 1 prior systemic therapy for the current malignancy and has recovered from any toxicity of the prior therapy at screening.Patient has adequate hematological and hepatic functions.@MONO@ADULTS@Phase 1@I@@@@@@@@@@BELINOSTAT@@@@@BELINOSTAT||||@SPECTRUM PHARMACEUTICALS@@@@@SPECTRUM PHARMACEUTICALS||||@World@@@@@World|||||||||@Solid Tumours@Haematological Malignancy@@@@Solid Tumours|Haematological Malignancy||||||||@BELEODAQ@@@@@BELEODAQ||||@HDAC@@@@@HDAC||||@PLASMA AND URINE CONCENTRATIONS@@@@@OVERALL INCIDENCE OF TREATMENT EMERGENT ADVERSE EVENTS@ADVERSE EVENTS@@@@RELAPSED@REFRACTORY@@@@NON RANDOMIZED@ASSIGNMENT@OPEN LABEL@PHARMACOKINETICS STUDY@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
16791363@Onco@@@@@300f1020ntsdm@@@@@@@@L01XE12@L01X@@LONDON, UNITED KINGDOM@@@An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGF2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis.@@16791363@Paediatric patients aged 5 to 18 with unresectable locally advanced or metastatic medullary thyroid carcinoma (MTC)@Both@NA@@@NO REVIEW@@@@@@@@16@@EMA, 16 December 2016@12/16/2016@@Yes@@@@@No@@@PAEDIATRIC@PAEDIATRIC@I/II@APPROVED@@@NA@@@@@@MONO@VANDETANIB@@@@@VANDETANIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Thyroid Cancer@@@@@Thyroid Cancer|||||||||@CAPRELSA@@@@@CAPRELSA||||@TK Inhibitor@VEGF@EGFR@Angiogenesis Inhibitor@@TK Inhibitor|VEGF|EGFR|Angiogenesis Inhibitor|@@@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@@@@@@1.2@m²@3733.355696@@@8@week@8 week@3733.36@3733.36@66.67@30@1.1229@5000.03@8252.05@5225.09@@@@@@@@@@0.56@1@@mg/m²@100@1@@@@@@@@@@@6/7/2017@166.67@166.67@41873023@COATED TABLET@EURO@@@@@@@@300@MG@300 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14923722@Onco@@@@@@@@@@@-@@L01XC07@L01X@-@BASEL, SWITZERLAND@@@Avastin (Bevacizumab) is a recombinant humanized monoclonalIgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems. Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF (1). Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models ofangiogenesis. Administration of Bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.@@14923722@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00139360@35@-@-@@@-@@5/1/2005@-@-@@-@-@@@II@II@@-@-@Not yet available@-@@@@MONO@BEVACIZUMAB@@@@@BEVACIZUMAB||||@ROCHE@@@@@ROCHE||||@Norway@@@@@Norway|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@AVASTIN@@@@@AVASTIN||||@mAb@Humanised@TK Inhibitor@VEGF@@mAb|Humanised|TK Inhibitor|VEGF|@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
16074362@Onco@@@@@@@@@@@Combination Therapy with Monotherapy Lead-In (Dose-Escalation), Experimental, BMS-986179 leading to combination of BMS-986179 + nivolumab, dose as specifiedCombination Therapy (Pharmacodynamic Sub-study), Experimental, BMS-986179 + nivolumab, dose as specifiedCohort Expansion Combination Therapy (Dose Expansion), Experimental, BMS-986179 + nivolumab, dose as specified@@@@@@5/1/2020@@@@16074362@A Phase 1/2a Study of BMS-986179 Administered in Combination With Nivolumab (BMS-936558) in Subjects With Advanced Solid Tumors@Both@@@@@Specified dose on specified days, intravenous (IV)@@@@@@NCT02754141@204@@@@@@@6/1/2016@@CA013-004@@@Men and women at least 18 years of age  -  Advanced solid tumors  -  Eastern Cooperative Oncology Group (ECOG) 0-1  -  Acceptable lab testing results  -  Allow biopsies@@ADULTS@Phase 1/Phase 2@I/II@@@@@@@@@COMBO@-@NIVOLUMAB@@@@-|NIVOLUMAB|||@BRISTOL-MYERS SQUIBB@@@@@BRISTOL-MYERS SQUIBB||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@BMS-986179@OPDIVO@@@@BMS-986179|OPDIVO|||@Other@@@@@Other||||@Number of adverse events (AE), serious adverse events (SAE), AEs leading to discontinuation, and deaths@@@@@BMS-986179 enzyme assays in pre- and on-treatment biopsies@BMS-986179 immunohistochemistry (IHC) in pre- and on-treatment biopsies@@@@ADVANCED@@@@@NON-RANDOMIZED@SAFETY/EFFICACY STUDY@PARALLEL ASSIGNMENT@OPEN LABEL@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
15370433@Onco@@@@@300f1008ntsdm@@@@@@@@L01XX42@L01X@@BASEL,SWITZERLAND@@@@@15370433@Treatment of relapsed and/or refractory multiple myeloma@@NA@31-Aug-15@8/31/2015@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@THIRD-LINE@@@20 mg, taken orally once every other day for 3 doses per week (on Days 1, 3, 5, 8, 10, and 12) of Weeks 1 and 2 of each 21-day cycle for 8 cycles@MHLW, 31 August 2015@8/31/2015@@@@@@@No@@@@@@APPROVED@@@NHI@@@@@@COMBO@PANOBINOSTAT@BORTEZOMIB@DEXAMETHASONE@@@PANOBINOSTAT|BORTEZOMIB|DEXAMETHASONE||@NOVARTIS@@@@@NOVARTIS||||@World@@@@@World|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@FARYDAK@VELCADE@@@@FARYDAK|VELCADE|||@HDAC@@@@@HDAC||||@@@@@@@@@@@RELAPSED@@@@@@@@@@1@1@5956439.04@@@48@week@48 week@5956439.04@5956439.04@17727.5@1@0.0091@46534.68@54875.8@@@@@@@@@@@3102.31@21@@mg@20@6@@@@@@@@@@@8/30/2017@46534.68@46534.68@4291040M2020@CAPSULE@YEN@@@@@@@@15@MG@15 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
16074358@Onco@@@@@@@@@@@Man participants should agree to use and utilize an adequate method of contraception throughout treatment and for at least 6 months after study is stopped  -  Patients should participate in the study voluntarily and sign informed consent@@@@@@10/1/2016@@@@16074358@Phase I Additional Study of Tolerance and Pharmacokinetics of Anlotinib in Patients With Advanced Solid Tumors@Both@@@@@Anlotinib QD po. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent@@the result of serum or urine pregnancy test should be negative within 7 days prior to study enrollment，and the patients required to be non-lactating@@@@NCT02752516@15@@@@@@@4/1/2016@@ALTN-I-07@@@Histological documentation of Advanced solid tumors except the digestive tract tumors,at least one measurable lesion (by RECIST1.1)  -  Lack of the standard treatment or treatment failure  -  18-65 years,ECOG PS:0-1,Life expectancy of more than 3 months  -  30 Days or more from the last cytotoxic therapy  -  Main organs function is normal  -  Women of childbearing potential should agree to use and utilize an adequate method of contraception (such as intrauterine device，contraceptive and condom) throughout treatment and for at least 6 months after study is stopped@MONO@ADULTS@Phase 1@I@@@@@@@@@@ANLOTINIB@@@@@ANLOTINIB||||@JIANGSU CHIA-TAI TIANQING PHARMACEUTICAL@@@@@JIANGSU CHIA-TAI TIANQING PHARMACEUTICAL||||@China@@@@@China|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@-@@@@@-||||@Other@@@@@Other||||@Anlotinib, Experimental,@Peak Plasma Concentration(Cmax)@Peak timeTmax）@@@OBJECTIVE RESPONSE RATE@@@@@ADVANCED@@@@@Pharmacokinetics/Dynamics Study@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
15038287@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NO LABELLED TRIAL@@D08A@D08A@@MALVERN, PENNSYLVANIA@@@@@15038287@Indicated for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL) in patients who have received prior skin-directed therapy.@@YES@@@NO REVIEW@@@@@@@@@@FDA, 23 August 2013@8/23/2013@@@@@@NO LABELLED TRIAL@No@@@@@@APPROVED@@@MEDICARE@@@@@@@MECHLORETHAMINE HCL@@@@@MECHLORETHAMINE HCL||||@CEPTARIS@@@@@CEPTARIS||||@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@Chronic Myeloid Leukaemia@Chronic Lymphocytic Leukaemia@@Haematological Malignancy|Hodgkin's Lymphoma|Chronic Myeloid Leukaemia|Chronic Lymphocytic Leukaemia||||||@VALCHLOR@@@@@VALCHLOR||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1@3355@@@@@@@@@@@@349.48@@@@@@@@@@@@@@@@8/2/2017@3355@3355@66215-0016-60@TOPICAL GEL - 60 G@US$@@@@@@@@9.6@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922998@Onco@@@@@@@@@@@-@@-@-@-@OSAKA, JAPAN@@@Hematide is a novel, synthetic pegylated peptide-based erythropoiesis stimulating agent (ESA) that acts on the erythropoietin receptor to stimulate the production of red blood cells. @@14922998@Anaemia associated with cancer and cancer chemotherapy.@@-@-@@NO REVIEW@@@STARTED IN DECEMBER 2005@-@Takeda initially licensed Japanese rights in February 2006; followed up with a global deal in June 2006; Affymax and Takeda will co-develop and co-market in the U.S. Takeda paid US$105 mil. upfront and could pay another US$430 mil.@-@NCT00272662@90@-@-@@@-@@@-@-@@-@-@@@II@DISCONTINUED@@-@-@>Takeda and Affymax suspend co-development of Hematide to treat chemotherapy-induced anemia and to focus all development efforts for Hematide on the treatment of chronic kidney disease related anemia. [Takeda, 29.08.2008]@-@@@@MONO@-@@@@@-||||@TAKEDA PHARMACEUTICAL@AFFYMAX@@@@TAKEDA PHARMACEUTICAL|AFFYMAX|||@@@@@@|||||||||@Supportive Care@@@@@Supportive Care|||||||||@HEMATIDE@AF-37702@@@@HEMATIDE|AF-37702|||@EPO@Synthetic Peptide@@@@EPO|Synthetic Peptide|||@-@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921715@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@"Patients will be vaccinated with weekly for 6 weeks,will ""rest"" for 4 weeks, then will receive 6 boost injections, each administered every other week for 12 weeks. Patients will be followed every 4 weeks until Week 54, then every 3 months for 1 year, then every 6 months up to approximately 5 years from the first vaccination or until relapse/progression."@@-@-@-@MENLO PARK, CALIFORNIA@12/1/2012@@@@14921715@A dendritic cell vaccine in patients with prostate cancer.@@-@-@@NO REVIEW@@@@-@Merck & Co licensed rights to telomerase vaccien as part of an equity purchase in Geron in July 2005; Geron also receives payments and potential royalties. Merck holds an option for GRN-VAC1.@-@NCT00510133@25@-@-@@@-@@7/1/2007@-@CP06-151@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@GERON@MERCK & CO@@@@GERON|MERCK & CO|||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@GRN-VAC1@@@@@GRN-VAC1||||@Vaccine@@@@@Vaccine||||@RESPONSE RATE@@@@@@@@@@-@@@@@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919586@Onco@@@@@300f1015ntsdm@@@@@@@@N02AB03@N02A@@CANONSBURG, PENNSYLVANIA@@@Fentanyl is a synthetic opiate with a clinical potency of 50 to 100 times that of morphine. Its onset of action is rapid and its duration of action is short. In man, a single iv dose of 0.5-1 mg/70 kg body weight immediately produces a pronounced state of surgical analgesia, respiratory depression, bradycardia and other typical morphine-like effects. The duration of action of the peak effects is about 30 minutes. All potent morphine-like drugs produce relief from pain, ventilatory depression, emesis, constipation, physical dependence, certain vagal effects and varying degrees of sedation. Fentanyl, however, differs from morphine not only by its short duration of action but also by its lack of emetic effect and minimal hypotensive activity in animals.@@14919586@Management of breakthrough cancer pain in patients with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain@@NO@@@NO REVIEW@@@@@Acquired via takeover of generics unit of Merck KGaA@@@@@Oct-92@@@@@@@@No@@@@@@APPROVED@@FREE PRICE IN HOSPITAL@HAUTE AUTORITÉ DE SANTÉ@RESULTS PENDING@@@@@@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@MYLAN@@@@@MYLAN||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@GENERIC@@@@@GENERIC||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
16161453@Onco@@@@@300f1008ntsdm@@@@@@@@L01XE35@L01X@@LONDON, UNITED KINGDOM@@@Osimertinib is kinase inhibitor of the epidermal growth factor receptor (EGFR), which binds irreversibly to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletion) at approximately 9-fold lower concentrations than wild-type.@@16161453@Indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC)@Both@NA@17-Jun-16@6/17/2016@NO REVIEW@@@@REIMBURSEMENT RANGES BETWEEN 50% AND 80%@@@@411@The recommended dose of TAGRISSO is 80 mg tablet once a day until disease progression or unacceptable toxicity.@MHLW, 25 May 2016@5/25/2016@5/25/2016@@@@@@No@@@EGFR T790M mutation-positive@ADULTS@@APPROVED@@@NHI@@@@@@MONO@OSIMERTINIB@@@@@OSIMERTINIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@TAGRISSO@@@@@TAGRISSO||||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@@@@@@@@@@@METASTATIC@@@@@MULTICENTER@SINGLE-ARM@OPEN-LABEL@@@1@1@5987692.178@@@9.7@month@9.7 month@5987692.18@5987692.18@20294.84@1@0.0091@20294.84@23932.6@@@@@@@@@@@253.69@1@@mg@80@1@@@@@@@@@@@8/30/2017@20294.84@20294.84@4291045F2023@TABLET@YEN@@@@@@@@80@MG@80 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14922300@Onco@@@@@@@@@@@Gemzar alone@@L01BC05@L01B@-@INDIANAPOLIS, INDIANA@@@Gemcitabine exhibits significant cytotoxicity activity against a variety of cultured murine and human tumour cells. It exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and under certain conditions blocking the progression of cells through the G1/S-phase boundary. In vitro the cytotoxic action of gemcitabine is both concentration and time dependent.@@14922300@Marginal zone lymphoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00337259@43@-@-@@@-@@6/1/2006@-@AMC 2006-60  @@-@-@@@II@II@@-@-@RESULTS PENDING (recruiting).@-@@@@MONO@GEMCITABINE HYDROCHLORIDE@@@@@GEMCITABINE HYDROCHLORIDE||||@LILLY@@@@@LILLY||||@South Korea@@@@@South Korea|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@GEMZAR@@@@@GEMZAR||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-GROUP@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921517@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@E7107 Administered Intravenously on Days 1 and 8 Every 21 Days @@-@-@-@TOKYO, JAPAN@4/1/2010@@@@14921517@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00499499@40@-@-@@@-@@7/1/2007@-@E7107-A001-101@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@EISAI@@@@@EISAI||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@E-7107@@@@@E-7107||||@RNA@@@@@RNA||||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921094@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Zarnestra and imatinib through to maximum tolerated dose@@-@-@-@NEW BRUNSWICK, NEW JERSEY@2/1/2005@@A nonpeptidomimetic quinolinone with potential antineoplastic activity. Tipifarnib binds to and inhibits the enzyme farnesyl protein transferase, an enzyme involved in protein processing (farnesylation) for signal transduction. By inhibiting the farnesylation of proteins, this agent prevents the activation of Ras oncogenes, inhibits cell growth, induces apoptosis, and inhibits angiogenesis.@@14921094@Chronic phase CML@@-@-@@NO REVIEW@@@@-@-@-@NCT00040105@30@-@-@@@-@@10/1/2002@-@ID02-169@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@COMBO@TIPIFARNIB@IMATINIB@@@@TIPIFARNIB|IMATINIB|||@JOHNSON & JOHNSON@@@@@JOHNSON & JOHNSON||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@ZARNESTRA@GLEEVEC@GLIVEC@@@ZARNESTRA|GLEEVEC|GLIVEC||@Farnesyltransferase Inhibitor@@@@@Farnesyltransferase Inhibitor||||@MAXIMUM TOLERATED DOSE@TOXICITY@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916806@Onco@@@@@@@@@@@Weekly R1507 9MG/KG with Tarceva 150MG oral daily [clinicaltrials.gov].@@-@-@-@BASEL, SWITZERLAND@11/1/2009@@R1507 is a fully human antibody created by Genmab under a collaboration with Roche. R1507 was selected from a large panel of antibodies and targets the Insulin-like Growth factor-1 Receptor (IGF-1R).  The IGF-1R molecule has been shown to be important in tumor growth and protecting tumor cells from being killed.  IGF-1R is over-expressed on a variety of tumors including breast, colon, prostate, lung, skin and pancreatic cancers and is a well validated target for an antibody therapeutic approach.  Roche filed an Investigational New Drug application with the US FDA for the antibody in December 2005. @@14916806@R1507 in Combination With Tarceva (Erlotinib) for Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC)@@-@-@@NO REVIEW@@@@-@In-licensed from Genmab@SECOND-LINE@NCT00760929@150@-@-@@@-@@8/1/2008@-@NO21160@@-@>> Male or female patients >= 18 years with histologically documented inoperable, locally advanced or metastatic (stage IIIB or IV) NSCLC    >> Patients must have failed at least one but no more than two standard chemotherapy regimens@@@II@II@@-@-@Trial registered. [Roche, 25.09.2008]@-@@@@COMBO@-@ERLOTINIB@@@@-|ERLOTINIB|||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@R-1507@TARCEVA@@@@R-1507|TARCEVA|||@mAb@@@@@mAb||||@PROGRESSION-FREE SURVIVAL@@@@@OVERALL SURVIVAL@SAFETY@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
15882734@Onco@@@@@300f1012ntsdm@@@@@@"mPC, Prostate cancer patients with bone metastases (mPC)mCRPC, Patients with castration-resistant prostate cancer with bone metastases (mCRPC)"@@@@@LEVERKUSEN, GERMANY@9/1/2016@@@@15882734@Second Primary Cancers in Patients With Castration Resistant Prostate Cancer (BOCARP)@Male@@@@@@@@@@@NCT02702908@2000@@@@@@@3/1/2016@@18044@@@Members of the mPC cohort will have to fulfill all of the following criteria:  -  Valid information on sex, age and the region of residence  -  A period of at least 12 months of continuous insurance preceding cohort entry  -  Diagnosis of PC (ICD-10 Code C61) in the study period (01-Jan-2004 to 31-Dec-2011)  -  Diagnosis of bone metastases (ICD-10 Code C79.5) in the enrolment period (01-Jan-2005 to 31-Dec-2011)  -  In addition to the criteria of the mPC cohort, members of the mCRPC will additionally have to fulfill:  -  One of the following in the enrolment period and before or at the same time with bone metastases  -  Discontinuation of the initial chemical castration, change of the agent or modality of the Androgen deprivation therapy (ADT), or start of treatment for advanced Prostate cancer (PC) after the primary ADT.  -  Surgical castration and initiation of ADT treatment  -  Treatment with medication specific to mCRPC.@MONO@ADULTS@N/A@-@@@@@@@@@@-@@@@@-||||@BAYER HEALTHCARE@@@@@BAYER HEALTHCARE||||@Germany@@@@@Germany|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@-@@@@@-||||@Other@@@@@Other||||@Incidences of Second primary malignancies are characterized by the following ICD-10 codes: C00-C76, C81-C96, D00-D09, D37-D48.@@@@@OVERALL SURVIVAL@@@@@CASTRATION-RESISTANT@@@@@Cohort@RETROSPECTIVE@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14919284@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@ABT-751 by mouth daily for 21 days, then off treatment for 7 days before next cycle begins.@@-@-@-@UNITED STATES@@@An orally bioavailable antimitotic sulfonamide. ABT-751 binds to the colchicine-binding site on beta-tubulin and inhibits the polymerization of microtubules, thereby preventing tumor cell replication. This agent also disrupts tumor neovascularization, reducing tumor blood flow and so inducing a cytotoxic effect@@14919284@Taxane-refractory@@-@-@@NO REVIEW@@@@-@-@-@NCT00063102@-@-@-@@@-@@@-@M02-447  @@-@PATIENTS WITH STAGE IIIB OR IV BREAST CANCER (NUMBER UNKNOWN)@@@II@II@@-@-@RESULTS PENDING (recruiting).@-@@@@MONO@-@@@@@-||||@ABBOTT@@@@@ABBOTT||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@ABT-751@@@@@ABT-751||||@Plant Alkaloid@Vascular Disrupting Agent@@@@Plant Alkaloid|Vascular Disrupting Agent|||@-@@@@@@@@@@REFRACTORY@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922663@Onco@@@@@@@@@@@Alimta (500mg/m2) alone day 1 of 21-day cycles@@L01BA04@L01B@-@INDIANAPOLIS, INDIANA@@@Pemetrexed is an antifolate containing the pyrrolopyrimidine-based nucleus that exerts its antineoplastic activity by disrupting folate-dependent metabolic processes essential for cell replication. In vitro studies have shown that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), all folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is transported into cells by both the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT. Polyglutamation is a time- and concentration-dependent process that occurs in tumor cells and, to a lesser extent, in normal tissues. Polyglutamated metabolites have an increased intracellular half-life resulting in prolonged drug action in malignant c@@14922663@Osteosarcoma@@-@-@@NO REVIEW@@@3 YEARS@-@-@SECOND-LINE@NCT00523419@32@-@-@@@-@@@-@11814H3E-EW-S115  @@-@-@@@II@II@@-@-@Completion expected in December 2010.@-@@@@MONO@PEMETREXED@@@@@PEMETREXED||||@LILLY@@@@@LILLY||||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@ALIMTA@@@@@ALIMTA||||@Anti-metabolite@Folic Acid Analogue@@@@Anti-metabolite|Folic Acid Analogue|||@RECIST@@@@@@@@@@ADVANCED@METASTATIC@@@@RANDOMISED@DOUBLE-BLIND@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@POWDER FOR INFUSION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916084@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Patients receive oral talabostat mesylate once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. SOURCE: clinicaltrials.gov@@-@-@-@BOSTON, MASSACHUSSETTS@@@This is a substance being studied in the treatment of cancer, including certain types of lung, pancreas, and brain cancer. Talabostat may help the immune system block the growth of cancer cells. It may also increase the growth of new blood cells. It is a type of enzyme inhibitor. @@14916084@-@@-@-@@NO REVIEW@@@@-@DARA and Point to merge; DARA will become wholly-owned subsidiary, whilst Point will change its name to DARA BiosSciences. SOURCE: Point, 10 October 2007@-@NCT00489710@30@-@-@@@-@@@-@UNMC-40105@@-@-@@@II@CLINICAL HOLD@@-@-@All clinical trials for talabostat put on hold following the interim results for the two Phase III NSCLC trials which showed no increase in PFS or overall survival. SOURCE: Point, 21 May 2007@-@@@@MONO@TALABOSTAT@@@@@TALABOSTAT||||@DARA BIOSCIENCES@@@@@DARA BIOSCIENCES||||@@@@@@|||||||||@Kidney Cancer@@@@@Kidney Cancer|||||||||@PT-100@@@@@PT-100||||@Immunotherapy@@@@@Immunotherapy||||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924962@Onco@@@@@300f1008ntsdm@@@@@@Gemzar/S-1 versus S-1 versus Gemzar@@-@-@-@-@@@S-1 is an oral fluorouracil anticancer product that combines 3 pharmacological agents in a certain ratio: tegafur which is a pro-drug of 5 fluoro-uracil; gimeracil (5-chloro-2,4 dihydropyridine (CDHP)) which inhibits dihydropyrimidine dehydrogenase (DPD) enzyme activity; and oteracil (potassium oxonate (Oxo)) a gastrointestinal side effects corrector.@@14924962@Unresectable pancreatic cancer@@-@-@@NO REVIEW@@@@-@sanofi-aventis returns its territory rights to Taiho Pharmaceutical for the development and commercialization of the oral anti-cancer agent S-1. Taiho will pursue further development of S-1 outside of Japan with gastric cancer included. SOURCE: Taiho, 18 July 2008@SECOND-LINE@NCT00498225@600@-@-@@@-@@@-@1023017@@-@-@@@III@III@@-@@Completion expected June 2012.@-@@@@BOTH@TEGAFUR GIMERACIL OTERACIL POTASSIUM @@@@@TEGAFUR GIMERACIL OTERACIL POTASSIUM ||||@TAIHO@@@@@TAIHO||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@S-1@@@@@S-1||||@Fluoropyrimidine@@@@@Fluoropyrimidine||||@OVERALL SURVIVAL@@@@@@@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14922978@Onco@@@@@@@@@@@Multiple-ascending dose of Acadra@@-@-@-@RUNCORN, UNITED KINGDOM@@@@@14922978@B-Cell@@-@-@@NO REVIEW@@@January 2007-@-@Licensed from Advancell in December 2006.@-@-@30@-@-@@@-@@@-@-@@-@-@@@I/II@II@@-@-@>>The results of this study demonstrated that Acadra has an acceptable safety and tolerability profile at doses that induce reduction in the leukemic tumor burden.[Advancell 16 February 2011 http://www.advancell.net/newsite/index.php?pt1=0&pt2=5&pt10=614&ptn=1 ]>>Preliminary data expected in H2 08; final data expected in H1 09. SOURCE: Protherics, January 2008.@-@@@@MONO@ACADESINE@@@@@ACADESINE||||@PROTHERICS@ADVANCELL@@@@PROTHERICS|ADVANCELL|||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@B-Cell Lymphoma@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia|B-Cell Lymphoma|||||||@ACADRA@@@@@ACADRA||||@Anti-metabolite@Purine Analogue@@@@Anti-metabolite|Purine Analogue|||@PHARMACOKINETICS@@@@@@@@@@RELAPSED@REFRACTORY@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14923401@Onco@@@@@300f1012ntsdm@@@@@@Patients receive gemcitabine plus cisplatin with or without Iressa.@@L01XE02@L01X@-@LONDON, UNITED KINGDOM@@@The mechanism of the clinical antitumor action of gefitinib is not fully characterized. Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinasesassociated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor (EGFR-TK). EGFR isexpressed on the cell surface of many normal cells and cancer cells. No clinical studies have been performed that demonstrate a correlation between EGFRreceptor expression and response to gefitinib@@14923401@Advanced or metastatic transitional cell carcinoma of the urothelium@@-@-@@NO REVIEW@@@@-@-@-@NCT00246974@125@-@-@@@-@@5/1/2003@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING (recruiting)@-@@@@COMBO@GEFITINIB@@@@@GEFITINIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Bladder Cancer@@@@@Bladder Cancer|||||||||@IRESSA@ZD-1839@@@@IRESSA|ZD-1839|||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@TIME TO PROGRESSION@@@@@@@@@@ADVANCED@METASTATIC@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TABLET@EURO@@@@@@@@250@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14921324@Onco@@@@@@@@@@@Biweekly docetaxel iv (50 mg/m2) on day 1 and 15 and capecitabine po 1250 mg/m2 x 2/day days 1-7 and 15-21, treatment cycle consisting of 21 days. SOURCE: clinicaltrials.gov@@L01CD02@L01C@-@PARIS, FRANCE@3/1/2009@@Docetaxel is an antineoplastic agent which acts by promoting the assembly of tubulin into stable microtubules and inhibits their disassembly which leads to a marked decrease of free tubulin. The binding of docetaxel to microtubules does not alter the number of protofilaments. Docetaxel has been shown in vitro to disrupt the microtubular network in cells which is essential for vital mitotic and interphase cellular functions. Docetaxel was found to be cytotoxic in vitro against various murine and human tumour cell lines and against freshly excised human tumour cells in clonogenic assays. Docetaxel achieves high intracellular concentrations with a long cell residence time. In addition, docetaxel was found to be active on some but not all cell lines over expressing the p-glycoprotein which is encoded by the multidrug resistance gene. In vivo, docetaxel is schedule independent and has a broad spectrum of experimental antitumour activity against advanced murine and human grafted tumours.@@14921324@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00669370@50@-@-@@@-@@6/1/2006@-@GAST-TAXXEL@@-@-@@@2005-002484-87, EudraCT no 2005-002484-87; @II@@-@-@RESULTS PENDING@-@@@@COMBO@DOCETAXEL@CAPECITABINE@@@@DOCETAXEL|CAPECITABINE|||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@Finland@@@@@Finland|||||||||@Stomach Cancer@@@@@Stomach Cancer|||||||||@TAXOTERE@XELODA@@@@TAXOTERE|XELODA|||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@QUALITY OF LIFE@@@@@@@@@@ADVANCED@@@@@OPEN-LABEL@SINGLE-ARM@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922100@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Single dose of 3x10e11 vector particles of AdV-tk delivered into remaining tumor or tumor bed after resection on day 0. Single course of valacyclovir at dose of 2 grams orally three times per day for 14 days starting on day 1-3 @@-@-@-@BOSTON, MASSACHUSETTS@9/1/2009@@@@14922100@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00589875@24@-@-@@@-@@3/1/2007@-@BrTK02,  @@-@-@@@5R44CA107745;@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@@@@@-||||@ADVANTAGENE@@@@@ADVANTAGENE||||@@@@@@|||||||||@Brain Cancer@Glioblastoma Multiforme@@@@Brain Cancer|Glioblastoma Multiforme||||||||@ADV-TK@@@@@ADV-TK||||@Immunotherapy@@@@@Immunotherapy||||@SAFETY@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921568@Onco@@@@@@@@@@@Patients treated with weekly paclitaxel were given dimesna or placebo.@@-@-@-@SAN ANTONIO, TEXAS@8/1/2007@@@@14921568@Chemotherapy-associated neuropathy in metastatic breast cancer@@-@-@@NO REVIEW@@@@-@Licensing and development deal with Takeda terminated in October 2006.@-@NCT00039780@750@-@-@@@-@@7/1/2001@-@DMS30203R@@-@-@@@Weekly Paclitaxel Breast Cancer Trial; @III@@-@-@July 2006; trial failed primary endpoint in total incidence of sever chemotherapy-associated neuropathy and difference in tumour response rates. A asubgroup analysis showed 84% decrease in severe neuropathy in the dimesna-treated patients versus placebo.@-@@@@MONO@DIMESNA@@@@@DIMESNA||||@BIONUMERIK@TAKEDA PHARMACEUTICAL@@@@BIONUMERIK|TAKEDA PHARMACEUTICAL|||@Russia@@@@@Russia|||||||||@Supportive Care@Breast Cancer@@@@Supportive Care|Breast Cancer||||||||@TAVOCEPT@BNP-7787@@@@TAVOCEPT|BNP-7787|||@Camptothecin@Topoisomerase I Inhibitor@@@@Camptothecin|Topoisomerase I Inhibitor|||@NEUROPATHY@@@@@@@@@@METASTATIC@@@@@PLACEBO-CONTROLLED@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922143@Onco@@@@@@@@@@@Ertumaxomab 10 µg, IV on day 0 followed by 100 µg every 7 days up to a maximum of 12 infusions [clinicaltrials.gov]@@-@-@-@-@@@Ertumaxomab is a trifunctional bispecific antibody targeting Her-2/neu on tumor cells and CD3 on T cells. Trifunctional antibodies represent a new concept for targeted anticancer therapy. This new antibody class has the capability to redirect T cells and accessory immune effector cells (e.g. macrophages, dendritic cells [DCs] and natural killer [NK] cells) to the tumor site. According to preclinical data, trifunctional antibodies activate these immune cells, which can trigger a complex anti-tumor immune response.@@14922143@Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine Treatment@@-@-@@NO REVIEW@@@MARCH 2007-@-@-@SECOND-LINE@NCT00452140@40@-@-@@@-@@@-@BC-03@@-@Metastatic (stage IV) and not curable adenocarcinoma of the breast HER-2 overexpression 3+ or 2+ FISH positive @@@II@II@@-@-@Trial registered [Fresenius, 26.03.2007]@-@@@@-@ERTUMAXOMAB@@@@@ERTUMAXOMAB||||@FRESENIUS BIOTECH@@@@@FRESENIUS BIOTECH||||@@@@@@|||||||||@Breast Cancer@HER2+@@@@Breast Cancer|HER2+||||||||@-@@@@@-||||@mAb@HER2@@@@mAb|HER2|||@RESPONSE RATE@@@@@TIME TO PROGRESSION@DURATION OF RESPONSE@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922501@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Paclitaxel combo with STA-4783@@-@-@-@LEXINGTON, MASSACHUSSETTS@10/1/2005@@Elesclomol acts through a novel mechanism of action with broad and exciting potential as a new category of anti-cancer therapy. In a series of in vitro and in vivo experiments, elesclomol has been shown to rapidly cause an increase in oxidative stress – the level of reactive oxygen species (ROS) – inside cancer cells.  This increase in ROS is observed through measuring levels of individual reactive oxygen species, such as hydrogen peroxide, directly; or through measuring the increased expression of genes that are induced by the presence of high levels of ROS, including stress proteins such as heat shock protein 70 (Hsp70).@@14922501@Soft tissue sarcoma@@-@-@@NO REVIEW@@@@-@In an October 2007 deal between GSK and Synta, the two firms split development and commercialisation duties in the US. Synta will continue to fund STA-4783's U.S. development in metastatic melanoma, but GSK will gain exclusive rights to the drug in other @-@NCT00087997@80@-@-@@@-@@7/1/2004@-@4783-04@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@COMBO@ELESCLOMOL@PACLITAXEL@@@@ELESCLOMOL|PACLITAXEL|||@SYNTA PHARAMECEUTICALS@GSK@@@@SYNTA PHARAMECEUTICALS|GSK|||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@STA-4783@@@@@STA-4783||||@Other@@@@@Other||||@SAFETY@RESPONSE RATE@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921888@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@BASEL, SWITZERLAND@@@"Vatalanib (PTK/ZK) is a ""small"" molecule tyrosine kinase inhibitor with broad specificity that targets all VEGF receptors (VEGFR), the platelet-derived growth factor receptor, and c-KIT. It is a multi-VEGFR inhibitor designed to block angiogenesis and lymphangiogenesis by binding the intracellular kinase domain of all three VEGFRs, VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3 (Flt-4). Vatalanib is a targeted drug that inhibits the activity of all known receptors that bind VEGF. The drug potently inhibits the formation of new blood vessels (angiogenesis). "@@14921888@Malignant mesothelioma in elderly patients with a median age of 75@@-@-@@NO REVIEW@@@@-@PTK/ZK was among 20 projects discontinued by Bayer Schering as part of its merger. SOURCE: Bayer, 19 June 2007Following a modified agreement in January 2005, Novartis and Schering AG will co-market vatalanib in Europe, North America and Japan for oncolo@-@NCT00053885@47@-@-@@@-@@@-@CALGB-30107@@-@-@ELDERLY@@II@II@@-@-@Results from 33 patients showed 3-month PFS at 44.9%; median duration of PFS was 2.66 months. Overall survival at 3 months was 76.3% and median duration of survival was 5.2 months. SOURCE: Novartis/World Conference on Lung Cancer, 5 July 2006@-@@@@MONO@VATALANIB@@@@@VATALANIB||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Mesothelioma@@@@@Mesothelioma|||||||||@PTK-787@ZK-222584@PTK/ZK@@@PTK-787|ZK-222584|PTK/ZK||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@MALIGNANT@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924567@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01DB06@L01D@YES@NEW YORK, NEW YORK@@@Idarubicin is an antimitotic and cytotoxic agent which intercalates with DNA and interacts with topoisomerase II and has an inhibitory effect on nucleic acid synthesis. The compound has a high lipophilicity which results in an increased rate of cellular uptake compared with doxorubicin and daunorubicin. Idarubicin has been shown to have a higher potency with respect to daunorubicin and to be an effective agent against murine leukaemia and lymphomas both by i.v. and oral routes. Studies in-vitro on human and murine anthracycline-resistant cells have shown a lower degree of cross-resistance for idarubicin compared with doxorubicin and daunorubicin. Cardiotoxicity studies in animals have indicated that idarubicin has a better therapeutic index than daunorubicin and doxorubicin. The main metabolite, idarubicinol, has shown in-vitro and in-vivo antitumoral activity in experimental models. In the rat, idarubicinol, administered at the same doses as the parent drug, is clearly less cardiotoxic than idarubicin.@@14924567@As a single agent in the treatment of advanced breast cancer after failure of front line chemotherapy not including anthracyclines.@@NO@@@NO REVIEW@@@@100%@Acquired via takeover of Pharmacia Corp.@@@@In advanced breast cancer the recommended dose schedule as single agent is 45 mg/m2 orally given either on a single day or divided over 3 consecutive days, to be repeated every 3 or 4 weeks based on the haematological recovery.@EMA, May 2002@@@@@@The drug should not be given to patients with pre-existing bone marrow depression induced by previous drug therapy or radiotherapy unless the benefit warrants the risk. Pre-existing heart disease and previous therapy with anthracyclines, especially at high cumulative doses, or other potentially cardiotoxic agents are co-factors for increased risk of idarubicin-induced cardiac toxicity: the benefit to risk ratio of idarubicin therapy in such patients should be weighed before starting treatment with Zavedos. In absence of sufficient data, the use of oral idarubicin is not recommended in patients with prior total body irradiation or bone marrow transplantation.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@IDARUBICIN HCL@@@@@IDARUBICIN HCL||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@ZAVEDOS@@@@@ZAVEDOS||||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@@@@@@@@@@@ADVANCED@@@@@@@@@@1.6@m²@Invalid Average Duration of Use@@@@@@@@@1@1.299@69.12@@@@@@@@@@@@6.91@24.5@@mg/m²@45@1@@@@@@@@@@@7/28/2017@69.12@69.12@4.46E+15@CAPSULE@GB£@@@@@@@@10@MG@10 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14921966@Onco@@@@@300f1037ntsdm@@@@@@Tamoxifen compared to ovarian ablation@@L02BA01@L02B@YES@LONDON, UNITED KINGDOM@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14921966@@@NO@@@NO REVIEW@@@@60%@@@@N/A@Adults: The recommended daily dose of tamoxifen is normally 20 mg. No additional benefit, in terms of delayed recurrence or improved survival in patients, has been demonstrated with higher doses. Substantive evidence supporting the use of treatment with 30–40 mg per day is not available, although these doses have been used in some patients with advanced disease.@EMA, 1 January 1998@1/1/1998@@@@@Menstruation is suppressed in a proportion of premenopausal women receiving Nolvadex for the treatment of breast cancer. An increased incidence of endometrial changes including hyperplasia, polyps, cancer and uterine sarcoma (mostly malignant mixed Mullerian tumours), has been reported in association with Nolvadex treatment. The underlying mechanism is unknown but may be related to the oestrogenlike effect of Nolvadex. Any patient receiving or having previously received Nolvadex who report abnormal gynaecological symptoms, especially vaginal bleeding, or who presents with menstrual irregularities, vaginal discharge and symptoms such as pelvic pain or pressure should be promptly investigated.@LABEL@No@@@@@III; METASTATIC BREAST CANCER@APPROVED@@NO REVIEW@SNS@The objective RR, time to treatment failure, and survival were similar with both treatments. In an overview analysis of survival data from the 3 studies, the hazard ratio for death (tamoxifen/ovarian ablation) was 1.00. Elevated serum and plasma oestrogens have been observed in premenopausal women receiving tamoxifen, but the data from the randomized studies do not suggest an adverse effect of this increase. A limited number of premenopausal patients with disease progression during tamoxifen therapy responded to subsequent ovarian ablation.@@@@@MONO@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@NOLVADEX@@@@@NOLVADEX||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RESPONSE RATE@@@@@@@@@@@@@@@PROSPECTIVE@RANDOMISED@@@@@@Invalid Factory Price@@@@@@@@@500@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@EURO@@@@@@@@20@MG@20 MG@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14922543@Onco@@@@@300f1014ntsdm@@@@@@Casodex as immediate hormonal therapy or adjuvant to radical prostatectomy or radiotherapy.@@L02BB03@L02B@NO@LONDON, UNITED KINGDOM@@@Casodex is a non-steroidal antiandrogen, devoid of other endocrine activity. It binds to androgen receptors without activating gene expression, and thus inhibits the androgen stimulus. Regression of prostatic tumours results from this inhibition. Clinically, discontinuation of Casodex can result in antiandrogen withdrawal syndrome in a subset of patients. Casodex is a racemate with its antiandrogenic activity being almost exclusively in the (R)-enantiomer.@@14922543@In patients with locally advanced prostate cancer (T3-T4, any N, M0; T1-T2, N+, M0), Casodex 150 mg is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. Casodex 150 mg is also indicated for the management of patients with locally advanced, non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.@@NO@@@NO REVIEW@@@@100%@@@@8113@The dosage is one 150 mg tablet to be taken orally once a day. Casodex 150 mg should be taken continuously for at least 2 years or until disease progression.@@@@@@@Casodex 150 mg should be used with caution in patients with moderate to severe hepatic impairment.@@No@@@@@III; THREE TRIALS@APPROVED@@Unrestricted reimbursement.@RAMQ@27.4% and 30.7% of all Casodex and placebotreated patients, respectively, had experienced objective disease progression. In the subgroup of locally advanced prostate cancer who did not receive treatment with radical prostatectomy or radiotherapy, immediate therapy with Casodex 150 mg significantly reduced the risk of objective disease progression (Hazard Ratio (HR)= 0.60; 95% CI 0.49 to 0.73). PFS events was 57.6% in the Casodex watchful waiting group, compared to 68.9% in the placebo group, whilst deaths were 49% and 57% respectively.@@@@@@BICALUTAMIDE@@@@@BICALUTAMIDE||||@PHARMEL@@@@@PHARMEL||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@PHL-BICALUTAMIDE@GENERIC@@@@PHL-BICALUTAMIDE|GENERIC|||@Hormone Antagonist@Anti-androgen@@@@Hormone Antagonist|Anti-androgen|||@DISEASE-FREE SURVIVAL@@@@@@@@@@LOCALLY ADVANCED@@@@@PLACEBO-CONTROLLED@DOUBLE-BLIND@@@@@@Invalid Factory Price@@@@@@@@@30@0.7881@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@C$@@@@@@@@150@MG@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
15117280@Onco@@@@@300f1014ntsdm@@@@@@Drug: treatment crizotinib 250mg orally continuous twice daily dosingDrug: treatment pemetrexed 500mg/m2 IV day 1 plus cisplatin 75mg/m2 IV day 1 every 21 days OR pemetrexed 500mg/m2 IV day 1 plus carboplatin AUC 5 or 6 day 1 every 21 days investigator's choice@@L01XE16@L01X@@NEW YORK, NEW YORK@11/1/2013@@@@15117280@XALKORI is indicated for the first-line treatment of adults with anaplastic lymphoma kinase(ALK)-positive advanced non-small cell lung cancer (NSCLC).@@@3-Feb-14@2/3/2014@NO REVIEW@@@@@Acquired through takeover of Pharmacia Corp., which acquired it from Sugen@FIRST-LINE@NCT01154140@343@The recommended dose of XALKORI is 250 mg orally, twice daily until disease progression or no longer tolerated by the patient. The recommended dose of XALKORI in patients with severe renal impairment (creatinine clearance <30 mL/min) not requiring dialysis is 250 mg orally, once daily.@Health Canada, 10 May 2012@5/10/2012@@@@1/1/2011@@A8081014, 2010-021336-33, XALCORI@No@@Proven diagnosis of locally advanced not suitable for local treatment, recurrent and metastatic non-squamous cell carcinoma of the lung - Positive for translocation or inversion events involving the ALK gene locus- No prior systemic treatment for locally advanced or metastatic disease; Patients with brain metastases only if treated and neurologically stable with no ongoing requirement for corticosteroids - Evidence of a personally signed and dated informed consent document and willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures including completion of patient reported outcome [PRO] measures - 18 years of age or older with the exception of India which has an upper age limit of 65 years old@(ALK)-positive@@@APPROVED@@@RAMQ@@@@@@MONO@CRIZOTINIB@@@@@CRIZOTINIB||||@PFIZER@@@@@PFIZER||||@World@@@@@World|||||||||@NSCLC@@@@@NSCLC|||||||||@XALKORI@@@@@XALKORI||||@PDGF@@@@@PDGF||||@OVERALL SURVIVAL@Objective response rate@DURATION OF RESPONSE@@@OBJECTIVE RESPONSE RATE@@@@@ADVANCED@@@@@RANDOMIZED@PARALLEL ASSIGNMENT@OPEN LABEL@@@1@1@107748.68@@@10.9@month@10.9 month@107748.68@107748.68@325@60@0.7881@7800@@@@@@@@@@@@0.65@1@@mg@500@1@@@@@@@@@@@7/19/2017@130@130@238425660@CAPSULE@C$@@@@@@@@200@MG@200 MG@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
16161177@Onco@@@@@@@@@@@Rovalpituzumab Tesirine, Experimental, Rovalpituzumab Tesirine 0.3 mg/kg IV infusionRovalpituzumab Tesirine followed by Cisplatin, Etoposide, Experimental, Rovalpituzumab Tesirine 0.3 mg/kg IV infusion followed by Cisplatin 80 mg/m2 and Etoposide 100 mg/m2 IV infusionRovalpituzumab Tesirine with Cisplatin, Etoposide, Experimental, Cisplatin 80 mg/m2 and Etoposide 100 mg/m2 IV infusion and Rovalpituzumab Tesirine 0.1 mg/kg IV infusionRovalpituzumab Tesirine following Cisplatin, Etoposide, Experimental, Cisplatin 80 mg/m2 and Etoposide 100 mg/m2 IV infusion followed by Rovalpituzumab Tesirine 0.3 mg/kg IV infusion@@@@@UNITED STATES@10/1/2020@@@@16161177@A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Delta-Like Protein 3-Expressing Extensive Stage Small Cell Lung Cancer@Both@@@@@Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC).@@@@@FIRST-LINE@NCT02819999@94@@@@@@@10/1/2016@@SCRX001-004@@@Inclusion Criteria:  -  Age ≥ 18 years with histologically- or cytologically-confirmed, extensive-stage, chemotherapy-naïve SCLC  -  DLL3-expressing SCLC based on central immunohistochemistry (IHC) assessment. Positive is defined as staining in ≥50% of tumor cells.  -  Eastern Cooperative Oncology Group performance status of 0 or 1.  -  Minimum life expectancy of at least 12 weeks.  -  Recovery to Grade 1 of any clinically significant toxicity (excluding alopecia) prior to initiation of study drug.  -  Satisfactory laboratory parameters within defined parameters (ANC, platelet count, Hb, total bilirubin, ALT, AST and GFR)  -  Subjects with a history of CNS metastases must have completed definitive treatment prior to first dose of study treatment, off or on a stable dose of corticosteroids  -  Use of effective contraception method during and for 1 year following study drug dosing if female of childbearing potential or sexually active male@DLL3@ADULTS@Phase 1@I@@@@@@@@@COMBO@ROVALPITUZUMAB TESIRINE@CISPLATIN@ETOPOSIDE@@@ROVALPITUZUMAB TESIRINE|CISPLATIN|ETOPOSIDE||@STEMCENTRX@@@@@STEMCENTRX||||@@@@@@|||||||||@SCLC@@@@@SCLC|||||||||@ROVA-T@@@@@ROVA-T||||@Other@@@@@Other||||@Dose limiting toxicities (DLT) of rovalpituzumab tesirine when administered as monotherapy, in series or in combination with frontline chemotherapy to subjects with delta-like protein 3 (DLL3)-expressing extensive-stage small cell lung cancer (SCLC)@Treatment emergent adverse events (TEAEs)@Incidence of subjects with CTCAE Grade >2 laboratory abnormalities@@@BEST OVERALL RESPONSE RATE@Duration of response (DOR)@@@@EXTENSIVE@@@@@RANDOMIZED@SAFETY/EFFICACY STUDY@PARALLEL ASSIGNMENT@OPEN LABEL@TREATMENT@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14923392@Onco@@@@@300f1012ntsdm@@@@@@Tamoxifen compared to ovarian ablation@@L02BA01@L02B@YES@PETACH TIKVA, ISRAEL@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14923392@@@NO@@@NO REVIEW@@@@@@@@N/A@Adjuvant treatment of breast cancer, Adults (including elderly): The recommended dose is 20mg, given either in divided doses twice daily or as a single dose once daily. The current recommended treatment duration is five years; however the optimum duration has not been established. Treatment of locally advanced or metastatic breast cancer: The recommended dose is 20mg to 40mg, given either in divided doses twice daily or as a single dose once daily.@@@@@@@Women should be informed of the potential risks to the foetus, should they become pregnant whilst taking tamoxifen; or within two months of cessation of therapy. A number of secondary primary tumours, occurring at sites other than the endometrium and the opposite breast, have been reported in clinical trials, following the treatment of breast cancer patients with tamoxifen. No causal link has been established and the clinical significance of these observations remains unclear.@LABEL@No@@@@@III METASTATIC BREAST CANCER@APPROVED@@@GKV@The objective RR, time to treatment failure, and survival were similar with both treatments. In an overview analysis of survival data from the 3 studies, the hazard ratio for death (tamoxifen/ovarian ablation) was 1.00. Elevated serum and plasma oestrogens have been observed in premenopausal women receiving tamoxifen, but the data from the randomized studies do not suggest an adverse effect of this increase. A limited number of premenopausal patients with disease progression during tamoxifen therapy responded to subsequent ovarian ablation.@@@@@ADJUVANT@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@TEVA PHARMACEUTICAL@@@@@TEVA PHARMACEUTICAL||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@TAMOX-TEVA@@@@@TAMOX-TEVA||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RESPONSE RATE@@@@@@@@@@@@@@@PROSPECTIVE@RANDOMISED@@@@@@Invalid Factory Price@@@@@@@@@30@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@EURO@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16520745@Onco@@@@@@@@@@@ONO-4538 group, Experimental, ONO-4538: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).Chemotherapy: S-1 Therapy or CapeOX Therapy is determined by the investigator.S-1 therapy(maximum 1 year):Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days offCapeOX Therapy(maximum 6 months):Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.Placebo group, Placebo Comparator, Placebo: Placebo solution intravenously for 30 min in every 3 weeks (maximum 1 year).Chemotherapy: S-1 Therapy or CapeOX Therapy is determined by the investigator.S-1 therapy(maximum 1 year):Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days offCapeOX Therapy(maximum 6 months):Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.@@L01XC17@L01X@@OSAKA, JAPAN@6/1/2021@@Nivolumab is an investigational, fully-human IgG4 anti-PD-1 receptor blocking monoclonal antibody that binds to the checkpoint receptor PD-1 (programmed death-1) expressed on activated T cells. Nivolumab inhibits the binding of PD-1 with its tumor-express@@16520745@A Multicenter, Double-blind, Randomized Study in Patients With Gastric Cancer Undergoing Postoperative Adjuvant Chemotherapy@Both@@@@@@@@@@FIRST-LINE@NCT03006705@700@@@@@@@12/1/2016@@ONO-4538-38@@@Patients with histologically confirmed adenocarcinoma of the stomach  -  Patients without a remnant cancer (R0) who have undergone gastrectomy  -  Gastric carcinoma according to the stage classification of AJCC/UICC TNM Classification, 7th Edition on the basis of overall postoperative findings  -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1@@ADULTS@Phase 3@III@@@@@@@@@MONO@NIVOLUMAB@@@@@NIVOLUMAB||||@ONO PHARMACEUTICALS@BRISTOL-MYERS SQUIBB@@@@ONO PHARMACEUTICALS|BRISTOL-MYERS SQUIBB|||@Japan@@@@@Japan|||||||||@GIST@@@@@GIST|||||||||@OPDIVO@@@@@OPDIVO||||@mAb@Human@PD-1 Inhibitor@@@mAb|Human|PD-1 Inhibitor||@Relapse-free survival (RFS)@@@@@Overall survival (OS)@3-year OS rate@@@@@@@@@Randomized@Safety/Efficacy Study@Parallel Assignment@Double Blind (Subject,  Caregiver,  Investigator,  Outcomes Assessor)@Treatment@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921414@Onco@@@@@@@@@@@ARM1: Amrubicin 45mg/m2 IV days 1, 2 3 of each 21-day cycle until disease progression; Amrubicin 40mg/m2 IV days 1, 2, 3 plus cisplatin 60mg/m<2> day 1 of each 21-day cycle until disease progression.ARM2: Above schedule versus Amrubicin 40mg/m2 IV days 1, 2, 3 plus Cisplatin 60mg/m2 day 1 of each 21-day cycle until disease progression and cisplatin 75mg/m2 IV day 1 plus etoposide 100mg/m2 IV day 1 and 200mg/m2 orally days 2, 3 or etoposide 100mg/m2 IV days 1, 2, 3 of each 21-day cycle until disease progressionARM3: Cisplatin 75mg/m<2> IV day 1 plus etoposide 100mg/m2 IV day 1 and 200mg/m2 orally days 2, 3 or etoposide 100mg/m2 IV days 1, 2, 3 of each 21-day cycle until disease progression. [clinicaltrials.gov]@@-@-@-@SUMMIT, NEW JERSEY@@@Amrubicin is a third-generation, synthetic anthracycline analogue that has demonstrated substantial clinical efficacy in the treatment of small cell lung cancer. Amrubicin is a potent topoisomerase II inhibitor and is being studied as a single agent and in combination with anti-cancer therapies for a variety of solid tumors, including lung cancer. Amrubicin is currently approved and marketed in Japan for the treatment of lung cancer by Nippon Kayaku, a Japanese pharmaceutical firm focused on oncology, which licensed Japanese marketing rights from Dainippon Sumitomo Pharma, the original developer of the therapy. Dainippon Sumitomo Pharma also licensed the North American and European Union rights of Amrubicin to Pharmion Corporation, which was acquired by Celgene Corporation in March 2008. Amrubicin has been granted orphan-drug designation for the treatment of small cell lung cancer in both the U.S. and European Union.@@14921414@Amrubicin With or Without Cisplatin Versus Etoposide-Cisplatin for Extensive Stage Small Cell Lung Cancer@@-@-@@NO REVIEW@@@November 2006-March 2010@-@Nippon Kayaku licensed Japanese rights from Dainippon Sumitomo; Pharmion acquired North American and European rights to Calsed through takeover of Cabrellis in November 2006.@FIRST-LINE@NCT00388960@81@-@-@@@FDA orphan drug designation. [Celgene, 25.03.2008]@@@-@EORTC 08062@@-@No prior systemic chemotherapy for small cell lung cancer @@@II@II@@-@-@Trial registered [Celgene, 13.10.2006]@-@@@@BOTH@AMRUBICIN@CISPLATIN@@@@AMRUBICIN|CISPLATIN|||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@SCLC@@@@@SCLC|||||||||@CALSED@@@@@CALSED||||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@RESPONSE RATE@RECIST@@@@@@@@@EXTENSIVE@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
16159506@Onco@@@@@300f1018ntsdm@@@@@@Experimental: crizotinib 250mg orally continuous twice daily dosing Active Comparator: pemetrexed 500mg/m2 IV day 1 plus cisplatin 75mg/m2 IV day 1 every 21 days OR pemetrexed 500mg/m2 IV day 1 plus carboplatin AUC 5 or 6 day 1 every 21 days investigator's choice@@L01XE16@L01X@@NEW YORK, NEW YORK@12/1/2014@@@@16159506@XALKORI is indicated for the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).@@NO@14-Nov@@NO REVIEW@@@@100%@Acquired through takeover of Pharmacia Corp., which acquired it from Sugen@SECOND-LINE@NCT00932893@347@The recommended dose schedule of XALKORI is 250 mg taken orally twice daily. Continue treatment as long as the patient is deriving clinical benefit from therapy.@TGA, 27 September 2013@9/27/2013@7/1/2015@Yes@@9/1/2009@@PROFILE 1007@No@@Histologically or cytologically proven diagnosis of non-small cell lung cancer positive for the ALK fusion gene (test provided by a central laboratory). Must have had disease progression after only one prior chemotherapy and that regimen but must have included one platinum drug@(ALK)-positive@@III@APPROVED@@@PBS@@@@@@MONO@CRIZOTINIB@@@@@CRIZOTINIB||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@XALKORI@@@@@XALKORI||||@PDGF@@@@@PDGF||||@PROGRESSION-FREE SURVIVAL@@@@@OBJECTIVE RESPONSE RATE@OVERALL SURVIVAL@@@@ADVANCED@@@@@OPEN-LABEL@RANDOMISED@PARALLEL ASSIGNMENT@@@1@1@55649.02235@@@7.7@month@7.7 month@55649.02@55649.02@237.61@60@0.779@7128.3@7275.17@7198.24@@@@@@@@@@0.48@1@@mg@500@1@@@@@@@@@@@8/1/2017@118.81@118.81@3616-0554-GE-PF@CAPSULE@A$@@@@@@@@250@MG@250 MG@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14917894@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Actiq for breakthrough cancer pain@@N02AB03@N02A@YES@FRAZER, PENNSYLVANIA@@@Fentanyl is a pure opioid agonist whose principal therapeutic action is analgesia. Other members of the class known as opioid agonists include substances such as morphine, oxycodone, hydromorphone, codeine, and hydrocodone.@@14917894@Indicated only for management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.@@NO@@@NO REVIEW@@@@@Licensed from Kyowa Hakko; supplied by Abbott. Acquired through US$444 mil. takeover of Anesta Corp in 2000.@@@130@Initial dose: 200 mcg. Prescribe an initial supply of six 200 mcg units.@FDA, 4 November 1998@11/4/1998@@@@@Must not be used in opioid non-tolerant patients; fentanyl is a Schedule II controlled substance; life-threatening hypoventilation can occur at any dose; contraindicated in acute or post-operative pain@LABEL@No@SEPTEMBER 2006 (EXCLUSIVITY; FEBRUARY 2010)@@@@III@APPROVED@@Prior authorisation; specialty drug; quantity limit 120 for 30 days@MEDICARE@92 of 130 patients (71% achieved a successful dose during titration. The most successful doses were 400mcg (21%) and 800mcg (20%).@@@@@MONO@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@CEPHALON@@@@@CEPHALON||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@ACTIQ@@@@@ACTIQ||||@Opioid Analgesic@@@@@Opioid Analgesic||||@RESPONSE RATE@MAXIMUM TOLERATED DOSE@@@@@@@@@@@@@@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@30@1@5064@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/2/2017@168.8@168.8@63459-0516-30@LOZENGE@US$@@@@@@@@1600@MCG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16384751@Onco@@@@@300f1014ntsdm@@@@@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384751@Indicated for the treatment of adult with Ph+ CML in blast crisis.@@EXPENSIVE ITEM APPENDIX III (LIMITED WHOLESALE MARGIN)@@@NO REVIEW@@@@@@@@260@The recommended dose of Glivec is 600 mg/day for adult patients in blast crisis.@@@@Yes@@@@Study 0102@No@@@ADULT@@@APPROVED@@@RAMQ@@@@@@MONO@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@GLEEVEC@@@@@GLEEVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@BLAST PHASE@@@@@@@@@@1@1@29279.00487@@@6.05@month@6.05 month@29279@29279@159.11@30@0.7881@3182.21@@@@@@@@@@@@0.27@1@@mg@600@1@@@@@@@@@@@7/19/2017@106.07@106.07@225328330@TABLET@C$@@@@@@@@400@MG@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14922828@Onco@@@@@300f1018ntsdm@@@@@@Romidepsin with Velcade@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@@@The cyclic peptide structure of romidepsin is unique among members of a new class of cancer drugs known as histone deacetylase, or HDAC, inhibitors. HDAC inhibition has been shown to increase acetylation of histones and other proteins, which is associated with anti-tumor activity including chromatin remodeling, tumor suppressor gene transcription, growth inhibition, and apoptosis. Preclinical studies suggest that romidepsin is among the most potent inhibitors of both Class I and Class II HDACs. @@14922828@-@@-@-@@NO REVIEW@@@@-@Global rights licensed from Fujisawa (Astellas) in April 2004@-@NCT00431990@25@-@-@@@Orphan Drug Designation from the  Therapeutics Goods Administration, Australia's regulatory agency for medical drugs and devices,for the treatment of patients with peripheral T-cell lymphoma and cutaneous T-cell lymphoma who have previously received systematic therapy.@@11/1/2006@-@-@@-@-@@@I/II@II@@-@-@Preliminary results on the first 10 evaluable patients: an overall response rate of 80% (8/10) was reported, with one complete response, six partial responses, and one minor response. The most common adverse events reported included nausea, fatigue, constipation/diarrhea, and neuropathy. The most common grade 3/4 event was thrombocytopenia. The phase I dose-escalation portion of the trial has been completed and the maximum tolerated dose was determined to be 1.3 mg/m2 of bortezomib, 20 mg of dexamethasone and 10 mg/m2 of romidepsin. Additional patients are being accrued at the maximum tolerated dose to assess clinical activity. SOURCE: ASH December 2007@-@@@@COMBO@ROMIDEPSIN@BORTEZOMIB@@@@ROMIDEPSIN|BORTEZOMIB|||@GLOUCESTER PHARMACEUTICALS@@@@@GLOUCESTER PHARMACEUTICALS||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@ISTODAX@VELCADE@@@@ISTODAX|VELCADE|||@HDAC@@@@@HDAC||||@TOXICITY@@@@@@@@@@RELAPSED@@@@@NON-RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14922107@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@BASEL, SWITZERLAND@1/1/2011@@The active substance in Afinitor, everolimus, is an anticancer medicine, which acts by blocking a protein called ‘mammalian target of rapamycin' (mTOR). In the body, everolimus attaches to a protein that is found inside cells to make a ‘complex'. This complex then blocks mTOR. Since mTOR is involved in the control of cell division and the growth of blood vessels, Afinitor prevents the division of cancer cells and reduces their blood supply. This slows down the growth and spread of kidney cancer.@@14922107@Combo after aromatase inhibitor failure@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00570921@44@-@-@@@EMEA issued positive opinion to grant Orphan Drug status for everolimus to treat neuroendocrine gastroenteropancreatic tumours@@1/1/2008@-@BRE-43-NP@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@EVEROLIMUS@FULVESTRANT@@@@EVEROLIMUS|FULVESTRANT|||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@AFINITOR@RAD-001@FASLODEX@@@AFINITOR|RAD-001|FASLODEX||@Immunotherapy@Immunosuppressive@mTOR Inhibitor@@@Immunotherapy|Immunosuppressive|mTOR Inhibitor||@TIME TO PROGRESSION@@@@@@@@@@METASTATIC@ADVANCED@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917728@Onco@@@@@300f1020ntsdm@@@@@@NO LABELLED TRIAL@@L01XX11@L01X@NO@NEW YORK, NEW YORK@@@Estramustine is a chemical compound of oestradiol and nitrogen mustard. It is effective in the treatment of advanced prostatic carcinoma. Estramustine has a dual mode of action. The intact molecule acts as an anti-miotic agent; after hydrolysis of the carbamate ester, the metabolites act to bridge the released oestrogens and exert an anti-gonadotrophic effect. The low level of clinical side effects may be due to the fact that estramustine binds to a protein present in the tumour tissue, so resulting in accumulation of the drug at the target site. Estracyt also has weak oestrogenic and anti-gonadotrophic properties. Estramustine causes little or no bone marrow depression at usual therapeutic dosage. Estramustine is effective in patients who have not previously received drug therapy, as well as in those who have shown no response to conventional hormone treatment.@@14917728@Carcinoma of the prostate, especially in cases unresponsive to, or relapsing after, treatment by conventional oestrogens (stilboestrol, polyestradiol phosphate etc.) or by orchidectomy.@@NO@-@@NO REVIEW@@@@100%@-@-@-@-@Dosage range may be from 1 to 10 capsules a day by mouth. The capsules should be taken not less than 1 hour before or 2 hours after meals. The capsules should not be taken with milk or milk products. Standard starting dosage is 4-6 capsules a day in divided doses with later adjustment according to response and gastrointestinal tolerance.@N/A@@@-@@@Use with caution in patients with moderate to severe bone marrow depression, thrombophlebitis, thrombosis, thromboembolic disorders, cardiovascular disease, coronary artery disease and congestive heart failure.@NO LABELLED TRIAL@No@-@-@@@-@APPROVED@@@SSN@NO LABELLED TRIAL@-@@@@-@ESTRAMUSTINE PHOSPHATE SODIUM@@@@@ESTRAMUSTINE PHOSPHATE SODIUM||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@ESTRACYT@@@@@ESTRACYT||||@Oestrogen@Nitrogen Mustard Analogue@@@@Oestrogen|Nitrogen Mustard Analogue|||@-@@@@@@@@@@REFRACTORY@@@@@-@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@40@1.1229@40.01@66.03@41.81@@@@@@@@@@@@@@@@@@@@@@@@@@6/7/2017@1@1@24397010@CAPSULE@EURO@@@@@@@@140@MG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
16510838@Onco@@@@@300f1012ntsdm@@@@@@Experimental: Arm A. Given until objective progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent, whichever occurs first.Interventions: Palbociclib + FulvestrantActive Comparator: Arm B. Given until objective progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent, whichever occurs first. Interventions: Placebo + Fulvestrant@@L01XE33@L01X@@NEW YORK, NEW YORK@12/1/2014@@@@16510838@IBRANCE is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in women who have received prior endocrine therapy.@Female@NA@18-May-17@5/18/2017@NO REVIEW@@@@0%@@SECOND-LINE@NCT01942135@521@The recommended dose is 125 mg of palbociclib once daily for 21 consecutive days followed by 7 days off treatment (Schedule 3/1) to comprise a complete cycle of 28 days. The treatment withIBRANCE should be continued as long as the patient is deriving clinical benefit from therapy or until unacceptable toxicity occurs.When coadministered with palbociclib, the recommended dose of fulvestrant is 500 mg administered intramuscularly on Days 1, 15, 29, and once monthly thereafter. Please refer to the Summary ofProduct Characteristics of fulvestrant. Prior to the start of treatment with the combination of palbociclib plus fulvestrant, and throughout its duration, pre/perimenopausal women should be treatedwith LHRH agonists according to local clinical practice.@EMA, 9 November 2016@11/9/2016@12/1/2016@No@@9/1/2013@@A5481023, 2013-002580-26@No@@@@ADULTS@Phase 3@APPROVED@@18 May 2017: no additional benefit [G_BA, https://www.g-ba.de/downloads/39-261-2947/2017-05-18_AM-RL-XII_Palbociclib_D-264.pdf]@@@@@@@COMBO@PALBOCICLIB@FULVESTRANT@@@@PALBOCICLIB|FULVESTRANT|||@PFIZER@@@@@PFIZER||||@World@@@@@World|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@IBRANCE@FASLODEX@@@@IBRANCE|FASLODEX|||@TK Inhibitor@@@@@TK Inhibitor||||@PROGRESSION-FREE SURVIVAL@@@@@OVERALL SURVIVAL@@@@@ADVANCED@METASTATIC@@@@RANDOMIZED@PARALLEL ASSIGNMENT@DOUBLE BLIND@@@1@1@53288.95347@@@11.2@month@11.2 month@53288.95@53288.95@156.43@21@1.1511@4380.01@5425.89@4418.51@@@@@@@@@@1.67@28@@mg@125@21@@@@@@@@@@@8/1/2017@208.57@208.57@11670092@HARD CAPSULE@EURO@@@@@@@@125@MG@125 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14918205@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01DB07@L01D@YES@CANONSBURG, PENNSYLVANIA@@@Although its mechanism of action has not been determined, mitoxantrone is a DNA-reactive agent. It has a cytocidal effect on proliferating and non-proliferating cultured human cells, suggesting activity against rapidly proliferating and slow-growing neoplasms.@@14918205@Mitoxantrone is indicated in the treatment of metastatic breast cancer, non-Hodgkin's lymphoma and adult acute non-lymphocytic leukaemia. Mitoxantrone has also been used in the palliation of non-resectable primary hepatocellular carcinoma.@@NO@5-May@@NO REVIEW@@@@@Acquired through takeover of generics unit of Merck KGaA@@@@HRPC: based on data from two Phase 3 comparative trials of mitoxantrone injection plus corticosteroids versus corticosteroids alone, the recommended dosage of mitoxantrone is 12 to 14 mg/m2 given as a short intravenous infusion every 21 days.@Jan-85@@@@@@HRPC: functional cardiac changes such as decreases in LVEF and congestive heart failure may occur in patients with HRPC treated with mitoxantrone. In a randomised comparative trial of mitoxantrone plus low-dose prednisone vs. low-dose prednisone, 7 of 128 patients (5.5 %) treated with mitoxantrone had a cardiac event defined as any decrease in LVEF below the normal range, CHF (n = 3), or myocardial ischemia. Two patients had a prior history of cardiac disease. The total mitoxantrone dose administered to patients with cardiac effects ranged from > 48 to 212 mg/m2. Among 112 patients evaluable for safety on the mitoxantrone + hydrocortisone arm of the CALGB trial, 18 patients (19%) had a reduction in cardiac function, 5 patients (5%) had cardiac ischemia, and 2 patients (2%) experienced pulmonary edema. The range of total mitoxantrone doses administered to these patients is not available.@NO LABELLED TRIAL@No@@@@@@APPROVED@@1@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@MITOXANTRONE@@@@@MITOXANTRONE||||@MYLAN@@@@@MYLAN||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@GENERIC@@@@@GENERIC||||@Cytotoxic Antibiotic@Anthracycline@Topoisomerase II Inhibitor@@@Cytotoxic Antibiotic|Anthracycline|Topoisomerase II Inhibitor||@@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14919765@Onco@@@@@300f1037ntsdm@@@@@@Tamoxifen compared to ovarian ablation@@L02BA01@L02B@YES@@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14919765@@@NO@@@NO REVIEW@@@@90%@@@@N/A@Adults: The recommended daily dose of tamoxifen is normally 20 mg. No additional benefit, in terms of delayed recurrence or improved survival in patients, has been demonstrated with higher doses. Substantive evidence supporting the use of treatment with 30–40 mg per day is not available, although these doses have been used in some patients with advanced disease.@1-Apr-89@4/1/1989@@@@@Menstruation is suppressed in a proportion of premenopausal women receiving Nolvadex for the treatment of breast cancer. An increased incidence of endometrial changes including hyperplasia, polyps, cancer and uterine sarcoma (mostly malignant mixed Mullerian tumours), has been reported in association with Nolvadex treatment. The underlying mechanism is unknown but may be related to the oestrogenlike effect of Nolvadex. Any patient receiving or having previously received Nolvadex who report abnormal gynaecological symptoms, especially vaginal bleeding, or who presents with menstrual irregularities, vaginal discharge and symptoms such as pelvic pain or pressure should be promptly investigated.@LABEL@No@@@@@III; METASTATIC BREAST CANCER@APPROVED@@NO REVIEW@SNS@The objective RR, time to treatment failure, and survival were similar with both treatments. In an overview analysis of survival data from the 3 studies, the hazard ratio for death (tamoxifen/ovarian ablation) was 1.00. Elevated serum and plasma oestrogens have been observed in premenopausal women receiving tamoxifen, but the data from the randomized studies do not suggest an adverse effect of this increase. A limited number of premenopausal patients with disease progression during tamoxifen therapy responded to subsequent ovarian ablation.@@@@@MONO@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@PRASFARMA@@@@@PRASFARMA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GENERIC@@@@@GENERIC||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RESPONSE RATE@@@@@@@@@@@@@@@PROSPECTIVE@RANDOMISED@@@@@@Invalid Factory Price@@@@@@@@@60@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@EURO@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
15357574@Onco@@@@@300f1037ntsdm@@@@@@Enzalutamide 160 mg orally per day@@L02BB04@L02B@@SAN FRANCISCO, CALIFORNIA@11/1/2012@@XTANDI is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.@@15357574@Treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy@Male@YES@1-Dec-14@12/1/2014@NO REVIEW@@@@90%@@SECOND-LINE@NCT00974311@1199@The recommended dose of XTANDI is 160 mg (four 40 mg capsules) administered orally once daily.@EMA, 24 June 2013@6/24/2013@11/11/2014@No@@9/1/2009@@CRPC2@No@@@@ADULTS@III@APPROVED@@@SNS@XTANDI-treated patients had a statistically-significant improvement in median overall survival compared to the placebo group: 18.4 months in the XTANDI group versus 13.6 months in the placebo group (P < 0.0001). XTANDI provided a 37% reduction in risk of death compared to placebo (hazard ratio = 0.631). [Medivation 31 August, 2012, http://investors.medivation.com/releasedetail.cfm?ReleaseID=703823 ]>>Trial registered [Medivation 9 September 2009]@The most common adverse reactions (= 5%) are asthenia/fatigue, back pain, diarrhea, arthralgia, hot flush, peripheral edema, musculoskeletal pain, headache, upper respiratory infection, muscular weakness, dizziness, insomnia, lower respiratory infection, spinal cord compression and cauda equina syndrome, hematuria, paresthesia, anxiety, and hypertension. Grade 3 and higher adverse reactions were reported among 47% of XTANDI-treated patients and 53% of placebo-treated patients.@@@@MONO@ENZALUTAMIDE@@@@@ENZALUTAMIDE||||@MEDIVATION INC@ASTELLAS@@@@MEDIVATION INC|ASTELLAS|||@@@@@@|||||||||@Prostate Cancer@HRPC@@@@Prostate Cancer|HRPC||||||||@XTANDI@@@@@XTANDI||||@Anti-androgen@@@@@Anti-androgen||||@OVERALL SURVIVAL@@@@@PROGRESSION FREE SURVIVAL@@@@@REFRACTORY@@@@@RANDOMISED@PARALLEL ASSIGNMENT@DOUBLE-BLIND@@@1@1@63772.14506@@@18.5@month@18.5 month@63772.15@63772.15@113.33@112@1.1511@3173.33@3358.41@3180.87@@@@@@@@@@0.71@1@@mg@160@1@@@@@@@@@@@8/4/2017@28.33@28.33@698718@SOFT CAPSULE@EURO@@@@@@@@40@MG@40 MG@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14991630@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@In Part 1, 26 to 62 patients will be enrolled depending on the number of dose levels reached during escalation. Patients in Part 1 will be divided into cohorts at various doses of HuMax-CD38, with each patient receiving 7 infusions. The first infusion will be followed by a 3 week period of safety monitoring with the following 6 doses to be given at weekly intervals. In Part 2, 60 patients will be enrolled with 20 patients in each of three dose levels. The highest dose in Part 2 will be the highest safe dose in Part 1 and two dose levels below. Patients in Part 2 will receive 6 infusions of HuMax-CD38 at weekly intervals. In each part of the study, patients will attend 12 follow up visits at 2 to 4 week intervals to assess safety and efficacy and will be followed every 12 weeks thereafter until disease progression, initiation of alternative treatment for MM or death for a maximum total of 2 years from study start.@@-@-@-@COPENHAGEN, DENMARK@@@HuMax-CD38 is a fully human IgG1,? antibody in development to treat multiple myeloma (MM).  HuMax-CD38 targets the CD38 molecule which is very highly expressed on the surface of multiple myeloma cells.  The antibody was selected from a large panel of antibodies based on its ability to bind to and kill multiple myeloma tumor cells. @@14991630@-@@-@-@@NO REVIEW@@@@-@Janssen acquires global rights to daratumumab) in August 2013@-@-@62@-@-@@@-@@12/1/2007@-@N/A@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@DARATUMUMAB@LENALIDOMIDE@DEXAMETHASONE@@@DARATUMUMAB|LENALIDOMIDE|DEXAMETHASONE||@GENMAB@JANSSEN@@@@GENMAB|JANSSEN|||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@HUMAX-CD38@@@@@HUMAX-CD38||||@mAb@Human@@@@mAb|Human|||@-@@@@@@@@@@-@@@@@OPEN-LABEL@DOSE ESCALATION@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920267@Onco@@@@@300f1014ntsdm@@@@@@@@L02BA01@L02B@YES@@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14920267@Nolvadex is indicated for: 1. The treatment of breast cancer. 2. The treatment of anovulatory infertility.@@NO@@@NO REVIEW@@@-@100%@@@@@Adults: The recommended daily dose of tamoxifen is normally 20 mg. No additional benefit, in terms of delayed recurrence or improved survival in patients, has been demonstrated with higher doses. Substantive evidence supporting the use of treatment with 30–40 mg per day is not available, although these doses have been used in some patients with advanced disease.@@@@@@@Menstruation is suppressed in a proportion of premenopausal women receiving Nolvadex for the treatment of breast cancer. An increased incidence of endometrial changes including hyperplasia, polyps, cancer and uterine sarcoma (mostly malignant mixed Mullerian tumours), has been reported in association with Nolvadex treatment. The underlying mechanism is unknown but may be related to the oestrogenlike effect of Nolvadex. Any patient receiving or having previously received Nolvadex who report abnormal gynaecological symptoms, especially vaginal bleeding, or who presents with menstrual irregularities, vaginal discharge and symptoms such as pelvic pain or pressure should be promptly investigated.@@No@@@@@@APPROVED@@Unrestricted reimbursement.@RAMQ@RESULTS PENDING@@@@@@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@GENPHARM@@@@@GENPHARM||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GEN-TAMOXIFEN@@@@@GEN-TAMOXIFEN||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@60@0.7881@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@C$@@@@@@@@10@MG@10 MG@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14923906@Onco@@@@@300f1010ntsdm@@@@@@Thyrogen alone@@H01AB01@H01A@NO@CAMBRIDGE, MASSACHUSSETTS@@@@@14923906@Indicated for use with serum thyroglobulin (Tg) testing with or without radioiodine imaging for the detection of thyroid remnants and well-differentiated thyroid cancer in post-thyroidectomy patients maintained on hormone suppression therapy (THST). Low risk patients with well-differentiated thyroid carcinoma who have undetectable serum Tg levels on THST and no rh TSH-stimulated increase of Tg levels may be followed-up by assaying rh TSH-stimulated Tg levels. Thyrogen is also indicated for pre-therapeutic stimulation in low risk post-thyroidectomy patients maintained on THST for the ablation of thyroid remnant tissue (in combination) with 100 mCi (3.7 GBq) radioactive iodine (131I).@@NO@@@NO REVIEW@@@@100%@@@@358@The recommended dose regimen is two doses of 0.9 mg thyrotropin alfa administered at a 24-hour interval by intramuscular injection only.@EMA, March 2000@@@@@@NONE@LABEL@No@@358 [WELL-DIFFERENTIATED THYROID CANCER]@@@III 2 STUDIES@APPROVED@@NO NICE REVIEW@NHS@Total positive withdrawal scans: 79% and 85% detected in first and second trials respectively, 13% and 15% not detected respectively.@@@@@MONO@THYROTROPIN ALFA@@@@@THYROTROPIN ALFA||||@GENZYME@@@@@GENZYME||||@@@@@@|||||||||@Thyroid Cancer@@@@@Thyroid Cancer|||||||||@THYROGEN@@@@@THYROGEN||||@Other@@@@@Other||||@DIAGNOSTIC@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@407.76@407.76@@2@1.299@583.04@@@@@@@@@@@@323.91@@@@@@@@@@@@@@@@7/28/2017@291.52@291.52@9.53E+15@POWDER FOR SOLUTION FOR INJECTION, VIAL@GB£@@@@@@@@0.9@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14925010@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Tarceva alternating with chemotherapy@@L01XE03@L01X@-@BASEL, SWITZERLAND@3/1/2010@@The mechanism of clinical antitumor action of erlotinib is not fully characterized. Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR). Specificity of inhibition with regard to other tyrosine kinase receptors has not been fully characterized. EGFR is expressed on the cell surface of normal cells and cancer cells.@@14925010@Tarceva in combination with chemotherapy@@-@-@@NO REVIEW@@@@-@>> Roche announces US$43.7 billion proposal to assume full control of Genentech. [Roche, 21 July 2008]      >> To meet FTC requirements for its merger with Warner Lambert, Pfizer was was forced to divest its stake in erlotinib in June 2000 back to OSI. In January 2001, Genentech and Roche licensed global co-development and commercialisation. [OSI, January 2001]       >> Pfizer acquired major stake in Oncogene (now OSI) to form a collaborative research programme. [Oncogene, 8.07.1986]@SECOND-LINE@NCT00642746@70@-@-@@@-@@3/1/2008@-@3753@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@ERLOTINIB HYDROCHLORIDE@@@@@ERLOTINIB HYDROCHLORIDE||||@ROCHE@GENENTECH@@@@ROCHE|GENENTECH|||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@TARCEVA@@@@@TARCEVA||||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@SAFETY@RECIST@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TABLET@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919395@Onco@@@@@300f1018ntsdm@@@@@@NO LABELLED TRIAL@@L01XA01@L01X@YES@NEW YORK, NEW YORK@@@Cisplatin has biochemical properties similar to those of bifunctional alkylating agents. The drug inhibits DNA synthesis by producing intrastrand and interstrand cross links in DNA. Protein and RNA synthesis are also inhibited to a lesser extent. Although the principal mechanism of action of cisplatin appears to be inhibition of DNA synthesis, other mechanisms, including enhancement of tumour immunogenicity, may be involved in its antineoplastic activity. Cisplatin also has immunosuppressive, radiosensitising, and antimicrobial properties.@@14919395@In combination with other chemotherapeutics and after appropriate surgigical and/or radiotherapeutic procedures, Platinol-AQ is indicated for for metastatic testicular tumours and metastatic ovarian tumours- an established combination for the latter is Platinol-AQ and Cytoxan. As a single agent, it is approved as a secondary therapy in patients with metastatic ovarian tumours refractory to standard chemotherapy but not received Platinol-AQ, and transitional cell bladder cancer which is no longer amenable to local treatments such as surgery and/or radiotherapy.@@NO@@@NO REVIEW@@@@100%@@@@@For monotherapy, the following two dosage regimens are recommended:- Single dose of 50 to 120 mg/m² body surface every 3 to 4 weeks; - 15 to 20 mg/m²/day for five days, every 3 to 4 weeks. If cisplatin is used in combination chemotherapy, the dose of cisplatin must be reduced. A typical dose is 20 mg/m² or more once every 3 to 4 weeks.@@@@@@@Platinol-AQ produces cumulative nephrotoxicity which is potentiated by aminoglycoside antibiotics. The serum creatinine, BUN, creatinine clearance, and magnesium, sodium, potassium, and calcium levels should be measured prior to initiating therapy, and prior to each subsequent course. At the recommended dosage, it should not be given more frequently than once every 3 to 4 weeks. Elderly patients may be more susceptible to nephrotoxicity. There are reports of severe neuropathies in patients in whom regimens are employed using higher doses or greater dose frequencies than those recommended. These neuropathies may be irreversible and are seen as paresthesias in a stocking-glove distribution, areflexia, and loss of proprioception and vibratory sensation. Elderly patients may be more susceptible to peripheral neuropathy. Loss of motor function has also been reported. Anaphylactic-like reactions have been reported within minutes of administration to patients with prior exposure, and have been alleviated by administration of epinephrine, corticosteroids, and antihistamines.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@PBS@NO LABELLED TRIAL@@@@@@CISPLATIN@@@@@CISPLATIN||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Ovarian Cancer@Testicular Cancer@Bladder Cancer@@@Ovarian Cancer|Testicular Cancer|Bladder Cancer|||||||@GENERIC@@@@@GENERIC||||@Platinum@@@@@Platinum||||@@@@@@@@@@@METASTATIC@ADVANCED@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@0.779@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@A$@@@@@@@@100@MG@1 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14922983@Onco@@@@@@@@@@@Part1:patients receive carboplatin(C) and placlitaxel(P) chemotherapy along with one of 2 doses of CDP791. Part2: 156 patients randomised to receive either C/P alone, or C/P plus one of 2 doses of CDP791. 6 cycles of chemotherapy with or without CDP791 will be administered.  @@-@-@-@BRUSSELS, BELGIUM@@@@@14922983@Locally advanced or metastic non-squamous NSCLC@@-@-@@NO REVIEW@@@STARTED IN AUGUST 2005 AND EXPECTED TO END IN DECEMBER 2007.@-@Celltech licensed wider-ranging PEG technology deal (also including Cimzia and CDP-484) from Inhale Therapeutics in October 2002. UCB terminated a 2005 co-development deal with ImClone in February 2007.@-@NCT00152477@165@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@A 17.7% improvement in the tumour response rate was observed between the higher dose 20mg/kg CDP791 plus chemotherapy treatment arm (37.7%) and the chemotherapy alone treatment arm (20.0%). The risk of tumour progression was reduced by 32% for patients receiving 20mg/kg CDP791 plus chemotherapy compared to chemotherapy alone.  Patients who received 20mg/kg CDP791 plus chemotherapy had a median time to progression of 30.1 weeks compared to 27.3 weeks for patients receiving chemotherapy alone.  While PROGRESSION-FREE SURVIVAL did not show a treatment effect in this exploratory Phase II trial, preliminary analysis of overall survival is sufficiently encouraging to support further development of the molecule. SOURCE: UCB, 31 March 2008@-@@@@COMBO@ANTIBODY FRAGMENT@CARBOPLATIN@PACLITAXEL@@@ANTIBODY FRAGMENT|CARBOPLATIN|PACLITAXEL||@UCB PHARMA@NEKTAR THERAPEUTICS@@@@UCB PHARMA|NEKTAR THERAPEUTICS|||@@@@@@|||||||||@Solid Tumours@NSCLC@@@@Solid Tumours|NSCLC||||||||@CDP-791@@@@@CDP-791||||@mAb@Humanised@VEGF@@@mAb|Humanised|VEGF||@OVERALL SURVIVAL@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@
14921108@Onco@@@@@@@@@@@980mg of zanolimumab once-weekly for 12 weeks@@-@-@-@COPENHAGEN, DENMARK@@@HuMax-CD4 is a high affinity human antibody that targets the CD4 receptor on T-lymphocytes. Genmab has run two Phase II studies using HuMax-CD4 to treat CTCL, one in early stage patients and the other for patients with advanced disease, both of which achieved positive results. Thirty-eight CTCL patients with MF, the most common form of CTCL, were treated in these studies. Genmab has US Orphan Drug designation for HuMax-CD4 to treat MF patients and is making plans for a pivotal study with HuMax-CD4 under an FDA Fast Track designation for patients who have failed available therapies.@@14921108@Non-cutaneous@@-@-@@NO REVIEW@@@@-@Genmab licensed global rights licensed to Merck Serono in August 2005, but regained in June 2007.@-@NCT00071084@21@-@-@@@-@@@-@Hx-CD4-008@@-@-@@@II@DISCONTINUED@@-@-@>> Development discontinued as part of a strategic review of Genmab's pipeline. Patient recruitment in CTCL was slow and the small market potential meant that Genmab did not consider this worth the investment. [Genmab, 8.10.2008]      >> Phase II data showed an objective tumour response in 5 patients, including 2 unconfirmed complete responses and 3 partial responses.@-@@@@MONO@ZANOLIMUMAB@@@@@ZANOLIMUMAB||||@GENMAB@MEDAREX@@@@GENMAB|MEDAREX|||@Sweden@@@@@Sweden|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@T-Cell Lymphoma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|T-Cell Lymphoma|||||||@HUMAX-CD4@@@@@HUMAX-CD4||||@mAb@Human@CD4@@@mAb|Human|CD4||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
15394364@Onco@@@@@300f1012ntsdm@@@@@@521 patients were randomised to treatment with Teysuno (25 mg/m2 orally twice daily for 21 days followed by a 7-day rest period) and cisplatin (75 mg/m2 intravenous infusion once every 4 weeks); and 508 patients were randomised to treatment with 5-FU (1000 mg/m2/24 hours as a continuous intravenous infusion on Days 1 through 5 repeated every 4 weeks) and cisplatin (100 mg/m2 as an intravenous infusion on Day 1 repeated every 4 weeks).@@L01BC53@L01B@@@@@Teysuno is an oral fluoropyrimidine anti-cancer medicinal product@@15394364@Indicated in adults for the treatment of advanced gastric cancer when given in combination with cisplatin@Both@@@@@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@1029@The recommended standard dose of Teysuno when administered in combination with cisplatin is25 mg/m2 (expressed as tegafur content) twice daily, morning and evening, for 21 consecutive daysfollowed by 7 days rest (1 treatment cycle). This treatment cycle is repeated every 4 weeks.@EMA, 14 March 2011@3/14/2011@@@@@@FLAGS@No@@@@ADULTS@III@APPROVED@@@GKV@@@@@@COMBO@GIMERACIL / OTERACIL / TEGAFUR@CISPLATIN@@@@GIMERACIL / OTERACIL / TEGAFUR|CISPLATIN|||@NORDIC PHARMA@@@@@NORDIC PHARMA||||@@@@@@|||||||||@Stomach Cancer@@@@@Stomach Cancer|||||||||@TEYSUNO@GENERIC@@@@TEYSUNO|GENERIC|||@Fluoropyrimidine@@@@@Fluoropyrimidine||||@OVERALL SURVIVAL@@@@@@@@@@ADVANCED@@@@@RANDOMIZED@CONTROLLED@OPEN-LABEL@@@1.75@m²@2001.67657@@@4.8@month@4.8 month@2001.68@2001.68@13.71@42@1.1511@131.62@177.39@136.46@@@@@@@@@@0.21@28@@mg/m²@50@21@@@@@@@@@@@8/1/2017@3.13@3.13@9391574@HARD CAPSULE@EURO@@@@@@@@15@MG@4.35 MG|11.8 MG|15 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14918891@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@L01CD01@L01C@-@SUMMIT, NEW JERSEY@@@Abraxane is an albumin-bound form of paclitaxel with a mean particle size of approximately 130 nanometers. Paclitaxel protein-bound particles for injectable suspension) is an antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. Paclitaxel induces abnormal arrays or “bundles” of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.@@14918891@Adjuvant treatment in node-positive breast cancer@@-@-@@NO REVIEW@@@@-@>>Celgene acquires Abraxis for US$2.9 billion [Celgene 30 June 2010 http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-newsArticle&ID=1442901&highlight= ]>> Abraxis BioScience has entered into an agreement with AstraZeneca to re-acquire the exclusive rights to market Abraxane in the United States. [Abraxis, 28.11.2008]       >> AstraZeneca paid US$200 mil to co-promote Abraxane in the U.S., whilst Abraxis bought AstraZeneca's anaesthetic/analgesia portfolio. India/certain Asia rights licensed to Biocon in August 2007.@-@-@N/A@-@ODAC REQUIRES NEW TRIAL TO SUPPORT APPROVAL IN THIS INDICATION IN SEPTEMBER 2006@@@-@@@-@N/A@@-@-@@@III@FILED@@-@-@N/A@-@@@@ADJUVANT@PACLITAXEL PROTEIN BOUND PARTICLES@@@@@PACLITAXEL PROTEIN BOUND PARTICLES||||@CELGENE@ABRAXIS@@@@CELGENE|ABRAXIS|||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@ABRAXANE@@@@@ABRAXANE||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@-@@@@@@@@@@-@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920988@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients receive p53 gene by intralesional injection on days 1 and 2. Patients also receive doxorubicin IV over 15 minutes followed 1 hour later by docetaxel IV over 1 hour on day 1. Treatment repeats every 3 weeks for up to 6 courses. After completion of chemotherapy, patients with a reasonable response undergo surgical resection. @@-@-@-@AUSTIN, TEXAS@@@Advexin therapy combines the p53 tumor suppressor with a non-replicating, non-integrating adenoviral delivery system we have developed and extensively tested. The p53 gene is one of the most potent members of a group of naturally-occurring tumor suppressors, which act to kill cancer cells, arrest cancer cell growth and protect cells from becoming cancerous. Introgen's clinical trial strategy for Advexin is to test it in a variety of life-threatening cancers for which there are no effective treatments. Introgen is seeking to register Advexin for the treatment of head and neck cancer and Li-Fraumeni Syndrome. Additional late stage clinical trials in breast and lung cancers will enable Introgen to add follow-on indications. @@14920988@Stage III/IV breast cancer Advexin with doxorubicin and docetaxel@@-@-@@NO REVIEW@@@@-@Introgen forms Gendux as a gene therapy subsidiary in the UK. [Introgen, 28.09.1998]@-@NCT00044993@UP TO 60 .@-@-@@@-@@@-@INTROGEN-201-010@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@CONTUSUGENE LADENOVEC@DOXORUBICIN@DOCETAXEL@@@CONTUSUGENE LADENOVEC|DOXORUBICIN|DOCETAXEL||@INTROGEN THERAPEUTICS@GENDUX@@@@INTROGEN THERAPEUTICS|GENDUX|||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@ADVEXIN@TAXOTERE@@@@ADVEXIN|TAXOTERE|||@Gene Therapy@@@@@Gene Therapy||||@RESPONSE RATE@@@@@@@@@@-@@@@@SINGLE-ARM@OPEN-LABEL@SINGLE-CENTRE@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916792@Onco@@@@@@@@@@@Patients are stratified according to number of positive nodes (1-3 vs 4-9 vs 10 or more), administration of hormonal therapy (tamoxifen vs anastrozole vs neither), surgery/radiotherapy (lumpectomy plus breast irradiation vs lumpectomy plus breast irradiation plus regional irradiation vs mastectomy without radiotherapy vs mastectomy with radiotherapy), paclitaxel schedule (every 3 weeks vs weekly), and participating center. Patients are randomized to one of two treatment arms.Arm I: Patients receive doxorubicin IV and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 4 courses. Approximately 3 weeks after the last course, patients receive paclitaxel IV over 3 hours every 21 days for 4 courses OR paclitaxel IV over 1 hour once weekly for 12 weeks (12 doses). Arm II: Patients receive chemotherapy as in arm I and trastuzumab (Herceptin) IV over 90 minutes on day 1 of the first course of paclitaxel. Trastuzumab is then administered IV over 30 minutes weekly for 51 weeks, beginning on day 8. SOURCE: clinicaltrials.gov@@-@-@-@BASEL, SWITZERLAND@@@Herceptin (trastuzumab) is a humanized IgG1 kappa monoclonal antibody that selectively binds with high affinity to the extracellular domain of the human epidermal growth factor receptor 2 protein, HER2. Trastuzumab is produced by recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary) culture containing the antibiotic gentamicin. Gentamicin is not detectable in the final product. The HER2 (or c-erbB2) proto-oncogene encodes a transmembrane receptor protein of 185 kDa, which is structurally related to the epidermal growth factor receptor. Herceptin has been shown, in both in vitro assays and in animals, to inhibit the proliferation of human tumor cells that overexpress HER2. Herceptin is a mediator of antibody-dependent cellular cytotoxicity (ADCC). In vitro, Herceptin-mediated ADCC has been shown to be preferentially exerted on HER2 overexpressing cancer cells compared with cancer cells that do not overexpress HER2@@14916792@Node-positive breast cancer@@-@-@@NO REVIEW@@@@-@Roche announces US$43.7 billion proposal to assume full control of Genentech. SOURCE: Roche, 21 July 2008@-@NCT00004067@2700@-@-@@@-@@2/1/2000@-@NSABP-B-31@@-@-@@@III@III@@-@-@Retrospective analysis showed no significant assocaiation between HER2 and ACTH. In 92 HER2 negative patients, 22% and 9% of patients on ACT and ACTH had disease progression (reaching statistical significance); 11% and 1% respectively died (also statistically significant).@-@@@@COMBO@TRASTUZUMAB@DOXORUBICIN@CYCLOPHOSPHAMIDE@PACLITAXEL@@TRASTUZUMAB|DOXORUBICIN|CYCLOPHOSPHAMIDE|PACLITAXEL|@ROCHE@GENENTECH@@@@ROCHE|GENENTECH|||@@@@@@|||||||||@Breast Cancer@HER2-@@@@Breast Cancer|HER2-||||||||@HERCEPTIN@@@@@HERCEPTIN||||@mAb@Humanised@TK Inhibitor@HER2@@mAb|Humanised|TK Inhibitor|HER2|@CARDIOTOXICITY@DISEASE-FREE SURVIVAL@@@@@@@@@-@@@@@RANDOMISED@ACTIVE CONTROL@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916226@Onco@@@@@300f1012ntsdm@@@@@@Actiq for breakthrough cancer pain@@N02AB03@N02A@YES@FRAZER, PENNSYLVANIA@@@Fentanyl is a pure opioid agonist whose principal therapeutic action is analgesia. Other members of the class known as opioid agonists include substances such as morphine, oxycodone, hydromorphone, codeine, and hydrocodone.@@14916226@Indicated only for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Patients considered opioid tolerant are those who are taking at least 60 mg of oral morphine/day, at least 25 mcg of transdermal fentanyl/hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer. This product must not be used in opioid non-tolerant patients because life-threatening hypoventilation could occur at any dose in patients not on a chronic regimen of opiates. September 2007: Dear Healthcare Professional letter issued to emphasise that it is not generic Actiq and ensure non-use in opioid non-tolerant patients or non-labelled indications.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@130@The initial dose of Actiq used should be 200 micrograms, titrating upwards as necessary through the range of available dosage strengths (200, 400, 600, 800, 1200 and 1600 micrograms). Patients should be carefully monitored until a dose is reached that provides adequate analgesia with acceptable side effects using a single dosage unit per episode of breakthrough pain. This is defined as the successful dose.@@@@@@@Must not be used in opioid non-tolerant patients; fentanyl is a Schedule II controlled substance; life-threatening hypoventilation can occur at any dose; contraindicated in acute or post-operative pain@LABEL@No@@@@@III@APPROVED@@@GKV@92 of 130 patients (71% achieved a successful dose during titration. The most successful doses were 400mcg (21%) and 800mcg (20%).@@@@@MONO@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@CEPHALON@@@@@CEPHALON||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@ACTIQ@@@@@ACTIQ||||@Opioid Analgesic@@@@@Opioid Analgesic||||@RESPONSE RATE@MAXIMUM TOLERATED DOSE@@@@@@@@@@@@@@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@30@1.1807@257.89@337.04@266.72@@@@@@@@@@@@@@@@@@@@@@@@@@8/15/2017@8.6@8.6@1525911@LOZENGE@EURO@@@@@@@@200@MCG@200 MCG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14922981@Onco@@@@@@@@@@@-@@-@-@-@BERLIN, GERMANY@@@Human G-CSF is a glycoprotein which regulates the production and release of functional neutrophils from the bone marrow. NEUPOGEN containing rmetHuGCSF (filgrastim) causes marked increases in peripheral blood neutrophil counts within twenty-four hours, with minor increases in monocytes. In some severe chronic neutropenia patients filgrastim can also induce a minor increase in the number of circulating eosinophils and basophils relative to baseline; some of these patients may present with eosinophilia or basophilia already prior to treatment. Elevations of neutrophil counts are dosedependent at recommended doses. Neutrophils produced in response to filgrastim show normal or enhanced function as demonstrated by tests of chemotactic and phagocytic function. Following termination of filgrastim therapy, circulating neutrophil counts decrease by 50% within 1 to 2 days, and to normal levels within 1 to 7 days.@@14922981@Indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. The safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy. It is indicated for the mobilisation of peripheral blood progenitor cells (PBPC). In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of 0.5 x 109/l, and a history of severe or recurrent infections, long term administration of Biograstim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events. It is indicated for the treatment of persistent neutropenia (ANC less than or equal to 1.0 x 109/l) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.@@-@-@@NO REVIEW@@@-@-@-@-@-@-@-@>> CHMP positive revised opinion. The CHMP concluded that the benefit-risk-balance for the use of the aforementioned treatments in patients with neutropenia continues to be positive and recommended the granting of marketing authorisations. [CHMP, 24 July 2008]              >> CHMP positive opinion for MAA. EMEA review period began on 21 February with an active review time of 209 days. [CHMP, 21 February 2008]@7/24/2008@@-@@@-@-@@-@-@@@-@FILED@@-@-@-@-@@@@-@FILGRASTIM@@@@@FILGRASTIM||||@CT ARZNEIMITTEL@@@@@CT ARZNEIMITTEL||||@@@@@@|||||||||@Supportive Care@Neutropaenia@@@@Supportive Care|Neutropaenia||||||||@BIOGRASTIM@BIOSIMILAR@@@@BIOGRASTIM|BIOSIMILAR|||@Immunotherapy@G-CSF@@@@Immunotherapy|G-CSF|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14919034@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Approximately 18.000 study subjects will either receive the HPV vaccine or a control vaccine (hepatitis A vaccine) administered intramuscularly according to a 0-1-6 month schedule.@@J07BM01@J07B@@BRENTFORD, UNITED KINGDOM@@@Cervarix is a non-infectious recombinant vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid L1 protein of oncogenic HPV types 16 and 18. Since the VLPs contain no viral DNA, they cannot infect cells, reproduce or cause disease. Animal studies have shown that the efficacy of L1 VLP vaccines is largely mediated by the development of a humoral immune response. HPV-16 and HPV-18 are responsible for approximately 70% of cervical cancers across all regions worldwide.@@14919034@@@NO@@@NO REVIEW@@@@@@@NCT00122681@18000@@FDA, 16 October 2009@10/16/2009@@@@@@HPV-008@No@FIRST PATENT EXPIRES IN 2017.@Subject must be free of obvious health problems as established by medical history and clinical examination before entering into the study.@@@III@APPROVED@@@@Mean length of follow-up for women in the primary analysis for efficacy at the time of the interim analysis was 14.8 (SD 4.9) months. Two cases of CIN2+ associated with HPV16 or HPV18 DNA were seen in the HPV16/18 vaccine group; 21 were recorded in the control group. Of the 23 cases, 14 (two in the HPV16/18 vaccine group, 12 in the control group) contained several oncogenic HPV types. Vaccine efficacy against CIN2+ containing HPV16/18 DNA was 90.4% (97.9% CI 53.4-99.3; p<0.0001). No clinically meaningful differences were noted in safety outcomes between the study groups. [Lancet. 2007 Jun 30;369(9580):2135-7.; http://www.ncbi.nlm.nih.gov/pubmed/17602732?dopt=Abstract] Trial registered. [GSK, 20 July 2005]@@@@@@HUMAN PAPILLOMAVIRUS@@@@@HUMAN PAPILLOMAVIRUS||||@GSK@@@@@GSK||||@@@@@@|||||||||@Cervical Cancer@@@@@Cervical Cancer|||||||||@CERVARIX@@@@@CERVARIX||||@Vaccine@@@@@Vaccine||||@CIN2+@@@@@@@@@@@@@@@PREVENTION@DOUBLE-BLIND@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@@@@@5@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@58160-0830-46@SUSPENSION FOR INJECTION - 0.5 ML@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918790@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01BA01@L01B@YES@LAKE FOREST, ILLINOIS@@@Methotrexate is an antimetabolite which acts principally by competitively inhibiting the enzyme, dihydrofolate reductase. In the process of DNA synthesis and cellular replication, folic acid must be reduced to tetrahydrofolic acid by this enzyme, and inhibition by methotrexate interferes with tissue cell reproduction. Actively proliferating tissues such as malignant cells are generally more sensitive to this effect of methotrexate. It also inhibits antibody synthesis.@@14918790@Methotrexate is indicated in the treatment of neoplastic disease, such as trophoblastic neoplasms and leukaemia, and the symptomatic treatment of severe recalcitrant disabling psoriasis which is not adequately responsive to other forms of therapy.@@NO@@@NO REVIEW@@@@100%@Via takeover of Mayne Pharma@@@@Breast Carcinoma: Prolonged cyclic combination with cyclophosphamide, methotrexate and fluorouracil has given good results when used as adjuvant treatment to radical mastectomy in primary breast cancer with positive axillary lymph nodes. Methotrexate dosage was 40mg/m2 intravenously on the first and eighth days.@@@@@@@Methotrexate should be used with extreme caution in patients with haematological depression, renal impairment, diarrhoea, ulcerative disorders of the GI tract and psychiatric disorders. Hepatic toxicity has been observed, usually associated with chronic hepatic disease. Renal lesions may develop if the urinary flow is impeded and urinary pH is low, especially if large doses have been administered. The administration of low doses of methotrexate for prolonged periods may give rise, in particular, to hepatic toxicity. Particular care and possible cessation of treatment are indicated if stomatitis or GI toxicity occurs as haemorrhagic enteritis and intestinal perforation may result.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@METHOTREXATE@@@@@METHOTREXATE||||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@Breast Cancer@NSCLC@Head & Neck Cancer@Bladder Cancer@Cervical Cancer@Breast Cancer|NSCLC|Head & Neck Cancer|Bladder Cancer|Cervical Cancer|||||@GENERIC@@@@@GENERIC||||@Anti-metabolite@Folic Acid Analogue@@@@Anti-metabolite|Folic Acid Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.299@36@@@@@@@@@@@@7.2@@@@@@@@@@@@@@@@7/28/2017@36@36@3.61E+15@INJECTION 2 ML@GB£@@@@@@@@5@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14918679@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01AX04@L01A@YES@@@@Dacarbazine is a cytostatic agent. The antineoplastic effect is due to an inhibition of cell growth which is independent of the cell cycle and due to an inhibition of DNA synthesis. An alkylating effect has also been shown and other cytostatic mechanisms may also be influenced by dacarbazine. Dacarbazine is considered not to show an antineoplastic effect by itself. However by microsomal N-demethylation it is quickly converted to 5-amino-imidazole-4-carboxamide and a methyl cation, which is responsible for the alkylating effect of the drug.@@14918679@Dacarbazine is indicated for the treatment of patients with metastatic malignant melanoma. Further indications for dacarbazine as part of combination chemotherapy are: • Hodgkin's disease • Advanced adult soft tissue sarcomas (except mesothelioma, Kaposi sarcoma)@@NO@@@NO REVIEW@@@@100%@@@@@Hodgkin's Disease: Dacarbazine is administered in a daily dose of 375 mg/m2 body surface area i.v. on day 1 and day 15 in combination with doxorubicin, bleomycin and vinblastine for each cycle of ABVD regimen.@EMA, November 1997@@@@@@It is recommended that DTIC-Dome (dacarbazine) be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Hemopoietic depression is the most common toxicity with DTIC-Dome (See WARNINGS). Hepatic necrosis has been reported. Studies have demonstrated this agent to have a carcinogenic and teratogenic effect when used in animals. In treatment of each patient, the physician must weigh carefully the possibility of achieving therapeutic benefit against the risk of toxicity.@NO LABELLED TRIAL@No@@@@@@APPROVED@@NO NICE REVIEW@NHS@NO LABELLED TRIAL@@@@@@DACARBAZINE@@@@@DACARBAZINE||||@MEDAC@@@@@MEDAC||||@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@Melanoma / Skin Cancer@@@Haematological Malignancy|Hodgkin's Lymphoma|Melanoma / Skin Cancer|||||||@GENERIC@@@@@GENERIC||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@METASTATIC@MALIGNANT@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@10@1.299@90@@@@@@@@@@@@0.09@@@@@@@@@@@@@@@@7/28/2017@9@9@7.32E+15@POWDER FOR SOLUTION FOR INJECTION VIAL@GB£@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14922182@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@RAD001 oral, 2.5 mg daily RAD001 oral, 5mg daily; Bevacizumab infusion (IV), 15 mg/kg every 21 days; Docetaxel infusion (IV), 75 mg/m^2 every 21 days@@-@-@-@BASEL, SWITZERLAND@1/1/2010@@The active substance in Afinitor, everolimus, is an anticancer medicine, which acts by blocking a protein called ‘mammalian target of rapamycin' (mTOR). In the body, everolimus attaches to a protein that is found inside cells to make a ‘complex'. This complex then blocks mTOR. Since mTOR is involved in the control of cell division and the growth of blood vessels, Afinitor prevents the division of cancer cells and reduces their blood supply. This slows down the growth and spread of kidney cancer.@@14922182@Avastin and RAD-001 with docetaxel in androgen independent prostate cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00574769@42@-@-@@@EMEA issued positive opinion to grant Orphan Drug status for everolimus to treat neuroendocrine gastroenteropancreatic tumours@@9/1/2007@-@AVF3955s,@@-@-@@@CRAD001CUS2468;@II@@-@-@RESULTS PENDING@-@@@@COMBO@EVEROLIMUS@BEVACIZUMAB@@@@EVEROLIMUS|BEVACIZUMAB|||@NOVARTIS@GENENTECH@@@@NOVARTIS|GENENTECH|||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@AFINITOR@RAD-001@AVASTIN@@@AFINITOR|RAD-001|AVASTIN||@Immunotherapy@Immunosuppressive@mTOR Inhibitor@@@Immunotherapy|Immunosuppressive|mTOR Inhibitor||@MAXIMUM TOLERATED DOSE@@@@@@@@@@ADVANCED@@@@@OPEN-LABEL@SINGLE-ARM@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921446@Onco@@@@@300f1012ntsdm@@@@@@Myocet/CPA (60/600MG/M2) versus doxorubicin/CPA (60/600MG/M2)@@L01DB01@L01D@YES@FRAZER, PENNSYLVANIA@@@The active substance in Myocet is doxorubicin HCl. Doxorubicin may exert its antitumour and toxic effects by a number of mechanisms including inhibition of topoisomerase II, intercalation with DNA and RNA polymerases, free radical formation and membrane binding. Liposomal-encapsulated compared with conventional doxorubicin was not found more active in doxorubicin resistant cell lines in vitro. In animals, liposome-encapsulated doxorubicin reduced the distribution to heart and gastrointestinal mucosa compared with conventional doxorubicin, while antitumoural efficacy in experimental tumours was maintained.@@14921446@Myocet, in combination with cyclophosphamide, is indicated for the first line treatment of metastatic breast cancer in women.@@NA@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@297@When Myocet is administered in combination with cyclophosphamide (600 mg/m2) the initial recommended dose of Myocet is 60-75 mg/m2 every three weeks.@@@@@@@Myelosuppression- Therapy with Myocet causes myelosuppression. Myocet should not be administered to individuals with absolute neutrophil counts (ANC) lower than 1,500 cells/µl or platelets less than 100,000/µl prior to the next cycle. Careful haematological monitoring (including white blood cell and platelet count, and haemoglobin) should be performed during therapy with Myocet.@LABEL@No@@@@@III@APPROVED@@@GKV@RR was 43% in both groups, whilst median PFS was 5.1 and 5.5 months in the Myocet and placebo group respectively.@@@@@COMBO@DOXORUBICIN, PEGYLATED LIPOSOMAL@@@@@DOXORUBICIN, PEGYLATED LIPOSOMAL||||@CEPHALON@@@@@CEPHALON||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@MYOCET@@@@@MYOCET||||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@RESPONSE RATE@PROGRESSION-FREE SURVIVAL@@@@@@@@@@@@@@PLACEBO-CONTROLLED@TWO-ARM@@@@@@Invalid Dosage Value Phase 1@@@@@@79316.49@79316.49@@1@1.1511@949.12@1210.97@979.72@@@@@@@@@@18.98@@@@@@@@@@@@@@@@8/1/2017@949.12@949.12@8819739@POWDER AND SOLVENT FOR CONCENTRATE FOR LIPOSOMAL INFUSION DISPERSION (SET)@EURO@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14919425@Onco@@@@@300f1018ntsdm@@@@@@@@L01BC05@L01B@NO@@@@Gemcitabine exhibits significant cytotoxicity activity against a variety of cultured murine and human tumour cells. It exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and under certain conditions blocking the progression of cells through the G1/S-phase boundary. In vitro the cytotoxic action of gemcitabine is both concentration and time dependent.@@14919425@Non-Small Cell Lung Cancer: Gemcitabine, in combination with cisplatin, is indicated as a first-line treatment of patients with locally advanced (inoperable Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer. Gemcitabine is indicated for the palliative treatment of adult patients with locally advanced or metastatic non-small cell lung cancer.Pancreatic Cancer: Gemcitabine is indicated for the treatment of adult patients with locally advanced or metastatic adenocarcinoma of the pancreas. Gemcitabine is indicated for patients with 5-FU refractory pancreatic cancer.Bladder Cancer: Gemcitabine is indicated for treatment of advanced bladder cancer (muscle invasive Stage IV tumours with or without metastases) in combination with cisplatin therapy.Breast Cancer: Gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline, unless clinically contra-indicated.@@YES@@@NO REVIEW@@@@100%@@SECOND-LINE@@@@@@@@@@Gemzar can suppress bone marrow function as manifested by leukopaenia, thrombocytopaenia, and anaemia, can increase toxicity when prolongation of the infusion time beyond 60 minutes and more frequent than weekly dosing. Pulmonary toxicity, Hemolytic Uremic Syndrome (HUS) and/or renal failure, leading to death or requiring dialysis, despite discontinuation of therapy have been reported. Occurence of rare cases of Serious hepatotoxicity, including liver failure and death.@@No@@@@@@APPROVED@@@PBS@@@@@@COMBO@GEMCITABINE HYDROCHLORIDE@@@@@GEMCITABINE HYDROCHLORIDE||||@SPIRIT PHARMACEUTICALS@@@@@SPIRIT PHARMACEUTICALS||||@@@@@@|||||||||@Breast Cancer@NSCLC@Ovarian Cancer@Pancreatic Cancer@@Breast Cancer|NSCLC|Ovarian Cancer|Pancreatic Cancer||||||@GENERIC@GEMCITE@@@@GENERIC|GEMCITE|||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@0.779@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@A$@@@@@@@@200@MG@20 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14923282@Onco@@@@@300f1037ntsdm@@@@@@NO LABELLED TRIAL@@L02AE01@L02A@NO@PARIS, FRANCE@@@@@14923282@For the treatment of advanced prostatic carcinoma (stage C or stage D) in which suppression of testosterone is indicated. Buserelin acts by blockade and subsequent down-regulation of pituitary LHRH receptor synthesis. Gonadotrophin release is consequently inhibited. As a result of this inhibition there is reduced stimulation of testosterone secretion and serum testosterone levels fall to castration range. Before inhibition occurs there is a brief stimulatory phase during which testosterone levels may rise.@@NO@@@NO REVIEW@@@@90%@Licensed from SRI International@@@@Initiation of therapy: is most conveniently carried out in hospital; 0.5 ml Suprefact injection should be injected subcutaneously at 8 hourly intervals for 7 days. Maintenance therapy: on the 8th day of treatment the patient is changed to intranasal administration of Suprefact. One spray dose is introduced into each nostril 6 times a day@1-Jun-86@6/1/1986@8/28/1986@@@@For the treatment of advanced prostatic carcinoma (stage C or stage D) in which suppression of testosterone is indicated. Buserelin acts by blockade and subsequent down-regulation of pituitary LHRH receptor synthesis. Gonadotrophin release is consequently inhibited. As a result of this inhibition there is reduced stimulation of testosterone secretion and serum testosterone levels fall to the castration range. Before inhibition occurs there is a brief stimulatory phase during which testosterone levels may rise.@NO LABELLED TRIAL@No@@@@@@APPROVED@@NO REVIEW@SNS@NO LABELLED TRIAL@@@@@@BUSERELIN ACETATE@@@@@BUSERELIN ACETATE||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@SUPREFACT NASAL SPRAY@@@@@SUPREFACT NASAL SPRAY||||@LH-RH Analog@@@@@LH-RH Analog||||@@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@2@1.1511@62.48@97.54@67.65@@@@@@@@@@3.12@@@@@@@@@@@@@@@@8/4/2017@31.24@31.24@969931@SOLUTION FOR NASAL PULVERIZATION, 10 ML@EURO@@@@@@@@10@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14919966@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NO LABELLED TRIAL@@L01CA04@L01C@YES@BEDFORD, OHIO@@@Vinorelbine is an antineoplastic active substance of the vinca alkaloid family, but in contrast to all other vinca alkaloids the catharanthine portion of vinorelbine has undergone a structural modification. On the molecular level it affects the dynamic equilibrium of tubulin in the microtubular system of the cell. Vinorelbine inhibits tubulin polymerisation and binds preferentially to mitotic microtubules, only affecting axonal microtubules at high concentrations. Spiralisation of the tubulin is induced to a lesser degree than with vincristine. Vinorelbine blocks mitosis in phase G2-M, causing cell death in interphase or at the following mitosis.@@14919966@Indicated as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced NSCLC. In patients with Stage IV NSCLC, it is indicated as a single agent or in combination with cisplatin. In Stage III NSCLC, it is indicated in combination with cisplatin.@@NO@@@NO REVIEW@@@@@@@@@Single-Agent Vinorelbine Injection: The usual initial dose of single-agent is 30 mg/m2 administered weekly.The recommended method of administration is an intravenous injection over 6 to 10 minutes. In controlled trials, single-agent Vinorelbine Injection, USP was given weekly until progression or doselimiting toxicity.@FDA, December 2003@@@@@@Vinorelbine should be administered in carefully adjusted doses by or under the supervision of a chemo-experienced physician. Patients treated with vinorelbine should be frequently monitored for myelosuppression both during and after therapy. Granulocytopaenia is dose-limiting. Granulocyte nadirs occur between 7 and 10 days after dosing with granulocyte count recovery usually within the following 7 to 14 days. Complete blood counts with differentials should be performed and results reviewed prior to administering each dose of vinorelthose@NO LABELLED TRIAL@No@@@@@@APPROVED@@@MEDICARE@NO LABELLED TRIAL@@@@@MONO@VINORELBINE TARTRATE@@@@@VINORELBINE TARTRATE||||@BEDFORD LABORATORIES@@@@@BEDFORD LABORATORIES||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Vinca Alkaloids@@@@Plant Alkaloid|Vinca Alkaloids|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@55390-0070-01@CONCENTRATE FOR IV INFUSION@US$@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924725@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Dastatinib monotherapy, dose-finding@@L01XE06@L01X@-@NEW YORK, NEW YORK@@@Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRß. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.@@14924725@Children or adolescents with relapsed or refractory leukaemia (Ph+ CML or Ph+ALL)@@NO@-@@NO REVIEW@@@@-@-@-@NCT00306202@50@-@-@@@-@@3/1/2006@-@-@@APRIL 2020 ('746); PATENT EXTENSION FILED.@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@DASATINIB@@@@@DASATINIB||||@BMS@@@@@BMS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@Acute Lymphocytic Leukaemia@@@Haematological Malignancy|Chronic Myeloid Leukaemia|Acute Lymphocytic Leukaemia|||||||@SPRYCEL@@@@@SPRYCEL||||@TK Inhibitor@bcr-abl@PDGF@@@TK Inhibitor|bcr-abl|PDGF||@MAXIMUM TOLERATED DOSE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15394365@Onco@@@@@300f1012ntsdm@@@@@@521 patients were randomised to treatment with Teysuno (25 mg/m2 orally twice daily for 21 days followed by a 7-day rest period) and cisplatin (75 mg/m2 intravenous infusion once every 4 weeks); and 508 patients were randomised to treatment with 5-FU (1000 mg/m2/24 hours as a continuous intravenous infusion on Days 1 through 5 repeated every 4 weeks) and cisplatin (100 mg/m2 as an intravenous infusion on Day 1 repeated every 4 weeks).@@L01BC53@L01B@@@@@Teysuno is an oral fluoropyrimidine anti-cancer medicinal product@@15394365@Indicated in adults for the treatment of advanced gastric cancer when given in combination with cisplatin@Both@@@@@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@1029@The recommended standard dose of Teysuno when administered in combination with cisplatin is25 mg/m2 (expressed as tegafur content) twice daily, morning and evening, for 21 consecutive daysfollowed by 7 days rest (1 treatment cycle). This treatment cycle is repeated every 4 weeks.@EMA, 14 March 2011@3/14/2011@@@@@@FLAGS@No@@@@ADULTS@III@APPROVED@@@GKV@@@@@@COMBO@GIMERACIL / OTERACIL / TEGAFUR@CISPLATIN@@@@GIMERACIL / OTERACIL / TEGAFUR|CISPLATIN|||@NORDIC PHARMA@@@@@NORDIC PHARMA||||@@@@@@|||||||||@Stomach Cancer@@@@@Stomach Cancer|||||||||@TEYSUNO@GENERIC@@@@TEYSUNO|GENERIC|||@Fluoropyrimidine@@@@@Fluoropyrimidine||||@OVERALL SURVIVAL@@@@@@@@@@ADVANCED@@@@@RANDOMIZED@CONTROLLED@OPEN-LABEL@@@1.75@m²@2001.752562@@@4.8@month@4.8 month@2001.75@2001.75@13.71@84@1.1511@263.25@343.81@272.24@@@@@@@@@@0.21@28@@mg/m²@50@21@@@@@@@@@@@8/1/2017@3.13@3.13@9736903@HARD CAPSULE@EURO@@@@@@@@15@MG@4.35 MG|11.8 MG|15 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
15045786@Onco@@@@@300f1037ntsdm@@@@@@@@L03AA02@L03A@@BERLIN, GERMANY@@@Human G-CSF is a glycoprotein which regulates the production and release of functional neutrophils from the bone marrow. NEUPOGEN containing rmetHuGCSF (filgrastim) causes marked increases in peripheral blood neutrophil counts within twenty-four hours, with minor increases in monocytes. In some severe chronic neutropenia patients filgrastim can also induce a minor increase in the number of circulating eosinophils and basophils relative to baseline; some of these patients may present with eosinophilia or basophilia already prior to treatment. Elevations of neutrophil counts are dosedependent at recommended doses. Neutrophils produced in response to filgrastim show normal or enhanced function as demonstrated by tests of chemotactic and phagocytic function. Following termination of filgrastim therapy, circulating neutrophil counts decrease by 50% within 1 to 2 days, and to normal levels within 1 to 7 days.@@15045786@Indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. The safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy. It is indicated for the mobilisation of peripheral blood progenitor cells (PBPC). In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of 0.5 x 109/l, and a history of severe or recurrent infections, long term administration of Biograstim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events. It is indicated for the treatment of persistent neutropenia (ANC less than or equal to 1.0 x 109/l) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.@@YES@@@NO REVIEW@@@@@@@@@@EMA, 24 July 2008@7/24/2008@@@@@@@No@@@@@@APPROVED@@@SNS@@@@@@@FILGRASTIM@@@@@FILGRASTIM||||@RATIOPHARM@@@@@RATIOPHARM||||@@@@@@|||||||||@Supportive Care@Neutropaenia@@@@Supportive Care|Neutropaenia||||||||@RATIOGRASTIM@BIOSIMILAR@@@@RATIOGRASTIM|BIOSIMILAR|||@Immunotherapy@G-CSF@@@@Immunotherapy|G-CSF|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@5@1.1511@170.63@225.2@178.17@@@@@@@@@@@@@@@@@@@@@@@@@@8/4/2017@34.13@34.13@660727@PREFILLED SYRINGE 0.5 ML@EURO@@@@@@@@300@MCG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
15048226@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Ponatinib: 45 mg tablet taken orally once daily@@L01XE24@L01X@YES@CAMBRIDGE, MASSACHUSSETTS@10/1/2020@@Ponatinib is an investigational BCR-ABL inhibitor that also selectively inhibits certain other tyrosine kinases in preclinical studies, including FLT3, RET, KIT, and the members of the FGFR and PDGFR families of kinases.@@15048226@Treatment of adult patients with T315I-positive Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) or Ph+ ALL for whom no other tyrosine kinase inhibitor (TKI) therapy is indicated.@@NA@@@NO REVIEW@@@@@@@NCT01207440@440@@FDA, 14 December 2012@12/14/2012@@Yes@@9/1/2010@Arterial ThrombosisHepatoxicity@PACE@No@@@@@II@APPROVED@@@NA@showed that 54 percent of chronic-phase CML patients who were resistant or intolerant to prior tyrosine kinase inhibitor therapy in the trial, including 70 percent of patients who have a T315I mutation, achieved a major cytogenetic response (MCyR) – the primary endpoint of the trial. Thirty percent of these same patients achieved a major molecular response (MMR). MMR is the primary endpoint of ARIAD's ongoing Phase 3 EPIC trial comparing ponatinib to imatinib in newly diagnosed chronic-phase CML patients. [Ariad, 30 August 2012, http://phx.corporate-ir.net/phoenix.zhtml?c=118422&p=irol-newsArticle&ID=1730090&highlight= ]@The US FDA investigates reports of serious and life-threatening blood clots in patients taking Iclusig[FDA, 11 October 2013, http://www.fda.gov/Drugs/DrugSafety/ucm370945.htm ]The most common side effects observed in the study to date were consistent with the known safety profile of ridaforolimus and included stomatitis (e.g., mouth sores), fatigue, diarrhea and thrombocytopenia.@@@@MONO@PONATINIB@@@@@PONATINIB||||@ARIAD PHARMACEUTICALS@MERCK & CO@@@@ARIAD PHARMACEUTICALS|MERCK & CO|||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@@@@Haematological Malignancy|Acute Lymphocytic Leukaemia||||||||@ICLUSIG@@@@@ICLUSIG||||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@RESPONSE RATE@@@@@@@@@@@@@@@OPEN LABEL@SINGLE-ARM@@@@1@1@Invalid Factory Price@@@81@day@81 day@@@@60@1@@@@@@@@@@@@@@1@@mg@45@1@@@@@@@@@@@@@@76189-0535-60@TABLET@US$@@@@@@@@15@MG@15 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15051145@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Ascending doses of BIBW-2992 [BI]@@-@-@-@INGELHEIM, GERMANY@7/1/2010@@This is an orally bioavailable dual receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. EGFR/HER2 tyrosine kinase inhibitor BIBW 2992 irreversibly binds to and inhibits human epidermal growth factor receptors 1 and 2 (EGFR-1; HER2), which may result in the inhibition of tumor growth and angiogenesis. EGFR/HER2 are RTKs that belong to the EGFR superfamily; both play major roles in tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types. @@15051145@BIBW 2992 in Treating Patients With Recurrent Glioblastoma Multiforme @@-@-@@NO REVIEW@@@@-@-@-@NCT00727506@140@-@-@@@-@@7/1/2008@-@1200.36@@-@Histologically-confirmed WHO Grade III or IV malignant glioma that is recurrent (Part II 1st recurrence only) after prior chemoradiotherapy. Patients with prior low-grade glioma are eligible if histologic assessment demonstrates transformation to WHO Grade III or IV malignant glioma. (Part II: Grade IV only)@@@I/II@II@@-@-@Trial registered. [BI, 31.07.2008]@-@@@@COMBO@AFATINIB@TEMOZOLOMIDE@@@@AFATINIB|TEMOZOLOMIDE|||@BOEHRINGER INGELHEIM@@@@@BOEHRINGER INGELHEIM||||@@@@@@|||||||||@Glioma@Glioblastoma Multiforme@Brain Cancer@@@Glioma|Glioblastoma Multiforme|Brain Cancer|||||||@BIBW-2992@TOVOK@TEMODAL@@@BIBW-2992|TOVOK|TEMODAL||@TK Inhibitor@EGFR@HER2@@@TK Inhibitor|EGFR|HER2||@DOSE-LIMITING TOXICITY@6-MONTH PFS@@@@PHARMACOKINETICS@RESPONSE RATE@PROGRESSION-FREE SURVIVAL@@@RELAPSED@MALIGNANT@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16384280@Onco@@@@@300f1008ntsdm@@@@@@@@L01XC08@L01X@@THOUSAND OAKS, CALIFORNIA@@@Panitumumab binds specifically to EGFR on both normal and tumor cells, and competitively inhibits the binding of ligands for EGFR. Nonclinical studies show that binding of panitumumab to the EGFR prevents ligand-induced receptor autophosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, decreased proinflammatory cytokine and vascular growth factor production, and internalization of the EGFR. In vitro assays and in vivo animal studies demonstrate that panitumumab inhibits the growth and survival of selected human tumor cell lines expressing EGFR.@@16384280@Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC) in first-line in combination with FOLFOX or FOLFIRI.@@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@Acquired through takeover of Abgenix, with which it was co-developing the drug, in December 2005. Takeda and Amgen signed a deal in February 2008 through which, in its first part, Takeda acquired Japanese rights for up to 13 molecules in Amgen's pipeline,@FIRST-LINE@@@@MHLW, 16 April 2010@4/16/2010@@No@@@@PRIME@No@@@@@@APPROVED@@@NHI@@@@@@COMBO@PANITUMUMAB@OXALIPLATIN@LEUCOVORIN@FLUOURACIL@@PANITUMUMAB|OXALIPLATIN|LEUCOVORIN|FLUOURACIL|@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@VECTIBIX@FOLFOX@@@@VECTIBIX|FOLFOX|||@mAb@Human@TK Inhibitor@EGFR@@mAb|Human|TK Inhibitor|EGFR|@@@@@@@@@@@METASTATIC@@@@@@@@@@76.5@kg@6704233.083@@@10.2@month@10.2 month@6704233.08@6704233.08@21609.61@1@0.0091@65911.65@77726@@@@@@@@@@@659.12@14@@mg/kg@6@1@@@@@@@@@@@8/30/2017@65911.65@65911.65@4291417A1020@CONCENTRATE FOR SOLUTION FOR INFUSION - 5 ML@YEN@@@@@@@@100@MG@20 MG/ML@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14916172@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Patients whose tumours progressed despite chemo in SATURN; Tarceva versus docetaxel@@L01XE03@L01X@-@BASEL, SWITZERLAND@@@The mechanism of clinical antitumor action of erlotinib is not fully characterized. Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR). Specificity of inhibition with regard to other tyrosine kinase receptors has not been fully characterized. EGFR is expressed on the cell surface of normal cells and cancer cells.@@14916172@Second-line NSCLC from SATURN trial@@-@-@@NO REVIEW@@@@-@>> Roche announces US$43.7 billion proposal to assume full control of Genentech. [Roche, 21 July 2008]      >> To meet FTC requirements for its merger with Warner Lambert, Pfizer was was forced to divest its stake in erlotinib in June 2000 back to OSI. In January 2001, Genentech and Roche licensed global co-development and commercialisation. [OSI, January 2001]       >> Pfizer acquired major stake in Oncogene (now OSI) to form a collaborative research programme. [Oncogene, 8.07.1986]@SECOND-LINE@-@N/A@-@-@@@-@@1/1/2006@-@TITAN@@-@-@@@IIIB@III@@-@-@RESULTS PENDING@-@@@@MONO@ERLOTINIB HYDROCHLORIDE@@@@@ERLOTINIB HYDROCHLORIDE||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@TARCEVA@@@@@TARCEVA||||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@OVERALL SURVIVAL@@@@@@@@@@METASTATIC@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TABLET@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917487@Onco@@@@@300f1012ntsdm@@@@@@Six monthly injections of Eligard 7.5mg@@L02AE02@L02A@NO@TOKYO, JAPAN@@@Leuprolide acetate, an LH-RH agonist, acts as a potent inhibitor of gonadotropin secretion when given continuously in therapeutic doses. Animal and human studies indicate that after an initial stimulation, chronic administration of leuprolide acetate results in suppression of ovarian and testicular steroidogenesis. This effect is reversible upon discontinuation of drug therapy. Eligard is a sterile polymeric matrix formulation of leuprolide acetate for subcutaneous injection. It is designed to deliver 7.5 mg of leuprolide acetate at a controlled rate over a one month therapeutic period.@@14917487@Palliative treatment of advanced prostate cancer@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Sanofi-Synthelabo licensed North American rights from pre-merger Atrix in 2001@FIRST-LINE@@120@One injection every month@@@@No@@@Transient increase in serum testosterone concentrations during first week; contraindicated in children; cases of ureteral obstruction and spinal cord compression, possibly contributing to paralysis with or without fatal complications, have bene reported with LH-RH agonists@LABEL@No@@120 PATIENTS WITH ADVANCED PROSTATE CANCER (89 WITH STAGE C AND 31 WITH STAGE D)@@@@APPROVED@@@GKV@Mean serum PSA values reduced 94% from baseline by Month 6 in patients whose baseline values were elevated above normal limit. Mean testosterone concentration increased from 361.3 ng/dL at baseline to 574.6ng/dL at Day 3, then decreased to below baseline by Day 10 and was 21.8ng/dL on Day 28 by Month 6, it was 6.1ng/dL. Serum testosterone suppressed to below castrate threshold of under 50ngdL by Day 28 in 119 (94%) patients- all remaining attained the level by Day 42@@@@@MONO@LEUPROLIDE ACETATE@@@@@LEUPROLIDE ACETATE||||@ASTELLAS PHARMA@@@@@ASTELLAS PHARMA||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@ELIGARD@@@@@ELIGARD||||@LH-RH Analog@@@@@LH-RH Analog||||@PSA@SERUM TESTOSTERONE@@@@@@@@@ADVANCED@@@@@OPEN-LABEL@MULTI-CENTRE@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@2@1.1807@688.68@881.69@711.07@@@@@@@@@@15.3@@@@@@@@@@@@@@@@8/15/2017@344.34@344.34@2726020@DRY POWDER + SOLVENT@EURO@@@@@@@@22.5@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16384274@Onco@@@@@300f1018ntsdm@@@@@@Vectibix in combination with FOLFIR compared to FOLFIRI alone.@@L01XC08@L01X@@THOUSAND OAKS, CALIFORNIA@@@Panitumumab binds specifically to EGFR on both normal and tumor cells, and competitively inhibits the binding of ligands for EGFR. Nonclinical studies show that binding of panitumumab to the EGFR prevents ligand-induced receptor autophosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, decreased proinflammatory cytokine and vascular growth factor production, and internalization of the EGFR. In vitro assays and in vivo animal studies demonstrate that panitumumab inhibits the growth and survival of selected human tumor cell lines expressing EGFR.@@16384274@Second line therapy in combination with FOLFIRI for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan).@@YES@@@NO REVIEW@@@@@Acquired through takeover of Abgenix, with which it was co-developing the drug, in December 2005. Takeda and Amgen signed a deal in February 2008 through which, in its first part, Takeda acquired Japanese rights for up to 13 molecules in Amgen's pipeline,@SECOND-LINE@NCT00339183@1100@The recommended dose of Vectibix is 6 mg/kg of bodyweight given once every two weeks.@TGA, 14 May 2008@5/14/2008@@No@@5/1/2006@@181 Trial@No@@1,100 PATIENTS WITH PREVIOUSLY TREATED MCRC@@@III@APPROVED@@@PBS@@@@@@COMBO@PANITUMUMAB@LEUCOVORIN@FLOROURACIL@IRINOTECAN@@PANITUMUMAB|LEUCOVORIN|FLOROURACIL|IRINOTECAN|@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@VECTIBIX@FOLFIRI@@@@VECTIBIX|FOLFIRI|||@mAb@Human@TK Inhibitor@EGFR@@mAb|Human|TK Inhibitor|EGFR|@OVERALL SURVIVAL@PROGRESSION-FREE SURVIVAL@@@@@@@@@METASTATIC@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@76.5@kg@46462.02163@@@6.4@month@6.4 month@46462.02@46462.02@238.68@1@0.779@728@@@@@@@@@@@@7.28@14@@mg/kg@6@1@@@@@@@@@@@8/1/2017@728@728@3548-2611-IN-AN@CONCENTRATE FOR SOLUTION FOR INFUSION - 5 ML@A$@@@@@@@@100@MG@20 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
16670308@Onco@@@@@300f1020ntsdm@@@@@@This study investigated the use of combination therapy of MPR (melphalan 0.18 mg/kg orally on days 1-4 of repeated 28-day cycles; prednisone 2 mg/kg orally on days 1-4 of repeated 28-day cycles; and lenalidomide10 mg/day orally on days 1-21 of repeated 28-day cycles) for induction therapy, up to 9 cycles. Patients who completed 9 cycles or who were unable to complete 9 cycles due to intolerance proceeded to maintenancemonotherapy starting with lenalidomide 10 mg orally on days 1-21 of repeated 28-day cycles until disease progression.@@L04AX04@L04A@@SUMMIT, NEW JERSEY@@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16670308@Treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant@Both@YES@20-Oct-16@10/20/2016@NO REVIEW@@@@@@FIRST-LINE@@459@@EMA, 11 February 2015@2/11/2015@@YES@@@@@No@@@@ADULTS@@APPROVED@@Added to the reimbursement list on 20 October 2016 [http://www.gazzettaufficiale.it/eli/id/2016/10/28/16A07750/sg;jsessionid=aYtec5ixDvhYP72a9v3pbw__.ntc-as2-guri2a]@SSN@@@@@@COMBO@LENALIDOMIDE@MELPHALAN@PREDNISONE@@@LENALIDOMIDE|MELPHALAN|PREDNISONE||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@REVLIMID@ALKERAN@GENERIC@@@REVLIMID|ALKERAN|GENERIC||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@PROGRESSION FREE SURVIVAL@@@@@@@@@@@@@@@RANDOMISED@DOUBLE BLIND@@@@1@1@375130.4767@@@27.4@month@27.4 month@375130.48@375130.48@450.12@21@1.1229@5041.36@8320.26@5268.28@@@@@@@@@@24.01@28@@mg@25@21@@@@@@@@@@@6/7/2017@240.06@240.06@38016022@HARD CAPSULE@EURO@@@@@@@@10@MG@10 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14923729@Onco@@@@@@@@@@@Patients received Genexol-PM by IV infusion 300MG/M2 over 3 hours every 3 weeks without premedication until disease progression or intolerability. The median number of cycles was 8 per patients (1-16), with a total of 331 cycles administered. SOURCE: Samyang@@-@-@-@-@@@@@14923729@Histologically confirmed mBC@@-@-@@NO REVIEW@@@@-@CJ Corp licensed rights to Genexol-PM, though details of the agreement have not been disclosed. SOURCE: Samyang, May 2007/19 December 2000Samyang and MacroMed terminated their collaboration agreement for Genexol using MacroMed's Regel drug delivery syst@-@-@41@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@Overall response rate was 59% (95% CI: 43.5-72.3) with 5 complete responses and 19 partials. 37 patients received the drug as first-line therapy and here the RR was 60%; 2 responses were reported in 4 patients treated in the second-line setting. Median TTP was 9 months (1-17 months). Grade III non-haematological toxicities included sensory peripheral neuropthy (51%) and myalgia (2.4%). 20% of patients had hypersensitivity, with grade III in 2 patients. Haematological toxicities included neutropaenia (51% grade III and 17% grade IV). There were no reports of febrile neutropaenia. SOURCE: Samyang/Breast Cancer Research and Treatment, 108(2): 241-250 2008@-@@@@MONO@PACLITAXEL, LOADED POLYMERIC MICELLE@@@@@PACLITAXEL, LOADED POLYMERIC MICELLE||||@SAMYANG@CJ CORP@@@@SAMYANG|CJ CORP|||@South Korea@@@@@South Korea|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GENEXOL-PM@@@@@GENEXOL-PM||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@SINGLE-ARM@MULTI-CENTRE@@@@@@Invalid Factory Price@@@@@-@-@@@1@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRAVENOUS@-@@@@@@@@30@MG@30 MG/5 ML@@@@@@@@@@@@@@@@@@@@@@@@@
14920849@Onco@@@@@300f1020ntsdm@@@@@@NO LABELLED TRIAL@@V03AF04@V03A@NO@MADISON, NEW JERSEY@@@Calcium folinate is the calcium salt of 5-formyl tetrahydrofolic acid. It is an active metabolite of folinic acid and an essential coenzyme for nucleic acid synthesis in cytotoxic therapy. Calcium folinate is frequently used to diminish the toxicity and counteract the action of folate antagonists, such as methotrexate. Calcium folinate and folate antagonists share the same membrane transport carrier and compete for transport into cells, stimulating folate antagonist efflux. It also protects cells from the effects of folate antagonist by repletion of the reduce folate pool. Calcium folinate serves as a pre-reduced source of H4 folate; it can therefore bypass folate antagonist blockage and provide a source for the various coenzyme forms of folic acid.@@14920849@Calcium folinate is indicated to diminish the toxicity and counteract the action of folic acid antagonists such as methotrexate in cytotoxic therapy and overdose in adults and children. In cytotoxic therapy, this procedure is commonly known as “Calcium Folinate Rescue”; also, in combination with 5-fluorouracil in cytotoxic therapy.@@NO@-@@NO REVIEW@@@@0%@Pfizer acquired Wyeth on 26 January 2009 in a deal worth U.S $68 billion [Pfizer 26.01.2009]@-@-@-@Advanced Colorectal Cancer: Either of the following two regimens is recommended: 1. Leucovorin is administered at 200 mg/m2 by slow intravenous injection over a minimum of 3 minutes, followed by 5-fluorouracil at 370 mg/m2 by intravenous injection. 2. Leucovorin is administered at 20 mg/m2 by intravenous injection followed by 5-fluorouracil at 425 mg/m2 by intravenous injection.@N/A@@@-@@@In the treatment of accidental overdosages of folic acid antagonists, intravenous leucovorin should be administered as promptly as possible. As the time interval between antifolate administration (e.g., methotrexate) and leucovorin rescue increases, leucovorin's effectiveness in counteracting toxicity decreases. In the treatment of accidental overdosages of intrathecally adminstered folic acid antagonists, do not adminster leucovorin intrathecally. Leucovorin may be fatal if given intrathecally. Monitoring of the serum methotrexate concentration is essential in determining the optimal dose and duration of treatment with leucovorin.@NO LABELLED TRIAL@No@-@-@@@-@APPROVED@@@@NO LABELLED TRIAL@-@@@@-@LEUCOVORIN CALCIUM@@@@@LEUCOVORIN CALCIUM||||@WYETH@PFIZER@@@@WYETH|PFIZER|||@@@@@@|||||||||@Sarcoma@Supportive Care@Colorectal Cancer@@@Sarcoma|Supportive Care|Colorectal Cancer|||||||@LEDERFOLIN@@@@@LEDERFOLIN||||@Detoxifying Agent@@@@@Detoxifying Agent||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@10@1.1229@10.23@16.8@10.69@@@@@@@@@@0.14@@@@@@@@@@@@@@@@6/7/2017@1.02@1.02@24659118@TABLET@EURO@@@@@@@@7.5@MG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14921326@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@L01XE04@L01X@-@NEW YORK, NEW YORK@@@Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFR? and PDGFRß), vascular endothelial growth factor receptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays. Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFRß, VEGFR2, KIT) in tumor xenografts expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit PDGFRß- and VEGFR2-dependent tumor angiogenesis in vivo.@@14921326@KIT mutations@@-@-@@NO REVIEW@@@@-@Acquired through takeover of Pharmacia Corp., which acquired it from Sugen@-@NCT00631618@-@-@-@@@-@@@-@GA6181DN@@JANUARY 2011 (NCE EXCLUSIVITY); FEBRUARY 2021 (GIST PATENT)@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@SUNITINIB MALEATE@@@@@SUNITINIB MALEATE||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@SUTENT@@@@@SUTENT||||@TK Inhibitor@VEGF@PDGF@SCF@@TK Inhibitor|VEGF|PDGF|SCF|@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916030@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@XL-647 administered daily@@-@-@-@SOUTH SAN FRANCISCO, CALIFORNIA@@@Principal Targets- Cell proliferation: EGFR and a variety of mutant forms of EGFR (e.g., T790M), HER2, Angiogenesis (VEGFR). EGFR and HER2 are targets for approved cancer therapies.  Signaling through VEGF/VEGFR2 is the target of approved cancer therapies. EGFR is mutationally activated in a subset of NSCLC patients, and some EGFR mutations are associated with resistance to erlotinib and gefitinib.@@14916030@NSCLC progressed after responding to Iressa or Tarceva@@-@-@@NO REVIEW@@@@-@XL647 is licensed to Symphony Evolution. GSK decided not to exercise an option for the drug in July 2007.@-@NCT00522145@34@-@-@@@-@@5/1/2007@-@XL647-203@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@EXELIXIS@SYMPHONY EVOLUTION@@@@EXELIXIS|SYMPHONY EVOLUTION|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@XL-647@@@@@XL-647||||@TK Inhibitor@EGFR@HER2@VEGF@Angiogenesis Inhibitor@TK Inhibitor|EGFR|HER2|VEGF|Angiogenesis Inhibitor@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924055@Onco@@@@@300f1010ntsdm@@@@@@-@@-@-@-@RUNCORN, UNITED KINGDOM@8/1/2009@@"Prolarix is a targeted chemotherapy being developed for the treatment of primary liver cancer(hepatocellular carcinomas, HCC) and other select tumours. Prolarix is a combinationtherapy of two low molecular weight compounds, a prodrug* (called tretazicar; previouslyCB1954) and an enzyme co-substrate* (called caricotamide; previously EP-0152R). Theprodrug tretazicar can be activated by an endogenous enzyme called NQO2, to a highlyreactive, short-lived cytotoxic agent which causes a high degree of DNA cross-linking. TheNQO2 enzyme is latent and therefore inactive in body tissue, but Protherics’ scientists havediscovered that the enzyme is active in the presence of a co-substrate called caricotamide.The NQO2 enzyme is absent or in low levels in many normal body tissues, including bonemarrow, but its activity is increased in certain tumour types (particularly hepatocellularcarcinomas). The coadministration of the prodrug tretazicar and the cosubstrate caricotamideis therefore expected to result in the enhanced activation of the prodrug in the target tumourcells, resulting in their death whilst minimising harm to healthy, non-cancerous cells."@@14924055@Hepatocellular carcinoma@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@9/1/2008@-@-@@-@-@@@II@II@@-@-@MTD reached; six additional patients with a range of tumour types will now be treated with up to six cycles of Prolarix at the MTD to further investigate drug effects in the tumour, safety and to make a preliminary assessment of potential efficacy. Cancer Research UK is expected to report the study in the first half of 2008. Meanwhile, Protherics is planning to start a phase 2 proof of concept study in the first half of 2008 to investigate the efficacy of Prolarix in primary liver cancer, where NQO2 levels have been found to be elevated. [Protherics, 12 July 2007]@-@@@@-@TRETAZICAR@CARICOTAMIDE@@@@TRETAZICAR|CARICOTAMIDE|||@PROTHERICS@@@@@PROTHERICS||||@@@@@@|||||||||@Liver Cancer@Hepatocellular Carcinoma@@@@Liver Cancer|Hepatocellular Carcinoma||||||||@PROLARIX@@@@@PROLARIX||||@Other@@@@@Other||||@RESPONSE RATE@MAXIMUM TOLERATED DOSE@@@@@@@@@-@@@@@-@-@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@GB£@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
16397632@Onco@@@@@300f1012ntsdm@@@@@@@@L01XC12@L01X@@SEATTLE, WASHINGTON@8/1/2014@@@@16397632@Treatment of adult patients with CD30+ HL at increased risk of relapse or progression following ASCT@Both@NA@19-Jan-17@1/19/2017@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@NCT01100502@329@The recommended dose is 1.8 mg/kg administered as an intravenous infusion over 30 minutes every 3 weeks.@EMA, 26 May 2016@5/26/2016@12/1/2012@Yes@@4/1/2010@@SGN35-005, 2009-016947-20@No@@Patients with HL who have received ASCT in the previous 30-45 days; Patients at high risk of residual HL post ASCT; Histologically-confirmed HL; ECOG of 0 or 1; Adequate organ function@@ADULTS@III@APPROVED@@Not quantifiable [G-BA, 19 January 2017, https://www.g-ba.de/downloads/39-261-2835/2017-01-19_AM-RL-XII_Brentuximab-Vedotin_D-253_BAnz.pdf]@GKV@@@@@@MONO@BRENTUXIMAB@@@@@BRENTUXIMAB||||@SEATTLE GENETICS@MILLENNIUM PHARMACEUTICALS@@@@SEATTLE GENETICS|MILLENNIUM PHARMACEUTICALS|||@World@@@@@World|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@@@@Haematological Malignancy|Hodgkin's Lymphoma||||||||@ADCETRIS@@@@@ADCETRIS||||@Other@CD30@@@@Other|CD30|||@PROGRESSION FREE SURVIVAL@@@@@OVERALL SURVIVAL@Incidence of Adverse Events@@@@RELAPSED@@@@@RANDOMISED@DOUBLE BLIND@PARALLEL ASSIGNMENT@@@76.5@kg@539033.7591@@@42.9@month@42.9 month@539033.76@539033.76@413.1@1@1.1511@3150.01@3918.28@3188.51@@@@@@@@@@63@21@@mg/kg@1.8@1@@@@@@@@@@@8/1/2017@3150.01@3150.01@9916870@POWDER FOR SOLUTION FOR  INJECTION / INFUSION@EURO@@@@@@@@50@MG@50 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14920920@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Administered intravenously weekly for 3 weeks every 4 weeks@@-@-@-@HAYWARD, CALIFORNIA@2/1/2005@@@@14920920@Patients who failed Taxotere-containing regiment@@-@-@@NO REVIEW@@@@-@BMS acquires Kosan Biosciences for US$190 million. SOURCE: BMS, 29 May 2008Partnership terminated due to reprioritisation at Roche. Kosan reacquires all rights. SOURCE: Kosan, 25 October 2007Kosan and Roche established a global development and commercialization agreement for epothilones to treat cancer in September 2002. Under@SECOND-LINE@NCT00104130@53@-@-@@@-@@12/1/2004@-@KOS-202NO18401@@-@-@@@II@DISCONTINUED@@-@-@While the first-generation compound R1492 (KOS-862) demonstrated meaningful objective response rates in metastatic breast cancer and non-small cell lung cancer, the companies have decided to discontinue its development and focus resources on advancing R1645. SOURCE: Kosan, 27 February 2007@-@@@@-@EPOTHILONE D@@@@@EPOTHILONE D||||@KOSAN BIOSCIENCES@BMS@@@@KOSAN BIOSCIENCES|BMS|||@@@@@@|||||||||@Prostate Cancer@HRPC@@@@Prostate Cancer|HRPC||||||||@KOS-862@R-1492@@@@KOS-862|R-1492|||@Epothilone@@@@@Epothilone||||@PSA@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924846@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@SOUTH SAN FRANCISCO, CALIFORNIA@@@XL184 inhibits MET, RET, and VEGFR2, which are key drivers of tumor growth, metastasis, survival, and angiogenesis. In pharmacodynamic studies in mice, oral administration of XL184 resulted in balanced and durable inhibition of these targets. The compound has also shown activity against common mutant forms of RET and MET. XL184 has exhibited dose-dependent tumor growth inhibition and tumor regression in a variety of tumor models, including breast cancer, colon cancer, MTC, non-small cell lung cancer, and glioblastoma.@@14924846@-@@-@-@@NO REVIEW@@@@-@GSK has decided not to exercise its option to license XL-184, as well as XL-228, XL-820 and XL-844. [Exelixis, 23.10.2008]@-@-@60@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@10 of 60 patients had partial RECIST responses. SOURCE: Exelixis/ASCO, 3 June 2008Across all tumor types, 10 patients had partial responses as determined by RECIST criteria: 9 partial responses were observed in patients with medullary thyroid cancer MTC (5 confirmed), and 1 in a patient with a neuroendocrine tumor. An additional 25 patients with various tumor types had stable disease for at least 3 months, including 8 patients with MTC. The disease control rate (percentage of patients with partial responses or prolonged stable disease >3 months) in patients with MTC was 100%, with 53% of evaluable MTC patients (9 of 17) experiencing partial responses. With a single exception, all of the evaluated MTC patients had reductions in the MTC-associated plasma markers calcitonin and carcinoembryonic antigen. Most of the MTC patients in the trial had previously failed other treatments, including tyrosine kinase inhibitors with anti-RET activity (e.g., vandetanib, sorafenib, motesanib), chemotherapeutics, immunotherapy, radioactive iodine, and radiotherapy. Based on initial signs of clinical activity in a number of patients with medullary thyroid cancer (MTC) during the dose-escalation phase, the trial has been expanded to treat an additional 20 patients with MTC at the MTD. SOURCE: Exelixis/ASCO, 1 June 2008@-@@@@MONO@-@@@@@-||||@EXELIXIS@@@@@EXELIXIS||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@XL-184@@@@@XL-184||||@TK Inhibitor@VEGF@Angiogenesis Inhibitor@@@TK Inhibitor|VEGF|Angiogenesis Inhibitor||@SAFETY@PHARMACOKINETICS@@@@@@@@@ADVANCED@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924521@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients randomised to receive ixabepilone 6mg/m2/day as a 60-minute infusion for 5 days; or ixabepilone 20mg/m2/day as a 60-minute infusion at days 1, 8 and 15.@@L01C@L01C@-@NEW YORK, NEW YORK@@@Ixabepilone is a microtubule inhibitor belonging to a class of antineoplastic agents, the epothilones and their analogs. The epothilones are isolated from the myxobacterium Sorangium cellulosum. Ixabepilone is a semisynthetic analog of epothilone B, a 16-membered polyketide macrolide, with a chemically modified lactam substitution for the naturally existing lactone. Ixabepilone is a semi-synthetic analog of epothilone B. Ixabepilone binds directly to ß-tubulin subunits on microtubules, leading to suppression of microtubule dynamics. Ixabepilone suppresses the dynamic instability of  ß-II and  ß-III microtubules. Ixabepilone possesses low in vitro susceptibility to multiple tumor resistance mechanisms including efflux transporters, such as MRP-1 and P-glycoprotein (P-gp). Ixabepilone blocks cells in the mitotic phase of the cell division cycle, leading to cell death.@@14924521@Metastatic or recurrent squamous cell cancer of the head and neck@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@-@84@-@-@@@-@@@-@-@@-@84 TAXANE-NAÏVE AND TAXANE-EXPOSED PATIENTS@@@II@II@@-@-@ECORTC-NCI-AACR Symposium November 2006; 1 response in 6mg group; among 34 patients in 20mg group, 5 experienced partial response, 11 had stable disease and 9 had progressive disease. Median PFS was 1.5-1.9 and 5.6-7.8 months in the low- and high-dose groups respectively.@-@@@@MONO@IXABEPILONE@@@@@IXABEPILONE||||@BMS@@@@@BMS||||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@IXEMPRA@BMS-247550@@@@IXEMPRA|BMS-247550|||@Epothilone@@@@@Epothilone||||@RESPONSE RATE@@@@@@@@@@METASTATIC@RELAPSED@@@@RANDOMISED@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916294@Onco@@@@@@@@@@@Patients will receive 37.5mg (3 x 12.5mg capsules) PO daily in the morning after breakfast. After 2 weeks without treatment-related adverse events grade = 2 (ECOG common toxicity criteria: refer to Protocol Attachment A.4) a dose escalation to 50mg (4 x 12.5mg capsules) PO daily has to be performed. Treatment will continue until patients develop progression of disease or until unacceptable adverse events occur. @@L01XE04@L01X@-@NEW YORK, NEW YORK@5/1/2009@@Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFR? and PDGFRß), vascular endothelial growth factor receptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays. Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFRß, VEGFR2, KIT) in tumor xenografts expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit PDGFRß- and VEGFR2-dependent tumor angiogenesis in vivo.@@14916294@-@@-@-@@NO REVIEW@@@@-@Acquired through takeover of Pharmacia Corp., which acquired it from Sugen@-@NCT00535379@70@-@-@@@-@@10/1/2007@-@SURGE01-07@@-@-@@@EUDRACT-Nr. 2007-002142-37; @II@@-@-@Endpoint at 6 months.@-@@@@MONO@SUNITINIB MALEATE@@@@@SUNITINIB MALEATE||||@PFIZER@@@@@PFIZER||||@Austria@@@@@Austria|||||||||@Brain Cancer@Glioblastoma Multiforme@@@@Brain Cancer|Glioblastoma Multiforme||||||||@SUTENT@@@@@SUTENT||||@TK Inhibitor@VEGF@PDGF@SCF@@TK Inhibitor|VEGF|PDGF|SCF|@PROGRESSION-FREE SURVIVAL@TIME TO PROGRESSION@@@@@@@@@RELAPSED@REFRACTORY@@@@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
16397633@Onco@@@@@300f1010ntsdm@@@@@@@@L01XC12@L01X@@SEATTLE, WASHINGTON@8/1/2014@@@@16397633@Treatment of adult patients with CD30+ HL at increased risk of relapse or progression following ASCT@Both@NO@@@NO REVIEW@@@@100%@@@NCT01100502@329@The recommended dose is 1.8 mg/kg administered as an intravenous infusion over 30 minutes every 3 weeks.@EMA, 26 May 2016@5/26/2016@11/23/2012@Yes@@4/1/2010@@SGN35-005, 2009-016947-20@No@@Patients with HL who have received ASCT in the previous 30-45 days; Patients at high risk of residual HL post ASCT; Histologically-confirmed HL; ECOG of 0 or 1; Adequate organ function@@ADULTS@III@APPROVED@@@NHS@@@@@@MONO@BRENTUXIMAB@@@@@BRENTUXIMAB||||@SEATTLE GENETICS@MILLENNIUM PHARMACEUTICALS@@@@SEATTLE GENETICS|MILLENNIUM PHARMACEUTICALS|||@World@@@@@World|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@@@@Haematological Malignancy|Hodgkin's Lymphoma||||||||@ADCETRIS@@@@@ADCETRIS||||@Other@CD30@@@@Other|CD30|||@PROGRESSION FREE SURVIVAL@@@@@OVERALL SURVIVAL@Incidence of Adverse Events@@@@RELAPSED@@@@@RANDOMISED@DOUBLE BLIND@PARALLEL ASSIGNMENT@@@76.5@kg@374327.811@@@42.9@month@42.9 month@374327.81@374327.81@286.87@1@1.299@2187.5@@2500@@@@@@@@@@43.75@21@@mg/kg@1.8@1@@@@@@@@@@@7/28/2017@2187.5@2187.5@2.16E+16@POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION, VIAL@GB£@@@@@@@@50@MG@50 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14919827@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@M05BA03@M05B@NO@LAKE FOREST, ILLINOIS@@@Pamidronate disodium is a potent inhibitor of osteoclastic bone resorption. It binds strongly to hydroxyapatite crystals and inhibits the formation and dissolution of these crystals in vitro. Inhibition of osteoclastic bone resorption in vivo may be at least partly due to binding of the drug to the bone mineral. Pamidronate suppresses the accession of osteoclast precursors onto the bone. However, the local and direct antiresorptive effect of bone-bound bisphosphonate appears to be the predominant mode of action in vitro and in vivo. Experimental studies have demonstrated that pamidronate inhibits tumour-induced osteolysis when given prior to or at the time of inoculation or transplantation with tumour cells. Biochemical changes reflecting the inhibitory effect of Aredia on tumour-induced hypercalcaemia, are characterised by a decrease in serum calcium and phosphate and secondarily by decreases in urinary excretion of calcium, phosphate, and hydroxyproline.@@14919827@The treatment of tumour-induced hypercalcaemia. The prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, hypercalcaemia and bone pain) in patients with breast cancer with bone metastases or multiple myeloma with bone lesions, in addition to the specific treatment of the tumour. Paget's disease of bone.@@NO@@@NO REVIEW@@@@100%@Via takeover of Mayne@@@@Tumour-induced hypercalcaemia; please see label for dosing ranges; the total dose of pamidronate disodium may be administered either in a single infusion or in multiple infusions over 2-4 consecutive days. The maximum dose per treatment course is 90 mg for both initial and repeat courses.@EMA, June 2001@@@@@@Pamidronate should never be given as a bolus injection since severe local reactions and thrombophlebitis may occur. It should always be diluted and then given as a slow intravenous infusion. It should not be co-administered with other bisphosphonates. If other calcium lowering agents are used in conjunction with pamidronate, significant hypocalcaemia may result. Convulsions have been precipitated in some patients with tumour-induced hypercalcaemia due to the electrolyte changes associated with this condition and its effective treatment.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@PAMIDRONATE DISODIUM@@@@@PAMIDRONATE DISODIUM||||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@Hypercalcaemia of Malignancy@@@@@Hypercalcaemia of Malignancy|||||||||@GENERIC@@@@@GENERIC||||@Bisphosphonate@@@@@Bisphosphonate||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.299@52.2@@59.66@@@@@@@@@@1.74@@@@@@@@@@@@@@@@7/28/2017@52.2@52.2@4.82E+15@SOLUTION FOR INFUSION - 10 ML@GB£@@@@@@@@30@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14922811@Onco@@@@@300f1018ntsdm@@@@@@NO LABELLED TRIAL@@L01BB02@L01B@NO@BRENTFORD, UNITED KINGDOM@@@@@14922811@Indicated for the treatment of acute leukaemia. It may be utilised in remission induction and it is particularly indicated for maintenance therapy in: acute lymphoblastic leukaemia; acute myelogenous leukaemia. Purinethol may be used in the treatment of chronic granulocytic leukaemia.@@NO@4-Nov@@NO REVIEW@@@@100%@@@@@For adults and children the usual starting dose is 2.5 mg/kg bodyweight per day, or 50-75 mg/m2 body surface area per day, but the dose and duration of administration depend on the nature and dosage of other cytotoxic agents given in conjunction with Puri-Nethol.@TGA, 1 December 1997@12/1/1997@@@@@Treatment with Puri-Nethol causes bone marrow suppression leading to leucopenia and thrombocytopenia and, less frequently, to anaemia. Full blood counts must be taken daily during remission induction and careful monitoring of haematological parameters should be conducted during maintenance therapy.@NO LABELLED TRIAL@No@@@@@@APPROVED@@Unrestricted reimbursement.@PBS@NO LABELLED TRIAL@@@@@@MERCAPTOPURINE@@@@@MERCAPTOPURINE||||@GSK@@@@@GSK||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Chronic Myeloid Leukaemia@@Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Chronic Myeloid Leukaemia||||||@PURINETHOL@@@@@PURINETHOL||||@Anti-metabolite@Purine Analogue@@@@Anti-metabolite|Purine Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@25@0.779@53.53@@57.56@@@@@@@@@@0.04@@@@@@@@@@@@@@@@8/1/2017@2.14@2.14@2818-1537-GE-AS@TABLET@A$@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14922035@Onco@@@@@@@@@@@A complete treatment cycle spans 28 days. Patients randomised to AS1402 will receive a 1-hour infusion of 9 mg/kg on day 1, 8, 15 and 22 of each cycle. Patients will receive letrozole (2.5 mg daily tablet). The second arm includes Femara only. [clinicaltrials.gov]@@-@-@-@LONDON, UNITED KINGDOM@8/1/2011@@AS1402 targets a cancer-associated form of the cell-surface protein MUC1. This form is found in approximately 90% of breast cancers and in a wide range of other tumours. Tissue culture studies have shown that AS1402 binds to MUC1 on cancer cells and leads to their destruction by antibody-dependent cellular cytotoxicity (ADCC), a process involving recruitment of the immune system. Recent studies have shown that MUC1 up-regulates the oestrogen signalling pathway targeted by endocrine therapies. This provides a particular rationale for combining AS1402 with letrozole in Antisoma's phase II trial.@@14922035@AS1402 Combined With Letrozole to Treat Breast Cancer@@-@-@@NO REVIEW@@@@-@Roche holds options to Antisoma products that entered the clinic before November 2007@-@NCT00770354@110@-@-@@@-@@9/1/2008@-@C-201@@-@>> Histologically or cytologically confirmed locally advanced or metastatic breast cancer not amenable to curative therapy     >> Measurable disease according to the RECIST criteria     >> Documented estrogen receptor-positive and/or progesterone receptor-positive tumour@@@II@II@@-@-@Trial registered and commenced. Results expected in 2010. [Antisoma, 30.09.2008]@-@@@@COMBO@-@LETROZOLE@@@@-|LETROZOLE|||@ANTISOMA@@@@@ANTISOMA||||@Russia@@@@@Russia|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@AS-1402@R-1550@FEMARA@@@AS-1402|R-1550|FEMARA||@mAb@Humanised@@@@mAb|Humanised|||@RESPONSE RATE@@@@@PROGRESSION-FREE SURVIVAL@TIME TO PROGRESSION@@@@METASTATIC@LOCALLY ADVANCED@@@@RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@ACTIVE CONTROL@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14971349@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Combo with prednisone versus mitoxantrone and prednisone@@L01CD04@L01C@@PARIS, FRANCE@9/1/2009@@@@14971349@Combo with prednisone in patients previously treated with Taxotere regimen@@@@@NO REVIEW@@@@@@SECOND-LINE@NCT00417079@720@@FDA, 17 June 2010@6/17/2010@@@@12/1/2006@@TROPIC@No@@@@@III@APPROVED@@@@"the combination of cabazitaxel and prednisone/prednisolone significantly reduced the risk of death by 28% [HR=0.72 (95% CI: 0.61-0.84); P<0.0001] with an improvement in the median overall survival of 15.1 months vs. 12.7 months in the mitoxantrone combination arm. [Sanofi-Aventis 27 May 2010 http://en.sanofi-aventis.com/press/press_releases/2010/ppc_28560.asp ] The drug ""has good expectation in terms of recruitment."" Submission is scheduled in 2010. SOURCE: sanofi-aventis Q4 earnings call, 12 February 2008"@The most frequent grade 3/4 hematological adverse events with cabazitaxel were neutropenia (81.7%) assessed by laboratory values, leukopenia (68.2%), anemia (10.5%), and febrile neutropenia (7.5%); the most frequent grade 3/4 non-hematological adverse events were diarrhea (6.2%), fatigue (4.9%), and asthenia (4.6%). Discontinuation of treatment due to adverse events occurred in 18.3% of patients in the cabazitaxel arm and 8.4% of patients in the mitoxantrone arm. Most frequent treatment-emergent adverse events leading to discontinuation in the cabazitaxel arm were neutropenia (2.4%), hematuria (1.3%), diarrhea (1.1%) and fatigue (1.1%). Grade 3/4 peripheral neuropathy occurred in 0.5% of patients in the cabazitaxel arm vs. 0.3% in the mitoxantrone arm. Deaths due to adverse events were 4.9% in the cabazitaxel arm (predominantly due to neutropenia and its complications) vs. 1.9% in the mitoxantrone arm.@@@@COMBO@CABAZITAXEL@PREDNISONE@@@@CABAZITAXEL|PREDNISONE|||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Prostate Cancer@HRPC@@@@Prostate Cancer|HRPC||||||||@JEVTANA@@@@@JEVTANA||||@Taxane@@@@@Taxane||||@OVERALL SURVIVAL@@@@@@@@@@METASTATIC@REFRACTORY@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@1.75@m²@157653.1934@@@15.1@month@15.1 month@157653.19@157653.19@343.26@1@1@9885.9@@@@@@@@@@@@164.77@21@@mg/m²@25@1@@@@@@@@@@@8/2/2017@9885.9@9885.9@00024-5824-11@CONCENTRATE AND SOLVENT FOR SOLUTION FOR INFUSION (CONCENTRATE 1.5 ML + SOLVENT 4.5 ML)@US$@@@@@@@@60@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918243@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@M04AA01@M04A@NO@LEICHINGEN, GERMANY@@@@@14918243@Indicated in the management of patients with signs and symptomas of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephroptahy; the management of patients with leukaemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment should be discontinued when the potential for overproduction of uric acid is no longer presents; and, the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800mg/day in male patients and 750mg/day in female patients. This is not an innocuous drug. It is not recommended for the treatment of asymptomatic hyperuricemia.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@Dosage in Adults: should be introduced at low dosage e.g. 100mg/day to reduce the risk of adverse reactions and increased only if the serum urate response is unsatisfactory. Extra caution should be exercised if renal function is poor. The following dosage schedules are suggested: 100 to 200 mg daily in mild conditions, 300 to 600 mg daily in moderately severe conditions, 700 to 900 mg daily in severe conditions. If dosage on a mg/kg bodyweight basis is required, 2 to 10 mg/kg bodyweight/day should be used. Dosage in children: Children under 15 years: 10 to 20 mg/kg bodyweight/day up to a maximum of 400 mg daily. Use in children is rarely indicated, except in malignant conditions (especially leukaemia) and certain enzyme disorders such as Lesch-Nyhan syndrome.@@@@@@@Should be discontinued at the first appearance of skin rash or other signs which may indicate an allergic rection. Dose should be adjusted if co-administered with Purinethol or Imuran.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@ALLOPURINOL@@@@@ALLOPURINOL||||@ALIUD PHARMA@@@@@ALIUD PHARMA||||@@@@@@|||||||||@Supportive Care@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Non-Hodgkin's Lymphoma@Supportive Care|Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Non-Hodgkin's Lymphoma|||||@GENERIC@@@@@GENERIC||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@50@1.1511@0.57@11.7@1.28@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@@@3399801@TABLET@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14921973@Onco@@@@@300f1008ntsdm@@@@@@-@@L02BA01@L02B@YES@-@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14921973@Nolvadex is indicated for: 1. The treatment of breast cancer. 2. The treatment of anovulatory infertility.@@NA@-@@NO REVIEW@@@@-@-@-@-@-@Adults: The recommended daily dose of tamoxifen is normally 20 mg. No additional benefit, in terms of delayed recurrence or improved survival in patients, has been demonstrated with higher doses. Substantive evidence supporting the use of treatment with 30–40 mg per day is not available, although these doses have been used in some patients with advanced disease.@-@@@-@@@Menstruation is suppressed in a proportion of premenopausal women receiving Nolvadex for the treatment of breast cancer. An increased incidence of endometrial changes including hyperplasia, polyps, cancer and uterine sarcoma (mostly malignant mixed Mullerian tumours), has been reported in association with Nolvadex treatment. The underlying mechanism is unknown but may be related to the oestrogenlike effect of Nolvadex. Any patient receiving or having previously received Nolvadex who report abnormal gynaecological symptoms, especially vaginal bleeding, or who presents with menstrual irregularities, vaginal discharge and symptoms such as pelvic pain or pressure should be promptly investigated.@-@No@-@-@@@-@DISCONTINUED@@-@NHI@RESULTS PENDING@-@@@@-@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@KOTOBUKI PHARMACEUTICAL@@@@@KOTOBUKI PHARMACEUTICAL||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@NORXIFEN@@@@@NORXIFEN||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@@@@1@0.01111@@@@@@@@@@@@@@@@@@@@@@@@@@@@@1/1/2015@@@4291003F1198@TABLETS@YEN@@@@@@@@10@MG@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14918885@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14918885@Breakthrough cancer pain@@-@-@@NO REVIEW@@@@-@Nastech spokesperson confirms that work has not been conducted on the drug since 2002 but that it is available for licensing. SOURCE: Nastech/Global Insight, 11 March 2008@-@-@N/A@-@-@@@-@@@-@N/A@@-@-@@@II@II@@-@-@Nastech spokesperson confirms that work on this product has not been conducted since 2002. SOURCE: Nastech/Global Insight, 11 March 2008The study data showed that intranasal morphine gluconate was rapidly absorbed, with onset of pain relief at an average of 2.2 minutes post dosing and a mean time to meaningful pain relief of 9.1 minutes. The median time to maximum concentration of the drug in the blood was 15 minutes and the maximum concentration of the drug in the blood was 64 nanograms per milliliter, which is similar to the injection, making intranasal morphine gluconate appropriate for treating opioid tolerant cancer patients with breakthrough pain. There was a statistically significant difference between baseline pain intensity versus post dose pain intensity. None of the patients needed to take another breakthrough pain medication (rescue medication) within 30 minutes after dosing, and 64 percent of the patients did not need rescue medication within the first hour. SOURCE: Nastech, 10 December 2002@-@@@@MONO@MORPHINE GLUCONATE@@@@@MORPHINE GLUCONATE||||@NASTECH@@@@@NASTECH||||@@@@@@|||||||||@Supportive Care@@@@@Supportive Care|||||||||@-@@@@@-||||@Opioid Analgesic@@@@@Opioid Analgesic||||@PAIN RELIEF@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRANASAL@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917735@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01CB01@L01C@YES@NEW YORK, NEW YORK@@@Etoposide is a semisynthetic derivative of podophyllotoxin used in the treatment of certain neoplastic diseases. Podophyllotoxins inhibit mitosis by blocking microtubular assembly. Etoposide inhibits cell cycle progression at a premitotic phase (late S and G2). It does not interfere with the synthesis of nucleinic acids.@@14917735@Used in combination therapy with other approved chemotherapeutics in patients with refractory testicular tumors who have already received appropriate surgical, chemotherapeutic, and radiotherapeutic therapy; used in combination with other approved chemotherapeutic agents as first-line treatment in patients with small cell lung cancer.@@YES@5-Dec@@NO REVIEW@@@@@@@@@The usual dose in testicular cancer in combination with other approved chemotherapeutic agents ranges from 50 to 100 mg/m2/day on days 1 through 5 to 100 mg/m2/day on days 1, 3, and 5. In small cell lung cancer, the dose in combination with other approved chemotherapeutic drugs ranges from 35 mg/m2/day for 4 days to 50 mg/m2/day for 5 days.@May-96@@5/1/1997@@@@Patients being treated with VePesid must be frequently observed for myelosuppression both during and after therapy. Myelosuppression resulting in death has been reported. Dose-limiting bone marrow suppression is the most significant toxicity associated with VePesid therapy. Therefore, the following studies should be obtained at the start of therapy and prior to each subsequent cycle of VePesid: platelet count, haemoglobin, white blood cell count, and differential. The occurrence of a platelet count below 50,000/mm3 or an absolute neutrophil count below 500/mm3 is an indication to withhold further therapy until the blood counts have sufficiently recovered.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@ETOPOSIDE PHOSPHATE@@@@@ETOPOSIDE PHOSPHATE||||@BMS@@@@@BMS||||@@@@@@|||||||||@Testicular Cancer@SCLC@@@@Testicular Cancer|SCLC||||||||@ETOPOPHOS@@@@@ETOPOPHOS||||@Plant Alkaloid@Topoisomerase II Inhibitor@@@@Plant Alkaloid|Topoisomerase II Inhibitor|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@9184438R@LYOPHILIZATE FOR PARENTERAL USE@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14924406@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01AD04@L01A@YES@NEW YORK, NEW YORK@@@@@14924406@Zanosar is indicated in the treatment of metastatic islet cell carcinoma of the pancreas. Responses have been obtained with both functional and nonfunctional carcinomas. Because of its inherent renal toxicity, therapy with this drug should be limited to patients with symptomatic or progressive metastatic disease.@@YES@5-May@@NO REVIEW@@@@100%@@@@@Weekly Schedule—The recommended initial dose for weekly intravenous administration is 1000 mg/m2 of body surface area at weekly intervals for the first two courses (weeks). In subsequent courses, drug doses may be escalated in patients who have not achieved a therapeutic response and who have not experienced significant toxicity with the previous course of treatment. However, a single dose of over 1500 mg/m2 should not be exceeded as a greater dose may cause azotemia. When administered on this schedule, the median time to onset of response is about 17 days and the median time to maximum response is about 35 days. The median total dose to onset of response is about 2000 mg/m2 body surface area and the median total dose to maximum response is about 4000 mg/m2 body surface area. The ideal duration of maintenance therapy has not yet been clearly established for either of the above schedules.@Feb-85@@9/1/1988@@@@Zanosar should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. A patient need not be hospitalized but should have access to a facility with laboratory and supportive resources sufficient to monitor drug tolerance and to protect and maintain a patient compromised by drug toxicity. Renal toxicity is dose-related and cumulative and may be severe or fatal. Other major toxicities are nausea and vomiting which may be severe and at times treatment-limiting. In addition, liver dysfunction, diarrhea, and haematological changes have been observed in some patients. Streptozocin is mutagenic. When administered parenterally, it has been found to be tumourigenic or carcinogenic in some rodents.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@STREPTOZOCIN@@@@@STREPTOZOCIN||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@ZANOSAR@@@@@ZANOSAR||||@Alkylating Agent@Nitrosourea@@@@Alkylating Agent|Nitrosourea|||@@@@@@@@@@@METASTATIC@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@135@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/2/2017@135@135@9123201R@LYOPHILIZATE FOR INJECTABLE PREPARATION@EURO@@@@@@@@1@G@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14921732@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@FOLFOX-4 with or without vatalanib@@-@-@-@BASEL, SWITZERLAND@10/1/2004@@"Vatalanib (PTK/ZK) is a ""small"" molecule tyrosine kinase inhibitor with broad specificity that targets all VEGF receptors (VEGFR), the platelet-derived growth factor receptor, and c-KIT. It is a multi-VEGFR inhibitor designed to block angiogenesis and lymphangiogenesis by binding the intracellular kinase domain of all three VEGFRs, VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3 (Flt-4). Vatalanib is a targeted drug that inhibits the activity of all known receptors that bind VEGF. The drug potently inhibits the formation of new blood vessels (angiogenesis). "@@14921732@Second-line colorectal cancer@@-@-@@NO REVIEW@@@@-@PTK/ZK was among 20 projects discontinued by Bayer Schering as part of its merger. SOURCE: Bayer, 19 June 2007Following a modified agreement in January 2005, Novartis and Schering AG will co-market vatalanib in Europe, North America and Japan for oncolo@SECOND-LINE@NCT00056446@830@-@-@@@-@@1/1/2003@-@CONFIRM 2@@-@-@@@III@III@@-@-@Independent DSMB found low probability that the trial would reach primary endpoint. Schering and Bayer reported improvement in the PFS secondary endpoint for vatalanib, particularly in patients with high lactate dehydrogenase levels. SOURCE: Novartis/Schering AG, 28 July 2005@-@@@@COMBO@VATALANIB@@@@@VATALANIB||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@PTK-787@ZK-222584@PTK/ZK@@@PTK-787|ZK-222584|PTK/ZK||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@OVERALL SURVIVAL@@@@@@@@@@METASTATIC@@@@@RANDOMISED@DOUBLE-BLIND@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16384789@Onco@@@@@300f1014ntsdm@@@@@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384789@Indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.@@EXPENSIVE ITEM APPENDIX III (LIMITED WHOLESALE MARGIN)@@@NO REVIEW@@@@@@FIRST-LINE@@@The recommended dose of Glivec is 600 mg/day for adult patients with Ph+ ALL.@@@@Yes@@@@@No@@@ADULT@@@APPROVED@@For treatment of CML in the chronic, blasic, or accelerated phase. For treatment of inoperable, recividant, or metastatic GIST with presence of c-kit receptor. [RAMQ 18 November 2009]@RAMQ@@@@@@BOTH@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@@@@Haematological Malignancy|Acute Lymphocytic Leukaemia||||||||@GLEEVEC@@@@@GLEEVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@@@@@@@@@@@1@1@58075.33104@@@1@year@1 year@58075.33@58075.33@159.11@120@0.7881@3182.21@@@@@@@@@@@@0.27@1@@mg@600@1@@@@@@@@@@@7/19/2017@26.52@26.52@2253275120@TABLET@C$@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14922313@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@AGS-003 with Sutent@@-@-@-@DURHAM, NORTH CAROLINA@@@@@14922313@Newly diagnosed Stage IV kidney cancer; Combo with Sutent@@-@-@@NO REVIEW@@@@-@Merger between Kyowa Hakko and Kirin announced in October 2007. Co-developing between Argos and Kirin@FIRST-LINE@NCT00272649@26@-@-@@@-@@1/1/2006@-@AGS-003-004@@-@AROUND 26 PATIENTS WITH NEWLY DIAGNOSED, METASTATIC MRCC@@@I/II ; Bukowski-8077, Logan-0506-05, Drabkin-05-0167, White-04-05-01A, Figlin-05-03-099-01; @II@@-@-@RESULTS PENDING@-@@@@-@-@SUNITINIB@@@@-|SUNITINIB|||@ARGOS THERAPEUTICS@KIRIN PHARMA@@@@ARGOS THERAPEUTICS|KIRIN PHARMA|||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@AGS-003@SUTENT@@@@AGS-003|SUTENT|||@Immunotherapy@@@@@Immunotherapy||||@RESPONSE RATE@PROGRESSION-FREE SURVIVAL@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16395654@Onco@@@@@300f1037ntsdm@@@@@@10 mg once daily or 10 mg once daily for 21 days every 28 days. Sequential dose reductions to 5 mg daily and 5 mg every other day, as well as dose delays, were allowed for toxicity.@@L04AX04@L04A@@SUMMIT, NEW JERSEY@@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16395654@Indicated for the treatment of patients with transfusiondependent anaemia due to low or intermediate1risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.@@YES@@@NO REVIEW@@@@@@@@148@The recommended starting dose of lenalidomide is 10 mg orally once daily on days 121 of repeated 28day cycles. Dosing is continued or modified based upon clinical and laboratory findings.@EMA, 25 April 2013@4/25/2013@@Yes@@@@MDS003@No@@148 PATIENTS WHO HAD RBC TRANSFUSION DEPENDENT ANEMIA. RBCTRANSFUSION DEPENDENCE WAS DEFINED AS HAVING RECEIVED = 2 UNITS OF RBCS WITHIN 8 WEEKS PRIOR TO STUDY TREATMENT. THE STUDY ENROLLED PATIENTS WITH ABSOLUTE NEUTROPHIL COUNTS (ANC) = 500 CELLS/MM3,@@@III@APPROVED@@@SNS@@@@@@MONO@LENALIDOMIDE@@@@@LENALIDOMIDE||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myelodysplastic Syndrome@@@@Haematological Malignancy|Myelodysplastic Syndrome||||||||@REVLIMID@@@@@REVLIMID||||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@@@@@@@@@@@@@@@@OPEN-LABEL@SINGLE-ARM@MULTI-CENTRE@@@1@1@10532.83997@@@56@day@56 day@10532.84@10532.84@188.09@21@1.1511@5266.42@5535.22@5273.96@@@@@@@@@@25.08@28@@mg@10@21@@@@@@@@@@@8/4/2017@250.78@250.78@652629@CAPSULE@EURO@@@@@@@@10@MG@10 MG@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14922596@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Alimta + Gemzar (with dexamethasone)@@L01BA04@L01B@-@INDIANAPOLIS, INDIANA@@@Pemetrexed is an antifolate containing the pyrrolopyrimidine-based nucleus that exerts its antineoplastic activity by disrupting folate-dependent metabolic processes essential for cell replication. In vitro studies have shown that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), all folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is transported into cells by both the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT. Polyglutamation is a time- and concentration-dependent process that occurs in tumor cells and, to a lesser extent, in normal tissues. Polyglutamated metabolites have an increased intracellular half-life resulting in prolonged drug action in malignant c@@14922596@Advanced non-clear cell renal cell cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00491075@40@-@-@@@-@@12/1/2005@-@2005-0516  @@FEBRUARY 2009 (NCE); FEBRUARY 2011 (ORPHAN)@-@@@II@II@@-@-@RESULTS PENDING (recruiting).@-@@@@COMBO@PEMETREXED@GEMCITABINE@@@@PEMETREXED|GEMCITABINE|||@LILLY@@@@@LILLY||||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@ALIMTA@GEMZAR@@@@ALIMTA|GEMZAR|||@Anti-metabolite@Folic Acid Analogue@@@@Anti-metabolite|Folic Acid Analogue|||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@POWDER FOR INFUSION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16394682@Onco@@@@@300f1010ntsdm@@@@@@@@L04AX04@L04A@@SUMMIT, NEW JERSEY@3/1/2017@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16394682@Treatment of adult patients with relapsed or refractory mantle cell lymphoma@Both@NO@@@NO REVIEW@@@@100%@@@NCT00875667@254@The recommended starting dose of lenalidomide is 25 mg orally once daily on days 121 of repeated 28day cycles.@EMA, 28 January 2016@1/28/2016@@Yes@@4/1/2009@@CC5013MCL002@No@@Biopsy proven mantle cell lymphoma; Patients who are refractory to their regimen or have relapsed once, twice or up to three times and who have documented progressive disease; Eastern Cooperative Oncology Group (ECOG) performance score 0,1, or 2; Willing to follow pregnancy precaution@@ADULTS@II@APPROVED@@@NHS@@@@@@MONO@LENALIDOMIDE@@@@@LENALIDOMIDE||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Non-Hodgkin's Lymphoma@Mantle Cell Lymphoma@@@@Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma||||||||@REVLIMID@@@@@REVLIMID||||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@PROGRESSION FREE SURVIVAL@@@@@OVERALL RESPONSE RATE@DURATION OF RESPONSE@TIME TO PROGRESSION@@@RELAPSED@REFRACTORY@@@@RANDOMISED@MULTI-CENTRE@OPEN LAB EL@@@1@1@48979.875@@@37.6@week@37.6 week@48979.88@48979.88@186.09@21@1.299@4168.5@@@@@@@@@@@@9.93@28@@mg@25@21@@@@@@@@@@@7/28/2017@198.5@198.5@2.99E+16@CAPSULE@GB£@@@@@@@@20@MG@20 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14918624@Onco@@@@@300f1020ntsdm@@@@@@NO LABELLED TRIAL@@-@-@YES@ULM, GERMANY@@@Paclitaxel is an antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilises microtubules by preventing depolymerisation. This stability inhibits the normal dynamic reorganisation of the microtubule network, which is essential for vital interphase and mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or bundles of microtubules throughout the cell cycle and multiple astersof microtubules during mitosis.@@14918624@Ovarian carcinoma: in the first-line chemotherapy of ovarian cancer, Taxol is indicated for the treatment of patients with advanced carcinoma of the ovary or with residual disease ( > 1 cm) after initial laparotomy, in combination with cisplatin. In the second-line chemotherapy of ovarian cancer, Taxol is indicated for the treatment of metastatic carcinoma of the ovary after failure of standard, platinum containing therapy. Breast carcinoma: In the adjuvant setting, Taxol is indicated for the treatment of patients with node-positive breast carcinoma following anthracycline and cyclophosphamide (AC) therapy. Adjuvant treatment with Taxol should be regarded as an alternative to extended AC therapy. Taxol is indicated for the initial treatment of locally advanced or metastatic breast cancer either in combination with an anthracycline in patients for whom anthracycline therapy is suitable, or in combination with trastuzumab, in patients who over-express HER-2 at a 3+ level as determined by immunohistochemistry and for whom an anthracycline is not suitable. As a single agent, Taxol is indicated for the treatment of metastatic carcinoma of the breast in patients who have failed, or are not candidates for standard, anthracycline containing therapy. Advanced non-small cell lung carcinoma: Taxol, in combination with cisplatin, is indicated for the treatment of non-small cell lung carcinoma (NSCLC) in patients who are not candidates for potentially curative surgery and/or radiation therapy. AIDS-related Kaposi's sarcoma: Taxol is indicated for the treatment of patients with advanced AIDS-related Kaposi's sarcoma (KS) who have failed prior liposomal anthracycline therapy.@@YES@-@@NO REVIEW@@@@100%@-@-@-@-@175 mg/m² administered over a period of 3 hours, with a 3 week interval between courses.@N/A@@@-@@@Paclitaxel should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. Since significant hypersensitivity reactions may occur, appropriate supportive equipment should be available. Patients must be pretreated with corticosteroids, antihistamines and H2 antagonists. Taxol should be given before cisplatin when used in combination.@NO LABELLED TRIAL@@-@-@@@-@APPROVED@@1@SSN@NO LABELLED TRIAL@-@@@@-@PACLITAXEL@@@@@PACLITAXEL||||@RATIOPHARM@@@@@RATIOPHARM||||@@@@@@|||||||||@Ovarian Cancer@NSCLC@Sarcoma@Kaposi's Sarcoma@@Ovarian Cancer|NSCLC|Sarcoma|Kaposi's Sarcoma||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@@@@@1@1.1229@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@EURO@@@@@@@@30@MG@6 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14920200@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Eloxatin + 5-FU/LV FOLFOX4 (1123): Day 1: Eloxatin: 85 mg/m2 (2-hour infusion) + LV: 200 mg/m2 (2-hour infusion), followed by 5-FU: 400 mg/m2 (bolus), 600 mg/m2 (22-hour infusion) ; Day 2: LV: 200 mg/m2 (2-hour infusion), followed by 5-FU: 400 mg/m2 (bolus), 600 mg/m2 (22-hour infusion) - every 2 weeks for 12 cycles 5-FU/LV alone (1123): Day 1: LV: 200 mg/m2 (2-hour infusion), followed by 5-FU: 400 mg/m2 (bolus), 600 mg/m2 (22-hour infusion) ; Day 2: LV: 200 mg/m2 (2-hour infusion), followed by 5-FU: 400 mg/m2 (bolus), 600 mg/m2 (22-hour infusion) - every 2 weeks for 12 cycles@@L01XA03@L01X@YES@@@@Eloxatin is an antineoplastic agent which is an organoplatinum complex in which the platinum atom is complexed with 1,2-DACH and with an oxalate ligand as a leaving group. It undergoes non-enzymatic conversion in physiologic solutions to active derivatives via displacement of the labil oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.@@14920200@In combination with infusional 5-FU/LV, is indicated for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumour. The indication is based on an improvement in disease-free survival, with no demonstrated benefit in overall survival after a median follow up of 4 years; used in combination with infusional 5-FU/LV, it is indicated for the treatment of advanced carcinoma of the colon or rectum.@@NO@@@NO REVIEW@@@@@@@@@Adjuvant Therapy in Patients with Stage III Colon Cancer- Adjuvant treatment in patients with stage III colon cancer is recommended for a total of 6 months, i.e., 12 cycles, every 2 weeks, according to the dose schedule described below for previously treated patients with advanced colorectal cancer.@@@@@@@Hypersensitivity and anaphylactic / anaphylactoid reactions to Eloxatin have been reported. Eloxatin may cause fetal harm when administered to a pregnant woman.@@No@8-Feb@@@@@APPROVED@@@MEDICARE@@@@@@@OXALIPLATIN@@@@@OXALIPLATIN||||@APP@@@@@APP||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@GENERIC@@@@@GENERIC||||@Platinum@@@@@Platinum||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1@449@@@@@@@@@@@@4.49@@@@@@@@@@@@@@@@8/2/2017@449@449@63323-0650-20@SOLUTION FOR INJECTION - 20 ML@US$@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15396678@Onco@@@@@300f1018ntsdm@@@@@@Ponatinib: 45 mg tablet taken orally once daily@@L01XE24@L01X@@CAMBRIDGE, MASSACHUSSETTS@10/1/2020@@Ponatinib is an investigational BCR-ABL inhibitor that also selectively inhibits certain other tyrosine kinases in preclinical studies, including FLT3, RET, KIT, and the members of the FGFR and PDGFR families of kinases.@@15396678@Iclusig is indicated for the treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic Ieukaemia (Ph+ ALL)whose disease is resistant to, or who are intolerant of dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or where thereis a T315I mutation.@@NO@1-Nov-15@11/1/2015@NO REVIEW@@@@100%@@@NCT01207440@440@The recommended starting dose of ICLUSIG is 45 mg once daily, taken at the same approximate time each day. Treatment should be continued as long as the patient does not show evidence of diseaseprogression or unacceptable toxicity.@TGA, 26 November 2014@11/26/2014@@No@@9/1/2010@@PACE@No@@@@@II@APPROVED@@@PBS@@@@@@MONO@PONATINIB@@@@@PONATINIB||||@ARIAD PHARMACEUTICALS@MERCK & CO@@@@ARIAD PHARMACEUTICALS|MERCK & CO|||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@@@@Haematological Malignancy|Acute Lymphocytic Leukaemia||||||||@ICLUSIG@@@@@ICLUSIG||||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@RESPONSE RATE@@@@@@@@@@@@@@@OPEN LABEL@SINGLE-ARM@@@@1@1@22714.87042@@@81@day@81 day@22714.87@22714.87@280.43@60@0.779@5608.61@5755.48@5678.55@@@@@@@@@@6.23@1@@mg@45@1@@@@@@@@@@@8/1/2017@93.48@93.48@1726-2073-GE-TS@FILM-COATED TABLET@A$@@@@@@@@15@MG@15 MG@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
16396620@Onco@@@@@300f1010ntsdm@@@@@@10 mg once daily or 10 mg once daily for 21 days every 28 days. Sequential dose reductions to 5 mg daily and 5 mg every other day, as well as dose delays, were allowed for toxicity.@@L04AX04@L04A@@SUMMIT, NEW JERSEY@@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16396620@Indicated for the treatment of patients with transfusiondependent anaemia due to low or intermediate1risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.@@NO@@@NO REVIEW@@@@100%@@@@148@The recommended starting dose of lenalidomide is 10 mg orally once daily on days 121 of repeated 28day cycles. Dosing is continued or modified based upon clinical and laboratory findings.@EMA, 25 April 2013@4/25/2013@@Yes@@@@MDS003@No@@148 PATIENTS WHO HAD RBC TRANSFUSION DEPENDENT ANEMIA. RBCTRANSFUSION DEPENDENCE WAS DEFINED AS HAVING RECEIVED = 2 UNITS OF RBCS WITHIN 8 WEEKS PRIOR TO STUDY TREATMENT. THE STUDY ENROLLED PATIENTS WITH ABSOLUTE NEUTROPHIL COUNTS (ANC) = 500 CELLS/MM3,@@@III@APPROVED@@@NHS@@@@@@MONO@LENALIDOMIDE@@@@@LENALIDOMIDE||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myelodysplastic Syndrome@@@@Haematological Malignancy|Myelodysplastic Syndrome||||||||@REVLIMID@@@@@REVLIMID||||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@@@@@@@@@@@@@@@@OPEN-LABEL@SINGLE-ARM@MULTI-CENTRE@@@1@1@5292@@@56@day@56 day@5292@5292@94.5@21@1.299@3969@@@@@@@@@@@@12.6@28@@mg@10@21@@@@@@@@@@@7/28/2017@189@189@1.18E+16@HARD CAPSULE@GB£@@@@@@@@15@MG@15 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14922999@Onco@@@@@@@@@@@Patients will be randomized either to continue or discontinue Herceptin treatment (6mg/kg iv infusion every 3 weeks) while receiving second-line chemotherapy of the investigator's choice@@-@-@-@BASEL, SWITZERLAND@@@Herceptin (trastuzumab) is a humanized IgG1 kappa monoclonal antibody that selectively binds with high affinity to the extracellular domain of the human epidermal growth factor receptor 2 protein, HER2. Trastuzumab is produced by recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary) culture containing the antibiotic gentamicin. Gentamicin is not detectable in the final product. The HER2 (or c-erbB2) proto-oncogene encodes a transmembrane receptor protein of 185 kDa, which is structurally related to the epidermal growth factor receptor. Herceptin has been shown, in both in vitro assays and in animals, to inhibit the proliferation of human tumor cells that overexpress HER2. Herceptin is a mediator of antibody-dependent cellular cytotoxicity (ADCC). In vitro, Herceptin-mediated ADCC has been shown to be preferentially exerted on HER2 overexpressing cancer cells compared with cancer cells that do not overexpress HER2@@14922999@Herceptin in combination with 2nd line chemotherapy, in patients with HER2 positive metastatic breast cancer whose condition has progressed on 1st line chemotherapy plus Herceptin@@-@-@@NO REVIEW@@@Started in March 2007@-@Roche announces US$43.7 billion proposal to assume full control of Genentech. SOURCE: Roche, 21 July 2008@SECOND-LINE@NCT00444587@-@-@-@@@-@@@-@-@@-@-@@@III@III@@-@-@RESULTS PENDING@-@@@@COMBO@TRASTUZUMAB@@@@@TRASTUZUMAB||||@ROCHE@GENENTECH@@@@ROCHE|GENENTECH|||@@@@@@|||||||||@Breast Cancer@HER2+@@@@Breast Cancer|HER2+||||||||@HERCEPTIN@@@@@HERCEPTIN||||@mAb@Humanised@TK Inhibitor@HER2@@mAb|Humanised|TK Inhibitor|HER2|@TIME TO PROGRESSION@@@@@@@@@@METASTATIC@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916108@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Single-agent mapatumumab@@-@-@-@ROCKVILLE, MARYLAND@@@HGS-ETR1 (mapatumumab) is an agonistic human monoclonal antibody that directly induces cancer-cell death by specifically binding to and activating the protein known as TRAIL receptor 1. Using genomic techniques, HGS originally identified the TRAIL receptor 1 protein. The HGS-ETR1 antibody was generated by HGS through collaboration with Cambridge Antibody Technology. HGS is developing HGS-ETR1 as a potential treatment for a broad range of cancers.@@14916108@-@@-@-@@NO REVIEW@@@@-@HGS reacquired rights to mapatumumab and lexatumumab from GSK in return for royalties due to HGS if Syncria albiglutide is commercialised. SOURCE: HGS, 16 April 2008GSK has exercised 1996 option to jointly develop and commercialise HGS-ETR1, equally sha@-@NCT00092924@N/A@-@-@@@-@@@-@TRM1-ST03@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@MAPATUMUMAB@@@@@MAPATUMUMAB||||@HUMAN GENOME SCIENCES@@@@@HUMAN GENOME SCIENCES||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@HGS-ETR1@@@@@HGS-ETR1||||@mAb@Human@TRAIL Receptor 1@@@mAb|Human|TRAIL Receptor 1||@SAFETY@RESPONSE RATE@@@@@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14923367@Onco@@@@@300f1014ntsdm@@@@@@@@L02BA01@L02B@YES@@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14923367@Nolvadex is indicated for: 1. The treatment of breast cancer. 2. The treatment of anovulatory infertility.@@NO@@@NO REVIEW@@@@100%@@@@@Adults: The recommended daily dose of tamoxifen is normally 20 mg. No additional benefit, in terms of delayed recurrence or improved survival in patients, has been demonstrated with higher doses. Substantive evidence supporting the use of treatment with 30–40 mg per day is not available, although these doses have been used in some patients with advanced disease.@@@@@@@Menstruation is suppressed in a proportion of premenopausal women receiving Nolvadex for the treatment of breast cancer. An increased incidence of endometrial changes including hyperplasia, polyps, cancer and uterine sarcoma (mostly malignant mixed Mullerian tumours), has been reported in association with Nolvadex treatment. The underlying mechanism is unknown but may be related to the oestrogenlike effect of Nolvadex. Any patient receiving or having previously received Nolvadex who report abnormal gynaecological symptoms, especially vaginal bleeding, or who presents with menstrual irregularities, vaginal discharge and symptoms such as pelvic pain or pressure should be promptly investigated.@@No@@@@@@APPROVED@@Unrestricted reimbursement.@RAMQ@RESULTS PENDING@@@@@@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@TAMOFEN 20@@@@@TAMOFEN 20||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@60@0.7881@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@C$@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14918705@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01BC02@L01B@YES@@@@Fluorouracil is an analogue of uracil, a component of ribonucleic acid. The drug is believed to function as an antimetabolite. After intracellular conversion to the active deoxynucleotide, it interferes with the synthesis of DNA by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase. Fluorouracil may also interfere with RNA synthesis.@@14918705@Fluorouracil may be used alone, or in combination, for the management of common malignancies particularly cancer of the colon and breast.@@YES@@@NO REVIEW@@@@100%@@@@@Intravenous infusion: 15mg/kg bodyweight but not more than 1g per infusion, diluted in 300 - 500ml of 5% glucose or 0.9% NaCl injection and given over 4 hours. Alternatively the daily dose may be infused over 30 - 60 minutes or may be given as a continuous infusion over 24 hours. The infusion may be repeated daily until there is evidence of toxicity or a total dose of 12 - 15g has been reached. Intravenousi Injection: l2mg/kg bodyweight may be given daily for 3 days and then, if there is no evidence of toxicity, 6mg/kg on alternate days for 3 further doses. An alternative regimen is 15mg/kg as a single intravenous injection once a week throughout the course. Intra-arterial infusion: 5/7.5mg/kg bodyweight daily may be given by 24 hour continuous intra-arterial infusion.@EMA, July 2003@@@@@@Intravenous infusion: 15mg/kg bodyweight but not more than 1g per infusion, diluted in 300 - 500ml of 5% glucose or 0.9% NaCl injection and given over 4 hours. Alternatively the daily dose may be infused over 30 - 60 minutes or may be given as a continuous infusion over 24 hours. The infusion may be repeated daily until there is evidence of toxicity or a total dose of 12 - 15g has been reached. Intravenousi Injection: l2mg/kg bodyweight may be given daily for 3 days and then, if there is no evidence of toxicity, 6mg/kg on alternate days for 3 further doses. An alternative regimen is 15mg/kg as a single intravenous injection once a week throughout the course. Intra-arterial infusion: 5/7.5mg/kg bodyweight daily may be given by 24 hour continuous intra-arterial infusion.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@FLUOROURACIL@@@@@FLUOROURACIL||||@MEDAC@@@@@MEDAC||||@@@@@@|||||||||@Colorectal Cancer@Breast Cancer@@@@Colorectal Cancer|Breast Cancer||||||||@GENERIC@@@@@GENERIC||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.299@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@SOLUTION FOR INJECTION@GB£@@@@@@@@250@MG@25MG/ML@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14916216@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@NO LABELLED TRIAL@@M04AA01@M04A@NO@@@@@@14916216@Indicated in the management of patients with signs and symptomas of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephroptahy; the management of patients with leukaemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment should be discontinued when the potential for overproduction of uric acid is no longer presents; and, the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800mg/day in male patients and 750mg/day in female patients. This is not an innocuous drug. It is not recommended for the treatment of asymptomatic hyperuricemia.@@NO@@@NO REVIEW@@@@@@@@@For the prevention of uric acid nephropathy during the vigorous therapy of neoplastic disease, treatment with 600 to 800 mg daily for two or three days is advisable together with a high fluid intake. Otherwise similar considerations to the above recommendations for treating patients with gout govern the regulation of dosage for maintenance purposes in secondary hyperuricemia.@@@@@@@Should be discontinued at the first appearance of skin rash or other signs which may indicate an allergic rection. Dose should be adjusted if co-administered with Purinethol or Imuran.@NO LABELLED TRIAL@No@@@@@@APPROVED@@Covered; preferred@MEDICARE@NO LABELLED TRIAL@@@@@@ALLOPURINOL@@@@@ALLOPURINOL||||@QUALITEST@@@@@QUALITEST||||@@@@@@|||||||||@Supportive Care@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Non-Hodgkin's Lymphoma@Supportive Care|Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Non-Hodgkin's Lymphoma|||||@GENERIC@@@@@GENERIC||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1000@1@363.64@@@@@@@@@@@@@@@@@@@@@@@@@@@@9/1/2017@0.36@0.36@00603-2115-32@TABLET@US$@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14925030@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@XL-184 with Tarceva in Phase I; alone or in combination with Tarceva in Phase II@@-@-@-@SOUTH SAN FRANCISCO, CALIFORNIA@@@XL184 inhibits MET, RET, and VEGFR2, which are key drivers of tumor growth, metastasis, survival, and angiogenesis. In pharmacodynamic studies in mice, oral administration of XL184 resulted in balanced and durable inhibition of these targets. The compound has also shown activity against common mutant forms of RET and MET. XL184 has exhibited dose-dependent tumor growth inhibition and tumor regression in a variety of tumor models, including breast cancer, colon cancer, MTC, non-small cell lung cancer, and glioblastoma.@@14925030@Progressed from Tarceva regimen@@-@-@@NO REVIEW@@@@-@GSK has decided not to exercise its option to license XL-184, as well as XL-228, XL-820 and XL-844. [Exelixis, 23.10.2008]@-@NCT00596648@86@-@-@@@-@@1/1/2008@-@202@@-@-@@@I/II@II@@-@-@-@-@@@@BOTH@-@ERLOTINIB@@@@-|ERLOTINIB|||@EXELIXIS@@@@@EXELIXIS||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@XL-184@@@@@XL-184||||@TK Inhibitor@VEGF@Angiogenesis Inhibitor@@@TK Inhibitor|VEGF|Angiogenesis Inhibitor||@SAFETY@PHARMACOKINETICS@@@@@@@@@RELAPSED@REFRACTORY@@@@DOSE ESCALATION@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916193@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Trastuzumab-MCC-DM1 IV repeating dose@@-@-@-@SAN FRANCISCO, CALIFORNIA@1/1/2012@@Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies: anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative). @@14916193@Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer@@-@-@@NO REVIEW@@@@-@">> Roche reaches a friendly agreement to purchase the latter's outstanding shares at a price of US$95 per share. The transaction will be valued at US$46.8 billion. [Genentech, 12 March 2009]>> Roche has made a formal announcement of cash tender offer for all outstanding shares of Genentech at US$86.50 per share for the 44.2% of Genentech not already held by Roche. Genentech's special committee, on the other hand, has responded to the offer by urging its shareholders ""to take no action at this time"". [Genentech, 10.02.2009]          >> Genentech rejects the acquisition bid. [Genentech, 14.08.2008]        >> Roche announces US$43.7 billion proposal to assume full control of Genentech. SOURCE: Roche, 21 July 2008"@-@NCT00679211@100@-@-@@@-@@7/1/2008@-@TDM4374g@@-@Histologically documented breast cancer HER2-positive disease Metastatic breast cancer Disease progression on the last chemotherapy regimen received in the metastatic setting@@@II@II@@-@-@Trial registered. SOURCE: Immunogen, 14 May 2008@-@@@@MONO@TRASTUZUMAB-DM1@@@@@TRASTUZUMAB-DM1||||@GENENTECH@IMMUNOGEN@@@@GENENTECH|IMMUNOGEN|||@@@@@@|||||||||@Breast Cancer@HER2+@@@@Breast Cancer|HER2+||||||||@TRASTUZUMAB-DM1@@@@@TRASTUZUMAB-DM1||||@mAb@Humanised@HER2@EGFR@@mAb|Humanised|HER2|EGFR|@SAFETY@RESPONSE RATE@@@@@@@@@METASTATIC@@@@@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922513@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Intravenous administration in 400MG, 700MG, 1000MG, 1 weekly dosing for 4 weeks@@-@-@-@SEATTLE, WASHINGTON@12/1/2010@@@@14922513@B-cell non-Hodgkin's lymphoma@@-@-@@NO REVIEW@@@@-@TRUBION GRANTED WORLDWIDE RIGHTS TO TRU-15 TO WYETH IN JANUARY 2006@-@NCT00521638@120@-@-@@@-@@12/1/2007@-@3206K2-104@@-@-@@@I/II@DISCONTINUED@@-@-@Wyeth, in reviewing the competitive landscape for CD20-directed therapies, has determined not to pursue such therapies for oncology indications and, as a result, has discontinued clinical development of TRU-015 for non-Hodgkin's lymphoma. SOURCE: Trubion, 27 March 2008@-@@@@MONO@-@@@@@-||||@TRUBION PHARMACEUTICALS@WYETH@@@@TRUBION PHARMACEUTICALS|WYETH|||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@B-Cell Lymphoma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|B-Cell Lymphoma|||||||@TRU-015@@@@@TRU-015||||@Immunotherapy@@@@@Immunotherapy||||@SAFETY@MAXIMUM TOLERATED DOSE@RESPONSE RATE@@@RESPONSE RATE@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924232@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Oral administration to healthy volunteers in sequential dose-escalating cohorts@@-@-@-@PETAH-TIKVA, ISRAEL@@@@@14924232@Liver disease, including liver cancer@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@EMEA COMP recommended for orphan drug status for multiple myeloma; early granted orphan drug designation for CLL and Hodgkin's lymphoma. SOURCE: GPC Biotech, 14 February 2006@2/14/2006@@EMEA COMP recommended for orphan drug status for multiple myeloma; early granted orphan drug designation for CLL and Hodgkin's lymphoma. SOURCE: GPC Biotech, 14 February 2006@@@-@-@@-@-@@@I@I@@-@-@The trial successfully met its objectives of evaluating the safety profile and PK of CF102 single doses, and of determining a dose range for future clinical studies. CF102 was very well-tolerated, with no severe adverse events (SAEs) seen and no dose-limiting toxicity observed. No effects on vital signs, clinical laboratory tests, or electrocardiograms were recorded. The half-life time of CF102 supports once- or twice-daily dosing and exposure levels are above those expected to have pharmacologic activity in HCV and HCC. SOURCE: Can-Fite, 5 May 2008@-@@@@MONO@-@@@@@-||||@CAN-FITE BIOPHARMA@@@@@CAN-FITE BIOPHARMA||||@@@@@@|||||||||@Liver Cancer@@@@@Liver Cancer|||||||||@CF-102@@@@@CF-102||||@Other@@@@@Other||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921641@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients treated with fludarabine phosphate and rituximab with vs without pixantrone. @@-@-@-@SEATTLE, WASHINGTON@@@Pixantrone is an investigational agent under development for the potential treatment of various hematological malignancies, solid tumors and immunological disorders. It was developed to improve the activity and safety of the anthracycline family of anti-cancer agents. Anthracyclines have been shown to be very active clinically in a number of tumor types. However, they are usually associated with cumulative heart damage that prevents them from being used in a large proportion of patients. Pixantrone has been designed to reduce the potential for these severe cardiotoxicities, as well as to potentially increase activity and simplified administration compared to the currently marketed anthracyclines.@@14921641@Relapsed indolent NHL@@-@-@@NO REVIEW@@@@-@Novartis holds an option to develop and commercialise pixantrone based on agreed terms from the Xyotax deal. If Novartis exercises its option on pixantrone under certain conditions, Novartis would pay CTI a US$7.5M fee and up to US$104M in registration an@-@NCT00551239@300@-@FDA FAST-TRACK DESIGNATION FOR RELAPSED OR REFRACTORY INDOELENT NHL GRANTED IN MAY 2007.@@@-@@8/1/2007@-@CTI-CRRI 0807003@@-@-@@@III@III@@-@-@70% confirmed response/unconfirmed response rate. Median duration of response was 25 months (from 2.3-43 months). PFS at 3 years was 50.4%.@-@@@@COMBO@PIXANTRONE@RITUXIMAB@FLUDARABINE@@@PIXANTRONE|RITUXIMAB|FLUDARABINE||@CELL THERAPEUTICS@@@@@CELL THERAPEUTICS||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@PIXUVRI@@@@@PIXUVRI||||@Anthracycline@Topoisomerase II Inhibitor@@@@Anthracycline|Topoisomerase II Inhibitor|||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@RELAPSED@REFRACTORY@@@@RANDOMISED@ACTIVE CONTROL@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919777@Onco@@@@@300f1037ntsdm@@@@@@Tamoxifen compared to ovarian ablation@@L02BA01@L02B@YES@HUARTE-PAMPLONA, SPAIN@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14919777@@@NO@@@NO REVIEW@@@@90%@@@@N/A@Adults: The recommended daily dose of tamoxifen is normally 20 mg. No additional benefit, in terms of delayed recurrence or improved survival in patients, has been demonstrated with higher doses. Substantive evidence supporting the use of treatment with 30–40 mg per day is not available, although these doses have been used in some patients with advanced disease.@1-Jan-91@1/1/1991@@@@@Menstruation is suppressed in a proportion of premenopausal women receiving Nolvadex for the treatment of breast cancer. An increased incidence of endometrial changes including hyperplasia, polyps, cancer and uterine sarcoma (mostly malignant mixed Mullerian tumours), has been reported in association with Nolvadex treatment. The underlying mechanism is unknown but may be related to the oestrogenlike effect of Nolvadex. Any patient receiving or having previously received Nolvadex who report abnormal gynaecological symptoms, especially vaginal bleeding, or who presents with menstrual irregularities, vaginal discharge and symptoms such as pelvic pain or pressure should be promptly investigated.@LABEL@No@@@@@III; METASTATIC BREAST CANCER@APPROVED@@NO REVIEW@SNS@The objective RR, time to treatment failure, and survival were similar with both treatments. In an overview analysis of survival data from the 3 studies, the hazard ratio for death (tamoxifen/ovarian ablation) was 1.00. Elevated serum and plasma oestrogens have been observed in premenopausal women receiving tamoxifen, but the data from the randomized studies do not suggest an adverse effect of this increase. A limited number of premenopausal patients with disease progression during tamoxifen therapy responded to subsequent ovarian ablation.@@@@@MONO@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@CINFA@@@@@CINFA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GENERIC@@@@@GENERIC||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RESPONSE RATE@@@@@@@@@@@@@@@PROSPECTIVE@RANDOMISED@@@@@@Invalid Factory Price@@@@@@@@@500@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@EURO@@@@@@@@10@MG@10 MG@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
16408069@Onco@@@@@@@@@@@"Cohort 1: Necitumumab + Gemcitabine and Carboplatin, Experimental, Predominately European sites. Gemcitabine administered intravenously (IV) and carboplatin IV plus necitumumab IV.Cohort 2: Necitumumab + Gemcitabine and Carboplatin, Experimental, Predominately United States sites. Gemcitabine administered IV and carboplatin IV plus necitumumab IV."@@L01XC22@L01X@@INDIANAPOLIS, INDIANA@11/1/2017@@Necitumumab is a recombinant human lgG1 monoclonal antibody that binds to the human epidermal growth factor receptor (EGFR) and blocks the binding of EGFR to its ligands. Expression and activation of EGFR has been correlated with malignant progression, in@@16408069@A Multicenter, Phase 2 Study of Gemcitabine-Carboplatin Plus Necitumumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)@Both@@@@@Administered IV@@@@@FIRST-LINE@NCT02941601@55@@@@@@@10/1/2016@@16535@@@-  Have confirmed diagnosis of locally advanced or metastatic NSCLC in Cohort 1 and metastatic NSCLC in Cohort 2, predominantly squamous histology. Squamous NSCLC diagnosis must be confirmed by histology or cytology local pathology report.  -  Participant@@ADULTS@Phase 2@II@@@@@@@@@COMBO@NECITUMUMAB@GEMCITABINE@CARBOPLATIN@@@NECITUMUMAB|GEMCITABINE|CARBOPLATIN||@LILLY@@@@@LILLY||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@PORTRAZZA@GENERIC@GENERIC@@@PORTRAZZA|GENERIC|GENERIC||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@Objective Response Rate (ORR): Percentage of Participants With a Complete or Partial Response@@@@@Overall Survival (OS)@Progression Free Survival (PFS)@@@@LOCALLY ADVANCED@METASTATIC@@@@Non-Randomized@Efficacy Study@Single Group Assignment@Open Label@Treatment@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14919360@Onco@@@@@300f1012ntsdm@@@@@@Patients received either Kytril Injection, 40 mcg/kg or the combination of chlorpromazine and dexamethasone. They were all treated with ifosfamide =3 g/m2/day for two or three days.@@A04AA02@A04A@NO@ULM, GERMANY@@@Granisetron is a potent anti-emetic and highly selective antagonist of 5-hydroxytryptamine (5-HT3) receptors. Radioligand binding studies have demonstrated that Granisetron has negligible affinity for other receptor types including 5-HT and dopamine D2 binding sites. Granisetron is effective orally prophylactically in abolishing the retching and vomiting evoked by cytostatic therapy.@@14919360@Kytril tablets are indicated for the prevention of nausea and vomiting induced by cytostatic therapy@@NO@-@@NO REVIEW@@@@0%@-@-@-@88@Adults The dose of Kytril is 1mg twice a day or 2mg once a day during cytostatic therapy. The first dose of Kytril should be administered within one hour before the start of cytostatic therapy. Concomitant use of dexamethasone: The efficacy of Kytril may be enhanced by the addition of dexamethasone. Maximum Dose and Duration of Treatment: Kytril is also available as ampoules for intravenous administration. The maximum dose of Kytril administered orally and/or intravenously over 24 hours should not exceed 9mg.@N/A@@@-@@@Hypersensitivity reactions may occur in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.@-@@-@88 PEDIATRIC PATIENTS RECEIVED EITHER KYTRIL INJECTION 20 MCG/KG OR CHLORPROMAZINE PLUS DEXAMETHASONE@PAEDIATRIC@@CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING / PEDIATRIC STUDIES@DISCONTINUED@@-@GKV@22% of Kytril Injection patients achieved complete response (no vomiting and no moderate or severe nausea in 24 hours) compared with 10% on the chlorpromazine regimen. The median number of vomiting episodes with Kytril Injection was 1.5; with chlorpromazine it was 7.0.@-@@@@MONO@GRANISETRON HYDROCHLORIDE@@@@@GRANISETRON HYDROCHLORIDE||||@RATIOPHARM@@@@@RATIOPHARM||||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@GENERIC@@@@@GENERIC||||@5-HT3 Receptor Antagonist@@@@@5-HT3 Receptor Antagonist||||@RESPONSE RATE@EMETIC EPISODES@@@@@@@@@-@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@1@1.3598@@@@@@@@@@@@@@@@@@@@@@@@@@@@@1/16/2015@@@6326197@FILM-COATED TABLET@EURO@@@@@@@@2@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14922363@Onco@@@@@300f1012ntsdm@@@@@@Triptorelin versus bilateral orchidectomy@@L02AE04@L02A@NO@PARIS, FRANCE@@@@@14922363@Treatment of patients with locally advanced, non-metastatic prostate cancer, as an alternative to surgical castration. Treatment of metastatic prostate cancer. Treatment of endometriosis. Treatment of precocious puberty (onset before 8 years in girls and 9 years in boys).@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@645@Prostate cancer: One intramuscular injection should be administered every 4 weeks (28 days). No dosage adjustment is necessary in the elderly.@HMA, 28 September 2004@9/28/2004@@@@@In adults the prolonged use of GnRH analogues may lead to bone loss which enhances the risk of osteoporosis. Prostate cancer  Initially, Decapeptyl SR like other GnRH analogues causes a transient increase in serum testosterone and consequent worsening of symptoms including increase in bone pain (and serum acid phosphatase levels). Continued treatment leads to suppression of testosterone (and dihydrotestosterone) and consequent improvement in the disease. During the first month of treatment, patients presenting with, or at particular risk of developing, urinary tract obstruction should be carefully monitored, as should those at risk of developing spinal cord compression. Consideration should be given to the use of an anti-androgen for three days prior to treatment, to counteract this initial rise in serum testosterone levels.@LABEL@No@@@@@III; LOCALLY ADVANCED/METASTATIC PROSTATE CANCER@APPROVED@@@GKV@No significant difference in the median survival rates in the triptorelin group versus the orchidectomy group. A study assessing the pharmacodynamic equivalence between triptorelin 3-month and 28-day prolonged release formulations in patients with locally advanced or metastatic prostate cancer, found that equivalent testosterone suppression was achieved, whether 3 doses of Decapeptyl SR 3mg (n=68) or a single dose of Decapeptyl SR 11.25mg (n=63) was given.@@@@@MONO@TRIPTORELIN@@@@@TRIPTORELIN||||@IPSEN@@@@@IPSEN||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@PAMORELIN LA@@@@@PAMORELIN LA||||@LH-RH Analog@@@@@LH-RH Analog||||@SERUM TESTOSTERONE@OVERALL SURVIVAL@@@@@@@@@METASTATIC@@@@@PLACEBO-CONTROLLED@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@142@190.52@147.18@@@@@@@@@@37.87@@@@@@@@@@@@@@@@8/1/2017@142@142@1010845@POWDER AND SOLVANT FOR SOLUTION FOR PERFUSION - 100 ML@EURO@@@@@@@@3.75@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14922772@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@L02AE01@L02A@NO@PARIS, FRANCE@@@@@14922772@For the treatment of advanced prostatic carcinoma (stage C or stage D) in which suppression of testosterone is indicated. Buserelin acts by blockade and subsequent down-regulation of pituitary LHRH receptor synthesis. Gonadotrophin release is consequently inhibited. As a result of this inhibition there is reduced stimulation of testosterone secretion and serum testosterone levels fall to castration range. Before inhibition occurs there is a brief stimulatory phase during which testosterone levels may rise.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Licensed from SRI International@@@@Initiation of therapy: is most conveniently carried out in hospital; 0.5ml Suprefact injection should be injected subcutaneously at 8 hourly intervals for 7 days. Maintenance therapy: on the 8th day of treatment the patient is changed to intranasal administration of Suprefact.@1-Mar-86@3/1/1986@@@@@Patients known to suffer from depression should be carefully monitored during treatment with Suprefact. Prostatic carcinoma: Monitoring of the effect of clinical effect of Suprefact is carried out by methods generally used in prostatic carcinoma. Initially serum testosterone levels rise and a clinical effect will not be seen until levels start to fall into therapeutic (castration) range. Disease flare (temporary deterioration of the patient's condition) has been reported at the beginning of the treatment. The incidence is variable, but of the order of the 10%. Symptoms are usually confined to transient increase in pain, but the exact nature depends on the site of the lesions. Neurological sequelae have been reported where secondary deposits impinge upon the spinal cord or CNS. Disease flare is prevented by the prophylactic use of an anti-androgen, e.g. cyproterone acetate, 300 mg daily. It is recommended that the treatment should be started at least 3 days before the first dose of Suprefact and continued for at least 3 weeks after commencement of the Suprefact therapy.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@BUSERELIN ACETATE@@@@@BUSERELIN ACETATE||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@PROFACT@@@@@PROFACT||||@LH-RH Analog@@@@@LH-RH Analog||||@@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@2@1.1511@55.82@81.56@58.28@@@@@@@@@@4.83@@@@@@@@@@@@@@@@8/1/2017@27.91@27.91@7267545@INJECTION SOLUTION - 5.5 ML@EURO@@@@@@@@5.775@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14917311@Onco@@@@@300f1010ntsdm@@@@@@VAB-6 alone or in combination with surgery@@@@YES@WHITEHOUSE STATION, NEW JERSEY@@@@@14917311@Cosmegen, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms' tumor, childhood rhabdomyosarcoma, Ewing's sarcoma and metastatic, nonseminomatous testicular cancer; aas a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. As a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies.@@NO@@@NO REVIEW@@@@100%@@@@142@Metastatic Nonseminomatous Testicular Cancer: 1000 mcg/m2 intravenously on Day 1 as part of a combination regimen with cyclophosphamide, bleomycin, vinblastine, and cisplatin.  The dose intensity per 2-week cycle for adults or children should not exceed 15 mcg/kg/day or 400-600 mcg/m2/day intravenously for five days. Calculation of the dosage for obese or edematous patients should be performed on the basis of surface area in an effort to more closely relate dosage to lean body mass.@@@@@@@Cosmegen should be administered only under the supervision of a physician who is experienced in the use of cancer chemotherapeutic agents. This drug is HIGHLY TOXIC and both powder and solution must be handled and administered with care. Inhalation of dust or vapors and contact with skin or mucous membranes, especially those of the eyes, must be avoided. Avoid exposure during pregnancy. Due to the toxic properties of dactinomycin (e.g., corrosivity, carcinogenicity, mutagenicity, teratogenicity), special handling procedures should be reviewed prior to handling and followed diligently. Dactinomycin is extremely corrosive to soft tissue. If extravasation occurs during intravenous use, severe damage to soft tissues will occur. In at least one instance, this has led to contracture of the arms.@LABEL@No@@@-@@LABEL: TESTICULAR CANCER@APPROVED@@100%; no NICE review@NHS@112 patients (79%) achieved complete response; relapse was 12% and 71% were alive without disease for 4 years.@@@@@ADJUVANT@DACTINOMYCIN@@@@@DACTINOMYCIN||||@MERCK & CO@@@@@MERCK & CO||||@@@@@@|||||||||@Testicular Cancer@@@@@Testicular Cancer|||||||||@COSMEGEN LYOVAC@@@@@COSMEGEN LYOVAC||||@Cytotoxic Antibiotic@@@@@Cytotoxic Antibiotic||||@COMPLETE RESPONSE@@@@@@@@@@@@@@@RETROSPECTIVE@@@@@@@Invalid Factory Price@@@@@@@@@1@1.2961@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@GB£@@@@@@@@0.5@MG@0.5 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14921030@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Twice weekly dosing for 4 weeks, total of 8 doses @@-@-@-@MORRIS PLAINS, NEW JERSEY@@@Naked humanized antibody targeting CD74 expressing tumors.  Primary use is for the treatment of multiple myeloma.  There are 14,000 new cases and 11,000 deaths every year related to multiple myeloma.  Phase I clinical trials in mutilple myeloma are ongoing. Studies in NHL/CLL are open to enrollment. @@14921030@Patients who have failed at least two prior therapies@@-@-@@NO REVIEW@@@@-@-@THIRD-LINE@NCT00421525@66@-@FDA orphan drug designation for multiple myeloma. SOURCE: Immunomedics press release, 18 March 2008@3/18/2008@@FDA orphan drug designation for multiple myeloma. SOURCE: Immunomedics press release, 18 March 2008@@1/1/2007@-@IMMU-115-01@@-@-@@@I/II@II@@-@-@Endpoint over first 12 weeks, then over 2 years.@-@@@@MONO@MILATUZUMAB@@@@@MILATUZUMAB||||@IMMUNOMEDICS@@@@@IMMUNOMEDICS||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@Chronic Lymphocytic Leukaemia@@@Haematological Malignancy|Myeloma|Chronic Lymphocytic Leukaemia|||||||@IMMU-115@@@@@IMMU-115||||@mAb@Humanised@CD20@@@mAb|Humanised|CD20||@SAFETY@TOLERABILITY@@@@@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924216@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@BASEL, SWITZERLAND@@@Erythropoietin is a glycoprotein that stimulates, as a mitosis-stimulating factor and differentiating hormone, the formation of erythrocytes from precursors of the stem cell compartment. The apparent molecular weight of erythropoietin is 32,000 to 40,000 dalton. The protein fraction of the molecule contributes about 58% and consists of 165 amino acids. The four carbohydrate chains are attached via three N-glycosidic bonds and one O-glycosidic bond to the protein. Epoetin alfa obtained by gene technology is glycosylated and is identical in its amino acid and carbohydrate composition to endogenous human erythropoietin that has been isolated from the urine of anaemic patients. Epoetin alfa has the highest possible purity according to the present state of the art. In particular, no residues of the cell line used for the production are detectable at the concentrations of the active ingredient that are used in humans.@@14924216@Treatment of cancer chemotherapy-associated anaemia@@-@-@@NO REVIEW@@@@-@Sandoz is the generics subsidiary of Novartis.@-@-@114@-@EMEA approval. [EMEA, 28.08.2007]@@@-@@@-@-@@-@-@@@III@III@@-@-@"HX575, biosimilar version, had effect on Hb response that EMEA said was similar to the ""expected effect of an epoetin in cancer patients with chemotherapy-induced anemia"". Hb response was defined as an in creasein Hb production of >2g/dL during weeks 5-12 of the study. In the intent-to-treat population, 61.7% of patients receiving HX575 responded vs 44.1% of patients receiving Eprex/Erypro epoetin alfa from JNJ."@-@@@@-@EPOETIN ALFA@@@@@EPOETIN ALFA||||@NOVARTIS@SANDOZ@@@@NOVARTIS|SANDOZ|||@@@@@@|||||||||@Supportive Care@Anaemia@@@@Supportive Care|Anaemia||||||||@BINOCRIT@BIOSIMILAR@@@@BINOCRIT|BIOSIMILAR|||@EPO@@@@@EPO||||@BIOEQUIVALENCE@@@@@@@@@@-@@@@@DOUBLE-BLIND@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16670310@Onco@@@@@300f1020ntsdm@@@@@@This study investigated the use of combination therapy of MPR (melphalan 0.18 mg/kg orally on days 1-4 of repeated 28-day cycles; prednisone 2 mg/kg orally on days 1-4 of repeated 28-day cycles; and lenalidomide10 mg/day orally on days 1-21 of repeated 28-day cycles) for induction therapy, up to 9 cycles. Patients who completed 9 cycles or who were unable to complete 9 cycles due to intolerance proceeded to maintenancemonotherapy starting with lenalidomide 10 mg orally on days 1-21 of repeated 28-day cycles until disease progression.@@L04AX04@L04A@@SUMMIT, NEW JERSEY@@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16670310@Treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant@Both@YES@20-Oct-16@10/20/2016@NO REVIEW@@@@@@FIRST-LINE@@459@@EMA, 11 February 2015@2/11/2015@@YES@@@@@No@@@@ADULTS@@APPROVED@@Added to the reimbursement list on 20 October 2016 [http://www.gazzettaufficiale.it/eli/id/2016/10/28/16A07750/sg;jsessionid=aYtec5ixDvhYP72a9v3pbw__.ntc-as2-guri2a]@SSN@@@@@@COMBO@LENALIDOMIDE@MELPHALAN@PREDNISONE@@@LENALIDOMIDE|MELPHALAN|PREDNISONE||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@REVLIMID@ALKERAN@GENERIC@@@REVLIMID|ALKERAN|GENERIC||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@PROGRESSION FREE SURVIVAL@@@@@@@@@@@@@@@RANDOMISED@DOUBLE BLIND@@@@1@1@173180.4846@@@27.4@month@27.4 month@173180.48@173180.48@207.8@21@1.1229@5818.41@9602.71@6080.3@@@@@@@@@@11.08@28@@mg@25@21@@@@@@@@@@@6/7/2017@277.07@277.07@38016046@HARD CAPSULE@EURO@@@@@@@@25@MG@25 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14924602@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@L01XX19@L01X@-@-@@@Nektar is developing NKTR-102, a PEGylated form of irinotecan, which was invented by Nektar using its world-leading small molecule PEGylation technology platform. The product is currently in a Phase 2a study to evaluate NKTR-102 in combination with cetuximab. Irinotecan is an important chemotherapeutic agent used for the treatment of solid tumors, including colorectal and lung cancers. By applying Nektar's small molecule PEGylation technology to irinotecan, NKTR-102 may prove to be a more powerful and tolerable anti-tumor agent. Preclinical studies show that treatment with NKTR-102 results in significant suppression of tumor growth in an irinotecan-resistant mouse colorectal tumor model and in similar models of breast and lung cancer. Administration of NKTR-102 in an animal model also results in a markedly improved time-concentration profile for SN38, the active metabolite of irinotecan, as compared to treatment with irinotecan. Nektar PEGylation technology can enhance the properties of therapeutic agents by increasing drug circulation time in the bloodstream, decreasing immunogenicity and dosing frequency, increasing bioavailability and improving drug solubility and stability. It can also be used to modify pharmaceutical agents to preferentially target certain systems within the body. It is a technique in which non-toxic polyethylene glycol (PEG) polymers are attached to therapeutic agents, and it is applicable to most major drug classes, including proteins, peptides, antibody fragments, small molecules, and other drugs. Nektar PEGylation technology is also used in eight additional approved partnered products in the U.S. or Europe today, including UCB's Cimzia for Crohn's Disease, Roche's PEGASYS for hepatitis C and Amgen's Neulasta for neutropenia. @@14924602@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@Trial to start in H2 2008. SOURCE: Nektar, 2 June 2008@-@@@@-@IRINOTECAN, PEGYLATED@@@@@IRINOTECAN, PEGYLATED||||@NEKTAR THERAPEUTICS@@@@@NEKTAR THERAPEUTICS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@NKTR-102@@@@@NKTR-102||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922851@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@M04AA01@M04A@NO@CUXHAVEN, GERMANY@@@@@14922851@Indicated in the management of patients with signs and symptomas of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephroptahy; the management of patients with leukaemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment should be discontinued when the potential for overproduction of uric acid is no longer presents; and, the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800mg/day in male patients and 750mg/day in female patients. This is not an innocuous drug. It is not recommended for the treatment of asymptomatic hyperuricemia. @@NO@-@@NO REVIEW@@@@0%@TAD Pharma was created in 2008 following the merger of Krka's Munich and Frankfurt subsidiaries.@-@-@-@Dosage in Adults: should be introduced at low dosage e.g. 100mg/day to reduce the risk of adverse reactions and increased only if the serum urate response is unsatisfactory. Extra caution should be exercised if renal function is poor. The following dosage schedules are suggested: 100 to 200 mg daily in mild conditions, 300 to 600 mg daily in moderately severe conditions, 700 to 900 mg daily in severe conditions. If dosage on a mg/kg bodyweight basis is required, 2 to 10 mg/kg bodyweight/day should be used. Dosage in children: Children under 15 years: 10 to 20 mg/kg bodyweight/day up to a maximum of 400 mg daily. Use in children is rarely indicated, except in malignant conditions (especially leukaemia) and certain enzyme disorders such as Lesch-Nyhan syndrome.@N/A@@@-@@@Should be discontinued at the first appearance of skin rash or other signs which may indicate an allergic rection. Dose should be adjusted if co-administered with Purinethol or Imuran.@NO LABELLED TRIAL@@-@-@@@-@DISCONTINUED@@-@GKV@NO LABELLED TRIAL@-@@@@-@ALLOPURINOL@@@@@ALLOPURINOL||||@TAD PHARMA@KRKA@@@@TAD PHARMA|KRKA|||@@@@@@|||||||||@Supportive Care@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Non-Hodgkin's Lymphoma@Supportive Care|Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Non-Hodgkin's Lymphoma|||||@REMID@@@@@REMID||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@100@1.3598@@@@@@@@@@@@@@@@@@@@@@@@@@@@@11/19/2014@@@2359573@TABLET@EURO@@@@@@@@300@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14916419@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@FOLFIRI plus Vectibix or Avastin@@L01XC08@L01X@@THOUSAND OAKS, CALIFORNIA@@@Panitumumab binds specifically to EGFR on both normal and tumor cells, and competitively inhibits the bindingof ligands for EGFR. Nonclinical studies show that binding of panitumumab to the EGFR prevents ligand-inducedreceptor autophosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth,induction of apoptosis, decreased proinflammatory cytokine and vascular growth factor production, andinternalization of the EGFR. In vitro assays and in vivo animal studies demonstrate that panitumumab inhibits thegrowth and survival of selected human tumor cell lines expressing EGFR.@@14916419@FOLFIRI plus Vectibix versus FOLFIRI plus Avastin@@@@@NO REVIEW@@@@@Acquired through takeover of Abgenix, with which it was co-developing the drug, in December 2005. Takeda and Amgen signed a deal in February 2008 through which, in its first part, Takeda acquired Japanese rights for up to 13 molecules in Amgen's pipeline,@SECOND-LINE@NCT00418938@200@@@@@@@11/1/2006@@SPIRITT@@PATENT STATUS REMAINS IN DISPUTE; AMGEN LICENSED THE SCHLESSINGER PATENT ('866) UNTIL 2017 IN SEPTEMBER 2006 FROM YEDA.@200 PATIENTS WITH MCRC FAILED FIRST-LINE THERAPY.@@@II@II@@@@RESULTS PENDING (recruiting).@@@@@COMBO@PANITUMUMAB@LEUCOVORIN@FLOROURACIL@IRINOTECAN@@PANITUMUMAB|LEUCOVORIN|FLOROURACIL|IRINOTECAN|@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@VECTIBIX@FOLFIRI@@@@VECTIBIX|FOLFIRI|||@mAb@Human@TK Inhibitor@EGFR@@mAb|Human|TK Inhibitor|EGFR|@RESPONSE RATE@COMPLETE RESPONSE@PARTIAL RESPONSE@@@PARTIAL RESPONSE@@@@@METASTATIC@@@@@RANDOMISED@OPEN-LABEL@UNCONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921633@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients received 200 mg b.i.d. x 7 days followed by 14 day - rest or 300 mg b.i.d. x 7 days followed by 14 day - rest or 400 mg b.i.d. x 3 days/week x 2 weeks followed by 7 day -rest @@-@-@-@BERKELEY HEIGHTS, NEW JERSEY@11/1/2009@@Sapacitabine acts through a dual mechanism, interfering with DNA synthesis by causing single-strand DNA breaks and inducing arrest of cell cycle progression mainly at G2/M-Phase. Both sapacitabine and CNDAC, its major metabolite, have demonstrated potent anti-tumor activity in preclinical studies. Sapacitabine to date has been given as a single agent to approximately 170 patients with both hematologic malignancies and solid tumors in four Phase 1 studies. In an earlier reported Phase 1 trial two treatment schedules of sapacitabine were evaluated in 47 pretreated patients with advanced leukemias or MDS. Six patients achieved complete remission or complete remission without platelet count recovery and a further 15 achieved non-detectable levels of leukemic blast cells in their bone marrow. In addition to the Phase 2 study in elderly AML and MDS patients, sapacitabine is being studied in a currently ongoing Phase 2 study in patients with advanced cutaneous T cell lymphoma.@@14921633@In elderly patients@@-@-@@NO REVIEW@@@@-@Licensed in 2003 from Daiichi Sankyo@-@NCT00590187@60@-@-@@@EMEA grants orphan drug designation for AML and MDS. SOURCE: Cyclacel, 27 May 2008@@12/1/2007@-@CYC682-06@@-@-@ELDERLY@@II@II@@-@-@>> Enrolment completed. Interim results expected by year-end, with final results in H2 2009. [Cyclacel, 10.10.2008]>> Protocal amended to expand this trial to include patients with second-line MDS. [Cyclacel, 12.09.2008]>> Endpoint is survival at one year.@-@@@@MONO@SAPACITABINE@@@@@SAPACITABINE||||@CYCLACEL PHARMACEUTICALS@@@@@CYCLACEL PHARMACEUTICALS||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@Myelodysplastic Syndrome@@@Haematological Malignancy|Acute Myeloid Leukaemia|Myelodysplastic Syndrome|||||||@CYC-682@@@@@CYC-682||||@Nucleoside Analogue@@@@@Nucleoside Analogue||||@OVERALL SURVIVAL@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@DOSE COMPARISON@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919393@Onco@@@@@300f1018ntsdm@@@@@@NO LABELLED TRIAL@@L01XA01@L01X@YES@NEW YORK, NEW YORK@@@Cisplatin has biochemical properties similar to those of bifunctional alkylating agents. The drug inhibits DNA synthesis by producing intrastrand and interstrand cross links in DNA. Protein and RNA synthesis are also inhibited to a lesser extent. Although the principal mechanism of action of cisplatin appears to be inhibition of DNA synthesis, other mechanisms, including enhancement of tumour immunogenicity, may be involved in its antineoplastic activity. Cisplatin also has immunosuppressive, radiosensitising, and antimicrobial properties.@@14919393@In combination with other chemotherapeutics and after appropriate surgigical and/or radiotherapeutic procedures, Platinol-AQ is indicated for for metastatic testicular tumours and metastatic ovarian tumours- an established combination for the latter is Platinol-AQ and Cytoxan. As a single agent, it is approved as a secondary therapy in patients with metastatic ovarian tumours refractory to standard chemotherapy but not received Platinol-AQ, and transitional cell bladder cancer which is no longer amenable to local treatments such as surgery and/or radiotherapy.@@NO@@@NO REVIEW@@@@100%@@@@@For monotherapy, the following two dosage regimens are recommended:- Single dose of 50 to 120 mg/m² body surface every 3 to 4 weeks; - 15 to 20 mg/m²/day for five days, every 3 to 4 weeks. If cisplatin is used in combination chemotherapy, the dose of cisplatin must be reduced. A typical dose is 20 mg/m² or more once every 3 to 4 weeks.@@@@@@@Platinol-AQ produces cumulative nephrotoxicity which is potentiated by aminoglycoside antibiotics. The serum creatinine, BUN, creatinine clearance, and magnesium, sodium, potassium, and calcium levels should be measured prior to initiating therapy, and prior to each subsequent course. At the recommended dosage, it should not be given more frequently than once every 3 to 4 weeks. Elderly patients may be more susceptible to nephrotoxicity. There are reports of severe neuropathies in patients in whom regimens are employed using higher doses or greater dose frequencies than those recommended. These neuropathies may be irreversible and are seen as paresthesias in a stocking-glove distribution, areflexia, and loss of proprioception and vibratory sensation. Elderly patients may be more susceptible to peripheral neuropathy. Loss of motor function has also been reported. Anaphylactic-like reactions have been reported within minutes of administration to patients with prior exposure, and have been alleviated by administration of epinephrine, corticosteroids, and antihistamines.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@PBS@NO LABELLED TRIAL@@@@@@CISPLATIN@@@@@CISPLATIN||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Ovarian Cancer@Testicular Cancer@Bladder Cancer@@@Ovarian Cancer|Testicular Cancer|Bladder Cancer|||||||@GENERIC@@@@@GENERIC||||@Platinum@@@@@Platinum||||@@@@@@@@@@@METASTATIC@ADVANCED@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@0.779@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@A$@@@@@@@@50@MG@1 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14921223@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Fludarabine and rituximab with or without Genasense@@-@-@-@BERKELEY HEIGHTS, NEW JERSEY@6/1/2009@@Genasense (oblimersen sodium) Injection is a drug that inhibits the production of a protein known as Bcl-2. By reducing production of Bcl-2 in cancer cells, it seeks to restore the basic biological process whereby cancer cells can be readily killed by treatment with current methods of anticancer therapy. Genta's clinical trials programs focus on treating cancer patients with Genasense along with the administration of anticancer therapy with the intention of potentiating the cancer-killing effects of treatment. Genta is developing Genasense Injection with the intention of potentiating the cancer-killing activity of standard anticancer therapies. In a typical example, Genasense might be administered for several days and then be immediately followed by regular doses of chemotherapy. This sequence would then be repeated, depending upon the particular type of chemotherapy regimen and indication. In other applications, Genasense might be administered concurrent with or after conventional chemotherapy, again depending on the chemotherapy and indication. Genasense has the potential to be used in combination with most types of anticancer therapy.@@14921223@Previously untreated@@-@-@@NO REVIEW@@@@-@-@-@NCT00517218@N/A@-@Confirmatory trial in response to failed EMEA application.@@@-@@6/1/2006@-@GL305@@-@-@@@III@III@@-@-@RESULTS PENDING@-@@@@COMBO@OBLIMERSEN SODIUM@FLUDARABINE@RITUXIMAB@@@OBLIMERSEN SODIUM|FLUDARABINE|RITUXIMAB||@GENTA@@@@@GENTA||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@GENASENSE@FLUDARA@RITUXAN@@@GENASENSE|FLUDARA|RITUXAN||@Bcl-2 Inhibitor@@@@@Bcl-2 Inhibitor||||@RESPONSE RATE@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922556@Onco@@@@@@@@@@@TK1258 2 Capsules at 100 mg each by mouth twice daily (total of 400 mg per day), 28 day cycle. @@-@-@-@BASEL, SWITZERLAND@2/1/2011@@TKI258 is an oral TKI that has been demonstrated preclinically to target multiple growth-factor receptors: Fibroblast growth-factor receptor (FGFR), which plays a role in cell development, angiogenesis, and tumorigenesis1 VEGFR, which mediates angiogenesis and lymphangiogenesis2 PDGFR, which is associated with tumor progression and metastasis3 KIT, a receptor that induces cell proliferation and inhibits apoptosis4 Fms-like tyrosine kinase 3 (FLT-3), which mediates cell growth and survival and inhibits tumor-cell differentiation and apoptosis5 Due to its target profile, TKI258 exhibits both antitumor and antiangiogenic activity, and induces apoptosis in preclinical models of various cancers (acute myelogenous leukemia [AML], multiple myeloma, prostate, breast, colon, lung, renal, melanoma, bladder, and ovarian).@@14922556@Observational Study of Continuous TKI258, in Castration-Resistant Prostate Cancer Patients Evaluating Markers of FGF Signaling in Bone Marrow Plasma@@-@-@@NO REVIEW@@@@-@-@-@NCT00831792@40@-@-@@@-@@2/1/2009@-@2008-0510@@-@Ongoing gonadal androgen deprivation therapy with luteinizing hormone-releasing hormone (LHRH) analogues or orchiectomy. Patients, who have not had an orchiectomy, must be maintained on standard dosing of LHRH analogue therapy at appropriate frequency for the duration of the study. Progression of disease despite androgen ablation (either documented osseous or soft tissue metastatic disease progression or by PSA criteria progression). a)Definition of Progressive disease by PSA evidence: a PSA level of at least 5 ng/ml which has risen on at least 2 successive occasions, at least 2 weeks apart. The participant will need a baseline test and a test to show that the PSA has increased@@@II@I@@-@-@Trial registered. [Novartis, 27.01.2009]@-@@@@MONO@-@@@@@-||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@TKI-258@@@@@TKI-258||||@TK Inhibitor@FGF@VEGF@@@TK Inhibitor|FGF|VEGF||@PSA@@@@@@@@@@REFRACTORY@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924553@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@MORRIS PLAINS, NEW JERSEY@@@Naked humanized antibody targeting CD22 receptors on B-lymphocytes.  Primary use is for the treatment of indolent and aggressive NHLs, and for autoimmune diseases such as systemic lupus erythematosus (SLE) and Sjögren's Syndrome.  Every year there are 56,000 newly diagnosed cases of NHL and 25,000 deaths.  SLE afflicts up to 1.4 million in the U.S.  In May 2006, epratuzumab was licensed to UCB, S.A. for all autoimmune disease indications worldwide.  A Phase IIb clinical trial for SLE is currently enrolling patients.  Additionally, there are three NCI-sponsored trials in oncology ongoing.@@14924553@-@@-@-@@NO REVIEW@@@@-@UCB Pharma holds non-oncology rights, with option for a buy-in. North American rights were licensed to Amgen, but returned to Immunomedics in April 2004.@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@III@@-@-@Registrational trial planned for 2009. [Immunomedics, 17.09.2008]@-@@@@-@EPRATUZUMAB@VELTUZUMAB@@@@EPRATUZUMAB|VELTUZUMAB|||@IMMUNOMEDICS@@@@@IMMUNOMEDICS||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@LYMPHOCIDE@IMMU-102@HA20@IMMU-106@@LYMPHOCIDE|IMMU-102|HA20|IMMU-106|@mAb@Humanised@CD22@@@mAb|Humanised|CD22||@-@@@@@@@@@@-@@@@@PIVOTAL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924951@Onco@@@@@300f1008ntsdm@@@@@@AMG-706 alone@@-@-@-@THOUSAND OAKS, CALIFORNIA@3/1/2008@@Motesanib diphosphate is a highly selective, oral agent that is being evaluated for its ability to inhibit angiogenesis and lymphangiogenesis by targeting vascular endothelial growth factor receptors 1, 2 and 3 (“VEGFR1-3”). It is also under investigation for its potential direct anti-tumor activity by targeting platelet-derived growth factor receptor (“PDGFR”) and stem cell factor receptor (“c-kit”) signaling, which may also confer direct anti-tumor activity. In February 2008, Amgen announced that Takeda will become the worldwide partner for motesanib diphosphate in addition to an exclusive collaboration on up to 13 other programs in the Japanese market. @@14924951@GIST patients who progressed or relapsed on Gleevec@@-@-@@NO REVIEW@@@@-@Motesanib was the unofficial key to the wide-ranging, two-part R&D deal with Amgen signed in February 2008 through which, in its first part, Takeda acquired Japanese rights for up to 13 molecules in Amgen's pipeline, including Vectibix (panitumumab), AMG-@SECOND-LINE@NCT00254267@35@-@-@@@-@@11/1/2005@-@20050129@@-@">> Diagnosis of histological confirmed GIST      >> Had prior imatinib mesylate therapy     >> Has at least 1 measurable leasion by modified RECIST "@@@II@II@@-@@Trial registered [Amgen, 14.11.2005]@-@@@@MONO@MOTESANIB DIPHOSPHATE@@@@@MOTESANIB DIPHOSPHATE||||@AMGEN@TAKEDA PHARMACEUTICAL@@@@AMGEN|TAKEDA PHARMACEUTICAL|||@@@@@@|||||||||@Sarcoma@GIST@@@@Sarcoma|GIST||||||||@AMG-706@@@@@AMG-706||||@TK Inhibitor@VEGF@PDGF@SCF@@TK Inhibitor|VEGF|PDGF|SCF|@RECIST@@@@@DURATION OF RESPONSE@PROGRESSION-FREE SURVIVAL@PHARMACOKINETICS@@@ADVANCED@RELAPSED@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14916476@Onco@@@@@300f1010ntsdm@@@@@@107 patients received oral melphalan (0.15MG/KG/day x 7 followed by 0.05MG/KG/day) with prednisone; 203 received IV melphalan (16MG/M2 q 2 weeks x 4 over 6 weeks followed by 4 weeks) with prednisone.@@L01AA03@L01A@YES@BRENTFORD, UNITED KINGDOM@@@Melphalan is a bifunctional alkylating agent. Formation of carbonium intermediates from each of the two bis-2-chloroethyl groups enables alkylation through covalent binding with the 7-nitrogen of guanine on DNA, cross-linking the two DNA strands and thereby preventing cell replication. @@14916476@Alkeran Tablets are indicated in the treatment of multiple myeloma and advanced ovarian adenocarcinoma. Alkeran either alone or in combination with other drugs has a significant therapeutic effect in a proportion of patients suffering from advanced breast carcinoma. Alkeran is effective in the treatment of a proportion of patients suffering from polycythaemia vera. @@NO@-@@NO REVIEW@@@@100%@-@-@-@310@Ovarian adenocarcinoma: A typical regimen is 0.2 mg/kg bodyweight/day orally for 5 days. This is repeated every 4-8 weeks, or as soon as the bone marrow has recovered. Alkeran has also been used intravenously in the treatment of ovarian carcinoma.@2-Nov@@@-@@@Melphalan should be administered under the supervision of a qualified physician experienced in the use of chemotherapeutic agents. Severe bone marrow suppression with resulting infection or bleeding may occur. Controlled trials comparing IV to oral melphalan have shown more myelosuppression with the IV formulation.@LABEL@@-@-@@@III@DISCONTINUED@@-@NHS@44% and 7% responded in the oral and IV groups respectively. Severe myelotoxicity and/or platelets occurred 28% and 11% respectively.@-@@@@COMBO@MELPHALAN HYDROCHLORIDE@PREDNISONE@@@@MELPHALAN HYDROCHLORIDE|PREDNISONE|||@GSK@@@@@GSK||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@ALKERAN@@@@@ALKERAN||||@Alkylating Agent@Nitrogen Mustard Analogue@@@@Alkylating Agent|Nitrogen Mustard Analogue|||@RESPONSE RATE@@@@@@@@@@-@@@@@RANDOMISED@@@@@@@Invalid Factory Price@@@@@-@-@@@25@1.5665@@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/25/2015@@@4.04E+15@TABLET@GB£@@@@@@@@2@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14917243@Onco@@@@@300f1037ntsdm@@@@@@Mixed with specially formulated diluent@@V03AF02@V03A@NO@BASEL, SWITZERLAND@@@The exact mechanism by which dexrazoxane exerts its cardioprotective effect has not been fully elucidated, however based on the available evidence the following mechanism has been suggested. The dose-dependent cardiotoxicity observed during anthracycline administration is due to anthracycline-induced iron-dependent free radical oxidative stress on the relatively unprotected cardiac muscle. Dexrazoxane, an analogue of EDTA (ethylene diamine tetra-acetic acid), is hydrolysed in cardiac cells to the ring-opened product ICRF-198. Both dexrazoxane (ICRF-187) and ICRF-198 are capable of chelating metal ions. It is generally thought that they can provide cardioprotection by scavenging metal ions thus preventing the Fe3+-anthracycline complex from redox cycling and forming reactive radicals.@@14917243@Indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m2 and who will continue to receive doxorubicin therapy to maintain tumor control. It is not recommended for use with the initiation of doxorubicin therapy.@@YES@@@NO REVIEW@@@@@@@@36@Savene should be given once daily for 3 consecutive days. The recommended dose is: Day one: 1000 mg/m2, Day two: 1000 mg/m2 Day three: 500 mg/m2@EMA, 31 March 2006@3/31/2006@@@@@Local examination should be performed on regular basis after treatment until resolution. If there is suspicion of extravasation by vesicant compounds other than anthracyclines through the same IV access, e.g. vincristine, mitomycin, and vinorelbine, Savene would not be effective against the reaction from these compounds. Savene will be administered to patients undergoing cytotoxic therapy with anthracycline containing chemotherapy and its cytotoxic potential (especially resulting in reversible haematological toxicity with a nadir occurring on days 11-12) will therefore be added to that of the other chemotherapy administered. Haematological monitoring should therefore be undertaken regularly.@LABEL@No@@@@@N/A@APPROVED@@NO REVIEW@SNS@1 of the patients required surgery.@@@@@MONO@DEXRAZOXANE HCL@@@@@DEXRAZOXANE HCL||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Breast Cancer@Supportive Care@@@@Breast Cancer|Supportive Care||||||||@CARDIOXANE@@@@@CARDIOXANE||||@Topoisomerase II Inhibitor@@@@@Topoisomerase II Inhibitor||||@EXTRAVASATIONS@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1807@84.24@131.51@91.21@@@@@@@@@@0.17@@@@@@@@@@@@@@@@8/23/2017@84.24@84.24@654125@POWDER FOR SOLUTION (VIAL)@EURO@@@@@@@@500@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14916109@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Single-agent mapatumumab@@-@-@-@ROCKVILLE, MARYLAND@@@HGS-ETR1 (mapatumumab) is an agonistic human monoclonal antibody that directly induces cancer-cell death by specifically binding to and activating the protein known as TRAIL receptor 1. Using genomic techniques, HGS originally identified the TRAIL receptor 1 protein. The HGS-ETR1 antibody was generated by HGS through collaboration with Cambridge Antibody Technology. HGS is developing HGS-ETR1 as a potential treatment for a broad range of cancers.@@14916109@-@@-@-@@NO REVIEW@@@@-@HGS reacquired rights to mapatumumab and lexatumumab from GSK in return for royalties due to HGS if Syncria albiglutide is commercialised. SOURCE: HGS, 16 April 2008GSK has exercised 1996 option to jointly develop and commercialise HGS-ETR1, equally sha@-@NCT00094848@N/A@-@-@@@-@@@-@TRM1-HM01@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@MAPATUMUMAB@@@@@MAPATUMUMAB||||@HUMAN GENOME SCIENCES@@@@@HUMAN GENOME SCIENCES||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@HGS-ETR1@@@@@HGS-ETR1||||@mAb@Human@TRAIL Receptor 1@@@mAb|Human|TRAIL Receptor 1||@SAFETY@RESPONSE RATE@@@@@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919776@Onco@@@@@300f1037ntsdm@@@@@@Tamoxifen compared to ovarian ablation@@L02BA01@L02B@YES@HUARTE-PAMPLONA, SPAIN@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14919776@@@NO@@@NO REVIEW@@@@90%@@@@N/A@Adults: The recommended daily dose of tamoxifen is normally 20 mg. No additional benefit, in terms of delayed recurrence or improved survival in patients, has been demonstrated with higher doses. Substantive evidence supporting the use of treatment with 30–40 mg per day is not available, although these doses have been used in some patients with advanced disease.@1-Apr-89@4/1/1989@@@@@Menstruation is suppressed in a proportion of premenopausal women receiving Nolvadex for the treatment of breast cancer. An increased incidence of endometrial changes including hyperplasia, polyps, cancer and uterine sarcoma (mostly malignant mixed Mullerian tumours), has been reported in association with Nolvadex treatment. The underlying mechanism is unknown but may be related to the oestrogenlike effect of Nolvadex. Any patient receiving or having previously received Nolvadex who report abnormal gynaecological symptoms, especially vaginal bleeding, or who presents with menstrual irregularities, vaginal discharge and symptoms such as pelvic pain or pressure should be promptly investigated.@LABEL@No@@@@@III; METASTATIC BREAST CANCER@APPROVED@@NO REVIEW@SNS@The objective RR, time to treatment failure, and survival were similar with both treatments. In an overview analysis of survival data from the 3 studies, the hazard ratio for death (tamoxifen/ovarian ablation) was 1.00. Elevated serum and plasma oestrogens have been observed in premenopausal women receiving tamoxifen, but the data from the randomized studies do not suggest an adverse effect of this increase. A limited number of premenopausal patients with disease progression during tamoxifen therapy responded to subsequent ovarian ablation.@@@@@MONO@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@CINFA@@@@@CINFA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GENERIC@@@@@GENERIC||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RESPONSE RATE@@@@@@@@@@@@@@@PROSPECTIVE@RANDOMISED@@@@@@Invalid Factory Price@@@@@@@@@60@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@EURO@@@@@@@@10@MG@10 MG@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14923949@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Mixed with specially formulated diluent@@@@NO@COPENHAGEN, DENMARK@@@The exact mechanism by which dexrazoxane exerts its cardioprotective effect has not been fully elucidated, however based on the available evidence the following mechanism has been suggested. The dose-dependent cardiotoxicity observed during anthracycline administration is due to anthracycline-induced iron-dependent free radical oxidative stress on the relatively unprotected cardiac muscle. Dexrazoxane, an analogue of EDTA (ethylene diamine tetra-acetic acid), is hydrolysed in cardiac cells to the ring-opened product ICRF-198. Both dexrazoxane (ICRF-187) and ICRF-198 are capable of chelating metal ions. It is generally thought that they can provide cardioprotection by scavenging metal ions thus preventing the Fe3+-anthracycline complex from redox cycling and forming reactive radicals.@@14923949@Indicated for the treatment of anthracycline extravasation@@@@@NO REVIEW@@@@@@@@36@Savene should be given once daily for 3 consecutive days. The recommended dose is: Day one: 1000 mg/m2, Day two: 1000 mg/m2 Day three: 500 mg/m2@FDA, 06 September 2007@9/6/2007@@@@@Local examination should be performed on regular basis after treatment until resolution. If there is suspicion of extravasation by vesicant compounds other than anthracyclines through thesame IV access, e.g. vincristine, mitomycin, and vinorelbine, Savene would not be effective against the reaction from these compounds. Savene will be administered to patients undergoing cytotoxic therapy with anthracycline containing chemotherapy and its cytotoxic potential (especially resulting in reversible haematological toxicity with a nadir occurring on days 11-12) will therefore be added to that of the other chemotherapy administered. Haematological monitoring should therefore be undertaken regularly.@LABEL@No@@@@@N/A@APPROVED@@@MEDICARE@1 of the patients required surgery.@@@@@MONO@DEXRAZOXANE HCL@@@@@DEXRAZOXANE HCL||||@TOPOTARGET@@@@@TOPOTARGET||||@@@@@@|||||||||@Supportive Care@@@@@Supportive Care|||||||||@TOTECT@@@@@TOTECT||||@Topoisomerase II Inhibitor@@@@@Topoisomerase II Inhibitor||||@EXTRAVASATIONS@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@10@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@US$@@@@@@@@500@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916417@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@All patients received doses of 48 mg/m2 every three weeks, the maximum-tolerated dose identified in Phase 1 clinical trials. @@-@-@-@SOUTH SAN FRANCISCO, CALIFORNIA@6/1/2008@@Voreloxin (also known as SNS-595) is a novel naphthyridine analog, structurally related to quinolones, a class of compounds which has not been used previously for the treatment of cancer. voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site- selective DNA damage, irreversible G2 arrest and rapid apoptosis. The topoisomerase II-associated DNA intercalation and DNA damage produced by voreloxin show greater selectivity for proliferating cells.  In nonclinical evaluations, voreloxin demonstrates broad and potent activity in tumor biopsies and in xenograft, syngeneic and drug-resistant tumor models. In addition to the REVEAL-1 Phase 2 clinical trial in elderly AML patients, voreloxin is being evaluated in combination with cytarabine in a Phase 1b clinical trial and as a single agent in a Phase 2 clinical trial in platinum-resistant ovarian cancer. In clinical trials conducted to date, voreloxin has been generally well tolerated and has shown objective responses in both solid and hematologic tumor types. @@14916417@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00298896@80@-@-@@@-@@2/1/2006@-@SPO-0006@@-@-@@@II@II@@-@-@With nine of eleven evaluable patients in the treatment-sensitive arm of the trial having stable disease or objective responses by the end of two cycles of treatment, the clinical results have exceeded the pre-specified requirement of at least two partial or complete responses in the first 20 evaluable patients for advancing to Stage 2. Based on the interim data analysis reported today, Sunesis plans to continue Phase 2 clinical evaluation of SNS-595 in treatment-sensitive small cell lung cancer patients who had previously responded to first-line therapy, but subsequently relapsed after more than three months. SOURCE: Sunesis, 29 January 2007@-@@@@MONO@VORELOXIN@@@@@VORELOXIN||||@SUNESIS PHARMACEUTICALS@@@@@SUNESIS PHARMACEUTICALS||||@@@@@@|||||||||@SCLC@@@@@SCLC|||||||||@SNS-595@@@@@SNS-595||||@Cytotoxic Antibiotic@@@@@Cytotoxic Antibiotic||||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922498@Onco@@@@@@@@@@@Equivalence of ANX-530 with Navelbine.@@-@-@-@SAN DIEGO, CALIFORNIA@@@Vinorelbine is an antineoplastic active substance of the vinca alkaloid family, but in contrast to all other vinca alkaloids the catharanthine portion of vinorelbine has undergone a structural modification. On the molecular level it affects the dynamic equilibrium of tubulin in the microtubular system of the cell. Vinorelbine inhibits tubulin polymerisation and binds preferentially to mitotic microtubules, only affecting axonal microtubules at high concentrations. Spiralisation of the tubulin is induced to a lesser degree than with vincristine. Vinorelbine blocks mitosis in phase G2-M, causing cell death in interphase or at the following mitosis.@@14922498@Marketing enabling bioequivalence study; Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion (ANX-530) in Patients With Advanced Cancer.@@-@-@@NO REVIEW@@@@-@"Adventrx is ""exploring strategic alternatives"", including the potential sale of its key oncology assets ANX-514 and ANX-530. The company has already reduced its size by 27% to 24 in October. [Adventrx, 22.12.2008]"@-@NCT00432562@28@-@>>NDA filed to the US FDA [Adventrix 4 January 2010 http://ir.adventrx.com/phoenix.zhtml?c=75414&p=irol-newsArticle&ID=1370119&highlight= ]>> NDA to be filed by year-end 2009 [Adventrx, 6 August 2009]>> NDA to be filed in Q2 2009 [Adventrx, 22.12.2008]             >> NDA to be filed by Q4 2008 [Adventrx, January 2008]         >> NDA to be filed by year-end 2007. [Adventrx, July 2008]@1/4/2010@@-@@2/1/2007@-@530-01@@-@28 PATIENTS WITH ADVANCED CANCER SENSITIVE TO VINORELBINE, BREAST CANCER, STAGE III/IV NSCLC, NHL ETC.@@@I@I@@-@-@ANX-530 met primary endpoint and NDA will be filed by year-end. SOURCE: Adventrx/AACR, 16 April 2008Additional data: ANX-530 had a significant reduction in injection site reaction to Navelbine. SOURCE: Adventrx January 2008.Enrollment of 28 patients completed; met primary endpoint of PK equivalence to Navelbine. SOURCE: Adventrx, December 2007@-@@@@MONO@VINORELBINE EMULSION@@@@@VINORELBINE EMULSION||||@ADVENTRX PHARMACEUTICAL@@@@@ADVENTRX PHARMACEUTICAL||||@Argentina@@@@@Argentina|||||||||@NSCLC@Breast Cancer@Haematological Malignancy@Non-Hodgkin's Lymphoma@@NSCLC|Breast Cancer|Haematological Malignancy|Non-Hodgkin's Lymphoma||||||@ANX-530@@@@@ANX-530||||@Plant Alkaloid@Vinca Alkaloids@@@@Plant Alkaloid|Vinca Alkaloids|||@BIOEQUIVALENCE@SAFETY@@@@@@@@@ADVANCED@@@@@PIVOTAL@RANDOMISED@OPEN-LABEL@BIOEQUIVALENCE@CROSSOVER@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14920076@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01XX19@L01X@YES@PETACH TIKVA, ISRAEL@@@Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks.@@14920076@Camptosar is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. It is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.@@NO@@@NO REVIEW@@@@@@FIRST-LINE@@@Regimen 1: 6-wk cycle with bolus 5-FU/LV (next cycle begins on day 43): Weekly Camptosar 125mg/m2 IV over 90 minutes on days 1, 8, 15 and 22, followed by 100mg/m2 on week 5 and 75mg/m2 on week 6@FDA, 28 February 2008@2/28/2008@@@@@Can induce both early and late forms of diarrhea. Both forms of diarrhea may be severe. Early diarrhea (occurring during or shortly after infusion may be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping. Late diarrhea (generally occurring more than 24 hours after administration) can be life threatening since it may be prolonged and may lead to dehydration, electrolyte imbalance, or sepsis. Patients with diarrhea should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated or antibiotic therapy if they develop ileus, fever, or severe neutropenia. Severe myelosuppression may also occur.@LABEL@No@@@@@@APPROVED@@Covered; part B; specialty drug@MEDICARE@@@@@@COMBO@IRINOTECAN@@@@@IRINOTECAN||||@TEVA PHARMACEUTICAL@@@@@TEVA PHARMACEUTICAL||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@5.5@month@5.5 month@@@@1@1@35.3@@@@@@@@@@@@0.35@@@@@@@@@@@@@@@@8/2/2017@35.3@35.3@00703-4434-11@INJECTION - 5 ML@US$@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919046@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Palifosfamide combo with doxorubicin@@L01AA06@L01A@-@BOSTON, MASSACHUSSETTS@@@"Palifosfamide (ZIO-201) is a novel molecule that is the functional active metabolite of ifosfamide, a standard of care for treating sarcoma, testicular cancer and other cancers. Palifosfamide delivers only the cancer fighting component of ifosfamide. It overcomes the resistance of ifosfamide and cyclophosphamide in certain cancers. It does not have the toxic metabolites that cause the debilitating side effects of ""fuzzy brain"" (encephalopathy) and severe bladder inflammation."@@14919046@-@@-@-@@NO REVIEW@@@@-@-@-@-@N/A@-@FDA granted orphan drug designation. SOURCE: Ziopharm, 9 May 2008@5/9/2008@@>> EMEA COMP issues positive opinion on orphan drug status for soft tissue sarcoma. [Ziopharm, 15.10.2008]      >> FDA granted orphan drug designation. [Ziopharm, 9 May 2008]@@2/1/2008@-@N/A@@-@-@@@I/II@II@@-@-@First-patient in (FPI). [Ziopharm, 4.02.2008]@-@@@@COMBO@PALIFOSFAMIDE@DOXORUBICIN@@@@PALIFOSFAMIDE|DOXORUBICIN|||@ZIOPHARM ONCOLOGY@@@@@ZIOPHARM ONCOLOGY||||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@ZIO-201@@@@@ZIO-201||||@Alkylating Agent@Nitrogen Mustard Analogue@@@@Alkylating Agent|Nitrogen Mustard Analogue|||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16401510@Onco@@@@@@@@@@@"Treatment, Experimental, Pomalidomide plus low-dose Dexamethasone"@@L04AX06@L04A@@CHINA@6/1/2018@@Pomalidomide has direct anti-myeloma tumoricidal activity, immunomodulatory activities and inhibits stromal cell support for multiple myeloma tumour cell growth. Specifically, pomalidomide inhibits proliferation and induces apoptosis of haematopoietic tum@@16401510@A Multicenter, Single-arm, Open-label Study to Evaluate the Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma@Both@@@@@4mg/day, d1-d21, 28 days per cycle@@@@@THIRD-LINE@NCT02916420@73@@@@@@@9/1/2016@@SIM-135-Ⅲ@@@-  Have a documented diagnosis of multiple myeloma  -  Subjects must have received at least 2 prior therapies. Subjects must have undergone prior treatment with at least 2 cycles of lenalidomide and at least 2 cycles of bortezomib (either in separate regi@@ADULTS@Phase 3@III@@@@@@@@@COMBO@POMALIDOMIDE@DEXAMETHASONE@@@@POMALIDOMIDE|DEXAMETHASONE|||@JIANGSU SIMCERE PHARMACEUTICAL@@@@@JIANGSU SIMCERE PHARMACEUTICAL||||@@@@@@|||||||||@Myeloma@@@@@Myeloma|||||||||@IMNOVID@GENERIC@@@@IMNOVID|GENERIC|||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@Objective Response Rate@@@@@Progression-free Survival@Duration of Response@@@@RELAPSED@REFRACTORY@@@@Safety/Efficacy Study@Single Group Assignment@Open Label@Treatment@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14920543@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01XX05@L01X@NO@NEW YORK, NEW YORK@@@@@14920543@The treatment of chronic myeloid leukaemia. The treatment of cancer of the cervix in conjunction with radiotherapy.@@NO@Aug-69@@NO REVIEW@@@@@@@@@Continuous therapy: Hydrea 20-30mg/kg should be given daily in single doses. Dosage should be based on the patient's actual or ideal weight, whichever is the less. Therapy should be monitored by repeat blood counts. Intermittent therapy: Hydrea 80mg/kg in single doses should be given every third day. Using the intermittent regimes the likelihood of WBC depression is diminished, but if low counts are produced, 1 or more doses of Hydrea should be omitted.@Jan-97@@1/19/1969@@@@The complete status of the blood, including bone marrow examination, if indicated, as well as kidney function and liver function should be determined prior to, and repeatedly during, treatment. The determination of haemoglobin level, total leukocyte counts, and platelet counts should be performed at least once a week throughout the course of hydroxycarbamide therapy. If WBC falls below 2.5x109/L or platelet count to <100x109/L, therapy should be interrupted. Counts should be rechecked after 3 days and treatment resumed when they rise significantly towards normal. Severe anaemia must be corrected with whole blood replacement before initiating therapy with hydroxycarbamide.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@HYDROXYCARBAMIDE@@@@@HYDROXYCARBAMIDE||||@BMS@@@@@BMS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@Cervical Cancer@@@Haematological Malignancy|Chronic Myeloid Leukaemia|Cervical Cancer|||||||@HYDREA@@@@@HYDREA||||@Anti-metabolite@@@@@Anti-metabolite||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@20@1.1511@4.05@5.28@4.35@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@0.2@0.2@3.40E+12@CAPSULE@EURO@@@@@@@@500@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
16384826@Onco@@@@@300f1008ntsdm@@@@@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384826@Indicated for the treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.@@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@FIRST-LINE@@@Dosing for children should be on the basis of body surface area (mg/m2). The dose of 340 mg/m2 daily is recommended for children with Ph+ ALL (@@@@@@@@@No@@@PAEDIATRIC@@@APPROVED@@@NHI@@@@@@BOTH@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@@@@Haematological Malignancy|Acute Lymphocytic Leukaemia||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@@@@@@@@@@@1.2@m²@3113530.008@@@1@year@1 year@3113530.01@3113530.01@8530.22@1@0.0091@2090.74@2465.5@@@@@@@@@@@20.91@1@@mg/m²@340@1@@@@@@@@@@@8/30/2017@2090.74@2090.74@4291011F1028@TABLET@YEN@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14917258@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@404 patients received Casodex 50mg once-daily, 409 received flutamide 250mg three-times daily, each in combination with goserelin acetate implant or leuprolide acetate depot.@@L02BB03@L02B@NO@LONDON, UNITED KINGDOM@@@Casodex is a non-steroidal antiandrogen, devoid of other endocrine activity. It binds to androgen receptors without activating gene expression, and thus inhibits the androgen stimulus. Regression of prostatic tumours results from this inhibition. Clinically, discontinuation of Casodex can result in antiandrogen withdrawal syndrome in a subset of patients. Casodex is a racemate with its antiandrogenic activity being almost exclusively in the (R)-enantiomer.@@14917258@Indicated for use in combination therapy with an LH-RH analogue for the treatment of Stage D2 metastatic carcinoma of the prostate.@@NO@@@NO REVIEW@@@@Co-pay tier 2. SOURCE: Aetna Preferred Drug Guide 2008@@FIRST-LINE@@813@The recommended dose is 50mg tablet once-daily with or without food.@FDA, 4 October 1995@10/4/1995@@@@@Rare cases of death or hospitalisation due to severe liver injury have been reported in post-marketing in association with Casdoex use.@N/A@No@Paediatric extension for 6 months in prostate cancer. [AstraZeneca, 23.09.2008]@813 PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED PROSTATE CANCER@@@III@APPROVED@@Covered; preferred brand; quantity limit 30 for 30 days@MEDICARE@Overall survival was not statistically significant; 52.7% of the Casodex/LHRH group had died, and 57.5% of the flutamide/LHRH group had died.@@@@@COMBO@BICALUTAMIDE@@@@@BICALUTAMIDE||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@CASODEX@@@@@CASODEX||||@Hormone Antagonist@Anti-androgen@@@@Hormone Antagonist|Anti-androgen|||@OVERALL SURVIVAL@@@@@@@@@@METASTATIC@@@@@MULTI-CENTRE@DOUBLE-BLIND@CONTROLLED@@@1@1@19603.36@@@160@week@160 week@19603.36@19603.36@17.5@100@1@1750.3@@@@@@@@@@@@0.35@1@@mg@50@1@@@@@@@@@@@9/1/2017@17.5@17.5@00310-0705-10@FILM-COATED TABLET@US$@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15361185@Onco@@@@@300f1008ntsdm@@@@@DASISION@Patients were randomized to receive either SPRYCEL 100 mg once daily or imatinib 400 mg once daily@@L01XE06@L01X@@NEW YORK, NEW YORK@12/1/2013@@Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRß. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.@@15361185@Indicated for the treatment of adults aged 18 years or over with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukaemia in the chronic phase.@Both@NA@@@@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@FIRST-LINE@NCT00481247@519@The recommended starting dosage for chronic phase CML is 100 mg administered orally once daily (QD).@@@@@@8/1/2007@@CA180-056/2006-005712-27@No@@Male & Female ≥18 years/Chronic Phase Ph+ CML/Eastern Cooperative Oncology Group Performance Status (ECOG PS) score 0-2@@ADULTS@III@APPROVED@@@NHI@@@@@@MONO@DASATINIB@@@@@DASATINIB||||@BMS@@@@@BMS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@SPRYCEL@@@@@SPRYCEL||||@TK Inhibitor@bcr-abl@PDGF@@@TK Inhibitor|bcr-abl|PDGF||@RATE OF CONFIRMED COMPLETE CYTOGENETIC RESPONSE@@@@@@@@@@CHRONIC PHASE@PH+@@@@OPEN-LABEL@MULTICENTER@RANDOMISED@@@1@1@6844626.844@@@14@month@14 month@6844626.84@6844626.84@16073.84@1@0.0091@8036.92@9477.5@@@@@@@@@@@160.74@1@@mg@100@1@@@@@@@@@@@8/30/2017@8036.92@8036.92@4291020F2023@TABLET@YEN@@@@@@@@50@MG@50 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14924481@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@6 weeks of standard Herceptin dosing versus HER2 gene amplification and no prior Herceptin or HER2-targeted treatment.@@-@-@-@MADISON, NEW JERSEY@@@HKI-272 is a potent inhibitor of HER-2 and is highly active against HER-2-overexpressing human breast cancer cell lines in vitro. It also inhibits the epidermal growth factor receptor (EGFR) kinase and the proliferation of EGFR-dependent cells. HKI-272 reduces HER-2 receptor autophosphorylation in cells at doses consistent with inhibition of cell proliferation and functions as an irreversible binding inhibitor, most likely by targeting a cysteine residue in the ATP-binding pocket of the receptor.@@14924481@-@@-@-@@NO REVIEW@@@@-@Pfizer acquired Wyeth on 26 January 2009 in a deal worth U.S $68 billion [Pfizer 26.01.2009]@-@NCT00300781@122@-@-@@@-@@@-@-@@-@122 WOMEN WITH ADVANCED BREAST CANCER@@@II@II@@-@-@RESULTS PENDING@-@@@@-@NERATINIB@@@@@NERATINIB||||@WYETH@PFIZER@@@@WYETH|PFIZER|||@@@@@@|||||||||@Breast Cancer@HER2+@@@@Breast Cancer|HER2+||||||||@HKI-272@@@@@HKI-272||||@TK Inhibitor@HER2@@@@TK Inhibitor|HER2|||@SAFETY@RESPONSE RATE@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16639032@Onco@@@@@300f1015ntsdm@@@@@@@@L01XE23@L01X@@LONDON, UNITED KINGDOM@7/1/2011@@Dabrafenib is an  orally bioavailable inhibitor of the BRAF protein.  Dabrafenib was discovered and developed at GSK.@@16639032@Dabrafenib is indicated in monotherapy for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.@Both@No@7-May-14@5/7/2014@@@@@100%@@@NCT01153763@92@The recommended dose of dabrafenib, either used as monotherapy or in combination with trametinib, is 150 mg (two 75 mg capsules) twice daily (corresponding to a total daily dose of 300 mg).@EMA, 26 August 2013@8/26/2013@10/7/2013@No@@8/1/2010@@BRF113710@No@@Must be at least 18 years of age; Must have histologically confirmed cutaneous metastatic melanoma (Stage IV) that is BRAF mutation-positive (V600 E/K) as determined via central testing with a BRAF mutation assay; Is treatment naive or has received prior treatment for metastatic melanoma; Must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1); Women of child-bearing potential must have a negative pregnancy test within 14 days prior to the first dose of study treatment; Women with reproductive potential must be willing to practice acceptable methods of birth control during the study and for up to 4 weeks after the last dose of study medication; Men with reproductive potential must be willing to practice acceptable methods of birth control during the study and for up to 16 weeks after the last dose of study medication; Must have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1; Adequate organ function.@BRAF V600 mutation@ADULTS@II@APPROVED@@ASMR V [http://www.has-sante.fr/portail/upload/docs/application/pdf/2015-10/tafinlar_summary_ct13242.pdf]@HAUTE AUTORITÉ DE SANTÉ@@@@@@MONO@DABRAFENIB@@@@@DABRAFENIB||||@GSK@@@@@GSK||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@TAFINLAR@@@@@TAFINLAR||||@Other@@@@@Other||||@OVERALL RESPONSE RATE@@@@@PROGRESSION FREE SURVIVAL@@@@@UNRESECTABLE@METASTATIC@@@@SINGLE GROUP@OPEN LABEL@@@@1@1@38476.23972@@@6.9@month@6.9 month@38476.24@38476.24@183.33@120@1.1511@5500@5745.39@5530@@@@@@@@@@0.61@1@@mg@300@1@@@@@@@@@@@8/1/2017@45.83@45.83@3.40E+12@CAPSULE@EURO@@@@@@@@75@MG@75 MG@@@@@@@@@@@@@@@@@@@@@@@@85@France
14918967@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@The recommended Phase 2 dose of KOS-1584 will be based on clinical activity, dose intensity, side effect profile and schedule compatibility with established chemotherapy regimens, and will be either 36 mg/m2 every 3 weeks or 25 mg/m2 twice every 3 weeks, depending on data from expanded dose cohorts. SOURCE: Kosan@@-@-@-@HAYWARD, CALIFORNIA@@@KOS-1584 is Kosan's lead epothilone and is designed to be differentiated from other epothilones and to have a broad therapeutic index. KOS-1584 is a highly potent compound with favorable tissue distribution, long half-life and ease of formulation. Many cancers are treated with a taxane (the active ingredient in Taxol and Taxotere). Taxanes are cytotoxic agents with a mechanism of action that induces cell death by inhibiting cell division. Epothilones are anticancer agents with a taxane-like mechanism of action that have demonstrated activity in taxane-sensitive and taxane-resistant tumors. Kosan's epothilones have demonstrated activity against a wide range of tumors and have the potential to overcome multi-drug resistance and to be synergistic with combination therapy@@14918967@-@@-@-@@NO REVIEW@@@@-@>> BMS acquires Kosan Biosciences for US$190 million. [BMS, 29 May 2008]      >> Partnership terminated due to reprioritisation at Roche. Kosan reacquires all rights. [Kosan, 25 October 2007]            >> Kosan and Roche established a global development and commercialization agreement for epothilones to treat cancer in September 2002.@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@II@II@@-@-@Trial commenced. SOURCE: Kosan, 14 April 2008Trial to begin in Q1 2008, and may pursue other indications. SOURCE: Kosan, 28 February 2008@-@@@@-@-@@@@@-||||@KOSAN BIOSCIENCES@BMS@@@@KOSAN BIOSCIENCES|BMS|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@KOS-1584@R-1645@@@@KOS-1584|R-1645|||@Epothilone@@@@@Epothilone||||@-@@@@@@@@@@-@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922852@Onco@@@@@300f1008ntsdm@@@@@@@@L02BA01@L02B@YES@@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14922852@Nolvadex is indicated for: 1. The treatment of breast cancer. 2. The treatment of anovulatory infertility.@@NA@@@NO REVIEW@@@@@@@@@Adults: The recommended daily dose of tamoxifen is normally 20 mg. No additional benefit, in terms of delayed recurrence or improved survival in patients, has been demonstrated with higher doses. Substantive evidence supporting the use of treatment with 30–40 mg per day is not available, although these doses have been used in some patients with advanced disease.@@@@@@@Menstruation is suppressed in a proportion of premenopausal women receiving Nolvadex for the treatment of breast cancer. An increased incidence of endometrial changes including hyperplasia, polyps, cancer and uterine sarcoma (mostly malignant mixed Mullerian tumours), has been reported in association with Nolvadex treatment. The underlying mechanism is unknown but may be related to the oestrogenlike effect of Nolvadex. Any patient receiving or having previously received Nolvadex who report abnormal gynaecological symptoms, especially vaginal bleeding, or who presents with menstrual irregularities, vaginal discharge and symptoms such as pelvic pain or pressure should be promptly investigated.@@No@@@@@@APPROVED@@@NHI@RESULTS PENDING@@@@@@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@WAKAMOTO PHARMACEUTICAL@@@@@WAKAMOTO PHARMACEUTICAL||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@RESPOL@@@@@RESPOL||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@0.0091@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14925056@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NO LABELLED TRIAL@@M04AA01@M04A@NO@@@@@@14925056@Indicated in the management of patients with signs and symptomas of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephroptahy; the management of patients with leukaemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment should be discontinued when the potential for overproduction of uric acid is no longer presents; and, the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800mg/day in male patients and 750mg/day in female patients. This is not an innocuous drug. It is not recommended for the treatment of asymptomatic hyperuricemia.@@NO@@@NO REVIEW@@@@@Licensed from Faro (which licensed it from Glaxo Wellcome) in 2001@@@@For the prevention of uric acid nephropathy during the vigorous therapy of neoplastic disease, treatment with 600 to 800 mg daily for two or three days is advisable together with a high fluid intake. Otherwise similar considerations to the above recommendations for treating patients with gout govern the regulation of dosage for maintenance purposes in secondary hyperuricemia.@FDA, 19 August 1966@8/19/1966@@@@@Should be discontinued at the first appearance of skin rash or other signs which may indicate an allergic rection. Dose should be adjusted if co-administered with Purinethol or Imuran.@NO LABELLED TRIAL@No@@@@@@APPROVED@@Covered; non-preferred@MEDICARE@NO LABELLED TRIAL@@@@@@ALLOPURINOL@@@@@ALLOPURINOL||||@PROMETHEUS@@@@@PROMETHEUS||||@@@@@@|||||||||@Supportive Care@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Non-Hodgkin's Lymphoma@Supportive Care|Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Non-Hodgkin's Lymphoma|||||@ZYLOPRIM@@@@@ZYLOPRIM||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@500@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@65483-0993-50@TABLET@US$@@@@@@@@300@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918242@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@M04AA01@M04A@NO@GERMANY@@@@@14918242@Indicated in the management of patients with signs and symptomas of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephroptahy; the management of patients with leukaemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment should be discontinued when the potential for overproduction of uric acid is no longer presents; and, the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800mg/day in male patients and 750mg/day in female patients. This is not an innocuous drug. It is not recommended for the treatment of asymptomatic hyperuricemia.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@Dosage in Adults: should be introduced at low dosage e.g. 100mg/day to reduce the risk of adverse reactions and increased only if the serum urate response is unsatisfactory. Extra caution should be exercised if renal function is poor. The following dosage schedules are suggested: 100 to 200 mg daily in mild conditions, 300 to 600 mg daily in moderately severe conditions, 700 to 900 mg daily in severe conditions. If dosage on a mg/kg bodyweight basis is required, 2 to 10 mg/kg bodyweight/day should be used. Dosage in children: Children under 15 years: 10 to 20 mg/kg bodyweight/day up to a maximum of 400 mg daily. Use in children is rarely indicated, except in malignant conditions (especially leukaemia) and certain enzyme disorders such as Lesch-Nyhan syndrome.@@@@@@@Should be discontinued at the first appearance of skin rash or other signs which may indicate an allergic rection. Dose should be adjusted if co-administered with Purinethol or Imuran.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@ALLOPURINOL@@@@@ALLOPURINOL||||@ABZ PHARMA@@@@@ABZ PHARMA||||@@@@@@|||||||||@Supportive Care@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Non-Hodgkin's Lymphoma@Supportive Care|Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Non-Hodgkin's Lymphoma|||||@GENERIC@@@@@GENERIC||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@100@1.1511@1.22@12.53@1.96@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@@@1014613@TABLET@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14922440@Onco@@@@@@@@@@@Arm A: irinotecan (180 mg/m) IV infusion, concurrently with leucovorin (400 mg/m) over 2 hours followed by 5-FU bolus (400 mg/m) and a subsequent 5-FU infusion (2400 mg/m over 46-48 hours), repeated every 2 weeks + AG-013736 continuous dosing . Arm B: irinotecan (180 mg/m) IV infusion over 90 minutes, concurrently with leucovorin (400 mg/m) over 2 hours followed immediately by 5-FU bolus (400 mg/m) and a subsequent 5-FU infusion (2400 mg/m over 46-48 hours), repeated every 2 weeks + bevacizumab every two weeks. Arm C: oxaliplatin (85 mg/m) IV infusion over 120 minutes, concurrently with leucovorin (400 mg/m) over 2 hours followed by 5-FU bolus (400 mg/m) and a subsequent 5-FU infusion (2400 mg/m over 46-48 hours), repeated every 2 weeks + AG-013736 continuous dosing. Arm D: oxaliplatin (85 mg/m) IV, concurrently with leucovorin (400 mg/m) over 2 hours followed by 5-FU bolus (400 mg/m) and a subsequent 5-FU infusion (2400 mg/m over 46-48 hours), repeated every 2 weeks + bevacizumab 5 mg/kg every two weeks. SOURCE: clinicaltrials.gov@@-@-@-@NEW YORK, NEW YORK@10/1/2009@@Axitinib is an oral, selective inhibitor of VEGFR 1, 2, 3 (vascular endothelial growth factor receptors 1, 2 and 3), which has been shown to induce tumor regression as a single-agent and in combination with chemotherapy. Inhibiting VEGF binding plays a key role in anti-angiogenesis - or blocking blood vessel formation which starves tumors of the blood and nutrients needed for growth. @@14922440@Second-line; axitinib with FOLFOX or FOLFORI versus FOLFIRI+Avastin or FOLFOX+Avastin@@-@-@@NO REVIEW@@@@-@Developed from Abgenix (now Amgen) mice, double-digit royalties to go to Medarex due to cross-licensing in this area@SECOND-LINE@NCT00615056@176@-@-@@@-@@2/1/2008@-@A4061034@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@AXITINIB@IRINOTECAN@@@@AXITINIB|IRINOTECAN|||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@AG-013736@CAMPTOSAR@@@@AG-013736|CAMPTOSAR|||@TK Inhibitor@VEGF@PDGF@SCF@Angiogenesis Inhibitor@TK Inhibitor|VEGF|PDGF|SCF|Angiogenesis Inhibitor@PROGRESSION-FREE SURVIVAL@@@@@@@@@@METASTATIC@@@@@RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14920174@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01XX19@L01X@YES@PETACH TIKVA, ISRAEL@@@Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks.@@14920174@Camptosar is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. It is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.@@NO@@@NO REVIEW@@@@No tiering. SOURCE: Aetna Preferred Drug Guide 2008@@FIRST-LINE@@@Regimen 1: 6-wk cycle with bolus 5-FU/LV (next cycle begins on day 43): Weekly Camptosar 125mg/m2 IV over 90 minutes on days 1, 8, 15 and 22, followed by 100mg/m2 on week 5 and 75mg/m2 on week 6@FDA, 28 February 2008@2/28/2008@@@@@Can induce both early and late forms of diarrhea. Both forms of diarrhea may be severe. Early diarrhea (occurring during or shortly after infusion may be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping. Late diarrhea (generally occurring more than 24 hours after administration) can be life threatening since it may be prolonged and may lead to dehydration, electrolyte imbalance, or sepsis. Patients with diarrhea should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated or antibiotic therapy if they develop ileus, fever, or severe neutropenia. Severe myelosuppression may also occur.@@No@@@@@@APPROVED@@Covered; part B; specialty drug@MEDICARE@@@@@@COMBO@IRINOTECAN@@@@@IRINOTECAN||||@TEVA PHARMACEUTICAL@@@@@TEVA PHARMACEUTICAL||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Factory Price@@@5.5@month@5.5 month@@@@1@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@US$@@@@@@@@40@MG@20 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15051147@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@At least 6 weeks of treatment with BIBW 2992. [BI]@@-@-@-@INGELHEIM, GERMANY@@@This is an orally bioavailable dual receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. EGFR/HER2 tyrosine kinase inhibitor BIBW 2992 irreversibly binds to and inhibits human epidermal growth factor receptors 1 and 2 (EGFR-1; HER2), which may result in the inhibition of tumor growth and angiogenesis. EGFR/HER2 are RTKs that belong to the EGFR superfamily; both play major roles in tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types. @@15051147@BIBW 2992 in Genetically Pre-Screened Cancers With EGFR and/or HER2 Gene Amplification or EFGR Activating Mutations@@-@-@@NO REVIEW@@@@-@-@-@NCT00748709@48@-@-@@@-@@10/1/2008@-@1200.26@@-@Histologically confirmed diagnosis of advanced cancer of one of the following four tumor type categories: Category 1, Gastric, GE junction, or Esophageal cancer Category 2, Biliary or gallbladder cancer Category 3, TCC bladder cancer, and Category 4, Gynecological cancers@@@II@II@@-@-@Trial registered. [BI, 08.09.2008]@-@@@@MONO@AFATINIB@@@@@AFATINIB||||@BOEHRINGER INGELHEIM@@@@@BOEHRINGER INGELHEIM||||@@@@@@|||||||||@Stomach Cancer@Cervical Cancer@Oesophageal Cancer@@@Stomach Cancer|Cervical Cancer|Oesophageal Cancer|||||||@BIBW-2992@TOVOK@@@@BIBW-2992|TOVOK|||@TK Inhibitor@EGFR@HER2@@@TK Inhibitor|EGFR|HER2||@RECIST@@@@@PHARMACOKINETICS@SKIN RASH@@@@-@@@@@SINGLE-ARM@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919071@Onco@@@@@300f1012ntsdm@@@@@@Dose levels of 0.5-5, 15, 30 and 60g/m2/24 hours@@-@-@-@-@5/1/2009@@"The BiTE antibody blinatumomab (MT103/MEDI-538) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful ""killer cells"" of the human immune system, to eliminate cancer cells. Micromet is developing blinatumomab in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc."@@14919071@Stage III/IV disease@@-@-@@NO REVIEW@@@@-@>> AstraZeneca acquires MedImmune in US$15 billion deal. [AstraZeneca, 23.04.2007]@FIFTH-LINE@NCT00274742@30@-@Orphan drug for mantle cell lymphoma.@@@Orphan drug for mantle cell lymphoma.@@6/1/2004@-@MT103-104@@-@-@@@I@I@@-@-@Proof of concept confirmed; response rate of 39%. SOURCE: Micromet/ASH, December 2007@-@@@@MONO@BLINATUMOMAB@@@@@BLINATUMOMAB||||@MICROMET@MEDIMMUNE@ASTRAZENECA@@@MICROMET|MEDIMMUNE|ASTRAZENECA||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@MT-103@MEDI-538@@@@MT-103|MEDI-538|||@mAb@@@@@mAb||||@RESPONSE RATE@@@@@@@@@@RELAPSED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14922315@Onco@@@@@@@@@@@DTIC with or without Genasense@@-@-@-@BERKELEY HEIGHTS, NEW JERSEY@@@Genasense (oblimersen sodium) Injection is a drug that inhibits the production of a protein known as Bcl-2. By reducing production of Bcl-2 in cancer cells, it seeks to restore the basic biological process whereby cancer cells can be readily killed by treatment with current methods of anticancer therapy. Genta's clinical trials programs focus on treating cancer patients with Genasense along with the administration of anticancer therapy with the intention of potentiating the cancer-killing effects of treatment. Genta is developing Genasense Injection with the intention of potentiating the cancer-killing activity of standard anticancer therapies. In a typical example, Genasense might be administered for several days and then be immediately followed by regular doses of chemotherapy. This sequence would then be repeated, depending upon the particular type of chemotherapy regimen and indication. In other applications, Genasense might be administered concurrent with or after conventional chemotherapy, again depending on the chemotherapy and indication. Genasense has the potential to be used in combination with most types of anticancer therapy.@@14922315@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00518895@300@-@Confirmatory trial in response to failed EMEA application.@@@-@@@-@AGENDA@@-@-@@@GM307;@III@@-@-@>> 60% of planned 300 patients have been accrued. Completion expected in Q1 2009. [Genta, 6.10.2008]     >> IDMC recommends completion of accrual. [Genta, 15.09.2008]     >> DSMB recommended trial to continue after initial review of blinded safety data. [Genta, 31 March 2008]     >> Accrual is expected to take 18 months and is due to be completed in Q408.@Serious adverse events profile is similar to previous trials.@@@@COMBO@OBLIMERSEN SODIUM@@@@@OBLIMERSEN SODIUM||||@GENTA@@@@@GENTA||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@GENASENSE@DTIC@@@@GENASENSE|DTIC|||@Bcl-2 Inhibitor@@@@@Bcl-2 Inhibitor||||@OVERALL SURVIVAL@PROGRESSION-FREE SURVIVAL@@@@@@@@@ADVANCED@@@@@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@
16389710@Onco@@@@@@@@@@@Nivolumab + Ipilimumab, Experimental, Nivolumab + Ipilimumab for 4 doses, followed by Nivolumab monotherapyXELOX (Oxaliplatin + Capecitabine), Active Comparator, FOLFOX (Oxaliplatin + Leucovorin + Fluorouracil), Active Comparator,@@L01XC17@L01X@@NEW YORK, NEW YORK@3/1/2019@@Nivolumab is an investigational, fully-human IgG4 anti-PD-1 receptor blocking monoclonal antibody that binds to the checkpoint receptor PD-1 (programmed death-1) expressed on activated T cells. Nivolumab inhibits the binding of PD-1 with its tumor-express@@16389710@A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab Versus Oxaliplatin Plus Fluoropyrimidine in Subjects With Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer@Both@@@@@Specified dose on specified days@@@@@FIRST-LINE@NCT02872116@750@@@@@@@9/1/2016@@CA209-649@@@Male or Female at least 18 years of age  -  Must have gastric cancer or gastroesophageal junction cancer that cannot be operated on and that is advanced or has spread out  -  Did not receive neoadjuvant or adjuvant treatment (chemotherapy, radiotherapy, or both) for their disease within the last 6 months  -  Must have full activity or, if limited, must be able to walk and carry out light activities such as light house work or office work  -  Must agree to provide tumor tissue sample, either from a previous surgery or biopsy within 6 months or fresh, prior to the start of treatment in this study@@ADULTS@Phase 3@III@@@@@@@@@COMBO@NIVOLUMAB@IPILIMUMAB@OXALIPLATIN@CAPECITABINE@LEUCOVORIN@NIVOLUMAB|IPILIMUMAB|OXALIPLATIN|CAPECITABINE|LEUCOVORIN@BMS@ONO PHARMACEUTICALS@@@@BMS|ONO PHARMACEUTICALS|||@@@@@@|||||||||@Stomach Cancer@GIST@@@@Stomach Cancer|GIST||||||||@OPDIVO@YERVOY@GENERIC@GENERIC@GENERIC@OPDIVO|YERVOY|GENERIC|GENERIC|GENERIC@PD-1 Inhibitor@@@@@PD-1 Inhibitor||||@Overall survival (OS) of nivolumab + ipilimumab versus oxaliplatin + fluoropyrimidine in subjects with programmed cell death ligand 1 (PD-L1) expressing tumors@@@@@OS of nivolumab + ipilimumab versus oxaliplatin + fluoropyrimidine in all randomized subjects@Progression-free Survival (PFS) of nivolumab + ipilimumab versus oxaliplatin + fluoropyrimidine in subjects with PD-L1 expressing tumors and all randomized subjects@@@@ADVANCED@UNRESECTABLE@@@@RANDOMIZED@Efficacy Study@PARALLEL ASSIGNMENT@OPEN LABEL@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916788@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@ARM1; hCRF 2mg/day; dexamethasone 4mg/day along with any open-label dexamethasone they may be taking. ARM2; placebo hCRF 2mg/day, dexamethasone 4mg/day and any open-label dexamethasone they may be taking @@-@-@-@HAMILTON, BERMUDA@@@Xerecept (corticorelin acetate injection) is a synthetic preparation of the natural human peptide CRF. In preclinical studies, it has been demonstrated to be an inhibitor of swelling, or edema. The compound is being developed for its ability to reduce peritumoral brain edema (swelling in the brain due to a tumor), a dangerous complication of brain cancer. It has the potential to be safer than synthetic corticosteroids, the existing standard treatment for cerebral edema, that have serious adverse effects at the chronic high doses required for efficacy. @@14916788@Primary glioma requiring dexamethasone for peritumoural brain edema@@-@-@@NO REVIEW@@@@-@Rights sold to Celtic Pharma in November 2005@-@NCT00226668@120@-@ORPHAN DRUG; FDA FILING EXPECTED IN 2008@@@ORPHAN DRUG; FDA FILING EXPECTED IN 2008@@@-@NTI0302@@-@-@@@III@III@@-@-@RESULTS PENDING@-@@@@-@CORTECORELIN ACETATE@@@@@CORTECORELIN ACETATE||||@CELTIC PHARMA@NEUROBIOLOGICAL TECHNOLOGIES@@@@CELTIC PHARMA|NEUROBIOLOGICAL TECHNOLOGIES|||@@@@@@|||||||||@Brain Cancer@@@@@Brain Cancer|||||||||@XERECEPT@@@@@XERECEPT||||@Immunotherapy@Synthetic Peptide@@@@Immunotherapy|Synthetic Peptide|||@DEXAMETHASONE USE@KARNOFSKY SCALE@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919164@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@MDX-1105 i.v.infusion, 5 cohorts,0.3,1,3,10,15mg/kg/dose every 14 days for a total of 3 infusions  SOURCE: Medarex@@-@-@-@PRINCETON, NEW JERSEY@@@@@14919164@Selected advanced or recurrent solid tumours.@@-@-@@NO REVIEW@@@@-@BMS acquires Medarex in July 2009@-@NCT00729664@40@-@-@@@-@@11/1/2008@-@MDX 1105-01@@-@ECOG performance status of 0 or 1 Criteria specific to each tumor type:RCC: Subjects must have a histologically confirmed diagnosis of renal cell carcinoma(clear cell component)with advanced or recurrent disease that is not amenable to cure by surgery or other means, and must have failed at least 1 previous systemic therapy, including, but not limited to, treatment with sunitinib, temsirolimus, sorafenib, interleukin-2 and or chemotherapy.NSCLC: Subjects must have refractory or recurrent histologically or cytologically confirmed advanced NSCLC. The malignancy must be deemed unresectable, and subjects must have failed at least 1 prior systemic taxane-based therapy.MEL: Subjects must have a histologically confirmed diagnosis of melanoma with advanced disease(previously treated, therapy-refractory or recurrent Stage III (unresectable) or Stage IV); disease no longer controlled by surgery, chemotherapy, or radiotherapy; and disease refractory to or relapsed after standard therapy(may include high-dose interleukin-2). All melanomas regardless of primary site of disease will be allowed.epOC: Subjects must have a histologically confirmed diagnosis of epithelial ovarian cancer with advanced or recurrent disease that is not amendable to cure by surgery or other means and must have failed at least 1 prior systemic platinum-based therapy.@@@I@I@@-@-@Trial registered and commenced. SOURCE: Medarex, 4 August 2008@-@@@@MONO@-@@@@@-||||@MEDAREX@@@@@MEDAREX||||@@@@@@|||||||||@Solid Tumours@Kidney Cancer@Renal Cell Carcinoma@Melanoma / Skin Cancer@Ovarian Cancer@Solid Tumours|Kidney Cancer|Renal Cell Carcinoma|Melanoma / Skin Cancer|Ovarian Cancer|NSCLC||||@MDX-1105@@@@@MDX-1105||||@Other@@@@@Other||||@MAXIMUM TOLERATED DOSE@DOSE-LIMITING TOXICITY@@@@RESPONSE RATE@@@@@ADVANCED@RELAPSED@@@@OPEN-LABEL@DOSE COMPARISON@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921901@Onco@@@@@@@@@@@ARM1: capecitabine + bevacizumab: Ca 1250 mg/m2 daily orally continuously, B 7.5 mg/kg i.v. q 3 w ARM2: observation [Roche]@@L01XC07@L01X@-@BASEL, SWITZERLAND@1/1/2010@@Avastin (Bevacizumab) is a recombinant humanized monoclonalIgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems. Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF (1). Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models ofangiogenesis. Administration of Bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.@@14921901@Maintenance treatment versus observation after induction@@-@-@@NO REVIEW@@@@-@-@-@NCT00442637@635@-@-@@@-@@1/1/2007@-@CAIRO-3@@-@>> Histologically proven advanced colorectal cancer (CRC); not amenable to curative surgery >> In case of a single metastasis, histological or cytological proof of colorectal carcinoma should be obtained prior to randomisation.@@@III@III@@-@-@Trial registered. [Roche, 28.02.2007]@-@@@@COMBO@BEVACIZUMAB@@@@@BEVACIZUMAB||||@ROCHE@@@@@ROCHE||||@Netherlands@@@@@Netherlands|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@AVASTIN@@@@@AVASTIN||||@mAb@Humanised@TK Inhibitor@VEGF@@mAb|Humanised|TK Inhibitor|VEGF|@PROGRESSION-FREE SURVIVAL@@@@@OVERALL SURVIVAL@QUALITY OF LIFE@TRANSLATIONAL RESEARCH@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@1@@@@@@@@@@@@@7.26@@@@@@@@@@@@@@@@@725.53@725.53@@INJECTION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916510@Onco@@@@@300f1012ntsdm@@@@@@107 patients received oral melphalan (0.15MG/KG/day x 7 followed by 0.05MG/KG/day) with prednisone; 203 received IV melphalan (16MG/M2 q 2 weeks x 4 over 6 weeks followed by 4 weeks) with prednisone.@@L01AA03@L01A@YES@@@@Melphalan is a bifunctional alkylating agent. Formation of carbonium intermediates from each of the two bis-2-chloroethyl groups enables alkylation through covalent binding with the 7-nitrogen of guanine on DNA, cross-linking the two DNA strands and thereby preventing cell replication.@@14916510@Alkeran Tablets are indicated in the treatment of multiple myeloma and advanced ovarian adenocarcinoma. Alkeran either alone or in combination with other drugs has a significant therapeutic effect in a proportion of patients suffering from advanced breast carcinoma. Alkeran is effective in the treatment of a proportion of patients suffering from polycythaemia vera.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@310@Ovarian adenocarcinoma: When used intravenously as a single agent, a dose of 1 mg/kg body weight (approximately 40 mg/m2 body surface area) given at intervals of 4 weeks has often been used. When combined with other cytotoxic drugs, intravenous doses of between 0.3 and 0.4 mg/kg body weight (12 to 16 mg/m2 body surface area) have been used at intervals of 4 to 6 weeks.@@@@@@@Melphalan should be administered under the supervision of a qualified physician experienced in the use of chemotherapeutic agents. Severe bone marrow suppression with resulting infection or bleeding may occur. Controlled trials comparing IV to oral melphalan have shown more myelosuppression with the IV formulation.@LABEL@No@@@@@III@APPROVED@@@GKV@44% and 7% responded in the oral and IV groups respectively. Severe myelotoxicity and/or platelets occurred 28% and 11% respectively.@@@@@COMBO@MELPHALAN HYDROCHLORIDE@PREDNISONE@@@@MELPHALAN HYDROCHLORIDE|PREDNISONE|||@ASPEN PHARMA@@@@@ASPEN PHARMA||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@ALKERAN@@@@@ALKERAN||||@Alkylating Agent@Nitrogen Mustard Analogue@@@@Alkylating Agent|Nitrogen Mustard Analogue|||@RESPONSE RATE@@@@@@@@@@@@@@@RANDOMISED@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1807@150@200.63@155.42@@@@@@@@@@3@@@@@@@@@@@@@@@@8/15/2017@150@150@4529192@DRY POWDER AND SOLVENT FOR IV INJECTION@EURO@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14922251@Onco@@@@@300f1014ntsdm@@@@@@Orally administered daily@@-@-@-@BOULDER, COLORADO@1/1/2009@@@@14922251@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00650572@50@-@-@@@-@@3/1/2008@-@ARRAY-380-101@@-@-@@@I@I@@-@-@"Interim results were presented on 17 HER2 positive metastatic breast cancer patients treated with ARRY-380 at doses greater than or equal to 200 mg BID. All of these patients had been previously treated with Herceptin(R) (trastuzumab), and 81 percent were previously treated with Tykerb(R) (lapatinib). Twenty-nine percent of these patients had a partial response or stable disease for six months or longer. Thirteen of the 17 patients had measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST); of these patients, seven (54 percent) had regressions in target lesions. Of the four patients with no measurable disease, three had regressions of non-target chest wall lesions as documented by photographic evaluation. ARRY-380 has been well-tolerated; the predominant treatment-related adverse events have been Grade 1. Because ARRY-380 is selective for HER2 and does not inhibit EGFR, there was, as expected, a low incidence and severity of diarrhea, rash and fatigue. The maximum tolerated dose of ARRY-380 established in this Phase 1 trial is 600 mg (twice daily). An expansion cohort in patients with HER2 positive metastatic breast cancer is ongoing to confirm safety and explore efficacy and pharmacodynamic markers. SOURCE: Array Biopharma, 01 Ocotber 2010 http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-newsArticle&ID=1478319&highlight="@"There were no Grade 4 events or adverse cardiac events reported. SOURCE: Array Biopharma, 01 Ocotber"@@@@MONO@-@@@@@-||||@ARRAY BIOPHARMA@@@@@ARRAY BIOPHARMA||||@@@@@@|||||||||@Solid Tumours@HER2+@@@@Solid Tumours|HER2+||||||||@ARRY-380@@@@@ARRY-380||||@TK Inhibitor@HER2@@@@TK Inhibitor|HER2|||@SAFETY@MAXIMUM TOLERATED DOSE@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@C$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14917594@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@L01AA01@L01A@NO@DEERFIELD, ILLINOIS@@@Cyclophosphamide is an antineoplastic agent which is converted in the body to an active alkylating metabolite. It also possesses marked immunosuppressant properties. The principal site of cyclophosphamide activation is the liver. The chemotherapeutic and immunosuppressant activity of cyclophosphamide is thought to be mediated by the cytotoxic intermediates produced by activation by mixed function oxidases in hepatic microsomes. Non-enzymatic cleavage, possibly taking place in the tumour cells, results in the formulation of highly cytotoxic forms of the drug.@@14917594@Cyclophosphamide has been used successfully to induce and maintain regressions in a wide range of neoplastic conditions, including leukaemias, lymphomas, soft tissue and osteogenic sarcomas, paediatric malignancies and adult solid tumours; in particular, breast and lung carcinomas. Cyclophosphamide is frequently used in combination chemotherapy regimens involving other cytotoxic drugs.@@NA@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@The recommended dose for cyclophosphamide tablets is 50-250 mg/m2 daily (doses towards the upper end of this range should be used only for short courses). The dose may be amended at the discretion of the physician.@@@@@@@Cyclophosphamide should be withheld in the presence of severe bone marrow depression and reduced doses should be used in the presence of lesser degrees of bone marrow depression. Regular blood counts should be performed in patients receiving cyclophosphamide. It should not normally be given to patients with severe infections and should be withdrawn if such infections become life threatening. Cyclophosphamide should be used with caution in debilitated patients and those with renal and/or hepatic failure. Cyclophosphamide is not recommended in patients with a plasma creatinine greater than 120 µmol/l (1.5 mg/100 ml) bilirubin greater than 17 µmol/l (1 mg/100 ml); or serum transaminases or alkaline phosphatase more than 2-3 times the upper limit of normal. In all such cases, dosage should be reduced.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@CYCLOPHOSPHAMIDE@@@@@CYCLOPHOSPHAMIDE||||@BAXTER HEALTHCARE@@@@@BAXTER HEALTHCARE||||@@@@@@|||||||||@Haematological Malignancy@Breast Cancer@NSCLC@Sarcoma@Solid Tumours@Haematological Malignancy|Breast Cancer|NSCLC|Sarcoma|Solid Tumours|||||@ENDOXAN@@@@@ENDOXAN||||@Alkylating Agent@Nitrogen Mustard Analogue@@@@Alkylating Agent|Nitrogen Mustard Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@6@1.1807@89.1@123.64@92.61@@@@@@@@@@@@@@@@@@@@@@@@@@8/15/2017@14.85@14.85@6317577@INJECTION IN BOTTLE@EURO@@@@@@@@1000@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14919556@Onco@@@@@300f1015ntsdm@@@@@@Tamoxifen compared to ovarian ablation@@L02BA01@L02B@YES@@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14919556@@@NO@1-May@@NO REVIEW@@@@@G Gam is the French arm of Hexal, purchased by Novartis in February 2005.@@@N/A@Adjuvant treatment of breast cancer, Adults (including elderly): The recommended dose is 20mg, given either in divided doses twice daily or as a single dose once daily. The current recommended treatment duration is five years; however the optimum duration has not been established. Treatment of locally advanced or metastatic breast cancer: The recommended dose is 20mg to 40mg, given either in divided doses twice daily or as a single dose once daily.@1-Feb@@@@@@Women should be informed of the potential risks to the foetus, should they become pregnant whilst taking tamoxifen; or within two months of cessation of therapy. A number of secondary primary tumours, occurring at sites other than the endometrium and the opposite breast, have been reported in clinical trials, following the treatment of breast cancer patients with tamoxifen. No causal link has been established and the clinical significance of these observations remains unclear.@LABEL@No@@@@@III; METASTATIC BREAST CANCER@APPROVED@@1@HAUTE AUTORITÉ DE SANTÉ@The objective RR, time to treatment failure, and survival were similar with both treatments. In an overview analysis of survival data from the 3 studies, the hazard ratio for death (tamoxifen/ovarian ablation) was 1.00. Elevated serum and plasma oestrogens have been observed in premenopausal women receiving tamoxifen, but the data from the randomized studies do not suggest an adverse effect of this increase. A limited number of premenopausal patients with disease progression during tamoxifen therapy responded to subsequent ovarian ablation.@@@@@MONO@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@G GAM@NOVARTIS@@@@G GAM|NOVARTIS|||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GENERIC@@@@@GENERIC||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RESPONSE RATE@@@@@@@@@@@@@@@PROSPECTIVE@RANDOMISED@@@@@@Invalid Factory Price@@@@@@@@@@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14919925@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NO LABELLED TRIAL@@M05BA03@M05B@NO@PETACH TIKVA, ISRAEL@@@Pamidronate disodium is a potent inhibitor of osteoclastic bone resorption. It binds strongly to hydroxyapatite crystals and inhibits the formation and dissolution of these crystals in vitro. Inhibition of osteoclastic bone resorption in vivo may be at least partly due to binding of the drug to the bone mineral. Pamidronate suppresses the accession of osteoclast precursors onto the bone. However, the local and direct antiresorptive effect of bone-bound bisphosphonate appears to be the predominant mode of action in vitro and in vivo. Experimental studies have demonstrated that pamidronate inhibits tumour-induced osteolysis when given prior to or at the time of inoculation or transplantation with tumour cells. Biochemical changes reflecting the inhibitory effect of Aredia on tumour-induced hypercalcaemia, are characterised by a decrease in serum calcium and phosphate and secondarily by decreases in urinary excretion of calcium, phosphate, and hydroxyproline.@@14919925@• Treatment of conditions associated with increased osteoclast activity: Tumour-induced hypercalcaemia • Osteolytic lesions and bone pain in patients with bone metastases associated with breast cancer or multiple myeloma • Paget's disease of bone.@@NO@@@NO REVIEW@@@@@@@@@Osteolytic lesions and bone pain in multiple myeloma - The recommended dose is 90 mg every 4 weeks. Osteolytic lesions and bone pain in bone metastases associated with breast cancer - The recommended dose is 90 mg every 4 weeks. This dose may also be administered at 3 weekly intervals to coincide with chemotherapy if desired.@@@@@@@Pamidronate should never be given as a bolus injection since severe local reactions and thrombophlebitis may occur. It should always be diluted and then given as a slow intravenous infusion. It should not be co-administered with other bisphosphonates. If other calcium lowering agents are used in conjunction with pamidronate, significant hypocalcaemia may result. Convulsions have been precipitated in some patients with tumour-induced hypercalcaemia due to the electrolyte changes associated with this condition and its effective treatment.@NO LABELLED TRIAL@No@5-Oct@@@@@APPROVED@@@MEDICARE@NO LABELLED TRIAL@@@@@@PAMIDRONATE DISODIUM@@@@@PAMIDRONATE DISODIUM||||@TEVA PHARMACEUTICAL@@@@@TEVA PHARMACEUTICAL||||@@@@@@|||||||||@Supportive Care@Breast Cancer@Haematological Malignancy@Myeloma@Bone Metastases@Supportive Care|Breast Cancer|Haematological Malignancy|Myeloma|Bone Metastases|||||@GENERIC@@@@@GENERIC||||@Bisphosphonate@@@@@Bisphosphonate||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@US$@@@@@@@@90@MG@9 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917729@Onco@@@@@300f1037ntsdm@@@@@@NO LABELLED TRIAL@@L01XX11@L01X@NO@NEW YORK, NEW YORK@@@Estramustine is a chemical compound of oestradiol and nitrogen mustard. It is effective in the treatment of advanced prostatic carcinoma. Estramustine has a dual mode of action. The intact molecule acts as an anti-miotic agent; after hydrolysis of the carbamate ester, the metabolites act to bridge the released oestrogens and exert an anti-gonadotrophic effect. The low level of clinical side effects may be due to the fact that estramustine binds to a protein present in the tumour tissue, so resulting in accumulation of the drug at the target site. Estracyt also has weak oestrogenic and anti-gonadotrophic properties. Estramustine causes little or no bone marrow depression at usual therapeutic dosage. Estramustine is effective in patients who have not previously received drug therapy, as well as in those who have shown no response to conventional hormone treatment.@@14917729@Carcinoma of the prostate, especially in cases unresponsive to, or relapsing after, treatment by conventional oestrogens (stilboestrol, polyestradiol phosphate etc.) or by orchidectomy.@@NO@@@NO REVIEW@@@@90%@@@@@Dosage range may be from 1 to 10 capsules a day by mouth. The capsules should be taken not less than 1 hour before or 2 hours after meals. The capsules should not be taken with milk or milk products. Standard starting dosage is 4-6 capsules a day in divided doses with later adjustment according to response and gastrointestinal tolerance.@HMA, 1 February 1978@2/1/1978@5/1/1978@@@@Use with caution in patients with moderate to severe bone marrow depression, thrombophlebitis, thrombosis, thromboembolic disorders, cardiovascular disease, coronary artery disease and congestive heart failure.@NO LABELLED TRIAL@No@@@@@@APPROVED@@NO REVIEW@SNS@NO LABELLED TRIAL@@@@@@ESTRAMUSTINE PHOSPHATE SODIUM@@@@@ESTRAMUSTINE PHOSPHATE SODIUM||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@ESTRACYT@@@@@ESTRACYT||||@Oestrogen@Nitrogen Mustard Analogue@@@@Oestrogen|Nitrogen Mustard Analogue|||@@@@@@@@@@@REFRACTORY@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@100@1.1511@77.2@120.52@83.59@@@@@@@@@@@@@@@@@@@@@@@@@@8/4/2017@0.77@0.77@753137@CAPSULE@EURO@@@@@@@@140@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14921783@Onco@@@@@@@@@@@Combo with Herceptin@@-@-@-@BASEL, SWITZERLAND@@@A cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing hyperacetylation of core histone proteins, which may result in modulation of cell cycle protein expression, cell cycle arrest in the G2/M phase and apoptosis. In addition, this agent appears to modulate the expression of angiogenesis-related genes, such as hypoxia-inducible factor-1alpha (HIF-1a) and vascular endothelial growth factor (VEGF), thus impairing endothelial cell chemotaxis and invasion. HDAC is an enzyme that deacetylates chromatin histone proteins. @@14921783@Adult females with HER2-positive metastatic breast cancer progressed on or after Herceptin@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00567879@118@-@EMEA PDCO recommended product-specific waiver. SOURCE: EMEA PDCO, January 2008Orphan designation was granted by the European Commission for panobinostat lactate for the treatment of cutaneous T cell lymphoma. [There is discussion of current treatments, the numbers or persons affected with this condition in the EU, and the mode of action & state of development of panobinostat lactate for the treatment of this condition. Panobinostat lactate was not authorised anywhere in the world for cutaneous T-cell lymphoma, or designated as orphan medicinal product elsewhere for this condition, at the time of submission. Designated orphan medicinal products are still investigational products which were considered for designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of the quality, safety and efficacy will be necessary before this product can be granted a marketing authorisation.] SOURCE: EMEA COMP, 6 November 2007@11/6/2007@@-@@12/1/2007@-@CLBH589C2204@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@COMBO@PANOBINOSTAT@TRASTUZUMAB@@@@PANOBINOSTAT|TRASTUZUMAB|||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@LBH-589@HERCEPTIN@@@@LBH-589|HERCEPTIN|||@HDAC@@@@@HDAC||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@REFRACTORY@METASTATIC@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
16617770@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01XX52@L01X@@@@@VENCLEXTA is a BCL-2 inhibitor indicated for the treatment of patientswith chronic lymphocytic leukemia (CLL) with 17p deletion, as detected byan FDA approved test, who have received at least one prior therapy@@16617770@VENCLEXTA is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least oneprior therapy.@@NA@@@NO REVIEW@@@@@@SECOND-LINE@@106@Week 1: 20 mg daily, week 2: 50 mg daily, week 3: 100 mg daily, week 4: 200 mg daily, week 5 onwards: 400 mg daily. VENCLEXTA should be taken orally once daily until disease progression or unacceptable toxicity is observed@FDA, 11 April 2016@4/11/2016@5/2/2016@@@@@@No@@@17p deletion@ADULTS@@APPROVED@@@@@@@@@MONO@VENETOCLAX@@@@@VENETOCLAX||||@ABBVIE@@@@@ABBVIE||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@VENCLEXTA@@@@@VENCLEXTA||||@Bcl-2 Inhibitor@@@@@Bcl-2 Inhibitor||||@@@@@@@@@@@@@@@@@@@@@1@1@143102.0918@@@12.1@month@12.1 month@143102.09@143102.09@388.83@100@1@10324.57@@@@@@@@@@@@1.03@28@1@mg@92.5@28@1@@mg@400@1@@@@@@8/2/2017@103.25@103.25@00074-0576-22@FILM-COATED TABLET (BOTTLE)@US$@@@@@@@@100@MG@100 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919783@Onco@@@@@300f1037ntsdm@@@@@@Tamoxifen compared to ovarian ablation@@L02BA01@L02B@YES@BAD VILBEL, GERMANY@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14919783@@@NO@@@NO REVIEW@@@@90%@@@@N/A@Adults: The recommended daily dose of tamoxifen is normally 20 mg. No additional benefit, in terms of delayed recurrence or improved survival in patients, has been demonstrated with higher doses. Substantive evidence supporting the use of treatment with 30–40 mg per day is not available, although these doses have been used in some patients with advanced disease.@1-Feb-89@2/1/1989@@@@@Menstruation is suppressed in a proportion of premenopausal women receiving Nolvadex for the treatment of breast cancer. An increased incidence of endometrial changes including hyperplasia, polyps, cancer and uterine sarcoma (mostly malignant mixed Mullerian tumours), has been reported in association with Nolvadex treatment. The underlying mechanism is unknown but may be related to the oestrogenlike effect of Nolvadex. Any patient receiving or having previously received Nolvadex who report abnormal gynaecological symptoms, especially vaginal bleeding, or who presents with menstrual irregularities, vaginal discharge and symptoms such as pelvic pain or pressure should be promptly investigated.@LABEL@No@@@@@III; METASTATIC BREAST CANCER@APPROVED@@NO REVIEW@SNS@The objective RR, time to treatment failure, and survival were similar with both treatments. In an overview analysis of survival data from the 3 studies, the hazard ratio for death (tamoxifen/ovarian ablation) was 1.00. Elevated serum and plasma oestrogens have been observed in premenopausal women receiving tamoxifen, but the data from the randomized studies do not suggest an adverse effect of this increase. A limited number of premenopausal patients with disease progression during tamoxifen therapy responded to subsequent ovarian ablation.@@@@@MONO@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@STADA ARZNEIMITTEL@BAYVIT@@@@STADA ARZNEIMITTEL|BAYVIT|||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GENERIC@@@@@GENERIC||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RESPONSE RATE@@@@@@@@@@@@@@@PROSPECTIVE@RANDOMISED@@@@@@Invalid Factory Price@@@@@@@@@30@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@EURO@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14924757@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Bevacizumab +-trastuzumab administered with 3 different docetaxel-based combination regimens @@L01CD02@L01C@-@PARIS, FRANCE@@@Docetaxel is an antineoplastic agent which acts by promoting the assembly of tubulin into stable microtubules and inhibits their disassembly which leads to a marked decrease of free tubulin. The binding of docetaxel to microtubules does not alter the number of protofilaments. Docetaxel has been shown in vitro to disrupt the microtubular network in cells which is essential for vital mitotic and interphase cellular functions. Docetaxel was found to be cytotoxic in vitro against various murine and human tumour cell lines and against freshly excised human tumour cells in clonogenic assays. Docetaxel achieves high intracellular concentrations with a long cell residence time. In addition, docetaxel was found to be active on some but not all cell lines over expressing the p-glycoprotein which is encoded by the multidrug resistance gene. In vivo, docetaxel is schedule independent and has a broad spectrum of experimental antitumour activity against advanced murine and human grafted tumours.@@14924757@Adjuvant treatment @@-@-@@NO REVIEW@@@@-@-@-@NCT00446030@225@-@-@@@-@@3/1/2007@-@-@@-@225 patients with node positive or high risk node negative breast cancer.@-@@II@II@@-@-@RESULTS PENDING@-@@@@ADJUVANT@DOCETAXEL@BEVACIZUMAB@TRASTUZUMAB@@@DOCETAXEL|BEVACIZUMAB|TRASTUZUMAB||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@TAXOTERE@AVASTIN@HERCEPTIN@@@TAXOTERE|AVASTIN|HERCEPTIN||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@SAFETY@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919048@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Half of the patients will be administered intravenous Zybrestat plus bevacizumab, carboplatin and paclitaxel, and half will receive the standard first-line regimen of a combination of bevacizumab, carboplatin and paclitaxel. SOURCE: Oxigene, 26 March 2008@@-@-@-@WALTHAM, MASSACHUSSETTS@@@@@14919048@Combo with Avastin@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@-@60@-@-@@@-@@3/1/2008@-@N/A@@-@-@@@II@II@@-@-@>> The updated analysis showed that the median time to progression for patients receiving ZYBRESTAT plus bevacizumab and chemotherapy was 9.5 months, compared with a median time to progression of 8.8 months for patients receiving bevacizumab and chemotherapy alone. Of the patients in the study arm (ZYBRESTAT combined with bevacizumab and carboplatin/paclitaxel chemotherapy), 50% achieved a partial response, compared with the control arm (bevacizumab and chemotherapy) of the trial, where only 38% of patients achieved a partial response. The combination regimen including ZYBRESTAT was observed to be well-tolerated with no significant cumulative toxicities when compared with the control arm of the study. [Oxigene, 19.11.10, http://investor.oxigene.com/releasedetail.cfm?ReleaseID=531854]@-@@@@COMBO@COMBRETASTATIN A4 PRODRUG@BEVACIZUMAB@@@@COMBRETASTATIN A4 PRODRUG|BEVACIZUMAB|||@OXIGENE@@@@@OXIGENE||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@ZYBRESTAT@AVASTIN@@@@ZYBRESTAT|AVASTIN|||@Vascular Disrupting Agent@@@@@Vascular Disrupting Agent||||@PROGRESSION-FREE SURVIVAL@SAFETY@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16396657@Onco@@@@@300f1018ntsdm@@@@@@10 mg once daily or 10 mg once daily for 21 days every 28 days. Sequential dose reductions to 5 mg daily and 5 mg every other day, as well as dose delays, were allowed for toxicity.@@L04AX04@L04A@@SUMMIT, NEW JERSEY@@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16396657@Revlimid is indicated for treatment of patients with transfusiondependent anaemia due to low or intermediate1 risk myelodysplastic syndromesassociated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.@@YES@13-Mar@@NO REVIEW@@@@@@@@148@The recommended starting dose of REVLIMID® for MDS patients is 10 mg daily for the first 21 days of repeated 28day cycles. Dosing is continued or modified based upon clinical and laboratory findings.@@@@No@@@@@No@@148 PATIENTS WHO HAD RBC TRANSFUSION DEPENDENT ANEMIA. RBCTRANSFUSION DEPENDENCE WAS DEFINED AS HAVING RECEIVED = 2 UNITS OF RBCS WITHIN 8 WEEKS PRIOR TO STUDY TREATMENT. THE STUDY ENROLLED PATIENTS WITH ABSOLUTE NEUTROPHIL COUNTS (ANC) = 500 CELLS/MM3,@@@III@APPROVED@@The PBAC recommended extending the current listing for lenalidomide to include treatment of transfusion-dependent, low risk/INT-1, 5q- myelodysplastic syndrome on the basis of acceptable cost effectiveness compared with best supportive care@PBS@@@@@@MONO@LENALIDOMIDE@@@@@LENALIDOMIDE||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myelodysplastic Syndrome@@@@Haematological Malignancy|Myelodysplastic Syndrome||||||||@REVLIMID@@@@@REVLIMID||||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@@@@@@@@@@@@@@@@@@@@@1@1@10722.31999@@@56@day@56 day@10722.32@10722.32@191.47@21@0.779@5361.16@5407.68@@@@@@@@@@@25.53@28@@mg@10@21@@@@@@@@@@@8/1/2017@255.29@255.29@2922-1419-HB-CJ@HARD CAPSULE@A$@@@@@@@@10@MG@10 MG@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14918139@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01CB01@L01C@YES@BASEL, SWITZERLAND@@@Etoposide is a semisynthetic derivative of podophyllotoxin used in the treatment of certain neoplastic diseases. Podophyllotoxins inhibit mitosis by blocking microtubular assembly. Etoposide inhibits cell cycle progression at a premitotic phase (late S and G2). It does not interfere with the synthesis of nucleinic acids.@@14918139@Used in combination therapy with other approved chemotherapeutics in patients with refractory testicular tumors who have already received appropriate surgical, chemotherapeutic, and radiotherapeutic therapy; used in combination with other approved chemotherapeutic agents as first-line treatment in patients with small cell lung cancer.@@YES@6-Sep@@NO REVIEW@@@@@Acquired through takeover of Hexal@@@@The usual dose in testicular cancer in combination with other approved chemotherapeutic agents ranges from 50 to 100 mg/m2/day on days 1 through 5 to 100 mg/m2/day on days 1, 3, and 5. In small cell lung cancer, the dose in combination with other approved chemotherapeutic drugs ranges from 35 mg/m2/day for 4 days to 50 mg/m2/day for 5 days.@5-Apr@@@@@@Patients being treated with VePesid must be frequently observed for myelosuppression both during and after therapy. Myelosuppression resulting in death has been reported. Dose-limiting bone marrow suppression is the most significant toxicity associated with VePesid therapy. Therefore, the following studies should be obtained at the start of therapy and prior to each subsequent cycle of VePesid: platelet count, haemoglobin, white blood cell count, and differential. The occurrence of a platelet count below 50,000/mm3 or an absolute neutrophil count below 500/mm3 is an indication to withhold further therapy until the blood counts have sufficiently recovered.@NO LABELLED TRIAL@No@@@@@@APPROVED@@1@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@ETOPOSIDE PHOSPHATE@@@@@ETOPOSIDE PHOSPHATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Testicular Cancer@SCLC@@@@Testicular Cancer|SCLC||||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Topoisomerase II Inhibitor@@@@Plant Alkaloid|Topoisomerase II Inhibitor|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14919595@Onco@@@@@300f1015ntsdm@@@@@@@@L01XX19@L01X@YES@@@@Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks.@@14919595@CAMPTO is indicated for the treatment of patients with advanced colorectal cancer as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen.@@YES@@@NO REVIEW@@@@@@SECOND-LINE@@@The recommended dosage of CAMPTO is 350 mg/m² administered as an intravenous infusion over a 30- to 90- minute period every three weeks.Treatment with CAMPTO should be continued until there is an objective progression of the disease or an unacceptable toxicity.@@@7/17/2009@@@@Can induce both early and late forms of diarrhea. Both forms of diarrhea may be severe. Early diarrhea (occurring during or shortly after infusion may be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping. Late diarrhea (generally occurring more than 24 hours after administration) can be life threatening since it may be prolonged and may lead to dehydration, electrolyte imbalance, or sepsis. Patients with diarrhea should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated or antibiotic therapy if they develop ileus, fever, or severe neutropenia. Severe myelosuppression may also occur.@@No@@@@@@APPROVED@@No ASMR/SMR rating@HAUTE AUTORITÉ DE SANTÉ@@@@@@MONO@IRINOTECAN@@@@@IRINOTECAN||||@KABI@@@@@KABI||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@@@@@@@@@@@ADVANCED@@@@@@@@@@1.75@m²@Invalid Factory Price@@@3.9@month@3.9 month@@@@1@1.1511@@@@@@@@@@@@@@21@@mg/m²@350@1@@@@@@@@@@@@@@9332778T@DILUTED SOLUTION FOR PERFUSION, 2 ML@EURO@@@@@@@@40@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
16396666@Onco@@@@@300f1018ntsdm@@@@@@@@L04AX04@L04A@@SUMMIT, NEW JERSEY@3/1/2017@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16396666@Indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.@Both@YES@@@NO REVIEW@@@@@@@NCT00875667@254@The recommended starting dose of lenalidomide is 25 mg orally once daily on days 121 of repeated 28day cycles.@TGA, 16 March 2016@3/16/2016@@Yes@@4/1/2009@@CC5013MCL002@No@@Biopsy proven mantle cell lymphoma; Patients who are refractory to their regimen or have relapsed once, twice or up to three times and who have documented progressive disease; Eastern Cooperative Oncology Group (ECOG) performance score 0,1, or 2; Willing to follow pregnancy precaution@@ADULTS@II@APPROVED@@@@@@@@@MONO@LENALIDOMIDE@@@@@LENALIDOMIDE||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Non-Hodgkin's Lymphoma@Mantle Cell Lymphoma@@@@Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma||||||||@REVLIMID@@@@@REVLIMID||||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@PROGRESSION FREE SURVIVAL@@@@@OVERALL RESPONSE RATE@DURATION OF RESPONSE@TIME TO PROGRESSION@@@RELAPSED@REFRACTORY@@@@RANDOMISED@MULTI-CENTRE@OPEN LAB EL@@@1@1@61922.406@@@37.6@week@37.6 week@61922.41@61922.41@235.27@21@0.779@6587.49@6634.01@@@@@@@@@@@12.55@28@@mg@25@21@@@@@@@@@@@8/1/2017@313.69@313.69@2922-1421-HB-CJ@HARD CAPSULE@A$@@@@@@@@25@MG@25 MG@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14916194@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Trastuzumab-MCC-DM1 IV repeating dose@@-@-@-@SAN FRANCISCO, CALIFORNIA@1/1/2010@@Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies: anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative). @@14916194@For patients who have progressed on Herceptin plus chemotherapy@@-@-@@NO REVIEW@@@@-@">> Roche reaches a friendly agreement to purchase the latter's outstanding shares at a price of US$95 per share. The transaction will be valued at US$46.8 billion. [Genentech, 12 March 2009]>> Roche has made a formal announcement of cash tender offer for all outstanding shares of Genentech at US$86.50 per share for the 44.2% of Genentech not already held by Roche. Genentech's special committee, on the other hand, has responded to the offer by urging its shareholders ""to take no action at this time"". [Genentech, 10.02.2009]          >> Genentech rejects the acquisition bid. [Genentech, 14.08.2008]        >> Roche announces US$43.7 billion proposal to assume full control of Genentech. SOURCE: Roche, 21 July 2008"@-@NCT00509769@100@-@-@@@-@@7/1/2007@-@TDM4258g@@-@Histologically documented breast cancer HER2-positive disease Metastatic breast cancer Disease progression on the last chemotherapy regimen received in the metastatic setting@@@II@II@@-@-@Go/No Go decision in 2008. SOURCE: Genentech, 10 April 2008FPI IN Q3 07@-@@@@MONO@TRASTUZUMAB-DM1@@@@@TRASTUZUMAB-DM1||||@GENENTECH@IMMUNOGEN@@@@GENENTECH|IMMUNOGEN|||@@@@@@|||||||||@Breast Cancer@HER2+@@@@Breast Cancer|HER2+||||||||@TRASTUZUMAB-DM1@@@@@TRASTUZUMAB-DM1||||@mAb@Humanised@HER2@EGFR@@mAb|Humanised|HER2|EGFR|@SAFETY@RESPONSE RATE@@@@@@@@@METASTATIC@@@@@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924872@Onco@@@@@@@@@@@Eligible patients will receive one infusion of ofatumumab at 300 mg followed by 7 once weekly infusions at 1000 mg. Maintenance treatment will consist of one 1000 mg infusion every two months for two years.  SOURCE: Genmab@@-@-@-@COPENHAGEN, DENMARK@@@Ofatumumab is an investigational new generation human monoclonal antibody that targets a distinct, membrane proximal, small loop epitope (specific antibody binding site) of the CD20 molecule on B cells. Ofatumumab is being developed to treat chronic lymphocytic leukemia, follicular non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, rheumatoid arthritis and relapsing remitting Multiple Sclerosis under a co-development and commercialization agreement between Genmab and GlaxoSmithKline. It is not yet approved in any country.@@14924872@Ofatumumab retreatment and maintenance treatment study@@-@-@@NO REVIEW@@@@-@>> Amendment to the licensing deal agreed; Genmab has sold its co-promotion option rights to GSK. The sale of the co-promotion option does not affect the royalty or milestone revenue that Genmab may receive. GSK will now be fully responsible for the entire sales organisation for ofatumumab. Genmab will receive a one-time payment of US$4.5 million from GSK upon the FDA's acceptance for review of the filing of the first BLA for ofatumumab in an oncology indication in the United States in exchange for terminating its option to co-promote ofatumumab. [Genmab, 19.12.2008]      >> GlaxoSmithKline acquired an exclusive worldwide license to ofatumumab as well as any other antibodies with affinity for CD20 which Genmab may develop. GSK and Genmab will co-develop ofatumumab; Genmab has an option to co-promote ofatumumab in a targeted oncology setting in the United States and in the Nordic region. In addition, if Genmab exercises the co-promotion option, Genmab would have had the option to co-promote GSK's Bexxar and Arranon in the United States and Atriance in the relevant countries of the Nordic region. [Genmab, December 2006]@-@-@-@-@-@@@-@@@-@-@@-@Refractory follicular NHL patients who participated in the ongoing Phase III NHL study and had disease progression following at least 6 months objective response to or stable disease on ofatumumab.@@@II@II@@-@-@Trial to start in 2008. [Genmab, 25 August 2008]@-@@@@MONO@OFATUMUMAB@@@@@OFATUMUMAB||||@GENMAB@MEDAREX@GSK@@@GENMAB|MEDAREX|GSK||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@ARZERRA@@@@@ARZERRA||||@mAb@Human@CD20@@@mAb|Human|CD20||@SAFETY@@@@@@@@@@REFRACTORY@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@-@@@@@@@@@@20 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@@
14922443@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@AG013736, tablets 5 mg po bid@@-@-@-@NEW YORK, NEW YORK@12/1/2008@@Axitinib is an oral, selective inhibitor of VEGFR 1, 2, 3 (vascular endothelial growth factor receptors 1, 2 and 3), which has been shown to induce tumor regression as a single-agent and in combination with chemotherapy. Inhibiting VEGF binding plays a key role in anti-angiogenesis - or blocking blood vessel formation which starves tumors of the blood and nutrients needed for growth. @@14922443@Doxorubicin-refractory or intolerant thyroid cancer@@-@-@@NO REVIEW@@@@-@Developed from Abgenix (now Amgen) mice, double-digit royalties to go to Medarex due to cross-licensing in this area@SECOND-LINE@NCT00389441@100@-@-@@@-@@12/1/2006@-@A4061027@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@AXITINIB@@@@@AXITINIB||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Thyroid Cancer@@@@@Thyroid Cancer|||||||||@AG-013736@@@@@AG-013736||||@TK Inhibitor@VEGF@PDGF@SCF@Angiogenesis Inhibitor@TK Inhibitor|VEGF|PDGF|SCF|Angiogenesis Inhibitor@RECIST@@@@@@@@@@REFRACTORY@RELAPSED@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14923020@Onco@@@@@@@@@@@-@@-@-@-@RUNCORN, UNITED KINGDOM@@@Voraxaze (glucarpidase, previously known as carboxypeptidase G2 or CPG2) is a biological product designed to rapidly reduce the amount of blood levels of methotrexate (MTX), a commonly used cancer drug in the blood. High doses of MTX can cause kidney damage in some cancer patients and this can delay the elimination of MTX from the body. Prolonged exposure to high concentrations of MTX commonly results in serious toxic effects such as mucositis (painful mouth sores), reduced platelet and white blood counts (myelosuppression) , kidney failure and an increased risk of sepsis and in some instances death. A number of cancer patients die every year from MTX induced toxicity, typically due to sepsis. Voraxaze is the only drug which can remove MTX from the blood; dialysis is the only other way to remove MTX from the blood.@@14923020@Treatment of patients experiencing or at risk of methotrexate toxicity due to delayed elimination@@-@-@@NO REVIEW@@@-@-@-@-@-@329@a 30-60 minute period once weekly for 3 weeks followed by weekly doses of 75 mg, infused over a@PROTHERICS WITHDREW MMA IN MAY 2007 AS THE ADDITIONAL DATA COULD NOT BE GENERATED IN THE TIMEFRAME AVAILABLE UNDER THE CENTRALISED PROCEDURE. IT WILL BE REFILED IF THE 12-PATIENT STUDY ASKED FOR BY THE FDA IS ACCEPTABLE. SUPPLIED ON A NAMED BASIS.MMA FILED IN JUNE 2005; EMEA REQUIRED MORE MANUFACTURING AND LEUCOVORIN DATA.@@@-@@@-@-@@-@-@@@-@FILED@@-@-@In one pivotal and two supportive studies, Voraxaze was able to achieve a clinically important reduction (CIR) in MTX to =1 µmol/L in the majority of patients treated. This is a generally accepted threshold below which the risk of severe MTX toxicity is considered to be reduced. It reduced plasma or serum MTX concentrations by an average of >98% within an hour of administration in each of the three studies. A total of 25/329 (8%) patients reported 50 adverse events with a possible relationship to Voraxaze; about a third of these were allergic reactions (burning sensation, flushing, hot flush, allergic dermatitis, feeling hot, pruritis, hypersensitivity). Two of the adverse events were considered serious, hypertension and arrhythmia, but neither was definitively associated with use of Voraxaze and the latter was considered more likely to be associated with MTX.@-@@@@-@GLUCARPIDASE@@@@@GLUCARPIDASE||||@PROTHERICS@@@@@PROTHERICS||||@@@@@@|||||||||@Supportive Care@@@@@Supportive Care|||||||||@VORAXAZE@@@@@VORAXAZE||||@Enzyme@@@@@Enzyme||||@SAFETY@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921903@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@The study drug will be administered by bolus intravenous infusion in an in-patient hospital setting under the supervision of a qualified physician experienced in the use of anti-cancer agents including high dose IL-2. An intensive care facility and specialists skilled in cardiopulmonary or intensive care medicine must be available. There are two treatment cycles. For each treatment cycle, patients will be admitted to the hospital, remain in the hospital during the study drug infusion period, and be discharged from the hospital the day after the last infusion at the Principal Investigator's discretion. There is a 10-day resting period between the treatment cycles. Tumor assessments will be done at weeks 7 and 11 after starting the study drug. SOURCE: clinicaltrials.gov@@-@-@-@MIRAMAR, FLORIDA@11/1/2008@@@@14921903@Progressive metastatic malignancies@@YES@-@@NO REVIEW@@@@-@-@-@NCT00496860@46@-@-@@@-@@5/1/2007@-@CA-ALT-801-01-06@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@ALTOR BIOSCIENCE@@@@@ALTOR BIOSCIENCE||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@ALT-801@@@@@ALT-801||||@Interleukin@@@@@Interleukin||||@SAFETY@MAXIMUM TOLERATED DOSE@PHARMACOKINETICS@@@PHARMACOKINETICS@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918752@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Herceptin and trastuzumab combination@@-@-@-@BASEL, SWITZERLAND@@@Pertuzumab is a humanized antibody and the first in a new class of agents known as HER dimerization inhibitors (HDIs). HDIs block the ability of the HER2 receptor to collaborate with other HER receptor family members (HER1/EGFR, HER3, and HER4). In cancer cells, interfering with HER2's ability to collaborate with other HER family receptors blocks cell signaling and may ultimately lead to cancer cell growth inhibition and death of the cancer cell. HDIs, because of their unique mode of action, have the potential to work in a wide variety of tumors, including those that do not overexpress HER2@@14918752@Unresectable locally advanced or metastatic breast cancer that did not respond to previous Herceptin therapy@@-@-@@NO REVIEW@@@@-@-@-@NCT00301899@37@-@-@@@-@@12/1/2005@-@NCI-06-C-0035, @@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@PERTUZUMAB@@@@@PERTUZUMAB||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Breast Cancer@HER2+@@@@Breast Cancer|HER2+||||||||@OMNITARG / R-1273@R-1273@@@@OMNITARG / R-1273|R-1273|||@mAb@Humanised@HER2@@@mAb|Humanised|HER2||@SAFETY@RESPONSE RATE@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16384753@Onco@@@@@300f1015ntsdm@@@@@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384753@Indicated for the treatment of adult patients with Ph+ CML in chronic phase after failure of interferon-alphatherapy@@NO@@@NO REVIEW@@@@@@SECOND-LINE@@532@The recommended dosage of Glivec is 400 mg/day for adult patients in chronic phase CML.@@@@Yes@@@@@No@@@ADULT@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@@@@@@MONO@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@CHRONIC PHASE@@@@@@@@@@1@1@Invalid Average Duration of Use@@@@@@@@@30@1.1511@2096.14@2270.33@2126.14@@@@@@@@@@0.17@1@@mg@400@1@@@@@@@@@@@8/1/2017@69.87@69.87@3.40E+12@FILM-COATED TABLET@EURO@@@@@@@@400@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14916473@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@R-ICE with or without SGN-40@@-@-@-@SEATTLE, WASHINGTON@@@@@14916473@Diffuse large B-cell lymphoma@@-@-@@NO REVIEW@@@@-@Roche announces US$43.7 billion proposal to assume full control of Genentech. SOURCE: Roche, 21 July 2008Genentech licensed the drug from Seattle Genetics in January 2007@SECOND-LINE@NCT00529503@N/A@-@-@@@-@@@-@SG040-0005@@-@-@@@II@II@@-@-@First-patient in (FPI) Q4 2007 (SOURCE; Genentech Q3 07 SEC).@-@@@@COMBO@DACETUZUMAB@@@@@DACETUZUMAB||||@SEATTLE GENETICS@GENENTECH@@@@SEATTLE GENETICS|GENENTECH|||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@B-Cell Lymphoma@DLBCL@@Haematological Malignancy|Non-Hodgkin's Lymphoma|B-Cell Lymphoma|DLBCL||||||@SGN-40@ANTI-CD40@@@@SGN-40|ANTI-CD40|||@mAb@Humanised@CD40@@@mAb|Humanised|CD40||@COMPLETE RESPONSE@SAFETY@TOLERABILITY@@@TOLERABILITY@@@@@-@@@@@RANDOMISED@PLACEBO-CONTROLLED@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15358231@Onco@@@@@300f1014ntsdm@@@@@@Experimental: Erlotinib. Participants received erlotinib, 150 milligrams (mg), orally (PO), daily from randomization until progressive disease (PD), death, or unacceptable toxicity.Placebo Comparator: Placebo. Participants received a placebo, PO, daily, from randomization until PD, death, or unacceptable toxicity.@@L01XE03@L01X@@BASEL, SWITZERLAND@11/1/2010@@The mechanism of clinical antitumor action of erlotinib is not fully characterized. Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR). Specificity of inhibition with regard to other tyrosine kinase receptors has not been fully characterized. EGFR is expressed on the cell surface of normal cells and cancer cells.@@15358231@Tarceva is indicated as monotherapy for maintenance treatment in patients with locally advanced or metastatic NSCLC with stable disease after 4 cycles of standard platinum-based first-linechemotherapy.@Both@YES@@@NO REVIEW@@@@@>> Roche announces US$43.7 billion proposal to assume full control of Genentech. [Roche, 21 July 2008]       >> To meet FTC requirements for its merger with Warner Lambert, Pfizer was was forced to divest its stake in erlotinib in June 2000 back to OSI. In January 2001, Genentech and Roche licensed global co-development and commercialisation. [OSI, January 2001]        >> Pfizer acquired major stake in Oncogene (now OSI) to form a collaborative research programme. [Oncogene, 8.07.1986]@MAINTENANCE@NCT00556712@889@The recommended daily dose is 150 mg. Treatment should continue until disease progression or unacceptable toxicity occurs.@Health Canada, 16 April 2010@4/16/2010@@@@1/1/2006@@BO18192@No@@histologically documented, locally advanced , recurrent or metastatic NSCLC;measurable disease;no disease progression after 4 cycles of platinum-based chemotherapy.@@ADULTS@III@APPROVED@@@@@@@@@MONO@ERLOTINIB HYDROCHLORIDE@@@@@ERLOTINIB HYDROCHLORIDE||||@ROCHE@CHUGAI PHARMACEUTICAL@@@@ROCHE|CHUGAI PHARMACEUTICAL|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@TARCEVA@@@@@TARCEVA||||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@RANDOMIZED@PARALLEL ASSIGNMENT@DOUBLE BLIND@@@1@@6887.999914@@@12.3@week@12.3 week@6888@6888@80@30@0.7881@1600@@@@@@@@@@@@0.53@1@@mg@150@1@@@@@@@@@@@7/19/2017@53.33@53.33@226901530@FILM-COATED TABLET (BLISTER PVC/ALU)@C$@@@@@@@@100@MG@100 MG@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
16384680@Onco@@@@@300f1015ntsdm@@@@@@@@L01CD02@L01C@@PARIS, FRANCE@@@Docetaxel is an antineoplastic agent which acts by promoting the assembly of tubulin into stable microtubules and inhibits their disassembly which leads to a marked decrease of free tubulin. The binding of docetaxel to microtubules does not alter the number of protofilaments. Docetaxel has been shown in vitro to disrupt the microtubular network in cells which is essential for vital mitotic and interphase cellular functions. Docetaxel was found to be cytotoxic in vitro against various murine and human tumour cell lines and against freshly excised human tumour cells in clonogenic assays. Docetaxel achieves high intracellular concentrations with a long cell residence time. In addition, docetaxel was found to be active on some but not all cell lines over expressing the p-glycoprotein which is encoded by the multidrug resistance gene. In vivo, docetaxel is schedule independent and has a broad spectrum of experimental antitumour activity against advanced murine and human grafted tumours.@@16384680@TAXOTERE is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy.@@@@@@@@@@@SECOND-LINE@@@For treatment after failure of prior platinum-based chemotherapy, the recommended dose is 75 mg/m² as a single agent. Docetaxel is administered as a one-hour infusion every three weeks.@@@@@@@@@No@@@@@@APPROVED@@@@@@@@@MONO@DOCETAXEL@@@@@DOCETAXEL||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@TAXOTERE@@@@@TAXOTERE||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@@@@@@@@@@@LOCALLY ADVANCED@UNRESECTABLE@@@@@@@@@1.75@m²@1879.1325@@@12.3@week@12.3 week@1879.13@1879.13@21.82@1@1.1511@69.84@@@@@@@@@@@@3.49@21@@mg/m²@75@1@@@@@@@@@@@8/2/2017@69.84@69.84@9178082R@CONCENTRATE AND SOLVENT FOR SOLUTION FOR INFUSION, 0.5 ML@EURO@@@@@@@@20@MG@20 MG/0.5 ML@@@@@@@@@@@@@@@@@@@@@@@@85@France
16384812@Onco@@@@@300f1015ntsdm@@@@@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384812@Indicated for the treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.@@NO@@@NO REVIEW@@@@@@FIRST-LINE@@@Dosing for children should be on the basis of body surface area (mg/m2). The dose of 340 mg/m2 daily is recommended for children with Ph+ ALL (@@@@Yes@@@@@No@@@PAEDIATRIC@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@@@@@@BOTH@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@@@@Haematological Malignancy|Acute Lymphocytic Leukaemia||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@@@@@@@@@@@1.2@m²@26013.09704@@@1@year@1 year@26013.1@26013.1@71.27@30@1.1511@2096.14@2270.33@2126.14@@@@@@@@@@0.17@1@@mg/m²@340@1@@@@@@@@@@@8/1/2017@69.87@69.87@3.40E+12@FILM-COATED TABLET@EURO@@@@@@@@400@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14919296@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Single agent weekly@@-@-@-@-@1/1/2009@@Asonep is a unique humanized antibody that binds to and inhibits S1P, a bioactive lipid that has multiple effects on cells, including cell proliferation, migration, and survival. S1P, which is up-regulated in tumor cells, also promotes tumor and endothelial-cell growth, angiogenesis, and inflammation, and, importantly, it prevents apoptosis (cell death). S1P is associated with several pathologies, including cancer, ocular disorders, autoimmune disease, and inflammatory- and fibrosis-related disorders. Further, S1P has been highly correlated with drug resistance across a wide array of tumor types, as well as with increased mortality of patients with many different types of cancer.  By inhibiting S1P activity, Asonep be able to increase survival in cancer patients, not only via its anti-angiogenic and anti-tumorigenic effects, but also via its ability to help patients overcome drug resistance. Asonep is the systemic version of sonepcizumab, which is the humanized version of Sphingomab.@@14919296@Human cancers@@-@-@@NO REVIEW@@@@-@Lpath and Merck Serono have entered into a worldwide alliance to develop and commercialize Asonep. Merck Serono will provide Lpath up to $23 million of upfront payments and R&D funding to support Lpath's completion of the Phase 1 clinical trial. If Merck Serono accepts the responsibility to develop ASONEP beyond Phase 1, it will pay Lpath an additional $28 million and will fund all continuing development activities. Further payments will be made on achievement of development, regulatory, and sales milestones that could total up to $422 million should Asonep be approved in multiple indications. As part of the alliance, Lpath licensed to Merck Serono exclusive, worldwide rights to develop and commercialize Asonep across all indications, and Lpath will receive royalties on commercial sales of the product. [Lpath, 29.10.2008]@-@NCT00661414@37@-@-@@@-@@4/1/2008@-@LT1009-Onc-001@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@SONEPCIZUMAB@@@@@SONEPCIZUMAB||||@LPATH INC.@MERCK KGAA@@@@LPATH INC.|MERCK KGAA|||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@ASONEP@LT-1009@@@@ASONEP|LT-1009|||@mAb@Humanised@@@@mAb|Humanised|||@SAFETY@@@@@@@@@@ADVANCED@@@@@OPEN-LABEL@SINGLE-ARM@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924573@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients received oral odanacatib 5 mg daily or intravenous zoledronic acid 4 mg on Day 1.  SOURCE: Merck@@-@-@-@WHITEHOUSE STATION, NEW JERSEY@@@Odanacatib is a highly selective, potent inhibitor of the cathepsin K enzyme.  Cathepsin K enzyme plays a key role in breaking down the protein in bone.  In cancer that has spread to the bones, tumor cells speed up the normal process of bone breakdown and formation, which in turn results in further tumor growth and bone destruction.  By inhibiting cathepsin K activity, odanacatib represents a potential novel therapeutic approach for metastatic bone disease that works differently from other commonly used medicines.@@14924573@-@@-@-@@NO REVIEW@@@@-@-@-@-@43@-@-@@@-@@@-@-@@-@The mean age of women was 60 years.  @@@II@II@@-@-@In this study, treatment with oral odanacatib 5 mg once daily (n=29) reduced the level of urinary N-telopeptide (uNTx), a commonly used marker of bone resorption (breakdown), by 77 percent from baseline levels over four weeks.  These results were seen as early as day seven, the first measurement point.  Treatment with intravenous zoledronic acid 4 mg (n=14) reduced uNTx by 73 percent.  In addition, decreases in other markers of bone turnover, including the marker of bone resorption urinary deoxpyridinoline (uDPD) and the marker of bone formation serum bone-specific alkaline phosphatase (sBSAP) were observed with odanacatib; as was an increase in serum crosslinked C-terminal peptide (s1CTP), a marker of cathepsin K activity. Phase III trial to commence. SOURCE: Merck/ASCO, 27 May 2008@The most common clinical adverse events reported included nausea, vomiting, headache and bone pain.  Two patients in the odanacatib group experienced mild skin adverse events (rash and pruritis), both of which resolved within one week without discontinuation of study medication.  Decreased lymphocyte count was the most common laboratory adverse event in both treatment groups.@@@@MONO@ODANACATIB@@@@@ODANACATIB||||@MERCK & CO@@@@@MERCK & CO||||@@@@@@|||||||||@Bone Metastases@Breast Cancer@@@@Bone Metastases|Breast Cancer||||||||@MK-822@@@@@MK-822||||@Other@@@@@Other||||@URINARY N-TELOPEPTIDE@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@MULTI-CENTRE@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14923904@Onco@@@@@300f1037ntsdm@@@@@@Thyrogen alone@@H01AB01@H01A@NO@CAMBRIDGE, MASSACHUSSETTS@@@@@14923904@Indicated for use with serum thyroglobulin (Tg) testing with or without radioiodine imaging for the detection of thyroid remnants and well-differentiated thyroid cancer in post-thyroidectomy patients maintained on hormone suppression therapy (THST). Low risk patients with well-differentiated thyroid carcinoma who have undetectable serum Tg levels on THST and no rh TSH-stimulated increase of Tg levels may be followed-up by assaying rh TSH-stimulated Tg levels. Thyrogen is also indicated for pre-therapeutic stimulation in low risk post-thyroidectomy patients maintained on THST for the ablation of thyroid remnant tissue (in combination) with 100 mCi (3.7 GBq) radioactive iodine (131I).@@YES@@@NO REVIEW@@@@@@@@358@The recommended dose regimen is two doses of 0.9 mg thyrotropin alfa administered at a 24-hour interval by intramuscular injection only.@EMA, 16 November 2001@11/16/2001@@@@@NONE@LABEL@No@@358 [WELL-DIFFERENTIATED THYROID CANCER]@@@III 2 STUDIES@APPROVED@@NO REVIEW@SNS@Total positive withdrawal scans: 79% and 85% detected in first and second trials respectively, 13% and 15% not detected respectively.@@@@@MONO@THYROTROPIN ALFA@@@@@THYROTROPIN ALFA||||@GENZYME@@@@@GENZYME||||@@@@@@|||||||||@Thyroid Cancer@@@@@Thyroid Cancer|||||||||@THYROGEN@@@@@THYROGEN||||@Other@@@@@Other||||@DIAGNOSTIC@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@2@1.1511@720.33@807.29@727.87@@@@@@@@@@400.18@@@@@@@@@@@@@@@@8/4/2017@360.17@360.17@792440@POWDER FOR SOLUTION FOR INJECTION, VIAL 5 ML@EURO@@@@@@@@0.9@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14924965@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Vatalanib once or twice daily at 1250MG@@-@-@-@BASEL, SWITZERLAND@@@"Vatalanib (PTK/ZK) is a ""small"" molecule tyrosine kinase inhibitor with broad specificity that targets all VEGF receptors (VEGFR), the platelet-derived growth factor receptor, and c-KIT. It is a multi-VEGFR inhibitor designed to block angiogenesis and lymphangiogenesis by binding the intracellular kinase domain of all three VEGFRs, VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3 (Flt-4). Vatalanib is a targeted drug that inhibits the activity of all known receptors that bind VEGF. The drug potently inhibits the formation of new blood vessels (angiogenesis). "@@14924965@Stage IIIB/IV NSCLC@@-@-@@NO REVIEW@@@@-@PTK/ZK was among 20 projects discontinued by Bayer Schering as part of its merger. SOURCE: Bayer, 19 June 2007Following a modified agreement in January 2005, Novartis and Schering AG will co-market vatalanib in Europe, North America and Japan for oncolo@SECOND-LINE@NCT00160043@55@-@-@@@-@@3/1/2005@-@308801@@-@-@@@II@II@@-@-@ASCO 2007; results showed PFS of 3.7 months and OS of 6.8 months. There were 4 partial responses and 18 patients with stable disease.@-@@@@MONO@VATALANIB@@@@@VATALANIB||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@PTK-787@ZK-222584@PTK/ZK@@@PTK-787|ZK-222584|PTK/ZK||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@RECIST@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921424@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@L01XX11@L01X@NO@OSAKA, JAPAN@@@Estramustine is a chemical compound of oestradiol and nitrogen mustard. It is effective in the treatment of advanced prostatic carcinoma. Estramustine has a dual mode of action. The intact molecule acts as an anti-miotic agent; after hydrolysis of the carbamate ester, the metabolites act to bridge the released oestrogens and exert an anti-gonadotrophic effect. The low level of clinical side effects may be due to the fact that estramustine binds to a protein present in the tumour tissue, so resulting in accumulation of the drug at the target site. Estracyt also has weak oestrogenic and anti-gonadotrophic properties. Estramustine causes little or no bone marrow depression at usual therapeutic dosage. Estramustine is effective in patients who have not previously received drug therapy, as well as in those who have shown no response to conventional hormone treatment.@@14921424@Carcinoma of the prostate, especially in cases unresponsive to, or relapsing after, treatment by conventional oestrogens (stilboestrol, polyestradiol phosphate etc.) or by orchidectomy.@@@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@Dosage range may be from 1 to 10 capsules a day by mouth. The capsules should be taken not less than 1 hour before or 2 hours after meals. The capsules should not be taken with milk or milk products. Standard starting dosage is 4-6 capsules a day in divided doses with later adjustment according to response and gastrointestinal tolerance.@@@@@@@Use with caution in patients with moderate to severe bone marrow depression, thrombophlebitis, thrombosis, thromboembolic disorders, cardiovascular disease, coronary artery disease and congestive heart failure.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@ESTRAMUSTINE PHOSPHATE SODIUM@@@@@ESTRAMUSTINE PHOSPHATE SODIUM||||@TAKEDA PHARMACEUTICAL@@@@@TAKEDA PHARMACEUTICAL||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@MULTOSIN@@@@@MULTOSIN||||@Oestrogen@Nitrogen Mustard Analogue@@@@Oestrogen|Nitrogen Mustard Analogue|||@@@@@@@@@@@REFRACTORY@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@30@1.1511@80.07@112.22@83.29@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@2.67@2.67@7428356@CAPSULE@EURO@@@@@@@@280@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16641008@Onco@@@@@300f1008ntsdm@@@@@KEYNOTE-001@@@L01XC18@L01X@@WHITEHOUSE STATION, NEW JERSEY@@@KEYTRUDA is a human programmed death receptor-1 (PD-1)-blocking  antibody indicated for the treatment of patients with unresectable or  metastatic melanoma and disease progression following ipilimumab  and, if BRAF V600 mutation positive, a BRAF inhibitor@@16641008@Unresectable malignant melanoma@Both@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@MULTIPLE@NCT01295827@276@The recommended dose of KEYTRUDA is 2 mg/kg administered intravenously over 30 minutes every 3 weeks. Patients should be treated with KEYTRUDA until disease progression or unacceptable toxicity.@MHLW, 28 September 2016@9/28/2016@@Yes@@3/1/2011@@P07990/MK-3475-001/2011-002371-42@No@@Patients with advanced melanoma who were previously-treated with ipilimumab (and, if BRAF V600 mutation-positive, a BRAF or MEK inhibitor) and patients who were ipilimumab-naïve.@@ADULTS@I@APPROVED@@@NHI@@@@@@MONO@PEMBROLIZUMAB@@@@@PEMBROLIZUMAB||||@MERCK & CO@@@@@MERCK & CO||||@Australia@France@Canada@Spain@United Kingdom@Australia|France|Canada|Spain|United Kingdom|United States|Italy|South Korea|Norway|Taiwan@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@KEYTRUDA@@@@@KEYTRUDA||||@PD-1 Inhibitor@@@@@PD-1 Inhibitor||||@@@@@@@@@@@UNRESECTABLE@MALIGNANT@@@@RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@76.5@kg@3780269.012@@@4.9@month@4.9 month@3780269.01@3780269.01@25364.4@1@0.0091@348138.77@410541@@@@@@@@@@@3481.39@21@@mg/kg@2@1@@@@@@@@@@@8/30/2017@348138.77@348138.77@4291435A2025@SOLUTION FOR INJECTION - 4 ML@YEN@@@@@@@@100@MG@100 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14921415@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Placebo Comparator: Best supportive care Experimental : ZD4054 10 mg once daily oral dose + best supportive care@@-@-@-@LONDON, UNITED KINGDOM@3/1/2011@@@@14921415@A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 (Zibotentan) 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients@@-@-@@NO REVIEW@@@@-@-@-@NCT00626548@2496@-@-@@@-@@1/1/2008@-@ENTHUSE M0@@-@Patients with: Confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate) that has NOT spread to the other parts of the body (metastases). Patients with lymph node involvement may be eligible if specified criteria is met. Increasing Prostate Specific Antigen (PSA), collected within one year of enrollment Currently receiving treatment with surgical or medical castration@@@III@III@@-@-@>>Halted following the results of an early efficacy review by the Independent Data Monitoring Committee, which indicated that zibotentan monotherapy was unlikely to meet its primary efficacy endpoints and therefore unlikely to benefit patients with non-metastatic CRPC.[AstraZeneca 7 February 2011 http://www.astrazeneca.com/Media/Press-releases/Article/0022011AstraZeneca-halts-phase-III-trial-of-ZIBOTENTAN ] >>RESULTS PENDING@-@@@@COMBO@ZIBOTENTAN@@@@@ZIBOTENTAN||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@ZD-4054@@@@@ZD-4054||||@Endothelin A Receptor Antagonist@@@@@Endothelin A Receptor Antagonist||||@PROGRESSION-FREE SURVIVAL@@@@@TOLERABILITY@SAFETY@QUALITY OF LIFE@@@NON-METASTATIC@@@@@RANDOMISED@PLACEBO-CONTROLLED@DOUBLE-BLIND@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919396@Onco@@@@@300f1018ntsdm@@@@@@NO LABELLED TRIAL@@L01CA01@L01C@YES@-@@@Although the mechanism of action has not been definitely established, vinblastine appears to bind to or crystallise critical microtubular proteins of the mitotic spindle, thus preventing their proper polymerisation and causing metaphase arrest. In high concentrations, vinblastine also exerts complex effects on nucleic acid and protein synthesis. Vinblastine reportedly also interferes with amino acid metabolism by blocking cellular utilisation of glutamic acid and thus inhibits purine synthesis, the citric acid cycle, and the formation of urea. Vinblastine exerts some immunosuppressive activity.@@14919396@Vinblastine sulphate is effective as a single agent, but its therapeutic effect is enhanced when used in combination with other antineoplastic drugs. Vinblastine sulphate has been used in the treatment of Hodgkin's disease (Stages III and IV); lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated); histiocytic lymphoma; advanced stages of mycosis fungoides; advanced carcinoma of the testis; Kaposi's sarcoma and Letterer-Siwe disease (histocytosis X). Vinblastine sulphate may be used in the treatment of choriocarcinoma resistant to other chemotherapeutic agents; carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy.@@NO@-@@NO REVIEW@@@-@1@-@-@-@-@Vinblastine sulphate is given intravenously at weekly intervals according to the needs of the patient. Therapy is initiated by a single intravenous dose of 3.7MG/M2 bsa followed by doses of 5.5, 7.4, 9.25 and 11.1MG/M2 bsa. For most adult patients this dosage will be 5.5 mg/m2 - 7.4 mg/m2, however, leucopenia can be produced at 3.7 mg/m2, other patients may require 11.1 mg/m2 and, very rarely, 18.5 mg/m2.@-@@@-@@@Fatal if given intrathecally; for intravenous use only, and should be administered by experienced physicians.@NO LABELLED TRIAL@@-@-@@@-@DISCONTINUED@@Unrestricted reimbursement.@PBS@NO LABELLED TRIAL@-@@@@-@VINBLASTINE SULPHATE@@@@@VINBLASTINE SULPHATE||||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@Non-Hodgkin's Lymphoma@Testicular Cancer@Choriocarcinoma@Haematological Malignancy|Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma|Testicular Cancer|Choriocarcinoma|||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Vinca Alkaloids@@@@Plant Alkaloid|Vinca Alkaloids|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@5@0.8893@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@L01CA012199RHH@SOLUTION FOR IV, INJECTION@A$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14922447@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Single agent AG-013736 starting dose 5 mg BID +/- 20% according to toxicity. Treatment until progression or unacceptable toxicity occurs.@@-@-@-@NEW YORK, NEW YORK@3/1/2008@@Axitinib is an oral, selective inhibitor of VEGFR 1, 2, 3 (vascular endothelial growth factor receptors 1, 2 and 3), which has been shown to induce tumor regression as a single-agent and in combination with chemotherapy. Inhibiting VEGF binding plays a key role in anti-angiogenesis - or blocking blood vessel formation which starves tumors of the blood and nutrients needed for growth. @@14922447@-@@-@-@@NO REVIEW@@@@-@Developed from Abgenix (now Amgen) mice, double-digit royalties to go to Medarex due to cross-licensing in this area@-@NCT00094107@32@-@-@@@-@@12/1/2004@-@A4061015@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@AXITINIB@@@@@AXITINIB||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@AG-013736@@@@@AG-013736||||@TK Inhibitor@VEGF@PDGF@SCF@Angiogenesis Inhibitor@TK Inhibitor|VEGF|PDGF|SCF|Angiogenesis Inhibitor@COMPLETE RESPONSE@PARTIAL RESPONSE@RECIST@@@RECIST@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917995@Onco@@@@@300f1037ntsdm@@@@@@NO LABELLED TRIAL@@J06BA02@J06B@YES@DEERFIELD, ILLINOIS@@@@@14917995@Indicated for prevention of bacterial infections in patients with hypogammaglobulinemia and/or recurrent bacterial infections associated with B-cell Chronic Lymphocytic Leukemia (CCL), for the prevention of coronary artery aneurysms associated with Kawasaki Syndrome and to induce rapid rise in platelet count when needed to prevent and/or to control bleeding in a patient with Idiopathic Thrombocytopenic Purpura (ITP).@@YES@-@@NO REVIEW@@@@@-@-@-@-@B-cell CLL: For patients with hypogammaglobulinemia and/or recurrent bacterial infections due to B-cell CLL, a dose of 400 mg/kg every 3 to 4 weeks is recommended.@6/1/1995@@@-@@@Immune Globulin Intravenous (Human) products have been reported to be associated with renal dysfunction, acute renal failure, osmotic nephrosis, and death.18 Patients predisposed to acute renal failure include patients with any degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Especially in such patients, IGIV products should be administered at the minimum concentration available and the minimum rate of infusion practicable. While these reports of renal dysfunction and acute renal failure have been associated with the use of many of the licensed IGIV products, those containing sucrose as a stabilizer accounted for a disproportionate share of the total number.@NO LABELLED TRIAL@@-@-@@@-@DISCONTINUED@@NO REVIEW@SNS@NO LABELLED TRIAL@-@@@@-@IMMUNOGLOBULIN (HUMAN)@@@@@IMMUNOGLOBULIN (HUMAN)||||@BAXTER HEALTHCARE@@@@@BAXTER HEALTHCARE||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@B-Cell Lymphoma@Supportive Care@@Haematological Malignancy|Chronic Lymphocytic Leukaemia|B-Cell Lymphoma|Supportive Care||||||@GAMMAGARD S/D@@@@@GAMMAGARD S/D||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@1@1.3598@@@@@@@@@@@@@@@@@@@@@@@@@@@@@7/13/2015@@@685669@INTRAVENOUS  INJECTION (LIOPHYLISATE VIAL), 10 ML@EURO@@@@@@@@0.5@G@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14921433@Onco@@@@@300f1012ntsdm@@@@@@N/A@@L01A@L01A@YES@BRENTFORD, UNITED KINGDOM@@@@@14921433@Myleran is indicated as conditioning treatment prior to haematopoietic progenitor cell transplantation in patients when the combination of high dose busulfan and cyclophosphamide is considered the best available option. Myleran is indicated for the palliative treatment of the chronic phase of chronic granulocytic leukaemia. Myleran is effective in producing prolonged remission in polycythaemia vera, particularly in cases with marked thrombocytosis. Myleran may be useful in selected cases of essential thrombocythaemia and myelofibrosis.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@N/A@• Adults: The recommended dose of busulfan in adult patients is 1 mg/kg every 6 hours for four days, starting seven days prior to transplantation. 60 mg/kg per day of cyclophosphamide is usually given for two days commencing 24 h after the final dose of Busulfan@@@@@@@Myleran is an active cytotoxic agent for use only under the direction of physicians experienced in the administration of such agents. Immunisation using a live organism vaccine has the potential to cause infection in immunocompromised hosts. Therefore, immunisations with live organism vaccines are not recommended. Myleran should be discontinued if lung toxicity develops.@LABEL@No@@@@@N/A@APPROVED@@@GKV@Approximately 90% of adults with previously untreated chronic myelogenous leukemia will obtain haematologic remission with regression or stabilization of organomegaly following the use of busulfan. It has been shown to be superior to splenic irradiation with respect to survival times and maintenance of haemoglobin levels, and to be equivalent to irradiation at controlling splenomegaly. It is not clear whether busulfan unequivocally prolongs the survival of responding patients beyond the 31 months experienced by an untreated group of historical controls. Median survival figures of 31 to 42 months have been reported for several groups of patients treated with busulfan, but concurrent control groups of comparable, untreated patients are not available.@@@@@MONO@BUSULFAN@@@@@BUSULFAN||||@GSK@@@@@GSK||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@Supportive Care@@@Haematological Malignancy|Chronic Myeloid Leukaemia|Supportive Care|||||||@MYLERAN@@@@@MYLERAN||||@Alkylating Agent@Alkylsulfonates@@@@Alkylating Agent|Alkylsulfonates|||@HAEMATOLOGIC RESPONSE@OVERALL SURVIVAL@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@100@1.1511@234.99@308.09@243.1@@@@@@@@@@1.17@@@@@@@@@@@@@@@@8/1/2017@2.35@2.35@461178@FILM-COATED TABLET@EURO@@@@@@@@2@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
15396679@Onco@@@@@300f1018ntsdm@@@@@@Ponatinib: 45 mg tablet taken orally once daily@@L01XE24@L01X@@CAMBRIDGE, MASSACHUSSETTS@10/1/2020@@Ponatinib is an investigational BCR-ABL inhibitor that also selectively inhibits certain other tyrosine kinases in preclinical studies, including FLT3, RET, KIT, and the members of the FGFR and PDGFR families of kinases.@@15396679@Iclusig is indicated for the treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic Ieukaemia (Ph+ ALL)whose disease is resistant to, or who are intolerant of dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or where thereis a T315I mutation.@@NO@1-Nov-15@11/1/2015@NO REVIEW@@@@100%@@@NCT01207440@440@The recommended starting dose of ICLUSIG is 45 mg once daily, taken at the same approximate time each day. Treatment should be continued as long as the patient does not show evidence of diseaseprogression or unacceptable toxicity.@TGA, 26 November 2014@11/26/2014@@No@@9/1/2010@@PACE@No@@@@@II@APPROVED@@@PBS@@@@@@MONO@PONATINIB@@@@@PONATINIB||||@ARIAD PHARMACEUTICALS@MERCK & CO@@@@ARIAD PHARMACEUTICALS|MERCK & CO|||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@@@@Haematological Malignancy|Acute Lymphocytic Leukaemia||||||||@ICLUSIG@@@@@ICLUSIG||||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@RESPONSE RATE@@@@@@@@@@@@@@@OPEN LABEL@SINGLE-ARM@@@@1@1@17085.735@@@81@day@81 day@17085.74@17085.74@210.94@30@0.779@6328.05@6474.92@6397.99@@@@@@@@@@4.69@1@@mg@45@1@@@@@@@@@@@8/1/2017@210.94@210.94@1726-2074-GE-TS@FILM-COATED TABLET@A$@@@@@@@@45@MG@15 MG@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
16613186@Onco@@@@@300f1015ntsdm@@@@@@@@L01XC17@L01X@@NEW YORK, NEW YORK@@@Nivolumab is an investigational, fully-human IgG4 anti-PD-1 receptor blocking monoclonal antibody that binds to the checkpoint receptor PD-1 (programmed death-1) expressed on activated T cells. Nivolumab inhibits the binding of PD-1 with its tumor-expressed ligands, programmed death-ligand 1 (PD-L1/B7-H1) and PD-L2 (B7-DC). Blocking of the interaction of the PD-1 receptor with its ligands may allow T-cells to elicit an anti-tumor immune response.@@16613186@Indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults.@@YES@13-Jan-16@1/13/2016@NO REVIEW@@@@@@@@@The recommended dose of OPDIVO is 3 mg/kg administered intravenously over 60 minutesevery 2 weeks. Treatment should be continued as long as clinical benefit is observed or until treatmentis no longer tolerated by the patient.@EMA, 19 June 2015@6/19/2015@9/1/2014@No@@@@@No@@@ADULTS@@@APPROVED@@ASMR III: 13 January 2016. [HAS, http://www.has-sante.fr/portail/upload/docs/application/pdf/2016-01/002_bms_avis_sem_opdivo_avis.pdf]@HAUTE AUTORITÉ DE SANTÉ@The European Commission's approval is based on data from two Phase 3 studies (CheckMate -066, -037).@@@@@MONO@NIVOLUMAB@@@@@NIVOLUMAB||||@BRISTOL-MYERS SQUIBB@@@@@BRISTOL-MYERS SQUIBB||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@OPDIVO@@@@@OPDIVO||||@PD-1 Inhibitor@@@@@PD-1 Inhibitor||||@@@@@@@@@@@UNRESECTABLE@METASTATIC@@@@@@@@@76.5@kg@29116.04732@@@5.1@month@5.1 month@29116.05@29116.05@187.7@1@1.1511@1145@@@@@@@@@@@@11.45@14@@mg/kg@3@1@@@@@@@@@@@8/2/2017@1145@1145@9409452T@CONCENTRATE FOR SOLUTION FOR INFUSION - 10 ML@EURO@@@@@@@@100@MG@10 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@85@France
16063871@Onco@@@@@300f1020ntsdm@@@@@@@@L01XC06@L01X@@NEW YORK, NEW YORK@@@Erbitux is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Cetuximab is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions and has an approximate molecular weight of 152 kDa. Cetuximab is produced in mammalian (murine myeloma) cell culture.@@16063871@Treatment of patients with epidermal growth factor receptor (EGFR)-expressing, KRAS wild-type metastatic colorectal cancer in combination with chemotherapy@@YES@@@NO REVIEW@@@@@>> Acquisition completed. [Lilly, 24.11.2008]          >> Lilly acquires ImClone for US$6.5 billion. [Lilly, 7.10.2008]        >> BMS Offers US$4.3Billion for ImClone or US$60.0 per share in cash. [BMS, 1 August 2008]      >> ImClone licensed co-development and co-promotion rights to BMS in North America and Japan, and to Merck KGaA in Europe.@@@@In all indications, Erbitux is administered once a week. The initial dose is 400 mg cetuximab per m2 body surface area. All subsequent weekly doses are 250 mg cetuximab per m2 each.@EMA, 17 July 2008@7/17/2008@@NO@@@@@No@@@(EGFR)-expressing, KRAS WILD-TYPE@@@APPROVED@@@SSN@@@@@@COMBO@CETUXIMAB@@@@@CETUXIMAB||||@BMS@IMCLONE@MERCK SERONO@@@BMS|IMCLONE|MERCK SERONO||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ERBITUX@@@@@ERBITUX||||@mAb@Chimeric@TK Inhibitor@EGFR@@mAb|Chimeric|TK Inhibitor|EGFR|@@@@@@@@@@@METASTATIC@@@@@@@@@@1.75@m²@13103.9752@@@3.7@month@3.7 month@13103.98@13103.98@116.44@1@1.1229@179.6@296.41@187.68@@@@@@@@@@1.8@7@1@mg/m²@400@1@7@@mg/m²@250@1@@@@@@6/7/2017@179.6@179.6@36584035@SOLUTION FOR INFUSION - 20 ML@EURO@@@@@@@@100@MG@5 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14922205@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients will be randomized 1:1 to receive either Avastin (15mg/kg iv q3weeks) + Herceptin (8mg/kg iv loading dose and 6mg/kg iv q3weeks maintenance) + docetaxel (100mg/m² iv q3weeks) or Herceptin + docetaxel alone. The anticipated time on study treatment is until disease progression.@@L01XC07@L01X@-@BASEL, SWITZERLAND@@@Avastin (Bevacizumab) is a recombinant humanized monoclonalIgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems. Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF (1). Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models ofangiogenesis. Administration of Bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.@@14922205@First-line combo with Herceptin in HER2-positive cancer@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00391092@100-500@-@-@@@-@@7/1/2006@-@AVEREL@@NOT YET AVAILABLE; POTENTIALLY 2018.@-@@@III; BO20231@III@@-@-@RESULTS PENDING (recruiting).@-@@@@-@BEVACIZUMAB@TRASTUZUMAB@@@@BEVACIZUMAB|TRASTUZUMAB|||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@AVASTIN@HERCEPTIN@@@@AVASTIN|HERCEPTIN|||@mAb@Humanised@TK Inhibitor@VEGF@@mAb|Humanised|TK Inhibitor|VEGF|@PROGRESSION-FREE SURVIVAL@@@@@@@@@@METASTATIC@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@1@@@@@@@@@@@@@7.26@@@@@@@@@@@@@@@@@725.53@725.53@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920597@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Ifex with cisplatin and either vinblastine or etoposide@@L01AA06@L01A@YES@NEW YORK, NEW YORK@@@@@14920597@In combination with other approved antineoplastics such as mesna for third-line chemotherapy of germ cell testicular cancer.@@YES@@@NO REVIEW@@@@@@THIRD-LINE@@50@Ifex should be administered intravenously at a dose of 1.2 g/m2 per day for 5 consecutive days. Treatment is repeated every 3 weeks or after recovery from haematologic toxicity (Platelets =100,000/µL, WBC =4,000/µL). In order to prevent bladder toxicity, it should be given with extensive hydration consisting of at least 2 liters of oral or intravenous fluid per day. A protector, such as mesna, should also be used to prevent hemorrhagic cystitis. Ifex should be administered as a slow intravenous infusion lasting a minimum of 30 minutes. Although it has been administered to a small number of patients with compromised hepatic and/or renal function, studies to establish optimal dose schedules in such patients have not been conducted.@@@@@@@Ifex should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Urotoxic side effects, especially haemorrhagic cystitis, as well as CNS toxicities such as confusion and coma have been associated with the use of Ifex When they occur, they may require cessation of Ifex therapy. Severe myelosuppression has been reported.@@No@8-Mar@@@@III: TESTICULAR CANCER@APPROVED@@@MEDICARE@10 of 50 fully evaluable patients were still alive 2 to 5 years after treatment. Four of the 10 long term survivors were rendered free of cancer by surgical resection after treatment with the ifosfamide regimen; median survival for the entire group of 50 fully evaluable patients was 53 weeks.@@@@@COMBO@IFOSFAMIDE@CISPLATIN@VINBLASTINE@ETOPOSIDE@@IFOSFAMIDE|CISPLATIN|VINBLASTINE|ETOPOSIDE|@BMS@BAXTER HEALTHCARE@@@@BMS|BAXTER HEALTHCARE|||@@@@@@|||||||||@Testicular Cancer@@@@@Testicular Cancer|||||||||@IFEX@@@@@IFEX||||@Alkylating Agent@Nitrogen Mustard Analogue@@@@Alkylating Agent|Nitrogen Mustard Analogue|||@OVERALL SURVIVAL@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1@104.63@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/2/2017@104.63@104.63@00338-3993-01@POWDER FOR INJECTION FOR RECONSTITUTION@US$@@@@@@@@3@G@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921851@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@L01XC04@L01X@-@LEVERKUSEN, GERMANY@@@Alemtuzumab binds to CD52, an antigen present on the surface of B andT lymphocytes, a majority of monocytes, macrophages, NK cells, anda subpopulation of granulocytes. A proportion of bone marrow cells,including some CD34+ cells, express variable levels of CD52. The proposedmechanism of action is antibody-dependent cellular-mediatedlysis following cell surface binding of alemtuzumab to the leukemic cells.@@14921851@Campath versus chlorambucil in progressive B-Cell lymphocytic leukaemia@@-@-@@NO REVIEW@@@@-@ILEX Oncology (acquired by Genzyme) and LeukoSite (acquired by Millennium Pharma) entered into a distribution and development agreement with Schering AG (now Bayer Schering) in August 1999. The agreement grants Schering AG exclusive marketing and distribution rights to Campath in the United States, Europe and the rest of the world except Japan and East Asia, where LeukoSite and ILEX have retained these rights. Millenniusm sold Campath rights to ILEX in 2001 for US$140 million plus royalties. Initial rights licensed by LeukoSite from BTG.@-@NCT00046683@284@-@-@@@-@@@-@CAM307@@-@-@@@III@III@@-@-@RESULTS PENDING@-@@@@MONO@ALEMTUZUMAB@CHLORAMBUCIL@@@@ALEMTUZUMAB|CHLORAMBUCIL|||@BAYER HEALTHCARE@GENZYME@@@@BAYER HEALTHCARE|GENZYME|||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@B-Cell Lymphoma@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia|B-Cell Lymphoma|||||||@CAMPATH@MABCAMPATH@@@@CAMPATH|MABCAMPATH|||@mAb@Humanised@CD52@@@mAb|Humanised|CD52||@RESPONSE RATE@@@@@OVERALL SURVIVAL@@@@@RELAPSED@REFRACTORY@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@15659.64@15659.64@42.9@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922666@Onco@@@@@300f1012ntsdm@@@@@@Enzastaurin before and conconitant with radiation therapy, followed by enzastaurin maintenance@@-@-@-@INDIANAPOLIS, INDIANA@@@Enzastaurin is an oral, serine threonine kinase inhibitor which selectively targets the PKCBeta and PI3/AKTsignaling pathways. By blocking these key pathways frequently over-expressed in a wide variety of cancers, enzastaurin suppresses tumor cell proliferation, induces tumor cell death and inhibits tumor-induced angiogenesis. Treatment has been well tolerated with minimal drug-related toxicity. Enzastaurin administration is associated with fatigue, diarrhea, nausea, decreased platelets, cough, vomiting, transaminase elevation, dyspnea, peripheral edema, and dizziness. Further testing in Phase III versus a placebo will provide us with a more complete look at the side effect profile for enzastaurin. In addition to DLBCL, enzastaurin is also being studied in other tumor types including breast, colon, lung, ovarian and prostate cancers@@14922666@-@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00509821@60@-@-@@@-@@@-@11491H6Q-MC-S039  @@-@-@@@II@II@@-@-@Completion expected in December 2010. Phase II trial in 40 patients showed 9 with SD over 3 months (December 2004).@-@@@@MONO@ENZASTAURIN@@@@@ENZASTAURIN||||@LILLY@@@@@LILLY||||@@@@@@|||||||||@Brain Cancer@Glioblastoma Multiforme@@@@Brain Cancer|Glioblastoma Multiforme||||||||@LY-317615@@@@@LY-317615||||@Angiogenesis Inhibitor@@@@@Angiogenesis Inhibitor||||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@-@@@@@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14921103@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Topotecan with pazopanib 400mg. [GSK]@@L01X X17@L01X@-@BRENTFORD, UNITED KINGDOM@@@Topoisomerase I relieves torsional strain in DNA by inducing reversible single strand breaks. Topotecan binds to the topoisomerase I-DNA complex and prevents religation of these single strand breaks. The cytotoxicity of topotecan is thought to be due to double strand DNA damage produced during DNA synthesis, when replication enzymes interact with the ternary complex formed by topotecan, topoisomerase I, and DNA. Mammalian cells cannot efficiently repair these double strand breaks.@@14921103@Two Schedules of Oral Topotecan in Combination With Pazopanib in Subjects With Advanced Solid Tumors@@-@-@@NO REVIEW@@@@-@Merck KGaA licensed marketing and sales rights from SmithKline Beecham in June 2000 for the U.K. only.@-@NCT00732420@50@-@-@@@-@@8/1/2008@-@HYT109091@@-@Subjects must have histologically or cytologically confirmed diagnosis of advanced cancer and a solid tumor malignancy that has relapsed or is refractory to standard therapy or for which there is no established therapy@@@I@I@@-@-@Trial registered [GSK, 11.08.2008]@-@@@@COMBO@TOPOTECAN HYDROCHLORIDE@PAZOPANIB@@@@TOPOTECAN HYDROCHLORIDE|PAZOPANIB|||@GSK@@@@@GSK||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@HYCAMTIN@@@@@HYCAMTIN||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@TOLERABILITY@@@@@BIOMARKER@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14923171@Onco@@@@@300f1012ntsdm@@@@@@Savene mixed with specially formulated diluent@@V03AF02@V03A@NO@COPENHAGEN, DENMARK@@@The exact mechanism by which dexrazoxane exerts its cardioprotective effect has not been fully elucidated, however based on the available evidence the following mechanism has been suggested. The dose-dependent cardiotoxicity observed during anthracycline administration is due to anthracycline-induced iron-dependent free radical oxidative stress on the relatively unprotected cardiac muscle. Dexrazoxane, an analogue of EDTA (ethylene diamine tetra-acetic acid), is hydrolysed in cardiac cells to the ring-opened product ICRF-198. Both dexrazoxane (ICRF-187) and ICRF-198 are capable of chelating metal ions. It is generally thought that they can provide cardioprotection by scavenging metal ions thus preventing the Fe3+-anthracycline complex from redox cycling and forming reactive radicals.@@14923171@Indicated for the treatment of anthracycline extravasation@@@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@36@Savene should be given once daily for 3 consecutive days. The recommended dose is: Day one: 1000 mg/m2, Day two: 1000 mg/m2 Day three: 500 mg/m2@@@@@@@Local examination should be performed on regular basis after treatment until resolution. If there is suspicion of extravasation by vesicant compounds other than anthracyclines through the same IV access, e.g. vincristine, mitomycin, and vinorelbine, Savene would not be effective against the reaction from these compounds. Savene will be administered to patients undergoing cytotoxic therapy with anthracycline containing chemotherapy and its cytotoxic potential (especially resulting in reversible haematological toxicity with a nadir occurring on days 11-12) will therefore be added to that of the other chemotherapy administered. Haematological monitoring should therefore be undertaken regularly.@LABEL@No@@@@@N/A@APPROVED@@@GKV@1 of the patients required surgery.@@@@@MONO@DEXRAZOXANE HCL@@@@@DEXRAZOXANE HCL||||@TOPOTARGET@@@@@TOPOTARGET||||@@@@@@|||||||||@Supportive Care@@@@@Supportive Care|||||||||@SAVENE@@@@@SAVENE||||@Topoisomerase II Inhibitor@@@@@Topoisomerase II Inhibitor||||@EXTRAVASATIONS@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@10@1.1511@9711.5@11960.7@9750@@@@@@@@@@1.94@@@@@@@@@@@@@@@@8/1/2017@971.15@971.15@2515317@POWDER AND SOLVANT FOR SOLUTION FOR PERFUSION - 100 ML@EURO@@@@@@@@500@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14917427@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01BC02@L01B@NO@ALISO VIEJO, CALIFORNIA@@@Fluorouracil is an analogue of uracil, a component of ribonucleic acid. The drug is believed to function as an antimetabolite. After intracellular conversion to the active deoxynucleotide, it interferes with the synthesis of DNA by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase. Fluorouracil may also interfere with RNA synthesis.@@14917427@Efudix is used for the topical treatment of superficial pre-malignant and malignant skin lesions; keratoses including senile, actinic and arsenical forms; keratoacanthoma; Bowen's disease; superficial basal-cell carcinoma. Deep, penetrating or nodular basal cell and squamous cell carcinomas do not usually respond to Efudix therapy. It should be used only as a palliative therapy in such cases where no other form of treatment is possible.@@NO@@@NO REVIEW@@@@65%@@@@@Pre-malignant conditions: The cream should be applied thinly to the affected area once or twice daily; an occlusive dressing is not essential. Malignant conditions: The cream should be applied once or twice daily under an occlusive dressing where this is practicable.@1-Aug-97@8/1/1997@12/19/1978@@@@Efudix is for topical use only and care should be taken to avoid contact with mucous membranes or the eyes. The hands should be washed carefully after applying the cream. The total area of skin being treated with Efudix at any one time should not exceed 500cm2 (approx. 23 x 23cm). Larger areas should be treated a section at a time.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@FLUOROURACIL@@@@@FLUOROURACIL||||@VALEANT PHARMACEUTICALS@@@@@VALEANT PHARMACEUTICALS||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@EFUDEX@@@@@EFUDEX||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1807@19@25.43@20.27@@@@@@@@@@0.02@@@@@@@@@@@@@@@@9/1/2017@19@19@3.40E+12@CREAM, 20 G@EURO@@@@@@@@1000@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14920967@Onco@@@@@300f1008ntsdm@@@@@@Half of all patients in the trial received Tavocept along with their chemotherapy, while the other half received a placebo and chemotherapy. SOURCE: Bionumerik@@-@-@-@SAN ANTONIO, TEXAS@@@@@14920967@with paclitaxel and cisplatin@@-@-@@NO REVIEW@@@@-@Licensing and development deal with Takeda terminated in October 2006.@FIRST-LINE@-@182@-@-@@@-@@@-@JAPAN TAVOCEPT TRIAL@@-@-@@@III@III@@-@@The trial results indicate that the number of patients reporting either severe sporadic or cumulative neuropathy was approximately 50% lower in the Tavocept arm of the trial compared to the placebo arm. While this outcome represents a strong trend in favor of Tavocept (p = 0.1565), the results are not statistically significant (p < 0.05) - (BioNumerik and ASKA believe the lack of statistical significance is likely due to the relatively small size of the trial.) There was an observed increase in the median survival time for patients receiving Tavocept as compared to those receiving placebo. The median survival time observed for patients receiving Tavocept was approximately 40 days longer than for patients receiving placebo. For patients with adenocarcinoma, the most frequently occurring type of lung cancer, the median survival time was increased by approximately 138 days for patients receiving Tavocept as compared to those receiving placebo. SOURCE: BioNumerik, 18 March 2008@-@@@@COMBO@DIMESNA@PACLITAXEL@CISPLATIN@@@DIMESNA|PACLITAXEL|CISPLATIN||@BIONUMERIK@ASKA PHARMACEUTICAL@@@@BIONUMERIK|ASKA PHARMACEUTICAL|||@@@@@@|||||||||@Supportive Care@NSCLC@@@@Supportive Care|NSCLC||||||||@TAVOCEPT@BNP-7787@@@@TAVOCEPT|BNP-7787|||@Camptothecin@Topoisomerase I Inhibitor@@@@Camptothecin|Topoisomerase I Inhibitor|||@NEUROPATHY@@@@@@@@@@ADVANCED@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14918877@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NO LABELLED TRIAL@@L01AD02@L01A@YES@NEW YORK, NEW YORK@@@@@14918877@CeeNU has been shown to be useful as a single agent in addition to other treatment modalities, or in established combination therapy with other approved chemotherapeutic agents in the following: Brain tumors—both primary and metastatic, in patients who have already received appropriate surgical and/or radiotherapeutic procedures. Hodgkin's Disease—secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy.@@YES@@@NO REVIEW@@@@@@@@@The recommended dose of CeeNU in adult and pediatric patients as a single agent in previously untreated patients is 130 mg/m2 as a single oral dose every 6 weeks.@FDA, August 1976@@@@@@CeeNU should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Bone marrow suppression, notably thrombocytopaenia and leukopaenia, which may contribute to bleeding and overwhelming infections in an already compromised patient, is the most common and severe of the toxic effects of CeeNU. Since the major toxicity is delayedbone marrow suppression, blood counts should be monitored weekly for at least 6 weeks after a dose. At the recommended dosage, courses of CeeNU should not be given more frequently than every 6 weeks. The bone marrow toxicity of CeeNU is cumulative and therefore dosage adjustment must be considered on the basis of nadir blood counts from prior dose@NO LABELLED TRIAL@No@@@@@@APPROVED@@@MEDICARE@NO LABELLED TRIAL@@@@@@LOMUSTINE@@@@@LOMUSTINE||||@BMS@@@@@BMS||||@@@@@@|||||||||@Brain Cancer@Haematological Malignancy@Hodgkin's Lymphoma@@@Brain Cancer|Haematological Malignancy|Hodgkin's Lymphoma|||||||@CEENU@@@@@CEENU||||@Alkylating Agent@Nitrosourea@@@@Alkylating Agent|Nitrosourea|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@20@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@00015-3030-20@CAPSULE@US$@@@@@@@@10@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921839@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@BASEL, SWITZERLAND@12/1/2009@@Nilotinib is an inhibitor of the Bcr-Abl kinase. Nilotinib binds to and stabilizes the inactive conformation of the kinase domain of Abl protein. In vitro, nilotinib inhibited Bcr-Abl mediated proliferation of murine leukemic cell lines and human cell lines derived from Ph+ CML patients. Under the conditions of the assays, nilotinib was able to overcome imatinib resistance resulting from Bcr-Abl kinase mutations, in 32 out of 33 mutations tested. In vivo, nilotinib reduced the tumor size in a murine Bcr-Abl xenograft model. Nilotinib inhibited the autophosphorylation of the following kinases at IC50 values as indicated: Bcr-Abl (20-60 nM), PDGFR (69 nM) and c-Kit (210 nM).@@14921839@Niltonib in GIST resistant/intolerant to imatinib and/or 2nd-line TK inhibitor@@-@-@@NO REVIEW@@@@-@-@THIRD-LINE@NCT00633295@15@-@-@@@-@@4/1/2008@-@CAMN107DIL02@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@NILOTINIB@@@@@NILOTINIB||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Sarcoma@GIST@@@@Sarcoma|GIST||||||||@TASIGNA@@@@@TASIGNA||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@RESPONSE RATE@@@@@@@@@@RELAPSED@REFRACTORY@@@@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16396598@Onco@@@@@300f1012ntsdm@@@@@@10 mg once daily or 10 mg once daily for 21 days every 28 days. Sequential dose reductions to 5 mg daily and 5 mg every other day, as well as dose delays, were allowed for toxicity.@@L04AX04@L04A@@SUMMIT, NEW JERSEY@@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16396598@Indicated for the treatment of patients with transfusiondependent anaemia due to low or intermediate1risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@148@The recommended starting dose of lenalidomide is 10 mg orally once daily on days 121 of repeated 28day cycles. Dosing is continued or modified based upon clinical and laboratory findings.@EMA, 25 April 2013@4/25/2013@@Yes@@@@MDS003@No@@148 PATIENTS WHO HAD RBC TRANSFUSION DEPENDENT ANEMIA. RBCTRANSFUSION DEPENDENCE WAS DEFINED AS HAVING RECEIVED = 2 UNITS OF RBCS WITHIN 8 WEEKS PRIOR TO STUDY TREATMENT. THE STUDY ENROLLED PATIENTS WITH ABSOLUTE NEUTROPHIL COUNTS (ANC) = 500 CELLS/MM3,@@@III@APPROVED@@@GKV@@@@@@MONO@LENALIDOMIDE@@@@@LENALIDOMIDE||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myelodysplastic Syndrome@@@@Haematological Malignancy|Myelodysplastic Syndrome||||||||@REVLIMID@@@@@REVLIMID||||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@@@@@@@@@@@@@@@@OPEN-LABEL@SINGLE-ARM@MULTI-CENTRE@@@1@1@5126.799972@@@56@day@56 day@5126.8@5126.8@91.55@21@1.1511@6408.5@7912.21@6447@@@@@@@@@@12.21@28@@mg@10@21@@@@@@@@@@@8/1/2017@305.17@305.17@1875284@HARD CAPSULE@EURO@@@@@@@@25@MG@25 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16159504@Onco@@@@@300f1018ntsdm@@@@@@Drug: treatment crizotinib 250mg orally continuous twice daily dosingDrug: treatment pemetrexed 500mg/m2 IV day 1 plus cisplatin 75mg/m2 IV day 1 every 21 days OR pemetrexed 500mg/m2 IV day 1 plus carboplatin AUC 5 or 6 day 1 every 21 days investigator's choice@@L01XE16@L01X@@NEW YORK, NEW YORK@11/1/2013@@@@16159504@XALKORI is indicated for the first-line treatment of adults with anaplastic lymphoma kinase(ALK)-positive advanced non-small cell lung cancer (NSCLC).@@NO@14-Nov@@NO REVIEW@@@@100%@Acquired through takeover of Pharmacia Corp., which acquired it from Sugen@FIRST-LINE@NCT01154140@343@The recommended dose schedule of XALKORI is 250 mg taken orally twice daily. Continue treatment as long as the patient is deriving clinical benefit from therapy.@TGA, 27 September 2013@9/27/2013@7/1/2015@Yes@@1/1/2011@@A8081014, 2010-021336-33, XALCORI@No@@Proven diagnosis of locally advanced not suitable for local treatment, recurrent and metastatic non-squamous cell carcinoma of the lung - Positive for translocation or inversion events involving the ALK gene locus- No prior systemic treatment for locally advanced or metastatic disease; Patients with brain metastases only if treated and neurologically stable with no ongoing requirement for corticosteroids - Evidence of a personally signed and dated informed consent document and willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures including completion of patient reported outcome [PRO] measures - 18 years of age or older with the exception of India which has an upper age limit of 65 years old@(ALK)-positive@@@APPROVED@@@PBS@@@@@@MONO@CRIZOTINIB@@@@@CRIZOTINIB||||@PFIZER@@@@@PFIZER||||@World@@@@@World|||||||||@NSCLC@@@@@NSCLC|||||||||@XALKORI@@@@@XALKORI||||@PDGF@@@@@PDGF||||@OVERALL SURVIVAL@Objective response rate@DURATION OF RESPONSE@@@OBJECTIVE RESPONSE RATE@@@@@ADVANCED@@@@@RANDOMIZED@PARALLEL ASSIGNMENT@OPEN LABEL@@@1@1@78775.88878@@@10.9@month@10.9 month@78775.89@78775.89@237.61@60@0.779@7128.3@7275.17@7198.24@@@@@@@@@@0.48@1@@mg@500@1@@@@@@@@@@@8/1/2017@118.81@118.81@3616-0554-GE-PF@CAPSULE@A$@@@@@@@@250@MG@250 MG@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14917381@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@L01AX04@L01A@YES@@@@Dacarbazine is a cytostatic agent. The antineoplastic effect is due to an inhibition of cell growth which is independent of the cell cycle and due to an inhibition of DNA synthesis. An alkylating effect has also been shown and other cytostatic mechanisms may also be influenced by dacarbazine. Dacarbazine is considered not to show an antineoplastic effect by itself. However by microsomal N-demethylation it is quickly converted to 5-amino-imidazole-4-carboxamide and a methyl cation, which is responsible for the alkylating effect of the drug.@@14917381@Dacarbazine is indicated for the treatment of patients with metastatic malignant melanoma. Further indications for dacarbazine as part of combination chemotherapy are: • Hodgkin's disease • Advanced adult soft tissue sarcomas (except mesothelioma, Kaposi sarcoma)@@YES@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@Hodgkin's Disease: Dacarbazine is administered in a daily dose of 375 mg/m2 body surface area i.v. on day 1 and day 15 in combination with doxorubicin, bleomycin and vinblastine for each cycle of ABVD regimen.@@@@@@@It is recommended that dacarbazine be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. 1. Hemopoietic depression is the most common toxicity with dacarbazine. 2. Hepatic necrosis has been reported. 3. Studies have demonstrated this agent to have a carcinogenic and teratogenic effect when used in animals. 4. In treatment of each patient, the physician must weigh carefully the possibility of achieving therapeutic benefit against the risk of toxicity.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@DACARBAZINE@@@@@DACARBAZINE||||@MEDAC@@@@@MEDAC||||@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@@@@Haematological Malignancy|Hodgkin's Lymphoma||||||||@DETIMEDAC@@@@@DETIMEDAC||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@METASTATIC@MALIGNANT@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1807@80@112.13@83.22@@@@@@@@@@0.16@@@@@@@@@@@@@@@@8/15/2017@80@80@4939412@VIAL@EURO@@@@@@@@500@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16384811@Onco@@@@@300f1015ntsdm@@@@@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384811@Indicated for the treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.@@NO@@@NO REVIEW@@@@@@FIRST-LINE@@@Dosing for children should be on the basis of body surface area (mg/m2). The dose of 340 mg/m2 daily is recommended for children with Ph+ ALL (@@@@Yes@@@@@No@@@PAEDIATRIC@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@@@@@@BOTH@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@@@@Haematological Malignancy|Acute Lymphocytic Leukaemia||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@@@@@@@@@@@1.2@m²@26013.09667@@@1@year@1 year@26013.1@26013.1@71.27@60@1.1511@1048.07@1172.57@1078.07@@@@@@@@@@0.17@1@@mg/m²@340@1@@@@@@@@@@@8/1/2017@17.47@17.47@3.40E+12@FILM-COATED TABLET@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14922183@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Avastin (10mg/kg) and metronomic Temodar (50mg/m2) for 12 cycles.@@L01AX03@L01A@-@KENILWORTH, NEW JERSEY@@@Temozolomide is not directly active but undergoes rapid nonenzymatic conversion at physiologic pH to the reactive compound MTIC. The cytotoxicity of MTIC is thought to be primarily due to alkylation of DNA. Alkylation (methylation) occurs mainly at the O6 and N7 positions of guanine.@@14922183@Recurrent glioma; combo with Avastin@@-@-@@NO REVIEW@@@@-@Merck & Co and Schering-Plough have announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. Based on the closing price of Merck stock on March 6, 2009, the consideration to be received by Schering-Plough shareholders is valued at $23.61 per share, or $41.1 billion in the aggregate. [Merck & Co, 9 March 2009]@SECOND-LINE@NCT00501891@32@-@-@@@-@@7/1/2007@-@AVF3821S@@-@-@@@P04860@II@@-@-@RESULTS PENDING (recruiting).@-@@@@COMBO@TEMOZOLOMIDE@BEVACIZUMAB@@@@TEMOZOLOMIDE|BEVACIZUMAB|||@SCHERING-PLOUGH@MERCK & CO@@@@SCHERING-PLOUGH|MERCK & CO|||@@@@@@|||||||||@Brain Cancer@@@@@Brain Cancer|||||||||@TEMODAR@AVASTIN@@@@TEMODAR|AVASTIN|||@Alkylating Agent@@@@@Alkylating Agent||||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@RELAPSED@MALIGNANT@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922741@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Sirolimus versus cyclosporine or tacrolimus@@-@-@-@MADISON, NEW JERSEY@10/1/2009@@Sirolimus inhibits T cell activation induced by most stimuli, by blocking calcium dependent and calcium independent intracellular signal transduction. Studies demonstrated that its effects are mediated by a mechanism that is different from that of ciclosporin, tacrolimus, and other immunosuppressive agents. Experimental evidence suggests that sirolimus binds to the specific cytosolic protein FKPB-12 and that the FKPB 12-sirolimus complex inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a critical kinase for cell cycle progression. The inhibition of mTOR results in blockage of several specific signal transduction pathways. The net result is the inhibition of lymphocyte activation, which results in immunosuppression.@@14922741@Non-melanoma skin cancer in kidney transplant@@-@-@@NO REVIEW@@@@-@Pfizer acquired Wyeth on 26 January 2009 in a deal worth U.S $68 billion [Pfizer 26.01.2009]@-@NCT00129961@200@-@-@@@-@@8/1/2005@-@0468H1-407@@-@-@@@IV@IV@@-@-@RESULTS PENDING@-@@@@MONO@SIROLIMUS@@@@@SIROLIMUS||||@WYETH@PFIZER@@@@WYETH|PFIZER|||@@@@@@|||||||||@Supportive Care@Melanoma / Skin Cancer@@@@Supportive Care|Melanoma / Skin Cancer||||||||@RAPAMUNE@@@@@RAPAMUNE||||@Immunotherapy@Immunosuppressive@@@@Immunotherapy|Immunosuppressive|||@NMSC LESIONS@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919437@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@@@YES@@@@Paclitaxel is an antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilises microtubules by preventing depolymerisation. This stability inhibits the normal dynamic reorganisation of the microtubule network, which is essential for vital interphase and mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or bundles of microtubules throughout the cell cycle and multiple astersof microtubules during mitosis.@@14919437@Ovarian carcinoma: in the first-line chemotherapy of ovarian cancer, Taxol is indicated for the treatment of patients with advanced carcinoma of the ovary or with residual disease ( > 1 cm) after initial laparotomy, in combination with cisplatin. In the second-line chemotherapy of ovarian cancer, Taxol is indicated for the treatment of metastatic carcinoma of the ovary after failure of standard, platinum containing therapy. Breast carcinoma: In the adjuvant setting, Taxol is indicated for the treatment of patients with node-positive breast carcinoma following anthracycline and cyclophosphamide (AC) therapy. Adjuvant treatment with Taxol should be regarded as an alternative to extended AC therapy. Taxol is indicated for the initial treatment of locally advanced or metastatic breast cancer either in combination with an anthracycline in patients for whom anthracycline therapy is suitable, or in combination with trastuzumab, in patients who over-express HER-2 at a 3+ level as determined by immunohistochemistry and for whom an anthracycline is not suitable. As a single agent, Taxol is indicated for the treatment of metastatic carcinoma of the breast in patients who have failed, or are not candidates for standard, anthracycline containing therapy. Advanced non-small cell lung carcinoma: Taxol, in combination with cisplatin, is indicated for the treatment of non-small cell lung carcinoma (NSCLC) in patients who are not candidates for potentially curative surgery and/or radiation therapy. AIDS-related Kaposi's sarcoma: Taxol is indicated for the treatment of patients with advanced AIDS-related Kaposi's sarcoma (KS) who have failed prior liposomal anthracycline therapy.@@YES@@@NO REVIEW@@@@@Teva acquires Barr. SOURCE: Teva, 21 July 2008@@@@175 mg/m² administered over a period of 3 hours, with a 3 week interval between courses.@EMA, 11 January 2008@1/11/2008@@@@@Paclitaxel should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. Since significant hypersensitivity reactions may occur, appropriate supportive equipment should be available. Patients must be pretreated with corticosteroids, antihistamines and H2 antagonists. Taxol should be given before cisplatin when used in combination.@NO LABELLED TRIAL@No@@@@@@APPROVED@@N/A@@NO LABELLED TRIAL@@@@@@PACLITAXEL@@@@@PACLITAXEL||||@PLIVA@BARR PHARMACEUTICALS@TEVA PHARMACEUTICAL@@@PLIVA|BARR PHARMACEUTICALS|TEVA PHARMACEUTICAL||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
16384843@Onco@@@@@300f1037ntsdm@@@@@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384843@Indicated for the adjuvant treatment of adult patients who are at significant risk of relapse followingresection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrenceshould not receive adjuvant treatment.@@YES@@@@@@@90%@@@@@The recommended dose of Glivec is 400 mg/day for the adjuvant treatment of adult patients followingresection of GIST. Optimal treatment duration is not yet established. Length of treatment in theclinical trial supporting this indication was 36 months@@@@Yes@@@@@No@@@@@@APPROVED@@@SNS@@@@@@ADJUVANT@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Sarcoma@GIST@@@@Sarcoma|GIST||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@@@@@@@@@@@1@1@86446.89231@@@36@month@36 month@86446.89@86446.89@78.95@60@1.1511@1184.23@1289.75@1191.77@@@@@@@@@@0.2@1@@mg@400@1@@@@@@@@@@@8/4/2017@19.74@19.74@779652@TABLET@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14924061@Onco@@@@@300f1020ntsdm@@@@@@NO LABELLED TRIAL@@L01CB01@L01C@YES@NEW YORK, NEW YORK@@@Etoposide is a semisynthetic derivative of podophyllotoxin used in the treatment of certain neoplastic diseases. Podophyllotoxins inhibit mitosis by blocking microtubular assembly. Etoposide inhibits cell cycle progression at a premitotic phase (late S and G2). It does not interfere with the synthesis of nucleinic acids.@@14924061@VePesid (etoposide) is indicated in the management of: Small Cell Lung Cancer—VePesid Capsules in combination with other approved chemotherapeutic agents as first line treatment in patients with small cell lung cancer.@@NO@-@@NO REVIEW@@@@100%@-@-@-@-@The usual dose in testicular cancer in combination with other approved chemotherapeutic agents ranges from 50 to 100 mg/m2/day on days 1 through 5 to 100 mg/m2/day on days 1, 3, and 5. In small cell lung cancer, the dose in combination with other approved chemotherapeutic drugs ranges from 35 mg/m2/day for 4 days to 50 mg/m2/day for 5 days.@N/A@@@-@@@Patients being treated with VePesid must be frequently observed for myelosuppression both during and after therapy. Myelosuppression resulting in death has been reported. Dose-limiting bone marrow suppression is the most significant toxicity associated with VePesid therapy. Therefore, the following studies should be obtained at the start of therapy and prior to each subsequent cycle of VePesid: platelet count, haemoglobin, white blood cell count, and differential. The occurrence of a platelet count below 50,000/mm3 or an absolute neutrophil count below 500/mm3 is an indication to withhold further therapy until the blood counts have sufficiently recovered.@NO LABELLED TRIAL@No@-@-@@@-@APPROVED@@@SSN@NO LABELLED TRIAL@-@@@@-@ETOPOSIDE PHOSPHATE@@@@@ETOPOSIDE PHOSPHATE||||@BMS@@@@@BMS||||@@@@@@|||||||||@SCLC@@@@@SCLC|||||||||@VEPESID@@@@@VEPESID||||@Plant Alkaloid@Topoisomerase II Inhibitor@@@@Plant Alkaloid|Topoisomerase II Inhibitor|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@10@1.1229@115.25@190.21@120.44@@@@@@@@@@0.12@@@@@@@@@@@@@@@@6/7/2017@11.53@11.53@24639041@CAPSULE@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14918729@Onco@@@@@300f1020ntsdm@@@@@@Arenegry with doxorubicin@@-@-@-@MILAN, ITALY@10/1/2009@@NGR-hTNF is a vascular targeting agent with unique mode of action, and a first-in-class compound in the class of peptide/cytokine complexes able to selectively target the tumourvasculature. It consists of a tumour homing peptide (NGR) selectively binding tumour blood vessels, fused to the powerful human anticancer cytokine TNF. The resulting molecule has unique biological properties, including induction of tumour vascular permeability and normalisation, and a direct biological antitumour activity. NGR-hTNF is undergoing clinical development both as single agent and in combination with several different chemotherapeutic agents: currently, in addition to mesothelioma and colorectal cancer, single agent Phase II trials are ongoing in hepatocellular carcinoma and small-cell lung cancer; for colorectal cancer, it is also being tested in a Phase II trial in combination with Xelox. Also ongoing is a Phase I trial in combination with cisplatin, while a Phase I trial in combination with doxorubicin was successfully completed.@@14918729@Soft tissue sarcomas@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00484341@37@-@-@@@-@@10/1/2007@-@NGR011@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@DOXORUBICIN@@@@-|DOXORUBICIN|||@MOLMED@@@@@MOLMED||||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@ARENEGYR@@@@@ARENEGYR||||@TK Inhibitor@VEGF@Angiogenesis Inhibitor@@@TK Inhibitor|VEGF|Angiogenesis Inhibitor||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@ADVANCED@METASTATIC@@@@NON-RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@1.0543@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14916673@Onco@@@@@300f1014ntsdm@300f1813ntsdm@@@@@@@L02BA01@L02B@YES@@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14916673@Nolvadex is indicated for: 1. The treatment of breast cancer. 2. The treatment of anovulatory infertility.@@NO@@@NO REVIEW@@@@@@@@@Adults: The recommended daily dose of tamoxifen is normally 20 mg. No additional benefit, in terms of delayed recurrence or improved survival in patients, has been demonstrated with higher doses. Substantive evidence supporting the use of treatment with 30–40 mg per day is not available, although these doses have been used in some patients with advanced disease.@@@@@@@Menstruation is suppressed in a proportion of premenopausal women receiving Nolvadex for the treatment of breast cancer. An increased incidence of endometrial changes including hyperplasia, polyps, cancer and uterine sarcoma (mostly malignant mixed Mullerian tumours), has been reported in association with Nolvadex treatment. The underlying mechanism is unknown but may be related to the oestrogenlike effect of Nolvadex. Any patient receiving or having previously received Nolvadex who report abnormal gynaecological symptoms, especially vaginal bleeding, or who presents with menstrual irregularities, vaginal discharge and symptoms such as pelvic pain or pressure should be promptly investigated.@@No@@@@@@APPROVED@@Unrestricted reimbursement.@RAMQ@RESULTS PENDING@@@@@@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@APOTEX@@@@@APOTEX||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@APO-TAMOX@@@@@APO-TAMOX||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@100@0.7934@35@@@@@@@@@@@@0.02@@@@@@@@@@@@@@@@8/18/2017@0.35@0.35@812390100@FILM COATED TABLET@C$@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
16384834@Onco@@@@@300f1015ntsdm@@@@@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384834@Indicated for the adjuvant treatment of adult patients who are at significant risk of relapse followingresection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrenceshould not receive adjuvant treatment.@@NO@@@@@@@@@@@@The recommended dose of Glivec is 400 mg/day for the adjuvant treatment of adult patients followingresection of GIST. Optimal treatment duration is not yet established. Length of treatment in theclinical trial supporting this indication was 36 months@@@@Yes@@@@@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@@@@@@ADJUVANT@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Sarcoma@GIST@@@@Sarcoma|GIST||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@@@@@@@@@@@1@1@76507.43272@@@36@month@36 month@76507.43@76507.43@69.87@30@1.1511@2096.14@2270.33@2126.14@@@@@@@@@@0.17@1@@mg@400@1@@@@@@@@@@@8/1/2017@69.87@69.87@3.40E+12@FILM-COATED TABLET@EURO@@@@@@@@400@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14922549@Onco@@@@@300f1010ntsdm@@@@@@Photofrin 2MG/KG followed by 2 non-thermal applications of 630NM laser light.@@L01XD01@L01X@NO@-@@@@@14922549@Photodynamic therapy with Photofrin is indicated for: - Palliation of patients with completely obstructing esophageal cancer, or of patients with partially obstructing esophageal cancer who, in the opinion of their physician, cannot be satisfactorily treated with Nd:YAG laser therapy. - Reduction of obstruction and palliation of symptoms in patients with completely or partially obstructing endobronchial non-small-cell lung cancer (NSCLC). - Treatment of microinvasive endobronchial NSCLC in patients for whom surgery and radiotherapy are not indicated. - Ablation of high-grade dysplasia in Barrett's esophagus patients who do not undergo esophagectomy.@@NO@-@@NO REVIEW@@@@100%@Licensed from QLT@-@-@17@Photodynamic therapy with Photofrin is a two-stage process requiring administration of both drug and light. The first stage of PDT is the intravenous injection at 2 mg/kg. Illumination with laser light 40–50 hours following injection constitutes the second stage of therapy. A second laser light application may be given 96-120 hours after injection, preceded by gentle debridement of residual tumor@-@@@-@@@Oesophageal Cancer: If the esophageal tumor is eroding into the trachea or bronchial tree, the likelihood of tracheoesophageal or bronchoesophageal fistula resulting from treatment is sufficiently high that PDT is not recommended.@LABEL@@-@-@@@N/A@DISCONTINUED@@-@NHS@Objective tumour response: 82% at week 1, 35% month 1, 94% any assessment. Improvement in dysphagia: 71% week1, 47% month 1, 76% any assessment.@-@@@@MONO@PORFIRMER SODIUM@@@@@PORFIRMER SODIUM||||@SINCLAIR PHARMA@@@@@SINCLAIR PHARMA||||@@@@@@|||||||||@NSCLC@Oesophageal Cancer@@@@NSCLC|Oesophageal Cancer||||||||@PHOTOFRIN@@@@@PHOTOFRIN||||@Other@@@@@Other||||@RESPONSE RATE@@@@@@@@@@-@@@@@SINGLE-ARM@@@@@@@Invalid Factory Price@@@@@-@@@@1@1.5665@@@@@@@@@@@@@@@@@@@@@@@@@@@@@12/29/2014@@@7.31E+15@INJECTION POWDER FOR RECONSTITUTION@GB£@@@@@@@@75@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
15413592@Onco@@@@@@@@@@@Experimental: Oral AG-120 + Subcutaneous (SC) azacitidine. Subjects with an IDH1 mutation will receive AG-120 at the RP2D orally QD on Days 1-28 of each 28-day cycle + azacitidine 75 mg/m2/day SC for 7 days of each 28-day cycle.Experimental: Oral AG-221 + Subcutaneous (SC) azacitidine. Subjects with an IDH2 mutation will receive AG-221 at the RP2D orally QD on Days 1-28 of each 28-day cycle + azacitidine 75 mg/m2/day SC for 7 days of each 28-day cycle.Experimental: Subcutaneous (SC) azacitidine. Subjects with either an IDH1 or IDH2 mutation will receive azacitidine 75 mg/m2/day SC for 7 days of each 28-day cycle.@@@@@SUMMIT, NEW JERSEY@12/1/2018@@@@15413592@This Phase 1b/2 study is an open-label, randomized, multicenter trial to evaluate the safety and efficacy of oral AG-120 + SC azacitidine and oral A-221 + Subcutaneous (SC) azacitidine in subjects with newly diagnosed Acute myeloid leukemia (AML) harboring an Isocitrate dehydrogenase 1 (IDH1) or an Isocitrate dehydrogenase 2 (IDH2) mutation, respectively.@Both@@@@@@@1034@@@FIRST-LINE@NCT02677922@150@@@@@@@2/1/2016@@AG-221-AML-005@@@Subject is ≥ 18 years of age at the time of signing the informed consent form (ICF).Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.Subject is willing and able to adhere to the study visit schedule and other protocol requirements.Subject has previously untreated Acute myeloid leukemia (AML) primary (ie, de novo) or secondary (progression of Myelodysplastic syndromes (MDS) or myeloproliferative neoplasms ([MPN], or therapy-related) AML according to the World Health Organization (WHO) classification with ≥ 20% leukemic blasts in the bone marrow: ◦Have an Isocitrate dehydrogenase 1 (IDH1) or Isocitrate dehydrogenase 2 (IDH2) gene mutation (R132, R140, or R172)◦Validated local testing may be used to confirm eligibility for Phase 1, but central testing must be performed to confirm eligibility for Phase 2.◦By the investigator's assessment who are not candidates to receive intensive inductive chemotherapy (IC).Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2@@ADULTS@Phase 1b/2@I/II@@@@@@@@@COMBO@-@AZACITIDINE@@@@-|AZACITIDINE|||@CELGENE@@@@@CELGENE||||@World@@@@@World|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@AG-120@VIDAZA@@@@AG-120|VIDAZA|||@Other@@@@@Other||||@DOSE LIMITING TOXICITIES@ADVERSE EVENTS@Pharmacokinetics- Cmax@PHARMACOKINETICS- TMAX@@OVERALL RESPONSE RATE@EVENT-FREE SURVIVAL@ADVERSE EVENTS@@@@@@@@RANDOMIZED@PARALLEL ASSIGNMENT@OPEN LABEL@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
16074593@Onco@@@@@300f1018ntsdm@@@@@@@@L01XC17@L01X@@NEW YORK, NEW YORK@@@Nivolumab is an investigational, fully-human IgG4 anti-PD-1 receptor blocking monoclonal antibody that binds to the checkpoint receptor PD-1 (programmed death-1) expressed on activated T cells. Nivolumab inhibits the binding of PD-1 with its tumor-expressed ligands, programmed death-ligand 1 (PD-L1/B7-H1) and PD-L2 (B7-DC). Blocking of the interaction of the PD-1 receptor with its ligands may allow T-cells to elicit an anti-tumor immune response.@@16074593@OPDIVO, as monotherapy is indicated for the treatment of patients with unresectable (Stage III) or metastatic (Stage IV) melanoma.@@YES@1-May-16@5/1/2016@NO REVIEW@@@@100%@@@@418@The recommended dose of OPDIVO as a monotherapy is 3 mg/kg administered intravenously over 60 minutes every 2 weeks. Treatment should be continued as long as clinical benefit is observed or until treatment is no longer tolerated by the patient.@TGA, 11 January 2016@1/11/2016@@No@@@@@No@@@@@3@APPROVED@@@PBS@@@@@@MONO@NIVOLUMAB@@@@@NIVOLUMAB||||@BRISTOL-MYERS SQUIBB@@@@@BRISTOL-MYERS SQUIBB||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@OPDIVO@@@@@OPDIVO||||@PD-1 Inhibitor@@@@@PD-1 Inhibitor||||@@@@@@@@@@@UNRESECTABLE@METASTATIC@@@@@@@@@76.5@kg@52809.38975@@@5.1@month@5.1 month@52809.39@52809.39@340.44@1@0.779@830.7@@@@@@@@@@@@20.77@14@@mg/kg@3@1@@@@@@@@@@@8/1/2017@830.7@830.7@2504-1869-IN-BQ@CONCENTRATE FOR SOLUTION FOR INFUSION (VIAL) - 4 ML@A$@@@@@@@@40@MG@10 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
16384748@Onco@@@@@300f1014ntsdm@@@@@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384748@Indicated for the treatment of adult patients with Ph+ CML in chronic phase after failure of interferon-alphatherapy@@EXPENSIVE ITEM APPENDIX III (LIMITED WHOLESALE MARGIN)@@@NO REVIEW@@@@@@SECOND-LINE@@532@The recommended dosage of Glivec is 400 mg/day for adult patients in chronic phase CML.@@@@Yes@@@@@No@@@ADULT@@@APPROVED@@@RAMQ@@@@@@MONO@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@GLEEVEC@@@@@GLEEVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@CHRONIC PHASE@@@@@@@@@@1@1@Invalid Average Duration of Use@@@@@@@@@120@0.7881@3182.21@@@@@@@@@@@@0.27@1@@mg@400@1@@@@@@@@@@@7/19/2017@26.52@26.52@2253275120@TABLET@C$@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14918257@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@M04AA01@M04A@NO@GERMANY@@@@@14918257@Indicated in the management of patients with signs and symptomas of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephroptahy; the management of patients with leukaemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment should be discontinued when the potential for overproduction of uric acid is no longer presents; and, the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800mg/day in male patients and 750mg/day in female patients. This is not an innocuous drug. It is not recommended for the treatment of asymptomatic hyperuricemia.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@Dosage in Adults: should be introduced at low dosage e.g. 100mg/day to reduce the risk of adverse reactions and increased only if the serum urate response is unsatisfactory. Extra caution should be exercised if renal function is poor. The following dosage schedules are suggested: 100 to 200 mg daily in mild conditions, 300 to 600 mg daily in moderately severe conditions, 700 to 900 mg daily in severe conditions. If dosage on a mg/kg bodyweight basis is required, 2 to 10 mg/kg bodyweight/day should be used. Dosage in children: Children under 15 years: 10 to 20 mg/kg bodyweight/day up to a maximum of 400 mg daily. Use in children is rarely indicated, except in malignant conditions (especially leukaemia) and certain enzyme disorders such as Lesch-Nyhan syndrome.@@@@@@@Should be discontinued at the first appearance of skin rash or other signs which may indicate an allergic rection. Dose should be adjusted if co-administered with Purinethol or Imuran.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@ALLOPURINOL@@@@@ALLOPURINOL||||@ABZ PHARMA@@@@@ABZ PHARMA||||@@@@@@|||||||||@Supportive Care@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Non-Hodgkin's Lymphoma@Supportive Care|Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Non-Hodgkin's Lymphoma|||||@GENERIC@@@@@GENERIC||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@30@1.1511@1.09@12.36@1.82@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@0.04@0.04@1014636@TABLET@EURO@@@@@@@@300@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16671837@Onco@@@@@300f1015ntsdm@@@@@The Nordic VII study@@@L01XC06@L01X@@NEW YORK, NEW YORK@@@Erbitux is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Cetuximab is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions and has an approximate molecular weight of 152 kDa. Cetuximab is produced in mammalian (murine myeloma) cell culture.@@16671837@Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer in first-line in combination with FOLFOX@@YES@@@@@@@@>> Acquisition completed. [Lilly, 24.11.2008]          >> Lilly acquires ImClone for US$6.5 billion. [Lilly, 7.10.2008]        >> BMS Offers US$4.3Billion for ImClone or US$60.0 per share in cash. [BMS, 1 August 2008]      >> ImClone licensed co-development and co-promotion rights to BMS in North America and Japan, and to Merck KGaA in Europe.@FIRST-LINE@@@In all indications, Erbitux is administered once a week. The initial dose is 400 mg cetuximab per m2 body surface area. All subsequent weekly doses are 250 mg cetuximab per m2 each.@EMA, 18 December 2013@12/18/2013@@No@@@@@No@@@(EGFR)-expressing, RAS WILD-TYPE@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@@@@@@COMBO@CETUXIMAB@FLUOROURACIL@LEUCOVORIN@OXALIPLATIN@@CETUXIMAB|FLUOROURACIL|LEUCOVORIN|OXALIPLATIN|@BMS@IMCLONE@MERCK SERONO@@@BMS|IMCLONE|MERCK SERONO||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ERBITUX@FOLFOX@@@@ERBITUX|FOLFOX|||@mAb@Chimeric@TK Inhibitor@EGFR@@mAb|Chimeric|TK Inhibitor|EGFR|@@@@@@@@@@@METASTATIC@@@@@RANDOMISED@@@@@1.75@m²@31936.036@@@7.9@month@7.9 month@31936.04@31936.04@132.91@1@1.1511@209@@@@@@@@@@@@2.09@7@1@mg/m²@400@1@7@@mg/m²@250@1@@@@@@8/2/2017@209@209@9260599T@SOLUTION FOR PERFUSION  50 ML@EURO@@@@@@@@100@MG@2 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@85@France
14916799@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@-@@-@-@-@SEATTLE, WASHINGTON@@@IL-21 has potent biological activity in regulating key classes of immune cells, including cytotoxic T cells and natural killer cells. These cell types play key roles in surveillance of the body to eliminate malignant and infected cells. Based upon the ability of IL-21 to inhibit tumor growth in a number of preclinical models, ZymoGenetics is developing IL-21 for the treatment of cancer, initially in renal cell carcinoma and metastatic melanoma. @@14916799@Stage IV@@-@-@@NO REVIEW@@@@-@>> ZymoGenetics announces the acquisition of ex-North American rights to Interleukin 21 (IL-21) from Novo Nordisk A/S, resulting in ZymoGenetics owning worldwide rights to IL-21. Novo Nordisk A/S agreed to license rest of world (ex-North American) development and commercialization rights for IL-21 to ZymoGenetics in exchange for potential regulatory approval milestones and royalties related to the ex-North American territory. In addition, upon licensing worldwide rights for IL-21 to a third party, Novo Nordisk A/S would receive a portion of related licensing fees if a certain threshold level were exceeded. [ZymoGenetics, 29.01.2009]            >> Novo Nordisk has exited all of its oncology interests as of February 2008.            >> Novo holds IL-21 rights outside of North America.@-@-@29@-@-@@@-@@1/1/2006@-@NOVO@@-@-@@@I/II@II@@-@-@AACR April 2006; IL-2 is well-tolerated and anti-tumour activity is present.@-@@@@-@-@@@@@-||||@ZYMOGENETICS@@@@@ZYMOGENETICS||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@IL-21@@@@@IL-21||||@Immunotherapy@@@@@Immunotherapy||||@SAFETY@MAXIMUM TOLERATED DOSE@@@@@@@@@MALIGNANT@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922456@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Docetaxel administered every 3 weeks. CP-751,871 administered every 3 weeks. CP-751,871 administration (20 mg/kg IV) will continue after the docetaxel is stopped. [clinicaltrials.gov]@@-@-@-@NEW YORK, NEW YORK@5/1/2012@@CP-751,871, a fully human monoclonal antibody, is a highly specific inhibitor of the IGF-1R pathway. The IGF-1R pathway is one of the key signaling pathways in cancer cells that lead to uncontrolled growth and survival of tumour cells. @@14922456@-@@-@-@@NO REVIEW@@@@-@Acquired through takeover of Pharmacia Corp.@-@NCT00678626@200@-@-@@@-@@4/1/2009@-@A4021008@@-@>> Histologically or cytologically confirmed diagnosis with evidence of either metastatic disease (Stage IV) of locally recurrent disease not amenable to curative resection or radiation therapy (Stage IIIB). >> Her-2negative breast cancer or unknown Her-2 status. At least 1 measurable lesion as defined by RECIST. >> ECOG status 0-1@@@II@II@@-@-@Trial registered. [Pfizer, 12.05.2008]@-@@@@COMBO@FIGITUMUMAB@DOCETAXEL@@@@FIGITUMUMAB|DOCETAXEL|||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@CP-751,871@TAXOTERE@@@@CP-751,871|TAXOTERE|||@mAb@Human@@@@mAb|Human|||@PROGRESSION-FREE SURVIVAL@@@@@BIOMARKER@RESPONSE RATE@PHARMACOKINETICS@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918903@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@SAN FRANCISCO, CALIFORNIA@@@@@14918903@-@@-@-@@NO REVIEW@@@@-@">> Roche reaches a friendly agreement to purchase the latter's outstanding shares at a price of US$95 per share. The transaction will be valued at US$46.8 billion. [Genentech, 12 March 2009]>> Roche has made a formal announcement of cash tender offer for all outstanding shares of Genentech at US$86.50 per share for the 44.2% of Genentech not already held by Roche. Genentech's special committee, on the other hand, has responded to the offer by urging its shareholders ""to take no action at this time"". [Genentech, 10.02.2009]          >> Genentech rejects the acquisition bid. [Genentech, 14.08.2008]        >> Roche announces US$43.7 billion proposal to assume full control of Genentech. SOURCE: Roche, 21 July 2008"@-@-@30-40@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@-@FPI due in Q2 08@-@@@@COMBO@-@RITUXIMAB@GEMCITABINE@@@-|RITUXIMAB|GEMCITABINE||@GENENTECH@@@@@GENENTECH||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@B-Cell Lymphoma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|B-Cell Lymphoma|||||||@ANTI-CD40@RITUXAN@MABTHERA@GEMZAR@@ANTI-CD40|RITUXAN|MABTHERA|GEMZAR|@mAb@CD40@@@@mAb|CD40|||@-@@@@@@@@@@RELAPSED@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924407@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01AD04@L01A@YES@NEW YORK, NEW YORK@@@@@14924407@Zanosar is indicated in the treatment of metastatic islet cell carcinoma of the pancreas. Responses have been obtained with both functional and nonfunctional carcinomas. Because of its inherent renal toxicity, therapy with this drug should be limited to patients with symptomatic or progressive metastatic disease.@@YES@5-May@@NO REVIEW@@@@100%@@@@@Daily Schedule—The recommended dose for daily intravenous administration is 500 mg/m2 of body surface area for five consecutive days every six weeks until maximum benefit or until treatment-limiting toxicity is observed. Dose escalation on this schedule is not recommended.@Feb-85@@9/1/1988@@@@Zanosar should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. A patient need not be hospitalized but should have access to a facility with laboratory and supportive resources sufficient to monitor drug tolerance and to protect and maintain a patient compromised by drug toxicity. Renal toxicity is dose-related and cumulative and may be severe or fatal. Other major toxicities are nausea and vomiting which may be severe and at times treatment-limiting. In addition, liver dysfunction, diarrhea, and haematological changes have been observed in some patients. Streptozocin is mutagenic. When administered parenterally, it has been found to be tumourigenic or carcinogenic in some rodents.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@STREPTOZOCIN@@@@@STREPTOZOCIN||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@ZANOSAR@@@@@ZANOSAR||||@Alkylating Agent@Nitrosourea@@@@Alkylating Agent|Nitrosourea|||@@@@@@@@@@@METASTATIC@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@135@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/2/2017@135@135@9123201R@LYOPHILIZATE FOR INJECTABLE PREPARATION@EURO@@@@@@@@1@G@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14916111@Onco@@@@@300f1037ntsdm@@@@@@Actiq for breakthrough cancer pain@@N02AB03@N02A@YES@FRAZER, PENNSYLVANIA@@@Fentanyl is a pure opioid agonist whose principal therapeutic action is analgesia. Other members of the class known as opioid agonists include substances such as morphine, oxycodone, hydromorphone, codeine, and hydrocodone.@@14916111@Indicated only for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Patients considered opioid tolerant are those who are taking at least 60 mg of oral morphine/day, at least 25 mcg of transdermal fentanyl/hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer. This product must not be used in opioid non-tolerant patients because life-threatening hypoventilation could occur at any dose in patients not on a chronic regimen of opiates. September 2007: Dear Healthcare Professional letter issued to emphasise that it is not generic Actiq and ensure non-use in opioid non-tolerant patients or non-labelled indications.@@NO@@@NO REVIEW@@@@90%@@@@130@The initial dose of Actiq used should be 200 micrograms, titrating upwards as necessary through the range of available dosage strengths (200, 400, 600, 800, 1200 and 1600 micrograms). Patients should be carefully monitored until a dose is reached that provides adequate analgesia with acceptable side effects using a single dosage unit per episode of breakthrough pain. This is defined as the successful dose.@HMA, 7 November 2001@11/7/2001@12/21/2001@@@@Must not be used in opioid non-tolerant patients; fentanyl is a Schedule II controlled substance; life-threatening hypoventilation can occur at any dose; contraindicated in acute or post-operative pain@LABEL@No@@@@@III@APPROVED@@RESTRICTED SUBSTANCE PRESCRIPTION@SNS@92 of 130 patients (71% achieved a successful dose during titration. The most successful doses were 400mcg (21%) and 800mcg (20%).@@@@@MONO@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@CEPHALON@@@@@CEPHALON||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@ACTIQ@@@@@ACTIQ||||@Opioid Analgesic@@@@@Opioid Analgesic||||@RESPONSE RATE@MAXIMUM TOLERATED DOSE@@@@@@@@@@@@@@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@3@1.1807@23.5@36.69@25.47@@@@@@@@@@@@@@@@@@@@@@@@@@8/23/2017@7.83@7.83@912485@CHEWABLE TABLET@EURO@@@@@@@@1200@MCG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
16670303@Onco@@@@@300f1015ntsdm@@@@@@@@L04AX04@L04A@@SUMMIT, NEW JERSEY@3/1/2017@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16670303@Treatment of adult patients with relapsed or refractory mantle cell lymphoma@Both@YES@8-Mar-17@3/8/2017@NO REVIEW@@@@8 March 2017: ASMR V  [http://www.has-sante.fr/portail/upload/docs/evamed/CT-15734_REVLIMID_PIC_EI_LCM_AvisPostObs_CT15734.pdf]@@@NCT00875667@254@The recommended starting dose of lenalidomide is 25 mg orally once daily on days 121 of repeated 28day cycles.@EMA, 28 January 2016@1/28/2016@9/1/2007@Yes@@4/1/2009@@CC5013MCL002@No@@Biopsy proven mantle cell lymphoma; Patients who are refractory to their regimen or have relapsed once, twice or up to three times and who have documented progressive disease; Eastern Cooperative Oncology Group (ECOG) performance score 0,1, or 2; Willing to follow pregnancy precaution@@ADULTS@II@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@@@@@@MONO@LENALIDOMIDE@@@@@LENALIDOMIDE||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Non-Hodgkin's Lymphoma@Mantle Cell Lymphoma@@@@Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma||||||||@REVLIMID@@@@@REVLIMID||||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@PROGRESSION FREE SURVIVAL@@@@@OVERALL RESPONSE RATE@DURATION OF RESPONSE@TIME TO PROGRESSION@@@RELAPSED@REFRACTORY@@@@RANDOMISED@MULTI-CENTRE@OPEN LAB EL@@@1@1@76620.81@@@37.6@week@37.6 week@76620.81@76620.81@291.11@1@1.1511@155.26@@@@@@@@@@@@15.53@28@@mg@25@21@@@@@@@@@@@8/2/2017@155.26@155.26@9298113R@CAPSULE@EURO@@@@@@@@10@MG@10 MG@@@@@@@@@@@@@@@@@@@@@@@@85@France
15399701@Onco@@@@@300f1020ntsdm@@@@@@@@L01XC17@L01X@@NEW YORK, NEW YORK@@@Nivolumab is an investigational, fully-human IgG4 anti-PD-1 receptor blocking monoclonal antibody that binds to the checkpoint receptor PD-1 (programmed death-1) expressed on activated T cells. Nivolumab inhibits the binding of PD-1 with its tumor-expressed ligands, programmed death-ligand 1 (PD-L1/B7-H1) and PD-L2 (B7-DC). Blocking of the interaction of the PD-1 receptor with its ligands may allow T-cells to elicit an anti-tumor immune response.@@15399701@Indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults.@@YES@22-Apr-16@4/22/2016@NO REVIEW@@@@@@@@@The recommended dose of OPDIVO is 3 mg/kg administered intravenously over 60 minutesevery 2 weeks. Treatment should be continued as long as clinical benefit is observed or until treatmentis no longer tolerated by the patient.@EMA, 19 June 2015@6/19/2015@@NO@@@@@No@@@ADULTS@@@APPROVED@@22 April 2016: added to the reimbursement list (Class H) [AIFA, http://www.agenziafarmaco.gov.it/it/content/pubblicazione-schede-di-monitoraggio-registro-opdivo-22042016]@SSN@The European Commission's approval is based on data from two Phase 3 studies (CheckMate -066, -037).@@@@@MONO@NIVOLUMAB@@@@@NIVOLUMAB||||@BRISTOL-MYERS SQUIBB@@@@@BRISTOL-MYERS SQUIBB||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@OPDIVO@@@@@OPDIVO||||@PD-1 Inhibitor@@@@@PD-1 Inhibitor||||@@@@@@@@@@@UNRESECTABLE@METASTATIC@@@@@@@@@76.5@kg@34202.4555@@@5.1@month@5.1 month@34202.46@34202.46@220.49@1@1.1229@538.01@887.93@562.23@@@@@@@@@@13.45@14@@mg/kg@3@1@@@@@@@@@@@6/7/2017@538.01@538.01@44291019@CONCENTRATE FOR SOLUTION FOR INFUSION - 4 ML@EURO@@@@@@@@40@MG@10 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
16396591@Onco@@@@@300f1012ntsdm@@@@@@This study investigated the use of combination therapy of MPR (melphalan 0.18 mg/kg orally on days 1-4 of repeated 28-day cycles; prednisone 2 mg/kg orally on days 1-4 of repeated 28-day cycles; and lenalidomide10 mg/day orally on days 1-21 of repeated 28-day cycles) for induction therapy, up to 9 cycles. Patients who completed 9 cycles or who were unable to complete 9 cycles due to intolerance proceeded to maintenancemonotherapy starting with lenalidomide 10 mg orally on days 1-21 of repeated 28-day cycles until disease progression.@@L04AX04@L04A@@SUMMIT, NEW JERSEY@@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16396591@Treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant@Both@NO@@@@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@FIRST-LINE@@459@The recommended starting dose is lenalidomide 10 mg/day orally on days 121 of repeated 28day cycles for up to 9 cycles, melphalan 0.18 mg/kg orally on days 14 of repeated 28 day cycles, prednisone2 mg/kg orally on days 14 of repeated 28day cycles. Patients who complete 9 cycles or who are unable to complete the combination therapy due to intolerance are treated with lenalidomide alone, 10 mg/dayorally on days 121 of repeated 28day cycles given until disease progression.@EMA, 11 February 2015@2/11/2015@@Yes@@@@@No@@@@ADULTS@@APPROVED@@@GKV@@@@@@COMBO@LENALIDOMIDE@MELPHALAN@PREDNISONE@@@LENALIDOMIDE|MELPHALAN|PREDNISONE||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@REVLIMID@ALKERAN@GENERIC@@@REVLIMID|ALKERAN|GENERIC||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@PROGRESSION FREE SURVIVAL@@@@@@@@@@@@@@@RANDOMISED@DOUBLE BLIND@@@@1@1@76297.6231@@@27.4@month@27.4 month@76297.62@76297.62@91.55@21@1.1511@6408.5@7912.21@6447@@@@@@@@@@12.21@28@@mg@10@21@@@@@@@@@@@8/1/2017@305.17@305.17@1875284@HARD CAPSULE@EURO@@@@@@@@25@MG@25 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14918689@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01AX04@L01A@YES@LAKE FOREST, ILLINOIS@@@Dacarbazine is a cytostatic agent. The antineoplastic effect is due to an inhibition of cell growth which is independent of the cell cycle and due to an inhibition of DNA synthesis. An alkylating effect has also been shown and other cytostatic mechanisms may also be influenced by dacarbazine. Dacarbazine is considered not to show an antineoplastic effect by itself. However by microsomal N-demethylation it is quickly converted to 5-amino-imidazole-4-carboxamide and a methyl cation, which is responsible for the alkylating effect of the drug.@@14918689@Dacarbazine is indicated for the treatment of patients with metastatic malignant melanoma. Further indications for dacarbazine as part of combination chemotherapy are: • Hodgkin's disease • Advanced adult soft tissue sarcomas (except mesothelioma, Kaposi sarcoma)@@@@@NO REVIEW@@@@100%@Via takeover of Mayne Pharma@@@@Hodgkin's Disease: Dacarbazine is administered in a daily dose of 375 mg/m2 body surface area i.v. on day 1 and day 15 in combination with doxorubicin, bleomycin and vinblastine for each cycle of ABVD regimen.@EMA, January 1996@@@@@@Haemopoietic depression is the most common toxic side effect of dacarbazine and involves primarily the leucocytes and platelets, although mild anaemia may sometimes occur. Leucopenia and thrombocytopenia may be severe enough to cause death. Possible bone marrow depression requires careful monitoring of white blood cells, red blood cells and platelet levels. Such toxicity may necessitate temporary suspension or cessation of therapy. Hepatic toxicity, accompanied by hepatic vein thrombosis and hepatocellular necrosis resulting in death, have been reported. The incidence of such reactions has been low. This toxicity has been observed mostly when dacarbazine has been administered concomitantly with other anti-neoplastic drugs; however, it has also been reported in some patients treated with dacarbazine alone. Therefore frequent monitoring of liver size, function and blood counts (especially eosinophils) is required. It is recommended that dacarbazine be administered by physicians experienced in the use of cytotoxic therapy. Laboratory facilities should be available for blood monitoring. The drug can produce severe and possibly fatal, haematologic or hepatic toxicity and severe GI reactions and should be administered to patients preferably within the hospital setting, where they can be observed frequently during and after therapy, particulary with regards to the haemopoietic toxicity.@NO LABELLED TRIAL@No@@@@@@APPROVED@@100%; no NICE review@NHS@NO LABELLED TRIAL@@@@@@DACARBAZINE@@@@@DACARBAZINE||||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@@@@Haematological Malignancy|Hodgkin's Lymphoma||||||||@GENERIC@@@@@GENERIC||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.299@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@GB£@@@@@@@@100@MG@100 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14923380@Onco@@@@@300f1012ntsdm@@@@@@Tamoxifen compared to ovarian ablation@@L02BA01@L02B@YES@LEICHINGEN, GERMANY@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14923380@@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@N/A@Adjuvant treatment of breast cancer, Adults (including elderly): The recommended dose is 20mg, given either in divided doses twice daily or as a single dose once daily. The current recommended treatment duration is five years; however the optimum duration has not been established. Treatment of locally advanced or metastatic breast cancer: The recommended dose is 20mg to 40mg, given either in divided doses twice daily or as a single dose once daily.@@@@@@@Women should be informed of the potential risks to the foetus, should they become pregnant whilst taking tamoxifen; or within two months of cessation of therapy. A number of secondary primary tumours, occurring at sites other than the endometrium and the opposite breast, have been reported in clinical trials, following the treatment of breast cancer patients with tamoxifen. No causal link has been established and the clinical significance of these observations remains unclear.@LABEL@No@@@@@III METASTATIC BREAST CANCER@APPROVED@@@GKV@The objective RR, time to treatment failure, and survival were similar with both treatments. In an overview analysis of survival data from the 3 studies, the hazard ratio for death (tamoxifen/ovarian ablation) was 1.00. Elevated serum and plasma oestrogens have been observed in premenopausal women receiving tamoxifen, but the data from the randomized studies do not suggest an adverse effect of this increase. A limited number of premenopausal patients with disease progression during tamoxifen therapy responded to subsequent ovarian ablation.@@@@@ADJUVANT@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@ALIUD PHARMA@@@@@ALIUD PHARMA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@TAMOXIFEN AL@@@@@TAMOXIFEN AL||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RESPONSE RATE@@@@@@@@@@@@@@@PROSPECTIVE@RANDOMISED@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@30@1.1511@2.67@14.36@3.45@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@0.09@0.09@3852301@TABLET@EURO@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16162118@Onco@@@@@@@@@@@Nivolumab and Ipilimumab, Experimental, Specified dose on specified daysNivolumab and Ipilimumab-placebo, Active Comparator, Specified dose on specified days@@L01XC17@L01X@@NEW YORK, NEW YORK@3/1/2018@@Nivolumab is an investigational, fully-human IgG4 anti-PD-1 receptor blocking monoclonal antibody that binds to the checkpoint receptor PD-1 (programmed death-1) expressed on activated T cells. Nivolumab inhibits the binding of PD-1 with its tumor-express@@16162118@A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)@Both@@@@@@@@@@FIRST-LINE@NCT02823574@315@@@@@@@9/1/2016@@CA209-714@@@Confirmed squamous cell head and neck cancer  -  Widespread (metastatic) disease, or returned after previous treatment (recurrent)  -  Tumor sample must be available for analysis of PDL1 (Programmed death-ligand 1) and HPV [Human Papilloma Virus (oropharynx only)]  -  Performance status ECOG 0-1 (Eastern Cooperative Oncology Group)@@ADULTS@Phase 2@II@@@@@@@@@COMBO@NIVOLUMAB@IPILIMUMAB@@@@NIVOLUMAB|IPILIMUMAB|||@BRISTOL-MYERS SQUIBB@@@@@BRISTOL-MYERS SQUIBB||||@World@@@@@World|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@OPDIVO@YERVOY@@@@OPDIVO|YERVOY|||@PD-1 Inhibitor@@@@@PD-1 Inhibitor||||@Overall response rate (ORR) in platinum refractory subgroup@@@@@ORR in platinum eligible subgroup@Progression Free Survival (PFS) in platinum eligible and refractory subgroups@@@@RECURRENT@METASTATIC@@@@RANDOMIZED@Efficacy Study@PARALLEL ASSIGNMENT@Double Blind (Subject,  Investigator)@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14920844@Onco@@@@@300f1020ntsdm@@@@@@NO LABELLED TRIAL@@-@-@YES@NEW YORK, NEW YORK@@@Etoposide is a semisynthetic derivative of podophyllotoxin used in the treatment of certain neoplastic diseases. Podophyllotoxins inhibit mitosis by blocking microtubular assembly. Etoposide inhibits cell cycle progression at a premitotic phase (late S and G2). It does not interfere with the synthesis of nucleinic acids.@@14920844@Etoposide is indicated for the management of - testicular tumours in combination with other chemotherapeutic agents - small cell lung cancer, in combination with other chemotherapeutic agents - monoblastic leukaemia (AML M5) and acute myelomonoblastic leukaemia (AML M4) when standard therapy has failed (in combination with other chemotherapeutic agents).@@NO@-@@NO REVIEW@@@@0%@-@-@-@-@Eposin, concentrate for solution for infusion 20 mg/ml must be diluted immediately prior to use with either 5 % dextrose in water, or 0.9 % sodium chloride solution to give a final concentration of 0.2 to 0.4 mg/ml. At higher concentrations precipitation of etoposide may occur. The usual dose of etoposide, in combination with other approved chemotherapeutic agents, ranges from 100-120 mg/m²/day via continuous infusion over 30 minutes for 3-5 days, followed by a resting period of 10-20 days. Generally 3 to 4 chemotherapy cycles are administered.@N/A@@@-@@@Patients being treated with VePesid must be frequently observed for myelosuppression both during and after therapy. Myelosuppression resulting in death has been reported. Dose-limiting bone marrow suppression is the most significant toxicity associated with VePesid therapy. Therefore, the following studies should be obtained at the start of therapy and prior to each subsequent cycle of VePesid: platelet count, haemoglobin, white blood cell count, and differential. The occurrence of a platelet count below 50,000/mm3 or an absolute neutrophil count below 500/mm3 is an indication to withhold further therapy until the blood counts have sufficiently recovered.@NO LABELLED TRIAL@@-@-@@@-@APPROVED@@@@NO LABELLED TRIAL@-@@@@-@ETOPOSIDE PHOSPHATE@@@@@ETOPOSIDE PHOSPHATE||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Testicular Cancer@SCLC@Haematological Malignancy@Acute Myeloid Leukaemia@@Testicular Cancer|SCLC|Haematological Malignancy|Acute Myeloid Leukaemia||||||@LASTET@@@@@LASTET||||@Plant Alkaloid@Topoisomerase II Inhibitor@@@@Plant Alkaloid|Topoisomerase II Inhibitor|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@@@@@10@1.1229@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@CAPSULE@EURO@@@@@@@@100@MG@100 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
16643797@Onco@@@@@@@@@@@pembrolizumab + BSC, Experimental, Participants receive pembrolizumab by intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus BSC.placebo + BSC, Placebo Comparator, Participants receive placebo by intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus BSC.@@L01XC18@L01X@@WHITEHOUSE STATION, NEW JERSEY@9/1/2019@@@@16643797@A Phase III Randomized Double-blind Study of Pembrolizumab Plus Best Supportive Care vs. Placebo Plus Best Supportive Care as Second-Line Therapy in Asian Subjects With Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-394)@Both@@@@@Administered as an intravenous (IV) infusion every 3 weeks (Q3W)@@@@@SECOND-LINE@NCT03062358@330@@@@@@@3/1/2017@@3475-394@@@Has a HCC diagnosis confirmed by radiology, histology, or cytology (fibrolamellar, and mixed hepatocellular/cholangiocarcinoma subtypes are not eligible)  -  Has Barcelona Clinic Liver Cancer (BCLC) Stage C disease or BCLC Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy and not amenable to a curative treatment approach  -  Has a Child-Pugh A liver score within 7 days prior to first dose of study medication  -  Has a life expectancy of >3 months  -  Has at least one measurable lesion based on RECIST version 1.1 as determined by investigator  -  Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 performed within 7 days prior to receiving the first dose of study medication  -  Has documented objective radiographic progression during or after treatment with sorafenib or oxaliplatin-based chemotherapy, or else intolerance to sorafenib or oxaliplatin-based chemotherapy  -  Female participants of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study therapy  -  Female and male participants of reproductive potential must agree to use adequate contraception starting from the first dose of study medication, throughout the study period, and for up to 120 days after the last dose of study medication@@ADULTS@Phase 3@III@@@@@@@@@COMBO@PEMBROLIZUMAB@BEST SUPPORTIVE CARE@@@@PEMBROLIZUMAB|BEST SUPPORTIVE CARE|||@MERCK & CO@@@@@MERCK & CO||||@@@@@@|||||||||@Liver Cancer@Hepatocellular Carcinoma@@@@Liver Cancer|Hepatocellular Carcinoma||||||||@KEYTRUDA@@@@@KEYTRUDA||||@PD-1 Inhibitor@@@@@PD-1 Inhibitor||||@Overall Survival (OS)@@@@@Progression Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR)@Objective Response Rate (ORR) per RECIST 1.1 by BICR@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14919818@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@M05BA03@M05B@NO@MUMBAI, INDIA@@@Pamidronate disodium is a potent inhibitor of osteoclastic bone resorption. It binds strongly to hydroxyapatite crystals and inhibits the formation and dissolution of these crystals in vitro. Inhibition of osteoclastic bone resorption in vivo may be at least partly due to binding of the drug to the bone mineral. Pamidronate suppresses the accession of osteoclast precursors onto the bone. However, the local and direct antiresorptive effect of bone-bound bisphosphonate appears to be the predominant mode of action in vitro and in vivo. Experimental studies have demonstrated that pamidronate inhibits tumour-induced osteolysis when given prior to or at the time of inoculation or transplantation with tumour cells. Biochemical changes reflecting the inhibitory effect of Aredia on tumour-induced hypercalcaemia, are characterised by a decrease in serum calcium and phosphate and secondarily by decreases in urinary excretion of calcium, phosphate, and hydroxyproline.@@14919818@Treatment of conditions associated with increased osteoclast activity - Tumour-induced hypercalcaemia - Osteolytic lesions in patients with bone metastases associated with breast cancer - Multiple myeloma stage III@@NO@@@NO REVIEW@@@@100%@@@@@Osteolytic lesions and bone pain in multiple myeloma - The recommended dose is 90 mg every 4 weeks. Osteolytic lesions and bone pain in bone metastases associated with breast cancer - The recommended dose is 90 mg every 4 weeks. This dose may also be administered at 3 weekly intervals to coincide with chemotherapy if desired.@EMA, April 2004@@@@@@Pamidronate should never be given as a bolus injection since severe local reactions and thrombophlebitis may occur. It should always be diluted and then given as a slow intravenous infusion. It should not be co-administered with other bisphosphonates. If other calcium lowering agents are used in conjunction with pamidronate, significant hypocalcaemia may result. Convulsions have been precipitated in some patients with tumour-induced hypercalcaemia due to the electrolyte changes associated with this condition and its effective treatment.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@PAMIDRONATE DISODIUM@@@@@PAMIDRONATE DISODIUM||||@WOCKHARDT@@@@@WOCKHARDT||||@@@@@@|||||||||@Supportive Care@Breast Cancer@Haematological Malignancy@Myeloma@Bone Metastases@Supportive Care|Breast Cancer|Haematological Malignancy|Myeloma|Bone Metastases|||||@GENERIC@@@@@GENERIC||||@Bisphosphonate@@@@@Bisphosphonate||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@4@1.299@104.41@@119.32@@@@@@@@@@1.74@@@@@@@@@@@@@@@@7/28/2017@26.1@26.1@9.47E+15@SOLUTION FOR INFUSION, AMPOULE - 1 ML@GB£@@@@@@@@15@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14918747@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Erbitux versus best supportive care.@@L01XC06@L01X@-@NEW YORK, NEW YORK@@@Erbitux is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Cetuximab is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions and has an approximate molecular weight of 152 kDa. Cetuximab is produced in mammalian (murine myeloma) cell culture.@@14918747@Refractory mCRC@@-@-@@NO REVIEW@@@@-@>> Acquisition completed. [Lilly, 24.11.2008]         >> Lilly acquires ImClone for US$6.5 billion. [Lilly, 7.10.2008]       >> BMS Offers US$4.3Billion for ImClone or US$60.0 per share in cash. [BMS, 1 August 2008]     >> ImClone licensed co-development and co-promotion rights to BMS in North America and Japan, and to Merck KGaA in Europe.@SECOND-LINE@-@572@-@-@@@-@@@-@NCIC CTG CO.17@@CURRENTLY IN DISPUTE; IMCLONE LOST PROCESS PATENT, EXPIRING IN 2017, TO YEDA IN 2006.@-@-@@III@III@@-@-@ASCO June 2007; NEJM November 2007; significantly improved OS and QoL versus patients on BSC. Additional Phase III data showed that median overall survival among 572 chemotherapy-refractory patients who received Erbitux + BSC was 6.1 months vs 4.6 months for BSC only. Erbitux patients also showed a significant improvement in PFS vs BSC alone. Partial responses were seen in 23 Erbitux patients, while no responses were observed in the BSC group.@-@@@@MONO@CETUXIMAB@@@@@CETUXIMAB||||@BMS@IMCLONE@@@@BMS|IMCLONE|||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ERBITUX@@@@@ERBITUX||||@mAb@Chimeric@TK Inhibitor@EGFR@@mAb|Chimeric|TK Inhibitor|EGFR|@OVERALL SURVIVAL@QUALITY OF LIFE@PROGRESSION-FREE SURVIVAL@@@PROGRESSION-FREE SURVIVAL@@@@@REFRACTORY@METASTATIC@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924496@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@0.16 or 0.64 mg/kg of subcutaneous IMO-2055 once weekly@@-@-@-@DARMSTADT, GERMANY@@@IMO-2055 is designed to act as an agonist of TLR9 and has demonstrated activity as an immune modulator in preclinical models, both in vitro and in vivo.   IMO-2055 anticancer activity has been observed in preclinical mouse models when administered as a single agent.  IMO-2055 also has shown potentiation of anticancer activity when administered in combinations with certain chemotherapeutic agents, antibodies, and newer biologically targeted agents approved for use in cancer therapy.@@14924496@Renal cell carcinoma@@-@-@@NO REVIEW@@@@-@Merck Serono licensed exclusive global development and marketing rights for IMO-2055 and IMO-2125 in exchange for US$40 mil. Upfront and up to US$381 mil in regulatory milestones and royalties. SOURCE: Idera, 19 December 2007@-@-@91@-@-@@@-@@@-@-@@-@91 patients, treatment-naïve and second-line@@@II@II@@-@-@>> The primary objective was not achieved in the study. Median progression-free survival for each of the four arms was 2 months, 3 months, 4 months, and 4 months. The Company expects to present detailed study results at a future scientific conference. [Idera, 1.10.2008]     >> Phase II data expected early 2008@IMO-2055 treatment was generally well-tolerated with good dose intensity in all arms of the trial. The most common adverse events were mild to moderate and included chills, fatigue, nausea, pyrexia, headache, myalgia, and vomiting. These flu-like symptoms were expected based on the immune stimulatory mechanism of action of IMO-2055. @@@@MONO@IMOXINE@@@@@IMOXINE||||@MERCK SERONO@IDERA PHARMACEUTICALS@@@@MERCK SERONO|IDERA PHARMACEUTICALS|||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@IMO-2055@@@@@IMO-2055||||@TLR-targeted@@@@@TLR-targeted||||@RECIST@SAFETY@TIME TO PROGRESSION@@@TIME TO PROGRESSION@@@@@-@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920081@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01XX19@L01X@YES@PETACH TIKVA, ISRAEL@@@Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks.@@14920081@Camptosar is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. It is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.@@NO@@@NO REVIEW@@@@@@SECOND-LINE@@@Once-every-3 week regimen: 350mg/m2 IV over 90 minutes, once every 3 weeks@FDA, 28 February 2008@2/28/2008@@@@@Can induce both early and late forms of diarrhea. Both forms of diarrhea may be severe. Early diarrhea (occurring during or shortly after infusion may be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping. Late diarrhea (generally occurring more than 24 hours after administration) can be life threatening since it may be prolonged and may lead to dehydration, electrolyte imbalance, or sepsis. Patients with diarrhea should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated or antibiotic therapy if they develop ileus, fever, or severe neutropenia. Severe myelosuppression may also occur.@LABEL@No@@@@@@APPROVED@@Covered; part B; specialty drug@MEDICARE@@@@@@MONO@IRINOTECAN@@@@@IRINOTECAN||||@TEVA PHARMACEUTICAL@@@@@TEVA PHARMACEUTICAL||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@@@@@@@@@@@ADVANCED@@@@@@@@@@1.75@m²@1221.31646@@@3.9@month@3.9 month@1221.32@1221.32@10.3@1@1@35.3@@@@@@@@@@@@0.35@21@@mg/m²@350@1@@@@@@@@@@@8/2/2017@35.3@35.3@00703-4434-11@INJECTION - 5 ML@US$@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922579@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Decitabine versus observation or standard chemo as maintenance therapy@@-@-@-@TOKYO, JAPAN@@@Dacogen was approved by the U.S. Food and Drug Administration on May 2, 2006 and is indicated for the treatment of patients with MDS, including previously treated and untreated, de novo and secondary MDS of all French-American-British (FAB) subtypes (refractory anemia, refractory anemia with rings sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, chronic myelomonocytic leukemia), and Intermediate-1, Intermediate-2, and High-Risk International Prognostic Scoring System (IPSS) groups.@@14922579@Maintenance therapy in adults with unfavourable risk AML in first complete remission or with relapsed AML in second or greater complete remission@@-@-@@NO REVIEW@@@@-@Dacogen for Injection was developed through a pivotal Phase 3 study by SuperGen and partnered to MGI  (acquired by Eisai Co., Ltd.). MGI subsequently sublicensed all Dacogen rights outside of North America to Janssen-Cilag, a Johnson & Johnson Company.@SECOND-LINE@NCT00398983@100@-@-@@@-@@4/1/2006@-@2006-0358@@-@-@@@II/III@III@@-@-@RESULTS PENDING@-@@@@MONO@DECITABINE@@@@@DECITABINE||||@EISAI@MGI PHARMA@SUPERGEN@@@EISAI|MGI PHARMA|SUPERGEN||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@DACOGEN@@@@@DACOGEN||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@RELAPSE-FREE SURVIVAL@@@@@@@@@@RELAPSED@REFRACTORY@@@@RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@FACTORIAL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916522@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Satraplatin with paclitaxel@@-@-@-@MUNICH, GERMANY@6/1/2007@@Satraplatin, an investigational drug, is a member of the platinum family of compounds. Platinum-based drugs are a critical part of modern chemotherapy treatments and are used to treat a wide variety of cancers. All platinum drugs currently on the market require intravenous administration. Satraplatin is an oral compound that clinical trial patients are able to take at home. Satraplatin is being studied in several cancer types and combinations. In clinical trials conducted by GPC Biotech and others, satraplatin has shown activity in prostate, lung and ovarian cancer.@@14916522@Stage III/IV NSCLC@@-@-@@NO REVIEW@@@@-@Celgene terminated its co-development and license agreement with GPC Biotech for satraplatin in Europe, Turkey, the Middle East, Australia and New Zealand. All rights to these territories will be returned to GPC Biotech. SOURCE: GPC, 6 August 2008GPC licensed rights from Spectrum; GPC then sold European rights Pharmion; Japanese rights licensed from GPC by Yakult Honsha in June 2007 for US$10 million (at least 21% royalties). After a dispute between GPC and Spectrum, an arbitration panel concluded@FIRST-LINE@NCT00268970@40@-@-@@@-@@12/1/2005@-@SAT2-05-05@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@SATRAPLATIN@PACLITAXEL@@@@SATRAPLATIN|PACLITAXEL|||@GPC BIOTECH@SPECTRUM@@@@GPC BIOTECH|SPECTRUM|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@ORPLATNA@@@@@ORPLATNA||||@Platinum@@@@@Platinum||||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920856@Onco@@@@@300f1020ntsdm@@@@@@NO LABELLED TRIAL@@V03AF04@V03A@NO@MADISON, NEW JERSEY@@@Calcium folinate is the calcium salt of 5-formyl tetrahydrofolic acid. It is an active metabolite of folinic acid and an essential coenzyme for nucleic acid synthesis in cytotoxic therapy. Calcium folinate is frequently used to diminish the toxicity and counteract the action of folate antagonists, such as methotrexate. Calcium folinate and folate antagonists share the same membrane transport carrier and compete for transport into cells, stimulating folate antagonist efflux. It also protects cells from the effects of folate antagonist by repletion of the reduce folate pool. Calcium folinate serves as a pre-reduced source of H4 folate; it can therefore bypass folate antagonist blockage and provide a source for the various coenzyme forms of folic acid.@@14920856@Calcium folinate is indicated to diminish the toxicity and counteract the action of folic acid antagonists such as methotrexate in cytotoxic therapy and overdose in adults and children. In cytotoxic therapy, this procedure is commonly known as “Calcium Folinate Rescue”; also, in combination with 5-fluorouracil in cytotoxic therapy.@@NO@-@@NO REVIEW@@@@0%@Pfizer acquired Wyeth on 26 January 2009 in a deal worth U.S $68 billion [Pfizer 26.01.2009]@-@-@-@Advanced Colorectal Cancer: Either of the following two regimens is recommended: 1. Leucovorin is administered at 200 mg/m2 by slow intravenous injection over a minimum of 3 minutes, followed by 5-fluorouracil at 370 mg/m2 by intravenous injection. 2. Leucovorin is administered at 20 mg/m2 by intravenous injection followed by 5-fluorouracil at 425 mg/m2 by intravenous injection.@N/A@@@-@@@In the treatment of accidental overdosages of folic acid antagonists, intravenous leucovorin should be administered as promptly as possible. As the time interval between antifolate administration (e.g., methotrexate) and leucovorin rescue increases, leucovorin's effectiveness in counteracting toxicity decreases. In the treatment of accidental overdosages of intrathecally adminstered folic acid antagonists, do not adminster leucovorin intrathecally. Leucovorin may be fatal if given intrathecally. Monitoring of the serum methotrexate concentration is essential in determining the optimal dose and duration of treatment with leucovorin.@NO LABELLED TRIAL@No@-@-@@@-@APPROVED@@@@NO LABELLED TRIAL@-@@@@-@LEUCOVORIN CALCIUM@@@@@LEUCOVORIN CALCIUM||||@WYETH@PFIZER@@@@WYETH|PFIZER|||@@@@@@|||||||||@Sarcoma@Supportive Care@Colorectal Cancer@@@Sarcoma|Supportive Care|Colorectal Cancer|||||||@LEDERFOLIN@@@@@LEDERFOLIN||||@Detoxifying Agent@@@@@Detoxifying Agent||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1229@5.73@9.4@5.99@@@@@@@@@@0.23@@@@@@@@@@@@@@@@6/7/2017@5.73@5.73@24659120@INJECTABLE PREPARATION@EURO@@@@@@@@25@MG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14922634@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@SEATTLE, WASHINGTON@@@@@14922634@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@FDA agreed to amend SPA to accelerate the expected timing of final IMPACT results by one year (H2 2009 instead of 2010) - it will accept positive interim or final analysis from the trial to amend the BLA. SOURCE: Dendreon press release, 12 March 2008RECEIVED AN FDA SPA IN JUNE 2003 FOR THE TRIAL. THIS WILL BE USED TO REPLY TO FDA APPROVABLE LETTER.@3/12/2008@@-@@@-@2000-2@@-@-@@@-@I@@-@-@>> A total of 37 patients were treated. The median T cell proliferative stimulation index in response to the immunizing antigen increased from 1.3 at baseline to 19.7 at Week 4 (p=0.0002), 19.4 at Week 8 (p<0.0001) and 20.7 at Week 16 (p=0.02). Immune monitoring performed in three of four patients who underwent repeat treatment suggested an increase in immune response following the booster treatments. Five patients had prolonged disease stabilization ranging from 48 to 94 weeks, without the addition of other cancer therapy other than the continuation of bisphosphonates. In addition, one patient experienced a partial response lasting approximately six months. [Dendreon, 6.11.2008]           >> APC-8024 induced immune reaction against tumours; 2 of 11 breast cancer patients had disease stabilisation for nearly a year after other treatment failure. [Dendreon, 14 April 2008]@Results from the integrated analysis showed that treatment was generally well tolerated. The majority of side effects were mild, including infusion-related fatigue, fever and chills. @@@@-@LAPALEUCEL-T@@@@@LAPALEUCEL-T||||@DENDREON@@@@@DENDREON||||@@@@@@|||||||||@Breast Cancer@Ovarian Cancer@Colorectal Cancer@@@Breast Cancer|Ovarian Cancer|Colorectal Cancer|||||||@APC-8024@NEUVENGE@@@@APC-8024|NEUVENGE|||@Vaccine@Immunotherapy@@@@Vaccine|Immunotherapy|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16643803@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01XE25@L01X@@BASEL, SWITZERLAND@@@Trametinib is a reversible, highly selective, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and kinase activity. MEK proteins are components of the extracellular signal-related kinase (ERK) pathway. In melanoma and other cancers, this pathway is often activated by mutated forms of BRAF which activates MEK. Trametinib inhibits activation of MEK by BRAF and inhibits MEK kinase activity. Trametinib inhibits growth of BRAF V600 mutant melanoma cell lines and demonstrates anti-tumour effects in BRAFV600 mutant melanoma animal models.@@16643803@MEKINIST, in combination with dabrafenib, is Treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.@Both@NA@@@NO REVIEW@@@@@@@@162@2 mg orally once daily until disease progression or unacceptable toxicity.@FDA, 8 January 2014@1/8/2014@@Yes@@@@@No@@@BRAF V600 or V600K mutation@ADULTS@@APPROVED@@@@@@@@@COMBO@TRAMETINIB@DABRAFENIB@@@@TRAMETINIB|DABRAFENIB|||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@MEKINIST@TAFINLAR@@@@MEKINIST|TAFINLAR|||@MEK Inhibitor@@@@@MEK Inhibitor||||@OVERALL RESPONSE RATE@@@@@DURATION OF RESPONSE@@@@@UNRESECTABLE@METASTATIC@@@@RANDOMISED@@@@@1@1@148729.3936@@@14@month@14 month@148729.39@148729.39@349.27@30@1@10478.23@@@@@@@@@@@@174.64@1@@mg@2@1@@@@@@@@@@@8/2/2017@349.27@349.27@00078-0668-15@FILM-COATED TABLET (BOTTLE)@US$@@@@@@@@2@MG@2 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14923954@Onco@@@@@300f1014ntsdm@@@@@@Patients given Trelstar or an approved GnRH agonist@@L02AE04@L02A@NO@@@@Triptorelin is a decapeptide analogue of GnRH which initially stimulates release of pituitary gonadotrophins.@@14923954@Indicated in the palliative treatment of advanced prostate cancer. It offers an alternative treatment for prostate cancer when orchiectomy or estrogen administration are either not indicated or unacceptable to the patient.@@EXPENSIVE ITEM APPENDIX III (LIMITED WHOLESALE MARGIN)@@@NO REVIEW@@@@No tiering. SOURCE: Aetna Preferred Drug Guide 2008@Ipsen exclusively in-licensed from Debiopharm know-how and new patent applications for the commercialisation rights of Decapeptyl in the world excluding North America, and some other countries (Sweden, Israel, Iran and Japan). [Ipsen, 31 October 2007]@@@227@The recommended dose is 3.75 mg incorporated in a depot formulation and is administered monthly as a single intramuscular injection.@1-Jun-00@6/1/2000@@@@@Initially, triptorelin, like other LHRH agonists, causes a transient increase in serum testosterone levels. As a result, isolated cases of worsening of signs and symptoms of prostate cancer during the first weeks of treatment have been reported with LHRH agonists. Patients may experience worsening of symptoms or onset of new symptoms, including bone pain, neuropathy, hematuria, or urethral or bladder outlet obstruction. Cases of spinal cord compression, which may contribute to paralysis with or without fatal complications, have been reported with LHRH agonists. If spinal cord compression or renal impairment develops, standard treatment of these complications should be instituted, and in extreme cases an immediate orchiectomy considered.@LABEL@No@@@@@III; ADVANCED PROSTATE CANCER@APPROVED@@@RAMQ@Primary endpoints achieved: castration reached by Day 29 and maintenance of castration from Day 57 to Day 253@@@@@MONO@TRIPTORELIN PAMOATE@@@@@TRIPTORELIN PAMOATE||||@PALADIN@@@@@PALADIN||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@TRELSTAR@@@@@TRELSTAR||||@LH-RH Analog@@@@@LH-RH Analog||||@SERUM TESTOSTERONE@@@@@@@@@@ADVANCED@@@@@RANDOMISED@ACTIVE CONTROL@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@0.7881@304.43@@@@@@@@@@@@81.18@@@@@@@@@@@@@@@@7/19/2017@304.43@304.43@22400001@POWDER FOR SUSPENSION, SUSTAINED-RELEASE@C$@@@@@@@@3.75@MG@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14919170@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NO LABELLED TRIAL@@J06BB04@J06B@YES@DEERFIELD, ILLINOIS@@@@@14919170@Indicated for prevention of bacterial infections in patients with hypogammaglobulinemia and/or recurrent bacterial infections associated with B-cell Chronic Lymphocytic Leukemia (CCL), for the prevention of coronary artery aneurysms associated with Kawasaki Syndrome and to induce rapid rise in platelet count when needed to prevent and/or to control bleeding in a patient with Idiopathic Thrombocytopenic Purpura (ITP).@@@@@NO REVIEW@@@@@@@@@B-cell CLL: For patients with hypogammaglobulinemia and/or recurrent bacterial infections due to B-cell CLL, a dose of 400 mg/kg every 3 to 4 weeks is recommended.@FDA, May 2005@@@@@@Immune Globulin Intravenous (Human) products have been reported to be associated with renal dysfunction, acute renal failure, osmotic nephrosis, and death.18 Patients predisposed to acute renal failure include patients with any degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Especially in such patients, IGIV products should be administered at the minimum concentration available and the minimum rate of infusion practicable. While these reports of renal dysfunction and acute renal failure have been associated with the use of many of the licensed IGIV products, those containing sucrose as a stabilizer accounted for a disproportionate share of the total number.@NO LABELLED TRIAL@No@N/A@@@@@APPROVED@@@MEDICARE@NO LABELLED TRIAL@@@@@@IMMUNOGLOBULIN (HUMAN)@@@@@IMMUNOGLOBULIN (HUMAN)||||@BAXTER HEALTHCARE@@@@@BAXTER HEALTHCARE||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@B-Cell Lymphoma@Supportive Care@@Haematological Malignancy|Chronic Lymphocytic Leukaemia|B-Cell Lymphoma|Supportive Care||||||@GAMMAGARD S/D@@@@@GAMMAGARD S/D||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1@326.53@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/2/2017@326.53@326.53@00944-2620-02@POWDER FOR INJECTION@US$@@@@@@@@2.5@G@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14923377@Onco@@@@@300f1012ntsdm@@@@@@Tamoxifen compared to ovarian ablation@@L02BA01@L02B@YES@GERMANY@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14923377@@@NO@@@NO REVIEW@@@@@@@@N/A@Adjuvant treatment of breast cancer, Adults (including elderly): The recommended dose is 20mg, given either in divided doses twice daily or as a single dose once daily. The current recommended treatment duration is five years; however the optimum duration has not been established. Treatment of locally advanced or metastatic breast cancer: The recommended dose is 20mg to 40mg, given either in divided doses twice daily or as a single dose once daily.@@@@@@@Women should be informed of the potential risks to the foetus, should they become pregnant whilst taking tamoxifen; or within two months of cessation of therapy. A number of secondary primary tumours, occurring at sites other than the endometrium and the opposite breast, have been reported in clinical trials, following the treatment of breast cancer patients with tamoxifen. No causal link has been established and the clinical significance of these observations remains unclear.@LABEL@No@@@@@III METASTATIC BREAST CANCER@APPROVED@@@GKV@The objective RR, time to treatment failure, and survival were similar with both treatments. In an overview analysis of survival data from the 3 studies, the hazard ratio for death (tamoxifen/ovarian ablation) was 1.00. Elevated serum and plasma oestrogens have been observed in premenopausal women receiving tamoxifen, but the data from the randomized studies do not suggest an adverse effect of this increase. A limited number of premenopausal patients with disease progression during tamoxifen therapy responded to subsequent ovarian ablation.@@@@@ADJUVANT@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@1 A PHARMA@@@@@1 A PHARMA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@TAMOX@@@@@TAMOX||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RESPONSE RATE@@@@@@@@@@@@@@@PROSPECTIVE@RANDOMISED@@@@@@Invalid Factory Price@@@@@@@@@120@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@EURO@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14916437@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Weekly Tocosol@@-@-@-@-@5/1/2003@@Tocosol Paclitaxel was previously developed by Sonus Pharmaceuticals prior to the combination of Sonus and OncoGenex Technologies to form the Company on August 21, 2008. They were evaluating alternative strategies for the program, including out-licensing, ahead of the Eagle partnership.@@14916437@Stage III/IV platinum-resistant ovarian cancer or primary peritoneal carcinoma@@-@-@@NO REVIEW@@@@-@>OncoGenex grants Eagle exclusive rights to develop and commercialise Tocosol in exchange for royalties and a percentage of sub-licensing royalty and milestones payments. All development expenses will be held by Eagle; no upfront payments were made. [OncoGenex, 02.09.2008]>Sonus and OncoGenex to merge, with the combined company operating as OncoGenex Pharmaceuticals. [OncoGenex/Sonus, 28.05.2008]>Sonus signed an agreement with Schering AG granting it an exclusive worldwide license to Tocosol. Schering made approximately a 15% equity investment in Sonus, which also received an upfront fee, milestone payments and royalties. [Sonus, October 2005]@-@NCT00034151@-@-@-@@@-@@3/1/2002@-@SON-8184-1061@@-@-@@@II@DISCONTINUED@@-@-@Discontinued in September 2007 after failure of pivotal breast cancer trial.@-@@@@MONO@PACLITAXEL, VITAMIN E-BASED @@@@@PACLITAXEL, VITAMIN E-BASED ||||@EAGLE PHARMACEUTICALS@@@@@EAGLE PHARMACEUTICALS||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@TOCOSOL@@@@@TOCOSOL||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@RESPONSE RATE@TIME TO PROGRESSION@DURATION OF RESPONSE@OVERALL SURVIVAL@@DURATION OF RESPONSE@OVERALL SURVIVAL@@@@REFRACTORY@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16671828@Onco@@@@@300f1015ntsdm@@@@@@@@L01XC06@L01X@@NEW YORK, NEW YORK@@@Erbitux is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Cetuximab is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions and has an approximate molecular weight of 152 kDa. Cetuximab is produced in mammalian (murine myeloma) cell culture.@@16671828@Treatment of patients with epidermal growth factor receptor (EGFR)-expressing, KRAS wild-type metastatic colorectal cancer in combination with FOLFOX4@Both@YES@@@@@@@@>> Acquisition completed. [Lilly, 24.11.2008]          >> Lilly acquires ImClone for US$6.5 billion. [Lilly, 7.10.2008]        >> BMS Offers US$4.3Billion for ImClone or US$60.0 per share in cash. [BMS, 1 August 2008]      >> ImClone licensed co-development and co-promotion rights to BMS in North America and Japan, and to Merck KGaA in Europe.@@@337@@EMA, 23 June 2011@6/23/2011@@No@@@@EMR 62 202-047@No@@@(EGFR)-expressing, KRAS WILD-TYPE@ADULTS@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@@@@@@COMBO@CETUXIMAB@OXALIPLATINE@LEUCOVORIN@5-FLOUROURACIL@@CETUXIMAB|OXALIPLATINE|LEUCOVORIN|5-FLOUROURACIL|@BMS@IMCLONE@MERCK SERONO@@@BMS|IMCLONE|MERCK SERONO||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ERBITUX@FOLFOX4@@@@ERBITUX|FOLFOX4|||@mAb@Chimeric@TK Inhibitor@EGFR@@mAb|Chimeric|TK Inhibitor|EGFR|@@@@@@@@@@@METASTATIC@@@@@@@@@@1.75@m²@48225.705@@@12@month@12 month@48225.71@48225.71@132.13@1@1.1511@209@@@@@@@@@@@@2.09@7@1@mg/m²@400@1@7@@mg/m²@250@1@@@@@@8/2/2017@209@209@9260599T@SOLUTION FOR PERFUSION  50 ML@EURO@@@@@@@@100@MG@2 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@85@France
14922561@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@RAD001 30 mg PO Weekly x 4 Weeks with erlotinib 150 mg PO Daily x 28 Days@@-@-@-@BASEL, SWITZERLAND@3/1/2009@@The active substance in Afinitor, everolimus, is an anticancer medicine, which acts by blocking a protein called ‘mammalian target of rapamycin' (mTOR). In the body, everolimus attaches to a protein that is found inside cells to make a ‘complex'. This complex then blocks mTOR. Since mTOR is involved in the control of cell division and the growth of blood vessels, Afinitor prevents the division of cancer cells and reduces their blood supply. This slows down the growth and spread of kidney cancer.@@14922561@-@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00640978@40@-@-@@@EMEA issued positive opinion to grant Orphan Drug status for everolimus to treat neuroendocrine gastroenteropancreatic tumours@@3/1/2008@-@2007-0666@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@EVEROLIMUS@ERLOTINIB@@@@EVEROLIMUS|ERLOTINIB|||@NOVARTIS@GENENTECH@@@@NOVARTIS|GENENTECH|||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@AFINITOR@RAD-001@TARCEVA@@@AFINITOR|RAD-001|TARCEVA||@Immunotherapy@Immunosuppressive@mTOR Inhibitor@@@Immunotherapy|Immunosuppressive|mTOR Inhibitor||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16668385@Onco@@@@@300f1015ntsdm@@@@@@Ibrutinib: 420 mg daily or 840 mg daily@@L01XE27@L01X@@BEERSE, BELGIUM@6/1/2013@@Ibrutinib was designed to specifically target and selectively inhibit an enzyme called Bruton's tyrosine kinase (BTK). BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel – regulating apoptosis, adhesion, and cell migration and homing. Through these multiple actions, BTK helps to direct malignant B-cells to lymphoid tissues, thus allowing access to a microenvironment necessary for survival.@@16668385@Indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy,@@YES@17-Jun-15@6/17/2015@NO REVIEW@@@@@@SECOND-LINE@NCT01105247@133@420 mg taken orally once daily (three 140 mg capsules once daily)@EMA, 21 October 2014@10/21/2014@11/21/2014@Yes@@4/1/2010@@PCYC-1102-CA@No@@@@@II@APPROVED@@17 June 2015: ASMR III. IMBRUVICA in monotherapy, like ZYDELIG in combination with rituximab, provides moderate clinical addedvalue** (CAV III) in the therapeutic strategy for adult patients with CLL who have received at least one priortreatment [http://www.has-sante.fr/portail/upload/docs/application/pdf/2016-10/imbruvica_summary_ct14012.pdf]@HAUTE AUTORITÉ DE SANTÉ@@@@@@MONO@IBRUTINIB@@@@@IBRUTINIB||||@JANSSEN PHARMACEUTICAL@@@@@JANSSEN PHARMACEUTICAL||||@@@@@@|||||||||@Chronic Lymphocytic Leukaemia@@@@@Chronic Lymphocytic Leukaemia|||||||||@IMBRUVICA@@@@@IMBRUVICA||||@TK Inhibitor@@@@@TK Inhibitor||||@SAFETY@@@@@PROGRESSION-FREE SURVIVAL@RESPONSE RATE@@@@@@@@@OPEN-LABEL@NON-RANDOMISED@SINGLE GROUP ASSIGNMENT@@@1@1@Invalid Factory Price@@@9@month@9 month@@@@120@1.1511@@@@@@@@@@@@@@1@@mg@420@1@@@@@@@@@@@@@@3.40E+12@CAPSULE@EURO@@@@@@@@140@MG@140 MG@@@@@@@@@@@@@@@@@@@@@@@@85@France
14916472@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@MP470 in combination with several standard of care chemotherapy regimens, including carboplatin/paclitaxel, carboplatin/etoposide, docetaxel, topotecan, and erlotinib.@@-@-@-@-@@@MP-470 is an oral, selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET and the mutant forms of c-KIT, PDGFR and FLT3. MP470 also suppresses Rad51 protein, a critical component of double-stranded DNA repair in cancer cells. Preclinical testing of MP-470 has identified anti- tumor activity against a wide spectrum of cancers.@@14916472@-@@-@-@@NO REVIEW@@@@-@-@MULTIPLE@NCT00602875@105@-@-@@@FDA granted orphan drug despigantion for GBM. SOURCE: Supergen, 7 August 2008@@12/1/2007@-@SGI-0470-02@@-@105 chemotherapy-naïve or experienced patients@@@IB@I@@-@-@MP-470 can be safely adminsitered in doses of up to 900MG per day; Rad51 expression is modulated in dose-dependent manner. SOURCE: Supergen/AACR, 15 April 2008First-patient in December 2007. SOURCE: Supergen, 17 December 2007@-@@@@COMBO@-@@@@@-||||@SUPERGEN@@@@@SUPERGEN||||@@@@@@|||||||||@Sarcoma@GIST@@@@Sarcoma|GIST||||||||@MP-470@@@@@MP-470||||@TK Inhibitor@@@@@TK Inhibitor||||@SAFETY@TOLERABILITY@MAXIMUM TOLERATED DOSE@BIOMARKER ASSESSMENTS@@MAXIMUM TOLERATED DOSE@BIOMARKER@@@@-@@@@@OPEN-LABEL@DOSE ESCALATION@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916059@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Single-agent pazopanib@@-@-@-@BRENTFORD, UNITED KINGDOM@@@Pazopanib is an investigational, oral, once-daily angiogenesis inhibitor targeting vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and c-kit. VEGF and PDGF are growth factors critical to the development and growth of blood vessels - a process known as angiogenesis. Angiogenesis plays a pivotal role in the growth and spread of several tumour types, with VEGF and PDGF overexpression linked to multiple cancers including cancers of the liver, lung, breast, kidney, bladder, ovaries, and colon. By inhibiting VEGFR, PDGFR, and c-kit pazopanib may stop or slow the rate of tumour growth and development. Pazopanib is currently being studied in a number of different tumour types; clinical trials are currently underway in renal cell carcinoma (Phase III), breast cancer (Phase III in inflammatory breast cancer), ovarian cancer, STS, NSCLC, cervical cancer and other solid tumours. It is being evaluated as a monotherapy, in combination with targeted therapies and in combination with cytotoxic chemotherapy. @@14916059@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00256880@100@-@-@@@-@@1/1/2005@-@VEG20006@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@PAZOPANIB@@@@@PAZOPANIB||||@GSK@@@@@GSK||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@ARMALA@GW-786034@@@@ARMALA|GW-786034|||@TK Inhibitor@VEGF@Angiogenesis Inhibitor@@@TK Inhibitor|VEGF|Angiogenesis Inhibitor||@SAFETY@TOLERABILITY@@@@@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921458@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L04AX04@L04A@@SUMMIT, NEW JERSEY@@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@14921458@Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib@@@@@NO REVIEW@@@@@-@@NCT00737529@133@@@@@@@10/1/2008@@EMERGE@@@Patients must have documents relapsed, refractory or PD after treatment with bortezomib      >> Must have measureable disease on cross sectional imaging by CT     >> ECOG performance score 0,1 or 2@@@II@II@@@@Trial registered. [Celgene, 15.08.2008]@@@@@MONO@LENALIDOMIDE@@@@@LENALIDOMIDE||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@Mantle Cell Lymphoma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma|||||||@REVLIMID@@@@@REVLIMID||||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@DURATION OF RESPONSE@RESPONSE RATE@@@@OVERALL SURVIVAL@TIME TO PROGRESSION@SKELETAL-RELATED EVENT@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@CAPSULE@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918179@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01BC02@L01B@YES@PETACH TIKVA, ISRAEL@@@Fluorouracil is an analogue of uracil, a component of ribonucleic acid. The drug is believed to function as an antimetabolite. After intracellular conversion to the active deoxynucleotide, it interferes with the synthesis of DNA by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase. Fluorouracil may also interfere with RNA synthesis.@@14918179@Fluorouracil may be used alone, or in combination, for the management of common malignancies particularly cancer of the colon and breast.@@YES@5-Dec@@NO REVIEW@@@@@@@@@Intravenous infusion: 15mg/kg bodyweight but not more than 1g per infusion, diluted in 300 - 500ml of 5% glucose or 0.9% NaCl injection and given over 4 hours. Alternatively the daily dose may be infused over 30 - 60 minutes or may be given as a continuous infusion over 24 hours. The infusion may be repeated daily until there is evidence of toxicity or a total dose of 12 - 15g has been reached. Intravenousi Injection: l2mg/kg bodyweight may be given daily for 3 days and then, if there is no evidence of toxicity, 6mg/kg on alternate days for 3 further doses. An alternative regimen is 15mg/kg as a single intravenous injection once a week throughout the course. Intra-arterial infusion: 5/7.5mg/kg bodyweight daily may be given by 24 hour continuous intra-arterial infusion.@Apr-97@@1/1/1998@@@@Intravenous infusion: 15mg/kg bodyweight but not more than 1g per infusion, diluted in 300 - 500ml of 5% glucose or 0.9% NaCl injection and given over 4 hours. Alternatively the daily dose may be infused over 30 - 60 minutes or may be given as a continuous infusion over 24 hours. The infusion may be repeated daily until there is evidence of toxicity or a total dose of 12 - 15g has been reached. Intravenousi Injection: l2mg/kg bodyweight may be given daily for 3 days and then, if there is no evidence of toxicity, 6mg/kg on alternate days for 3 further doses. An alternative regimen is 15mg/kg as a single intravenous injection once a week throughout the course. Intra-arterial infusion: 5/7.5mg/kg bodyweight daily may be given by 24 hour continuous intra-arterial infusion.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@FLUOROURACIL@@@@@FLUOROURACIL||||@TEVA PHARMACEUTICAL@@@@@TEVA PHARMACEUTICAL||||@@@@@@|||||||||@Colorectal Cancer@Breast Cancer@@@@Colorectal Cancer|Breast Cancer||||||||@GENERIC@@@@@GENERIC||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@2.08@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/2/2017@2.08@2.08@9196192R@SOLUTION FOR PERFUSION  (VIAL 10 ML)@EURO@@@@@@@@500@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14916661@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Weekly bavituximab dose of 3 mg/kg until disease progression, and up to 6 cycles of carboplatin at a dose of AUC=5 and paclitaxel 175 mg/m2 every 21 days (21-day cycles) @@-@-@-@TUSTIN, CALIFORNIA@1/1/2009@@Bavituximab is a monoclonal antibody that binds to the cellular membrane component PS that is usually located inside cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. By binding to PS, bavituximab is believed to help mobilize the body's immune system to destroy the tumor and the tumor blood vessels.@@14916661@Combo with carboplatin and paclitaxel@@-@-@@NO REVIEW@@@@-@-@-@NCT00687817@49@-@FDA HAS GRANTED ORPHAN DRUG AND FAST-TRACK DESIGNATIONS FOR GBM AND ANAPLASTIC ASTROCYTOMA@@@FDA HAS GRANTED ORPHAN DRUG AND FAST-TRACK DESIGNATIONS FOR GBM AND ANAPLASTIC ASTROCYTOMA@@6/1/2008@-@PPHM 0701@@-@Histologically or cytologically confirmed non-small cell lung cancer at stage IIIB (with pleural effusion), stage IV, or recurrence @@@II@II@@-@-@>>Trial achieved the primary efficacy endpoint in the first stage of trial. Seventeen of the 21 patients enrolled in Stage A were deemed evaluable for tumor response by the end of four treatment cycles, with six patients achieving partial tumor responses and one patient achieving a complete tumor response, according to RECIST criteria. [Peregrine 04 February 2009]>>Trial registered. SOURCE: Peregrine, 28 May 2008>>Protocol submitted with FDA. SOURCE: Peregrine, 11 July 2007@-@@@@COMBO@BAVITUXIMAB@CARBOPLATIN@PACLITAXEL@@@BAVITUXIMAB|CARBOPLATIN|PACLITAXEL||@PEREGRINE PHARMACEUTICALS@@@@@PEREGRINE PHARMACEUTICALS||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@-@@@@@-||||@mAb@@@@@mAb||||@RECIST@@@@@TIME TO PROGRESSION@OVERALL SURVIVAL@@@@-@@@@@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16639057@Onco@@@@@300f1008ntsdm@@@@@@dabrafenib 150 mg twice dailydabrafenib plus trametinib placebo (dabrafenib 150 mg twice daily and trametinib placebo, trametinib 2 mg once daily)@@L01XE23@L01X@@BASEL, SWITZERLAND@8/1/2013@@Dabrafenib is an  orally bioavailable inhibitor of the BRAF protein.  Dabrafenib was discovered and developed at GSK.@@16639057@Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation@Both@NA@17-Jun-16@6/17/2016@NO REVIEW@@@@@@@NCT01584648@423@The recommended dose of dabrafenib, either used as monotherapy or in combination with trametinib, is 150 mg (two 75 mg capsules) twice daily (corresponding to a total daily dose of 300 mg).@MHLW, 28 March 2016@3/28/2016@@Yes@@5/1/2012@@115306@No@@Histologically confirmed cutaneous melanoma that is either Stage IIIC (unresectable) or Stage IV (metastatic), and determined to be BRAF V600E/K mutation-positive using the bioMerieux (bMx) investigational use only (IUO) THxID BRAF Assay (IDE: G120011). The assay will be conducted by a central reference laboratory. Subjects with ocular or mucosal melanoma are not eligible.The subject must have a radiologically measurable tumorThe subject is able to carry out daily life activities without significant difficulty (ECOG performance status score of 0 or 1).@BRAF V600 mutation@ADULTS@III@APPROVED@@@NHI@@@@@@COMBO@DABRAFENIB@TRAMETINIB@@@@DABRAFENIB|TRAMETINIB|||@NOVARTIS @@@@@NOVARTIS ||||@World@@@@@World|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@TAFINLAR@MEKINIST@@@@TAFINLAR|MEKINIST|||@Other@@@@@Other||||@PROGRESSION-FREE SURVIVAL@@@@@OVERALL SURVIVAL@@@@@UNRESECTABLE@METASTATIC@@@@RANDOMISED@DOUBLE-BLIND@PARALLEL ASSIGNMENT@@@1@1@8269447.575@@@11.2@month@11.2 month@8269447.57@8269447.57@24274.84@1@0.0091@6068.71@7156.5@@@@@@@@@@@80.92@1@@mg@300@1@@@@@@@@@@@8/30/2017@6068.71@6068.71@4291046M2027@CAPSULE@YEN@@@@@@@@75@MG@75 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14924151@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@QUEBEC, QUEBEC@@@@@14924151@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@>> In all, 44 patients entered the study. Of these, 1 patient was withdrawn prior to start of treatment and 2 patients entered as replacement for patients withdrawn for reasons other than progressive disease. Of 43 patients treated with AEZS-108, 39 were evaluable for efficacy. Responses confirmed by independent review included 2 patients with complete response (CR; 5.1%), 10 patients with partial response (PR; 25.6%), and 17 patients with stable disease (SD; 43.6%). Based on those data, an Overall Response Rate (ORR = CR+PR) of 30.8 % and a Clinical Benefit Rate (CBR = CR+PR+SD) of 74.4% can be estimated. Responses were also achieved in patients with prior chemotherapy, 1 CR, 1 PR and 2 SDs in 8 of the patients pre-treated with platinum/taxane regimens. Median time to progression (TTP) and overall survival (OS) were 7 months (30 weeks) and 14.3 months (62 weeks), respectively.Overall, tolerability of AEZS-108 was good and commonly allowed retreatment as scheduled. Only one patient (2%) had a dose reduction, and 17 (8%) courses were given with a delay, including also 11 cases in which delay was not related to toxicity. Severe (Grade 3 or 4) toxicity was mainly restricted to rapidly reversible hematologic toxicity (leukopenia/neutropenia) associated with fever in 1 case only, a patient who had been treated only 3 weeks after a surgery. Good tolerability of AEZS-108 was also reflected by a low rate of severe possibly drug-related non-hematological adverse events and which included single cases (2.4%) each of nausea, diarrhea, fatigue, general health deterioration (Grade 4), creatinine elevation, and blood potassium decrease. No cardiac toxicity was reported. [ Aeterna Zentaris, 18.11.10, http://www.aezsinc.com/en/page.php?p=60&q=413]>>Phase II to commence year-end 2007@-@@@@-@-@@@@@-||||@AETERNA ZENTARIS@@@@@AETERNA ZENTARIS||||@@@@@@|||||||||@Endometrial Cancer@@@@@Endometrial Cancer|||||||||@AEZS-108@@@@@AEZS-108||||@LH-RH Analog@@@@@LH-RH Analog||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918678@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01AX04@L01A@YES@@@@Dacarbazine is a cytostatic agent. The antineoplastic effect is due to an inhibition of cell growth which is independent of the cell cycle and due to an inhibition of DNA synthesis. An alkylating effect has also been shown and other cytostatic mechanisms may also be influenced by dacarbazine. Dacarbazine is considered not to show an antineoplastic effect by itself. However by microsomal N-demethylation it is quickly converted to 5-amino-imidazole-4-carboxamide and a methyl cation, which is responsible for the alkylating effect of the drug.@@14918678@Dacarbazine is indicated for the treatment of patients with metastatic malignant melanoma. Further indications for dacarbazine as part of combination chemotherapy are: • Hodgkin's disease • Advanced adult soft tissue sarcomas (except mesothelioma, Kaposi sarcoma)@@NO@@@NO REVIEW@@@@100%@@@@@Malignant Melanoma: Dacarbazine can be administered as single agent in doses of 200 to 250 mg/m² body surface area/day as an i.v. injection for 5 days every 3 weeks. As an alternative to an intravenous bolus injection dacarbazine can be administered as a short-term infusion (over 15 - 30 minutes). It is also possible to give 850 mg/m² body surface area on day 1 and then once every 3 weeks as intravenous infusion.@EMA, November 1997@@@@@@It is recommended that dacarbazine be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. 1. Hemopoietic depression is the most common toxicity with dacarbazine. 2. Hepatic necrosis has been reported. 3. Studies have demonstrated this agent to have a carcinogenic and teratogenic effect when used in animals. 4. In treatment of each patient, the physician must weigh carefully the possibility of achieving therapeutic benefit against the risk of toxicity.@NO LABELLED TRIAL@No@@@@@@APPROVED@@NO NICE REVIEW@NHS@NO LABELLED TRIAL@@@@@@DACARBAZINE@@@@@DACARBAZINE||||@MEDAC@@@@@MEDAC||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@GENERIC@@@@@GENERIC||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@METASTATIC@MALIGNANT@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@10@1.299@90@@@@@@@@@@@@0.09@@@@@@@@@@@@@@@@7/28/2017@9@9@7.32E+15@POWDER FOR SOLUTION FOR INJECTION VIAL@GB£@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14921863@Onco@@@@@300f1015ntsdm@@@@@@Caelyx (30mg/m2 every 4 weeks during 6 cycles) plus carboplatin (AUC5 every 3/4 weeks for 6 cycles) versus paclitaxel (175mg/m2 at day 1 every 3 weeks for 6 cycles) and carboplatin (AUC5 every 3/4 weeks for 6 cycles)@@L01DB01@L01D@-@KENILWORTH, NEW JERSEY@@@The active ingredient of Caelyx is doxorubicin hydrochloride, a cytotoxic anthracycline antibiotic obtained from Streptomyces peucetius var. caesius. The exact mechanism of the antitumour activity of doxorubicin is not known. It is generally believed that inhibition of DNA, RNA and protein synthesis is responsible for the majority of the cytotoxic effects. This is probably the result of intercalation of the anthracycline between adjacent base pairs of the DNA double helix thus preventing their unwinding for replication.@@14921863@Epithelial ovarian cancer@@-@-@@NO REVIEW@@@@-@Merck & Co and Schering-Plough have announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. Based on the closing price of Merck stock on March 6, 2009, the consideration to be received by Schering-Plough shareholders is valued at $23.61 per share, or $41.1 billion in the aggregate. [Merck & Co, 9 March 2009]@THIRD-LINE@NCT00189553@974@-@-@@@-@@@-@CALYPSO@@-@-@@@EUDRACT 2004-04456-39 / @III@@-@-@RESULTS PENDING (recruiting).@-@@@@COMBO@DOXORUBICIN, PEGYLATED LIPOSOMAL @CARBOPLATIN@@@@DOXORUBICIN, PEGYLATED LIPOSOMAL |CARBOPLATIN|||@SCHERING-PLOUGH@MERCK & CO@@@@SCHERING-PLOUGH|MERCK & CO|||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@CAELYX@@@@@CAELYX||||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@RELAPSED@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
16384777@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384777@Indicated for the treatment of adult patients with Ph+ CML in chronic phase after failure of interferon-alphatherapy@@NO@@@NO REVIEW@@@@Co-pay tier 2. SOURCE: Aetna Preferred Drug Guide 2008@@SECOND-LINE@@532@The recommended dosage of Glivec is 400 mg/day for adult patients in chronic phase CML.@@@@Yes@@@@@No@@@ADULT@@@APPROVED@@@MEDICARE@@@@@@MONO@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@CHRONIC PHASE@@@@@@@@@@1@1@Invalid Average Duration of Use@@@@@@@@@90@1@8427.44@@@@@@@@@@@@0.94@1@@mg@400@1@@@@@@@@@@@8/2/2017@93.64@93.64@00078-0401-34@TABLET@US$@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916507@Onco@@@@@300f1012ntsdm@@@@@@107 patients received oral melphalan (0.15MG/KG/day x 7 followed by 0.05MG/KG/day) with prednisone; 203 received IV melphalan (16MG/M2 q 2 weeks x 4 over 6 weeks followed by 4 weeks) with prednisone.@@L01AA03@L01A@YES@BRENTFORD, UNITED KINGDOM@@@Melphalan is a bifunctional alkylating agent. Formation of carbonium intermediates from each of the two bis-2-chloroethyl groups enables alkylation through covalent binding with the 7-nitrogen of guanine on DNA, cross-linking the two DNA strands and thereby preventing cell replication.@@14916507@Alkeran Tablets are indicated in the treatment of multiple myeloma and advanced ovarian adenocarcinoma. Alkeran either alone or in combination with other drugs has a significant therapeutic effect in a proportion of patients suffering from advanced breast carcinoma. Alkeran is effective in the treatment of a proportion of patients suffering from polycythaemia vera.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@310@Ovarian adenocarcinoma: When used intravenously as a single agent, a dose of 1 mg/kg body weight (approximately 40 mg/m2 body surface area) given at intervals of 4 weeks has often been used. When combined with other cytotoxic drugs, intravenous doses of between 0.3 and 0.4 mg/kg body weight (12 to 16 mg/m2 body surface area) have been used at intervals of 4 to 6 weeks.@@@@@@@Melphalan should be administered under the supervision of a qualified physician experienced in the use of chemotherapeutic agents. Severe bone marrow suppression with resulting infection or bleeding may occur. Controlled trials comparing IV to oral melphalan have shown more myelosuppression with the IV formulation.@LABEL@No@@@@@III@APPROVED@@@GKV@44% and 7% responded in the oral and IV groups respectively. Severe myelotoxicity and/or platelets occurred 28% and 11% respectively.@@@@@COMBO@MELPHALAN HYDROCHLORIDE@PREDNISONE@@@@MELPHALAN HYDROCHLORIDE|PREDNISONE|||@GSK@@@@@GSK||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@ALKERAN@@@@@ALKERAN||||@Alkylating Agent@Nitrogen Mustard Analogue@@@@Alkylating Agent|Nitrogen Mustard Analogue|||@RESPONSE RATE@@@@@@@@@@@@@@@RANDOMISED@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@25@1.1807@66@94.43@68.78@@@@@@@@@@1.32@@@@@@@@@@@@@@@@8/15/2017@2.64@2.64@1263931@FILM-COATED TABLET@EURO@@@@@@@@2@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14920964@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01AD02@L01A@YES@@@@@@14920964@"As palliative or supplementary treatment, usually in combination with radiotherapy and/or surgery as part of multiple drug regimens in: Brain tumours (primary or metastatic); Lung tumours (especially oat-cell carcinoma); Hodgkin's disease (resistant to conventional combination chemotherapy); Malignant melanoma (metastatic). Lomustine ""medac"" may also be of value as second-line treatment in Non-Hodgkin's lymphoma, myelomatosis, gastrointestinal tumours, carcinoma of the kidney, the testis, the ovary, the cervix uteri and the breast."@@NO@@@NO REVIEW@@@@100%@@@@@"The recommended dose in patients with normally functioning bone marrow receiving Lomustine ""medac"" as their only chemotherapy is 120-130 mg/m² as a single dose every six to eight weeks (or as a divided dose over 3 days, e.g. 40 mg/m²/day)."@EMA, August 2006@@@@@@CeeNU should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Bone marrow suppression, notably thrombocytopaenia and leukopaenia, which may contribute to bleeding and overwhelming infections in an already compromised patient, is the most common and severe of the toxic effects of CeeNU. Since the major toxicity is delayedbone marrow suppression, blood counts should be monitored weekly for at least 6 weeks after a dose. At the recommended dosage, courses of CeeNU should not be given more frequently than every 6 weeks. The bone marrow toxicity of CeeNU is cumulative and therefore dosage adjustment must be considered on the basis of nadir blood counts from prior dose@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@LOMUSTINE@@@@@LOMUSTINE||||@MEDAC@@@@@MEDAC||||@@@@@@|||||||||@Brain Cancer@NSCLC@Melanoma / Skin Cancer@Haematological Malignancy@Hodgkin's Lymphoma@Brain Cancer|NSCLC|Melanoma / Skin Cancer|Haematological Malignancy|Hodgkin's Lymphoma|||||@LOMUSTINE@@@@@LOMUSTINE||||@Alkylating Agent@Nitrosourea@@@@Alkylating Agent|Nitrosourea|||@@@@@@@@@@@METASTATIC@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@20@1.299@780.82@@@@@@@@@@@@0.98@@@@@@@@@@@@@@@@7/28/2017@39.04@39.04@4.37E+15@CAPSULES@GB£@@@@@@@@40@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14922304@Onco@@@@@@@@@@@N/A@@-@-@-@BASEL, SWITZERLAND@@@A cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing hyperacetylation of core histone proteins, which may result in modulation of cell cycle protein expression, cell cycle arrest in the G2/M phase and apoptosis. In addition, this agent appears to modulate the expression of angiogenesis-related genes, such as hypoxia-inducible factor-1alpha (HIF-1a) and vascular endothelial growth factor (VEGF), thus impairing endothelial cell chemotaxis and invasion. HDAC is an enzyme that deacetylates chromatin histone proteins. @@14922304@Adult patients who have received at least two prior therapies including Velcade or Revlimid@@-@-@@NO REVIEW@@@@-@-@THIRD-LINE@NCT00445068@144@-@EMEA PDCO recommended product-specific waiver. SOURCE: EMEA PDCO, January 2008Orphan designation was granted by the European Commission for panobinostat lactate for the treatment of cutaneous T cell lymphoma. [There is discussion of current treatments, the numbers or persons affected with this condition in the EU, and the mode of action & state of development of panobinostat lactate for the treatment of this condition. Panobinostat lactate was not authorised anywhere in the world for cutaneous T-cell lymphoma, or designated as orphan medicinal product elsewhere for this condition, at the time of submission. Designated orphan medicinal products are still investigational products which were considered for designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of the quality, safety and efficacy will be necessary before this product can be granted a marketing authorisation.] SOURCE: EMEA COMP, 6 November 2007@11/6/2007@@-@@3/1/2007@-@ALPHA-MM @@-@-@@@II/III CLBH589B2203;@III@@-@-@RESULTS PENDING@-@@@@MONO@PANOBINOSTAT@@@@@PANOBINOSTAT||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@LBH-589@@@@@LBH-589||||@HDAC@@@@@HDAC||||@BLADÉ CRITERIA@@@@@@@@@@REFRACTORY@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921143@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@ARM1; Drug: Paclitaxel 200 mg/m^2 IV (in the vein), on day 1 of each 21 day cycle Drug: Carboplatin AUC 6.0 mg min/ml IV (in the vein), on day 1 of each 21 day cycle ARM2: Biological: Mapatumumab 10 mg/kg IV (in the vein), on day 1 of each 21 day cycle Drug: Paclitaxel 200 mg/m^2 IV (in the vein), on day 1 of each 21 day cycle Drug: Carboplatin AUC 6.0 mg min/ml IV (in the vein), on day 1 of each 21 day cycle ARM3: Biological: Mapatumumab 30 mg/kg IV (in the vein), on day 1 of each 21 day cycle Drug: Paclitaxel 200 mg/m^2 IV (in the vein), on day 1 of each 21 day cycle Drug: Carboplatin AUC 6.0 mg min/ml IV (in the vein), on day 1 of each 21 day cycle@@-@-@-@ROCKVILLE, MARYLAND@1/1/2010@@HGS-ETR1 (mapatumumab) is an agonistic human monoclonal antibody that directly induces cancer-cell death by specifically binding to and activating the protein known as TRAIL receptor 1. Using genomic techniques, HGS originally identified the TRAIL receptor 1 protein. The HGS-ETR1 antibody was generated by HGS through collaboration with Cambridge Antibody Technology. HGS is developing HGS-ETR1 as a potential treatment for a broad range of cancers.@@14921143@Combo with carboplatin and paclitaxel@@-@-@@NO REVIEW@@@@-@HGS reacquired rights to mapatumumab and lexatumumab from GSK in return for royalties due to HGS if Syncria albiglutide is commercialised. SOURCE: HGS, 16 April 2008GSK has exercised 1996 option to jointly develop and commercialise HGS-ETR1, equally sha@FIRST-LINE@NCT00583830@105@-@-@@@-@@11/1/2007@-@HGS1012-C1072@@-@-@@@II@II@@-@-@In December 2007, HGS initiated dosing of patients in a randomized Phase 2 trial of HGS-ETR1 in combination with paclitaxel and carboplatin as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC). The NSCLC trial will continue the enrollment and randomization of patients throughout 2008. SOURCE: HGS: 7 January 2008@-@@@@COMBO@MAPATUMUMAB@CARBOPLATIN@PACLITAXEL@@@MAPATUMUMAB|CARBOPLATIN|PACLITAXEL||@HUMAN GENOME SCIENCES@@@@@HUMAN GENOME SCIENCES||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@HGS-ETR1@@@@@HGS-ETR1||||@mAb@Human@TRAIL Receptor 1@@@mAb|Human|TRAIL Receptor 1||@RESPONSE RATE@PROGRESSION-FREE SURVIVAL@@@@@@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918708@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01BC02@L01B@YES@MUMBAI, INDIA@@@Fluorouracil is an analogue of uracil, a component of ribonucleic acid. The drug is believed to function as an antimetabolite. After intracellular conversion to the active deoxynucleotide, it interferes with the synthesis of DNA by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase. Fluorouracil may also interfere with RNA synthesis.@@14918708@Fluorouracil may be used alone, or in combination, for the management of common malignancies particularly cancer of the colon and breast.@@YES@@@NO REVIEW@@@@100%@@@@@Intravenous infusion: 15mg/kg bodyweight but not more than 1g per infusion, diluted in 300 - 500ml of 5% glucose or 0.9% NaCl injection and given over 4 hours. Alternatively the daily dose may be infused over 30 - 60 minutes or may be given as a continuous infusion over 24 hours. The infusion may be repeated daily until there is evidence of toxicity or a total dose of 12 - 15g has been reached. Intravenousi Injection: l2mg/kg bodyweight may be given daily for 3 days and then, if there is no evidence of toxicity, 6mg/kg on alternate days for 3 further doses. An alternative regimen is 15mg/kg as a single intravenous injection once a week throughout the course. Intra-arterial infusion: 5/7.5mg/kg bodyweight daily may be given by 24 hour continuous intra-arterial infusion.@EMA, September 2006@@@@@@Intravenous infusion: 15mg/kg bodyweight but not more than 1g per infusion, diluted in 300 - 500ml of 5% glucose or 0.9% NaCl injection and given over 4 hours. Alternatively the daily dose may be infused over 30 - 60 minutes or may be given as a continuous infusion over 24 hours. The infusion may be repeated daily until there is evidence of toxicity or a total dose of 12 - 15g has been reached. Intravenousi Injection: l2mg/kg bodyweight may be given daily for 3 days and then, if there is no evidence of toxicity, 6mg/kg on alternate days for 3 further doses. An alternative regimen is 15mg/kg as a single intravenous injection once a week throughout the course. Intra-arterial infusion: 5/7.5mg/kg bodyweight daily may be given by 24 hour continuous intra-arterial infusion.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@FLUOROURACIL@@@@@FLUOROURACIL||||@WOCKHARDT@@@@@WOCKHARDT||||@@@@@@|||||||||@Colorectal Cancer@Breast Cancer@@@@Colorectal Cancer|Breast Cancer||||||||@GENERIC@@@@@GENERIC||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.299@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@SOLUTION FOR INJECTION@GB£@@@@@@@@5000@MG@50 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14919394@Onco@@@@@300f1018ntsdm@@@@@@NO LABELLED TRIAL@@L01XA01@L01X@YES@NEW YORK, NEW YORK@@@Cisplatin has biochemical properties similar to those of bifunctional alkylating agents. The drug inhibits DNA synthesis by producing intrastrand and interstrand cross links in DNA. Protein and RNA synthesis are also inhibited to a lesser extent. Although the principal mechanism of action of cisplatin appears to be inhibition of DNA synthesis, other mechanisms, including enhancement of tumour immunogenicity, may be involved in its antineoplastic activity. Cisplatin also has immunosuppressive, radiosensitising, and antimicrobial properties.@@14919394@In combination with other chemotherapeutics and after appropriate surgigical and/or radiotherapeutic procedures, Platinol-AQ is indicated for for metastatic testicular tumours and metastatic ovarian tumours- an established combination for the latter is Platinol-AQ and Cytoxan. As a single agent, it is approved as a secondary therapy in patients with metastatic ovarian tumours refractory to standard chemotherapy but not received Platinol-AQ, and transitional cell bladder cancer which is no longer amenable to local treatments such as surgery and/or radiotherapy.@@NO@@@NO REVIEW@@@@100%@@@@@For monotherapy, the following two dosage regimens are recommended:- Single dose of 50 to 120 mg/m² body surface every 3 to 4 weeks; - 15 to 20 mg/m²/day for five days, every 3 to 4 weeks. If cisplatin is used in combination chemotherapy, the dose of cisplatin must be reduced. A typical dose is 20 mg/m² or more once every 3 to 4 weeks.@@@@@@@Platinol-AQ produces cumulative nephrotoxicity which is potentiated by aminoglycoside antibiotics. The serum creatinine, BUN, creatinine clearance, and magnesium, sodium, potassium, and calcium levels should be measured prior to initiating therapy, and prior to each subsequent course. At the recommended dosage, it should not be given more frequently than once every 3 to 4 weeks. Elderly patients may be more susceptible to nephrotoxicity. There are reports of severe neuropathies in patients in whom regimens are employed using higher doses or greater dose frequencies than those recommended. These neuropathies may be irreversible and are seen as paresthesias in a stocking-glove distribution, areflexia, and loss of proprioception and vibratory sensation. Elderly patients may be more susceptible to peripheral neuropathy. Loss of motor function has also been reported. Anaphylactic-like reactions have been reported within minutes of administration to patients with prior exposure, and have been alleviated by administration of epinephrine, corticosteroids, and antihistamines.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@PBS@NO LABELLED TRIAL@@@@@@CISPLATIN@@@@@CISPLATIN||||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@Ovarian Cancer@Testicular Cancer@Bladder Cancer@@@Ovarian Cancer|Testicular Cancer|Bladder Cancer|||||||@GENERIC@@@@@GENERIC||||@Platinum@@@@@Platinum||||@@@@@@@@@@@METASTATIC@ADVANCED@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@0.779@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@A$@@@@@@@@100@MG@1 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14922848@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@M04AA01@M04A@NO@CUXHAVEN, GERMANY@@@@@14922848@Indicated in the management of patients with signs and symptomas of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephroptahy; the management of patients with leukaemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment should be discontinued when the potential for overproduction of uric acid is no longer presents; and, the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800mg/day in male patients and 750mg/day in female patients. This is not an innocuous drug. It is not recommended for the treatment of asymptomatic hyperuricemia.@@NO@@@NO REVIEW@@@@@TAD Pharma was created in 2008 following the merger of Krka's Munich and Frankfurt subsidiaries.@@@@Dosage in Adults: should be introduced at low dosage e.g. 100mg/day to reduce the risk of adverse reactions and increased only if the serum urate response is unsatisfactory. Extra caution should be exercised if renal function is poor. The following dosage schedules are suggested: 100 to 200 mg daily in mild conditions, 300 to 600 mg daily in moderately severe conditions, 700 to 900 mg daily in severe conditions. If dosage on a mg/kg bodyweight basis is required, 2 to 10 mg/kg bodyweight/day should be used. Dosage in children: Children under 15 years: 10 to 20 mg/kg bodyweight/day up to a maximum of 400 mg daily. Use in children is rarely indicated, except in malignant conditions (especially leukaemia) and certain enzyme disorders such as Lesch-Nyhan syndrome.@@@@@@@Should be discontinued at the first appearance of skin rash or other signs which may indicate an allergic rection. Dose should be adjusted if co-administered with Purinethol or Imuran.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@ALLOPURINOL@@@@@ALLOPURINOL||||@TAD PHARMA@KRKA@@@@TAD PHARMA|KRKA|||@@@@@@|||||||||@Supportive Care@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Non-Hodgkin's Lymphoma@Supportive Care|Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Non-Hodgkin's Lymphoma|||||@REMID@@@@@REMID||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@100@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@EURO@@@@@@@@100@MG@100 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14919550@Onco@@@@@300f1015ntsdm@@@@@@Tamoxifen compared to ovarian ablation@@L02BA01@L02B@YES@ULM, GERMANY@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14919550@@@NO@Feb-97@@NO REVIEW@@@@@@@@N/A@Adjuvant treatment of breast cancer, Adults (including elderly): The recommended dose is 20mg, given either in divided doses twice daily or as a single dose once daily. The current recommended treatment duration is five years; however the optimum duration has not been established. Treatment of locally advanced or metastatic breast cancer: The recommended dose is 20mg to 40mg, given either in divided doses twice daily or as a single dose once daily.@May-96@@@@@@Women should be informed of the potential risks to the foetus, should they become pregnant whilst taking tamoxifen; or within two months of cessation of therapy. A number of secondary primary tumours, occurring at sites other than the endometrium and the opposite breast, have been reported in clinical trials, following the treatment of breast cancer patients with tamoxifen. No causal link has been established and the clinical significance of these observations remains unclear.@LABEL@No@@@@@III; METASTATIC BREAST CANCER@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@The objective RR, time to treatment failure, and survival were similar with both treatments. In an overview analysis of survival data from the 3 studies, the hazard ratio for death (tamoxifen/ovarian ablation) was 1.00. Elevated serum and plasma oestrogens have been observed in premenopausal women receiving tamoxifen, but the data from the randomized studies do not suggest an adverse effect of this increase. A limited number of premenopausal patients with disease progression during tamoxifen therapy responded to subsequent ovarian ablation.@@@@@MONO@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@RATIOPHARM@@@@@RATIOPHARM||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GENERIC@@@@@GENERIC||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RESPONSE RATE@@@@@@@@@@@@@@@PROSPECTIVE@RANDOMISED@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@30@1.1511@2.63@3.69@2.93@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@0.09@0.09@3.40E+12@TABLET@EURO@@@@@@@@10@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14923724@Onco@@@@@@@@@@@Increasing doses of Abraxane plus carboplatin@@L01CD01@L01C@-@SUMMIT, NEW JERSEY@6/1/2008@@Abraxane is an albumin-bound form of paclitaxel with a mean particle size of approximately 130 nanometers. Paclitaxel protein-bound particles for injectable suspension) is an antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. Paclitaxel induces abnormal arrays or “bundles” of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.@@14923724@-@@-@9-Sep-08@9/9/2008@NO REVIEW@@@@-@>>Celgene acquires Abraxis for US$2.9 billion [Celgene 30 June 2010 http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-newsArticle&ID=1442901&highlight= ]>> Abraxis BioScience has entered into an agreement with AstraZeneca to re-acquire the exclusive rights to market Abraxane in the United States. [Abraxis, 28.11.2008]       >> AstraZeneca paid US$200 mil to co-promote Abraxane in the U.S., whilst Abraxis bought AstraZeneca's anaesthetic/analgesia portfolio. India/certain Asia rights licensed to Biocon in August 2007.@-@NCT00274443@250@-@-@@@-@@3/1/2005@-@-@@-@-@@@II@II@@Abraxane may be substituted for either paclitaxel or docetaxel in patients who have experienced hypersensitivity reactions after receiving paclitaxel or docetaxel despite premedication, or for patients in who standard premedications are contraindicated. [NCCN, 9.09.2008]@-@RESULTS PENDING- results expected mid-2008. At ASCO 2006, an open-label, dose-escalating US phase I/II trial was conducted in 50 patients with stage IV NSCLC who have not had prior chemotherapy treatment, 30% of patients had an objective response with median survival of 10.9 months; haematological toxicity was minimal, and the most common grade 3 toxicities were fatigue and sensory neuropathy. In a phase II combination trial of ABI 007 and carboplatin, 51 chemotherapy-naive patients showed 2% of patients had a complete response, and 45% achieved a partial response; median time to disease progression was 28 weeks.@-@@@@COMBO@PACLITAXEL PROTEIN BOUND PARTICLES@CARBOPLATIN@@@@PACLITAXEL PROTEIN BOUND PARTICLES|CARBOPLATIN|||@CELGENE@ABRAXIS@@@@CELGENE|ABRAXIS|||@Russia@@@@@Russia|||||||||@NSCLC@@@@@NSCLC|||||||||@ABRAXANE@@@@@ABRAXANE||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@SAFETY@@@@@@@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@DOSE COMPARISON@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
15361182@Onco@@@@@300f1018ntsdm@@@@@DASISION@Patients were randomized to receive either SPRYCEL 100 mg once daily or imatinib 400 mg once daily@@L01XE06@L01X@@NEW YORK, NEW YORK@12/1/2013@@Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRß. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.@@15361182@Indicated for the treatment of adults aged 18 years or over with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukaemia in the chronic phase.@Both@NO@@@@@@@@@FIRST-LINE@NCT00481247@519@The recommended starting dosage for chronic phase CML is 100 mg administered orally once daily (QD).@@@@@@8/1/2007@@CA180-056/2006-005712-27@No@@Male & Female ≥18 years/Chronic Phase Ph+ CML/Eastern Cooperative Oncology Group Performance Status (ECOG PS) score 0-2@@ADULTS@III@APPROVED@@@PBS@@@@@@MONO@DASATINIB@@@@@DASATINIB||||@BMS@@@@@BMS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@SPRYCEL@@@@@SPRYCEL||||@TK Inhibitor@bcr-abl@PDGF@@@TK Inhibitor|bcr-abl|PDGF||@RATE OF CONFIRMED COMPLETE CYTOGENETIC RESPONSE@@@@@@@@@@CHRONIC PHASE@PH+@@@@OPEN-LABEL@MULTICENTER@RANDOMISED@@@1@1@99417.12928@@@14@month@14 month@99417.13@99417.13@233.47@60@0.779@2801.64@2948.51@2871.58@@@@@@@@@@2.33@1@@mg@100@1@@@@@@@@@@@8/1/2017@46.69@46.69@3139-0615-GE-BQ@TABLET@A$@@@@@@@@20@MG@20 MG@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
16617767@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01XX52@L01X@@@@@VENCLEXTA is a BCL-2 inhibitor indicated for the treatment of patientswith chronic lymphocytic leukemia (CLL) with 17p deletion, as detected byan FDA approved test, who have received at least one prior therapy@@16617767@VENCLEXTA is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least oneprior therapy.@Both@NA@@@NO REVIEW@@@@@@SECOND-LINE@@106@Week 1: 20 mg daily, week 2: 50 mg daily, week 3: 100 mg daily, week 4: 200 mg daily, week 5 onwards: 400 mg daily. VENCLEXTA should be taken orally once daily until disease progression or unacceptable toxicity is observed@FDA, 11 April 2016@4/11/2016@5/2/2016@@@@@@No@@@17p deletion@ADULTS@@APPROVED@@@@@@@@@MONO@VENETOCLAX@@@@@VENETOCLAX||||@ABBVIE@@@@@ABBVIE||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@VENCLEXTA@@@@@VENCLEXTA||||@Bcl-2 Inhibitor@@@@@Bcl-2 Inhibitor||||@OVERALL RESPONSE RATE@@@@@@@@@@@@@@@@@@@@1@1@16695.61597@@@12.1@month@12.1 month@16695.62@16695.62@45.36@50@1@301.14@@@@@@@@@@@@0.12@28@1@mg@92.5@28@1@@mg@400@1@@@@@@8/2/2017@6.02@6.02@00074-0566-07@FILM-COATED TABLET@US$@@@@@@@@50@MG@50 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16067011@Onco@@@@@300f1012ntsdm@@@@@@Nivolumab, Experimental, Specified dose on specified days.Placebo, Placebo Comparator, Specified dose on specified days.@@L01XC17@L01X@@NEW YORK, NEW YORK@3/1/2020@@Nivolumab is an investigational, fully-human IgG4 anti-PD-1 receptor blocking monoclonal antibody that binds to the checkpoint receptor PD-1 (programmed death-1) expressed on activated T cells. Nivolumab inhibits the binding of PD-1 with its tumor-expressed ligands, programmed death-ligand 1 (PD-L1/B7-H1) and PD-L2 (B7-DC). Blocking of the interaction of the PD-1 receptor with its ligands may allow T-cells to elicit an anti-tumor immune response.@@16067011@A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal, or Gastroesophageal Junction Cancer@Both@@@@@Specified dose on specified days@@@@@@NCT02743494@760@@@@@@@5/1/2016@@CA209-577@@@Diagnosed with Stage II/III carcinoma of the esophagus or gastroesophageal junction  -  Completed pre-operative chemo radiotherapy followed by surgery  -  Diagnosed with residual pathologic disease after being surgically rendered free of disease with negative margins following complete resection@MONO@ADULTS@Phase 3@III@@@@@@@@@ADJUVANT@NIVOLUMAB@@@@@NIVOLUMAB||||@BRISTOL-MYERS SQUIBB@@@@@BRISTOL-MYERS SQUIBB||||@Germany@@@@@Germany|||||||||@Oesophageal Cancer@@@@@Oesophageal Cancer|||||||||@OPDIVO@@@@@OPDIVO||||@PD-1 Inhibitor@@@@@PD-1 Inhibitor||||@DISEASE-FREE SURVIVAL@OVERALL SURVIVAL@@@@OVERALL SURVIVAL RATE@@@@@ADVANCED@@@@@RANDOMIZED@Efficacy Study@PARALLEL ASSIGNMENT@DOUBLE BLIND@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
15361181@Onco@@@@@300f1018ntsdm@@@@@DASISION@Patients were randomized to receive either SPRYCEL 100 mg once daily or imatinib 400 mg once daily@@L01XE06@L01X@@NEW YORK, NEW YORK@12/1/2013@@Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRß. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.@@15361181@Indicated for the treatment of adults aged 18 years or over with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukaemia in the chronic phase.@Both@NO@@@@@@@@@FIRST-LINE@NCT00481247@519@The recommended starting dosage for chronic phase CML is 100 mg administered orally once daily (QD).@@@@@@8/1/2007@@CA180-056/2006-005712-27@No@@Male & Female ≥18 years/Chronic Phase Ph+ CML/Eastern Cooperative Oncology Group Performance Status (ECOG PS) score 0-2@@ADULTS@III@APPROVED@@@PBS@@@@@@MONO@DASATINIB@@@@@DASATINIB||||@BMS@@@@@BMS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@SPRYCEL@@@@@SPRYCEL||||@TK Inhibitor@bcr-abl@PDGF@@@TK Inhibitor|bcr-abl|PDGF||@RATE OF CONFIRMED COMPLETE CYTOGENETIC RESPONSE@@@@@@@@@@CHRONIC PHASE@PH+@@@@OPEN-LABEL@MULTICENTER@RANDOMISED@@@1@1@65499.82186@@@14@month@14 month@65499.82@65499.82@153.82@30@0.779@4614.57@4761.44@4684.51@@@@@@@@@@1.54@1@@mg@100@1@@@@@@@@@@@8/1/2017@153.82@153.82@3139-0614-GE-BQ@TABLET@A$@@@@@@@@100@MG@100 MG@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14957529@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@MORAb-003 either as combination (n=8) or single therapy (n=7)@@-@-@-@TOKYO, JAPAN@@@MORAb-003 is a humanized IgG1 antibody that targets Folate Receptor Alpha which is over-expressed on a number of epithelial-derived cancers such as ovarian, breast, renal, lung, colorectal and brain cancers. MORAb-003 received orphan drug designation by the FDA for ovarian cancer. MORAb-003 is currently being developed as a therapeutic antibody for the treatment of ovarian cancer. Investigational New Drug (IND) application was opened for MORAb-003 in 2005. A Phase I study conducted at Memorial Sloan Kettering Cancer Center showed the antibody to be well tolerated. A multi-institutional Phase II Study is currently being conducted in platinum-sensitive ovarian cancer patients in North America and Europe.@@14957529@Platinum-sensitive@@-@-@@NO REVIEW@@@@-@Acquired through takeover of Morphotek in April 2007; Ludwig Institute@SECOND-LINE@-@15@-@Orphan drug status granted by EC for ovarian cancer. SOURCE: Morphotek, 16 April 2008FDA GRANTED ORPHAN DRUG STATUS FOR OVARIAN CANCER IN JUNE 2006.@4/16/2008@@Orphan drug status granted by EC for ovarian cancer. SOURCE: Morphotek, 16 April 2008FDA GRANTED ORPHAN DRUG STATUS FOR OVARIAN CANCER IN JUNE 2006.@@@-@-@@-@-@@@II@II@@-@-@Preliminary update; no significant adverse events reported; all patients reached CA125 normalisation and reduction of tumour size (CR or PR). [Morphotek/ASCO, June 2007]@-@@@@BOTH@FARLETUZUMAB@@@@@FARLETUZUMAB||||@EISAI@MORPHOTEK@@@@EISAI|MORPHOTEK|||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@MORAB-003@@@@@MORAB-003||||@mAb@Humanised@@@@mAb|Humanised|||@RESPONSE RATE@RECIST@@@@@@@@@REFRACTORY@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919104@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@For the Phase 1a portion, MK4287 will be administered orally once daily in capsule form in 21 day cycles. An accelerated dose escalation design followed by a 3+3 dose escalation design will be used to determine the maximum tolerated dose (MTD). The dose confirmation portion will expand upon one or more of the doses studied in the dose escalation portion. In Phase 1b, MK4827 will be administered orally in capsule form at a starting dose and regimen determined in the Phase 1a portion of the study. [clinicaltrials.gov]@@-@-@-@WHITESTATION, NEW JERSEY@8/1/2010@@-@@14919104@MK4827 in Patients With Advanced Solid Tumors and BRCA Mutant Ovarian Cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00749502@66@-@-@@@-@@9/1/2008@-@MK4827-001@@NOT YET AVAILABLE; POTENTIALLY 2018.@>> For the Phase Ia portion, patients must have a cytologically- or histologically-confirmed metastatic or locally advanced solid tumor for which standard therapy does not exist or the patients have refused standard therapy     >> For the Phase Ib portion, patients must have a cytologically- or histologically-confirmed locally advanced or metastatic solid tumor with documented BRCA1 or BRCA2 mutation (in tumor or germline) for which standard therapy does not exist or the patients have refused standard therapy   >> Patient must have performance status of less than or equal to 2 on the ECOG Performance Scale@@@I@I@@-@-@>>Phase I registered. (Merck, 21.10.10]>>Trial registered. [Merck, 05.09.2008]@-@@@@MONO@BEVACIZUMAB@@@@@BEVACIZUMAB||||@MERCK & CO@@@@@MERCK & CO||||@@@@@@|||||||||@Solid Tumours@Ovarian Cancer@@@@Solid Tumours|Ovarian Cancer||||||||@MK-4827@@@@@MK-4827||||@PARP Inhibitor@@@@@PARP Inhibitor||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924828@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@In phase I, groups of 3-6 patients receive escalating doses of cloretazine until the maximum tolerated dose (MTD) is established. In phase II, patients receive oral temozolomide on days 1-7 and intravenous cloretazine over 15-30 minutes 2 hours after the last dose of temozolomide on day 7. In the absence of disease progression or unacceptable toxicity, treatment repeats every 7 weeks. @@-@-@-@NEW HAVEN, CONNECTICUT@@@Cloretazine (VNP40101M) is a small molecule that works by damaging DNA. Cloretazine releases the DNA chloroethylating agent 90CE after entering the blood stream. 90CE chloroethylates the O6 position of guanine residues, ultimately resulting in an interstrand DNA cross-link. Interstrand DNA cross-links are difficult to repair and are toxic to cells. Cloretazine demonstrated a broad spectrum of anticancer activity in preclinical studies, including activity in selected cell lines resistant to other alkylating agents such as BCNU, cyclophosphamide and melphalan. In preclinical studies, Cloretazine has been combined with other anticancer agents such as cytarabine (Ara-C). In addition, Cloretazine or its metabolite, has been shown to be capable of crossing the blood brain barrier in preclinical models.@@14924828@Adult malignant gliomas@@-@-@@NO REVIEW@@@@-@-@-@NCT00516282@29@-@-@@@-@@9/1/2007@-@-@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@COMBO@CLORETAZINE@@@@@CLORETAZINE||||@VION PHARMACEUTICALS@@@@@VION PHARMACEUTICALS||||@@@@@@|||||||||@Brain Cancer@@@@@Brain Cancer|||||||||@VNP-40101M@@@@@VNP-40101M||||@Alkylating Agent@@@@@Alkylating Agent||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@RELAPSED@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924829@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Cloretazine 600mg/m2 in 30-60 minute infusion on day 1 with an option for additional 400mg/m2 as a consolidation for responders.@@-@-@-@NEW HAVEN, CONNECTICUT@5/1/2006@@Cloretazine (VNP40101M) is a small molecule that works by damaging DNA. Cloretazine releases the DNA chloroethylating agent 90CE after entering the blood stream. 90CE chloroethylates the O6 position of guanine residues, ultimately resulting in an interstrand DNA cross-link. Interstrand DNA cross-links are difficult to repair and are toxic to cells. Cloretazine demonstrated a broad spectrum of anticancer activity in preclinical studies, including activity in selected cell lines resistant to other alkylating agents such as BCNU, cyclophosphamide and melphalan. In preclinical studies, Cloretazine has been combined with other anticancer agents such as cytarabine (Ara-C). In addition, Cloretazine or its metabolite, has been shown to be capable of crossing the blood brain barrier in preclinical models.@@14924829@AML and high-risk myelodysplastic syndromes@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@-@129@-@-@@@-@@3/1/2004@-@-@@-@129 PATIENTS AGED 60 OR OVER WITH PREVIOUSLY UNTREATED AML OR HIGH-RISK MDS.@@@II@II@@-@-@EHA June 2007 data in 59 patients; overall RR in patients with unfavourable cytogenetics was 25% (by diagnosis: de novo AML 48%, MDS 30% and secondary AML 7%). 12 patients (20%) died within 30 days of induction therapy.@-@@@@MONO@CLORETAZINE@@@@@CLORETAZINE||||@VION PHARMACEUTICALS@@@@@VION PHARMACEUTICALS||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@VNP-40101M@@@@@VNP-40101M||||@Alkylating Agent@@@@@Alkylating Agent||||@COMPLETE RESPONSE@@@@@@@@@@-@@@@@MULTI-CENTRE@INTERNATIONAL@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15402452@Onco@@@@@300f1010ntsdm@@@@@@@@L01XE23@L01X@@BASEL, SWITZERLAND@3/1/2013@@Trametinib is a reversible, highly selective, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and kinase activity. MEK proteins are components of the extracellular signal-related kinase (ERK) pathway. In melanoma and other cancers, this pathway is often activated by mutated forms of BRAF which activates MEK. Trametinib inhibits activation of MEK by BRAF and inhibits MEK kinase activity. Trametinib inhibits growth of BRAF V600 mutant melanoma cell lines and demonstrates anti-tumour effects in BRAF V600 mutant melanoma animal models.@@15402452@Trametinib as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.@Both@NO@@@NO REVIEW@@@@100%@@@NCT01245062@322@The recommended dose of trametinib, either used as monotherapy or in combination with dabrafenib, is 2 mg once daily.@EMA, 30 June 2014@6/30/2014@12/1/2015@No@@11/1/2010@@METRIC, 114267@No@@Stage III unresectable (Stage IIIc) or metastatic (Stage IV) cutaneous melanoma which is also determined to be BRAF V600E/K mutation-positive by the central laboratory Received no prior treatment or up to one prior regimen of chemotherapy for advanced or metastatic melanoma. Prior treatment with immunotherapy (with the exception of prior ipilimumab, which is only allowed if given in the adjuvant setting), cytokine therapy, biological or vaccine regimen is permitted. Prior use of sorafenib is allowed Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1)@BRAF V600 mutation@ADULTS@III@APPROVED@@@NHS@@@@@@MONO@TRAMETINIB@@@@@TRAMETINIB||||@NOVARTIS @@@@@NOVARTIS ||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@MEKINIST@@@@@MEKINIST||||@MEK Inhibitor@@@@@MEK Inhibitor||||@PROGRESSION-FREE SURVIVAL@@@@@OVERALL SURVIVAL@@@@@UNRESECTABLE@METASTATIC@@@@RANDOMISED@OPEN-LABEL@CROSSOVER@@@1@1@23359.488@@@4.8@month@4.8 month@23359.49@23359.49@160@7@1.299@1120@@@@@@@@@@@@80@1@@mg@2@1@@@@@@@@@@@7/28/2017@160@160@3.11E+16@FILM COATED TABLET@GB£@@@@@@@@2@MG@2 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14924952@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@AMG-706 alone@@-@-@-@THOUSAND OAKS, CALIFORNIA@@@Motesanib diphosphate is a highly selective, oral agent that is being evaluated for its ability to inhibit angiogenesis and lymphangiogenesis by targeting vascular endothelial growth factor receptors 1, 2 and 3 (“VEGFR1-3”). It is also under investigation for its potential direct anti-tumor activity by targeting platelet-derived growth factor receptor (“PDGFR”) and stem cell factor receptor (“c-kit”) signaling, which may also confer direct anti-tumor activity. In February 2008, Amgen announced that Takeda will become the worldwide partner for motesanib diphosphate in addition to an exclusive collaboration on up to 13 other programs in the Japanese market. @@14924952@Locally advanced or metastatic thyroid cancer@@-@-@@NO REVIEW@@@@-@Motesanib was the unofficial key to the wide-ranging, two-part R&D deal with Amgen signed in February 2008 through which, in its first part, Takeda acquired Japanese rights for up to 13 molecules in Amgen's pipeline, including Vectibix (panitumumab), AMG-@-@NCT00121628@184@-@-@@@-@@7/1/2005@-@20040273@@-@>> Histologically confirmed locally advanced or metastatic thyroid cancer - Measurable disease - Normal blood pressure (if history of hypertension, blood pressure must be controlled with medication) - Evidence of disease progression within 6 months before starting study (for differentiated thyroid cancer subjects) @@@II@II@@-@-@Trial registered [Amgen, 12.07.2005]@-@@@@MONO@MOTESANIB DIPHOSPHATE@@@@@MOTESANIB DIPHOSPHATE||||@AMGEN@TAKEDA PHARMACEUTICAL@@@@AMGEN|TAKEDA PHARMACEUTICAL|||@@@@@@|||||||||@Thyroid Cancer@@@@@Thyroid Cancer|||||||||@AMG-706@@@@@AMG-706||||@TK Inhibitor@VEGF@PDGF@SCF@@TK Inhibitor|VEGF|PDGF|SCF|@RECIST@@@@@DURATION OF RESPONSE@PROGRESSION-FREE SURVIVAL@BIOMARKERS@@@LOCALLY ADVANCED@METASTATIC@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917411@Onco@@@@@300f1037ntsdm@@@@@@NO LABELLED TRIAL@@L01AX04@L01A@YES@@@@Dacarbazine is a cytostatic agent. The antineoplastic effect is due to an inhibition of cell growth which is independent of the cell cycle and due to an inhibition of DNA synthesis. An alkylating effect has also been shown and other cytostatic mechanisms may also be influenced by dacarbazine. Dacarbazine is considered not to show an antineoplastic effect by itself. However by microsomal N-demethylation it is quickly converted to 5-amino-imidazole-4-carboxamide and a methyl cation, which is responsible for the alkylating effect of the drug.@@14917411@Dacarbazine is indicated for the treatment of patients with metastatic malignant melanoma. Further indications for dacarbazine as part of combination chemotherapy are: • Hodgkin's disease • Advanced adult soft tissue sarcomas (except mesothelioma, Kaposi sarcoma)@@YES@@@NO REVIEW@@@@90%@@@@@Hodgkin's Disease: Dacarbazine is administered in a daily dose of 375 mg/m2 body surface area i.v. on day 1 and day 15 in combination with doxorubicin, bleomycin and vinblastine for each cycle of ABVD regimen.@10-Jul-07@7/10/2007@@@@@It is recommended that dacarbazine be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. 1. Hemopoietic depression is the most common toxicity with dacarbazine. 2. Hepatic necrosis has been reported. 3. Studies have demonstrated this agent to have a carcinogenic and teratogenic effect when used in animals. 4. In treatment of each patient, the physician must weigh carefully the possibility of achieving therapeutic benefit against the risk of toxicity.@NO LABELLED TRIAL@No@@@@@@APPROVED@@NO REVIEW@SNS@NO LABELLED TRIAL@@@@@@DACARBAZINE@@@@@DACARBAZINE||||@MADAUS@@@@@MADAUS||||@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@@@@Haematological Malignancy|Hodgkin's Lymphoma||||||||@DTIC-DOME@@@@@DTIC-DOME||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@METASTATIC@MALIGNANT@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.1807@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@EURO@@@@@@@@500@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14921731@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Oxaliplatin/5-FU/leucovorin plus vatalanib versus this therapy without vatalanib.@@-@-@-@LEVERKUSEN, GERMANY@5/1/2004@@"Vatalanib (PTK/ZK) is a ""small"" molecule tyrosine kinase inhibitor with broad specificity that targets all VEGF receptors (VEGFR), the platelet-derived growth factor receptor, and c-KIT. It is a multi-VEGFR inhibitor designed to block angiogenesis and lymphangiogenesis by binding the intracellular kinase domain of all three VEGFRs, VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3 (Flt-4). Vatalanib is a targeted drug that inhibits the activity of all known receptors that bind VEGF. The drug potently inhibits the formation of new blood vessels (angiogenesis). "@@14921731@Metastatic first-line colorectal cancer@@-@-@@NO REVIEW@@@@-@Following a modified agreement in January 2005, Novartis and Schering AG co-market vatalanib in Europe, North America and Japan for oncology indications, whilst Schering AG maintains marketing rights for Latin America, Africa, Australia and Novartis for A@FIRST-LINE@NCT00056459@1090@-@-@@@-@@2/1/2003@-@CONFIRM-1@@-@-@@@III@DISCONTINUED@@-@-@Discontinued as part of strategic review by Bayer Schering in June 2007.@-@@@@COMBO@VATALANIB@@@@@VATALANIB||||@BAYER HEALTHCARE@NOVARTIS@@@@BAYER HEALTHCARE|NOVARTIS|||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@PTK-787@ZK-222584@PTK/ZK@@@PTK-787|ZK-222584|PTK/ZK||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@OVERALL SURVIVAL@PROGRESSION-FREE SURVIVAL@@@@@@@@@METASTATIC@@@@@RANDOMISED@DOUBLE-BLIND@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922132@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@2 x 100mg capsules daily @@-@-@-@BIRMINGHAM, ALABAMA@6/1/2009@@Forodesine HCl is a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP). The drug is currently being studied in clinical trials for indications including T-cell acute lymphoblastic leukemia (T-ALL), cutaneous T-cell lymphoma (CTCL) and chronic lymphocytic leukemia (CLL). @@14922132@Elderly patients@@-@-@@NO REVIEW@@@@-@In February 2006, BioCryst announced an exclusive licensing agreement with Mundipharma to develop and commercialise forodesine HCL for use in the treatment of oncology in markets across Europe, Asia, Australia and certain neighbouring countries.@FIRST-LINE@NCT00640523@26@-@-@@@-@@3/1/2008@-@BCX1777-210@@-@-@ELDERLY@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@FORODESINE@@@@@FORODESINE||||@BIOCRYST PHARMACEUTICALS@MUNDIPHARMA@@@@BIOCRYST PHARMACEUTICALS|MUNDIPHARMA|||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@FODOSINE@BCX-1777@@@@FODOSINE|BCX-1777|||@PNP Inhibitor@@@@@PNP Inhibitor||||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924524@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Ixabepilone 40 mg/m2 was administered as a 3-hour intravenous infusion on day 1 of a 21-day cycle for four or fewer cycles. [BMS]@@L01C@L01C@-@NEW YORK, NEW YORK@@@Ixabepilone is a microtubule inhibitor belonging to a class of antineoplastic agents, the epothilones and their analogs. The epothilones are isolated from the myxobacterium Sorangium cellulosum. Ixabepilone is a semisynthetic analog of epothilone B, a 16-membered polyketide macrolide, with a chemically modified lactam substitution for the naturally existing lactone. Ixabepilone is a semi-synthetic analog of epothilone B. Ixabepilone binds directly to ß-tubulin subunits on microtubules, leading to suppression of microtubule dynamics. Ixabepilone suppresses the dynamic instability of  ß-II and  ß-III microtubules. Ixabepilone possesses low in vitro susceptibility to multiple tumor resistance mechanisms including efflux transporters, such as MRP-1 and P-glycoprotein (P-gp). Ixabepilone blocks cells in the mitotic phase of the cell division cycle, leading to cell death.@@14924524@Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer@@-@-@@NO REVIEW@@@@-@-@-@-@161@-@-@@@-@@@-@-@@-@Patients with invasive breast cancer  3 cm but not amenable to breast conservation surgery were eligible.@@@II@II@@-@-@The overall complete pathologic response (pCR) rate was 18% in breast and 29% in estrogen receptor (ER) –negative patients. Gene expression data were available for 134 patients. ER gene expression (ER1) was inversely related to pCR in breast and had a positive predictive value (PPV) of 37% and negative predictive value (NPV) of 92%. A 10-gene penalized logistic regression (PLR) model developed from 200 genes predictive of ixabepilone sensitivity in preclinical experiments included ER and tau and had higher PPV (45%) and comparable NPV (89%) to ER1. [Journal of Clinical Oncology, Vol 27, No 4 (February 1), 2009: pp. 526-534]@Grade 3 to 4 adverse events (AEs) were reported for 32% of patients. Except for neutropenia and leukopenia, all grade 3 to 4 AEs occurred in  3% of patients. Reversible peripheral neuropathy was experienced by 3% of patients. @@@@NEOADJUVANT@IXABEPILONE@@@@@IXABEPILONE||||@BMS@@@@@BMS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@IXEMPRA@BMS-247550@@@@IXEMPRA|BMS-247550|||@Epothilone@@@@@Epothilone||||@GENE EXPRESSION@RESPONSE RATE@@@@SAFETY@@@@@-@@@@@SINGLE-ARM@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921147@Onco@@@@@300f1012ntsdm@@@@@@Tamoxifen compared to ovarian ablation@@L02BA01@L02B@YES@@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14921147@@@NO@@@NO REVIEW@@@@@@@@N/A@Adjuvant treatment of breast cancer, Adults (including elderly): The recommended dose is 20mg, given either in divided doses twice daily or as a single dose once daily. The current recommended treatment duration is five years; however the optimum duration has not been established. Treatment of locally advanced or metastatic breast cancer: The recommended dose is 20mg to 40mg, given either in divided doses twice daily or as a single dose once daily.@@@@@@@Women should be informed of the potential risks to the foetus, should they become pregnant whilst taking tamoxifen; or within two months of cessation of therapy. A number of secondary primary tumours, occurring at sites other than the endometrium and the opposite breast, have been reported in clinical trials, following the treatment of breast cancer patients with tamoxifen. No causal link has been established and the clinical significance of these observations remains unclear.@LABEL@No@@@@@III METASTATIC BREAST CANCER@APPROVED@@@GKV@The objective RR, time to treatment failure, and survival were similar with both treatments. In an overview analysis of survival data from the 3 studies, the hazard ratio for death (tamoxifen/ovarian ablation) was 1.00. Elevated serum and plasma oestrogens have been observed in premenopausal women receiving tamoxifen, but the data from the randomized studies do not suggest an adverse effect of this increase. A limited number of premenopausal patients with disease progression during tamoxifen therapy responded to subsequent ovarian ablation.@@@@@ADJUVANT@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@JUTA PHARMA@Q-PHARM@@@@JUTA PHARMA|Q-PHARM|||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@MANDOFEN@@@@@MANDOFEN||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RESPONSE RATE@@@@@@@@@@@@@@@PROSPECTIVE@RANDOMISED@@@@@@Invalid Factory Price@@@@@@@@@100@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@EURO@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14916012@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Zalutumumab combo with best supportive care versus BSC alone.@@-@-@-@COPENHAGEN, DENMARK@@@Zalutumumab is a fully human, high-affinity antibody targeted at the Epidermal Growth Factor receptor (EGFr) and is in clinical development to treat head and neck cancer, non small cell lung cancer (NSCLC) and colorectal cancer. EGFr is a receptor molecule found on the surface of many cancer cells. Activation of EGFr by the appropriate growth factor molecule promotes the growth of tumor cells. @@14916012@Non-curable squamous cell carcinoma of the head and neck.@@-@-@@NO REVIEW@@@@-@No licensing partner@MULTIPLE@NCT00382031@273@-@-@@@-@@@-@ZALUTE@@-@PATIENTS WITH SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY, OROPHARYNX, HYPOPHARYNX OR LARYNX WHO HAVE FAILED STANDARD PLATINUM-BASED CHEMO.@@@Hx-EGFr-202@III@@-@-@A planned interim analysis will take place based on the survival data for patients participating in the study. At present, the Company expects this analysis to occur in 2008, but the exact timing cannot be predicted. SOURCE: Genmab, 29 May 2008@-@@@@-@ZALUTUMUMAB@@@@@ZALUTUMUMAB||||@GENMAB@@@@@GENMAB||||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@HUMAX-EGFR@@@@@HUMAX-EGFR||||@mAb@Human@TK Inhibitor@EGFR@@mAb|Human|TK Inhibitor|EGFR|@OVERALL SURVIVAL@SAFETY@TIME TO PROGRESSION@@@TIME TO PROGRESSION@@@@@REFRACTORY@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922605@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Avastin with Tarceva@@L01XC07@L01X@-@SAN FRANCISCO, CALIFORNIA@@@Avastin (Bevacizumab) is a recombinant humanized monoclonalIgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems. Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF (1). Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models ofangiogenesis. Administration of Bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.@@14922605@Unresectable hepatocellular cancer with Tarceva@@-@-@@NO REVIEW@@@@-@">> Roche reaches a friendly agreement to purchase the latter's outstanding shares at a price of US$95 per share. The transaction will be valued at US$46.8 billion. [Genentech, 12 March 2009]>> Roche has made a formal announcement of cash tender offer for all outstanding shares of Genentech at US$86.50 per share for the 44.2% of Genentech not already held by Roche. Genentech's special committee, on the other hand, has responded to the offer by urging its shareholders ""to take no action at this time"". [Genentech, 10.02.2009]          >> Genentech rejects the acquisition bid. [Genentech, 14.08.2008]        >> Roche announces US$43.7 billion proposal to assume full control of Genentech. SOURCE: Roche, 21 July 2008"@-@NCT00242502@40@-@-@@@-@@10/1/2005@-@2004-0874@@NOT YET AVAILABLE; POTENTIALLY 2018.@-@@@II@II@@-@-@RESULTS PENDING (recruiting).@-@@@@COMBO@BEVACIZUMAB@ERLOTINIB@@@@BEVACIZUMAB|ERLOTINIB|||@GENENTECH@@@@@GENENTECH||||@@@@@@|||||||||@Liver Cancer@@@@@Liver Cancer|||||||||@AVASTIN@TARCEVA@@@@AVASTIN|TARCEVA|||@mAb@Humanised@TK Inhibitor@VEGF@@mAb|Humanised|TK Inhibitor|VEGF|@PROGRESSION-FREE SURVIVAL@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16671824@Onco@@@@@300f1012ntsdm@@@@@@@@L01XC06@L01X@@NEW YORK, NEW YORK@@@Erbitux is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Cetuximab is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions and has an approximate molecular weight of 152 kDa. Cetuximab is produced in mammalian (murine myeloma) cell culture.@@16671824@Treatment of patients with epidermal growth factor receptor (EGFR)-expressing, KRAS wild-type metastatic colorectal cancer in combination with FOLFOX4@Both@YES@@@@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@>> Acquisition completed. [Lilly, 24.11.2008]          >> Lilly acquires ImClone for US$6.5 billion. [Lilly, 7.10.2008]        >> BMS Offers US$4.3Billion for ImClone or US$60.0 per share in cash. [BMS, 1 August 2008]      >> ImClone licensed co-development and co-promotion rights to BMS in North America and Japan, and to Merck KGaA in Europe.@@@337@@EMA, 23 June 2011@6/23/2011@@No@@@@EMR 62 202-047@No@@@(EGFR)-expressing, KRAS WILD-TYPE@ADULTS@@APPROVED@@@GKV@@@@@@COMBO@CETUXIMAB@OXALIPLATINE@LEUCOVORIN@5-FLOUROURACIL@@CETUXIMAB|OXALIPLATINE|LEUCOVORIN|5-FLOUROURACIL|@BMS@IMCLONE@MERCK SERONO@@@BMS|IMCLONE|MERCK SERONO||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ERBITUX@FOLFOX4@@@@ERBITUX|FOLFOX4|||@mAb@Chimeric@TK Inhibitor@EGFR@@mAb|Chimeric|TK Inhibitor|EGFR|@@@@@@@@@@@METASTATIC@@@@@@@@@@1.75@m²@53052.8904@@@12@month@12 month@53052.89@53052.89@145.35@1@1.1511@229.92@301.68@237.87@@@@@@@@@@2.3@7@1@mg/m²@400@1@7@@mg/m²@250@1@@@@@@8/1/2017@229.92@229.92@493528@SOLUTION FOR INFUSION 20 MG@EURO@@@@@@@@100@MG@5 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14918152@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01BC02@L01B@YES@CANONSBURG, PENNSYLVANIA@@@Fluorouracil is an analogue of uracil, a component of ribonucleic acid. The drug is believed to function as an antimetabolite. After intracellular conversion to the active deoxynucleotide, it interferes with the synthesis of DNA by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase. Fluorouracil may also interfere with RNA synthesis.@@14918152@Fluorouracil may be used alone, or in combination, for the management of common malignancies particularly cancer of the colon and breast.@@YES@5-Dec@@NO REVIEW@@@@@Acquired through takeover of generics unit of Merck KGaA@@@@Intravenous infusion: 15mg/kg bodyweight but not more than 1g per infusion, diluted in 300 - 500ml of 5% glucose or 0.9% NaCl injection and given over 4 hours. Alternatively the daily dose may be infused over 30 - 60 minutes or may be given as a continuous infusion over 24 hours. The infusion may be repeated daily until there is evidence of toxicity or a total dose of 12 - 15g has been reached. Intravenousi Injection: l2mg/kg bodyweight may be given daily for 3 days and then, if there is no evidence of toxicity, 6mg/kg on alternate days for 3 further doses. An alternative regimen is 15mg/kg as a single intravenous injection once a week throughout the course. Intra-arterial infusion: 5/7.5mg/kg bodyweight daily may be given by 24 hour continuous intra-arterial infusion.@1-Nov-00@11/1/2000@6/1/2001@@@@Intravenous infusion: 15mg/kg bodyweight but not more than 1g per infusion, diluted in 300 - 500ml of 5% glucose or 0.9% NaCl injection and given over 4 hours. Alternatively the daily dose may be infused over 30 - 60 minutes or may be given as a continuous infusion over 24 hours. The infusion may be repeated daily until there is evidence of toxicity or a total dose of 12 - 15g has been reached. Intravenousi Injection: l2mg/kg bodyweight may be given daily for 3 days and then, if there is no evidence of toxicity, 6mg/kg on alternate days for 3 further doses. An alternative regimen is 15mg/kg as a single intravenous injection once a week throughout the course. Intra-arterial infusion: 5/7.5mg/kg bodyweight daily may be given by 24 hour continuous intra-arterial infusion.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@FLUOROURACIL@@@@@FLUOROURACIL||||@MYLAN@@@@@MYLAN||||@@@@@@|||||||||@Colorectal Cancer@Breast Cancer@@@@Colorectal Cancer|Breast Cancer||||||||@GENERIC@@@@@GENERIC||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@2.08@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/2/2017@2.08@2.08@9227685R@SOLUTION FOR PERFUSION  (VIAL 10 ML)@EURO@@@@@@@@500@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14922463@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Escalating doses of CP-675,206 will be administered by IV infusion on day 1 of each 84-day treatment cycles (doses of 6, 10 and 15 mg/kg are planned). Gemcitabine will be administered by IV infusion, at a fixed dose of 1000 mg/m2 on days 1 (prior to CP-675,206) and again on days 8, 15, 29, 36, 43, 57, 64, and 71. Repeated cycles of gemcitabine and CP-675,206 will be administered until patients develop progressive disease or unacceptable toxicity, or for a maximum of 4 cycles, whichever occurs first. SOURCE: clinicaltrials.gov@@-@-@-@NEW YORK, NEW YORK@9/1/2009@@Tremelimumab is a fully human anti-CTLA4 (cytotoxic T-lymphocyte antigen 4) IgG2 monoclonal antibody developed by Pfizer for its potential therapeutic application in melanoma, non-small cell lung cancer (NSCLC) and colorectal cancer. CTLA4 is a CD28-family receptor expressed mainly on T-lymphocyte that acts to inhibit T-lymphocyte function.@@14922463@Combo with Gemzar; previously treated melanoma@@-@-@@NO REVIEW@@@@-@Medarex entitled to royalties@-@NCT00556023@48@-@-@@@-@@3/1/2008@-@A3671016@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@COMBO@TREMELIMUMAB@TICILIMUMAB@GEMCITABINE@@@TREMELIMUMAB|TICILIMUMAB|GEMCITABINE||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@CP-675206@GEMZAR@@@@CP-675206|GEMZAR|||@mAb@CTLA4 Receptor Antagonist@@@@mAb|CTLA4 Receptor Antagonist|||@DOSE-LIMITING TOXICITY@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919883@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Evista 60mg once daily versus placebo@@G03XC01@G03X@YES@INDIANAPOLIS, INDIANA@@@As a selective oestrogen receptor modulator (SERM), raloxifene has selective agonist or antagonist activities on tissues responsive to oestrogen. It acts as an agonist on bone and partially on cholesterol metabolism (decrease in total and LDL-cholesterol), but not in the hypothalamus or in the uterine or breast tissues. Raloxifene's biological actions, like those of oestrogen, are mediated through high affinity binding to oestrogen receptors and regulation of gene expression. This binding results in differential expression of multiple oestrogen-regulated genes in different tissues. Recent data suggests that the oestrogen receptor can regulate gene expression by at least two distinct pathways which are ligand-, tissue-, and/or gene-specific.@@14919883@Indicated for the treatment and prevention of osteoporosis in postmenopausal women. September 2007; label expanded to include reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis, and reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer. Important Limitations: Evista is not indicated for the treatment of invasive breast cancer, reduction of the risk of recurrence of breast cancer, or reduction of risk of noninvasive breast cancer@@@@@NO REVIEW@@@@Co-pay tier 2. SOURCE: Aetna Preferred Drug Guide 2008@@@@N/A@The recommended dosage is one 60mg tablet daily, which may be administered any time of day without regard to meals. For the indications in risk of invasive breast cancer the optimum duration of treatment is not known.@FDA, 13 September 2007@9/13/2007@@@@@Increased risk of deep vein thrombosis and pulmonary embolism have been reported with Evista. Women with active or past history of venous thromboembolism should not take Evista. Increased risk of death due to stroke occurred in a trial in postmenopausal women with documented coronary heart disease or at increased risk for major coronary events. Consider risk-benefit balance in women at risk for stroke.@MORE@No@JULY 2012 (OSTEOPOROSIS); MARCH 2017@@@@III@APPROVED@@Covered; preferred brand; special coverage@MEDICARE@Evista reduced breast cancers by 62% and invasive BC by 71%; reduced ER-positive IBCs by 80%.@@@@@MONO@RALOXIFENE HYDROCHLORIDE@@@@@RALOXIFENE HYDROCHLORIDE||||@LILLY@@@@@LILLY||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@EVISTA@@@@@EVISTA||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RISK RATIO@@@@@@@@@@@@@@@RANDOMISED@PLACEBO-CONTROLLED@DOUBLE-BLIND@@@@@Invalid Factory Price@@@@@@@@@2000@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@00002-4165-07@TABLET@US$@@@@@@@@60@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920916@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@1 hr IV infusion of 18 mg/m2 Q 21 days. @@-@-@-@BRENTFORD, UNITED KINGDOM@@@Ispinesib is a novel small molecule drug candidate that inhibits cell proliferation and promotes cancer cell death by specifically disrupting the function of a cytoskeletal protein known as kinesin spindle protein, or KSP. Current drugs that inhibit cell proliferation, such as paclitaxel and docetaxel, are standard treatments for many types of cancers, but these drugs also target other proteins that are essential to other important cellular functions and thus, their use is limited by side effects. @@14920916@Platinum/taxane resistant or refractory ovarian cancer@@-@-@@NO REVIEW@@@@-@Part of wide-ranging 2001 partnership between Cytokinetics and GSK to discover and commercialise small moleculaes targeting mitotic kinesins in cancer; being positioned against Nexavar and Sutent@-@NCT00097409@IN STAGE I, 20 EVALUABLE PTS WERE ENROLLED.@-@-@@@-@@1/1/2004@-@KSP20008@@-@IN STAGE I, 20 EVALUABLE PTS WERE ENROLLED.@@@II@DISCONTINUED@@-@-@>> Cytokinetics is discontinuing research activities related to oncology. [Cytokinetics, 16.09.2008]>> The best CA-125 response was SD in 10 pts (45%); 12 pts had PD (55%). The best radiographic response was a confirmed PR lasting > 30 weeks in one pt who also met CA-125 progression criteria (5%); 5 pts (26%) had SD; and 13 pts (68%) had PD. The most common AEs, in decreasing order, were neutropaenia, fatigue, anaemia, leukopaenia, thrombocytopaenia, diarrhoea, nausea, vomiting, and decreased appetite. The most frequent Gr 3/4 AE was neutropaenia. Conclusion: The study was terminated after Stage I as there was no CA-125 response (Rustin criteria). [Cytokinetics, June 2006]@-@@@@-@ISPINESIB@@@@@ISPINESIB||||@GSK@CYTOKINETICS@@@@GSK|CYTOKINETICS|||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@SB-715992@@@@@SB-715992||||@KSP Inhibitor@@@@@KSP Inhibitor||||@STABLE DISEASE@RESPONSE RATE@RECIST@@@RECIST@@@@@REFRACTORY@REFRACTORY@@@@2-STAGE@GREEN-DAHLBERG@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924555@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@REDWOOD, CALIFORNIA@@@Volociximab is a chimeric monoclonal antibody that inhibits the functional activity of a5ß1 integrin, a protein found on activated endothelial cells that are involved in the formation of blood vessels. Volociximab is currently being investigated in Phase 2 clinical trials in patients with advanced solid tumors. PDL BioPharma and Biogen Idec have a broad collaboration for the joint development, manufacture and commercialization of volociximab.@@14924555@Renal cell carcinoma metastases@@-@-@@NO REVIEW@@@@-@Biogen Idec and PDL announced a broad collaboration for the joint development, manufacture and commercialization of three Phase II antibody products. The agreement provides for shared development and commercialization of daclizumab in multiple sclerosis and indications other than transplant and respiratory diseases, and for shared development and commercialization of M200 (volociximab) and HuZAF(TM) (fontolizumab) in all indications. Under terms of the agreement, PDL will receive an upfront payment of $40 million, and Biogen Idec will purchase $100 million of common stock from PDL. If multiple products were developed successfully in multiple indications and all milestones were achieved, PDL could receive certain development and commercialization milestone payments totaling up to $660 million. Of these, $560 million are related to development and $100 million are related to commercialization of collaboration products. Biogen Idec and PDL will share equally the costs of all development activities and all operating profits from each collaboration product within the United States and Europe. The companies will jointly oversee development, manufacturing and commercialization plans for collaboration products and intend to divide implementation responsibilities to leverage each company's capabilities and expertise. Each party will have co-promotion rights in the United States and Europe. Outside the United States and Europe, Biogen Idec will fund all incremental development and commercialization costs and pay a royalty to PDL on sales of collaboration products. [Biogen, 2.08.2005]@-@NCT-00100685@60@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@VOLOCIXIMAB@@@@@VOLOCIXIMAB||||@PDL BIOPHARMA@BIOGEN IDEC@@@@PDL BIOPHARMA|BIOGEN IDEC|||@@@@@@|||||||||@Kidney Cancer@@@@@Kidney Cancer|||||||||@M-200@@@@@M-200||||@mAb@Chimeric@Angiogenesis Inhibitor@@@mAb|Chimeric|Angiogenesis Inhibitor||@RESPONSE RATE@TIME TO PROGRESSION@DURATION OF RESPONSE@@@DURATION OF RESPONSE@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920899@Onco@@@@@300f1037ntsdm@@@@@@NO LABELLED TRIAL@@L01AA02@L01A@YES@BRENTFORD, UNITED KINGDOM@@@Leukeran is a bifunctional alkylating agent of the nitrogen mustard type that has been found active against selected human neoplastic diseases.@@14920899@Leukeran is indicated in the treatment of Hodgkin's disease, certain forms of non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, and Waldenstrom's macroglobulinaemia@@NO@-@@NO REVIEW@@@@90%@-@-@-@-@Hodgkin's Disease: Used as a single agent in the palliative treatment of advanced disease a typical dosage is 0.2 mg/kg/day for 4-8 weeks. Leukeran is usually included in combination therapy and a number of regimes have been used. Leukeran has been used as an alternative to nitrogen mustard with a reduction in toxicity but similar therapeutic results. Non-Hodgkin's Lymphoma: Used as a single agent the usual dosage is 0.1-0.2 mg/kg/day for 4-8 weeks initially, maintenance therapy is then given either by a reduced daily dosage or intermittent courses of treatment. Leukeran is useful in the management of patients with advanced diffuse lymphocytic lymphoma and those who have relapsed after radiotherapy. There is no significant difference in the overall response rate obtained with chlorambucil as a single agent and combination chemotherapy in patients with advanced non-Hodgkin's lymphocytic lymphoma. Chronic Lymphocytic Leukaemia: Treatment with Leukeran is usually started after the patient has developed symptoms or when there is evidence of impaired bone marrow function (but not bone marrow failure) as indicated by the peripheral blood count. Initially Leukeran is given at a dosage of 0.15 mg/kg/day until the total leucocyte count has fallen to 10,000 per µL. Treatment may be resumed 4 weeks after the end of the first course and continued at a dosage of 0.1 mg/kg/day.@4/22/2004@@@-@@@Can severely suppress bone marrow function. Chlorambucil is a carcinogen in humans. Chlorambucil is probably mutagenic and teratogenic in humans. Chlorambucil produces human infertility@NO LABELLED TRIAL@No@-@-@@@-@DISCONTINUED@@NO REVIEW@SNS@NO LABELLED TRIAL@-@@@@-@CHLORAMBUCIL@@@@@CHLORAMBUCIL||||@GSK@@@@@GSK||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@Hodgkin's Lymphoma@Non-Hodgkin's Lymphoma@@Haematological Malignancy|Chronic Lymphocytic Leukaemia|Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma||||||@LEUKERAN@@@@@LEUKERAN||||@Alkylating Agent@@@@@Alkylating Agent||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@100@1.3598@@@@@@@@@@@@@@@@@@@@@@@@@@@@@9/2/2015@@@779363@FILM-COATED TABLET@EURO@@@@@@@@2@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14924560@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@MDX-010 with or without prophylactic oral budesonide (Entocort EC).@@-@-@-@PRINCETON, NEW JERSEY@@@Ipilimumab is a fully human antibody that binds to CTLA-4 (cytotoxic T lymphocyte-associated antigen 4), a molecule on T-cells that plays a critical role in regulating natural immune responses. The absence or presence of CTLA-4 can augment or suppress the immune system's T-cell response in fighting disease. Ipilimumab is designed to block the activity of CTLA-4, thereby sustaining an active immune response in its attack on cancer cells.@@14924560@Previously treated unresectable stage III/IV malignant melanoma@@-@-@@NO REVIEW@@@@-@>>BMS acquires Medarex in July 2009>>BMS and Medarex announced a worldwide collaboration to develop and commercialize MDX-010. The collaboration also includes MDX-1379, an investigational gp100 peptide vaccine, which will be developed for potential use in combination with MDX-010 in melanoma. BMS and Medarex have agreed to jointly continue to investigate the development of MDX-010 in additional tumor types. BMS and Medarex will share in the costs of developing MDX-010 and MDX-1379 in the United States and Europe based on a pre-agreed percentage allocation.  BMS will be responsible for all development outside of these territories. Medarex will receive an initial cash payment of $50 million, of which $25 million will be a purchase of Medarex's common stock by Bristol-Myers Squibb at a premium to the market price.  Medarex could receive up to $205 million if all regulatory milestones are met, and up to $275 million in sales- related milestones.  Medarex will have an option to co-promote and share profits with BMS in the United States based on a pre-agreed percentage split. Bristol-Myers Squibb will receive an exclusive license ex-US and pay royalties to Medarex. [BMS, 8.11.2004]@SECOND-LINE@NCT00135408@110@-@-@@@-@@11/1/2005@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@IPILIMUMAB@@@@@IPILIMUMAB||||@MEDAREX@BMS@@@@MEDAREX|BMS|||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@YERVOY@@@@@YERVOY||||@mAb@Human@CTLA4 Receptor Antagonist@@@mAb|Human|CTLA4 Receptor Antagonist||@DIARRHOEA@@@@@@@@@@REFRACTORY@MALIGNANT@@@@RANDOMISED@DOUBLE-BLIND@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRAVENOUS@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921787@Onco@@@@@@@@@@@N/A@@-@-@-@BASEL, SWITZERLAND@@@A cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing hyperacetylation of core histone proteins, which may result in modulation of cell cycle protein expression, cell cycle arrest in the G2/M phase and apoptosis. In addition, this agent appears to modulate the expression of angiogenesis-related genes, such as hypoxia-inducible factor-1alpha (HIF-1a) and vascular endothelial growth factor (VEGF), thus impairing endothelial cell chemotaxis and invasion. HDAC is an enzyme that deacetylates chromatin histone proteins.@@14921787@Adult patients; combo of Revlimid and dexamethasone with LBH-589@@-@-@@NO REVIEW@@@@-@-@-@NCT00532675@45@-@EMEA PDCO recommended product-specific waiver. SOURCE: EMEA PDCO, January 2008Orphan designation was granted by the European Commission for panobinostat lactate for the treatment of cutaneous T cell lymphoma. [There is discussion of current treatments, the numbers or persons affected with this condition in the EU, and the mode of action & state of development of panobinostat lactate for the treatment of this condition. Panobinostat lactate was not authorised anywhere in the world for cutaneous T-cell lymphoma, or designated as orphan medicinal product elsewhere for this condition, at the time of submission. Designated orphan medicinal products are still investigational products which were considered for designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of the quality, safety and efficacy will be necessary before this product can be granted a marketing authorisation.] SOURCE: EMEA COMP, 6 November 2007@11/6/2007@@-@@9/1/2007@-@CLBH589B2206@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@COMBO@PANOBINOSTAT@LENALIDOMIDE@@@@PANOBINOSTAT|LENALIDOMIDE|||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@LBH-589@REVLIMID@@@@LBH-589|REVLIMID|||@HDAC@@@@@HDAC||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@-@@@@@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14919882@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Evista 60mg once daily versus placebo@@G03XC01@G03X@YES@INDIANAPOLIS, INDIANA@@@As a selective oestrogen receptor modulator (SERM), raloxifene has selective agonist or antagonist activities on tissues responsive to oestrogen. It acts as an agonist on bone and partially on cholesterol metabolism (decrease in total and LDL-cholesterol), but not in the hypothalamus or in the uterine or breast tissues. Raloxifene's biological actions, like those of oestrogen, are mediated through high affinity binding to oestrogen receptors and regulation of gene expression. This binding results in differential expression of multiple oestrogen-regulated genes in different tissues. Recent data suggests that the oestrogen receptor can regulate gene expression by at least two distinct pathways which are ligand-, tissue-, and/or gene-specific.@@14919882@Indicated for the treatment and prevention of osteoporosis in postmenopausal women. September 2007; label expanded to include reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis, and reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer. Important Limitations: Evista is not indicated for the treatment of invasive breast cancer, reduction of the risk of recurrence of breast cancer, or reduction of risk of noninvasive breast cancer@@@@@NO REVIEW@@@@Co-pay tier 2. SOURCE: Aetna Preferred Drug Guide 2008@@@@N/A@The recommended dosage is one 60mg tablet daily, which may be administered any time of day without regard to meals. For the indications in risk of invasive breast cancer the optimum duration of treatment is not known.@FDA, 13 September 2007@9/13/2007@@@@@Increased risk of deep vein thrombosis and pulmonary embolism have been reported with Evista. Women with active or past history of venous thromboembolism should not take Evista. Increased risk of death due to stroke occurred in a trial in postmenopausal women with documented coronary heart disease or at increased risk for major coronary events. Consider risk-benefit balance in women at risk for stroke.@MORE@No@JULY 2012 (OSTEOPOROSIS); MARCH 2017@@@@III@APPROVED@@Covered; preferred brand; special coverage@MEDICARE@Evista reduced breast cancers by 62% and invasive BC by 71%; reduced ER-positive IBCs by 80%.@@@@@MONO@RALOXIFENE HYDROCHLORIDE@@@@@RALOXIFENE HYDROCHLORIDE||||@LILLY@@@@@LILLY||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@EVISTA@@@@@EVISTA||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RISK RATIO@@@@@@@@@@@@@@@RANDOMISED@PLACEBO-CONTROLLED@DOUBLE-BLIND@@@@@Invalid Factory Price@@@@@@@@@100@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@00002-4165-02@TABLET@US$@@@@@@@@60@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919181@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@The treatment consistS of 1-3 selective hepatic artery embolizations at approximately 5-week intervals, based upon the extent of hepatic involvement with the tumour. Sunitinib malate (Sutent) will be administered daily on days 1-28 of a 42 day cycle.@@L01XE04@L01X@-@NEW YORK, NEW YORK@@@Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFR? and PDGFRß), vascular endothelial growth factor receptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays. Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFRß, VEGFR2, KIT) in tumor xenografts expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit PDGFRß- and VEGFR2-dependent tumor angiogenesis in vivo.@@14919181@Hepatic artery embolisation for metastatic gastrointestinal neuroendocrine tumours@@-@-@@NO REVIEW@@@@-@Acquired through takeover of Pharmacia Corp., which acquired it from Sugen@-@NCT00434109@39@-@-@@@-@@11/1/2006@-@MCC-14888@@JANUARY 2011 (NCE EXCLUSIVITY); FEBRUARY 2021 (GIST PATENT)@-@@@II@II@@-@-@Endpoint at 1 year.@-@@@@MONO@SUNITINIB MALEATE@@@@@SUNITINIB MALEATE||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Carcinoid / Neuroendocrine Tumour@@@@@Carcinoid / Neuroendocrine Tumour|||||||||@SUTENT@@@@@SUTENT||||@TK Inhibitor@VEGF@PDGF@SCF@@TK Inhibitor|VEGF|PDGF|SCF|@PROGRESSION-FREE SURVIVAL@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16380377@Onco@@@@@300f1008ntsdm@@@@@@@@L01BC07@L01B@@SUMMIT, NEW JERSEY@@@Vidaza is a nucleoside analog of cytidine and is believed to exert its antineoplastic effects by causing hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow. By inhibiting hypermethylation, Vidaza may restore normal expression to silent genes critical to cell differentiation and proliferation. Vidaza appears to exhibit its effects, inhibition of hypermethylation and direct toxicity, when cells are actively dividing.1 Because all cells are not in the same phase simultaneously, longer treatment time will expose more rapidly dividing cells to Vidaza. Vidaza also causes death of rapidly dividing cancer cells no longer responsive to normal growth control mechanisms.1 Cells that do not divide rapidly are relatively insensitive to Vidaza.@@16380377@Treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with intermediate-2 and high-risk MDS according to the International Prognostic Scoring System (IPSS); chronic myelomonocytic leukaemia (CMML) with 10-29 percent marrow blasts without myeloproliferative disorder; or Acute Myeloid Leukemia (AML) with 20-30 percent blasts and multi-lineage dysplasia, according to World Health Organization (WHO) classification.@@NA@1-Apr-10@4/1/2010@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@@@53@The recommended starting dose for the first treatment cycle, for all patients regardless of baseline haematology laboratory values, is 75 mg/m2 of body surface area, injected subcutaneously, daily for 7 days, followed by a rest period of 21 days (28-day treatment cycle). It is recommended that patients be treated for a minimum of 6 cycles. Treatment should be continued as long as the patient continues to benefit or until disease progression.@@@3/11/2011@@@@@@No@@@@@@APPROVED@@@NHI@@@@@@MONO@AZACITIDINE@@@@@AZACITIDINE||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myelodysplastic Syndrome@@@@Haematological Malignancy|Myelodysplastic Syndrome||||||||@VIDAZA@@@@@VIDAZA||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@@@@@@@@@@@@@@@@@@@@@1.75@m²@7211178.529@@@504@day@504 day@7211178.53@7211178.53@14307.89@1@0.0091@43605.01@51421@@@@@@@@@@@436.05@28@@mg/m²@75@7@@@@@@@@@@@8/30/2017@43605.01@43605.01@4291419D1026@POWDER FOR INJECTABLE SUSPENSION - 4 ML@YEN@@@@@@@@100@MG@100 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14919597@Onco@@@@@300f1015ntsdm@@@@@@@@L01XX19@L01X@YES@CANONSBURG, PENNSYLVANIA@@@Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks.@@14919597@CAMPTO is indicated for the treatment of patients with advanced colorectal cancer as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen.@@YES@@@NO REVIEW@@@@@@SECOND-LINE@@@The recommended dosage of CAMPTO is 350 mg/m² administered as an intravenous infusion over a 30- to 90- minute period every three weeks.Treatment with CAMPTO should be continued until there is an objective progression of the disease or an unacceptable toxicity.@@@7/17/2009@@@@Can induce both early and late forms of diarrhea. Both forms of diarrhea may be severe. Early diarrhea (occurring during or shortly after infusion may be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping. Late diarrhea (generally occurring more than 24 hours after administration) can be life threatening since it may be prolonged and may lead to dehydration, electrolyte imbalance, or sepsis. Patients with diarrhea should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated or antibiotic therapy if they develop ileus, fever, or severe neutropenia. Severe myelosuppression may also occur.@@No@@@@@@APPROVED@@No ASMR/SMR rating@HAUTE AUTORITÉ DE SANTÉ@@@@@@MONO@IRINOTECAN@@@@@IRINOTECAN||||@MYLAN@@@@@MYLAN||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@@@@@@@@@@@ADVANCED@@@@@@@@@@1.75@m²@Invalid Factory Price@@@3.9@month@3.9 month@@@@1@1.1511@@@@@@@@@@@@@@21@@mg/m²@350@1@@@@@@@@@@@@@@9326246T@DILUTED SOLUTION FOR PERFUSION, 2 ML@EURO@@@@@@@@40@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
16395632@Onco@@@@@300f1012ntsdm@@@@@@@@L04AX04@L04A@@SUMMIT, NEW JERSEY@3/1/2017@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16395632@Treatment of adult patients with relapsed or refractory mantle cell lymphoma@Both@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@NCT00875667@254@The recommended starting dose of lenalidomide is 25 mg orally once daily on days 121 of repeated 28day cycles.@EMA, 28 January 2016@1/28/2016@@Yes@@4/1/2009@@CC5013MCL002@No@@Biopsy proven mantle cell lymphoma; Patients who are refractory to their regimen or have relapsed once, twice or up to three times and who have documented progressive disease; Eastern Cooperative Oncology Group (ECOG) performance score 0,1, or 2; Willing to follow pregnancy precaution@@ADULTS@II@APPROVED@@@GKV@@@@@@MONO@LENALIDOMIDE@@@@@LENALIDOMIDE||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Non-Hodgkin's Lymphoma@Mantle Cell Lymphoma@@@@Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma||||||||@REVLIMID@@@@@REVLIMID||||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@PROGRESSION FREE SURVIVAL@@@@@OVERALL RESPONSE RATE@DURATION OF RESPONSE@TIME TO PROGRESSION@@@RELAPSED@REFRACTORY@@@@RANDOMISED@MULTI-CENTRE@OPEN LAB EL@@@1@1@91516.83311@@@37.6@week@37.6 week@91516.83@91516.83@347.71@21@1.1511@5841.5@7217.24@5880@@@@@@@@@@18.54@28@@mg@25@21@@@@@@@@@@@8/1/2017@278.17@278.17@1875278@HARD CAPSULE@EURO@@@@@@@@15@MG@15 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14922283@Onco@@@@@@@@@@@Equivalence of ANX-530 75 mg/m2  with Taxotere 75 mg/m2 [Adventrx]  @@-@-@-@SAN DIEGO, CALIFORNIA@@@ANX-514 is a novel nano-emulsion formulation of the chemotherapy drug docetaxel, which is marketed under the brand name Taxotere. ANX-514 is formulated without polysorbate 80 or other detergents and is intended to reduce the severity and/or incidence of hypersensitivity reactions. Docetaxel is an anti-cancer agent that acts by disrupting the cellular microtubular network that is essential for cell division. Immunosuppressant premedication is recommended for docetaxel therapy to reduce the incidence and severity of hypersensitivity reactions. Docetaxel is approved to treat breast, non-small cell lung, prostate, gastric and head and neck cancers.@@14922283@A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer@@-@-@@NO REVIEW@@@@-@"Adventrx is ""exploring strategic alternatives"", including the potential sale of its key oncology assets ANX-514 and ANX-530. The company has already reduced its size by 27% to 24 in October. [Adventrx, 22.12.2008]"@-@NCT00664170@28@-@>> NDA to be filed in Q2 2009 [Adventrx, 22.12.2008]             >> NDA to be filed by Q4 2008 [Adventrx, January 2008]         >> NDA to be filed by year-end 2007. [Adventrx, July 2008]@@@-@@4/1/2008@-@ANX 514-01@@-@Advanced cancer potentially sensitive to single agent docetaxel; ie.. locally advanced or metastatic breast cancer, locally advanced non-small cell lung cancer, hormone refractory metastatic prostate cancer, other tumor type with no standard treatment. @@@I@I@@-@-@>> Patient enrolment completed [Adventrx, 5 February 2009] >> Trial registered. [Adventrx, 18.04.2008]@-@@@@MONO@DOCETAXEL EMULSION@DOCETAXEL@@@@DOCETAXEL EMULSION|DOCETAXEL|||@ADVENTRX PHARMACEUTICAL@@@@@ADVENTRX PHARMACEUTICAL||||@Argentina@@@@@Argentina|||||||||@Solid Tumours@Breast Cancer@NSCLC@HRPC@@Solid Tumours|Breast Cancer|NSCLC|HRPC||||||@ANX-514@TAXOTERE@@@@ANX-514|TAXOTERE|||@Taxane@@@@@Taxane||||@BIOEQUIVALENCE@SAFETY@@@@@@@@@ADVANCED@@@@@PIVOTAL@RANDOMISED@OPEN-LABEL@BIOEQUIVALENCE@CROSSOVER@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924187@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@MADRID, SPAIN@@@Aplidin is a novel marine-derived anti-tumour agent, originally isolated from the tunicate Aplidium albicans and currently obtained by total synthesis. Aplidin, is PharmaMar's second most advanced compound, currently in Phase II clinical trials. Aplidin mechanism of action is still under investigation. Aplidin induces apoptosis rapidly and persistently, inhibits VEGF secretion and blocks cell-cycle. @@14924187@Paediatric trial including neuroblastoma, medulloblastoma and pancreatoblastoma@@-@-@@NO REVIEW@@@@-@PharmaMar is part of the Zeltia Group.@-@-@22@-@-@@@-@@@-@-@@-@-@PAEDIATRIC@@I/II@II@@-@-@Discussions ongoing with EMEA and FDA to commence a pivotal programme in neuroblastoma with malignancy. SOURCE: Zeltia, 28 February 2008The observed toxicity and pharmacokinetic profiles in the paediatric population were similar to that seen in adults, with most toxicities being mild to moderate. Bone marrow toxicity was low. Pharmacokinetic studies confirm a long half life and extensive tissue distribution with clearance increasing with age. The recommended dose in paediatric patients is 5mg/m2, the same as in adults. Preliminary anti-tumour activity was observed in neuroblastoma, medulloblastoma and pancreatoblastoma. SOURCE: PharmaMar/EORTC, 14 November 2006@-@@@@-@PLITIDEPSIN@@@@@PLITIDEPSIN||||@PHARMAMAR@ZELTIA GROUP@@@@PHARMAMAR|ZELTIA GROUP|||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@APLIDIN@@@@@APLIDIN||||@Depsipeptide@VEGF@Angiogenesis Inhibitor@@@Depsipeptide|VEGF|Angiogenesis Inhibitor||@RESPONSE RATE@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16384813@Onco@@@@@300f1012ntsdm@@@@@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384813@Indicated for the treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@FIRST-LINE@@@Dosing for children should be on the basis of body surface area (mg/m2). The dose of 340 mg/m2 daily is recommended for children with Ph+ ALL (@@@@Yes@@@@@No@@@PAEDIATRIC@@@APPROVED@@@GKV@@@@@@BOTH@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@@@@Haematological Malignancy|Acute Lymphocytic Leukaemia||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@@@@@@@@@@@1.2@m²@35624.6424@@@1@year@1 year@35624.64@35624.64@97.6@60@1.1511@1435.32@1816.59@1473.82@@@@@@@@@@0.24@1@@mg/m²@340@1@@@@@@@@@@@8/1/2017@23.92@23.92@1755166@FILM-COATED TABLET@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
15260917@Onco@@@@@300f1020ntsdm@@@@@@Enzalutamide 160 mg orally per day@@L02BB04@L02B@@SAN FRANCISCO, CALIFORNIA@11/1/2012@@XTANDI is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.@@15260917@Treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.@Male@YES@26-Nov-14@11/26/2014@NO REVIEW@@@@@@SECOND-LINE@NCT00974311@1199@The recommended dose of XTANDI is 160 mg (four 40 mg capsules) administered orally once daily.@EMA, 24 June 2013@6/24/2013@@No@@9/1/2009@@CRPC2@No@@@@ADULTS@III@APPROVED@@26 November 2014: Added to the reimbursement list (Class H) [http://www.gazzettaufficiale.it/eli/id/2014/12/10/14A09421/sg;jsessionid=prTEz4ACmsfvmIHjx5vp7g__.ntc-as3-guri2b]@SSN@XTANDI-treated patients had a statistically-significant improvement in median overall survival compared to the placebo group: 18.4 months in the XTANDI group versus 13.6 months in the placebo group (P < 0.0001). XTANDI provided a 37% reduction in risk of death compared to placebo (hazard ratio = 0.631). [Medivation 31 August, 2012, http://investors.medivation.com/releasedetail.cfm?ReleaseID=703823 ]>>Trial registered [Medivation 9 September 2009]@The most common adverse reactions (= 5%) are asthenia/fatigue, back pain, diarrhea, arthralgia, hot flush, peripheral edema, musculoskeletal pain, headache, upper respiratory infection, muscular weakness, dizziness, insomnia, lower respiratory infection, spinal cord compression and cauda equina syndrome, hematuria, paresthesia, anxiety, and hypertension. Grade 3 and higher adverse reactions were reported among 47% of XTANDI-treated patients and 53% of placebo-treated patients.@@@@MONO@ENZALUTAMIDE@@@@@ENZALUTAMIDE||||@MEDIVATION INC@ASTELLAS@@@@MEDIVATION INC|ASTELLAS|||@@@@@@|||||||||@Prostate Cancer@HRPC@@@@Prostate Cancer|HRPC||||||||@XTANDI@@@@@XTANDI||||@Anti-androgen@@@@@Anti-androgen||||@OVERALL SURVIVAL@@@@@PROGRESSION FREE SURVIVAL@@@@@REFRACTORY@@@@@RANDOMISED@PARALLEL ASSIGNMENT@DOUBLE-BLIND@@@1@1@68430.46441@@@18.5@month@18.5 month@68430.46@68430.46@121.61@112@1.1229@3405.13@5619.83@3558.4@@@@@@@@@@0.76@1@@mg@160@1@@@@@@@@@@@6/7/2017@30.4@30.4@42868012@CAPSULE@EURO@@@@@@@@40@MG@40 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14916459@Onco@@@@@300f1015ntsdm@@@@@@107 patients received oral melphalan (0.15MG/KG/day x 7 followed by 0.05MG/KG/day) with prednisone; 203 received IV melphalan (16MG/M2 q 2 weeks x 4 over 6 weeks followed by 4 weeks) with prednisone.@@L01AA03@L01A@YES@BRENTFORD, UNITED KINGDOM@@@Melphalan is a bifunctional alkylating agent. Formation of carbonium intermediates from each of the two bis-2-chloroethyl groups enables alkylation through covalent binding with the 7-nitrogen of guanine on DNA, cross-linking the two DNA strands and thereby preventing cell replication.@@14916459@Alkeran Tablets are indicated in the treatment of multiple myeloma and advanced ovarian adenocarcinoma. Alkeran either alone or in combination with other drugs has a significant therapeutic effect in a proportion of patients suffering from advanced breast carcinoma. Alkeran is effective in the treatment of a proportion of patients suffering from polycythaemia vera.@@NO@3-Aug@@NO REVIEW@@@@100%@@@@310@Ovarian adenocarcinoma: A typical regimen is 0.2 mg/kg bodyweight/day orally for 5 days. This is repeated every 4-8 weeks, or as soon as the bone marrow has recovered. Alkeran has also been used intravenously in the treatment of ovarian carcinoma.@1-Aug-98@8/1/1998@11/13/2003@@@@Melphalan should be administered under the supervision of a qualified physician experienced in the use of chemotherapeutic agents. Severe bone marrow suppression with resulting infection or bleeding may occur. Controlled trials comparing IV to oral melphalan have shown more myelosuppression with the IV formulation.@LABEL@No@@@@@III@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@44% and 7% responded in the oral and IV groups respectively. Severe myelotoxicity and/or platelets occurred 28% and 11% respectively.@@@@@COMBO@MELPHALAN HYDROCHLORIDE@PREDNISONE@@@@MELPHALAN HYDROCHLORIDE|PREDNISONE|||@GSK@@@@@GSK||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@ALKERAN@@@@@ALKERAN||||@Alkylating Agent@Nitrogen Mustard Analogue@@@@Alkylating Agent|Nitrogen Mustard Analogue|||@RESPONSE RATE@@@@@@@@@@@@@@@RANDOMISED@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@50@1.1807@96@116.66@102.41@@@@@@@@@@0.96@@@@@@@@@@@@@@@@9/1/2017@1.92@1.92@3.40E+12@FILM-COATED TABLET (IN BOTTLE)@EURO@@@@@@@@2@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14921427@Onco@@@@@300f1014ntsdm@@@@@@NO LABELLED TRIAL@@L01A@L01A@YES@@@@@@14921427@Mustargen administered intravenously, is indicated for the palliative treatment of Hodgkin's disease (Stages III and IV), lymphosarcoma, chronic myelocytic or chronic lymphocytic leukemia, polycythemia vera, mycosis fungoides, and bronchogenic carcinoma. Mustargen, administered intrapleurally, intraperitoneally, or intrapericardially, is indicated for the palliative treatment of metastatic carcinoma resulting in effusion.@@YES@-@@NO REVIEW@@@@No tiering. SOURCE: Aetna Preferred Drug Guide 2008@Licensed from Merck & Co@-@-@-@A total dose of 0.4 mg/kg of body weight for each course usually is given either as a single dose or in divided doses of 0.1 to 0.2 mg/kg per day. Dosage should be based on ideal dry body weight.@Mar-49@@@-@@@Mustargen should be administered only under the supervision of a physician who is experienced in the use of cancer chemotherapeutic agents. This drug is HIGHLY TOXIC and both powder and solution must be handled and administered with care. Inhalation of dust or vapors and contact with skin or mucous membranes, especially those of the eyes, must be avoided. Avoid exposure during pregnancy. Due to the toxic properties of mechlorethamine (e.g., corrosivity, carcinogenicity, mutagenicity, teratogenicity), special handling procedures should be reviewed prior to handling and followed diligently.@NO LABELLED TRIAL@@N/A@-@@@-@DISCONTINUED@@N/A@RAMQ@NO LABELLED TRIAL@-@@@@-@MECHLORETHAMINE HCL@@@@@MECHLORETHAMINE HCL||||@MERCK & CO@@@@@MERCK & CO||||@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@Chronic Myeloid Leukaemia@Chronic Lymphocytic Leukaemia@@Haematological Malignancy|Hodgkin's Lymphoma|Chronic Myeloid Leukaemia|Chronic Lymphocytic Leukaemia||||||@MUSTARGEN@@@@@MUSTARGEN||||@Alkylating Agent@@@@@Alkylating Agent||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@1@0.9531@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@1606320@POWDER FOR IV INJECTION, 20 ML@C$@@@@@@@@10@MG@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
16394687@Onco@@@@@300f1010ntsdm@@@@@@@@L04AX04@L04A@@SUMMIT, NEW JERSEY@3/1/2017@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16394687@Treatment of adult patients with relapsed or refractory mantle cell lymphoma@Both@NO@@@NO REVIEW@@@@100%@@@NCT00875667@254@The recommended starting dose of lenalidomide is 25 mg orally once daily on days 121 of repeated 28day cycles.@EMA, 28 January 2016@1/28/2016@@Yes@@4/1/2009@@CC5013MCL002@No@@Biopsy proven mantle cell lymphoma; Patients who are refractory to their regimen or have relapsed once, twice or up to three times and who have documented progressive disease; Eastern Cooperative Oncology Group (ECOG) performance score 0,1, or 2; Willing to follow pregnancy precaution@@ADULTS@II@APPROVED@@@NHS@@@@@@MONO@LENALIDOMIDE@@@@@LENALIDOMIDE||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Non-Hodgkin's Lymphoma@Mantle Cell Lymphoma@@@@Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma||||||||@REVLIMID@@@@@REVLIMID||||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@PROGRESSION FREE SURVIVAL@@@@@OVERALL RESPONSE RATE@DURATION OF RESPONSE@TIME TO PROGRESSION@@@RELAPSED@REFRACTORY@@@@RANDOMISED@MULTI-CENTRE@OPEN LAB EL@@@1@1@41059.2@@@37.6@week@37.6 week@41059.2@41059.2@156@21@1.299@4368@@@@@@@@@@@@8.32@28@@mg@25@21@@@@@@@@@@@7/28/2017@208@208@1.18E+16@HARD CAPSULE@GB£@@@@@@@@25@MG@25 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14922129@Onco@@@@@@@@@@@Patients receive Avastin with FOLFOX, CAPOX, FOLFIRI and Xeloda. [Roche]@@L01XC07@L01X@-@BASEL, SWITZERLAND@@@Avastin (Bevacizumab) is a recombinant humanized monoclonalIgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems. Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF (1). Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models ofangiogenesis. Administration of Bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.@@14922129@Avastin with first-line chemotherapy@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@-@1927@-@-@@@-@@@-@BEAT@@NOT YET AVAILABLE; POTENTIALLY 2018.@-@@@IV@IV@@-@-@>> Avastin-based therapy delivers a median overall survival benefit of 22.7 months. Patients receiving Avastin plus chemotherapy and underwent complete resection doubled their chances of surviving at 2 years compared to those who didn't (89% versus 44%). [Roche/ESMO, 12.09.2008]>> Median PFS is 10.2 months, independent of the chemotherapy used. [Roche, 3.06.2007]@-@@@@COMBO@BEVACIZUMAB@@@@@BEVACIZUMAB||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@AVASTIN@FOLFOX@CAPOX@FOLFIRI@@AVASTIN|FOLFOX|CAPOX|FOLFIRI|@mAb@Humanised@TK Inhibitor@VEGF@@mAb|Humanised|TK Inhibitor|VEGF|@-@@@@@@@@@@ADVANCED@@@@@OPEN-LABEL@MULTI-CENTRE@@@@@@Invalid Factory Price@@@@@-@-@@@@1@@@@@@@@@@@@@7.26@@@@@@@@@@@@@@@@@725.53@725.53@@INJECTION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924611@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Intravenously on days 1 and 4 of each of three consecutive weeks with the treatment cycle repeated every 28 days and any side effects that might be associated with the regimen. @@-@-@-@SOMERSET, NEW JERSEY@@@Onconase is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, it has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. It triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.@@14924611@-@@-@-@@NO REVIEW@@@@-@>> Alfacell's auditors have indicated that they are not convinced that the company can continue following the failure of Onconase. [Alfacell, 23.10.2008]      >> Alfacell continues to explore strategic alternatives for the drug. [Alfacell, 17.09.2008]       >> Alfacell has granted Megapharm exclusive rights in Israel for the marketing, sales and distribution of Onconase. Alfacell will receive 50% of all sales in the territory. In addition, Alfacell will manufacture and supply the product to Megapharm, while Megapharm will be responsible for all activities and costs related to regulatory filings and commercial activities in the territory. [Alfacell, 15 July 2008]      >> On 26 July 2007, Alfacell signed a distribution agreement with USP Pharma Spolka ZOO (USP Pharma), an affiliate of US Pharmacia, relating to the commercialisation of ranpirnase in Eastern Europe.@-@-@-@-@Fast track and orphan designation in the U.S., Europe and Australia.@@@Fast track and orphan designation in the U.S., Europe and Australia.@@@-@-@@-@-@@@I/II@II@@-@-@According to the company, results from the first part of this trial will be used to expand the clinical program in the initiation of phase II trials in oesophageal and refractory breast cancers after the submission of the full NDA in mesothelioma.@-@@@@MONO@RANPIRNASE@@@@@RANPIRNASE||||@ALFACELL@@@@@ALFACELL||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@ONCONASE@@@@@ONCONASE||||@Enzyme@RNA@@@@Enzyme|RNA|||@RESPONSE RATE@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917097@Onco@@@@@300f1008ntsdm@@@@@@NO LABELLED TRIAL@@L01DC01@L01D@YES@@@@@@14917097@a. Squamous cell carcinoma affecting the mouth, nasopharynx and paranasal sinuses, larynx, oesophagus, external genitalia, cervix or skin. Well differentiated tumours usually respond better than anaplastic ones. b. Hodgkin's disease and other malignant lymphomas, including mycosis fungoides. c. Testicular teratoma d. Malignant effusions of serous cavities. e. Secondary indications in which Bleomycin has been shown to be of some value (alone or in combination with other drugs) include metastatic malignant melanoma, carcinoma of the thyroid, lung and bladder@@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@Merger between Kyowa Hakko and Kirin Pharma announced in October 2007.@@@@Malignant lymphomas: Used alone the recommended dosage regime is 15 x 10³ IU (1 vial) once or twice a week, intramuscularly, to a total dose of 225 x 10³ IU (15 vials). Dosage should be reduced in the elderly. The dose may need to be adjusted when bleomycin is used in combination chemotherapy.@@@@@@@Patients undergoing treatment with bleomycin should have chest X-rays weekly. These should continue to be taken for up to 4 weeks after completion of the course. If breathlessness or infiltrates appear, not obviously attributable to tumour or to co-existent lung disease, administration of the drug must be stopped immediately and patients should be treated with a corticosteriod and a broad spectrum antibiotic. High oxygen concentrations should be used with caution in these cases. Lung function tests which use 100% oxygen should not be used in patients who have been treated with Bleomycin. Lung function tests using less than 21% oxygen are recommended as an alternative.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHI@NO LABELLED TRIAL@@@@@@BLEOMYCIN@@@@@BLEOMYCIN||||@KYOWA HAKKO KOGYO@KIRIN PHARMA@@@@KYOWA HAKKO KOGYO|KIRIN PHARMA|||@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@Non-Hodgkin's Lymphoma@@@Haematological Malignancy|Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma|||||||@BLEO@@@@@BLEO||||@Cytotoxic Antibiotic@@@@@Cytotoxic Antibiotic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@408.6@408.6@@1@0.0091@4373.98@5158@@@@@@@@@@@291.6@@@@@@@@@@@@@@@@8/30/2017@4373.98@4373.98@4234400D5039@INJECTION@YEN@@@@@@@@15@MG@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
15400329@Onco@@@@@300f1015ntsdm@@@@@@Investing arms: nilotinib 300mg bid or nilotinb 400 mg bidControl arm: imatinib 400mg QD@@L01XE08@L01X@@BASEL, SWITZERLAND@@@Nilotinib is an inhibitor of the Bcr-Abl kinase. Nilotinib binds to and stabilizes the inactive conformation of the kinase domain of Abl protein. In vitro, nilotinib inhibited Bcr-Abl mediated proliferation of murine leukemic cell lines and human cell lines derived from Ph+ CML patients. Under the conditions of the assays, nilotinib was able to overcome imatinib resistance resulting from Bcr-Abl kinase mutations, in 32 out of 33 mutations tested. In vivo, nilotinib reduced the tumor size in a murine Bcr-Abl xenograft model. Nilotinib inhibited the autophosphorylation of the following kinases at IC50 values as indicated: Bcr-Abl (20-60 nM), PDGFR (69 nM) and c-Kit (210 nM).@@15400329@Indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase.@Both@NO@6-Apr-11@4/6/2011@NO REVIEW@@@@@@FIRST-LINE@NCT00471497@846@The recommended dose of Tasigna is 300 mg twice daily. Treatment should be continued as long as the patient continues to benefit.@EMA, 23 September 2010@9/23/2010@6/21/2012@Yes@@@@ENEST@No@@Chronic myelogenous leukemia in chronic phase patients within the first 6 months of diagnosis.Diagnosis of chronic myelogenous leukemia in chronic phase with confirmation of Philadelphia chromosome@ADULT@Adult@III@APPROVED@@ASMR IV@HAUTE AUTORITÉ DE SANTÉ@@@@@@MONO@NILOTINIB@@@@@NILOTINIB||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@TASIGNA@@@@@TASIGNA||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@MOLECULAR RESPONSE RATE@@@@@@@@@@CHRONIC PHASE@@@@@RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@1@1@32429.27787@@@12@month@12 month@32429.28@32429.28@88.85@28@1.1511@829.26@935.47@859.26@@@@@@@@@@0.15@1@@mg@600@1@@@@@@@@@@@8/1/2017@29.62@29.62@3.40E+12@CAPSULE@EURO@@@@@@@@200@MG@200 MG@@@@@@@@@@@@@@@@@@@@@@@@85@France
14918593@Onco@@@@@300f1012ntsdm@@@@@@Tamoxifen compared to ovarian ablation@@L02BA01@L02B@YES@GERMANY@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14918593@@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@N/A@Adjuvant treatment of breast cancer, Adults (including elderly): The recommended dose is 20mg, given either in divided doses twice daily or as a single dose once daily. The current recommended treatment duration is five years; however the optimum duration has not been established. Treatment of locally advanced or metastatic breast cancer: The recommended dose is 20mg to 40mg, given either in divided doses twice daily or as a single dose once daily.@@@@@@@Women should be informed of the potential risks to the foetus, should they become pregnant whilst taking tamoxifen; or within two months of cessation of therapy. A number of secondary primary tumours, occurring at sites other than the endometrium and the opposite breast, have been reported in clinical trials, following the treatment of breast cancer patients with tamoxifen. No causal link has been established and the clinical significance of these observations remains unclear.@LABEL@No@@@@@III METASTATIC BREAST CANCER@APPROVED@@@GKV@The objective RR, time to treatment failure, and survival were similar with both treatments. In an overview analysis of survival data from the 3 studies, the hazard ratio for death (tamoxifen/ovarian ablation) was 1.00. Elevated serum and plasma oestrogens have been observed in premenopausal women receiving tamoxifen, but the data from the randomized studies do not suggest an adverse effect of this increase. A limited number of premenopausal patients with disease progression during tamoxifen therapy responded to subsequent ovarian ablation.@@@@@ADJUVANT@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@ABZ PHARMA@@@@@ABZ PHARMA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GENERIC@@@@@GENERIC||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RESPONSE RATE@@@@@@@@@@@@@@@PROSPECTIVE@RANDOMISED@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@100@1.1511@7.97@21.06@8.92@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@0.08@0.08@1017020@FILM-COATED TABLET@EURO@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14923675@Onco@@@@@300f1008ntsdm@@@@@@-@@N02AB03@N02A@-@-@@@Fentanyl is a synthetic opiate with a clinical potency of 50 to 100 times that of morphine. Its onset of action is rapid and its duration of action is short. In man, a single iv dose of 0.5-1 mg/70 kg body weight immediately produces a pronounced state of surgical analgesia, respiratory depression, bradycardia and other typical morphine-like effects. The duration of action of the peak effects is about 30 minutes. All potent morphine-like drugs produce relief from pain, ventilatory depression, emesis, constipation, physical dependence, certain vagal effects and varying degrees of sedation. Fentanyl, however, differs from morphine not only by its short duration of action but also by its lack of emetic effect and minimal hypotensive activity in animals. @@14923675@Cancer pain@@-@-@@NO REVIEW@@@@-@"Hisamitsu has entered into an agreement with Kyowa Hakko for the joint sales in Japan of transdermal fentanyl cancer analgesic HFT-290. Under the terms of the agreement, each company will carry out independent distribution and marketing activities for the product, but will use the same brand name. SOURCE: Kyowa Hakko, 19 June 2008Licensing deal signed in April 2005"@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@@-@-@@@@-@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@NIPPON SHINYAKU@HISAMITSU@KYOWA HAKKO KOGYO@KIRIN PHARMA@@NIPPON SHINYAKU|HISAMITSU|KYOWA HAKKO KOGYO|KIRIN PHARMA|@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@HFT-290@@@@@HFT-290||||@Opioid Analgesic@@@@@Opioid Analgesic||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TRANSDERMAL@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
16396609@Onco@@@@@300f1010ntsdm@@@@@@This study investigated the use of combination therapy of MPR (melphalan 0.18 mg/kg orally on days 1-4 of repeated 28-day cycles; prednisone 2 mg/kg orally on days 1-4 of repeated 28-day cycles; and lenalidomide10 mg/day orally on days 1-21 of repeated 28-day cycles) for induction therapy, up to 9 cycles. Patients who completed 9 cycles or who were unable to complete 9 cycles due to intolerance proceeded to maintenancemonotherapy starting with lenalidomide 10 mg orally on days 1-21 of repeated 28-day cycles until disease progression.@@L04AX04@L04A@@SUMMIT, NEW JERSEY@@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16396609@Treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant@Both@NO@@@NO REVIEW@@@@100%@@FIRST-LINE@@459@The recommended starting dose is lenalidomide 10 mg/day orally on days 121 of repeated 28day cycles for up to 9 cycles, melphalan 0.18 mg/kg orally on days 14 of repeated 28 day cycles, prednisone2 mg/kg orally on days 14 of repeated 28day cycles. Patients who complete 9 cycles or who are unable to complete the combination therapy due to intolerance are treated with lenalidomide alone, 10 mg/dayorally on days 121 of repeated 28day cycles given until disease progression.@EMA, 11 February 2015@2/11/2015@@Yes@@@@@No@@@@ADULTS@@APPROVED@@@NHS@@@@@@COMBO@LENALIDOMIDE@MELPHALAN@PREDNISONE@@@LENALIDOMIDE|MELPHALAN|PREDNISONE||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@REVLIMID@ALKERAN@GENERIC@@@REVLIMID|ALKERAN|GENERIC||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@PROGRESSION FREE SURVIVAL@@@@@@@@@@@@@@@RANDOMISED@DOUBLE BLIND@@@@1@1@62036.0934@@@27.4@month@27.4 month@62036.09@62036.09@74.44@21@1.299@4168.5@@@@@@@@@@@@9.93@28@@mg@10@21@@@@@@@@@@@7/28/2017@198.5@198.5@2.99E+16@CAPSULE@GB£@@@@@@@@20@MG@20 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14922184@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Intravenous bevacizumab (Days 1 and 15 of a 28 day cycle) in combination with weekly topotecan (Days 1, 8, 15 of a 28 day cycle) in patients with platinum resistant recurrent ovarian, fallopian tube and primary peritoneal cancer. [clinicaltrials.gov]@@L01X X17@L01X@-@BRENTFORD, UNITED KINGDOM@@@Topoisomerase I relieves torsional strain in DNA by inducing reversible single strand breaks. Topotecan binds to the topoisomerase I-DNA complex and prevents religation of these single strand breaks. The cytotoxicity of topotecan is thought to be due to double strand DNA damage produced during DNA synthesis, when replication enzymes interact with the ternary complex formed by topotecan, topoisomerase I, and DNA. Mammalian cells cannot efficiently repair these double strand breaks.@@14922184@Weekly Topotecan With Bevacizumab in Platinum Resistant Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers @@-@-@@NO REVIEW@@@@-@Merck KGaA licensed marketing and sales rights from SmithKline Beecham in June 2000 for the U.K. only.@-@NCT00343044@40@-@-@@@-@@6/1/2006@-@AVF3648s@@-@>> must have received primary taxane and platinum-based chemotherapy and no more than 1 other chemotherapy regimen >> must have platinum resistant disease(defined as recurrence within 6 months of receiving platinum based chemotherapy, first or second line)@@@II@II@@-@-@Trial registered [GSK, 20.06.2006]@-@@@@COMBO@TOPOTECAN HYDROCHLORIDE@BEVACIZUMAB@@@@TOPOTECAN HYDROCHLORIDE|BEVACIZUMAB|||@GSK@GENENTECH@@@@GSK|GENENTECH|||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@HYCAMTIN@AVASTIN@@@@HYCAMTIN|AVASTIN|||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@PROGRESSION-FREE SURVIVAL@@@@@OVERALL SURVIVAL@CA-125 LEVEL@TOXICITY@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@CAPSULE@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918923@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Approximately 18.000 study subjects will either receive the HPV vaccine or a control vaccine (hepatitis A vaccine) administered intramuscularly according to a 0-1-6 month schedule.@@J07BM01@J07B@@BRENTFORD, UNITED KINGDOM@@@Cervarix is a non-infectious recombinant vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid L1 protein of oncogenic HPV types 16 and 18. Since the VLPs contain no viral DNA, they cannot infect cells, reproduce or cause disease. Animal studies have shown that the efficacy of L1 VLP vaccines is largely mediated by the development of a humoral immune response. HPV-16 and HPV-18 are responsible for approximately 70% of cervical cancers across all regions worldwide.@@14918923@@@NO@@@NO REVIEW@@@@@@@NCT00122681@18000@@FDA, 16 October 2009@10/16/2009@@@@@@HPV-008@No@FIRST PATENT EXPIRES IN 2017.@Subject must be free of obvious health problems as established by medical history and clinical examination before entering into the study.@@@III@APPROVED@@@@Mean length of follow-up for women in the primary analysis for efficacy at the time of the interim analysis was 14.8 (SD 4.9) months. Two cases of CIN2+ associated with HPV16 or HPV18 DNA were seen in the HPV16/18 vaccine group; 21 were recorded in the control group. Of the 23 cases, 14 (two in the HPV16/18 vaccine group, 12 in the control group) contained several oncogenic HPV types. Vaccine efficacy against CIN2+ containing HPV16/18 DNA was 90.4% (97.9% CI 53.4-99.3; p<0.0001). No clinically meaningful differences were noted in safety outcomes between the study groups. [Lancet. 2007 Jun 30;369(9580):2135-7.; http://www.ncbi.nlm.nih.gov/pubmed/17602732?dopt=Abstract] Trial registered. [GSK, 20 July 2005]@@@@@@HUMAN PAPILLOMAVIRUS@@@@@HUMAN PAPILLOMAVIRUS||||@GSK@@@@@GSK||||@@@@@@|||||||||@Cervical Cancer@@@@@Cervical Cancer|||||||||@CERVARIX@@@@@CERVARIX||||@Vaccine@@@@@Vaccine||||@CIN2+@@@@@@@@@@@@@@@PREVENTION@DOUBLE-BLIND@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@@@@@10@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@58160-0830-11@SUSPENSION FOR INJECTION - 0.5 ML@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16522242@Onco@@@@@@@@@@@"Talacotuzumab, Experimental, Participants will receive talacotuzumab 9 milligram per kilogram (mg/kg) intravenously (IV) on Days 1 and 15 for all cycles. Each treatment cycle is of 28 days.Daratumumab, Experimental, Participants will receive daratumumab 16 mg/kg IV on Days 1, 8, 15, and 22 for Cycles 1 and 2; on Days 1 and 15 for Cycles 3 to 6; and on Day 1 for all subsequent cycles. Each treatment cycle is of 28 days."@@@@@BEERSE, BELGIUM@12/1/2018@@@@16522242@A Phase 2 Proof-of-Concept Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment@Both@@@@@Talacotuzumab 9 mg/kg will be administered as an IV infusion.@@@@@SECOND-LINE@NCT03011034@60@@@@@@@1/1/2017@@CR108261@@@Inclusion Criteria:  -  Myelodysplastic Syndrome (MDS) according to World Health Organization (WHO) criteria confirmed by bone marrow aspirate and biopsy within 12 weeks prior to first dose. A local laboratory report from this diagnostic bone marrow aspirate and biopsy must be approved by the sponsor  -  International Prognostic Scoring System (IPSS) low risk or intermediate-1 risk MDS  -  Red blood cell (RBC) transfusion dependent, 1) Received at least 4 units of RBCs over any 8 consecutive weeks during the 16 weeks prior to randomization, 2) Pretransfusion Hb must have been less than or equal to (<=)9.0 gram per deciliter (g/dL)  -  Adequate iron stores, defined as transferrin saturation greater than 20 percent (%) and serum ferritin greater than 400 nanogram per Milliliter (ng/mL), measured within the screening period, or adequate iron stores as demonstrated by recent (within 12 weeks prior to first dose) bone marrow examination with iron stain  -  Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2@@ADULTS@Phase 2@II@@@@@@@@@MONO@TALACOTUZUMAB@Daratumumab@@@@TALACOTUZUMAB|Daratumumab|||@JANSSEN CILAG@@@@@JANSSEN CILAG||||@Belgium@France@Netherlands@Spain@United States@Belgium|France|Netherlands|Spain|United States|||||@Myelodysplastic Syndrome@@@@@Myelodysplastic Syndrome|||||||||@JNJ-56022473@DARZALEX@@@@JNJ-56022473|DARZALEX|||@Other@@@@@Other||||@Red Blood Cell (RBC) Transfusion Independence (TI) for 8 Weeks@@@@@Number of Participants With Transfusion Independence Lasting 168 days (24 weeks)@Time to Transfusion Independence (TI)@@@@RELAPSED@REFRACTORY@@@@Randomized@Parallel Assignment@Open Label@Treatment@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@14916665@Onco@@@@@300f1014ntsdm@300f1813ntsdm@@@@@Patients receive a loading dose of oral perifosine on days 1 and 2 and once daily on days 3-21 during course 1. Patients receive oral perifosine once daily on days 1-21 in each subsequent course. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response may receive 2 additional courses. SOURCE: clinicaltrials.gov@@-@-@-@NEW YORK, NEW YORK@@@KRX-0401 (perifosine) is a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, and a number of other key signal transduction pathways, including the JNK and MAPK pathways, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. The effects of perifosine on Akt are of particular interest because of the importance of this pathway in the development of most cancers, the evidence that it is often activated in tumors that are resistant to other forms of anticancer therapy, and the difficulty encountered thus far in the discovery of drugs that will inhibit this pathway without causing excessive toxicity. High levels of activated Akt (pAkt) are seen frequently in many types of cancer and have been correlated with poor prognosis in patients with soft-tissue sarcoma, gastric, hepatocellular, endometrial, prostate, renal cell, head and neck cancers and hematological malignancies, as well as glioblastoma. The majority of tumors expressing high levels of pAkt were high-grade, advanced stage or had other features associated with poor prognosis. High pAkt is often seen in tumors that are resistant to conventional cancer treatments, including radiotherapy, chemotherapy, endocrine therapy, and especially therapy with some of the newer biologicals. Published data suggest that the Akt pathway is frequently activated in renal cell cancer and that this tumor type may be particularly responsive to Akt inhibition.@@14916665@-@@-@-@@NO REVIEW@@@@-@"Keryx receives notice from Nasdaq that the company is not in compliance with the US$1 minimum bid price for continued listing and most reach this within 180 days. SOURCE: Keryx, 28 April 2008Keryx in-licensed North American rights for perifosine from Ae"@-@NCT00054145@18-35@-@-@@@-@@@-@PMH-PHL-014@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@PERIFOSINE@@@@@PERIFOSINE||||@KERYX BIOPHARMACEUTICALS@AETERNA ZENTARIS@@@@KERYX BIOPHARMACEUTICALS|AETERNA ZENTARIS|||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@KRX-0401@@@@@KRX-0401||||@Other@@@@@Other||||@RESPONSE RATE@@@@@@@@@@RELAPSED@METASTATIC@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @C$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14922063@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Low-dose cytarabine with Trisenox versus cytarabine alone@@LO1XX27@LO1X@-@FRAZER, PENNSYLVANIA@@@The mechanism of action is not completely understood. Arsenic trioxide causes morphological changes and DNA fragmentation characteristic of apoptosis in NB4 human promyelocytic leukemia cells in vitro. Arsenic trioxide also causes damage or degradation of the fusion protein PML/RAR-alpha.@@14922063@Elderly patients with AML; with cytarabine@@-@-@@NO REVIEW@@@@-@Global rights licensed from Cell Therapeutics in June 2005@-@NCT00513305@210@-@EMEA COMP POSITIVE OPINION FOR ORPHAN DRUG DESIGNATION FOR AML IN JULY 2007@@@EMEA COMP POSITIVE OPINION FOR ORPHAN DRUG DESIGNATION FOR AML IN JULY 2007@@9/1/2007@-@C184773059AMUS-CA  @@-@-@ELDERLY@@III@III@@-@-@Trial registered. Completion expected in October 2012. [Cephalon, 06.08.2007]@-@@@@COMBO@ARSENIC TRIOXIDE@CYTARABINE@@@@ARSENIC TRIOXIDE|CYTARABINE|||@CEPHALON@@@@@CEPHALON||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@TRISENOX@@@@@TRISENOX||||@Arsenical@@@@@Arsenical||||@N/A@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919093@Onco@@@@@300f1020ntsdm@@@@@@4 MG/KG (LOADING DOSE) FOLLOWED BY 2 MG/KG INTRAVENOUSLY FOR A MAXIMUM NUMBER OF 18 WEEKLY CYCLES@@@@@BASEL, SWITZERLAND@12/1/2013@@Herceptin (trastuzumab) is a humanized IgG1 kappa monoclonal antibody that selectively binds with high affinity to the extracellular domain of the human epidermal growth factor receptor 2 protein, HER2. Trastuzumab is produced by recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary) culture containing the antibiotic gentamicin. Gentamicin is not detectable in the final product. The HER2 (or c-erbB2) proto-oncogene encodes a transmembrane receptor protein of 185 kDa, which is structurally related to the epidermal growth factor receptor. Herceptin has been shown, in both in vitro assays and in animals, to inhibit the proliferation of human tumor cells that overexpress HER2. Herceptin is a mediator of antibody-dependent cellular cytotoxicity (ADCC). In vitro, Herceptin-mediated ADCC has been shown to be preferentially exerted on HER2 overexpressing cancer cells compared with cancer cells that do not overexpress HER2@@14919093@A MULTICENTER, OPEN LABEL STUDY TO ASSESS THE EFFECT OF TRASTUZUMAB + WHOLE BRAIN RADIOTHERAPY (WBRT) ON BRAIN METASTASES FROM HER-2 POSITIVE BREAST CANCER (BHERT-2)@@@@@@@@@@@@NCT01363986@66@@@@@@@6/1/2011@@ML25432@@@DIAGNOSIS OF BREAST CARCINOMA WITH HER-2 OVEREXPRESSION  -  AT LEAST ONE MEASURABLE BRAIN METASTASIS  -  PATIENTS FOR WHOM, ACCORDING TO INVESTIGATOR ASSESSMENT, WHOLE BRAIN RADIOTHERAPY IS THE BEST THERAPEUTIC OPTION  -  PERFORMANCE STATUS (WHO) </=2  -  LIFE EXPECTANCY >/=3 MONTHS@@@II@II@@@@Trial registered [Roche, 31 May 200]@@@@@@TRASTUZUMAB@@@@@TRASTUZUMAB||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@HERCEPTIN@@@@@HERCEPTIN||||@mAb@Humanised@TK Inhibitor@HER2@@mAb|Humanised|TK Inhibitor|HER2|@BRAIN RESPONSE RATE TO TRASTUZUMAB AND WHOLE BRAIN RADIOTHERAPY [ Time Frame: Week 7 ]@@@@@BRAIN RESPONSE RATE TO TRASTUZUMAB AND WHOLE BRAIN RADIOTHERAPY [ Time Frame: Week 15 ]@BRAIN PROGRESSION-FREE SURVIVAL@@@@@@@@@NON-RANDOMIZED@SAFETY@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@Invalid Factory Price@@@@@@@@@@1.0543@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
15000095@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Erbitux with three oxaliplatin-based therapies@@L01XC06@L01X@-@NEW YORK, NEW YORK@@@Erbitux is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Cetuximab is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions and has an approximate molecular weight of 152 kDa. Cetuximab is produced in mammalian (murine myeloma) cell culture.@@15000095@Erbitux with oxaliplatin-based therapies.@@-@-@@NO REVIEW@@@@-@>> Acquisition completed. [Lilly, 24.11.2008]         >> Lilly acquires ImClone for US$6.5 billion. [Lilly, 7.10.2008]       >> BMS Offers US$4.3Billion for ImClone or US$60.0 per share in cash. [BMS, 1 August 2008]     >> ImClone licensed co-development and co-promotion rights to BMS in North America and Japan, and to Merck KGaA in Europe.@-@-@-@-@-@@@-@@@-@COIN@@CURRENTLY IN DISPUTE; IMCLONE LOST PROCESS PATENT, EXPIRING IN 2017, TO YEDA IN 2006.@-@-@@III@III@@-@-@No PFS or OS benefit demonstrated [Lancet, 18 June 2011, http://www.ncbi.nlm.nih.gov/pubmed/21641636]ASCO June 2007; Erbitux can be used safely combined with 3 Eloxatin-based regimes.@-@@@@COMBO@CETUXIMAB@@@@@CETUXIMAB||||@BMS@IMCLONE@@@@BMS|IMCLONE|||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ERBITUX@@@@@ERBITUX||||@mAb@Chimeric@TK Inhibitor@EGFR@@mAb|Chimeric|TK Inhibitor|EGFR|@-@@@@@@@@@@-@@@@@RANDOMISED@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919373@Onco@@@@@300f1037ntsdm@@@@@@NO LABELLED TRIAL@@L01AX04@L01A@YES@@@@Dacarbazine is a cytostatic agent. The antineoplastic effect is due to an inhibition of cell growth which is independent of the cell cycle and due to an inhibition of DNA synthesis. An alkylating effect has also been shown and other cytostatic mechanisms may also be influenced by dacarbazine. Dacarbazine is considered not to show an antineoplastic effect by itself. However by microsomal N-demethylation it is quickly converted to 5-amino-imidazole-4-carboxamide and a methyl cation, which is responsible for the alkylating effect of the drug.@@14919373@Dacarbazine is indicated for the treatment of patients with metastatic malignant melanoma. Further indications for dacarbazine as part of combination chemotherapy are: • Hodgkin's disease • Advanced adult soft tissue sarcomas (except mesothelioma, Kaposi sarcoma)@@YES@@@NO REVIEW@@@@60%@@@@@Hodgkin's Disease: Dacarbazine is administered in a daily dose of 375 mg/m2 body surface area i.v. on day 1 and day 15 in combination with doxorubicin, bleomycin and vinblastine for each cycle of ABVD regimen.@10-Jul-07@7/10/2007@@@@@It is recommended that dacarbazine be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. 1. Hemopoietic depression is the most common toxicity with dacarbazine. 2. Hepatic necrosis has been reported. 3. Studies have demonstrated this agent to have a carcinogenic and teratogenic effect when used in animals. 4. In treatment of each patient, the physician must weigh carefully the possibility of achieving therapeutic benefit against the risk of toxicity.@NO LABELLED TRIAL@No@@@@@@APPROVED@@NO REVIEW@SNS@NO LABELLED TRIAL@@@@@@DACARBAZINE@@@@@DACARBAZINE||||@MADAUS@@@@@MADAUS||||@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@@@@Haematological Malignancy|Hodgkin's Lymphoma||||||||@GENERIC@@@@@GENERIC||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@METASTATIC@MALIGNANT@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@EURO@@@@@@@@500@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14923721@Onco@@@@@@@@@@@Capecitabine, oxaliplatin and bevacizumab regimen versus capecitabine and oxaliplatin alone applied as adjuvant treatment@@L01XC07@L01X@-@BASEL, SWITZERLAND@12/1/2013@@Avastin (Bevacizumab) is a recombinant humanized monoclonalIgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems. Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF (1). Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models ofangiogenesis. Administration of Bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.@@14923721@Avastin in combination with Xeloda and Eloxatin in patients with colorectal cancer who have had after a radical resection of liver metastases.@@-@-@@NO REVIEW@@@@-@-@-@NCT00394992@500@-@-@@@-@@12/1/2006@-@-@@-@-@@@III@III@@-@-@Not yet available@-@@@@COMBO@BEVACIZUMAB@CAPECITABINE@OXALIPLATIN@@@BEVACIZUMAB|CAPECITABINE|OXALIPLATIN||@ROCHE@SANOFI-AVENTIS@@@@ROCHE|SANOFI-AVENTIS|||@Netherlands@@@@@Netherlands|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@AVASTIN@XELODA@ELOXATIN@@@AVASTIN|XELODA|ELOXATIN||@mAb@Humanised@TK Inhibitor@VEGF@@mAb|Humanised|TK Inhibitor|VEGF|@DISEASE-FREE SURVIVAL@OVERALL SURVIVAL@@@@@@@@@METASTATIC@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@1@@@@@@@@@@@@@7.26@@@@@@@@@@@@@@@@@725.53@725.53@@INJECTION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14919184@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Dose-intensive Temodar@@L01AX03@L01A@-@KENILWORTH, NEW JERSEY@@@Temozolomide is not directly active but undergoes rapid nonenzymatic conversion at physiologic pH to the reactive compound MTIC. The cytotoxicity of MTIC is thought to be primarily due to alkylation of DNA. Alkylation (methylation) occurs mainly at the O6 and N7 positions of guanine.@@14919184@Newly diagnosed@@-@-@@NO REVIEW@@@@-@Merck & Co and Schering-Plough have announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. Based on the closing price of Merck stock on March 6, 2009, the consideration to be received by Schering-Plough shareholders is valued at $23.61 per share, or $41.1 billion in the aggregate. [Merck & Co, 9 March 2009]@FIRST-LINE@NCT00365222@79@-@-@@@-@@7/1/2006@-@MCC-14714  @@-@-@@@II@II@@-@-@RESULTS PENDING (recruiting).@-@@@@MONO@TEMOZOLOMIDE@@@@@TEMOZOLOMIDE||||@SCHERING-PLOUGH@MERCK & CO@@@@SCHERING-PLOUGH|MERCK & CO|||@@@@@@|||||||||@Brain Cancer@Glioblastoma Multiforme@@@@Brain Cancer|Glioblastoma Multiforme||||||||@TEMODAR@@@@@TEMODAR||||@Alkylating Agent@@@@@Alkylating Agent||||@OVERALL SURVIVAL@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921673@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Escalating dose of everolimus@@-@-@-@BASEL, SWITZERLAND@@@The active substance in Afinitor, everolimus, is an anticancer medicine, which acts by blocking a protein called ‘mammalian target of rapamycin' (mTOR). In the body, everolimus attaches to a protein that is found inside cells to make a ‘complex'. This complex then blocks mTOR. Since mTOR is involved in the control of cell division and the growth of blood vessels, Afinitor prevents the division of cancer cells and reduces their blood supply. This slows down the growth and spread of kidney cancer.@@14921673@Cancer progressed from prior therapy with EGFR antibody, Avastin, fluoropyrimidine, oxaliplatin and irinotecan-based regimens@@-@-@@NO REVIEW@@@@-@-@-@NCT00419159@100@-@-@@@EMEA issued positive opinion to grant Orphan Drug status for everolimus to treat neuroendocrine gastroenteropancreatic tumours@@12/1/2006@-@CRAD001C2241@@-@-@@@II/III@III@@-@-@RESULTS PENDING@-@@@@MONO@EVEROLIMUS@@@@@EVEROLIMUS||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@AFINITOR@RAD-001@@@@AFINITOR|RAD-001|||@Immunotherapy@Immunosuppressive@mTOR Inhibitor@@@Immunotherapy|Immunosuppressive|mTOR Inhibitor||@OVERALL SURVIVAL@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922517@Onco@@@@@@@@@@@Rituximab by IV injection at a dose level of 375 mg/m² on day 1 of each cycle followed by inotuzumab ozogamicin administered by IV injection at a dose level of 1.8 mg/m2 on day 2. The sequence will be repeated every 28 days. Investigator's choice from the following Rituxan/MabThera -containing regimens: R-CVP or R-FND. The investigator's choice will be administered every 21 days. Dosing for R-CVP will be IV rituximab at a dose of 375 mg/m2 on day 1, IV cyclophosphamide at a dose of 750 mg/m2 on day 1, IV vincristine at a dose of 1.4 mg/m2 (not to exceed 2 mg) on day 1, and prednisone/prednisolone PO at a dose of 40 mg/m2 on days 1 through 5. Dosing for R-FND will be as follows: rituximab 375 mg/m2 iby IV injection on day 1, mitoxantrone 10 mg/m2 by IV injection on day 2, fludarabine 25 mg/m2 by IV injection on days 2 through 4 and oral dexamethasone 20 mg/day on days 1 through 5. SOURCE: clinicaltrials.gov@@-@-@-@MADISON, NEW JERSEY@9/1/2014@@@@14922517@Follicular B-cell CD22 NHL@@-@-@@NO REVIEW@@@@-@Pfizer acquired Wyeth on 26 January 2009 in a deal worth U.S $68 billion [Pfizer 26.01.2009]@SECOND-LINE@NCT00562965@978@-@-@@@-@@11/1/2007@-@3129K4-3301@@-@-@@@III@III@@-@-@Initial data expected in 2011. SOURCE: Global Insight@-@@@@COMBO@INOTUZUMAB OZOGAMICIN@RITUXIMAB@@@@INOTUZUMAB OZOGAMICIN|RITUXIMAB|||@WYETH@PFIZER@@@@WYETH|PFIZER|||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@B-Cell Lymphoma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|B-Cell Lymphoma|||||||@CMC-544@RITUXAN@MABTHERA@@@CMC-544|RITUXAN|MABTHERA||@mAb@@@@@mAb||||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@RELAPSED@REFRACTORY@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922690@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients will be treated with SOM-230 (pasireotide) LAR 60mg IM once every 28 days and with RAD001 (Everolimus) 10mg PO daily. Each cycle is 28 days. An optional biopsy may be requested required after weeks of therapy. The biopsy may be performed between days 28 and 42. [Novartis]@@-@-@-@BASEL, SWITZERLAND@11/1/2013@@The active substance in Afinitor, everolimus, is an anticancer medicine, which acts by blocking a protein called ‘mammalian target of rapamycin' (mTOR). In the body, everolimus attaches to a protein that is found inside cells to make a ‘complex'. This complex then blocks mTOR. Since mTOR is involved in the control of cell division and the growth of blood vessels, Afinitor prevents the division of cancer cells and reduces their blood supply. This slows down the growth and spread of kidney cancer.@@14922690@A Phase II Study of RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma@@-@-@@NO REVIEW@@@@-@-@-@NCT01252251@25@-@-@@@EMEA issued positive opinion to grant Orphan Drug status for everolimus to treat neuroendocrine gastroenteropancreatic tumours@@11/1/2010@-@10-123@@-@-@@@II@II@@-@-@Trial registered. [Novartis, 1 December 2010]@The most frequent adverse events in patients taking RAD001 alone were stomatitis (44%), rash (40%), diarrhea (37%), fatigue (29%), nausea (26%), vomiting (17%), asthenia (16%), anemia (12%) and weight decrease (11%). The most frequent adverse events in patients taking RAD001 with Sandostatin LAR were stomatitis (49%), rash (40%), diarrhea (29%), fatigue (33%), nausea (33%), vomiting (13%), asthenia (11%), anemia (18%) and weight decrease (16%).@@@@COMBO@EVEROLIMUS@PASIREOTIDE@@@@EVEROLIMUS|PASIREOTIDE|||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Melanoma / Skin Cancer@Other@@@@Melanoma / Skin Cancer|Other||||||||@AFINITOR@RAD-001@SOM230@@@AFINITOR|RAD-001|SOM230||@Immunotherapy@Immunosuppressive@mTOR Inhibitor@@@Immunotherapy|Immunosuppressive|mTOR Inhibitor||@RESPONSE RATE@@@@@SURVIVAL@ADVERSE EVENTS@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922622@Onco@@@@@300f1014ntsdm@@@@@@404 patients received Casodex 50mg once-daily, 409 received flutamide 250mg three-times daily, each in combination with goserelin acetate implant or leuprolide acetate depot.@@L02BB03@L02B@NO@LONDON, UNITED KINGDOM@@@Casodex is a non-steroidal antiandrogen, devoid of other endocrine activity. It binds to androgen receptors without activating gene expression, and thus inhibits the androgen stimulus. Regression of prostatic tumours results from this inhibition. Clinically, discontinuation of Casodex can result in antiandrogen withdrawal syndrome in a subset of patients. Casodex is a racemate with its antiandrogenic activity being almost exclusively in the (R)-enantiomer.@@14922622@Indicated for use in combination therapy with an LH-RH analogue for the treatment of Stage D2 metastatic carcinoma of the prostate.@@NO@@@NO REVIEW@@@@@@FIRST-LINE@@813@Adult males including the elderly: one tablet (50mg) once a day. Treatment with 'Casodex' should be started at least 3 days before commencing treatment with an LHRH analogue, or at the same time as surgical castration.@@@@@@@Rare cases of death or hospitalisation due to severe liver injury have been reported in post-marketing in association with Casdoex use.@N/A@No@@813 PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED PROSTATE CANCER@@@III@APPROVED@@Unrestricted reimbursement.@RAMQ@Overall survival was not statistically significant; 52.7% of the Casodex/LHRH group had died, and 57.5% of the flutamide/LHRH group had died.@@@@@COMBO@BICALUTAMIDE@@@@@BICALUTAMIDE||||@PHMSCIENCE@@@@@PHMSCIENCE||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@PMS-BICALUTAMIDE@GENERIC@@@@PMS-BICALUTAMIDE|GENERIC|||@Hormone Antagonist@Anti-androgen@@@@Hormone Antagonist|Anti-androgen|||@OVERALL SURVIVAL@@@@@@@@@@METASTATIC@@@@@MULTI-CENTRE@DOUBLE-BLIND@CONTROLLED@@@@@Invalid Dosage Value Phase 1@@@@@@1459.92@1459.92@@100@0.7881@161@@@@@@@@@@@@0.03@@@@@@@@@@@@@@@@7/19/2017@1.61@1.61@2275589100@TABLET@C$@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14919781@Onco@@@@@300f1037ntsdm@@@@@@Tamoxifen compared to ovarian ablation@@L02BA01@L02B@YES@HUARTE-PAMPLONA, SPAIN@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14919781@@@NO@@@NO REVIEW@@@@90%@@@@N/A@Adults: The recommended daily dose of tamoxifen is normally 20 mg. No additional benefit, in terms of delayed recurrence or improved survival in patients, has been demonstrated with higher doses. Substantive evidence supporting the use of treatment with 30–40 mg per day is not available, although these doses have been used in some patients with advanced disease.@1-Jan-98@1/1/1998@@@@@Menstruation is suppressed in a proportion of premenopausal women receiving Nolvadex for the treatment of breast cancer. An increased incidence of endometrial changes including hyperplasia, polyps, cancer and uterine sarcoma (mostly malignant mixed Mullerian tumours), has been reported in association with Nolvadex treatment. The underlying mechanism is unknown but may be related to the oestrogenlike effect of Nolvadex. Any patient receiving or having previously received Nolvadex who report abnormal gynaecological symptoms, especially vaginal bleeding, or who presents with menstrual irregularities, vaginal discharge and symptoms such as pelvic pain or pressure should be promptly investigated.@LABEL@No@@@@@III; METASTATIC BREAST CANCER@APPROVED@@NO REVIEW@SNS@The objective RR, time to treatment failure, and survival were similar with both treatments. In an overview analysis of survival data from the 3 studies, the hazard ratio for death (tamoxifen/ovarian ablation) was 1.00. Elevated serum and plasma oestrogens have been observed in premenopausal women receiving tamoxifen, but the data from the randomized studies do not suggest an adverse effect of this increase. A limited number of premenopausal patients with disease progression during tamoxifen therapy responded to subsequent ovarian ablation.@@@@@MONO@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@CINFA@@@@@CINFA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GENERIC@@@@@GENERIC||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RESPONSE RATE@@@@@@@@@@@@@@@PROSPECTIVE@RANDOMISED@@@@@@Invalid Factory Price@@@@@@@@@100@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@EURO@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14920794@Onco@@@@@300f1020ntsdm@@@@@@Patients received either Kytril Injection, 40 mcg/kg or the combination of chlorpromazine and dexamethasone. They were all treated with ifosfamide =3 g/m2/day for two or three days.@@A04AA02@A04A@NO@BASEL, SWITZERLAND@@@Granisetron is a potent anti-emetic and highly selective antagonist of 5-hydroxytryptamine (5-HT3) receptors. Radioligand binding studies have demonstrated that Granisetron has negligible affinity for other receptor types including 5-HT and dopamine D2 binding sites. Granisetron is effective orally prophylactically in abolishing the retching and vomiting evoked by cytostatic therapy.@@14920794@Kytril tablets are indicated for the prevention of nausea and vomiting induced by cytostatic therapy@@NO@-@@NO REVIEW@@@@100%@-@-@-@88@Adults The dose of Kytril is 1mg twice a day or 2mg once a day during cytostatic therapy. The first dose of Kytril should be administered within one hour before the start of cytostatic therapy. Concomitant use of dexamethasone: The efficacy of Kytril may be enhanced by the addition of dexamethasone. Maximum Dose and Duration of Treatment: Kytril is also available as ampoules for intravenous administration. The maximum dose of Kytril administered orally and/or intravenously over 24 hours should not exceed 9mg.@N/A@@@-@@@Hypersensitivity reactions may occur in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.@-@No@-@88 PEDIATRIC PATIENTS RECEIVED EITHER KYTRIL INJECTION 20 MCG/KG OR CHLORPROMAZINE PLUS DEXAMETHASONE@PAEDIATRIC@@CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING / PEDIATRIC STUDIES@APPROVED@@@SSN@22% of Kytril Injection patients achieved complete response (no vomiting and no moderate or severe nausea in 24 hours) compared with 10% on the chlorpromazine regimen. The median number of vomiting episodes with Kytril Injection was 1.5; with chlorpromazine it was 7.0.@-@@@@MONO@GRANISETRON HYDROCHLORIDE@@@@@GRANISETRON HYDROCHLORIDE||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@KYTRIL@@@@@KYTRIL||||@5-HT3 Receptor Antagonist@@@@@5-HT3 Receptor Antagonist||||@RESPONSE RATE@EMETIC EPISODES@@@@@@@@@-@@@@@N/A@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@10@1.1229@38.12@62.91@39.83@@@@@@@@@@3.81@@@@@@@@@@@@@@@@6/7/2017@3.81@3.81@28093021@FILM-COATED TABLET@EURO@@@@@@@@1@MG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14917588@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@L01AA01@L01A@NO@DEERFIELD, ILLINOIS@@@Cyclophosphamide is an antineoplastic agent which is converted in the body to an active alkylating metabolite. It also possesses marked immunosuppressant properties. The principal site of cyclophosphamide activation is the liver. The chemotherapeutic and immunosuppressant activity of cyclophosphamide is thought to be mediated by the cytotoxic intermediates produced by activation by mixed function oxidases in hepatic microsomes. Non-enzymatic cleavage, possibly taking place in the tumour cells, results in the formulation of highly cytotoxic forms of the drug.@@14917588@Cyclophosphamide has been used successfully to induce and maintain regressions in a wide range of neoplastic conditions, including leukaemias, lymphomas, soft tissue and osteogenic sarcomas, paediatric malignancies and adult solid tumours; in particular, breast and lung carcinomas. Cyclophosphamide is frequently used in combination chemotherapy regimens involving other cytotoxic drugs.@@NA@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@The recommended dose for cyclophosphamide tablets is 50-250 mg/m2 daily (doses towards the upper end of this range should be used only for short courses). The dose may be amended at the discretion of the physician.@@@@@@@Cyclophosphamide should be withheld in the presence of severe bone marrow depression and reduced doses should be used in the presence of lesser degrees of bone marrow depression. Regular blood counts should be performed in patients receiving cyclophosphamide. It should not normally be given to patients with severe infections and should be withdrawn if such infections become life threatening. Cyclophosphamide should be used with caution in debilitated patients and those with renal and/or hepatic failure. Cyclophosphamide is not recommended in patients with a plasma creatinine greater than 120 µmol/l (1.5 mg/100 ml) bilirubin greater than 17 µmol/l (1 mg/100 ml); or serum transaminases or alkaline phosphatase more than 2-3 times the upper limit of normal. In all such cases, dosage should be reduced.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@CYCLOPHOSPHAMIDE@@@@@CYCLOPHOSPHAMIDE||||@BAXTER HEALTHCARE@@@@@BAXTER HEALTHCARE||||@@@@@@|||||||||@Haematological Malignancy@Breast Cancer@NSCLC@Sarcoma@Solid Tumours@Haematological Malignancy|Breast Cancer|NSCLC|Sarcoma|Solid Tumours|||||@ENDOXAN@@@@@ENDOXAN||||@Alkylating Agent@Nitrogen Mustard Analogue@@@@Alkylating Agent|Nitrogen Mustard Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1807@9.35@22.8@10.34@@@@@@@@@@0.02@@@@@@@@@@@@@@@@8/15/2017@9.35@9.35@1667261@INJECTION IN BOTTLE@EURO@@@@@@@@500@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14921135@Onco@@@@@@@@@@@Dexamethasone, cisplatin and cytarabine in combination with etoposide, ifosfamide and methotrexate with or without Rituxan; followed by carmustine, etoposide, cytarabine, melphalan and APBSCT.@@L01XC02@L01X@-@BASEL, SWITZERLAND@@@Rituximab binds specifically to the antigen CD20 (human B-lymphocyte-restricted differentiation antigen, Bp35), a hydrophobic transmembrane protein with a molecular weight of approximately 35 kD located on pre-B and mature B lymphocytes. The antigen is expressed on >90% of B-cell non-Hodgkin's lymphomas (NHL), but the antigen is not found on hematopoietic stem cells, pro-B-cells, normal plasma cells or other normal tissues. CD20 regulates an early step(s) in the activation process for cell cycle initiation and differentiation, and possibly functions as a calcium ion channel. CD20 is not shed from the cell surface and does not internalize upon antibody binding. Free CD20 antigen is not found in the circulation. B cells are believed to play a role in the pathogenesis of rheumatoid arthritis (RA) and associated chronic synovitis. In this setting, B cells may be acting at multiple sites in the autoimmune/inflammatory process, including through production of rheumatoid factor (RF) and other autoantibodies, antigen presentation, T-cell activation, and/or proinflammatory cytokine production. Mechanism of Action: The Fab domain of rituximab binds to the CD20 antigen on B lymphocytes, and the Fc domain recruits immune effector functions to mediate B-cell lysis in vitro. Possible mechanisms of cell lysis include complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). The antibody has been shown to induce apoptosis in the DHL-4 human B-cell lymphoma line. Normal Tissue Cross-reactivity: Rituximab binding was observed on lymphoid cells in the thymus, the white pulp of the spleen, and a majority of B lymphocytes in peripheral blood and lymph nodes. Little or no binding was observed in the non-lymphoid tissues examined.@@14921135@Relapsed, CD20+, aggressive B-Cell NHL@@-@-@@NO REVIEW@@@@-@-@-@NCT00012051@UP TO 340 @-@Nov-97@@@-@@@-@HOVON-44@@-@-@@@III / CKTO-2000-06 / - EU20042 / ISRCTN95614846@III@@-@-@Trial registered. SOURCE: Roche, 3 March 2001@-@@@@-@RITUXIMAB@@@@@RITUXIMAB||||@ROCHE@@@@@ROCHE||||@Netherlands@@@@@Netherlands|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@RITUXAN@@@@@RITUXAN||||@mAb@Chimeric@CD20@@@mAb|Chimeric|CD20||@-@@@@@@@@@@RELAPSED@ADVANCED@@@@RANDOMISED@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924111@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@L1A@L1A@-@RIDGEFIELD PARK, NEW JERSEY@@@Glufosfamide combines the active part of an approved alkylator, a member of a widely used class of chemotherapy drugs, with a glucose molecule. The linkage between glucose and the alkylator is cleaved to release the active drug. With glucose as the side product, glufosfamide has fewer side effects than other drugs in its class, which are known to cause hemorrhagic cystitis, a serious condition characterized by severe bladder bleeding.@@14924111@Advanced soft tissue sarcoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00441467@22@-@-@@@-@@3/1/2007@-@-@@-@PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC DISEASE WITH NO STANDARD CURATIVE THERAPY@@@II@II@@-@-@Eight of 18 (44%) evaluable patients demonstrated clinical benefit with a RECIST assessment of stable disease or partial response. SOURCE: Threshold, 18 January 2008@The most common severe adverse event was renal failure (5 of 22 patients). Renal toxicity was higher than in other glufosfamide studies but several risk factors were identified. @@@@MONO@GLUFOSFAMIDE@@@@@GLUFOSFAMIDE||||@THRESHOLD PHARMACEUTICALS@@@@@THRESHOLD PHARMACEUTICALS||||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@-@@@@@-||||@Alkylating Agent@@@@@Alkylating Agent||||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916134@Onco@@@@@@@@@@@Triptorelin embonate 22.5 mg 6 month formulation to be injected every 24 weeks [Debiopharm]@@L02AE04@L02A@-@PARIS, FRANCE@8/1/2007@@Triptorelin is a decapeptide analogue of GnRH which initially stimulates release of pituitary gonadotrophins. @@14916134@Two Injections of Triptorelin Embonate 22.5 mg 6-Month Formulation in Patients With Advanced Prostate Cancer.@@-@-@@NO REVIEW@@@@-@Ipsen exclusively in-licensed from Debiopharm know-how and new patent applications for the commercialisation rights of Decapeptyl in the world excluding North America, and some other countries (Sweden, Israel, Iran and Japan). [Ipsen, 31 October 2007]@FIRST-LINE@NCT00751790@120@-@-@@@-@@7/1/2006@-@TRI6M-301@@2010@The prostate cancer should be staged T3-4NxMx or TxN1-3Mx or TxNxM1 according to the TNM classification or the patient should have rising PSA after failed local therapy and be candidate for androgen deprivation therapy.  Serum testosterone levels >5 nmol/L.@@@III@III@@-@-@97.5% of patients achieved castrate levels of serum testosterone 28 days after the first injection and that 93% of the patients maintained serum testosterone levels below castrate level (defined as < 1.735 nmol/L or 50 ng/dL) from week 8 to 48. These efficacy and safety results are similar to those obtained previously with repeated administrations of the 1- and 3-month formulations of triptorelin in previous studies. Furthermore, local tolerance is good with only 6.7% of the patients treated reporting spontaneously site injection adverse events. [Debiopharm/9th International Symposium on GnRH, 12 February 2008]@The adverse event profile of the new 6-month formulation of triptorelin is fully comparable to that observed with the 1- and 3-month formulations.@@@@MONO@TRIPTORELIN PAMOATE@@@@@TRIPTORELIN PAMOATE||||@IPSEN@DEBIOPHARM@@@@IPSEN|DEBIOPHARM|||@South Africa@@@@@South Africa|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@DECAPEPTYL@@@@@DECAPEPTYL||||@LH-RH Analog@@@@@LH-RH Analog||||@SERUM TESTOSTERONE@@@@@@@@@@ADVANCED@@@@@MULTI-CENTRE@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@
16384683@Onco@@@@@300f1012ntsdm@@@@@@@@L01CD02@L01C@@PARIS, FRANCE@@@Docetaxel is an antineoplastic agent which acts by promoting the assembly of tubulin into stable microtubules and inhibits their disassembly which leads to a marked decrease of free tubulin. The binding of docetaxel to microtubules does not alter the number of protofilaments. Docetaxel has been shown in vitro to disrupt the microtubular network in cells which is essential for vital mitotic and interphase cellular functions. Docetaxel was found to be cytotoxic in vitro against various murine and human tumour cell lines and against freshly excised human tumour cells in clonogenic assays. Docetaxel achieves high intracellular concentrations with a long cell residence time. In addition, docetaxel was found to be active on some but not all cell lines over expressing the p-glycoprotein which is encoded by the multidrug resistance gene. In vivo, docetaxel is schedule independent and has a broad spectrum of experimental antitumour activity against advanced murine and human grafted tumours.@@16384683@TAXOTERE is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy.@@@@@NO REVIEW@@@@@@SECOND-LINE@@@For treatment after failure of prior platinum-based chemotherapy, the recommended dose is 75 mg/m² as a single agent. Docetaxel is administered as a one-hour infusion every three weeks.@@@@@@@@@No@@@@@@APPROVED@@@@@@@@@MONO@DOCETAXEL@@@@@DOCETAXEL||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@TAXOTERE@@@@@TAXOTERE||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@@@@@@@@@@@LOCALLY ADVANCED@UNRESECTABLE@@@@@@@@@1.75@m²@4094.593125@@@12.3@week@12.3 week@4094.59@4094.59@47.56@1@1.1511@152.18@203.39@157.68@@@@@@@@@@7.61@21@@mg/m²@75@1@@@@@@@@@@@8/1/2017@152.18@152.18@5859388@INFUSION SOLUTION CONCENTRATE, 1 ML@EURO@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14916117@Onco@@@@@300f1020ntsdm@@@@@@Actiq for breakthrough cancer pain@@N02AB03@N02A@YES@FRAZER, PENNSYLVANIA@@@Fentanyl is a pure opioid agonist whose principal therapeutic action is analgesia. Other members of the class known as opioid agonists include substances such as morphine, oxycodone, hydromorphone, codeine, and hydrocodone.@@14916117@Indicated only for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Patients considered opioid tolerant are those who are taking at least 60 mg of oral morphine/day, at least 25 mcg of transdermal fentanyl/hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer. This product must not be used in opioid non-tolerant patients because life-threatening hypoventilation could occur at any dose in patients not on a chronic regimen of opiates. September 2007: Dear Healthcare Professional letter issued to emphasise that it is not generic Actiq and ensure non-use in opioid non-tolerant patients or non-labelled indications.@@NO@-@@NO REVIEW@@@@100%@-@-@-@130@The initial dose of Actiq used should be 200 micrograms, titrating upwards as necessary through the range of available dosage strengths (200, 400, 600, 800, 1200 and 1600 micrograms). Patients should be carefully monitored until a dose is reached that provides adequate analgesia with acceptable side effects using a single dosage unit per episode of breakthrough pain. This is defined as the successful dose.@N/A@@@-@@@Must not be used in opioid non-tolerant patients; fentanyl is a Schedule II controlled substance; life-threatening hypoventilation can occur at any dose; contraindicated in acute or post-operative pain@LABEL@No@-@-@@@III@APPROVED@@@SSN@92 of 130 patients (71% achieved a successful dose during titration. The most successful doses were 400mcg (21%) and 800mcg (20%).@-@@@@MONO@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@CEPHALON@@@@@CEPHALON||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@ACTIQ@@@@@ACTIQ||||@Opioid Analgesic@@@@@Opioid Analgesic||||@RESPONSE RATE@MAXIMUM TOLERATED DOSE@@@@@@@@@-@@@@@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@3@1.1807@17.6@29.04@18.39@@@@@@@@@@@@@@@@@@@@@@@@@@8/31/2017@5.87@5.87@35399219@ORODISPERSIBLE SUBLINGUAL TABLET@EURO@@@@@@@@1600@MCG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14922710@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@IV decitabine qd for 5 days; carboplatin on day 8@@-@-@-@TOKYO, JAPAN@12/1/2008@@Dacogen was approved by the U.S. Food and Drug Administration on May 2, 2006 and is indicated for the treatment of patients with MDS, including previously treated and untreated, de novo and secondary MDS of all French-American-British (FAB) subtypes (refractory anemia, refractory anemia with rings sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, chronic myelomonocytic leukemia), and Intermediate-1, Intermediate-2, and High-Risk International Prognostic Scoring System (IPSS) groups.@@14922710@Platinum-resistant recurrent ovarian cancer@@-@-@@NO REVIEW@@@@-@Dacogen for Injection was developed through a pivotal Phase 3 study by SuperGen and partnered to MGI  (acquired by Eisai Co., Ltd.). MGI subsequently sublicensed all Dacogen rights outside of North America to Janssen-Cilag, a Johnson & Johnson Company.@SECOND-LINE@NCT00477386@29@-@-@@@-@@7/1/2007@-@0704-07 IUCRO-0185@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@COMBO@DECITABINE@CARBOPLATIN@@@@DECITABINE|CARBOPLATIN|||@EISAI@MGI PHARMA@SUPERGEN@@@EISAI|MGI PHARMA|SUPERGEN||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@DACOGEN@@@@@DACOGEN||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@RECIST@@@@@@@@@@REFRACTORY@RELAPSED@@@@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924204@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Dosing of Asentar with or before docetaxel, after platinum-based therapy- given every 3 weeks or weekly up to 180ug.@@-@-@-@SOUTH SAN FRANCISCO, CALIFORNIA@@@@@14924204@-@@-@-@@NO REVIEW@@@@-@Schering-Plough dropped out of licensing agreement with all rights returning to Novacea. SOURCE: Novacea, 9 April 2008In May 2007, Schering-Plough licensed global rights for US$60 million, common stock purchase, milestone payments of up to US$380 millio@SECOND-LINE@-@-@-@-@@@-@@@-@-@@-@-@@@I/II@DISCONTINUED@@-@-@>> FDA lifts clinical hold, but Novacea has decided against further development. [Novacea, 12.09.2008]>> MTD of Asentar not yet reached. Not unexpected toxicities; less reports of stomatitis and grade 3/4 asthenia. Weekly Asentar with Taxotere (rather than before) appeared better than Taxotere alone. [Novacea/ASCO, June 2007]@-@@@@COMBO@CALCITRIOL, HIGH-DOSE ORAL@@@@@CALCITRIOL, HIGH-DOSE ORAL||||@NOVACEA@@@@@NOVACEA||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@ASENTAR@DN-1010@@@@ASENTAR|DN-1010|||@Vitamin D Analogue@@@@@Vitamin D Analogue||||@MAXIMUM TOLERATED DOSE@SAFETY@@@@@@@@@-@@@@@MULTI-CENTRE@OPEN-LABEL@DOSE-RANGING@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916033@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@XL184  Gelatin capsules supplied in 25-mg and 100-mg strengths administered orally daily versus placebo@@-@-@-@SOUTH SAN FRANCISCO, CALIFORNIA@3/1/2013@@XL184 inhibits MET, RET, and VEGFR2, which are key drivers of tumor growth, metastasis, survival, and angiogenesis. In pharmacodynamic studies in mice, oral administration of XL184 resulted in balanced and durable inhibition of these targets. The compound has also shown activity against common mutant forms of RET and MET. XL184 has exhibited dose-dependent tumor growth inhibition and tumor regression in a variety of tumor models, including breast cancer, colon cancer, MTC, non-small cell lung cancer, and glioblastoma.@@14916033@Medullary thyroid cancer@@-@-@@NO REVIEW@@@@-@GSK has decided not to exercise its option to license XL-184, as well as XL-228, XL-820 and XL-844. [Exelixis, 23.10.2008]@-@NCT00704730@315@-@-@@@-@@6/1/2008@-@XL184-301@@-@The subject has a histologically confirmed diagnosis of MTC that is unresectable, locally advanced, or metastatic. The subject is at least 18 years old. The subject has an ECOG (Eastern Cooperative Oncology Group) performance status = 2.@ADULT@@III@III@@-@-@Trial registered. SOURCE: Exelixis, 23 June 2008@-@@@@MONO@-@@@@@-||||@EXELIXIS@@@@@EXELIXIS||||@@@@@@|||||||||@Thyroid Cancer@@@@@Thyroid Cancer|||||||||@XL-184@@@@@XL-184||||@TK Inhibitor@VEGF@Angiogenesis Inhibitor@@@TK Inhibitor|VEGF|Angiogenesis Inhibitor||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@UNRESECTABLE@LOCALLY ADVANCED@@@@RANDOMISED@DOUBLE-BLIND@PARALLEL ASSIGNMENT@PLACEBO-CONTROLLED@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16063872@Onco@@@@@300f1037ntsdm@@@@@@@@L01XC06@L01X@@NEW YORK, NEW YORK@@@Erbitux is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Cetuximab is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions and has an approximate molecular weight of 152 kDa. Cetuximab is produced in mammalian (murine myeloma) cell culture.@@16063872@Treatment of patients with epidermal growth factor receptor (EGFR)-expressing, KRAS wild-type metastatic colorectal cancer in combination with chemotherapy@@YES@@@NO REVIEW@@@@@>> Acquisition completed. [Lilly, 24.11.2008]          >> Lilly acquires ImClone for US$6.5 billion. [Lilly, 7.10.2008]        >> BMS Offers US$4.3Billion for ImClone or US$60.0 per share in cash. [BMS, 1 August 2008]      >> ImClone licensed co-development and co-promotion rights to BMS in North America and Japan, and to Merck KGaA in Europe.@@@@In all indications, Erbitux is administered once a week. The initial dose is 400 mg cetuximab per m2 body surface area. All subsequent weekly doses are 250 mg cetuximab per m2 each.@EMA, 17 July 2008@7/17/2008@@No@@@@@No@@@(EGFR)-expressing, KRAS WILD-TYPE@@@APPROVED@@@SNS@@@@@@COMBO@CETUXIMAB@@@@@CETUXIMAB||||@BMS@IMCLONE@MERCK SERONO@@@BMS|IMCLONE|MERCK SERONO||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ERBITUX@@@@@ERBITUX||||@mAb@Chimeric@TK Inhibitor@EGFR@@mAb|Chimeric|TK Inhibitor|EGFR|@@@@@@@@@@@METASTATIC@@@@@@@@@@1.75@m²@14030.5926@@@3.7@month@3.7 month@14030.59@14030.59@124.67@1@1.1511@192.3@247.74@199.84@@@@@@@@@@1.92@7@1@mg/m²@400@1@7@@mg/m²@250@1@@@@@@8/4/2017@192.3@192.3@658752@SOLUTION FOR INFUSION (VIAL) - 20 ML@EURO@@@@@@@@100@MG@5 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14924109@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@L1A@L1A@-@RIDGEFIELD PARK, NEW JERSEY@@@Glufosfamide combines the active part of an approved alkylator, a member of a widely used class of chemotherapy drugs, with a glucose molecule. The linkage between glucose and the alkylator is cleaved to release the active drug. With glucose as the side product, glufosfamide has fewer side effects than other drugs in its class, which are known to cause hemorrhagic cystitis, a serious condition characterized by severe bladder bleeding.@@14924109@Platinum-sensitive@@-@SDMB stopped Phase II trial early for efficacy@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00442598@45@-@-@@@-@@1/1/2007@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@The rate of enrollment in the trial has been problematic. After multiple prior chemotherapies including platinum-containing regimens, otherwise eligible patients did not have adequate renal function for enrollment. In addition, only one confirmed CA-125 response and no confirmed tumor responses have been reported. Due to a lack of efficacy and enrollment challenges, the company has decided to stop further enrollment and not pursue further clinical investigation in this indication.SOURCE: Threshold, 18 January 2008@@@@MONO@GLUFOSFAMIDE@@@@@GLUFOSFAMIDE||||@THRESHOLD PHARMACEUTICALS@@@@@THRESHOLD PHARMACEUTICALS||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@-@@@@@-||||@Alkylating Agent@@@@@Alkylating Agent||||@RESPONSE RATE@PROGRESSION-FREE SURVIVAL@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916731@Onco@@@@@300f1014ntsdm@300f1813ntsdm@@@@@Continuous dose-intense Temodar after progression@@-@-@-@KENILWORTH, NEW JERSEY@@@Temozolomide is not directly active but undergoes rapid nonenzymatic conversion at physiologic pH to the reactive compound MTIC. The cytotoxicity of MTIC is thought to be primarily due to alkylation of DNA. Alkylation (methylation) occurs mainly at the O6 and N7 positions of guanine.@@14916731@Glioma@@-@-@@NO REVIEW@@@@-@Merck & Co and Schering-Plough have announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. Based on the closing price of Merck stock on March 6, 2009, the consideration to be received by Schering-Plough shareholders is valued at $23.61 per share, or $41.1 billion in the aggregate. [Merck & Co, 9 March 2009]@-@NCT00392171@90@-@-@@@-@@6/1/2006@-@P04601@@-@-@@@II@II@@-@-@RESULTS PENDING (recruiting).@-@@@@MONO@TEMOZOLOMIDE@@@@@TEMOZOLOMIDE||||@SCHERING-PLOUGH@MERCK & CO@@@@SCHERING-PLOUGH|MERCK & CO|||@@@@@@|||||||||@Brain Cancer@@@@@Brain Cancer|||||||||@TEMODAR@@@@@TEMODAR||||@Alkylating Agent@@@@@Alkylating Agent||||@RESPONSE RATE@@@@@@@@@@RELAPSED@METASTATIC@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@C$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14916277@Onco@@@@@300f1008ntsdm@@@@@@-@@L02BA01@L02B@YES@-@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14916277@Nolvadex is indicated for: 1. The treatment of breast cancer. 2. The treatment of anovulatory infertility.@@NA@-@@NO REVIEW@@@@-@-@-@-@-@Adults: The recommended daily dose of tamoxifen is normally 20 mg. No additional benefit, in terms of delayed recurrence or improved survival in patients, has been demonstrated with higher doses. Substantive evidence supporting the use of treatment with 30–40 mg per day is not available, although these doses have been used in some patients with advanced disease.@-@@@-@@@Menstruation is suppressed in a proportion of premenopausal women receiving Nolvadex for the treatment of breast cancer. An increased incidence of endometrial changes including hyperplasia, polyps, cancer and uterine sarcoma (mostly malignant mixed Mullerian tumours), has been reported in association with Nolvadex treatment. The underlying mechanism is unknown but may be related to the oestrogenlike effect of Nolvadex. Any patient receiving or having previously received Nolvadex who report abnormal gynaecological symptoms, especially vaginal bleeding, or who presents with menstrual irregularities, vaginal discharge and symptoms such as pelvic pain or pressure should be promptly investigated.@-@No@-@-@@@-@DISCONTINUED@@-@NHI@RESULTS PENDING@-@@@@-@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@SAWAI PHARMACEUTICAL@@@@@SAWAI PHARMACEUTICAL||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@ADOPAN@@@@@ADOPAN||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@1@0.01111@@@@@@@@@@@@@@@@@@@@@@@@@@@@@1/1/2015@@@4291003F1171@FILM COATED TABLET@YEN@@@@@@@@10@MG@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14916396@Onco@@@@@300f1020ntsdm@@@@@@107 patients received oral melphalan (0.15MG/KG/day x 7 followed by 0.05MG/KG/day) with prednisone; 203 received IV melphalan (16MG/M2 q 2 weeks x 4 over 6 weeks followed by 4 weeks) with prednisone.@@L01AA03@L01A@YES@BRENTFORD, UNITED KINGDOM@@@Melphalan is a bifunctional alkylating agent. Formation of carbonium intermediates from each of the two bis-2-chloroethyl groups enables alkylation through covalent binding with the 7-nitrogen of guanine on DNA, cross-linking the two DNA strands and thereby preventing cell replication.@@14916396@Alkeran Injection, at conventional intravenous dosage, is indicated in the treatment of multiple myeloma and ovarian cancer. Alkeran Injection, at high intravenous dosage, is indicated, with or without haematopoietic stem cell transplantation, for the treatment of multiple myeloma and childhood neuroblastoma. Alkeran Injection, administered by regional arterial perfusion, is indicated in the treatment of localised malignant melanoma of the extremities and localised soft tissue sarcoma of the extremities.@@YES@-@@NO REVIEW@@@@@-@-@-@310@Ovarian adenocarcinoma: When used intravenously as a single agent, a dose of 1 mg/kg body weight (approximately 40 mg/m2 body surface area) given at intervals of 4 weeks has often been used. When combined with other cytotoxic drugs, intravenous doses of between 0.3 and 0.4 mg/kg body weight (12 to 16 mg/m2 body surface area) have been used at intervals of 4 to 6 weeks.@N/A@@@-@@@Melphalan should be administered under the supervision of a qualified physician experienced in the use of chemotherapeutic agents. Severe bone marrow suppression with resulting infection or bleeding may occur. Controlled trials comparing IV to oral melphalan have shown more myelosuppression with the IV formulation.@LABEL@No@-@-@@@III@APPROVED@@@@44% and 7% responded in the oral and IV groups respectively. Severe myelotoxicity and/or platelets occurred 28% and 11% respectively.@-@@@@COMBO@MELPHALAN HYDROCHLORIDE@PREDNISONE@@@@MELPHALAN HYDROCHLORIDE|PREDNISONE|||@GSK@@@@@GSK||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@ALKERAN@@@@@ALKERAN||||@Alkylating Agent@Nitrogen Mustard Analogue@@@@Alkylating Agent|Nitrogen Mustard Analogue|||@RESPONSE RATE@@@@@@@@@@-@@@@@RANDOMISED@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1807@3008.06@4964.5@3143.46@@@@@@@@@@60.16@@@@@@@@@@@@@@@@8/31/2017@3008.06@3008.06@42448011@POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION@EURO@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14916224@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@NO LABELLED TRIAL@@M04AA01@M04A@NO@ONTARIO, CANADA@@@@@14916224@Indicated in the management of patients with signs and symptomas of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephroptahy; the management of patients with leukaemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment should be discontinued when the potential for overproduction of uric acid is no longer presents; and, the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800mg/day in male patients and 750mg/day in female patients. This is not an innocuous drug. It is not recommended for the treatment of asymptomatic hyperuricemia.@@NO@@@NO REVIEW@@@@@@@@@For the prevention of uric acid nephropathy during the vigorous therapy of neoplastic disease, treatment with 600 to 800 mg daily for two or three days is advisable together with a high fluid intake. Otherwise similar considerations to the above recommendations for treating patients with gout govern the regulation of dosage for maintenance purposes in secondary hyperuricemia.@@@@@@@Should be discontinued at the first appearance of skin rash or other signs which may indicate an allergic rection. Dose should be adjusted if co-administered with Purinethol or Imuran.@NO LABELLED TRIAL@No@@@@@@APPROVED@@Covered; preferred@MEDICARE@NO LABELLED TRIAL@@@@@@ALLOPURINOL@@@@@ALLOPURINOL||||@APOTEX@@@@@APOTEX||||@@@@@@|||||||||@Supportive Care@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Non-Hodgkin's Lymphoma@Supportive Care|Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Non-Hodgkin's Lymphoma|||||@GENERIC@@@@@GENERIC||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1000@1@493.75@@@@@@@@@@@@@@@@@@@@@@@@@@@@9/1/2017@0.49@0.49@60505-2517-03@TABLET@US$@@@@@@@@300@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922694@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@TRC105 administered i.v. on days 1 and 15 of each 28 day cycle; until progression or unacceptable toxicity develops. @@-@-@-@SAN DIEGO, CALIFORNIA@6/1/2008@@TRC093 is a first-in-class humanized monoclonal antibody that inhibits angiogenesis and tumor cell growth by binding cleaved collagen, a component of the extracellular matrix of tumors that serves as the scaffold for new blood vessel and tumor growth.  TRC093 has shown activity, as monotherapy or when combined with chemotherapy, in pre-clinical studies of melanoma, breast and pancreatic cancer.@@14922694@-@@-@-@@NO REVIEW@@@@-@Tracon licensed worldwide rights to develop this drug from Micromet in March 2007. [Tracon, March 2007]@-@NCT00492830@24@-@-@@@-@@6/1/2007@-@093ST101@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@TRACON PHARMACEUTICALS@MICROMET@@@@TRACON PHARMACEUTICALS|MICROMET|||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@TRC-093@MT-293@@@@TRC-093|MT-293|||@mAb@Humanised@Angiogenesis Inhibitor@@@mAb|Humanised|Angiogenesis Inhibitor||@SAFETY@DOSE-LIMITING TOXICITY@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14923429@Onco@@@@@300f1012ntsdm@@@@@@Dose levels of 0.5-5, 15, 30 and 60g/m2/24 hours@@-@-@-@-@@@"The BiTE antibody blinatumomab (MT103/MEDI-538) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful ""killer cells"" of the human immune system, to eliminate cancer cells. Micromet is developing blinatumomab in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc."@@14923429@-@@-@-@@NO REVIEW@@@@-@>> AstraZeneca acquires MedImmune in US$15 billion deal. [AstraZeneca, 23.04.2007]@-@-@-@-@Orphan drug for mantle cell lymphoma.@@@Orphan drug for mantle cell lymphoma.@@@-@-@@-@-@@@I@I@@-@-@Interim data; doses as low as 0.005 milligrams per square meter per day in non–Hodgkin's lymphoma patients led to an elimination of target cells in blood. Partial and complete tumor regressions were first observed at a dose level of 0.015 milligrams, and all seven patients treated at a dose level of 0.06 milligrams experienced a tumor regression. Blinatumomab also led to clearance of tumor cells from bone marrow and liver. T cell–engaging antibodies appear to have therapeutic potential for the treatment of malignant diseases. SOURCE: Micromet, 15 August (Science, Vol. 321, no. 5891, pp.974-977).Proof of concept confirmed; response rate of 39%. SOURCE: Micromet/ASH, December 2007@-@@@@MONO@BLINATUMOMAB@@@@@BLINATUMOMAB||||@MICROMET@MEDIMMUNE@ASTRAZENECA@@@MICROMET|MEDIMMUNE|ASTRAZENECA||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@MT-103@MEDI-538@@@@MT-103|MEDI-538|||@mAb@@@@@mAb||||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14919100@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Oral MKC-1 capsules, administered twice daily, for 14 consecutive days, in a 28-day cycle @@-@-@-@ROCKVILLE, MARYLAND@@@MKC-1 is an orally-active, small molecule, cell cycle inhibitor with in vitro and in vivo efficacy against a broad range of human solid tumor cell lines, including multi-drug resistant cell lines. MKC-1 acts through multiple mechanisms of action (MOA), arresting cellular mitosis and inducing cell death (apoptosis) by binding to tubulin and to members of the importin ß family, which are proteins involved in nuclear transport, spindle formation, and mitotic progression. MKC-1 also inhibits activation of the oncogenic kinase Akt and the mTOR pathway through a mechanism that is a subject of intensive investigation by EntreMed scientists. MKC-1 has demonstrated broad antitumor effects in multiple preclinical models, including paclitaxel-resistant models, and was evaluated in several Phase 1 and 2 clinical studies involving nearly 270 patients prior to the licensing of the drug from Roche. These studies resulted in extensive pharmacokinetic and safety data.@@14919100@Patients who have failed at least one prior chemo regimen; unresectable pancreatic cancer@@-@-@@NO REVIEW@@@@-@>> Entremed announces restructuring plan, including the loss of 60% of staff and core focus on development of ENMD-2076. [EntreMed, 19.12.2008]        >> Acquired through takeover of Miikana Therapeutics in December 2005; originally developed by Roche, but EntreMed has exclusive worldwide license.@MULTIPLE@NCT00568646@N/A@-@-@@@-@@12/1/2007@-@MKC-105@@-@-@@@II@II@@-@-@Interim data to be presented in Q4 08. SOURCE: Entremed press release, 13 March 2008@-@@@@MONO@-@@@@@-||||@ENTREMED@@@@@ENTREMED||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@MKC-1@@@@@MKC-1||||@mTOR Inhibitor@@@@@mTOR Inhibitor||||@RESPONSE RATE@SAFETY@OVERALL SURVIVAL@@@OVERALL SURVIVAL@@@@@ADVANCED@METASTATIC@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@CAPSULE@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920990@Onco@@@@@@@@@@@Avastin plus Torisel versus Avastin with interferon alpha. SOURCE: Wyeth@@-@-@-@MADISON, NEW JERSEY@2/1/2012@@Temsirolimus is an inhibitor of mTOR (mammalian target of rapamycin). Temsirolimus binds toan intracellular protein (FKBP-12), and the protein-drug complex inhibits the activity of mTORthat controls cell division. Inhibition of mTOR activity resulted in a G1 growth arrest in treatedtumor cells. When mTOR was inhibited, its ability to phosphorylate p70S6k and S6 ribosomalprotein, which are downstream of mTOR in the PI3 kinase/AKT pathway was blocked. In invitro studies using renal cell carcinoma cell lines, temsirolimus inhibited the activity of mTORand resulted in reduced levels of the hypoxia-inducible factors HIF-1 and HIF-2 alpha, and thevascular endothelial growth factor.@@14920990@First-line treatment of advanced renal cell carcinoma@@-@-@@NO REVIEW@@@@-@Pfizer acquired Wyeth on 26 January 2009 in a deal worth U.S $68 billion [Pfizer 26.01.2009]@FIRST-LINE@NCT00631371@800@-@-@@@-@@5/1/2008@-@INTORACT@@-@Histologically and/or cytologically confirmed to have advanced renal cell carcinoma (RCC) Majority component of conventional clear-cell type is mandatory@@@III@III@@-@-@Trial started. SOURCE: Wyeth, 30 May 2008@-@@@@COMBO@TEMSIROLIMUS@BEVACIZUMAB@@@@TEMSIROLIMUS|BEVACIZUMAB|||@WYETH@PFIZER@@@@WYETH|PFIZER|||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@TORISEL@AVASTIN@@@@TORISEL|AVASTIN|||@Immunotherapy@Immunosuppressive@mTOR Inhibitor@@@Immunotherapy|Immunosuppressive|mTOR Inhibitor||@PROGRESSION-FREE SURVIVAL@RESPONSE RATE@@@@SAFETY@@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916214@Onco@@@@@300f1010ntsdm@@@@@@Actiq for breakthrough cancer pain@@N02AB03@N02A@YES@FRAZER, PENNSYLVANIA@@@Fentanyl is a pure opioid agonist whose principal therapeutic action is analgesia. Other members of the class known as opioid agonists include substances such as morphine, oxycodone, hydromorphone, codeine, and hydrocodone.@@14916214@Indicated for the management of breakthrough pain in patients already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.@@NO@@@NO REVIEW@@@@100%@Licensed from Kyowa Hakko; supplied by Abbott. Acquired through US$444 mil. takeover of Anesta Corp in 2000.@@@130@The initial dose of Actiq used should be 200 micrograms, titrating upwards as necessary through the range of available dosage strengths (200, 400, 600, 800, 1200 and 1600 micrograms). Patients should be carefully monitored until a dose is reached that provides adequate analgesia with acceptable side effects using a single dosage unit per episode of breakthrough pain. This is defined as the successful dose.@EMA, August 2002@@@@@@Must not be used in opioid non-tolerant patients; fentanyl is a Schedule II controlled substance; life-threatening hypoventilation can occur at any dose; contraindicated in acute or post-operative pain@LABEL@No@@@@@III@APPROVED@@NO NICE REVIEW@NHS@92 of 130 patients (71% achieved a successful dose during titration. The most successful doses were 400mcg (21%) and 800mcg (20%).@@@@@MONO@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@CEPHALON@@@@@CEPHALON||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@ACTIQ@@@@@ACTIQ||||@Opioid Analgesic@@@@@Opioid Analgesic||||@RESPONSE RATE@MAXIMUM TOLERATED DOSE@@@@@@@@@@@@@@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@3@1.2961@21.05@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/21/2017@7.02@7.02@2.69E+15@LOZENGE@GB£@@@@@@@@400@MCG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14923379@Onco@@@@@300f1012ntsdm@@@@@@Tamoxifen compared to ovarian ablation@@L02BA01@L02B@YES@GERMANY@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14923379@@@NO@@@NO REVIEW@@@@@@@@N/A@Adjuvant treatment of breast cancer, Adults (including elderly): The recommended dose is 20mg, given either in divided doses twice daily or as a single dose once daily. The current recommended treatment duration is five years; however the optimum duration has not been established. Treatment of locally advanced or metastatic breast cancer: The recommended dose is 20mg to 40mg, given either in divided doses twice daily or as a single dose once daily.@@@@@@@Women should be informed of the potential risks to the foetus, should they become pregnant whilst taking tamoxifen; or within two months of cessation of therapy. A number of secondary primary tumours, occurring at sites other than the endometrium and the opposite breast, have been reported in clinical trials, following the treatment of breast cancer patients with tamoxifen. No causal link has been established and the clinical significance of these observations remains unclear.@LABEL@No@@@@@III METASTATIC BREAST CANCER@APPROVED@@@GKV@The objective RR, time to treatment failure, and survival were similar with both treatments. In an overview analysis of survival data from the 3 studies, the hazard ratio for death (tamoxifen/ovarian ablation) was 1.00. Elevated serum and plasma oestrogens have been observed in premenopausal women receiving tamoxifen, but the data from the randomized studies do not suggest an adverse effect of this increase. A limited number of premenopausal patients with disease progression during tamoxifen therapy responded to subsequent ovarian ablation.@@@@@ADJUVANT@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@1 A PHARMA@@@@@1 A PHARMA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@TAMOX@@@@@TAMOX||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RESPONSE RATE@@@@@@@@@@@@@@@PROSPECTIVE@RANDOMISED@@@@@@Invalid Factory Price@@@@@@@@@100@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@EURO@@@@@@@@40@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14917489@Onco@@@@@300f1037ntsdm@@@@@@Six monthly injections of Eligard 7.5mg@@L02AE02@L02A@NO@TOKYO, JAPAN@@@Leuprolide acetate, an LH-RH agonist, acts as a potent inhibitor of gonadotropin secretion when given continuously in therapeutic doses. Animal and human studies indicate that after an initial stimulation, chronic administration of leuprolide acetate results in suppression of ovarian and testicular steroidogenesis. This effect is reversible upon discontinuation of drug therapy. Eligard is a sterile polymeric matrix formulation of leuprolide acetate for subcutaneous injection. It is designed to deliver 7.5 mg of leuprolide acetate at a controlled rate over a one month therapeutic period.@@14917489@Palliative treatment of advanced prostate cancer@@NO@-@@NO REVIEW@@@@90%@Sanofi-Synthelabo licensed North American rights from pre-merger Atrix in 2001@FIRST-LINE@-@120@One injection every month@12/20/2004@@@NO@@@Transient increase in serum testosterone concentrations during first week; contraindicated in children; cases of ureteral obstruction and spinal cord compression, possibly contributing to paralysis with or without fatal complications, have bene reported with LH-RH agonists@LABEL@@-@120 PATIENTS WITH ADVANCED PROSTATE CANCER (89 WITH STAGE C AND 31 WITH STAGE D)@@@-@DISCONTINUED@@NO REVIEW@SNS@Mean serum PSA values reduced 94% from baseline by Month 6 in patients whose baseline values were elevated above normal limit. Mean testosterone concentration increased from 361.3 ng/dL at baseline to 574.6ng/dL at Day 3, then decreased to below baseline by Day 10 and was 21.8ng/dL on Day 28 by Month 6, it was 6.1ng/dL. Serum testosterone suppressed to below castrate threshold of under 50ngdL by Day 28 in 119 (94%) patients- all remaining attained the level by Day 42@-@@@@MONO@LEUPROLIDE ACETATE@@@@@LEUPROLIDE ACETATE||||@ASTELLAS PHARMA@@@@@ASTELLAS PHARMA||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@ELIGARD@@@@@ELIGARD||||@LH-RH Analog@@@@@LH-RH Analog||||@PSA@SERUM TESTOSTERONE@@@@@@@@@ADVANCED@@@@@OPEN-LABEL@MULTI-CENTRE@@@@@@Invalid Factory Price@@@6@month@6 month@-@@@2@1.3598@@@@@@@@@@@@@@@@@@@@@@@@@@@@@9/2/2015@@@660036@PREFILLED SYRINGE (POWDER + SOLVANT)@EURO@@@@@@@@45@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
16639048@Onco@@@@@300f1020ntsdm@@@@@@@@L01XE23@L01X@@BASEL, SWITZERLAND@7/1/2011@@Dabrafenib is an  orally bioavailable inhibitor of the BRAF protein.  Dabrafenib was discovered and developed at GSK.@@16639048@Dabrafenib is indicated in monotherapy for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.@Both@Yes@8-Oct-14@10/8/2014@NO REVIEW@@@@@@@NCT01153763@92@The recommended dose of dabrafenib, either used as monotherapy or in combination with trametinib, is 150 mg (two 75 mg capsules) twice daily (corresponding to a total daily dose of 300 mg).@EMA, 26 August 2013@8/26/2013@11/29/2014@NO@@8/1/2010@@BRF113710@No@@Must be at least 18 years of age; Must have histologically confirmed cutaneous metastatic melanoma (Stage IV) that is BRAF mutation-positive (V600 E/K) as determined via central testing with a BRAF mutation assay; Is treatment naive or has received prior treatment for metastatic melanoma; Must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1); Women of child-bearing potential must have a negative pregnancy test within 14 days prior to the first dose of study treatment; Women with reproductive potential must be willing to practice acceptable methods of birth control during the study and for up to 4 weeks after the last dose of study medication; Men with reproductive potential must be willing to practice acceptable methods of birth control during the study and for up to 16 weeks after the last dose of study medication; Must have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1; Adequate organ function.@BRAF V600 mutation@ADULTS@II@APPROVED@@@SSN@@@@@@MONO@DABRAFENIB@@@@@DABRAFENIB||||@NOVARTIS @@@@@NOVARTIS ||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@TAFINLAR@@@@@TAFINLAR||||@Other@@@@@Other||||@OVERALL RESPONSE RATE@@@@@PROGRESSION FREE SURVIVAL@@@@@UNRESECTABLE@METASTATIC@@@@SINGLE GROUP@OPEN LABEL@@@@1@1@42210.75298@@@5.2@month@5.2 month@42210.75@42210.75@266.88@120@1.1229@8006.43@13213.81@8366.81@@@@@@@@@@0.89@1@@mg@300@1@@@@@@@@@@@6/7/2017@66.72@66.72@42923045@HARD CAPSULE@EURO@@@@@@@@75@MG@75 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14918758@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients receive oral tandutinib twice daily for 7 days. Patients then undergo biopsy or surgery to remove the tumor. Within 2 weeks after biopsy or surgery, patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Phase I: Patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of tandutinib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD. Phase II: Patients receive tandutinib as in phase I at the MTD determined in phase I. SOURCE: clinicaltrials.gov@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@1/1/2008@@MLN518 is a novel, oral, small molecule designed to inhibit type III receptor tyrosine kinases, including FLT3, PDGFR and c-KIT. Tyrosine kinases are enzymes involved in several cellular processes and are known to be activated in cancer cells to drive tumor growth. AML patients with FLT3 mutations experience earlier disease relapse and shorter survival rates compared to patients without these mutations. Approximately 25 to 30 percent of all adult AML patients have a mutation of the FLT3 gene. The use of MLN518 to treat AML has been granted fast-track status by the U.S. Food and Drug Administration. Phase I/II trials are underway.@@14918758@-@@-@-@@NO REVIEW@@@@-@>> Takeda acquisition of Millennium completed. [Millennium, 14 May 2008]       >> Takeda acquired Millennium Pharma on 10 April 2008 in a US$8.8 bil. deal. Millennium Pharma will continue to operate as a standalone unit. [Takeda, 10 April 2008]@-@NCT00379080@85@-@-@@@-@@1/1/2007@-@NABTT-0504@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@TANDUTINIB@@@@@TANDUTINIB||||@MILLENNIUM PHARMACEUTICALS@TAKEDA PHARMACEUTICAL@@@@MILLENNIUM PHARMACEUTICALS|TAKEDA PHARMACEUTICAL|||@@@@@@|||||||||@Brain Cancer@Glioblastoma Multiforme@@@@Brain Cancer|Glioblastoma Multiforme||||||||@MLN-518@@@@@MLN-518||||@TK Inhibitor@PDGF@@@@TK Inhibitor|PDGF|||@MAXIMUM TOLERATED DOSE@@@@@@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16392214@Onco@@@@@@@@@@@"RC48-ADC, Experimental, The phase I component has three dose levels of RC48-ADC (0.1mg/kg, 0.5 mg/kg, 1.0mg/kg, 1.5mg/kg, 2.0mg/kg, 2.5mg/kg, 3.0mg/kg, 3.5mg/kg and 4.0 mg/m2) and is designed as a traditional dose-escalation study in which cohorts of 3 patients are evaluated for the incidence of dose-liming toxicity (DLT) at each dose level."@@@@@CHINA@12/1/2016@@@@16392214@A Tolerance, Safety and Pharmacokinetic Ascending Dose Phase I Study of RC48-ADC Administered Subcutaneously to Subjects With HER2-Positive Malignant in Advanced Malignant Solid Tumors@Both@@@@@@@@@@MULTIPLE@NCT02881190@50@@@@@@@11/1/2015@@C002 CANCER@@@Inclusion Criteria:  -  Signed informed consent form;  -  Aged 18-75 years;  -  ECOG physical condition is 0 or 1;  -  Life expectancy greater than 12 weeks;  -  Patients with locally advanced or metastatic malignant solid tumors diagnosed by pathology and refractory to standard of care therapy, or for whom no standard of care therapy is available histology standard of care therapy, or for whom no standard of care therapy is available;  -  Human epidermal growth factor receptor 2 (HER2)-positive refers to immunohistochemistry (IHC 2+or 3+);  -  Patients with measurable and appreciable tumor lesions according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1);  -  Adequate organ function as defined by the following criteria:  -  absolute neutrophil count(ANC) >= 1.5 x 10(9)/L;  -  platelets>=70*10(9)/L;  -  Total serum bilirubin <=1.5*ULN;  -  serum aspartate transaminase (AST) and serum alanine transaminase (ALT) <=3.0*upper limit of normal (ULN), or AST and ALT<=5*ULN if liver function abnormalities are due to underlying malignancy;  -  normal serum creatinine;  -  international normalized ratio(INR) and activated partial thromboplastin time (aPTT) must be less than or equal to 1.5 times the upper limit of the normal range (ULN);  -  Women of child-bearing potential and men must agree to use adequate contraception (e.g., condoms, implants, injectables, combined oral contraceptives, some intrauterine devices [IUDs], complete sexual abstinence, or sterilized partner) prior to study entry and during the period of therapy and for 30 days after the last dose of study drug;  -  Left ventricular ejection fraction (LVEF) >= 50% as assessed by echocardiogram.@HER2-POSITIVE@ADULTS@Phase 1@I@@@@@@@@@MONO@RC48-ADC@@@@@RC48-ADC||||@REMEGEN@@@@@REMEGEN||||@China@@@@@China|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@-@@@@@-||||@Other@@@@@Other||||@maximal tolerance dose (MTD) of RC48-ADC@@@@@Safety (the drug safety as assessed by NCI-CTCAE v4.0)@@@@@ADVANCED@METASTATIC@@@@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
15045764@Onco@@@@@300f1020ntsdm@@@@@@Provenge or placebo@@-@-@-@SEATTLE, WASHINGTON@@@Sipuleucel–T contains mature, autologous antigen Antigen Presenting Cells (APCs). APCs are obtained from the patient via a standard leukapheresis Leukapheresis procedure approximately two days before each scheduled infusion. The patient's APCs are then transported to a Dendreon manufacturing facility where they are co-cultured with a recombinant fusion protein containing prostatic acid phosphatase (PAP). The activated, antigen-loaded APCs (now sipuleucel–T) are then delivered to the physician's office (infusion site) for infusion into the patient. Sipuleucel–T is then infused into the patient, where it can potentially stimulate a T cell response against prostate cancer cells. The process is performed three times over the course of a four-week period, upon which treatment is completed.@@15045764@Androgen dependent prostate cancer@@-@-@@NO REVIEW@@@@@-@-@NCT00005947@170@-@EMA, 17 September 2013@9/17/2013@@-@@6/1/2005@-@PROTECT@@-@170 MEN WITH NON-METASTATIC ADPC@@@III; P-11 / DEN-D9901, NCI-G00-1789;@APPROVED@@@@Researchers evaluated cumulative product release parameters including CD54 upregulation and the number of total nucleated cells (TNCs) among patients treated with sipuleucel-T (n=146). Results showed that Provenge patients experienced improved survival if they received more cells across the three doses (higher cumulative TNC count (p=0.019)) or higher cumulative CD54 upregulation values (p=0.009). The effect on survival for TNCs appeared to reflect in part the patients' baseline prognostic factors. However, the CD54 upregulation ratio appeared to be an independent predictor of survival in patients who received Provenge as the correlation remained strong even after adjusting for baseline prognostic factors (p=0.022). SOURCE: Dendreon, 14 February 2008@-@@@@MONO@SIPULEUCEL-T@@@@@SIPULEUCEL-T||||@DENDREON@@@@@DENDREON||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@PROVENGE@@@@@PROVENGE||||@Vaccine@Immunotherapy@@@@Vaccine|Immunotherapy|||@PSADT@@@@@@@@@@-@@@@@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@@Invalid Factory Price@@@@@@@@@1@1.1229@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INTRAVENOUS@EURO@@@@@@@@@@250 ML@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14919372@Onco@@@@@300f1037ntsdm@@@@@@NO LABELLED TRIAL@@L01AX04@L01A@YES@@@@Dacarbazine is a cytostatic agent. The antineoplastic effect is due to an inhibition of cell growth which is independent of the cell cycle and due to an inhibition of DNA synthesis. An alkylating effect has also been shown and other cytostatic mechanisms may also be influenced by dacarbazine. Dacarbazine is considered not to show an antineoplastic effect by itself. However by microsomal N-demethylation it is quickly converted to 5-amino-imidazole-4-carboxamide and a methyl cation, which is responsible for the alkylating effect of the drug.@@14919372@Dacarbazine is indicated for the treatment of patients with metastatic malignant melanoma. Further indications for dacarbazine as part of combination chemotherapy are: • Hodgkin's disease • Advanced adult soft tissue sarcomas (except mesothelioma, Kaposi sarcoma)@@YES@@@NO REVIEW@@@@60%@@@@@Hodgkin's Disease: Dacarbazine is administered in a daily dose of 375 mg/m2 body surface area i.v. on day 1 and day 15 in combination with doxorubicin, bleomycin and vinblastine for each cycle of ABVD regimen.@27-May-03@5/27/2003@@@@@It is recommended that dacarbazine be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. 1. Hemopoietic depression is the most common toxicity with dacarbazine. 2. Hepatic necrosis has been reported. 3. Studies have demonstrated this agent to have a carcinogenic and teratogenic effect when used in animals. 4. In treatment of each patient, the physician must weigh carefully the possibility of achieving therapeutic benefit against the risk of toxicity.@NO LABELLED TRIAL@No@@@@@@APPROVED@@NO REVIEW@SNS@NO LABELLED TRIAL@@@@@@DACARBAZINE@@@@@DACARBAZINE||||@MADAUS@@@@@MADAUS||||@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@@@@Haematological Malignancy|Hodgkin's Lymphoma||||||||@GENERIC@@@@@GENERIC||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@METASTATIC@MALIGNANT@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@EURO@@@@@@@@1000@MG@1000 MG@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14922835@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@V03AF03@V03A@NO@NEW YORK, NEW YORK@@@Calcium folinate is the calcium salt of 5-formyl tetrahydrofolic acid. It is an active metabolite of folinic acid and an essential coenzyme for nucleic acid synthesis in cytotoxic therapy. Calcium folinate is frequently used to diminish the toxicity and counteract the action of folate antagonists, such as methotrexate. Calcium folinate and folate antagonists share the same membrane transport carrier and compete for transport into cells, stimulating folate antagonist efflux. It also protects cells from the effects of folate antagonist by repletion of the reduce folate pool. Calcium folinate serves as a pre-reduced source of H4 folate; it can therefore bypass folate antagonist blockage and provide a source for the various coenzyme forms of folic acid.@@14922835@Leucovorin is used in cytotoxic therapy as an antidote to folic acid antagonists such as methotrexate. Leucovorin is effective in the treatment of megaloblastic anaemia.@@NO@@@NO REVIEW@@@@100%@Acquired through takeover of Pharmacia Corp.@@@@Advanced Colorectal Cancer: Either of the following two regimens is recommended: 1. Leucovorin is administered at 200 mg/m2 by slow intravenous injection over a minimum of 3 minutes, followed by 5-fluorouracil at 370 mg/m2 by intravenous injection. 2. Leucovorin is administered at 20 mg/m2 by intravenous injection followed by 5-fluorouracil at 425 mg/m2 by intravenous injection.@EMA, December 2005@@@@@@Leucovorin rescue: Depending upon the dose of methotrexate administered, dosage regimens of leucovorin calcium vary. Up to 120 mg leucovorin calcium are generally given, usually in divided doses over 12-24 hours by intramuscular injection, bolus intravenous injection or intravenous infusion in normal saline. This is followed by 12-15 mg intramuscularly or 15 mg orally every 6 hours for 48 hours. Rescue therapy is usually started 24 hours after the commencement of methotrexate administration. Megaloblastic anaemia (folate deficiency): 15 mg (one tablet) leucovorin per day.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@LEUCOVORIN CALCIUM@@@@@LEUCOVORIN CALCIUM||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Supportive Care@@@@@Supportive Care|||||||||@REFOLINON@@@@@REFOLINON||||@Detoxifying Agent@@@@@Detoxifying Agent||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@30@1.299@85.74@@@@@@@@@@@@0.19@@@@@@@@@@@@@@@@7/28/2017@2.86@2.86@3.81E+15@TABLET@GB£@@@@@@@@15@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14918734@Onco@@@@@300f1020ntsdm@@@@@@GRhTNF administered at low (0.8 mcg/sqm) and high (45 mcg/sqm) doses in combination with a standard oxaliplatin-based regimen@@-@-@-@MILAN, ITALY@12/1/2009@@NGR-hTNF is a vascular targeting agent with unique mode of action, and a first-in-class compound in the class of peptide/cytokine complexes able to selectively target the tumourvasculature. It consists of a tumour homing peptide (NGR) selectively binding tumour blood vessels, fused to the powerful human anticancer cytokine TNF. The resulting molecule has unique biological properties, including induction of tumour vascular permeability and normalisation, and a direct biological antitumour activity. NGR-hTNF is undergoing clinical development both as single agent and in combination with several different chemotherapeutic agents: currently, in addition to mesothelioma and colorectal cancer, single agent Phase II trials are ongoing in hepatocellular carcinoma and small-cell lung cancer; for colorectal cancer, it is also being tested in a Phase II trial in combination with Xelox. Also ongoing is a Phase I trial in combination with cisplatin, while a Phase I trial in combination with doxorubicin was successfully completed.@@14918734@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00675012@24@-@-@@@-@@12/1/2007@-@NGR005@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@OXALIPLATIN@@@@-|OXALIPLATIN|||@MOLMED@@@@@MOLMED||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ARENEGYR@ELOXATIN@@@@ARENEGYR|ELOXATIN|||@TK Inhibitor@VEGF@Angiogenesis Inhibitor@@@TK Inhibitor|VEGF|Angiogenesis Inhibitor||@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@1.0543@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14920812@Onco@@@@@300f1015ntsdm@@@@@@Kytril Injection at a dose of 40 mcg/kg was administered for 2, 4 or at least 6 cycles of chemotherapy@@A04AA02@A04A@NO@BASEL, SWITZERLAND@@@Granisetron is a potent anti-emetic and highly selective antagonist of 5-hydroxytryptamine (5-HT3) receptors. Radioligand binding studies have demonstrated that Granisetron has negligible affinity for other receptor types including 5-HT and dopamine D2 binding sites. Granisetron is effective orally prophylactically in abolishing the retching and vomiting evoked by cytostatic therapy.@@14920812@Kytril tablets are indicated for the prevention of nausea and vomiting induced by cytostatic therapy@@NO@Nov-96@@NO REVIEW@@@@@@@@512@Adults The dose of Kytril is 1mg twice a day or 2mg once a day during cytostatic therapy. The first dose of Kytril should be administered within one hour before the start of cytostatic therapy. Concomitant use of dexamethasone: The efficacy of Kytril may be enhanced by the addition of dexamethasone. Maximum Dose and Duration of Treatment: Kytril is also available as ampoules for intravenous administration. The maximum dose of Kytril administered orally and/or intravenously over 24 hours should not exceed 9mg.@1-Mar-94@3/1/1994@12/19/1996@@@@Hypersensitivity reactions may occur in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.@LABEL@No@@512 CANCER PATIENTS RECEIVED KYTRIL INJECTION, PROPHYLACTICALLY, FOR TWO CYCLES OF CHEMOTHERAPY, 224 PATIENTS RECEIVED IT FOR AT LEAST FOUR CYCLES, AND 108 PATIENTS RECEIVED IT FOR AT LEAST SIX CYCLES.@@@CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING / REPEAT-CYCLE CHEMOTHERAPY@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@Kytril Injection efficacy remained relatively constant over the first six repeat cycles, with complete response rates (no vomiting and no moderate or severe nausea in 24 hours) of 60% to 69%.@@@@@MONO@GRANISETRON HYDROCHLORIDE@@@@@GRANISETRON HYDROCHLORIDE||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@KYTRIL@@@@@KYTRIL||||@5-HT3 Receptor Antagonist@@@@@5-HT3 Receptor Antagonist||||@RESPONSE RATE@@@@@@@@@@@@@@@UNCONTROLLED@@@@@@@Invalid Dosage Value Phase 1@@@@@@2135.16@2135.16@@2@1.1511@8.71@11.54@9.29@@@@@@@@@@4.36@@@@@@@@@@@@@@@@8/1/2017@4.36@4.36@3.40E+12@FILM-COATED TABLET@EURO@@@@@@@@1@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
16077381@Onco@@@@@300f1037ntsdm@@@@@@150 mg once daily until disease progression or unacceptable toxicity@@L01XX43@L01X@@BASEL, SWITZERLAND@8/1/2013@@@@16077381@Indicated for the treatment of adult patients with: symptomatic metastatic basal cell carcinoma or locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy@Both@YES@@@@@@@REIMBURSEMENT RANGES FROM 40% TO 60% DEPENDING ON REVENUES@@@NCT01367665@150@The recommended dose is one 150 mg capsule taken once daily. In clinical trials, treatment with Erivedge was continued until disease progression or until unacceptable toxicity.@EMA, 12 July 2013@7/12/2013@12/5/2016@No@@6/1/2011@@MO25616, 2011-000195-34@No@@Metastatic or locally advanced basal cell carcinoma considered inoperable or that surgery is contraindicated and radiotherapy is contraindicated or inappropriateEastern Cooperative Oncology Group (ECOG) Performance Status 0-2@@ADULTS@II@APPROVED@@@SNS@The study showed Erivedge shrank lesions (objective response rate, or ORR) in 43 percent (27/63) of patients with locally advanced BCC and 30 percent of patients (10/33) with metastatic BCC, as assessed by independent review, the primary endpoint of the study. The median duration of response was 7.6 months.[Roche, 30 January 2012 http://www.roche.com/media/media_releases/med-cor-2012-01-30.htm]>>Trial registered [Roche 30 May 2011]@The most common side effects of Erivedge are muscle spasms, hair loss, change in how things taste or loss of taste, weight loss, tiredness, nausea, diarrhoea, decreased appetite, constipation, vomitting and joint aches. Other side effects may include missed monthly periods in females who can become pregnant, low levels of sodium in the blood, low potassium levels, and a higher than normal blood level of urea or other nitrogen containing compounds in the blood.@@@@@VISMODEGIB@@@@@VISMODEGIB||||@ROCHE@CURIS@@@@ROCHE|CURIS|||@@@@@@|||||||||@Other@@@@@Other|||||||||@ERIVEDGE@@@@@ERIVEDGE||||@Hedgehog Pathway Inhibitor@@@@@Hedgehog Pathway Inhibitor||||@SAFETY@@@@@RESPONSE@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@@ADVANCED@METASTATIC@@@@SINGLE-ARM@OPEN-LABEL@@@@1@1@57790.4@@@9.5@month@9.5 month@57790.4@57790.4@200@28@1.1511@5600@5882.15@5607.54@@@@@@@@@@1.33@1@@mg@150@1@@@@@@@@@@@8/4/2017@200@200@698799@HARD CAPSULE@EURO@@@@@@@@150@MG@150 MG@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
16159508@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Experimental: crizotinib 250mg orally continuous twice daily dosing Active Comparator: pemetrexed 500mg/m2 IV day 1 plus cisplatin 75mg/m2 IV day 1 every 21 days OR pemetrexed 500mg/m2 IV day 1 plus carboplatin AUC 5 or 6 day 1 every 21 days investigator's choice@@L01XE16@L01X@@NEW YORK, NEW YORK@12/1/2014@@@@16159508@XALKORI is indicated for the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).@@NA@@@NO REVIEW@@@@@Acquired through takeover of Pharmacia Corp., which acquired it from Sugen@SECOND-LINE@NCT00932893@347@The recommended dose of XALKORI is 250 mg orally, twice daily until disease progression or no longer tolerated by the patient. The recommended dose of XALKORI in patients with severe renal impairment (creatinine clearance <30 mL/min) not requiring dialysis is 250 mg orally, once daily.@FDA, 26 August 2011@8/26/2011@@Yes@@9/1/2009@@PROFILE 1007@No@@Histologically or cytologically proven diagnosis of non-small cell lung cancer positive for the ALK fusion gene (test provided by a central laboratory). Must have had disease progression after only one prior chemotherapy and that regimen but must have included one platinum drug@(ALK)-positive@@III@APPROVED@@@NA@@@@@@MONO@CRIZOTINIB@@@@@CRIZOTINIB||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@XALKORI@@@@@XALKORI||||@PDGF@@@@@PDGF||||@PROGRESSION-FREE SURVIVAL@@@@@OBJECTIVE RESPONSE RATE@OVERALL SURVIVAL@@@@METASTATIC@@@@@OPEN-LABEL@RANDOMISED@PARALLEL ASSIGNMENT@@@1@1@119375.3224@@@7.7@month@7.7 month@119375.32@119375.32@509.71@60@1@15291.25@@@@@@@@@@@@1.02@1@@mg@500@1@@@@@@@@@@@8/2/2017@254.85@254.85@00069-8140-20@HARD CAPSULE@US$@@@@@@@@250@MG@250 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16829137@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01XC05@L01X@@MADISON, NEW JERSEY@@@Gemtuzumab ozogamicin (marketed as Mylotarg) is a monoclonal antibody used to treat acute myelogenous leukaemia. It is a monoclonal antibody to CD33 linked to a cytotoxic agent, calicheamicin. CD33 is expressed in most leukaemic blast cells but is not found on normal hematopoietic stem cells. When given to patients in first relapse, 15% of patients achieve a complete remission. In the United States, it was approved by the FDA for use in patients over the age of 60 with relapsed AML who are not considered candidates for standard chemotherapy. A notable complication of therapy with gemtuzumab is the increased risk of veno-occlusive disease in the absence of bone marrow transplantation. The onset of VOD can also be delayed and can occur at increased frequency following bone marrow transplantation.@@16829137@Treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older.@@NA@@@NO REVIEW@@@@@Pfizer acquired Wyeth on 26 January 2009 in a deal worth U.S $68 billion [Pfizer 26.01.2009]@@@57@3 mg/m2 (up to one 4.5 mg vial) on Days 1, 4, and 7@FDA, 1 September 2017@9/1/2017@@Yes@@@@MyloFrance-1@No@@@PAEDIATRIC CD33-positive@@II@APPROVED@@@@@@@@@MONO@GEMTUZUMAB OZOGAMICIN@@@@@GEMTUZUMAB OZOGAMICIN||||@WYETH@@@@@WYETH||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@MYLOTARG@@@@@MYLOTARG||||@mAb@Humanised@CD33@@@mAb|Humanised|CD33||@@@@@@@@@@@REMAPSED@REFRACTORY@@@@SINGLE-ARM@OPEN-LABEL@@@@1.2@m²@Invalid Factory Price@@@7@day@7 day@@@@1@1@@@@@@@@@@@@@@7@@mg/m²@3@3@@@@@@@@@@@@@@00008-4510-01@POWDER FOR SOLUTION FOR INFUSION (VIAL)@US$@@@@@@@@5@MG@5 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16159501@Onco@@@@@@@@@@@Phase Ia Dose-Escalation Stage: MTIG7192A, Experimental, Cohorts of at least 3 participants each will be treated with escalating doses of MTIG7192A to determine the MTD or maximum administered dose (MAD).Phase Ia Expansion Stage: MTIG7192A, Experimental, Approximately 20 to 40 participants will be enrolled in the expansion stage to better characterize the safety, tolerability, PK variability, and preliminary efficacy of MTIG7192A in different cancer types.Phase Ib Dose-Escalation Stage: MTIG7192A+Atezolizumab, Experimental, Cohorts of at least 3 participants each will be treated with escalating doses of MTIG7192A in combination with a fixed dose of atezolizumab to determine the MTD or MAD.Phase Ib Expansion Stage: MTIG7192A+Atezolizumab, Experimental, At least approximately 160 participants will be enrolled in the expansion stage to better characterize the safety, tolerability, PK variability, and preliminary efficacy of MTIG7192A in combination with atezolizumab in different cancer types.@@-@-@@@9/1/2019@@@@16159501@A Phase Ia/Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors@Both@@@@@Atezolizumab will be given as 1200 mg via IV infusion on Day 1 of each 21-day cycle in combination with MTIG7192A. Combination treatment may continue until disease progression or loss of clinical benefit.@@@@@FIRST-LINE@NCT02794571@300@@@@@@@5/1/2016@@GO30103@@@-  Adults 18 years of age or older  -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1  -  Life expectancy at least 12 weeks  -  Adequate hematologic and end organ function  -  Histologic documentation of locally advanced, recurrent@@Adult@Phase 1@I@@@@@@@@@COMBO@ATEZOLIZUMAB@-@@@@ATEZOLIZUMAB|-|||@GENETECH@@@@@GENETECH||||@Australia@Canada@France@South Korea@Spain@Australia|Canada|France|South Korea|Spain|United States||||@Solid Tumours@@@@@Solid Tumours|||||||||@-@MTIG7192A@@@@-|MTIG7192A|||@Other@@@@@Other||||@Percentage of Participants with Dose-Limiting Toxicities (DLTs)@Percentage of Participants with Adverse Events (AEs)@Number of Cycles with MTIG7192A@@@PK@PK@@@@ADVANCED@METASTATIC@@@@NON-RANDOMIZED@Safety Study@PARALLEL ASSIGNMENT@OPEN LABEL@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
16066633@Onco@@@@@300f1020ntsdm@@@@@@Pembrolizumab (MK-3475), Experimental, Pembrolizumab (MK-3475) will be administered at the dose of 200mg, as a 30-minute intravenous infusion, every 3 weeks, for a total of 3 cycles prior to radical cystectomy.@@L01XC18@L01X@@WHITEHOUSE STATION, NEW JERSEY@11/1/2017@@@@16066633@An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab (MK-3475) Before Cystectomy for Patients With Muscle-invasive Urothelial Bladder Cancer.@Both@@@@@@@@@@@NCT02736266@90@@@@@@@5/1/2016@@PURE-01@@@Willing and able to provide written informed consent. - Ability to comply with the protocol. - Age ≥ 18 years.  - Histopathologically confirmed transitional cell carcinoma. Patients with mixed histologies are required to have a dominant (i.e. 50% at least) transitional cell pattern.  -  Fit and planned for cystectomy (according to local guidelines).  - Clinical stage T2-T4a N0 M0 disease by CT (or MRI) + PET/CT (within 4 weeks of randomization by RECIST v1.1).  -  Residual disease after TURB (surgical opinion, cystoscopy or radiological presence). -  Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens (blocks preferred) or at least 15 unstained slides, with an associated pathology report, for testing at the study sponsor site and determined to be evaluable for tumor PD-L1 expression prior to study enrolment; patients with fewer than 15 unstained slides available at baseline (but no fewer than 10) may be eligible following discussion with Merck representatives.  -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.  10. Adequate hematologic and end-organ function tests.@@ADULTS@Phase 2@II@@@@@@@@@NEOADJUVANT@PEMBROLIZUMAB@@@@@PEMBROLIZUMAB||||@MERCK & CO@@@@@MERCK & CO||||@Italy@@@@@Italy|||||||||@Bladder Cancer@@@@@Bladder Cancer|||||||||@KEYTRUDA@@@@@KEYTRUDA||||@PD-1 Inhibitor@@@@@PD-1 Inhibitor||||@Pathologic complete response@@@@@ADVERSE EVENTS@Percentage of treatment-related delay in surgery@@@@@@@@@SAFETY/EFFICACY STUDY@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@@Invalid Factory Price@@@@@@@@@@1.0543@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14922492@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Dose of Gleevec will be 400 mg in 1st cohort & will be increased to 600 mg po/day & then to 400 mg bid in successive cohorts. Prescribed dose should be administered orally, w large glass of water. Pts should not eat large or high fat meal within 1 hour before or after gleevec dosing. Doses of 600 mg or less should be administered once daily, whereas doses greater than 600 mg should be administered as equal doses twice day. It is recommended that pts take their prescribed Gleevec at same time that they take their prescribed RAD001 & hydroxyurea, however, 30-60 minute interval between agents is acceptable if required for practical or other compliance issues.@@-@-@-@BASEL, SWITZERLAND@5/1/2010@@The active substance in Afinitor, everolimus, is an anticancer medicine, which acts by blocking a protein called ‘mammalian target of rapamycin' (mTOR). In the body, everolimus attaches to a protein that is found inside cells to make a ‘complex'. This complex then blocks mTOR. Since mTOR is involved in the control of cell division and the growth of blood vessels, Afinitor prevents the division of cancer cells and reduces their blood supply. This slows down the growth and spread of kidney cancer.@@14922492@Recurrent malignant gliomas@@-@-@@NO REVIEW@@@@-@-@-@NCT00613132@72@-@-@@@EMEA issued positive opinion to grant Orphan Drug status for everolimus to treat neuroendocrine gastroenteropancreatic tumours@@5/1/2005@-@7020-07-32@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@COMBO@EVEROLIMUS@IMATINIB@@@@EVEROLIMUS|IMATINIB|||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Brain Cancer@Glioblastoma Multiforme@@@@Brain Cancer|Glioblastoma Multiforme||||||||@AFINITOR@RAD-001@GLEEVEC@GLIVEC@@AFINITOR|RAD-001|GLEEVEC|GLIVEC|@Immunotherapy@Immunosuppressive@mTOR Inhibitor@@@Immunotherapy|Immunosuppressive|mTOR Inhibitor||@MAXIMUM TOLERATED DOSE@DOSE-LIMITING TOXICITY@@@@@@@@@RELAPSED@MALIGNANT@@@@NON-RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924953@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Vectibix with AMG-706 and FOLFIRI or FOLFOX-4@@-@-@-@THOUSAND OAKS, CALIFORNIA@@@Motesanib diphosphate is a highly selective, oral agent that is being evaluated for its ability to inhibit angiogenesis and lymphangiogenesis by targeting vascular endothelial growth factor receptors 1, 2 and 3 (“VEGFR1-3”). It is also under investigation for its potential direct anti-tumor activity by targeting platelet-derived growth factor receptor (“PDGFR”) and stem cell factor receptor (“c-kit”) signaling, which may also confer direct anti-tumor activity. In February 2008, Amgen announced that Takeda will become the worldwide partner for motesanib diphosphate in addition to an exclusive collaboration on up to 13 other programs in the Japanese market. @@14924953@AMG-706 plus Vectibix and chemo@@-@-@@NO REVIEW@@@@-@Motesanib was the unofficial key to the wide-ranging, two-part R&D deal with Amgen signed in February 2008 through which, in its first part, Takeda acquired Japanese rights for up to 13 molecules in Amgen's pipeline, including Vectibix (panitumumab), AMG-@-@NCT00101894@148@-@-@@@-@@12/1/2004@-@20040205@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@COMBO@MOTESANIB DIPHOSPHATE@PANITUMUMAB@@@@MOTESANIB DIPHOSPHATE|PANITUMUMAB|||@AMGEN@TAKEDA PHARMACEUTICAL@@@@AMGEN|TAKEDA PHARMACEUTICAL|||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@AMG-706@FOLFIRI@FOLFOX4@@@AMG-706|FOLFIRI|FOLFOX4||@TK Inhibitor@VEGF@PDGF@SCF@@TK Inhibitor|VEGF|PDGF|SCF|@ADVERSE EVENTS@RESPONSE RATE@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16384268@Onco@@@@@300f1015ntsdm@@@@@@"5-Fluorouracil + Epirubicin + Cyclophosphamide, Active Comparator, Neoadjuvant treatment (Period 1): Participants will receive 4 cycles (cycle length = 21 days) of 5-FU + epirubicin + cyclophosphamide. Surgery will be performed 5 (+/- 1) weeks after the last cycle. Adjuvant treatment (Period 2): Participants will receive 4 cycles (cycle length = 21 days) of docetaxel.Capecitabine + Epirubicin + Cyclophosphamide, Experimental, Neoadjuvant treatment (Period 1): Participants will receive 4 cycles (cycle length = 21 days) of capecitabine + epirubicin + cyclophosphamide. Surgery will be performed 5 (+/- 1) weeks after the last cycle. Adjuvant treatment (Period 2): Participants will receive 4 cycles (cycle length = 21 days) of docetaxel."@@L01BC02@L01B@@BASEL, SWITZERLAND@12/1/2011@@Fluorouracil is an analogue of uracil, a component of ribonucleic acid. The drug is believed to function as an antimetabolite. After intracellular conversion to the active deoxynucleotide, it interferes with the synthesis of DNA by blocking the conversion@@16384268@An Open-Label, Multicenter, Randomized, Phase II Study to Evaluate the Efficacy and Safety of Two Combination Dose Regimens: Capecitabine + Epirubicin + Cyclophosphamide (CEX) Versus 5-FU + Epirubicin + Cyclophosphamide (FEC 100) as Neoadjuvant Therapy in Females Presenting With Operable Breast Cancer@Female@@@@@5-FU will be administered at 500 mg/m^2 by short IV infusion on Day 1 of each 21-day cycle during neoadjuvant treatment period for 4 cycles.@@@@@FIRST-LINE@NCT02846428@182@@@@@@@3/1/2004@@ML16986@@@-  Females with a unilateral, non-inflammatory, non-multicentric, non-metastatic breast adenocarcinoma, not considered candidates for conservative management, and whose diagnosis had been histologically confirmed as T2-3, N0-1, M0 according to the tumor-n@@ADULTS@Phase 2@II@@@@@@@@@COMBO@FLUOROURACIL@CAPECITABINE@CYCLOPHOSPHAMIDE@@@FLUOROURACIL|CAPECITABINE|CYCLOPHOSPHAMIDE||@ROCHE@@@@@ROCHE||||@France@@@@@France|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@XELODA@GENERIC@TAXOTERE@@@GENERIC||XELODA|GENERIC|TAXOTERE@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@Percentage of participants with pathological complete tumor response Assessed by Expert Blinded Independent Review according to the Sataloff classification\n@@@@@Percentage of participants with pathological complete tumor response Assessed by Investigator according to the Sataloff classification@Percentage of participants with breast conserving surgery@@@@@@@@@RANDOMIZED@SAFETY/EFFICACY STUDY@PARALLEL ASSIGNMENT@OPEN LABEL@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14921638@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@CUDC-101 will be administered on days one to five of a fourteen day cycle. [Curis]@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@@@This is a first-in-class small molecule drug candidate that has been designed as an inhibitor of epidermal growth factor receptor (EGFR), epidermal growth factor receptor 2 (Her2) and histone deacetylase (HDAC). CUDC-101 has been designed to simultaneously inhibit kinase activity of EGFR and Her2 while also interfering with other key drivers of the cancer cell signaling network involved in tumor cell growth and survival through its HDAC inhibitory activity.@@14921638@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00728793@-@-@-@@@-@@8/1/2008@-@CUDC-101-101@@-@>>Subjects with advanced, refractory solid tumors and a histopathologically confirmed diagnosis >>Subjects must have no further standard of care options or have refused standard therapy@@@I@I@@-@-@>>FPI dosing begun. [Curis, 26.08.2008]>>IND filing due in Q1 2008 and trial to start in 2008. [Curis, January 2008]@-@@@@MONO@-@@@@@-||||@CURIS@@@@@CURIS||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@CUDC-101@@@@@CUDC-101||||@HDAC@TK Inhibitor@EGFR@HER2@@HDAC|TK Inhibitor|EGFR|HER2|@SAFETY@MAXIMUM TOLERATED DOSE@DOSE-LIMITING TOXICITY@@@PHARMACOKINETICS@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922118@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@1000 MG IV ON DAYS 1, 8 AND 15 OF CYCLE 1 AND ON DAY 1 OF CYCLES 2-8 (21-DAY CYCLES) OR CYCLES 2-6 (28-DAY CYCLES); FOLLOWED BY 1000 MG IV EVERY 2 MONTHS IN RESPONDERS UNTIL DISEASE PROGRESSION, FOR UP TO 2 YEARS@@@@@BASEL, SWITZERLAND@7/1/2023@@@@14922118@A MULTICENTRE, PHASE III, OPEN LABEL, RANDOMIZED STUDY IN PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED INDOLENT NON-HODGKIN'S LYMPHOMA EVALUATING THE BENEFIT OF GA101 (RO5072759) + CHEMOTHERAPY COMPARED TO RITUXIMAB + CHEMOTHERAPY FOLLOWED BY GA101 OR RITUXIMAB MAINTENANCE THERAPY IN RESPONDERS.@@@@@@@@@@@@NCT01332968@1400@@@@@@@7/1/2011@@BO21223@@@CD20-POSITIVE INDOLENT B-CELL NON-HODGKIN'S LYMPHOMA (FOLLICULAR LYMPHOMA OR SPLENIC, NODAL OR EXTRANODAL MARGINAL ZONE LYMPHOMA)  -  STAGE III OR IV DISEASE, OR STAGE II BULKY DISEASE, REQUIRING TREATMENT  -  AT LEAST ONE BI-DIMENSIONALLY MEASURABLE LESION (>2 CM IN ITS LARGEST DIMENSION BY CT SCAN OR MRI)  -  EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG) PERFORMANCE STATUS 0, 1 OR 2  -  ADEQUATE HEMATOLOGIC FUNCTION@@@II@II@@@@Trial registered [Roche 8 April 2011]@@@@@@RO5072759@@@@@RO5072759||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Non-Hodgkin's Lymphoma@@@@@Non-Hodgkin's Lymphoma|||||||||@-@@@@@-||||@Other@@@@@Other||||@PROGRESSION-FREE SURVIVAL IN PATIENTS WITH FOLLICULAR LYMPHOMA, INVESTIGATOR-ASSESSED ACCORDING TO THE REVISED RESPONSE CRITERIA FOR MALIGNANT LYMPHOMA@PROGRESSION-FREE SURVIVAL@@@@RESPONSE@PROGRESSION-FREE SURVIVAL@@@@@@@@@RANDOMISED@SAFETY@PARALLEL ASSIGNMENT@OPEN LABEL@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922077@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Oncophage once-weekly for four consecutive weeks followed by once every two weeks@@-@-@-@NEW YORK, NEW YORK@@@Based on proprietary heat shock protein technology, the Oncophage vaccine is designed to capture the particular cancer's ‘fingerprint.' This fingerprint contains unique antigens (substances that can provoke an immune response) that are present only on that particular patient's specific cancer cells. Injection of the vaccine is intended to stimulate the patient's immune system to recognize and attack any cells bearing the specific cancer fingerpri@@14922077@Indolent lymphoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00081809@35@-@-@@@-@@@-@C-100-09,@@-@-@@@II@II@@-@-@ASCO 2003; demonstrated that Oncophage vaccination was associated with clinical response in six patients: one partial response, two minor responses and three disease stabilizations. All responding patients were either previously untreated or received only one prior treatment regimen. Oncophage was well tolerated, with no adverse effects. Antigenics' confirmation, data analysis and finalization of results reported by study investigators are ongoing.@-@@@@MONO@VITESPAN@@@@@VITESPAN||||@ANTIGENICS@@@@@ANTIGENICS||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@Waldenstrom's Macroglobinaemia@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|Waldenstrom's Macroglobinaemia|||||||@ONCOPHAGE@@@@@ONCOPHAGE||||@Vaccine@@@@@Vaccine||||@COMPLETE RESPONSE@PARTIAL RESPONSE@TIME TO PROGRESSION@@@TIME TO PROGRESSION@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922729@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Velcade + Rituxan@@L01XX32@L01X@-@CAMBRIDGE, MASSACHUSSETTS@@@Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targeted proteolysis, which can affect multiple signaling cascades within the cell. This disruption of normal homeostatic mechanisms can lead to cell death. Experiments have demonstrated that bortezomib is cytotoxic to a variety of cancer cell types in vitro. Bortezomib causes a delay in tumor growth in vivo in nonclinical tumor models, including multiple myeloma.@@14922729@-@@-@-@@NO REVIEW@@@@-@>> Takeda acquisition of Millennium completed. [Millennium, 14 May 2008]      >> Takeda acquired Millennium Pharma on 10 April 2008 in a US$8.8 bil. deal. Millennium Pharma will continue to operate as a standalone unit. [Takeda, 10 April 2008]      >> Ortho Biotech and Janssen-Cilag pay double-digit royalties and other milestones.@-@NCT00422799@45@-@-@@@-@@9/1/2006@-@06-008@@MAY 2010 (ORPHAN); MARCH 2012 (ORPHAN) WITH EXTENDED EXPIRATION TO MAY 2017.@-@@@II@II@@-@-@Trial registered [Millennium, 12.01.2007]@-@@@@COMBO@BORTEZOMIB@RITUXIMAB@@@@BORTEZOMIB|RITUXIMAB|||@MILLENNIUM PHARMACEUTICALS@TAKEDA PHARMACEUTICAL@@@@MILLENNIUM PHARMACEUTICALS|TAKEDA PHARMACEUTICAL|||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@Waldenstrom's Macroglobinaemia@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|Waldenstrom's Macroglobinaemia|||||||@VELCADE@RITUXAN@MABTHERA@@@VELCADE|RITUXAN|MABTHERA||@Proteasome Inhibitor@@@@@Proteasome Inhibitor||||@RESPONSE RATE@@@@@@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-GROUP@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917251@Onco@@@@@300f1020ntsdm@@@@@@404 patients received Casodex 50mg once-daily, 409 received flutamide 250mg three-times daily, each in combination with goserelin acetate implant or leuprolide acetate depot.@@L02BB03@L02B@NO@LONDON, UNITED KINGDOM@@@Casodex is a non-steroidal antiandrogen, devoid of other endocrine activity. It binds to androgen receptors without activating gene expression, and thus inhibits the androgen stimulus. Regression of prostatic tumours results from this inhibition. Clinically, discontinuation of Casodex can result in antiandrogen withdrawal syndrome in a subset of patients. Casodex is a racemate with its antiandrogenic activity being almost exclusively in the (R)-enantiomer.@@14917251@Indicated for use in combination therapy with an LH-RH analogue for the treatment of Stage D2 metastatic carcinoma of the prostate.@@NO@-@@NO REVIEW@@@@100%@-@FIRST-LINE@-@813@Adult males including the elderly: one tablet (50mg) once a day. Treatment with 'Casodex' should be started at least 3 days before commencing treatment with an LHRH analogue, or at the same time as surgical castration.@N/A@@@-@@@Rare cases of death or hospitalisation due to severe liver injury have been reported in post-marketing in association with Casdoex use.@N/A@No@-@813 PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED PROSTATE CANCER@@@III@APPROVED@@-@SSN@Overall survival was not statistically significant; 52.7% of the Casodex/LHRH group had died, and 57.5% of the flutamide/LHRH group had died.@-@@@@COMBO@BICALUTAMIDE@@@@@BICALUTAMIDE||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@CASODEX@@@@@CASODEX||||@Hormone Antagonist@Anti-androgen@@@@Hormone Antagonist|Anti-androgen|||@OVERALL SURVIVAL@@@@@@@@@@METASTATIC@@@@@MULTI-CENTRE@DOUBLE-BLIND@CONTROLLED@@@@@Invalid Dosage Value Phase 1@@@@@@@@@28@1.1807@79.18@130.68@82.74@@@@@@@@@@0.02@@@@@@@@@@@@@@@@8/31/2017@2.83@2.83@31113020@FILM COATED TABLET@EURO@@@@@@@@150@MG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14924500@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@WILMINGTON, DELAWARE@@@@@14924500@HER2+ breast cancer@@-@-@@NO REVIEW@@@@-@-@-@-@5@-@-@@@-@@@-@-@@-@-@@@IB@I@@-@-@There was a marked reduction (greater than 60%) in ECD levels early after the initiation of treatment. All five of the HER2+ patients in the study had previously failed trastuzumab-containing regimens and, in 4 of the 5 patients, INCB7839 produced stable disease for 2-4 months, including both patients with elevated ECD. Two of the HER2+ patients who achieved stable disease did not have elevated serum ECD, suggesting that blocking the generation of the truncated highly active HER2 receptor can also benefit patients who do not have elevated plasma ECD levels. Additionally, demonstrable inhibition of ligand shedding was achieved for both TGF-alpha and heregulin, suggesting that INCB7839 can interfere with EGFR-based signaling by reducing EGFR ligand levels, and pathway activation. INCB7839 was generally well tolerated. The dose limiting effect was thrombosis. Alternative dosing regimens, including dose interruption with low level prophylactic anticoagulation, are currently being evaluated in a cohort of this study. SOURCE: Incyte, San Antonio Breast Cancer Symposium, 16 December 2007@-@@@@MONO@-@@@@@-||||@INCYTE CORP.@@@@@INCYTE CORP.||||@@@@@@|||||||||@Breast Cancer@HER2+@@@@Breast Cancer|HER2+||||||||@INCB-7839@@@@@INCB-7839||||@Other@HER2@@@@Other|HER2|||@RESPONSE RATE@@@@@@@@@@-@@@@@MULTI-CENTRE@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15051151@Onco@@@@@300f1010ntsdm@@@@@@-@@-@-@-@INGELHEIM, GERMANY@6/1/2012@@This is an orally bioavailable dual receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. EGFR/HER2 tyrosine kinase inhibitor BIBW 2992 irreversibly binds to and inhibits human epidermal growth factor receptors 1 and 2 (EGFR-1; HER2), which may result in the inhibition of tumor growth and angiogenesis. EGFR/HER2 are RTKs that belong to the EGFR superfamily; both play major roles in tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types. @@15051151@: Phase I, Open Label Trial to Explore Safety of Combining BIBW 2992 and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiforme @@-@-@@NO REVIEW@@@@-@-@-@NCT00977431@38@-@-@@@-@@9/1/2009@-@1200.38@@-@"Histologically-confirmed WHO Grade IV newly diagnosed malignant glioma. Proven MGMT gene promoter methylation status "@@@I@I@@-@-@Trial registered. [BI, 14 September 2009 ]@-@@@@COMBO@AFATINIB@"TEMOZOLOMIDE"@@@@"AFATINIB|TEMOZOLOMIDE|||"@BOEHRINGER INGELHEIM@@@@@BOEHRINGER INGELHEIM||||@@@@@@|||||||||@Glioblastoma Multiforme@@@@@Glioblastoma Multiforme|||||||||@BIBW-2992@TEMODAL@@@@BIBW-2992|TEMODAL|||@TK Inhibitor@EGFR@HER2@@@TK Inhibitor|EGFR|HER2||@MAXIMUM TOLERATED DOSE@@@@@SAFETY@OBJECTIVE RESPONSE RATE@PHARMACODYNAMICS@@@@@@@@PARALLEL ASSIGNMENT@SAFETY@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14915999@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@IL-21@@-@-@-@SEATTLE, WASHINGTON@@@IL-21 has potent biological activity in regulating key classes of immune cells, including cytotoxic T cells and natural killer cells. These cell types play key roles in surveillance of the body to eliminate malignant and infected cells. Based upon the ability of IL-21 to inhibit tumor growth in a number of preclinical models, ZymoGenetics is developing IL-21 for the treatment of cancer, initially in renal cell carcinoma and metastatic melanoma. @@14915999@Stage IV@@-@-@@NO REVIEW@@@@-@>> ZymoGenetics announces the acquisition of ex-North American rights to Interleukin 21 (IL-21) from Novo Nordisk A/S, resulting in ZymoGenetics owning worldwide rights to IL-21. Novo Nordisk A/S agreed to license rest of world (ex-North American) development and commercialization rights for IL-21 to ZymoGenetics in exchange for potential regulatory approval milestones and royalties related to the ex-North American territory. In addition, upon licensing worldwide rights for IL-21 to a third party, Novo Nordisk A/S would receive a portion of related licensing fees if a certain threshold level were exceeded. [ZymoGenetics, 29.01.2009]            >> Novo Nordisk has exited all of its oncology interests as of February 2008.            >> Novo holds IL-21 rights outside of North America.@-@-@-@-@-@@@-@@10/1/2007@-@ZYMOGENETICS@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@ZYMOGENETICS@@@@@ZYMOGENETICS||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@IL-21@@@@@IL-21||||@Immunotherapy@@@@@Immunotherapy||||@-@-@@@@@@@@@MALIGNANT@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16671816@Onco@@@@@300f1010ntsdm@@@@@@@@L01XC06@L01X@@NEW YORK, NEW YORK@@@Erbitux is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Cetuximab is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions and has an approximate molecular weight of 152 kDa. Cetuximab is produced in mammalian (murine myeloma) cell culture.@@16671816@Treatment of patients with epidermal growth factor receptor (EGFR)-expressing, KRAS wild-type metastatic colorectal cancer in combination with irinotecan-based chemotherapy@@YES@@@@@@@100%@>> Acquisition completed. [Lilly, 24.11.2008]          >> Lilly acquires ImClone for US$6.5 billion. [Lilly, 7.10.2008]        >> BMS Offers US$4.3Billion for ImClone or US$60.0 per share in cash. [BMS, 1 August 2008]      >> ImClone licensed co-development and co-promotion rights to BMS in North America and Japan, and to Merck KGaA in Europe.@@@@@EMA, 23 June 2011@6/23/2011@@No@@@@@No@@@(EGFR)-expressing, KRAS WILD-TYPE@@@APPROVED@@@NHS@@@@@@COMBO@CETUXIMAB@IRINOTECAN@@@@CETUXIMAB|IRINOTECAN|||@BMS@IMCLONE@MERCK SERONO@@@BMS|IMCLONE|MERCK SERONO||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ERBITUX@GENERIC@@@@ERBITUX|GENERIC|||@mAb@Chimeric@TK Inhibitor@EGFR@@mAb|Chimeric|TK Inhibitor|EGFR|@@@@@@@@@@@METASTATIC@@@@@@@@@@1.75@m²@Invalid Average Duration of Use@@@@@@@@@1@1.299@890.5@@@@@@@@@@@@1.78@7@1@mg/m²@400@1@7@@mg/m²@250@1@@@@@@7/28/2017@890.5@890.5@1.15E+16@SOLUTION FOR IV INFUSION - 100 ML@GB£@@@@@@@@500@MG@5 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14924287@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Each patient will receive 6 cycles of chemotherapy of Oxaliplatin and Navelbine. IV Oxaliplatin is given every 21 days and IV Navelbine is administered on day 1 and day 8 every 21 days. @@L01XA03@L01X@-@PARIS, FRANCE@@@Eloxatin is an antineoplastic agent which is an organoplatinum complex in which the platinum atom is complexed with 1,2-DACH and with an oxalate ligand as a leaving group. It undergoes non-enzymatic conversion in physiologic solutions to active derivatives via displacement of the labil oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.@@14924287@Second-line treatment of advanced and metastatic NSCLC@@-@-@@NO REVIEW@@@@-@sanofi-aventis licensed U.S. and European rights from Debiopharm.@SECOND-LINE@NCT00238849@40@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@-@-@@@@COMBO@OXALIPLATIN@@@@@OXALIPLATIN||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@ELOXATIN@@@@@ELOXATIN||||@Platinum@@@@@Platinum||||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918946@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Obatoclax 3.5-14MG/M2 one-hour infusion (n=12) or obatoclax 20-40mg/m2 as 3 hour infusion (n=13).@@-@-@-@-@@@Obatoclax (GX15-070) is a small molecule indole bipyrrole drug compound that was discovered and is being developed at Gemin X. The attractive safety profile and mechanism of action of obatoclax offers the opportunity to treat many forms of cancer as both a single agent and in combination with current treatments. Obatoclax  is a pan-inhibitor of the pro-survival members of the Bcl-2 family of apoptosis regulators. Many of the cellular events that initiate malignant transformation of a normal cell (e.g., activation of oncogenes) also activate oncogenic stress pathways that usually cause the cell to self destruct by a process called apoptosis [3]. In order for these cells to survive and cause cancer, they typically must have acquired changes in other cellular pathways to prevent apoptosis. The Bcl-2 family of proteins are important regulators and executioners of the cellular decision to live or die. Moreover, this family of proteins also dictates whether or not many current cancer therapies are effective, because most of these treatments result in stress signals that ultimately must activate the cancer cell's apoptosis machinery.@@14918946@Patients who failed a median of four treatments@@-@-@@NO REVIEW@@@@-@-@-@-@25@-@-@@@-@@@-@N/A@@-@-@@@I/II@II@@-@-@One patient had partial response and 9 had stable disease above six weeks. 4 out of 14 patients with low platelet counts showed sustained increase of over 50%, and 3 of 11 anaemia patients had sustained elevations of haemoglobin, with 2 of those 3 achieving transfusion independence. Maximum tolerated dose was 28MG/M2 as a 3 hours infusion once every 3 weeks. Dose-limiting toxicities were somnolence, ataxia and dysphoria.@-@@@@MONO@OBATOCLAX MESYLATE@@@@@OBATOCLAX MESYLATE||||@GEMIN X@@@@@GEMIN X||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@GX15-070@@@@@GX15-070||||@Bcl-2 Inhibitor@@@@@Bcl-2 Inhibitor||||@RESPONSE RATE@@@@@@@@@@-@@@@@RANDOMISED@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRAVENOUS@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16387809@Onco@@@@@300f1014ntsdm@@@@@@@@L02BG03@L02B@@LONDON, UNITED KINGDOM@@@Arimidex is a potent and highly selective non-steroidal aromatase inhibitor. In postmenopausal women, estradiol is produced primarily from the conversion of androstenedione to estrone through the aromatase enzyme complex in peripheral tissues. Estrone is subsequently converted to estradiol. Reducing circulating estradiol levels has been shown to produce a beneficial effect in women with breast cancer. In postmenopausal women, Arimidex at a daily dose of 1 mg produced estradiol suppression of greater than 80% using a highly sensitive assay. Arimidex does not possess any progestogenic, androgenic or oestrogenic activity. Daily doses of Arimidex up to 10 mg do not have any effect on cortisol or aldosterone secretion, measured before or after standard ACTH challenge testing. Corticoid supplements are therefore not needed.@@16387809@Treatment of advanced breast cancer in post-menopausal women with disease progression following tamoxifen therapy.@@NO@@@NO REVIEW@@@@@@SECOND-LINE@@375@The dose of Arimidex is one 1 mg tablet taken once a day. For patients with advanced breast cancer, Arimidex should be continued until tumour progression.@@@@@@@Arimidex can cause fetal harm when administered to a pregnant woman.@@No@@@@@@APPROVED@@@@@@@@@MONO@ANASTROZOLE@@@@@ANASTROZOLE||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@ARIMIDEX@@@@@ARIMIDEX||||@Hormone Antagonist@Aromatase Inhibitor@@@@Hormone Antagonist|Aromatase Inhibitor|||@@@@@@@@@@@ADVANCED@@@@@CONTROLLED@DOUBLE-BLIND@@@@1@1@778.986609@@@5.03@month@5.03 month@778.99@778.99@5.09@30@0.7881@152.75@@@@@@@@@@@@5.09@1@@mg@1@1@@@@@@@@@@@7/19/2017@5.09@5.09@222413530@FILM-COATED TABLET@C$@@@@@@@@1@MG@1 MG@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14916735@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Sch-721015 intravesical administraion@@-@-@-@KENILWORTH, NEW JERSEY@5/1/2009@@@@14916735@Transitional cell carcinoma of the bladder@@-@-@@NO REVIEW@@@@-@Merck & Co and Schering-Plough have announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. Based on the closing price of Merck stock on March 6, 2009, the consideration to be received by Schering-Plough shareholders is valued at $23.61 per share, or $41.1 billion in the aggregate. [Merck & Co, 9 March 2009]@-@NCT00536588@30@-@-@@@-@@11/1/2006@-@P03816AM4@@-@-@@@I@I@@-@-@RESULTS PENDING (recruiting).@-@@@@MONO@RAD-IFN@@@@@RAD-IFN||||@SCHERING-PLOUGH@MERCK & CO@@@@SCHERING-PLOUGH|MERCK & CO|||@@@@@@|||||||||@Bladder Cancer@@@@@Bladder Cancer|||||||||@SCH-721015@@@@@SCH-721015||||@Other@@@@@Other||||@ADVERSE EVENTS@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16382369@Onco@@@@@300f1014ntsdm@@@@@@AMG-162 versus placebo@@M05BX04@M05B@@THOUSAND OAKS, CALIFORNIA@5/1/2010@@Denosumab is a fully human monoclonal antibody that specifically targets the receptor activator of nuclear factor kappa B ligand (“RANKL”), a key mediator of the cells responsible for bone breakdown. Denosumab is being studied across a range of conditions, including osteoporosis, treatment-induced bone loss, bone metastases, rheumatoid arthritis, and multiple myeloma.@@16382369@PROLIA is indicated as a treatment to increase bone mass in men with nonmetastatic prostate cancer receiving androgen deprivation therapy (ADT), who are at high risk for fracture@@@@@NO REVIEW@@@@@Japanese rights licensed to Daiichi Sankyo for US$20 mil upfront and royalties in July 2007, and Daiichi Sankyo will pay US$150 mil of expected worldwide development costs through 2009.@@NCT00089674@1468@The recommended dose of PROLIA (denosumab) is a single SC injection of 60 mg, once every 6 months.@@@@@@8/1/2004@@@No@@@@@III@APPROVED@@@@@@@@@MONO@DENOSUMAB@@@@@DENOSUMAB||||@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Bone Metastases@Prostate Cancer@@@@Bone Metastases|Prostate Cancer||||||||@PROLIA@@@@@PROLIA||||@mAb@Human@RANK Ligand@@@mAb|Human|RANK Ligand||@Percentage change from baseline in lumbar spine BMD to month 24@@@@@@@@@@@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@1@1@660@@@1@year@1 year@660@660@1.81@1@0.7881@330@@@@@@@@@@@@5.5@182.5@@mg@60@1@@@@@@@@@@@7/19/2017@330@330@23435411@SOLUTION FOR INJECTION - 1 ML@C$@@@@@@@@60@MG@60 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14916005@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Iressa alone once-daily for 4 weeks, then also receive PEG-interferon subcutaneiously once-weekly.@@L01XE02@L01X@-@LONDON, UNITED KINGDOM@@@The mechanism of the clinical antitumor action of gefitinib is not fully characterized. Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinasesassociated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor (EGFR-TK). EGFR isexpressed on the cell surface of many normal cells and cancer cells. No clinical studies have been performed that demonstrate a correlation between EGFRreceptor expression and response to gefitinib@@14916005@With PEG-Interferon alpha-2a for unresectable or metastatic skin cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00423397@16@-@-@@@-@@9/1/2006@-@ZENECA-IRUSIRES0488  @@-@-@@@I/II@II@@-@-@RESULTS PENDING (recruiting). ASCO June 2007; genotyping of EGFR CAn is a predictive marker for skin rashes in Iressa use. @-@@@@COMBO@GEFITINIB@@@@@GEFITINIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@IRESSA@ZD-1839@@@@IRESSA|ZD-1839|||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@SAFETY@INCIDENCE OF RASH@@@@@@@@@METASTATIC@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TABLET@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919042@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@FRAZER, PENNSYLVANIA@@@Bendamustine is an alkylating that is a bifunctional mechlorethamine derivative. Mechlorethamine and its derivatives dissociate into electrophilic alkyl groups. These groups form covalent bonds with electron-rich nucleophilic moieties. The bifunctional covalent linkage can lead to cell death via several pathways. The exact mechanism of action of bendamustine remains unknown. Bendamustine is active against both quiescent and dividing cells.@@14919042@Advanced indolent NHL refractory to Rituxan@@-@-@@NO REVIEW@@@@-@Cephalon acquired U.S. rights through takeover of Salmedix, which licensed it from Fujisawa (Astellas. It is marketed by MundiPharma as Ribomustin in Germany as a single or combination agent for indolent NHL, MM and CLL under the name Ribomustin. SymBio h@MULTIPLE@-@74@-@-@@@-@@@-@N/A@@-@-@@@II@II@@-@-@Final data: Treanda had an overall RR of 77%; 15% with confirmed CRs; 43% with PRs. Median duration of response was 6.7 months. Grade III/IV haematological toxicities included neutropaenia (54%), thrombocytopaenia (25%) and anaemia (12%). SOURCE: Journal of Clinical Oncology, January 2008.74% had objective responses, including 35% Cr, 7% SD and 16% disease progression. Among the 28-patient subgroup, 64% responded to Treanda. SOURCE: ASH December 2005.@-@@@@MONO@BENDAMUSTINE@@@@@BENDAMUSTINE||||@CEPHALON@ASTELLAS PHARMA@@@@CEPHALON|ASTELLAS PHARMA|||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@TREANDA@RIBOMUSTIN@@@@TREANDA|RIBOMUSTIN|||@Alkylating Agent@Nitrogen Mustard Analogue@@@@Alkylating Agent|Nitrogen Mustard Analogue|||@RESPONSE RATE@PARTIAL RESPONSE@STABLE DISEASE@@@STABLE DISEASE@@@@@ADVANCED@REFRACTORY@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919007@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@The trial utilises a Simon 2-stage design and patients will receive belinostat administered by intravenous infusion once daily for 5 days every 3 weeks. Patients will continue to receive treatment with belinostat until disease progression. @@-@-@-@COPENHAGEN, DENMARK@@@Belinostat is a promising small molecule HDAC inhibitor being investigated for its role in the treatment of a wide range of solid tumors and hematologic malignancies either as a singleagent,or in combination with other active anti-cancer agents, including carboplatin, paclitaxel, cis-retinoic acid, azacitidine and Velcade (bortezomib) for injection. HDAC inhibitors represent a new mechanistic class of anti-cancer therapeutics that target HDAC enzymes, and have been shown to arrest growth of cancer cells (including drug resistant subtypes); induce apoptosis, or programmed cell death; promote differentiation; inhibit angiogenesis; and sensitize cancer cells to overcome drug resistance when used in combination with other anti-cancer agents.@@14919007@Thymoma and thymic carcinoma@@-@-@@NO REVIEW@@@@-@TopoTarget licenses back global rights in exchange for US$26-mil. Payment to CuraGen, 5 mil newly issued shares, and a 10% milestone payment on first US$60 mil of rvenues generated whether in sales or partnership deals. SOURCE: TopoTarget, 22 April 2008@-@-@33@-@-@@@-@@12/1/2007@-@N/A@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@BELINOSTAT@@@@@BELINOSTAT||||@TOPOTARGET@@@@@TOPOTARGET||||@@@@@@|||||||||@Other@@@@@Other|||||||||@PXD-101@@@@@PXD-101||||@HDAC@@@@@HDAC||||@DISEASE-FREE SURVIVAL@@@@@@@@@@-@@@@@OPEN-LABEL@MULTI-CENTRE@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRAVENOUS@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924673@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@GEELONG, AUSTRALIA@@@@@14924673@Pre-treated patients in a variety of solid tumours@@-@-@@NO REVIEW@@@@-@Available for partnering.@SECOND-LINE@-@-@-@-@@@-@@@-@-@@-@-@@@I/II@II@@-@-@ASCO 2007; confirmation that genotyping of patients prior to treatment allowed for optimised personalised dosing and improved drug tolerance. Patients with rapid and intermediate acetylator genotypes achieved MTD of 320 mg/m2 weekly, whilst patients with slow acetylator genotypes achieved an MTD of 400 mg/m2 weekly (three weeks on treatment followed by one week off treatment, repeated). Using these dosing regimens, 64% of rapid and intermediate acetylators and 77% of slow acetylators showed no dose-limiting drug toxicities or dose-delay/holds during treatment. 3 prostate cancer patients showed a decline in PSA, with one of these achieving a PR. 2 patients with ovarian cancer achieved stable disease. 1 patient with GIST demonstrated stable disease which was sustained over 18 monthly cycles of amonafide. @-@@@@MONO@AMONAFIDE DIHYDROCHLORIDE@@@@@AMONAFIDE DIHYDROCHLORIDE||||@CHEMGENEX@@@@@CHEMGENEX||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@QUINAMED@@@@@QUINAMED||||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@MAXIMUM TOLERATED DOSE@RESPONSE RATE@SAFETY@@@SAFETY@@@@@-@@@@@DOSE ESCALATION@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916121@Onco@@@@@300f1020ntsdm@@@@@@Actiq for breakthrough cancer pain@@N02AB03@N02A@YES@FRAZER, PENNSYLVANIA@@@Fentanyl is a pure opioid agonist whose principal therapeutic action is analgesia. Other members of the class known as opioid agonists include substances such as morphine, oxycodone, hydromorphone, codeine, and hydrocodone.@@14916121@Indicated only for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Patients considered opioid tolerant are those who are taking at least 60 mg of oral morphine/day, at least 25 mcg of transdermal fentanyl/hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer. This product must not be used in opioid non-tolerant patients because life-threatening hypoventilation could occur at any dose in patients not on a chronic regimen of opiates. September 2007: Dear Healthcare Professional letter issued to emphasise that it is not generic Actiq and ensure non-use in opioid non-tolerant patients or non-labelled indications.@@NO@-@@NO REVIEW@@@@100%@-@-@-@130@The initial dose of Actiq used should be 200 micrograms, titrating upwards as necessary through the range of available dosage strengths (200, 400, 600, 800, 1200 and 1600 micrograms). Patients should be carefully monitored until a dose is reached that provides adequate analgesia with acceptable side effects using a single dosage unit per episode of breakthrough pain. This is defined as the successful dose.@N/A@@@-@@@Must not be used in opioid non-tolerant patients; fentanyl is a Schedule II controlled substance; life-threatening hypoventilation can occur at any dose; contraindicated in acute or post-operative pain@LABEL@No@-@-@@@III@APPROVED@@@SSN@92 of 130 patients (71% achieved a successful dose during titration. The most successful doses were 400mcg (21%) and 800mcg (20%).@-@@@@MONO@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@CEPHALON@@@@@CEPHALON||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@ACTIQ@@@@@ACTIQ||||@Opioid Analgesic@@@@@Opioid Analgesic||||@RESPONSE RATE@MAXIMUM TOLERATED DOSE@@@@@@@@@-@@@@@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@3@1.1807@17.6@29.04@18.39@@@@@@@@@@@@@@@@@@@@@@@@@@8/31/2017@5.87@5.87@35399017@SUBLINGUAL TABLET@EURO@@@@@@@@200@MCG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14916738@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Lonafarnib versus placebo@@-@-@-@KENILWORTH, NEW JERSEY@@@@@14916738@Patients with either MDS or CML.@@-@-@@NO REVIEW@@@@-@Merck & Co and Schering-Plough have announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. Based on the closing price of Merck stock on March 6, 2009, the consideration to be received by Schering-Plough shareholders is valued at $23.61 per share, or $41.1 billion in the aggregate. [Merck & Co, 9 March 2009]@-@NCT00109538@200@-@-@@@-@@@-@P02978  @@-@200 PLATELET-TRANSFUSION DEPENDENT PATIENTS WITH OR WITHOUT ANAEMIA@@@III@III@@-@-@Completion expected in October 2007.@-@@@@MONO@LONAFARNIB@@@@@LONAFARNIB||||@SCHERING-PLOUGH@MERCK & CO@@@@SCHERING-PLOUGH|MERCK & CO|||@@@@@@|||||||||@Haematological Malignancy@Myelodysplastic Syndrome@Chronic Myeloid Leukaemia@@@Haematological Malignancy|Myelodysplastic Syndrome|Chronic Myeloid Leukaemia|||||||@SARASAR@@@@@SARASAR||||@Farnesyltransferase Inhibitor@@@@@Farnesyltransferase Inhibitor||||@PLATELET TRANSFUSION INDEPENDENCE@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924581@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients were randomly distributed in two study arms: a high dose (6 mg/kg) and a low dose group (2 mg adecatumumab/kg body weight). Within the groups patients were stratifiedaccording to their EpCAM expression of the primary tumor in high EpCAM and low to moderate EpCAM subgroups.@@-@-@-@DARMSTADT, GERMANY@@@Adecatumumab, also known as MT201, is a human monoclonal antibody that targets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors, and is Micromet's third candidate. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer.@@14924581@-@@-@-@@NO REVIEW@@@@-@Microment responsible for Phase Ib trial with docetaxel for metastatic breast cancer and monotherapy for solid tumours; Serono reimburses Micromet for its costs. SOURCE: Micromet, 5 December 2006@-@-@87@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@Sera from 81 patients were analyzed for Immunogenicity 5 weeks and 14 weeks after end of treatment. All sera except for one were termed negative (80 out of 81) after 5 weeks.@-@@@@MONO@ADECATUMUMAB@@@@@ADECATUMUMAB||||@MERCK SERONO@MICROMET@@@@MERCK SERONO|MICROMET|||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@MT-201@@@@@MT-201||||@mAb@Human@EPCAM@@@mAb|Human|EPCAM||@IMMUNOGENICITY@@@@@@@@@@METASTATIC@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924101@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@@@Caplostatin is the combination of two functional parts: a MetAP2 inhibitor clinically proven in over 300 cancer patients coupled to a bio-compatible polymer, cinically proven to improve safety, bio-distribution, tumor targeting, and pharmacokinetics of the attached drug. This rational drug model represents the next generation of targeted cancer therapy.@@14924101@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@FDA confirmed that the Phase II trial provided the basis for moving forward with a large, pivotal Phase III trial in NSCLC and that the Phase II trial could provide supporting data for a BLA. The FDA also provided Fast Track designation for the development of talactoferrin as a first-line treatment in NSCLC. The FDA agreed that (i) the trial can be global without a requirement for any minimum number of patients from the U.S., provided that the standard of care is uniform across countries and that patients are appropriately stratified by region; (ii) it is appropriate to use carboplatin + paclitaxel (the chemotherapy used in Phase II) as the comparator arm even with the approval of Avastin, since Avastin's approval only applies to about 50% of patients with locally advanced or metastatic NSCLC and is associated with significant toxicities; (iii) PFS can be the primary endpoint for accelerated approval with the trial also powered to eventually look at overall survival for full approval; and (iv) a single pivotal trial powered for a high degree of statistical significance (p=0.01) for the PFS primary endpoint is acceptable. SPA package has been submitted.@@@-@@@-@-@@-@-@@@-@I@@-@-@Clinical trial to start in 2009. [SynDevRx, 25.07.2008]@-@@@@-@CAPLOSTATIN@@@@@CAPLOSTATIN||||@SYNDEVRX@@@@@SYNDEVRX||||@@@@@@|||||||||@Other@@@@@Other|||||||||@-@@@@@-||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922664@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients in the TARGET NHL Trial who progress after achieving at least a partial response with a time to progression of at least six months in either arm of the trial will be eligible to enroll into an open-label retreatment trial (114-NH-302) of galiximab in combination with rituximab.@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@12/1/2012@@A humanized IgG1 monoclonal antibody directed against CD80, the natural ligand for the T-cell antigen CD28 which mediates T-cell and B-cell adhesion. Galiximab binds to CD80 expressed on the cell surfaces of follicular lymphomas, resulting in antibody-dependent cell-mediated cytotoxicity (ADCC). CD80 is expressed on activated B-cells and gamma-interferon-stimulated monocytes and is often expressed at low levels on the surfaces of follicular lymphoma cells and other lymphoid malignancies. @@14922664@Patients who previously responded in Study 114-NH-301@@-@-@@NO REVIEW@@@@-@Mitsubishi Pharma discontinued its involvement in the Asian development of the drgu in March 2003.@-@NCT00384150@345@-@The trial is being conducted under a US FDA Special Protocol Assessment, granted in July 2006. @@@-@@11/1/2007@-@114-NH-302@@-@-@@@III@III@@-@-@Data due in August 2015.@-@@@@COMBO@GALIXIMAB@@@@@GALIXIMAB||||@BIOGEN IDEC@@@@@BIOGEN IDEC||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@IDEC-114@ANTI-CD80 MAB@@@@IDEC-114|ANTI-CD80 MAB|||@mAb@Humanised@CD80@@@mAb|Humanised|CD80||@SAFETY@@@@@@@@@@RELAPSED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16639894@Onco@@@@@@@@@@@"Copanlisib/gemcitabine, Experimental, "@@@@@@12/1/2021@@@@16639894@Prospective, Multicenter, Open-labeled, Phase I/II Study of the Efficacy and Safety of Copanlisib (BAY 80-6946) and Gemcitabine Combination in Patients With Relapsed/Refractory Peripheral T-cell or NK/T-cell Lymphoma@Both@@@@@For phase I study, participants will receive copanlisib (in combination with gemcitabine) IV infusion at a dose of 45 mg or 60 mg on Days 1, 8, and 15 of each 28-day treatment cycle. During phase I study, participants will be treated at the level of 45 mg/dose (level1), or 60 mg/dose (level II) of copanlisib. Maximal tolerated dose will be determined by standard 3+3 dose escalation design For phase II study, copanlisib dose level, determined during phase I study, will be administered on Days 1, 8, and 15. Maximum 6 cycles of gemcitabine and copanlisib combination and subsequent copanlisib monotherapy in participants with ≥ SD to copanlisib and gemcitabine until maximum 12 cycles will be given for this study.@@@@@@NCT03052933@36@@@@@@@@@COPGEM@@@Inclusion Criteria:  -  Histologically confirmed relapsed or refractory PTCL or NK/T-cell lymphomas, excluding primary cutaneous T-cell lymphoma, and Sezary syndrome based on WHO classification,  -  Age ≥ 19  -  ECOG performance status ≤ 2  -  at least one bi-dimensional measurable lesion  -  Laboratory values  -  Serum Cr < 1.5 mg/dL or CrCl > 50 mL/min  -  Transaminase (AST/ALT) < 2.5 x ULN (or < 5 x ULN in the presence of lymphoma involvement of the liver)  -  Bilirubin < 1.5 x UNL ( or < 3 x ULN in the presence of lymphoma involvement of the liver or Gilbert syndrome)  -  PT (INR) ≤ 1.5 x ULN and aPTT ≤ 1.5 x ULN  -  Lipase ≤ 1.5 x ULN  -  Hematologic functions: absolute neutrophil count (ANC) ≥ 1,500/µL and platelet count ≥ 75,000/µL, hemoglobin ≥ 8 g/dL  -  Left ventricular ejection fraction (LVEF) ≥ the lower limit of normal for the institution  -  Women of childbearing potential and men must agree to use adequate contraception when sexually active  -  Written informed consent@@ADULTS@Phase 1/Phase 2@I/II@@@@@@@@@COMBO@COPANLISIB@GEMCITABINE@@@@COPANLISIB|GEMCITABINE|||@BAYER HEALTHCARE@@@@@BAYER HEALTHCARE||||@South Korea@@@@@South Korea|||||||||@Haematological Malignancy@T-Cell Lymphoma@@@@Haematological Malignancy|T-Cell Lymphoma||||||||@BAY 80-6946@GENERIC@@@@BAY 80-6946|GENERIC|||@Other@@@@@Other||||@Dose limiting toxicity (DLT), Maximum tolerated dose (MTD) for phase I@Objective response rate for phase II@@@@adverse events@Progression-free survival (PFS)@@@@REFRACTORY@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916243@Onco@@@@@300f1010ntsdm@@@@@@Stable doses of either long-acting oral opioid or transdermal fentanyl with Actiq (200, 400, 600, 800, 1200 and 1600mcg)@@N02AB03@N02A@YES@FRAZER, PENNSYLVANIA@@@Fentanyl is a pure opioid agonist whose principal therapeutic action is analgesia. Other members of the class known as opioid agonists include substances such as morphine, oxycodone, hydromorphone, codeine, and hydrocodone.@@14916243@Indicated for the management of breakthrough pain in patients already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.@@NO@@@NO REVIEW@@@@100%@Licensed from Kyowa Hakko; supplied by Abbott. Acquired through US$444 mil. takeover of Anesta Corp in 2000.@@@257@The initial dose of Actiq used should be 200 micrograms, titrating upwards as necessary through the range of available dosage strengths (200, 400, 600, 800, 1200 and 1600 micrograms). Patients should be carefully monitored until a dose is reached that provides adequate analgesia with acceptable side effects using a single dosage unit per episode of breakthrough pain. This is defined as the successful dose.@EMA, August 2002@@@@@@Must not be used in opioid non-tolerant patients; fentanyl is a Schedule II controlled substance; life-threatening hypoventilation can occur at any dose; contraindicated in acute or post-operative pain@LABEL@No@@257 OPIOID-TOLERANT ADULT CANCER PATIENTS@@@III; TWO DOSE TITRATION STUDIES@APPROVED@@NO NICE REVIEW@NHS@95 of 127 patients (75%) titrated to a successful dose of Actiq (could be used consistently for at least 2 days without unacceptable side-effects). 11% and 14% withdrew due to adverse events or other reasons respectively.@@@@@MONO@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@CEPHALON@@@@@CEPHALON||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@ACTIQ@@@@@ACTIQ||||@Opioid Analgesic@@@@@Opioid Analgesic||||@RESPONSE RATE@MAXIMUM TOLERATED DOSE@@@@@@@@@@@@@@DOSE-RANGING@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@30@1.2961@210.41@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/21/2017@7.01@7.01@2.69E+15@LOZENGE@GB£@@@@@@@@600@MCG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14924971@Onco@@@@@@@@@@@All patients will receive the same immunotherapeutic treatment with GSK1572932A, but they will be recruited into four cohorts according to the details of their disease. Cohort 1: Patients with resected stage IB, II or IIIA tumors who are due for standard chemotherapy with cisplatin and vinorelbine. These patients will receive chemo-and immunotherapy in parallel. Cohort 2: Patients with resected stage IB, II or IIIA tumors who are due for standard chemotherapy with cisplatin and vinorelbine. These patients will first receive chemotherapy and then immunotherapy. Cohort 3: Patients with resected stage IB, II or IIIA tumors who are not due for chemotherapy. These patients will receive immunotherapy only. Cohort 4: Patients with unresectable stage III tumors, following standard chemotherapy and/or radiotherapy. These patients will receive immunotherapy only. Immunotherapeutic treatment will comprise eight doses of GSK1572932A. Doses will be administered at three-week intervals; in Cohort 1 this may be adapted to fit in with the patient's chemotherapy. During the study, adjuvant radiotherapy is allowed in Cohorts 1, 2 and 3 for patients in stage III only and is prohibited in Cohort 4. Chemotherapy during the study is allowed in Cohort 1 only as described above, and is prohibited in Cohorts 2-4. The total maximum duration of the study for a patient will be 30-35 weeks. [clinicaltrials.gov]@@-@-@-@BRENTFORD, UNITED KINGDOM@@@MAGE-A3 is a tumour-specific antigen that is expressed in a large variety of cancers, including Melanoma, Non-Small Cell Lung Cancer, Head and Neck Cancer, Bladder Cancer, with no expression in normal cells.  Expression of the MAGE-A3 gene has been observed in testicular cells but without antigen presentation capabilities.@@14924971@GSK1572932A as Adjuvant Therapy for Patients With MAGE-A3-Positive Non-Small Cell Lung Cancer@@-@-@@NO REVIEW@@@@-@MAGE-A3 protein has been in-licensed by GSK from the Ludwig Institute for Cancer Research, the largest international academic institute dedicated to understanding and controlling cancer. @-@NCT00455572@72@-@-@@@-@@5/1/2007@-@107240@@-@>> Pathologically proven stage IB, II or III NSCLC     >> Tumor expresses MAGE-A3      >> Free of distant metastasis@@@I@I@@-@-@Trial registered [GSK, 02.04.2007]@-@@@@ADJUVANT@MAGE-3 RECOMBINANT PHARMACCINE@@@@@MAGE-3 RECOMBINANT PHARMACCINE||||@GSK@@@@@GSK||||@Belgium@@@@@Belgium|||||||||@NSCLC@@@@@NSCLC|||||||||@MAGE-A3@GSK-1572932A@@@@MAGE-A3|GSK-1572932A|||@Vaccine@@@@@Vaccine||||@MAGE-A3 SEROCONVERSION@ADVERSE EVENTS@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
15400331@Onco@@@@@300f1015ntsdm@@@@@@Investing arms: nilotinib 300mg bid or nilotinb 400 mg bidControl arm: imatinib 400mg QD@@L01XE08@L01X@@BASEL, SWITZERLAND@@@Nilotinib is an inhibitor of the Bcr-Abl kinase. Nilotinib binds to and stabilizes the inactive conformation of the kinase domain of Abl protein. In vitro, nilotinib inhibited Bcr-Abl mediated proliferation of murine leukemic cell lines and human cell lines derived from Ph+ CML patients. Under the conditions of the assays, nilotinib was able to overcome imatinib resistance resulting from Bcr-Abl kinase mutations, in 32 out of 33 mutations tested. In vivo, nilotinib reduced the tumor size in a murine Bcr-Abl xenograft model. Nilotinib inhibited the autophosphorylation of the following kinases at IC50 values as indicated: Bcr-Abl (20-60 nM), PDGFR (69 nM) and c-Kit (210 nM).@@15400331@Indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase.@Both@NO@6-Apr-11@4/6/2011@NO REVIEW@@@@@@FIRST-LINE@NCT00471497@846@The recommended dose of Tasigna is 300 mg twice daily. Treatment should be continued as long as the patient continues to benefit.@EMA, 23 September 2010@9/23/2010@7/12/2012@Yes@@@@ENEST@No@@Chronic myelogenous leukemia in chronic phase patients within the first 6 months of diagnosis.Diagnosis of chronic myelogenous leukemia in chronic phase with confirmation of Philadelphia chromosome@ADULT@Adult@III@APPROVED@@ASMR IV@HAUTE AUTORITÉ DE SANTÉ@@@@@@MONO@NILOTINIB@@@@@NILOTINIB||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@TASIGNA@@@@@TASIGNA||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@MOLECULAR RESPONSE RATE@@@@@@@@@@CHRONIC PHASE@@@@@RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@1@1@32429.47387@@@12@month@12 month@32429.47@32429.47@88.85@112@1.1511@3317.06@3516.61@3347.06@@@@@@@@@@0.15@1@@mg@600@1@@@@@@@@@@@8/1/2017@29.62@29.62@3.40E+12@CAPSULE@EURO@@@@@@@@200@MG@200 MG@@@@@@@@@@@@@@@@@@@@@@@@85@France
16384822@Onco@@@@@300f1010ntsdm@@@@@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384822@Indicated for the treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.@@NO@@@NO REVIEW@@@@100%@@FIRST-LINE@@@Dosing for children should be on the basis of body surface area (mg/m2). The dose of 340 mg/m2 daily is recommended for children with Ph+ ALL (@@@@Yes@@@@@No@@@PAEDIATRIC@@@APPROVED@@@NHS@@@@@@BOTH@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@@@@Haematological Malignancy|Acute Lymphocytic Leukaemia||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@@@@@@@@@@@1.2@m²@24157.8024@@@1@year@1 year@24157.8@24157.8@66.19@60@1.299@973.32@@@@@@@@@@@@0.16@1@@mg/m²@340@1@@@@@@@@@@@7/28/2017@16.22@16.22@8.09E+15@FILM-COATED TABLET@GB£@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14924989@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Nexavar alone@@L01XE05@L01X@-@LEVERKUSEN, GERMANY@@@Sorafenib is a multikinase inhibitor that decreases tumour cell proliferation in vitro. Sorafenib inhibits tumour growth of a broad spectrum of human tumour xenografts in athymic mice accompanied by a reduction of tumour angiogenesis. Sorafenib inhibits the activity of targets present in the tumour cell (CRAF, BRAF, V600E BRAF, c-KIT, and FLT-3) and in the tumour vasculature (CRAF, VEGFR-2, VEGFR-3, and PDGFR-ß). RAF kinases are serine/threonine kinases, whereas c-KIT, FLT-3, VEGFR-2, VEGFR-3, and PDGFR-ß are receptor tyrosine kinases. @@14924989@-@@-@-@@NO REVIEW@@@@-@Bayer Schering and Onyx have global co-development rights for Nexavar except Japan, where Bayer Schering has exclusive rights.@-@NCT00510289@58@-@-@@@-@@@-@8662@@DECEMBER 2010 (NCE); DECEMBER 2012 (ORPHAN); JUNE 2022 (EXTENSION)@-@@@II@II@@-@-@Completion expected December 2014@-@@@@MONO@SORAFENIB TOSYLATE@@@@@SORAFENIB TOSYLATE||||@BAYER HEALTHCARE@@@@@BAYER HEALTHCARE||||@@@@@@|||||||||@Haematological Malignancy@Myelodysplastic Syndrome@@@@Haematological Malignancy|Myelodysplastic Syndrome||||||||@NEXAVAR@@@@@NEXAVAR||||@TK Inhibitor@VEGF@PDGF@Angiogenesis Inhibitor@@TK Inhibitor|VEGF|PDGF|Angiogenesis Inhibitor|@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16395634@Onco@@@@@300f1012ntsdm@@@@@@@@L04AX04@L04A@@SUMMIT, NEW JERSEY@3/1/2017@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16395634@Treatment of adult patients with relapsed or refractory mantle cell lymphoma@Both@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@NCT00875667@254@The recommended starting dose of lenalidomide is 25 mg orally once daily on days 121 of repeated 28day cycles.@EMA, 28 January 2016@1/28/2016@@Yes@@4/1/2009@@CC5013MCL002@No@@Biopsy proven mantle cell lymphoma; Patients who are refractory to their regimen or have relapsed once, twice or up to three times and who have documented progressive disease; Eastern Cooperative Oncology Group (ECOG) performance score 0,1, or 2; Willing to follow pregnancy precaution@@ADULTS@II@APPROVED@@@GKV@@@@@@MONO@LENALIDOMIDE@@@@@LENALIDOMIDE||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Non-Hodgkin's Lymphoma@Mantle Cell Lymphoma@@@@Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma||||||||@REVLIMID@@@@@REVLIMID||||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@PROGRESSION FREE SURVIVAL@@@@@OVERALL RESPONSE RATE@DURATION OF RESPONSE@TIME TO PROGRESSION@@@RELAPSED@REFRACTORY@@@@RANDOMISED@MULTI-CENTRE@OPEN LAB EL@@@1@1@71968.74974@@@37.6@week@37.6 week@71968.75@71968.75@273.44@21@1.1511@6125@7564.73@6163.5@@@@@@@@@@14.58@28@@mg@25@21@@@@@@@@@@@8/1/2017@291.67@291.67@11056162@HARD CAPSULE@EURO@@@@@@@@20@MG@20 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14920191@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NO LABELLED TRIAL@@L01DB07@L01D@YES@BEDFORD, OHIO@@@Although its mechanism of action has not been determined, mitoxantrone is a DNA-reactive agent. It has a cytocidal effect on proliferating and non-proliferating cultured human cells, suggesting activity against rapidly proliferating and slow-growing neoplasms.@@14920191@Mitoxantrone Injection in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced HRPC; in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias.@@NO@@@NO REVIEW@@@@@@@@@HRPC: based on data from two Phase 3 comparative trials of mitoxantrone injection plus corticosteroids versus corticosteroids alone, the recommended dosage of mitoxantrone is 12 to 14 mg/m2 given as a short intravenous infusion every 21 days.@@@@@@@HRPC: functional cardiac changes such as decreases in LVEF and congestive heart failure may occur in patients with HRPC treated with mitoxantrone. In a randomised comparative trial of mitoxantrone plus low-dose prednisone vs. low-dose prednisone, 7 of 128 patients (5.5 %) treated with mitoxantrone had a cardiac event defined as any decrease in LVEF below the normal range, CHF (n = 3), or myocardial ischemia. Two patients had a prior history of cardiac disease. The total mitoxantrone dose administered to patients with cardiac effects ranged from > 48 to 212 mg/m2. Among 112 patients evaluable for safety on the mitoxantrone + hydrocortisone arm of the CALGB trial, 18 patients (19%) had a reduction in cardiac function, 5 patients (5%) had cardiac ischemia, and 2 patients (2%) experienced pulmonary edema. The range of total mitoxantrone doses administered to these patients is not available.@@No@@@@@NO LABELLED TRIAL@APPROVED@@Covered; part B; specialty drug@MEDICARE@NO LABELLED TRIAL@@@@@@MITOXANTRONE@@@@@MITOXANTRONE||||@BEDFORD LABORATORIES@@@@@BEDFORD LABORATORIES||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@GENERIC@@@@@GENERIC||||@Cytotoxic Antibiotic@Anthracycline@Topoisomerase II Inhibitor@@@Cytotoxic Antibiotic|Anthracycline|Topoisomerase II Inhibitor||@@@@@@@@@@@ADVANCED@@@@@NO LABELLED TRIAL@@@@@@@Invalid Factory Price@@@@@@@@@1@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@55390-0084-01@INJECTION@US$@@@@@@@@25@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924961@Onco@@@@@@@@@@@0.5 mcg/kg; subsequent doses: individual, based on pre-treatment level of anti-SEA/E-120, body weight, and toxicities observed in prior patients on study; IV; one bolus injection each day for 5 consecutive days; up to 3 cycles @@-@-@-@LUND, SWEDEN@12/1/2006@@Naptumomab estafenatox is a monoclonal antibody and which it is used to treat cancers. It has a chelator, estafenatox. It binds to 5T4 Fab.@@14924961@Advanced RCC, NSCLC or pancreatic cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00056537@44@-@ORPHAN DRUG STATUS APPROVED BY EMEA IN JULY 2007.@@@ORPHAN DRUG STATUS APPROVED BY EMEA IN JULY 2007.@@4/1/2003@-@1762001@@-@Patients with histologically or cytologically confirmed non-small cell lung cancer, which is refractory to (progressed on or following) currently available standard therapies. Patients must have received (or declined) at least one standard regimen for advanced/metastatic disease. ECOG performance status of 0 or 1.@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@NAPTUMOMAB ESTAFENATOX@@@@@NAPTUMOMAB ESTAFENATOX||||@ACTIVE BIOTECH@@@@@ACTIVE BIOTECH||||@Norway@@@@@Norway|||||||||@Kidney Cancer@Renal Cell Carcinoma@Pancreatic Cancer@NSCLC@@Kidney Cancer|Renal Cell Carcinoma|Pancreatic Cancer|NSCLC||||||@ANYARA@ABR-217620@@@@ANYARA|ABR-217620|||@Immunotherapy@@@@@Immunotherapy||||@MAXIMUM TOLERATED DOSE@@@@@PHARMACOKINETICS@SAFETY@RESPONSE RATE@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@SINGLE GROUP@@@@Invalid Factory Price@@@@@3 CYCLES@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916081@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Velcade dexamethasone versus Velcade, thalidomide and dexamethasone versus Velcade, melphalan and prednisone@@L01XX32@L01X@-@CAMBRIDGE, MASSACHUSSETTS@@@Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targeted proteolysis, which can affect multiple signaling cascades within the cell. This disruption of normal homeostatic mechanisms can lead to cell death. Experiments have demonstrated that bortezomib is cytotoxic to a variety of cancer cell types in vitro. Bortezomib causes a delay in tumor growth in vivo in nonclinical tumor models, including multiple myeloma.@@14916081@Previously untreated MM@@-@-@@NO REVIEW@@@@-@>> Takeda acquisition of Millennium completed. [Millennium, 14 May 2008]      >> Takeda acquired Millennium Pharma on 10 April 2008 in a US$8.8 bil. deal. Millennium Pharma will continue to operate as a standalone unit. [Takeda, 10 April 2008]      >> Ortho Biotech and Janssen-Cilag pay double-digit royalties and other milestones.@FIRST-LINE@NCT00507416@500@-@-@@@-@@7/1/2007@-@UPFRONT@@MAY 2010 (ORPHAN); MARCH 2012 (ORPHAN) WITH EXTENDED EXPIRATION TO MAY 2017.@-@@@III@III@@-@-@Trial registered. [25.07.2007]@-@@@@COMBO@BORTEZOMIB@THALIDOMIDE@DEXAMETHASONE@@@BORTEZOMIB|THALIDOMIDE|DEXAMETHASONE||@MILLENNIUM PHARMACEUTICALS@TAKEDA PHARMACEUTICAL@@@@MILLENNIUM PHARMACEUTICALS|TAKEDA PHARMACEUTICAL|||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@VELCADE@THALOMID@@@@VELCADE|THALOMID|||@Proteasome Inhibitor@@@@@Proteasome Inhibitor||||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918702@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01BC02@L01B@YES@@@@Fluorouracil is an analogue of uracil, a component of ribonucleic acid. The drug is believed to function as an antimetabolite. After intracellular conversion to the active deoxynucleotide, it interferes with the synthesis of DNA by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase. Fluorouracil may also interfere with RNA synthesis.@@14918702@Fluorouracil may be used alone, or in combination, for the management of common malignancies particularly cancer of the colon and breast.@@NO@@@NO REVIEW@@@@100%@@@@@Intravenous infusion: 15mg/kg bodyweight but not more than 1g per infusion, diluted in 300 - 500ml of 5% glucose or 0.9% NaCl injection and given over 4 hours. Alternatively the daily dose may be infused over 30 - 60 minutes or may be given as a continuous infusion over 24 hours. The infusion may be repeated daily until there is evidence of toxicity or a total dose of 12 - 15g has been reached. Intravenousi Injection: l2mg/kg bodyweight may be given daily for 3 days and then, if there is no evidence of toxicity, 6mg/kg on alternate days for 3 further doses. An alternative regimen is 15mg/kg as a single intravenous injection once a week throughout the course. Intra-arterial infusion: 5/7.5mg/kg bodyweight daily may be given by 24 hour continuous intra-arterial infusion.@EMA, July 2003@@@@@@Intravenous infusion: 15mg/kg bodyweight but not more than 1g per infusion, diluted in 300 - 500ml of 5% glucose or 0.9% NaCl injection and given over 4 hours. Alternatively the daily dose may be infused over 30 - 60 minutes or may be given as a continuous infusion over 24 hours. The infusion may be repeated daily until there is evidence of toxicity or a total dose of 12 - 15g has been reached. Intravenousi Injection: l2mg/kg bodyweight may be given daily for 3 days and then, if there is no evidence of toxicity, 6mg/kg on alternate days for 3 further doses. An alternative regimen is 15mg/kg as a single intravenous injection once a week throughout the course. Intra-arterial infusion: 5/7.5mg/kg bodyweight daily may be given by 24 hour continuous intra-arterial infusion.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@FLUOROURACIL@@@@@FLUOROURACIL||||@MEDAC@@@@@MEDAC||||@@@@@@|||||||||@Colorectal Cancer@Breast Cancer@@@@Colorectal Cancer|Breast Cancer||||||||@GENERIC@@@@@GENERIC||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.299@6.4@@@@@@@@@@@@@@@@@@@@@@@@@@@@7/28/2017@6.4@6.4@4.95E+15@SOLUTION FOR INJECTION VIAL, 10 ML@GB£@@@@@@@@0.5@G@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
16639033@Onco@@@@@300f1015ntsdm@@@@@@dabrafenib 150 mg twice dailydabrafenib plus trametinib placebo (dabrafenib 150 mg twice daily and trametinib placebo, trametinib 2 mg once daily)@@L01XE23@L01X@@LONDON, UNITED KINGDOM@8/1/2013@@Dabrafenib is an  orally bioavailable inhibitor of the BRAF protein.  Dabrafenib was discovered and developed at GSK.@@16639033@Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation@Both@No@30-Nov-16@11/30/2016@@@@@100%@@@NCT01584648@423@The recommended dose of dabrafenib, either used as monotherapy or in combination with trametinib, is 150 mg (two 75 mg capsules) twice daily (corresponding to a total daily dose of 300 mg).@EMA, 25 August 2015@8/25/2015@10/7/2013@No@@5/1/2012@@115306@No@@Histologically confirmed cutaneous melanoma that is either Stage IIIC (unresectable) or Stage IV (metastatic), and determined to be BRAF V600E/K mutation-positive using the bioMerieux (bMx) investigational use only (IUO) THxID BRAF Assay (IDE: G120011). The assay will be conducted by a central reference laboratory. Subjects with ocular or mucosal melanoma are not eligible.The subject must have a radiologically measurable tumorThe subject is able to carry out daily life activities without significant difficulty (ECOG performance status score of 0 or 1).@BRAF V600 mutation@ADULTS@III@APPROVED@@ASMR III. Same assessment as Mekinist [http://www.has-sante.fr/portail/upload/docs/application/pdf/2016-10/mekinist_summary_ct14705.pdf]@HAS@@@@@@COMBO@DABRAFENIB@TRAMETINIB@@@@DABRAFENIB|TRAMETINIB|||@GSK@@@@@GSK||||@World@@@@@World|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@TAFINLAR@MEKINIST@@@@TAFINLAR|MEKINIST|||@Other@@@@@Other||||@PROGRESSION-FREE SURVIVAL@@@@@OVERALL SURVIVAL@@@@@UNRESECTABLE@METASTATIC@@@@RANDOMISED@DOUBLE-BLIND@PARALLEL ASSIGNMENT@@@1@1@62454.07311@@@11.2@month@11.2 month@62454.07@62454.07@183.33@120@1.1511@3666.66@3873.55@3696.66@@@@@@@@@@0.61@1@@mg@300@1@@@@@@@@@@@8/1/2017@30.56@30.56@3.40E+12@CAPSULE@EURO@@@@@@@@50@MG@50 MG@@@@@@@@@@@@@@@@@@@@@@@@85@France
14921805@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Intravenous administration of homoharringtonine @@-@-@-@GEELONG, AUSTRALIA@@@Omacetaxine mepesuccinate (formerly known as Ceflatonin, homoharringtonine or HHT) is a first-in-class small molecule with established clinical activity as a single agent in a range of hematological malignancies. Omacetaxine has a novel mechanism of action, and induces apoptosis by inhibition of protein synthesis, particularly Mcl-1. As omacetaxine acts independently of tyrosine kinase inhibitors, it has therapeutic advantages for patients who have developed resistance to tyrosine kinase inhibitor therapy. Omacetaxine is administered subcutaneously.@@14921805@-@@-@-@@NO REVIEW@@@@-@ChemGenex acquires global patent portfolio and full European rights to omacetaxine mepesuccinate from Stragen Pharma. Stragen remains supplier of the drug and significant shareholder in ChemGenex. SOURCE: ChemGenex, 10 June 2008Available for partnering. In June 2005, ChemGenex exclusively licensed the global rights to Stragen's patented manufacturing process for a semi-synthetic highly purified form of homoharringtonine. ChemGenex now has access to Stragen's manufacturing proces@-@-@30@-@>>FDA: Fast-track awarded in November 2006 for chronic, accelerated and blast-phase CML who have failed previous therapy. Orphan drug designation since March 2006.drug designation since March 2006.@@@>>FDA grants orphan drug status for treatment of MDS. [ChemGenex 20.01.2009]                                                                                                                                                                                              >>FDA: Fast-track awarded in November 2006 for chronic, accelerated and blast-phase CML who have failed previous therapy.@@@-@CGX-635-MDS-201@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@OMACETAXINE MEPESUCCINATE@@@@@OMACETAXINE MEPESUCCINATE||||@CHEMGENEX@@@@@CHEMGENEX||||@@@@@@|||||||||@Haematological Malignancy@Myelodysplastic Syndrome@@@@Haematological Malignancy|Myelodysplastic Syndrome||||||||@OMAPRO@@@@@OMAPRO||||@TK Inhibitor@VEGF@Angiogenesis Inhibitor@@@TK Inhibitor|VEGF|Angiogenesis Inhibitor||@SAFETY@RESPONSE RATE@@@@@@@@@-@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916378@Onco@@@@@300f1015ntsdm@@@@@@107 patients received oral melphalan (0.15MG/KG/day x 7 followed by 0.05MG/KG/day) with prednisone; 203 received IV melphalan (16MG/M2 q 2 weeks x 4 over 6 weeks followed by 4 weeks) with prednisone.@@L01AA03@L01A@YES@BRENTFORD, UNITED KINGDOM@@@Melphalan is a bifunctional alkylating agent. Formation of carbonium intermediates from each of the two bis-2-chloroethyl groups enables alkylation through covalent binding with the 7-nitrogen of guanine on DNA, cross-linking the two DNA strands and thereby preventing cell replication.@@14916378@Alkeran Injection, at conventional intravenous dosage, is indicated in the treatment of multiple myeloma and ovarian cancer. Alkeran Injection, at high intravenous dosage, is indicated, with or without haematopoietic stem cell transplantation, for the treatment of multiple myeloma and childhood neuroblastoma. Alkeran Injection, administered by regional arterial perfusion, is indicated in the treatment of localised malignant melanoma of the extremities and localised soft tissue sarcoma of the extremities.@@YES@5-May@@NO REVIEW@@@@100%@@@@310@Advanced neuroblastoma: Doses of between 100 and 240 mg/m2 body surface area (sometimes divided equally over 3 consecutive days) together with haematopoietic stem cell rescue, have been used either alone or in combination with radiotherapy and/or other cytotoxic drugs.@Feb-96@@9/19/1997@@@@Melphalan should be administered under the supervision of a qualified physician experienced in the use of chemotherapeutic agents. Severe bone marrow suppression with resulting infection or bleeding may occur. Controlled trials comparing IV to oral melphalan have shown more myelosuppression with the IV formulation.@LABEL@No@@@@@III@APPROVED@@1@HAUTE AUTORITÉ DE SANTÉ@44% and 7% responded in the oral and IV groups respectively. Severe myelotoxicity and/or platelets occurred 28% and 11% respectively.@@@@@COMBO@MELPHALAN HYDROCHLORIDE@PREDNISONE@@@@MELPHALAN HYDROCHLORIDE|PREDNISONE|||@GSK@@@@@GSK||||@@@@@@|||||||||@Carcinoid / Neuroendocrine Tumour@@@@@Carcinoid / Neuroendocrine Tumour|||||||||@ALKERAN@@@@@ALKERAN||||@Alkylating Agent@Nitrogen Mustard Analogue@@@@Alkylating Agent|Nitrogen Mustard Analogue|||@RESPONSE RATE@@@@@@@@@@@@@@@RANDOMISED@@@@@@@Invalid Factory Price@@@@@@@@@1@1.1807@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@9182356R@LYOPHILISATE AND SOLUTION FOR PARENTHERAL USE, 10 ML@EURO@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14920187@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NO LABELLED TRIAL@@L01DB07@L01D@YES@BEDFORD, OHIO@@@Although its mechanism of action has not been determined, mitoxantrone is a DNA-reactive agent. It has a cytocidal effect on proliferating and non-proliferating cultured human cells, suggesting activity against rapidly proliferating and slow-growing neoplasms.@@14920187@Mitoxantrone Injection in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced HRPC; in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias.@@NO@@@NO REVIEW@@@@@@@@@HRPC: based on data from two Phase 3 comparative trials of mitoxantrone injection plus corticosteroids versus corticosteroids alone, the recommended dosage of mitoxantrone is 12 to 14 mg/m2 given as a short intravenous infusion every 21 days.@@@@@@@HRPC: functional cardiac changes such as decreases in LVEF and congestive heart failure may occur in patients with HRPC treated with mitoxantrone. In a randomised comparative trial of mitoxantrone plus low-dose prednisone vs. low-dose prednisone, 7 of 128 patients (5.5 %) treated with mitoxantrone had a cardiac event defined as any decrease in LVEF below the normal range, CHF (n = 3), or myocardial ischemia. Two patients had a prior history of cardiac disease. The total mitoxantrone dose administered to patients with cardiac effects ranged from > 48 to 212 mg/m2. Among 112 patients evaluable for safety on the mitoxantrone + hydrocortisone arm of the CALGB trial, 18 patients (19%) had a reduction in cardiac function, 5 patients (5%) had cardiac ischemia, and 2 patients (2%) experienced pulmonary edema. The range of total mitoxantrone doses administered to these patients is not available.@@No@@@@@NO LABELLED TRIAL@APPROVED@@Covered; part B; specialty drug@MEDICARE@NO LABELLED TRIAL@@@@@@MITOXANTRONE@@@@@MITOXANTRONE||||@BEDFORD LABORATORIES@@@@@BEDFORD LABORATORIES||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@GENERIC@@@@@GENERIC||||@Cytotoxic Antibiotic@Anthracycline@Topoisomerase II Inhibitor@@@Cytotoxic Antibiotic|Anthracycline|Topoisomerase II Inhibitor||@@@@@@@@@@@ADVANCED@@@@@NO LABELLED TRIAL@@@@@@@Invalid Factory Price@@@@@@@@@1@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@55390-0085-01@INJECTION@US$@@@@@@@@30@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916614@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@-@@-@-@-@SAN FRANCISCO, CALIFORNIA@6/1/2012@@@@14916614@An Open-Label, Single-Arm, Phase 2 Study of Carfilzomib in Patients With Relapsed Multiple Myeloma@@-@-@@NO REVIEW@@@@-@-@-@NCT00530816@155@-@-@@@FDA orphan drug for multiple myeloma and Waldenstrom's macroglobulinaemia. SOURCE: Proteolix, 2 April 2008@@9/1/2007@-@PX-171-004@@-@Subjects must have measurable disease, defined as one or more of the following:Serum M-protein = 1 g/dLUrine M-protein = 200 mg/24 hoursSubjects must have been responsive (i.e., achieve an MR or better) to standard, first line therapy@@@II@II@@-@-@>>. In 67 evaluable patients, carfilzomib achieved an overall response rate (ORR) of 52 percent and a clinical benefit rate (CBR) of 64 percent when administered at 27mg/m2. Sixty-four percent of patients were refractory to their most recent therapy prior to entering the trial. Overall response is defined as a partial response or greater.[i] The median time-to-progression (TTP), duration of response (DOR) and overall survival (OS) were not reached in this study, designed to provide patients with up to 12 cycles of carfilzomib. Forty-two percent of patients completed greater than 10 cycles and 22 patients continued treatment beyond one year in the extension protocol PX-171-010.[Onyx 12 December 2011 http://www.onyx-pharm.com/news/onyx-pharmaceuticals-presents-carfilzomib-data-at-53rd-american-society-of-hematology-annual-meeting ]>>Trial registered [Onyx 14 September 2007]@-@@@@MONO@CARFILZOMIB@@@@@CARFILZOMIB||||@ONYX@@@@@ONYX||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@PR-171@@@@@PR-171||||@Proteasome Inhibitor@@@@@Proteasome Inhibitor||||@RESPONSE RATE@@@@@SAFETY@@@@@RELAPSED@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921395@Onco@@@@@@@@@@@Cetuximab + Capecitabine and Cisplatin  q week + XP q 3 weeks SOURCE: Merck KGaA@@L01XC06@L01X@-@DARMSTADT, GERMANY@3/1/2012@@Erbitux is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Cetuximab is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions and has an approximate molecular weight of 152 kDa. Cetuximab is produced in mammalian (murine myeloma) cell culture.@@14921395@Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-Gastric Cancer@@-@-@@NO REVIEW@@@@-@>> Acquisition completed. [Lilly, 24.11.2008]         >> Lilly acquires ImClone for US$6.5 billion. [Lilly, 7.10.2008]       >> BMS Offers US$4.3Billion for ImClone or US$60.0 per share in cash. [BMS, 1 August 2008]     >> ImClone licensed co-development and co-promotion rights to BMS in North America and Japan, and to Merck KGaA in Europe.@FIRST-LINE@NCT00678535@870@-@-@@@-@@5/1/2008@-@EXPAND@@CURRENTLY IN DISPUTE; IMCLONE LOST PROCESS PATENT, EXPIRING IN 2017, TO YEDA IN 2006.@Histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction (AEG types I-III according to Siewert classification) Archived tumor material sample for at least subsequent standardized EGFR expression assessment. Investigators must make sure in advance that appropriate archived tumor material is available from a potentially eligible subject, and that a sample can be shipped to a central repository if the subject agrees to participate. Unresectable advanced (M0) or unresectable metastatic (M1) disease At least one radiographically documented measurable lesion in a previously non-irradiated area according to RECIST ECOG performance status 0-1@-@@III@III@@-@-@Trial started. SOURCE: Merck KGaA, 9 July 2008@-@@@@COMBO@CETUXIMAB@@@@@CETUXIMAB||||@MERCK SERONO@IMCLONE@@@@MERCK SERONO|IMCLONE|||@@@@@@|||||||||@Stomach Cancer@Oesophageal Cancer@@@@Stomach Cancer|Oesophageal Cancer||||||||@ERBITUX@@@@@ERBITUX||||@mAb@Chimeric@TK Inhibitor@EGFR@@mAb|Chimeric|TK Inhibitor|EGFR|@PROGRESSION-FREE SURVIVAL@@@@@@@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14917348@Onco@@@@@300f1020ntsdm@@@@@@NO LABELLED TRIAL@@L02AE04@L02A@NO@PARIS, FRANCE@@@Triptorelin is a decapeptide analogue of GnRH which initially stimulates release of pituitary gonadotrophins.@@14917348@Men: Treatment of advanced, hormone-dependent prostate carcinoma. Women: Preoperative reduction of myoma size to reduce the symptoms of bleeding and pain in women with symptomatic uterine myomas. Symptomatic endometriosis confirmed by laparoscopy when suppression of the ovarian hormonogenesis is indicated to the extent that surgical therapy is not primarily indicated. Children: Treatment of confirmed central precocious puberty (girls under 9 years, boys under 10 years).@@NO@-@@NO REVIEW@@@@100%@Ipsen exclusively in-licensed from Debiopharm know-how and new patent applications for the commercialisation rights of Decapeptyl in the world excluding North America, and some other countries (Sweden, Israel, Iran and Japan). [Ipsen, 31 October 2007]@-@-@-@The dosage of one syringe, equivalent to 3.75 mg triptorelin, is injected every 28 days either subcutaneously (e.g. into the skin of the abdomen, the buttock or thigh) or deep intramuscularly. The injection site should be changed each time. Men: Once every four weeks an injection with one syringe, equivalent to 3.75 mg triptorelin. In order to continually suppress testosterone levels, it is important to comply with a 4-weekly administration.@N/A@@@-@@@In adults the prolonged use of GnRH analogues may lead to bone loss which enhances the risk of osteoporosis. Prostate cancer  Initially, Decapeptyl SR like other GnRH analogues causes a transient increase in serum testosterone and consequent worsening of symptoms including increase in bone pain (and serum acid phosphatase levels). Continued treatment leads to suppression of testosterone (and dihydrotestosterone) and consequent improvement in the disease. During the first month of treatment, patients presenting with, or at particular risk of developing, urinary tract obstruction should be carefully monitored, as should those at risk of developing spinal cord compression. Consideration should be given to the use of an anti-androgen for three days prior to treatment, to counteract this initial rise in serum testosterone levels.@NO LABELLED TRIAL@No@-@-@@@-@APPROVED@@@SSN@NO LABELLED TRIAL@-@@@@-@TRIPTORELIN PAMOATE@@@@@TRIPTORELIN PAMOATE||||@IPSEN@@@@@IPSEN||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@DECAPEPTYL SR@@@@@DECAPEPTYL SR||||@LH-RH Analog@@@@@LH-RH Analog||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1807@301.96@498.36@315.55@@@@@@@@@@26.84@@@@@@@@@@@@@@@@8/31/2017@301.96@301.96@26999058@INJECTABLE PREPARATION, 2 ML@EURO@@@@@@@@11.25@MG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14919390@Onco@@@@@300f1018ntsdm@@@@@@NO LABELLED TRIAL@@L01DC01@L01D@YES@@@@@@14919390@a. Squamous cell carcinoma affecting the mouth, nasopharynx and paranasal sinuses, larynx, oesophagus, external genitalia, cervix or skin. Well differentiated tumours usually respond better than anaplastic ones. b. Hodgkin's disease and other malignant lymphomas, including mycosis fungoides. c. Testicular teratoma d. Malignant effusions of serous cavities. e. Secondary indications in which Bleomycin has been shown to be of some value (alone or in combination with other drugs) include metastatic malignant melanoma, carcinoma of the thyroid, lung and bladder@@Special patient contribution applies@@@NO REVIEW@@@@100%@Merger between Kyowa Hakko and Kirin Pharma announced in October 2007.@@@@Malignant lymphomas: Used alone the recommended dosage regime is 15 x 10³ IU (1 vial) once or twice a week, intramuscularly, to a total dose of 225 x 10³ IU (15 vials). Dosage should be reduced in the elderly. The dose may need to be adjusted when bleomycin is used in combination chemotherapy.@@@@@@@Patients undergoing treatment with bleomycin should have chest X-rays weekly. These should continue to be taken for up to 4 weeks after completion of the course. If breathlessness or infiltrates appear, not obviously attributable to tumour or to co-existent lung disease, administration of the drug must be stopped immediately and patients should be treated with a corticosteriod and a broad spectrum antibiotic. High oxygen concentrations should be used with caution in these cases. Lung function tests which use 100% oxygen should not be used in patients who have been treated with Bleomycin. Lung function tests using less than 21% oxygen are recommended as an alternative.@NO LABELLED TRIAL@No@@@@@@APPROVED@@No PBAC review.@PBS@NO LABELLED TRIAL@@@@@@BLEOMYCIN@@@@@BLEOMYCIN||||@BMS@@@@@BMS||||@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@Non-Hodgkin's Lymphoma@@@Haematological Malignancy|Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma|||||||@GENERIC@@@@@GENERIC||||@Cytotoxic Antibiotic@@@@@Cytotoxic Antibiotic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@10@0.779@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@A$@@@@@@@@15000@IU@15000 IU@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14920841@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01BB03@L01B@NO@BRENTFORD, UNITED KINGDOM@@@@@14920841@Lanvis is indicated primarily for the treatment of acute leukaemias especially acute myelogenous leukaemia and acute lymphoblastic leukaemia. Lanvis is also used in the treatment of chronic granulocytic leukaemia.@@NO@-@@NO REVIEW@@@@100%@-@-@-@-@Adults: The usual dosage of Lanvis is between 100 and 200 mg/m2 body surface area, per day. Children: Similar dosages to those used in adults, with appropriate correction for body surface area, have been used.@Oct-97@@@-@@@Lanvis is an active cytotoxic agent for use only under the direction of physicians experienced in the administration of such agents. Immunisation using a live organism vaccine has the potential to cause infection in immunocompromised hosts. Therefore, immunisations with live organism vaccines are not recommended. Hepatic Effects: Lanvis is not recommended for maintenance therapy or similar long-term continuous treatments due to the high risk of liver toxicity associated with vascular endothelial damage @NO LABELLED TRIAL@@-@-@@@-@DISCONTINUED@@-@NHS@NO LABELLED TRIAL@-@@@@-@TIOGUANINE@@@@@TIOGUANINE||||@GSK@@@@@GSK||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Chronic Myeloid Leukaemia@@Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Chronic Myeloid Leukaemia||||||@LANVIS@@@@@LANVIS||||@Anti-metabolite@Purine Analogue@@@@Anti-metabolite|Purine Analogue|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@@@@25@1.5665@@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/25/2015@@@4.20E+15@TABLET@GB£@@@@@@@@40@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
16384756@Onco@@@@@300f1012ntsdm@@@@@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384756@Indicated for the treatment of adult patients with Ph+ CML in chronic phase after failure of interferon-alphatherapy@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@SECOND-LINE@@532@The recommended dosage of Glivec is 400 mg/day for adult patients in chronic phase CML.@@@@Yes@@@@@No@@@ADULT@@@APPROVED@@@GKV@@@@@@MONO@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@CHRONIC PHASE@@@@@@@@@@1@1@Invalid Average Duration of Use@@@@@@@@@60@1.1511@1435.32@1816.59@1473.82@@@@@@@@@@0.24@1@@mg@400@1@@@@@@@@@@@8/1/2017@23.92@23.92@1755166@FILM-COATED TABLET@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14924983@Onco@@@@@300f1010ntsdm@@@@@@Patients will be treated with BAY 73-4506 160 mg po qd for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off). Patients will continue treatment with BAY 73-4506 until disease progression, intolerable toxicity, or patient refusal to continue with the study or investigator decision to remove the patient from study. [clinicaltrials.gov]@@-@-@-@LEVERKUSEN, GERMANY@5/1/2009@@"DAST (BAY 73-4506) is a novel oral substance for cancertherapy in the early stages of clinical development. Thename DAST (Dual Acting Signal Transduction Inhibitor)stands for the dual mechanism of action of the activesubstance, which, by its inhibitory action on variousenzymes (kinases), inhibits both the signalling pathways incancer cell proliferation and also new blood vesselformation. In preclinical studies, DAST has proved to beeffective in various tumor models, including pancreaticcancer, lung cancer, colon cancer, and breast cancer.Currently, two phase I clinical studies are being conductedwith DAST. The first provisional data from these studiesare very promising."@@14924983@"Uncontrolled Study of BAY 73-4506 in Previously Untreated Patients With Metastatic or Unresectable Renal Cell Cancer (RCC)"@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00664326@52@-@-@@@-@@4/1/2008@-@11726@@-@"Male or female patients > 18 years of age. Patients, who suffer from unresectable and/or metastatic, measurable predominantly clear cell RCC histologically or cytologically documented. Patients with rare subtypes of RCC such as pure papillary cell tumor, mixed tumor containing predominantly sarcomatoid cells, Bellini carcinoma, medullary carcinoma, or chromophobe oncocytic tumors are excluded from study participation"@@@II@II@@-@-@Trial registered. [Bayer, 17 April 2008]@-@@@@MONO@FLUOROSORAFENIB@@@@@FLUOROSORAFENIB||||@BAYER HEALTHCARE@@@@@BAYER HEALTHCARE||||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@BAY-734506@DAST@@@@BAY-734506|DAST|||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@RESPONSE RATE@@@@@PROGRESSION-FREE SURVIVAL@TIME TO PROGRESSION@DURATION OF RESPONSE@@@METASTATIC@UNRESECTABLE@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14916027@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@XL-880 alone@@-@-@-@SOUTH SAN FRANCISCO, CALIFORNIA@@@MET is mutationally activated in hereditary papillary renal cell carcinoma and in some non-small cell lung tumors, activated or overexpressed in head and neck cancer, glioma, and other solid tumors, and amplified in a subset of gastric and lung cancers. MET also appears to cooperate with VEGF in the response of tumors to hypoxia. VEGF and HGF (the ligand for MET) act cooperatively to stimulate angiogenesis. In response to hypoxia, tumor cells upregulate VEGF to stimulate angiogenesis, and MET to promote survival and stimulate migration to better-oxygenated tissue. Dual targeting of MET and VEGFR2 therefore blocks two of the major mechanisms tumors use to overcome hypoxia. @@14916027@Metastatic, poorly differentiated diffuse gastric cancer@@-@-@@NO REVIEW@@@@-@In December 2007, GSK exercised its option to exclusively license XL-880, from an agreement signed in October 2002. It triggered a US$35 million payment, and Exelixis is to be paid royalties; it also has certain U.S. co-promotion rights.@-@NCT00415480@40@-@-@@@-@@12/1/2006@-@XL880-204@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@EXELIXIS@GSK@@@@EXELIXIS|GSK|||@@@@@@|||||||||@Stomach Cancer@@@@@Stomach Cancer|||||||||@XL-880@GSK-1363089@@@@XL-880|GSK-1363089|||@TK Inhibitor@VEGF@Angiogenesis Inhibitor@@@TK Inhibitor|VEGF|Angiogenesis Inhibitor||@RESPONSE RATE@SAFETY@TOLERABILITY@@@TOLERABILITY@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16670306@Onco@@@@@300f1015ntsdm@@@@@@@@L04AX04@L04A@@SUMMIT, NEW JERSEY@3/1/2017@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16670306@Treatment of adult patients with relapsed or refractory mantle cell lymphoma@Both@YES@8-Mar-17@3/8/2017@NO REVIEW@@@@8 March 2017: ASMR V  [http://www.has-sante.fr/portail/upload/docs/evamed/CT-15734_REVLIMID_PIC_EI_LCM_AvisPostObs_CT15734.pdf]@@@NCT00875667@254@The recommended starting dose of lenalidomide is 25 mg orally once daily on days 121 of repeated 28day cycles.@EMA, 28 January 2016@1/28/2016@9/1/2007@Yes@@4/1/2009@@CC5013MCL002@No@@Biopsy proven mantle cell lymphoma; Patients who are refractory to their regimen or have relapsed once, twice or up to three times and who have documented progressive disease; Eastern Cooperative Oncology Group (ECOG) performance score 0,1, or 2; Willing to follow pregnancy precaution@@ADULTS@II@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@@@@@@MONO@LENALIDOMIDE@@@@@LENALIDOMIDE||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Non-Hodgkin's Lymphoma@Mantle Cell Lymphoma@@@@Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma||||||||@REVLIMID@@@@@REVLIMID||||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@PROGRESSION FREE SURVIVAL@@@@@OVERALL RESPONSE RATE@DURATION OF RESPONSE@TIME TO PROGRESSION@@@RELAPSED@REFRACTORY@@@@RANDOMISED@MULTI-CENTRE@OPEN LAB EL@@@1@1@146154.96@@@37.6@week@37.6 week@146154.96@146154.96@555.3@1@1.1511@148.08@@@@@@@@@@@@29.62@28@@mg@25@21@@@@@@@@@@@8/2/2017@148.08@148.08@9298159R@CAPSULE@EURO@@@@@@@@5@MG@5 MG@@@@@@@@@@@@@@@@@@@@@@@@85@France
14919559@Onco@@@@@300f1015ntsdm@@@@@@Tamoxifen compared to ovarian ablation@@L02BA01@L02B@YES@COLOMBES, FRANCE@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14919559@@@NO@Sep-98@@NO REVIEW@@@@@@@@N/A@Adjuvant treatment of breast cancer, Adults (including elderly): The recommended dose is 20mg, given either in divided doses twice daily or as a single dose once daily. The current recommended treatment duration is five years; however the optimum duration has not been established. Treatment of locally advanced or metastatic breast cancer: The recommended dose is 20mg to 40mg, given either in divided doses twice daily or as a single dose once daily.@1-Mar-98@3/1/1998@10/20/1998@@@@Women should be informed of the potential risks to the foetus, should they become pregnant whilst taking tamoxifen; or within two months of cessation of therapy. A number of secondary primary tumours, occurring at sites other than the endometrium and the opposite breast, have been reported in clinical trials, following the treatment of breast cancer patients with tamoxifen. No causal link has been established and the clinical significance of these observations remains unclear.@LABEL@No@@@@@III; METASTATIC BREAST CANCER@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@The objective RR, time to treatment failure, and survival were similar with both treatments. In an overview analysis of survival data from the 3 studies, the hazard ratio for death (tamoxifen/ovarian ablation) was 1.00. Elevated serum and plasma oestrogens have been observed in premenopausal women receiving tamoxifen, but the data from the randomized studies do not suggest an adverse effect of this increase. A limited number of premenopausal patients with disease progression during tamoxifen therapy responded to subsequent ovarian ablation.@@@@@MONO@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@BIOGARAN@@@@@BIOGARAN||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GENERIC@@@@@GENERIC||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RESPONSE RATE@@@@@@@@@@@@@@@PROSPECTIVE@RANDOMISED@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@30@1.1511@5.45@7.62@5.81@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@0.18@0.18@3.40E+12@TABLET@EURO@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
15361166@Onco@@@@@300f1020ntsdm@@@@@DASISION@Patients were randomized to receive either SPRYCEL 100 mg once daily or imatinib 400 mg once daily@@L01XE06@L01X@@NEW YORK, NEW YORK@12/1/2013@@Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRß. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.@@15361166@Indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase.@Both@YES@@@@@@@@@FIRST-LINE@NCT00481247@519@The recommended starting dose for chronic phase CML is 100 mg dasatinib once daily, administered orally.@EMA, 6 December 2010@12/6/2010@@YES@@8/1/2007@@CA180-056/2006-005712-27@No@@Male & Female ≥18 years/Chronic Phase Ph+ CML/Eastern Cooperative Oncology Group Performance Status (ECOG PS) score 0-2@@ADULTS@III@APPROVED@@@@@@@@@MONO@DASATINIB@@@@@DASATINIB||||@BMS@@@@@BMS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@SPRYCEL@@@@@SPRYCEL||||@TK Inhibitor@bcr-abl@PDGF@@@TK Inhibitor|bcr-abl|PDGF||@RATE OF CONFIRMED COMPLETE CYTOGENETIC RESPONSE@@@@@@@@@@CHRONIC PHASE@PH+@@@@OPEN-LABEL@MULTICENTER@RANDOMISED@@@1@1@71242.83861@@@14@month@14 month@71242.84@71242.84@167.31@30@1.1229@4015.34@6626.92@4196.07@@@@@@@@@@1.67@1@@mg@100@1@@@@@@@@@@@6/7/2017@133.84@133.84@37400138@FILM COATED TABLET@EURO@@@@@@@@80@MG@80 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14921920@Onco@@@@@@@@@@@Tablets, Oral, Exemestane 25 mg + Dasatinib 100 mg, once daily, until disease progression or unacceptable toxicity versus Aromasin with placebo. [BMS]@@L01XE06@L01X@-@NEW YORK, NEW YORK@12/1/2010@@Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRß. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.@@14921920@Exemestane plus dasatinib@@NO@-@@NO REVIEW@@@@-@-@-@NCT00767520@156@-@-@@@-@@11/1/2008@-@CA180-261@@APRIL 2020 ('746); PATENT EXTENSION FILED.@>> Invasive estrogen receptor positive breast cancer, locally-advanced or metastatic, with tumor tissue from prior surgery available for analysis     >> Prior therapy with a non-steroidal aromatase inhibitor in the adjuvant or advanced setting@@@II@II@@-@-@Trial registered. [BMS, 6.10.2008]@-@@@@COMBO@DASATINIB@EXEMESTANE@@@@DASATINIB|EXEMESTANE|||@BMS@@@@@BMS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@SPRYCEL@AROMASIN@@@@SPRYCEL|AROMASIN|||@TK Inhibitor@bcr-abl@PDGF@@@TK Inhibitor|bcr-abl|PDGF||@PROGRESSION-FREE SURVIVAL@@@@@FREEDOM-FROM-PROGRESSION@@@@@ER+@@@@@RANDOMISED@DOUBLE-BLIND@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916599@Onco@@@@@300f1014ntsdm@300f1813ntsdm@@@@@Casodex as immediate hormonal therapy or adjuvant to radical prostatectomy or radiotherapy.@@L02BB03@L02B@NO@LONDON, UNITED KINGDOM@@@Casodex is a non-steroidal antiandrogen, devoid of other endocrine activity. It binds to androgen receptors without activating gene expression, and thus inhibits the androgen stimulus. Regression of prostatic tumours results from this inhibition. Clinically, discontinuation of Casodex can result in antiandrogen withdrawal syndrome in a subset of patients. Casodex is a racemate with its antiandrogenic activity being almost exclusively in the (R)-enantiomer.@@14916599@In patients with locally advanced prostate cancer (T3-T4, any N, M0; T1-T2, N+, M0), Casodex 150 mg is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. Casodex 150 mg is also indicated for the management of patients with locally advanced, non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.@@NO@@@NO REVIEW@@@@100%@@@@8113@The dosage is one 150 mg tablet to be taken orally once a day. Casodex 150 mg should be taken continuously for at least 2 years or until disease progression.@@@@@@@Casodex 150 mg should be used with caution in patients with moderate to severe hepatic impairment.@@No@@@@@III; THREE TRIALS@APPROVED@@Unrestricted reimbursement.@RAMQ@27.4% and 30.7% of all Casodex and placebotreated patients, respectively, had experienced objective disease progression. In the subgroup of locally advanced prostate cancer who did not receive treatment with radical prostatectomy or radiotherapy, immediate therapy with Casodex 150 mg significantly reduced the risk of objective disease progression (Hazard Ratio (HR)= 0.60; 95% CI 0.49 to 0.73). PFS events was 57.6% in the Casodex watchful waiting group, compared to 68.9% in the placebo group, whilst deaths were 49% and 57% respectively.@@@@@@BICALUTAMIDE@@@@@BICALUTAMIDE||||@APOTEX@@@@@APOTEX||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@APO-BICALUTAMIDE@GENERIC@@@@APO-BICALUTAMIDE|GENERIC|||@Hormone Antagonist@Anti-androgen@@@@Hormone Antagonist|Anti-androgen|||@DISEASE-FREE SURVIVAL@@@@@@@@@@LOCALLY ADVANCED@@@@@PLACEBO-CONTROLLED@DOUBLE-BLIND@@@@@@Invalid Factory Price@@@@@@@@@30@0.7934@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@C$@@@@@@@@150@MG@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
16439813@Onco@@@@@@@@@@@"PLB1001, Experimental, There are 4 dose cohorts, including 50mg BID,100mg BID, 200mg BID and 300mg BID in the dose escalation stage and PLB1001 will be administered orally to patients twice daily for each dose cohort."@@@@@CHINA@6/1/2018@@"PLB1001 is a potent selective c-Met inhibitor. PLB1001 acts on cancer by blocking abnormal cMET-mediated signaling (including PTPRZ1-MET fusion gene), leading to profound tumor growth inhibition in xenografts of PTPRZ1-MET fusion gene positive glioblastoma tumor."@@16439813@A Phase I, Open-label, Dose Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas@Both@@@@@PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.@@@@@SECOND-LINE@NCT02978261@20@@@@@@@9/1/2016@@HMO-PLB1001-I-GBM-01@@@-  Signed Informed Consent Form  -  Age≥18 years  -  Histologically or cytologically confirmed recurrent high-grade glioma after concurrent or adjuvant chemoradiotherapy  -  Prior treatment with temozolomide  -  Must have evidence of PTPRZ1-MET fusion gen@PTPRZ1-MET Fusion Gene Positive@ADULTS@Phase 1@I@@@@@@@@@MONO@Bozitinib@@@@@Bozitinib||||@BEIJING PEARL BIOTECHNOLOGY@@@@@BEIJING PEARL BIOTECHNOLOGY||||@China@@@@@China|||||||||@Glioma@@@@@Glioma|||||||||@PLB1001@@@@@PLB1001||||@Other@@@@@Other||||@Percentage of participants with dose-limiting toxicities@@@@@Area under the plasma concentration versus time curve (AUC) of PLB1001 and its metabolite@Maximum plasma concentration observed (Cmax) of PLB1001 and its metabolite@@@@RECURRENT@@@@@Safety/Efficacy Study@Single Group Assignment@Open Label@Treatment@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
16387795@Onco@@@@@300f1012ntsdm@@@@@@@@L02BG03@L02B@@LONDON, UNITED KINGDOM@@@Arimidex is a potent and highly selective non-steroidal aromatase inhibitor. In postmenopausal women, estradiol is produced primarily from the conversion of androstenedione to estrone through the aromatase enzyme complex in peripheral tissues. Estrone is subsequently converted to estradiol. Reducing circulating estradiol levels has been shown to produce a beneficial effect in women with breast cancer. In postmenopausal women, Arimidex at a daily dose of 1 mg produced estradiol suppression of greater than 80% using a highly sensitive assay. Arimidex does not possess any progestogenic, androgenic or oestrogenic activity. Daily doses of Arimidex up to 10 mg do not have any effect on cortisol or aldosterone secretion, measured before or after standard ACTH challenge testing. Corticoid supplements are therefore not needed.@@16387795@Adjuvant treatment of hormone receptor-positive early invasive breast cancer in postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@SECOND-LINE@@2579@The dose of Arimidex is one 1 mg tablet taken once a day. For patients with advanced breast cancer, Arimidex should be continued until tumour progression.@EMA, 27 December 1996@12/27/1996@@@@@@@No@@@@@III@APPROVED@@@GKV@@@@@@ADJUVANT@ANASTROZOLE@@@@@ANASTROZOLE||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@ARIMIDEX@@@@@ARIMIDEX||||@Hormone Antagonist@Aromatase Inhibitor@@@@Hormone Antagonist|Aromatase Inhibitor|||@@@@@@@@@@@EARLY@@@@@CONTROLLED@DOUBLE-BLIND@@@@1@1@3354.933466@@@24@month@24 month@3354.93@3354.93@4.6@100@1.1511@459.59@592.05@474.77@@@@@@@@@@4.6@1@@mg@1@1@@@@@@@@@@@8/1/2017@4.6@4.6@7511991@FILM-COATED TABLET@EURO@@@@@@@@1@MG@1 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14920917@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@BRENTFORD, UNITED KINGDOM@@@Ispinesib is a novel small molecule drug candidate that inhibits cell proliferation and promotes cancer cell death by specifically disrupting the function of a cytoskeletal protein known as kinesin spindle protein, or KSP. Current drugs that inhibit cell proliferation, such as paclitaxel and docetaxel, are standard treatments for many types of cancers, but these drugs also target other proteins that are essential to other important cellular functions and thus, their use is limited by side effects. @@14920917@Platinum-sensitive or -refractory NSCLC@@-@-@@NO REVIEW@@@@-@Part of wide-ranging 2001 partnership between Cytokinetics and GSK to discover and commercialise small moleculaes targeting mitotic kinesins in cancer; being positioned against Nexavar and Sutent@SECOND-LINE@NCT00085813@70@-@-@@@-@@12/1/2003@-@KSP20007@@-@-@@@II@DISCONTINUED@@-@-@>> Cytokinetics is discontinuing research activities related to oncology. [Cytokinetics, 16.09.2008]>> Ispinesib has not satisfied the criteria for advancement to the next stage in the platinum-sensitive treatment arm. The trial was designed to require a minimum of 1 confirmed PR or CR out of 20 patients to proceed to Stage 2 in either treatment arm. The best overall responses to date in the platinum-sensitive treatment arm have been disease stabilisation in 10 of 20 evaluable patients.Median TTP was 6 weeks; in the 10 patients whose best response was stable disease, median TTP was 17 weeks. In September 2005, the platinum-refractory treatment arm also did not satisfy the criteria for advancement to the next stage of evaluation. Disease stabilisation was 5 of 20 evaluable patients. Overall, median TTP was 6 weeks; in the 5 patients whose best response was stable disease, median TTP was 12 weeks. The most significant side effect observed was Grade 4 neutropaenia in 10 patients. With the exception of neutropaenia (11 patients), febrile neutropaenia (3 patients) and fatigue (2 patients), no other significant side effects of higher than Grade 2 were observed. [Cytokinetics, March 2006]@-@@@@MONO@ISPINESIB@@@@@ISPINESIB||||@GSK@CYTOKINETICS@@@@GSK|CYTOKINETICS|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@SB-715992@@@@@SB-715992||||@KSP Inhibitor@@@@@KSP Inhibitor||||@RESPONSE RATE@RECIST@@@@@@@@@REFRACTORY@RELAPSED@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16384797@Onco@@@@@300f1012ntsdm@@@@@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384797@Indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@FIRST-LINE@@@The recommended dose of Glivec is 600 mg/day for adult patients with Ph+ ALL.@@@@Yes@@@@@No@@@ADULT@@@APPROVED@@NO REVIEW@GKV@@@@@@BOTH@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@@@@Haematological Malignancy|Acute Lymphocytic Leukaemia||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@@@@@@@@@@@1@1@49889.11214@@@1@year@1 year@49889.11@49889.11@136.68@90@1.1511@8200.95@10109.22@8239.45@@@@@@@@@@0.23@1@@mg@600@1@@@@@@@@@@@8/1/2017@91.12@91.12@1755203@FILM-COATED TABLET@EURO@@@@@@@@400@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
15354712@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients were split into 2 groups. The first group took IBRANCE and letrozole together, while the second group took letrozole alone.@@L01XE33@L01X@NO@NEW YORK, NEW YORK@@@@@15354712@Treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease.@Female@NA@@@NO REVIEW@@@@@@FIRST-LINE@@165@125 mg capsule taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days@FDA, 02 Mar 2015@3/2/2015@@No@@@@@No@@@HR-positive, HER2-negative@ADULTS@@APPROVED@@@NA@In the trial, patients in the IBRANCE plus letrozole group lived approximately 20.2 months without their disease pregoressing, compared to approximately 10.2 months in the group receiving letrozole alone.[FDA, 3 February 2015]@IBRANCE may cause serious side effects, including low white blood cell counts, infections, and blood clots in the arteries of your lungs (pulmonary embolism).The most common side effects included low levels of infection-fighting white blood cells called neutrophils (neutropenia), low levels of white blood cells (leukopenia), fatigue, low red blood cell counts (anemia), and upper respiratory tract infections. [FDA, February 2015, https://www.centerwatch.com/drug-information/fda-approved-drugs/drug/100070/farydak-panobinostat]@@@@COMBO@PALBOCICLIB@LETROZOLE@@@@PALBOCICLIB|LETROZOLE|||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@IBRANCE@GENERIC@@@@IBRANCE|GENERIC|||@TK Inhibitor@@@@@TK Inhibitor||||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@ADVANCED@METASTATIC@@@@RANDOMIZED@OPEN-LABEL@MULTICENTER@@@1@1@400936.488@@@20.2@month@20.2 month@400936.49@400936.49@652.56@21@1@10963.05@@@@@@@@@@@@6.96@28@@mg@125@21@@@@@@@@@@@8/2/2017@522.05@522.05@00069-0187-21@CAPSULE@US$@@@@@@@@75@MG@75 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16161178@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Intralesional TALIMOGENE LAHERPAREPVEC with radiotherapy, Experimental, Patients will receive 3 radiotherapy treatments (one treatment every 3-5 days) during weeks 3 and 4. The first treatment will occur 6 (+/- 2) hours after the Talimogene Laherparepvec administration at week 3.Talimogene Laherparepvec will be administered at weeks 0, 3, 5, 7, 9, 11, 13 and 15. The first dose of Talimogene Laherparepvec will be 10^6 plaque forming units (PFU)/mL, followed three weeks later by a dose of 10^8 pfu/mL.Intralesional TALIMOGENE LAHERPAREPVEC without radiotherapy, Experimental, Patients will receive Talimogene Laherparepvec alone, as described above, without radiotherapy.@@@@@THOUSAND OAKS, CALIFORNIA@6/1/2019@@@@16161178@A Phase II Randomized Trial of Intralesional Talimogene Laherparepvec (TALIMOGENE LAHERPAREPVEC) With or Without Radiotherapy for Cutaneous Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors@Both@@@@@@@@@@FIRST-LINE@NCT02819843@34@@@@@@@6/1/2016@@16-224@@@Inclusion Criteria:  -  Man or woman ≥ 18 years old  -  Life expectancy > 4 months  -  Histopathologically confirmed melanoma, Merkel cell carcinoma or other solid tumor malignancy  -  Cutaneous metastasis not suitable for surgical resection  -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2  -  Cutaneous metastasis that is amenable to injection and irradiation and > 10 mm in longest dimension  ° Cutaneous metastasis in a region of previous radiation therapy is not amenable to radiation therapy as part of this protocol  -  Visceral metastasis that is > 10 mm in longest dimension  -  Adequate coagulation function (platelet count >50 k/mcL, international normalized ratio of < 1.5)  -  Completion of other cancer therapy (targeted therapy, chemotherapy, investigational therapy, immunotherapy, radiotherapy, surgery) 28 days prior to first dose of protocol therapy  -  Resolution or stabilization of clinically significant adverse events from prior therapy (completed at least 28 days prior to first dose of TVEC)  -  Able to provide valid written informed consent@@ADULTS@Phase 2@II@@@@@@@@@COMBO@TALIMOGENE LAHERPAREPVEC@@@@@TALIMOGENE LAHERPAREPVEC||||@AMGEN@@@@@AMGEN||||@United States@@@@@United States|||||||||@Melanoma / Skin Cancer@Solid Tumours@@@@Melanoma / Skin Cancer|Solid Tumours||||||||@IMLYGIC@@@@@IMLYGIC||||@Other@@@@@Other||||@response [ Time Frame: 16 weeks ]@@@@@@@@@@METASTATIC@@@@@RANDOMIZED@SAFETY/EFFICACY STUDY@SINGLE GROUP ASSIGNMENT@OPEN LABEL@TREATMENT@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15056602@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Ibrutinib: 420 mg daily or 840 mg daily@@L01XE27@L01X@@BEERSE, BELGIUM@6/1/2013@@Ibrutinib was designed to specifically target and selectively inhibit an enzyme called Bruton's tyrosine kinase (BTK). BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel – regulating apoptosis, adhesion, and cell migration and homing. Through these multiple actions, BTK helps to direct malignant B-cells to lymphoid tissues, thus allowing access to a microenvironment necessary for survival.@@15056602@Chronic lymphocytic leukemia (CLL) who have received at least one prior treatment@@NA@@@NO REVIEW@@@@@@SECOND-LINE@NCT01105247@133@420 mg taken orally once daily (three 140 mg capsules once daily)@FDA, 12 February 2014@2/12/2014@@No@@4/1/2010@@PCYC-1102-CA@No@@@@@II@APPROVED@@@@@@@@@MONO@IBRUTINIB@@@@@IBRUTINIB||||@JANSSEN PHARMACEUTICAL@PHARMACYCLICS@@@@JANSSEN PHARMACEUTICAL|PHARMACYCLICS|||@@@@@@|||||||||@Chronic Lymphocytic Leukaemia@@@@@Chronic Lymphocytic Leukaemia|||||||||@IMBRUVICA@@@@@IMBRUVICA||||@TK Inhibitor@@@@@TK Inhibitor||||@SAFETY@@@@@PROGRESSION-FREE SURVIVAL@RESPONSE RATE@@@@@@@@@OPEN-LABEL@NON-RANDOMISED@SINGLE GROUP ASSIGNMENT@@@1@1@101311.8326@@@9@month@9 month@101311.83@101311.83@370.1@120@1@14803.88@@@@@@@@@@@@0.88@1@@mg@420@1@@@@@@@@@@@8/2/2017@123.37@123.37@57962-0140-12@CAPSULE@US$@@@@@@@@140@MG@140 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916197@Onco@@@@@300f1015ntsdm@@@@@@Stable doses of either long-acting oral opioid or transdermal fentanyl with Actiq (200, 400, 600, 800, 1200 and 1600mcg)@@N02AB03@N02A@YES@FRAZER, PENNSYLVANIA@@@Fentanyl is a pure opioid agonist whose principal therapeutic action is analgesia. Other members of the class known as opioid agonists include substances such as morphine, oxycodone, hydromorphone, codeine, and hydrocodone.@@14916197@Indicated for the management of breakthrough pain in patients already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.@@NO@@@NO REVIEW@@@@65%@Licensed from Kyowa Hakko; supplied by Abbott. Acquired through US$444 mil. takeover of Anesta Corp in 2000.@@@257@The initial dose of Actiq used should be 200 micrograms, titrating upwards as necessary through the range of available dosage strengths (200, 400, 600, 800, 1200 and 1600 micrograms). Patients should be carefully monitored until a dose is reached that provides adequate analgesia with acceptable side effects using a single dosage unit per episode of breakthrough pain. This is defined as the successful dose.@1-Aug-02@8/1/2002@9/2/2002@@@@Must not be used in opioid non-tolerant patients; fentanyl is a Schedule II controlled substance; life-threatening hypoventilation can occur at any dose; contraindicated in acute or post-operative pain@LABEL@No@@257 OPIOID-TOLERANT ADULT CANCER PATIENTS@@@III; TWO DOSE TITRATION STUDIES@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@95 of 127 patients (75%) titrated to a successful dose of Actiq (could be used consistently for at least 2 days without unacceptable side-effects). 11% and 14% withdrew due to adverse events or other reasons respectively.@@@@@MONO@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@CEPHALON@@@@@CEPHALON||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@ACTIQ@@@@@ACTIQ||||@Opioid Analgesic@@@@@Opioid Analgesic||||@RESPONSE RATE@MAXIMUM TOLERATED DOSE@@@@@@@@@@@@@@DOSE-RANGING@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@3@1.1807@19.71@26.39@21.03@@@@@@@@@@@@@@@@@@@@@@@@@@9/1/2017@6.57@6.57@3.40E+12@TABLET WITH ORAL APPLICATOR@EURO@@@@@@@@1600@MCG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
16395637@Onco@@@@@300f1012ntsdm@@@@@@@@L04AX04@L04A@@SUMMIT, NEW JERSEY@3/1/2017@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16395637@Treatment of adult patients with relapsed or refractory mantle cell lymphoma@Both@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@NCT00875667@254@The recommended starting dose of lenalidomide is 25 mg orally once daily on days 121 of repeated 28day cycles.@EMA, 28 January 2016@1/28/2016@@Yes@@4/1/2009@@CC5013MCL002@No@@Biopsy proven mantle cell lymphoma; Patients who are refractory to their regimen or have relapsed once, twice or up to three times and who have documented progressive disease; Eastern Cooperative Oncology Group (ECOG) performance score 0,1, or 2; Willing to follow pregnancy precaution@@ADULTS@II@APPROVED@@@GKV@@@@@@MONO@LENALIDOMIDE@@@@@LENALIDOMIDE||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Non-Hodgkin's Lymphoma@Mantle Cell Lymphoma@@@@Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma||||||||@REVLIMID@@@@@REVLIMID||||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@PROGRESSION FREE SURVIVAL@@@@@OVERALL RESPONSE RATE@DURATION OF RESPONSE@TIME TO PROGRESSION@@@RELAPSED@REFRACTORY@@@@RANDOMISED@MULTI-CENTRE@OPEN LAB EL@@@1@1@169215.6662@@@37.6@week@37.6 week@169215.67@169215.67@642.92@21@1.1511@5400.5@6676.71@5439@@@@@@@@@@34.29@28@@mg@25@21@@@@@@@@@@@8/1/2017@257.17@257.17@11056179@HARD CAPSULE@EURO@@@@@@@@7.5@MG@7.5 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14919074@Onco@@@@@@@@@@@251 NSCLC patients and 150 patients with brain metastases from other solid tumors; @@-@-@-@SUNNYVALE, CALIFORNIA@@@Motexafin gadolinium (MGd) is a small-molecule drug with a novel mechanism of action; it accumulates selectively in cancer cells due to their increased rates of metabolism. Once inside the cell, MGd induces apoptosis (programmed cell death) by disrupting redox-dependent pathways. MGd inhibits the enzyme thioredoxin reductase, which is a tumor growth promoter. This mechanism provides the opportunity to use MGd in a wide range of cancers. MGd is paramagnetic, and therefore is detectable by magnetic resonance imaging (MRI), allowing the visualization of the drug in tumors.@@14919074@Patient undergoing whole brain radiation therapy@@-@-@@NO REVIEW@@@@-@Available for outlicensing.@-@NCT00003563@401@-@FDA non-approvable letter for combo use with radiotherapy for NSCLC with brain metastases. SOURCE: Pharmacyclics, 21 December 2007NDA accepted with PDUFA date of 31 December. Pharmacyclics requested the FDA take into consideration the poor quality control in radiotherapy in France in its assessment of the clinical trial data. SOURCE: Pharmacyclics, 23 April 2007File over protest. SOURCE: Pharmacyclics, 4 April 2007FDA refusal to file the NDA, citing that the company's application is not sufficiently complete to permit a substantive review based on clinical studies that failed to demonstrate statistically significant differences between treatment arms in the primary endpoints. SOURCE: Pharmacyclics, 21 February 2007NDA of the two Phase III trials filed. SOURCE: Pharmacyclics, 22 December 2006@12/21/2007@@-@@@-@MSKCC-00088@@-@-@@@III@III@@-@-@An integrated analysis of the 805 lung cancer patients in the two filed Phase III studies demonstrated a statistically significant 6.4 month improvement in time to neurologic progression for patients receiving Xcytrin plus whole brain radiation therapy compared to those receiving radiation alone. The median time to neurologic progression was 15.4 months compared to 9.0 months, respectively, with a p-value equal to 0.016. Several secondary endpoints also showed a significant benefit for Xcytrin plus whole brain radiation compared to radiation alone: time to neurologic progression as determined by investigators, P = 0.015 and time to neurocognitive progression, P = 0.02. In addition to this consistent treatment effect, Xcytrin plus radiation therapy was generally well tolerated across all studies. Final results: did not show a statistically significant benefit overall but did show a clinically and statistically significant improvement in time to neurologic progression in the subset of patients with NSCLC.@-@@@@COMBO@MOTEXAFIN GADOLINIUM@@@@@MOTEXAFIN GADOLINIUM||||@PHARMACYCLICS@@@@@PHARMACYCLICS||||@@@@@@|||||||||@Brain Cancer@@@@@Brain Cancer|||||||||@XCYTRIN@@@@@XCYTRIN||||@Radiation Sensitiser@@@@@Radiation Sensitiser||||@NEUROLOGIC FUNCTION@@@@@@@@@@-@@@@@RANDOMISED@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
15400327@Onco@@@@@300f1008ntsdm@@@@@@Investing arms: nilotinib 300mg bid or nilotinb 400 mg bidControl arm: imatinib 400mg QD@@L01XE08@L01X@@BASEL, SWITZERLAND@@@Nilotinib is an inhibitor of the Bcr-Abl kinase. Nilotinib binds to and stabilizes the inactive conformation of the kinase domain of Abl protein. In vitro, nilotinib inhibited Bcr-Abl mediated proliferation of murine leukemic cell lines and human cell lines derived from Ph+ CML patients. Under the conditions of the assays, nilotinib was able to overcome imatinib resistance resulting from Bcr-Abl kinase mutations, in 32 out of 33 mutations tested. In vivo, nilotinib reduced the tumor size in a murine Bcr-Abl xenograft model. Nilotinib inhibited the autophosphorylation of the following kinases at IC50 values as indicated: Bcr-Abl (20-60 nM), PDGFR (69 nM) and c-Kit (210 nM).@@15400327@@Both@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@FIRST-LINE@NCT00471497@846@The recommended dose of Tasigna is 300 mg twice daily@@@@@@@@ENEST@No@@Chronic myelogenous leukemia in chronic phase patients within the first 6 months of diagnosis.Diagnosis of chronic myelogenous leukemia in chronic phase with confirmation of Philadelphia chromosome@ADULT@Adult@III@APPROVED@@@NHI@@@@@@MONO@NILOTINIB@@@@@NILOTINIB||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@TASIGNA@@@@@TASIGNA||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@MOLECULAR RESPONSE RATE@@@@@@@@@@CHRONIC PHASE@@@@@RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@1@1@4478043.049@@@12@month@12 month@4478043.05@4478043.05@12268.88@1@0.0091@3067.22@3617@@@@@@@@@@@20.45@1@@mg@600@1@@@@@@@@@@@8/30/2017@3067.22@3067.22@4291021M2027@CAPSULE@YEN@@@@@@@@150@MG@150 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14920921@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Administered intravenously weekly for 3 weeks every 4 weeks@@-@-@-@HAYWARD, CALIFORNIA@11/1/2004@@@@14920921@Patients having failed one prior platinum-containing regimen@@-@-@@NO REVIEW@@@@-@BMS acquires Kosan Biosciences for US$190 million. SOURCE: BMS, 29 May 2008Partnership terminated due to reprioritisation at Roche. Kosan reacquires all rights. SOURCE: Kosan, 25 October 2007Kosan and Roche established a global development and commercialization agreement for epothilones to treat cancer in September 2002. Under@SECOND-LINE@NCT00080509@85@-@-@@@-@@12/1/2003@-@KOS-201NO17352@@-@-@@@II@DISCONTINUED@@-@-@While the first-generation compound R1492 (KOS-862) demonstrated meaningful objective response rates in metastatic breast cancer and non-small cell lung cancer, the companies have decided to discontinue its development and focus resources on advancing R1645. SOURCE: Kosan, 27 February 2007@-@@@@MONO@EPOTHILONE D@@@@@EPOTHILONE D||||@KOSAN BIOSCIENCES@BMS@@@@KOSAN BIOSCIENCES|BMS|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@KOS-862@R-1492@@@@KOS-862|R-1492|||@Epothilone@@@@@Epothilone||||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918321@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@L01XX11@L01X@NO@HOLZKIRCHEN, GERMANY@@@Estramustine is a chemical compound of oestradiol and nitrogen mustard. It is effective in the treatment of advanced prostatic carcinoma. Estramustine has a dual mode of action. The intact molecule acts as an anti-miotic agent; after hydrolysis of the carbamate ester, the metabolites act to bridge the released oestrogens and exert an anti-gonadotrophic effect. The low level of clinical side effects may be due to the fact that estramustine binds to a protein present in the tumour tissue, so resulting in accumulation of the drug at the target site. Estracyt also has weak oestrogenic and anti-gonadotrophic properties. Estramustine causes little or no bone marrow depression at usual therapeutic dosage. Estramustine is effective in patients who have not previously received drug therapy, as well as in those who have shown no response to conventional hormone treatment.@@14918321@Carcinoma of the prostate, especially in cases unresponsive to, or relapsing after, treatment by conventional oestrogens (stilboestrol, polyestradiol phosphate etc.) or by orchidectomy.@@@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Novartis purchases Hexal and Eon Labs in a 5.65 billion euro deal. [Novartis, 21.02.2005]@@@@Dosage range may be from 1 to 10 capsules a day by mouth. The capsules should be taken not less than 1 hour before or 2 hours after meals. The capsules should not be taken with milk or milk products. Standard starting dosage is 4-6 capsules a day in divided doses with later adjustment according to response and gastrointestinal tolerance.@@@@@@@Use with caution in patients with moderate to severe bone marrow depression, thrombophlebitis, thrombosis, thromboembolic disorders, cardiovascular disease, coronary artery disease and congestive heart failure.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@ESTRAMUSTINE PHOSPHATE SODIUM@@@@@ESTRAMUSTINE PHOSPHATE SODIUM||||@HEXAL@NOVARTIS@@@@HEXAL|NOVARTIS|||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@GENERIC@@@@@GENERIC||||@Oestrogen@Nitrogen Mustard Analogue@@@@Oestrogen|Nitrogen Mustard Analogue|||@@@@@@@@@@@REFRACTORY@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@50@1.1511@58.58@85.05@61.13@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@1.17@1.17@882709@HARD CAPSULE@EURO@@@@@@@@140@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14922679@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Camptosar/Erbitux with or without enzastuarin@@-@-@-@INDIANAPOLIS, INDIANA@@@Enzastaurin is an oral, serine threonine kinase inhibitor which selectively targets the PKCBeta and PI3/AKTsignaling pathways. By blocking these key pathways frequently over-expressed in a wide variety of cancers, enzastaurin suppresses tumor cell proliferation, induces tumor cell death and inhibits tumor-induced angiogenesis. Treatment has been well tolerated with minimal drug-related toxicity. Enzastaurin administration is associated with fatigue, diarrhea, nausea, decreased platelets, cough, vomiting, transaminase elevation, dyspnea, peripheral edema, and dizziness. Further testing in Phase III versus a placebo will provide us with a more complete look at the side effect profile for enzastaurin. In addition to DLBCL, enzastaurin is also being studied in other tumor types including breast, colon, lung, ovarian and prostate cancers@@14922679@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00437268@115@-@-@@@-@@@-@10538H6Q-MC-S018@@-@-@@@II@II@@-@-@Completion expected September 2009.@-@@@@COMBO@ENZASTAURIN@IRINOTECAN@CETUXIMAB@@@ENZASTAURIN|IRINOTECAN|CETUXIMAB||@LILLY@@@@@LILLY||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@LY-317615@CAMPTOSAR@ERBITUX@@@LY-317615|CAMPTOSAR|ERBITUX||@Angiogenesis Inhibitor@@@@@Angiogenesis Inhibitor||||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@RELAPSED@@@@@RANDOMISED@OPEN-LABEL@UNCONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16066131@Onco@@@@@300f1020ntsdm@@@@@@@@L01XX32@L01X@@BEERSE, BELGIUM@@@Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targeted proteolysis, which can affect multiple signaling cascades within the cell. This disruption of normal homeostatic mechanisms can lead to cell death. Experiments have demonstrated that bortezomib is cytotoxic to a variety of cancer cell types in vitro. Bortezomib causes a delay in tumor growth in vivo in nonclinical tumor models, including multiple myeloma.@@16066131@Extension of the indication to allow patients who have received at least one prior therapy (instead of at least two) to be treated. Treatment of patients with multiple myeloma who have received at least one prior therapies and have demonstrated disease progression on the last therapy.@@YES@16-Jun-15@6/16/2015@NO REVIEW@@@@@Ortho Biotech and Janssen-Cilag pay double-digit royalties and other milestones for extra-U.S. marketing rights since the US$15 mil deal (plus US$125 mil following European approval) between Ortho and Millennium in June 2003. Ortho also reimbursed around@SECOND-LINE@@@The recommended starting dose of bortezomib is 1.3 mg/m2 body surface area twice weekly for two weeks (days 1, 4, 8, and 11) followed by a 10-day rest period (days 12-21). This 3-week period is considered a treatment cycle. At least 72 hours should elapse between consecutive doses. It is recommended that patients with a confirmed complete response receive 2 additional cycles beyond a confirmation. It is also recommended that responding patients who do not achieve a complete remission receive a total of 8 cycles.@EMA, 20 April 2005@4/20/2005@4/4/2005@YES@@@@@No@@@ADULT@@@APPROVED@@@SSN@@@@@@MONO@BORTEZOMIB@@@@@BORTEZOMIB||||@JANSSEN CILAG@@@@@JANSSEN CILAG||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@VELCADE@@@@@VELCADE||||@Proteasome Inhibitor@@@@@Proteasome Inhibitor||||@@@@@@@@@@@ADVANCED@@@@@@@@@@1.75@m²@24403.6@@@168@day@168 day@24403.6@24403.6@145.26@1@1.1229@1173.25@1936.33@1226.06@@@@@@@@@@335.21@21@@mg/m²@1.3@4@@@@@@@@@@@6/7/2017@1173.25@1173.25@36559019@POWDER FOR INJECTION SOLUTION - 3.5 ML@EURO@@@@@@@@3.5@MG@3.5 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14921661@Onco@@@@@@@@@@@ARM1: Sutent 50 mg capsule OD PO for 28 days followed by 14 days of rest until tumour progression. ARM2: Placebo 50 mg capsule OD PO for 28 days then 14 days rest until disease progression@@L01XE04@L01X@-@NEW YORK, NEW YORK@@@Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFR? and PDGFRß), vascular endothelial growth factor receptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays. Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFRß, VEGFR2, KIT) in tumor xenografts expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit PDGFRß- and VEGFR2-dependent tumor angiogenesis in vivo.@@14921661@Bronchoalevolar carcinoma or never-somkers with any lung adenocarcinoma@@-@-@@NO REVIEW@@@@-@Acquired through takeover of Pharmacia Corp., which acquired it from Sugen@-@NCT00430261@10@-@-@@@-@@1/1/2007@-@CRC 05160@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@SUNITINIB MALEATE@@@@@SUNITINIB MALEATE||||@PFIZER@@@@@PFIZER||||@Sweden@@@@@Sweden|||||||||@NSCLC@@@@@NSCLC|||||||||@SUTENT@@@@@SUTENT||||@TK Inhibitor@VEGF@PDGF@SCF@@TK Inhibitor|VEGF|PDGF|SCF|@PROGRESSION-FREE SURVIVAL@TIME TO PROGRESSION@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14917254@Onco@@@@@300f1037ntsdm@@@@@@404 patients received Casodex 50mg once-daily, 409 received flutamide 250mg three-times daily, each in combination with goserelin acetate implant or leuprolide acetate depot.@@L02BB03@L02B@NO@LONDON, UNITED KINGDOM@@@Casodex is a non-steroidal antiandrogen, devoid of other endocrine activity. It binds to androgen receptors without activating gene expression, and thus inhibits the androgen stimulus. Regression of prostatic tumours results from this inhibition. Clinically, discontinuation of Casodex can result in antiandrogen withdrawal syndrome in a subset of patients. Casodex is a racemate with its antiandrogenic activity being almost exclusively in the (R)-enantiomer.@@14917254@Indicated for use in combination therapy with an LH-RH analogue for the treatment of Stage D2 metastatic carcinoma of the prostate.@@NO@@@NO REVIEW@@@@90%@@FIRST-LINE@@813@Adult males including the elderly: one tablet (50mg) once a day. Treatment with 'Casodex' should be started at least 3 days before commencing treatment with an LHRH analogue, or at the same time as surgical castration.@HMA, 9 January 1996@1/9/1996@11/20/1996@@@@Rare cases of death or hospitalisation due to severe liver injury have been reported in post-marketing in association with Casdoex use.@N/A@No@@813 PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED PROSTATE CANCER@@@III@APPROVED@@NO REVIEW@SNS@Overall survival was not statistically significant; 52.7% of the Casodex/LHRH group had died, and 57.5% of the flutamide/LHRH group had died.@@@@@COMBO@BICALUTAMIDE@@@@@BICALUTAMIDE||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@CASODEX@@@@@CASODEX||||@Hormone Antagonist@Anti-androgen@@@@Hormone Antagonist|Anti-androgen|||@OVERALL SURVIVAL@@@@@@@@@@METASTATIC@@@@@MULTI-CENTRE@DOUBLE-BLIND@CONTROLLED@@@@@Invalid Dosage Value Phase 1@@@160@week@160 week@@@@30@1.1807@27.14@42.37@29.39@@@@@@@@@@0.02@@@@@@@@@@@@@@@@8/23/2017@0.9@0.9@679910@FILM-COATED TABLET@EURO@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
16671825@Onco@@@@@300f1010ntsdm@@@@@@@@L01XC06@L01X@@NEW YORK, NEW YORK@@@Erbitux is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Cetuximab is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions and has an approximate molecular weight of 152 kDa. Cetuximab is produced in mammalian (murine myeloma) cell culture.@@16671825@Treatment of patients with epidermal growth factor receptor (EGFR)-expressing, KRAS wild-type metastatic colorectal cancer in combination with FOLFOX4@Both@YES@@@@@@@100%@>> Acquisition completed. [Lilly, 24.11.2008]          >> Lilly acquires ImClone for US$6.5 billion. [Lilly, 7.10.2008]        >> BMS Offers US$4.3Billion for ImClone or US$60.0 per share in cash. [BMS, 1 August 2008]      >> ImClone licensed co-development and co-promotion rights to BMS in North America and Japan, and to Merck KGaA in Europe.@@@337@@EMA, 23 June 2011@6/23/2011@@No@@@@EMR 62 202-047@No@@@(EGFR)-expressing, KRAS WILD-TYPE@ADULTS@@APPROVED@@@NHS@@@@@@COMBO@CETUXIMAB@OXALIPLATINE@LEUCOVORIN@5-FLOUROURACIL@@CETUXIMAB|OXALIPLATINE|LEUCOVORIN|5-FLOUROURACIL|@BMS@IMCLONE@MERCK SERONO@@@BMS|IMCLONE|MERCK SERONO||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ERBITUX@FOLFOX4@@@@ERBITUX|FOLFOX4|||@mAb@Chimeric@TK Inhibitor@EGFR@@mAb|Chimeric|TK Inhibitor|EGFR|@@@@@@@@@@@METASTATIC@@@@@@@@@@1.75@m²@41095.6845@@@12@month@12 month@41095.68@41095.68@112.59@1@1.299@890.5@@@@@@@@@@@@1.78@7@1@mg/m²@400@1@7@@mg/m²@250@1@@@@@@7/28/2017@890.5@890.5@1.15E+16@SOLUTION FOR IV INFUSION - 100 ML@GB£@@@@@@@@500@MG@5 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
16384802@Onco@@@@@300f1010ntsdm@@@@@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384802@Indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.@@NO@@@NO REVIEW@@@@100%@@FIRST-LINE@@@The recommended dose of Glivec is 600 mg/day for adult patients with Ph+ ALL.@@@@Yes@@@@@No@@@ADULT@@@APPROVED@@NO NICE REVIEW@NHS@@@@@@BOTH@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@@@@Haematological Malignancy|Acute Lymphocytic Leukaemia||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@@@@@@@@@@@1@1@35526.18@@@1@year@1 year@35526.18@35526.18@97.33@60@1.299@973.32@@@@@@@@@@@@0.16@1@@mg@600@1@@@@@@@@@@@7/28/2017@16.22@16.22@8.09E+15@FILM-COATED TABLET@GB£@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14918259@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@M04AA01@M04A@NO@GERMANY@@@@@14918259@Indicated in the management of patients with signs and symptomas of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephroptahy; the management of patients with leukaemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment should be discontinued when the potential for overproduction of uric acid is no longer presents; and, the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800mg/day in male patients and 750mg/day in female patients. This is not an innocuous drug. It is not recommended for the treatment of asymptomatic hyperuricemia.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@Dosage in Adults: should be introduced at low dosage e.g. 100mg/day to reduce the risk of adverse reactions and increased only if the serum urate response is unsatisfactory. Extra caution should be exercised if renal function is poor. The following dosage schedules are suggested: 100 to 200 mg daily in mild conditions, 300 to 600 mg daily in moderately severe conditions, 700 to 900 mg daily in severe conditions. If dosage on a mg/kg bodyweight basis is required, 2 to 10 mg/kg bodyweight/day should be used. Dosage in children: Children under 15 years: 10 to 20 mg/kg bodyweight/day up to a maximum of 400 mg daily. Use in children is rarely indicated, except in malignant conditions (especially leukaemia) and certain enzyme disorders such as Lesch-Nyhan syndrome.@@@@@@@Should be discontinued at the first appearance of skin rash or other signs which may indicate an allergic rection. Dose should be adjusted if co-administered with Purinethol or Imuran.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@ALLOPURINOL@@@@@ALLOPURINOL||||@ABZ PHARMA@@@@@ABZ PHARMA||||@@@@@@|||||||||@Supportive Care@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Non-Hodgkin's Lymphoma@Supportive Care|Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Non-Hodgkin's Lymphoma|||||@GENERIC@@@@@GENERIC||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@100@1.1511@3.4@15.28@4.2@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@0.03@0.03@1014642@TABLET@EURO@@@@@@@@300@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14921312@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@40 mg obatoclax over 3 hrs q/weekly or 60 mg obatoclax over 24 hours, q/weekly; both for 12 weeks, with 4 weeks combo with Rituxan, then another 8 weeks single-agent obatoclax@@-@-@-@-@12/1/2008@@Obatoclax (GX15-070) is a small molecule indole bipyrrole drug compound that was discovered and is being developed at Gemin X. The attractive safety profile and mechanism of action of obatoclax offers the opportunity to treat many forms of cancer as both a single agent and in combination with current treatments. Obatoclax  is a pan-inhibitor of the pro-survival members of the Bcl-2 family of apoptosis regulators. Many of the cellular events that initiate malignant transformation of a normal cell (e.g., activation of oncogenes) also activate oncogenic stress pathways that usually cause the cell to self destruct by a process called apoptosis [3]. In order for these cells to survive and cause cancer, they typically must have acquired changes in other cellular pathways to prevent apoptosis. The Bcl-2 family of proteins are important regulators and executioners of the cellular decision to live or die. Moreover, this family of proteins also dictates whether or not many current cancer therapies are effective, because most of these treatments result in stress signals that ultimately must activate the cancer cell's apoptosis machinery.@@14921312@Previously untreated follicular lymphoma@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00427856@36@-@-@@@-@@3/1/2007@-@GEM014@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@OBATOCLAX MESYLATE@RITUXIMAB@@@@OBATOCLAX MESYLATE|RITUXIMAB|||@GEMIN X@@@@@GEMIN X||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@Follicular lymphoma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|Follicular lymphoma|||||||@GX15-070@RITUXAN@@@@GX15-070|RITUXAN|||@Bcl-2 Inhibitor@@@@@Bcl-2 Inhibitor||||@RESPONSE RATE@SAFETY@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRAVENOUS@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919275@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@REDWOOD, CALIFORNIA@@@Volociximab is a chimeric monoclonal antibody that inhibits the functional activity of a5ß1 integrin, a protein found on activated endothelial cells that are involved in the formation of blood vessels. Volociximab is currently being investigated in Phase 2 clinical trials in patients with advanced solid tumors. PDL BioPharma and Biogen Idec have a broad collaboration for the joint development, manufacture and commercialization of volociximab.@@14919275@-@@-@-@@NO REVIEW@@@@-@Biogen Idec and PDL announced a broad collaboration for the joint development, manufacture and commercialization of three Phase II antibody products. The agreement provides for shared development and commercialization of daclizumab in multiple sclerosis and indications other than transplant and respiratory diseases, and for shared development and commercialization of M200 (volociximab) and HuZAF(TM) (fontolizumab) in all indications. Under terms of the agreement, PDL will receive an upfront payment of $40 million, and Biogen Idec will purchase $100 million of common stock from PDL. If multiple products were developed successfully in multiple indications and all milestones were achieved, PDL could receive certain development and commercialization milestone payments totaling up to $660 million. Of these, $560 million are related to development and $100 million are related to commercialization of collaboration products. Biogen Idec and PDL will share equally the costs of all development activities and all operating profits from each collaboration product within the United States and Europe. The companies will jointly oversee development, manufacturing and commercialization plans for collaboration products and intend to divide implementation responsibilities to leverage each company's capabilities and expertise. Each party will have co-promotion rights in the United States and Europe. Outside the United States and Europe, Biogen Idec will fund all incremental development and commercialization costs and pay a royalty to PDL on sales of collaboration products. [Biogen, 2.08.2005]@FIRST-LINE@NCT00401570@40@-@-@@@-@@@-@M200-1205@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@VOLOCIXIMAB@GEMCITABINE@@@@VOLOCIXIMAB|GEMCITABINE|||@PDL BIOPHARMA@BIOGEN IDEC@@@@PDL BIOPHARMA|BIOGEN IDEC|||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@M-200@GEMZAR@@@@M-200|GEMZAR|||@mAb@Chimeric@Angiogenesis Inhibitor@@@mAb|Chimeric|Angiogenesis Inhibitor||@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922458@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@CP-751,871 given at 20 mg/kg IV on day 1 of each 21 day cycle. Exemestane given at 25 mg orally once a day. Treatment until progression or toxicity. [clinicaltrials.gov]@@-@-@-@NEW YORK, NEW YORK@11/1/2011@@CP-751,871, a fully human monoclonal antibody, is a highly specific inhibitor of the IGF-1R pathway. The IGF-1R pathway is one of the key signaling pathways in cancer cells that lead to uncontrolled growth and survival of tumour cells. @@14922458@CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer@@-@-@@NO REVIEW@@@@-@Acquired through takeover of Pharmacia Corp.@-@NCT00372996@150@-@-@@@-@@2/1/2007@-@A4021004@@-@-@@@II@II@@-@-@Trial registered. [Pfizer, 05.09.2006]@-@@@@COMBO@FIGITUMUMAB@EXEMESTANE@@@@FIGITUMUMAB|EXEMESTANE|||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@CP-751,871@AROMASIN@@@@CP-751,871|AROMASIN|||@mAb@Human@@@@mAb|Human|||@PROGRESSION-FREE SURVIVAL@@@@@SAFETY@PHARMACOKINETICS@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917559@Onco@@@@@300f1010ntsdm@@@@@@Patients receiving cisplatin over 50mg/m2 (mean dose of 80.2mg/m2) were given aprepitant 125mg, dexamethasone 12mg and ondansetraon 32mg IV on day 1, and aprepitant 80mg and dexamethasone 8mg for days 2-3.@@A04AD12@A04A@NO@WHITEHOUSE STATION, NEW JERSEY@@@@@14917559@Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy. Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.Emend is given as part of combination therapy@@NO@NO NICE REVIEW@@NO REVIEW@@@@100%@Japanese rights with Ono.@@@1105@Emend is given for 3 days as part of a regimen that includes a corticosteroid and a 5-HT3 antagonist. The recommended dose is 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) and 80 mg once daily in the morning on Days 2 and 3. Dosing is the same for Days 1-3 for highly and moderately emetogenic cancer chemotherapy.@EMA, November 2003@@@@@@Emend should be used with caution in patients receiving concomitant orally administered medicinal products, including chemotherapy agents that are primarily metabolised through CYP3A4. Moderate inhibition of CYP3A4 by aprepitant, 125 mg/80 mg regimen, could result in elevated plasma concentrations of these concomitant medicinal products. Weak inhibition of CYP3A4 by a single 40 mg dose of aprepitant is not expected to alter the plasma concentrations of concomitant medicinal products that are primarily metabolised through CYP3A4 to a clinically significant degree.@@No@@@@@III; HIGHLY EMETOGENIC CHEMOTHERAPY; 2 RANDOMISED, PARALLEL ASSIGNMENT, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS.@APPROVED@@NO NICE REVIEW@NHS@Complete response was seen in 89% and 78% for the aprepitant and standard groups respectively for the acute phase, and 75% and 56% for the delayed phase.@@@@@COMBO@APREPITANT@@@@@APREPITANT||||@MERCK & CO@@@@@MERCK & CO||||@@@@@@|||||||||@Supportive Care@CINV@PONV@@@Supportive Care|CINV|PONV|||||||@EMEND@@@@@EMEND||||@NK1 Antagonist@@@@@NK1 Antagonist||||@COMPLETE RESPONSE@@@@@@@@@@@@@@@RANDOMISED@PARALLEL ASSIGNMENT@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@Invalid Dosage Value Phase 1@@@@@@41.76@41.76@@3@1.2961@41.49@@47.42@@@@@@@@@@@@@@@@@@@@@@@@@@8/21/2017@13.83@13.83@7.53E+15@HARD CAPSULE (1X 125 MG + 2X 80 MG)@GB£@@@@@@@@@@125 MG + 80 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
15360091@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01XX45@L01X@@SAN FRANCISCO, CALIFORNIA@@@@@15360091@Indicated as a single agent for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy.@Both@@@@NO REVIEW@@@@@@THIRD-LINE@@266@@FDA, 20 July 2012@7/20/2012@@Yes@@@@@No@@Eligible patients were those with relapsed multiple myeloma who had received at least two prior therapies (including bortezomib and thalidomide and/or lenalidomide) and had less than or equal to 25% response to the most recent therapy or had disease progression during or within 60 days of the most recent therapy.@@ADULTS@@APPROVED@@@@The safety and effectiveness of Kyprolis, which is administered directly into a patient's vein (intravenously), was evaluated in a study of 266 patients with relapsed multiple myeloma who had received at least two prior therapies, including Velcade and Thalomid (thalidomide). The study was designed to measure the percentage of patients who experienced complete or partial disappearance of tumor after treatment (overall response rate). The overall response rate was 23 percent. The median duration of response was 7.8 months.[FDA, 20 July 2012, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312920.htm]@The most common side effects observed in more than 30 percent of the study participants were fatigue, low blood cell count and blood platelet levels, shortness of breath, diarrhea, and fever. Serious side effects seen with Kyprolis included heart failure and shortness of breath. Patients should be monitored closely and treatment withheld if these serious side effects occur.[FDA, 20 July 2012, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312920.htm]@@@@MONO@CARFILZOMIB@@@@@CARFILZOMIB||||@ONYX@@@@@ONYX||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@KYPROLIS@@@@@KYPROLIS||||@Proteasome Inhibitor@@@@@Proteasome Inhibitor||||@OVERALL RESPONSE RATE@@@@@@@@@@RELAPSED@REFRACTORY@@@@SINGLE-ARM@MULTICENTER@@@@1.75@m²@81171.78926@@@7.8@month@7.8 month@81171.79@81171.79@342.14@1@1@2048.38@@@@@@@@@@@@34.14@28@1@mg/m²@24.67@6@28@@mg/m²@27@6@@@@@@8/2/2017@2048.38@2048.38@76075-0101-01@LYOPHILISATE FOR SOLUTION FOR INJECTION@US$@@@@@@@@60@MG@60 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16406118@Onco@@@@@300f1037ntsdm@@@@@@Drug: treatment crizotinib 250mg orally continuous twice daily dosingDrug: treatment pemetrexed 500mg/m2 IV day 1 plus cisplatin 75mg/m2 IV day 1 every 21 days OR pemetrexed 500mg/m2 IV day 1 plus carboplatin AUC 5 or 6 day 1 every 21 days investigator's choice@@L01XE16@L01X@@NEW YORK, NEW YORK@11/1/2013@@@@16406118@XALKORI is indicated for the first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).@@YES@16-Jun-16@6/16/2016@NO REVIEW@@@@@Acquired through takeover of Pharmacia Corp., which acquired it from Sugen@FIRST-LINE@NCT01154140@343@The recommended dose schedule of XALKORI is 250 mg twice daily (500 mg daily) taken continuously.@EMA, 23 November 2015@11/23/2015@12/1/2013@No@@1/1/2011@@A8081014, 2010-021336-33, XALCORI@No@@Proven diagnosis of locally advanced not suitable for local treatment, recurrent and metastatic non-squamous cell carcinoma of the lung - Positive for translocation or inversion events involving the ALK gene locus- No prior systemic treatment for locally advanced or metastatic disease; Patients with brain metastases only if treated and neurologically stable with no ongoing requirement for corticosteroids - Evidence of a personally signed and dated informed consent document and willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures including completion of patient reported outcome [PRO] measures - 18 years of age or older with the exception of India which has an upper age limit of 65 years old@(ALK)-positive@@@APPROVED@@@SNS@@@@@@MONO@CRIZOTINIB@@@@@CRIZOTINIB||||@PFIZER@@@@@PFIZER||||@World@@@@@World|||||||||@NSCLC@@@@@NSCLC|||||||||@XALKORI@@@@@XALKORI||||@PDGF@@@@@PDGF||||@OVERALL SURVIVAL@Objective response rate@DURATION OF RESPONSE@@@OBJECTIVE RESPONSE RATE@@@@@ADVANCED@@@@@RANDOMIZED@PARALLEL ASSIGNMENT@OPEN LABEL@@@1@1@72249.63412@@@10.9@month@10.9 month@72249.63@72249.63@217.92@60@1.1511@5230.2@5497.55@5237.74@@@@@@@@@@0.44@1@@mg@500@1@@@@@@@@@@@8/4/2017@87.17@87.17@694400@CAPSULE@EURO@@@@@@@@200@MG@200 MG@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14916061@Onco@@@@@300f1015ntsdm@@@@@@Actiq for breakthrough cancer pain@@N02AB03@N02A@YES@FRAZER, PENNSYLVANIA@@@Fentanyl is a pure opioid agonist whose principal therapeutic action is analgesia. Other members of the class known as opioid agonists include substances such as morphine, oxycodone, hydromorphone, codeine, and hydrocodone.@@14916061@Indicated for the management of breakthrough pain in patients already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.@@NO@@@NO REVIEW@@@@65%@Licensed from Kyowa Hakko; supplied by Abbott. Acquired through US$444 mil. takeover of Anesta Corp in 2000.@@@130@The initial dose of Actiq used should be 200 micrograms, titrating upwards as necessary through the range of available dosage strengths (200, 400, 600, 800, 1200 and 1600 micrograms). Patients should be carefully monitored until a dose is reached that provides adequate analgesia with acceptable side effects using a single dosage unit per episode of breakthrough pain. This is defined as the successful dose.@1-Aug-02@8/1/2002@9/2/2002@@@@Must not be used in opioid non-tolerant patients; fentanyl is a Schedule II controlled substance; life-threatening hypoventilation can occur at any dose; contraindicated in acute or post-operative pain@LABEL@No@@@@@III@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@92 of 130 patients (71% achieved a successful dose during titration. The most successful doses were 400mcg (21%) and 800mcg (20%).@@@@@MONO@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@CEPHALON@@@@@CEPHALON||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@ACTIQ@@@@@ACTIQ||||@Opioid Analgesic@@@@@Opioid Analgesic||||@RESPONSE RATE@MAXIMUM TOLERATED DOSE@@@@@@@@@@@@@@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@3@1.1807@19.71@26.39@21.03@@@@@@@@@@@@@@@@@@@@@@@@@@9/1/2017@6.57@6.57@3.40E+12@TABLET WITH ORAL APPLICATOR@EURO@@@@@@@@200@MCG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
15318117@Onco@@@@@300f1020ntsdm@@@@@@120 mg administered as a single subcutaneous injection once every 4 weeks into the thigh, abdomen or upper arm.@@M05BX04@M05B@-@THOUSAND OAKS, CALIFORNIA@@@Denosumab is a fully human monoclonal antibody that specifically targets the receptor activator of nuclear factor kappa B ligand (“RANKL”), a key mediator of the cells responsible for bone breakdown. Denosumab is being studied across a range of conditions, including osteoporosis, treatment-induced bone loss, bone metastases, rheumatoid arthritis, and multiple myeloma.@@15318117@Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumours.@@YES@21-Feb-13@2/21/2013@NO REVIEW@@@@@Japanese rights licensed to Daiichi Sankyo for US$20 mil upfront and royalties in July 2007, and Daiichi Sankyo will pay US$150 mil of expected worldwide development costs through 2009.@-@@2862@The recommended dose of XGEVA for the prevention of skeletal related events is 120 mg administered as a single subcutaneous injection once every 4 weeks into the thigh, abdomen or upper arm.@EMA, 15 July 2011@7/15/2011@@NO@@@-@-@No@-@-@@@III@APPROVED@@@SSN@>> Denosumab treatment produced statistically significantly greater increases in bone mineral density (BMD) at the lumbar spine (primary endpoint) and non-vertebral sites compared with placebo at multiple time points. These improvements in BMD were consistent with those seen in other denosumab studies evaluating BMD in women with breast cancer receiving aromatase inhibitor therapy, and in post-menopausal women with low bone mass. [Amgen, 14 July 2008]          >> Trial registered. [Amgen, 02.02.2006]@-@@@@MONO@DENOSUMAB@@@@@DENOSUMAB||||@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Supportive Care@Bone Loss@@@@Supportive Care|Bone Loss||||||||@XGEVA@@@@@XGEVA||||@mAb@Human@RANK Ligand@@@mAb|Human|RANK Ligand||@@@@@@@@@@@-@@@@@@@@@@1@1@8454.778971@@@27.6@month@27.6 month@8454.78@8454.78@10.07@1@1.1229@282@465.42@294.7@@@@@@@@@@2.35@28@@mg@120@1@@@@@@@@@@@6/7/2017@282@282@41300017@SOLUTION FOR INJECTION, 1.7 ML@EURO@@@@@@@@120@MG@120 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14916730@Onco@@@@@300f1014ntsdm@300f1813ntsdm@@@@@Low-dose Temodar for 2 weeks@@-@-@-@KENILWORTH, NEW JERSEY@@@Temozolomide is not directly active but undergoes rapid nonenzymatic conversion at physiologic pH to the reactive compound MTIC. The cytotoxicity of MTIC is thought to be primarily due to alkylation of DNA. Alkylation (methylation) occurs mainly at the O6 and N7 positions of guanine.@@14916730@Low dose Temodar@@-@-@@NO REVIEW@@@@-@Merck & Co and Schering-Plough have announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. Based on the closing price of Merck stock on March 6, 2009, the consideration to be received by Schering-Plough shareholders is valued at $23.61 per share, or $41.1 billion in the aggregate. [Merck & Co, 9 March 2009]@-@NCT00424554@50@-@-@@@-@@6/1/2006@-@P04602@@-@-@@@II@II@@-@-@RESULTS PENDING (recruiting).@-@@@@MONO@TEMOZOLOMIDE@@@@@TEMOZOLOMIDE||||@SCHERING-PLOUGH@MERCK & CO@@@@SCHERING-PLOUGH|MERCK & CO|||@@@@@@|||||||||@Brain Cancer@@@@@Brain Cancer|||||||||@TEMODAR@@@@@TEMODAR||||@Alkylating Agent@@@@@Alkylating Agent||||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@C$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14922544@Onco@@@@@300f1014ntsdm@@@@@@Casodex as immediate hormonal therapy or adjuvant to radical prostatectomy or radiotherapy.@@L02BB03@L02B@NO@LONDON, UNITED KINGDOM@@@Casodex is a non-steroidal antiandrogen, devoid of other endocrine activity. It binds to androgen receptors without activating gene expression, and thus inhibits the androgen stimulus. Regression of prostatic tumours results from this inhibition. Clinically, discontinuation of Casodex can result in antiandrogen withdrawal syndrome in a subset of patients. Casodex is a racemate with its antiandrogenic activity being almost exclusively in the (R)-enantiomer.@@14922544@In patients with locally advanced prostate cancer (T3-T4, any N, M0; T1-T2, N+, M0), Casodex 150 mg is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. Casodex 150 mg is also indicated for the management of patients with locally advanced, non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.@@NO@@@NO REVIEW@@@@100%@@@@8113@The dosage is one 150 mg tablet to be taken orally once a day. Casodex 150 mg should be taken continuously for at least 2 years or until disease progression.@@@@@@@Casodex 150 mg should be used with caution in patients with moderate to severe hepatic impairment.@@No@@@@@III; THREE TRIALS@APPROVED@@Unrestricted reimbursement.@RAMQ@27.4% and 30.7% of all Casodex and placebotreated patients, respectively, had experienced objective disease progression. In the subgroup of locally advanced prostate cancer who did not receive treatment with radical prostatectomy or radiotherapy, immediate therapy with Casodex 150 mg significantly reduced the risk of objective disease progression (Hazard Ratio (HR)= 0.60; 95% CI 0.49 to 0.73). PFS events was 57.6% in the Casodex watchful waiting group, compared to 68.9% in the placebo group, whilst deaths were 49% and 57% respectively.@@@@@@BICALUTAMIDE@@@@@BICALUTAMIDE||||@PHARMEL@@@@@PHARMEL||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@PHL-BICALUTAMIDE@GENERIC@@@@PHL-BICALUTAMIDE|GENERIC|||@Hormone Antagonist@Anti-androgen@@@@Hormone Antagonist|Anti-androgen|||@DISEASE-FREE SURVIVAL@@@@@@@@@@LOCALLY ADVANCED@@@@@PLACEBO-CONTROLLED@DOUBLE-BLIND@@@@@@Invalid Factory Price@@@@@@@@@100@0.7881@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@C$@@@@@@@@150@MG@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14918680@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01AX04@L01A@YES@@@@Dacarbazine is a cytostatic agent. The antineoplastic effect is due to an inhibition of cell growth which is independent of the cell cycle and due to an inhibition of DNA synthesis. An alkylating effect has also been shown and other cytostatic mechanisms may also be influenced by dacarbazine. Dacarbazine is considered not to show an antineoplastic effect by itself. However by microsomal N-demethylation it is quickly converted to 5-amino-imidazole-4-carboxamide and a methyl cation, which is responsible for the alkylating effect of the drug.@@14918680@Dacarbazine is indicated for the treatment of patients with metastatic malignant melanoma. Further indications for dacarbazine as part of combination chemotherapy are: • Hodgkin's disease • Advanced adult soft tissue sarcomas (except mesothelioma, Kaposi sarcoma)@@NO@@@NO REVIEW@@@@100%@@@@@Hodgkin's Disease: Dacarbazine is administered in a daily dose of 375 mg/m2 body surface area i.v. on day 1 and day 15 in combination with doxorubicin, bleomycin and vinblastine for each cycle of ABVD regimen.@EMA, November 1997@@@@@@It is recommended that DTIC-Dome (dacarbazine) be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Hemopoietic depression is the most common toxicity with DTIC-Dome (See WARNINGS). Hepatic necrosis has been reported. Studies have demonstrated this agent to have a carcinogenic and teratogenic effect when used in animals. In treatment of each patient, the physician must weigh carefully the possibility of achieving therapeutic benefit against the risk of toxicity.@NO LABELLED TRIAL@No@@@@@@APPROVED@@NO NICE REVIEW@NHS@NO LABELLED TRIAL@@@@@@DACARBAZINE@@@@@DACARBAZINE||||@MEDAC@@@@@MEDAC||||@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@Melanoma / Skin Cancer@@@Haematological Malignancy|Hodgkin's Lymphoma|Melanoma / Skin Cancer|||||||@GENERIC@@@@@GENERIC||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@METASTATIC@MALIGNANT@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@10@1.299@90@@@@@@@@@@@@0.09@@@@@@@@@@@@@@@@7/28/2017@9@9@7.32E+15@POWDER FOR SOLUTION FOR INJECTION VIAL@GB£@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14920176@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01XX19@L01X@YES@LAKE FOREST, ILLINOIS@@@Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks.@@14920176@Camptosar is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. It is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.@@NO@@@NO REVIEW@@@@@@SECOND-LINE@@@Weekly regimen: Camptosar 125mg/m2 IV over 90 minutes days 1, 8, 15, 22, then two-week rest@FDA, 27 February 2008@2/27/2008@@@@@Can induce both early and late forms of diarrhea. Both forms of diarrhea may be severe. Early diarrhea (occurring during or shortly after infusion may be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping. Late diarrhea (generally occurring more than 24 hours after administration) can be life threatening since it may be prolonged and may lead to dehydration, electrolyte imbalance, or sepsis. Patients with diarrhea should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated or antibiotic therapy if they develop ileus, fever, or severe neutropenia. Severe myelosuppression may also occur.@@No@@@@@@APPROVED@@Covered; part B; specialty drug@MEDICARE@@@@@@MONO@IRINOTECAN@@@@@IRINOTECAN||||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@@@@@@@@@@@ADVANCED@@@@@@@@@@1.75@m²@716.775852@@@3.9@month@3.9 month@716.78@716.78@6.04@1@1@145.02@@@@@@@@@@@@0.29@42@@mg/m²@125@4@@@@@@@@@@@8/2/2017@145.02@145.02@61703-0349-36@INJECTION - 25 ML@US$@@@@@@@@500@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922621@Onco@@@@@300f1014ntsdm@@@@@@404 patients received Casodex 50mg once-daily, 409 received flutamide 250mg three-times daily, each in combination with goserelin acetate implant or leuprolide acetate depot.@@L02BB03@L02B@NO@LONDON, UNITED KINGDOM@@@Casodex is a non-steroidal antiandrogen, devoid of other endocrine activity. It binds to androgen receptors without activating gene expression, and thus inhibits the androgen stimulus. Regression of prostatic tumours results from this inhibition. Clinically, discontinuation of Casodex can result in antiandrogen withdrawal syndrome in a subset of patients. Casodex is a racemate with its antiandrogenic activity being almost exclusively in the (R)-enantiomer.@@14922621@Indicated for use in combination therapy with an LH-RH analogue for the treatment of Stage D2 metastatic carcinoma of the prostate.@@NO@@@NO REVIEW@@@@@@FIRST-LINE@@813@Adult males including the elderly: one tablet (50mg) once a day. Treatment with 'Casodex' should be started at least 3 days before commencing treatment with an LHRH analogue, or at the same time as surgical castration.@@@@@@@Rare cases of death or hospitalisation due to severe liver injury have been reported in post-marketing in association with Casdoex use.@N/A@No@@813 PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED PROSTATE CANCER@@@III@APPROVED@@Unrestricted reimbursement.@RAMQ@Overall survival was not statistically significant; 52.7% of the Casodex/LHRH group had died, and 57.5% of the flutamide/LHRH group had died.@@@@@COMBO@BICALUTAMIDE@@@@@BICALUTAMIDE||||@PHMSCIENCE@@@@@PHMSCIENCE||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@PMS-BICALUTAMIDE@GENERIC@@@@PMS-BICALUTAMIDE|GENERIC|||@Hormone Antagonist@Anti-androgen@@@@Hormone Antagonist|Anti-androgen|||@OVERALL SURVIVAL@@@@@@@@@@METASTATIC@@@@@MULTI-CENTRE@DOUBLE-BLIND@CONTROLLED@@@@@Invalid Dosage Value Phase 1@@@@@@1459.92@1459.92@@30@0.7881@48.3@@@@@@@@@@@@0.03@@@@@@@@@@@@@@@@7/19/2017@1.61@1.61@227558930@TABLET@C$@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14921192@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Biological: dHER2 + AS15 ASCIDrug: Lapatinib@@-@-@-@BRENTFORD, UNITED KINGDOM@7/1/2011@@Lapatinib is a 4-anilinoquinazoline kinase inhibitor of the intracellular tyrosine kinase domains of both Epidermal Growth Factor Receptor (EGFR [ErbB1]) and of Human Epidermal Receptor Type 2 (HER2 [ErbB2]) receptors (estimated Kiapp values of 3nM and 13nM, respectively) with a dissociation half-life of =300 minutes. Lapatinib inhibits ErbB-driven tumor cell growth in vitro and in various animal models. An additive effect was demonstrated in an in vitro study when lapatinib and 5-FU (the active metabolite of capecitabine) were used in combination in the 4 tumor cell lines tested. The growth inhibitory effects of lapatinib were evaluated in trastuzumab-conditioned cell lines. Lapatinib retained significant activity against breast cancer cell lines selected for long-term growth in trastuzumab-containing medium in vitro. These in vitro findings suggest non-cross-resistance between these two agents.@@14921192@A Monocentric, Open-label Phase I/II Study to Assess dHER2+AS15 Cancer Immunotherapeutic Given in Combination With Lapatinib to Patients With ErbB2 Overexpressing Metastatic Breast Cancer Refractory to Trastuzumab@@-@-@@NO REVIEW@@@@-@-@-@NCT00952692@18@-@-@@@-@@7/1/2009@-@GSK-dHER2AS15@@-@-@@@II@II@@-@-@Trial Initiated[GSK 4 August 2009]@@@@@COMBO@LAPATINIB@MAGE-3 RECOMBINANT PHARMACCINE@@@@LAPATINIB|MAGE-3 RECOMBINANT PHARMACCINE|||@GSK@@@@@GSK||||@@@@@@|||||||||@Breast Cancer@HER2+@@@@Breast Cancer|HER2+||||||||@TYKERB@MAGE-3 RECOMBINANT PHARMACCINE@@@@TYKERB|MAGE-3 RECOMBINANT PHARMACCINE|||@TK Inhibitor@HER2@EGFR@@@TK Inhibitor|HER2|EGFR||@SAFETY@@@@@RESPONSE RATE@@@@@METASTATIC@REFRACTORY@@@@OPEN-LABEL@SINGLE ARM@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16671829@Onco@@@@@300f1015ntsdm@@@@@@@@L01XC06@L01X@@NEW YORK, NEW YORK@@@Erbitux is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Cetuximab is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions and has an approximate molecular weight of 152 kDa. Cetuximab is produced in mammalian (murine myeloma) cell culture.@@16671829@Treatment of patients with epidermal growth factor receptor (EGFR)-expressing, KRAS wild-type metastatic colorectal cancer in combination with FOLFOX4@Both@YES@@@@@@@@>> Acquisition completed. [Lilly, 24.11.2008]          >> Lilly acquires ImClone for US$6.5 billion. [Lilly, 7.10.2008]        >> BMS Offers US$4.3Billion for ImClone or US$60.0 per share in cash. [BMS, 1 August 2008]      >> ImClone licensed co-development and co-promotion rights to BMS in North America and Japan, and to Merck KGaA in Europe.@@@337@@EMA, 23 June 2011@6/23/2011@@No@@@@EMR 62 202-047@No@@@(EGFR)-expressing, KRAS WILD-TYPE@ADULTS@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@@@@@@COMBO@CETUXIMAB@OXALIPLATINE@LEUCOVORIN@5-FLOUROURACIL@@CETUXIMAB|OXALIPLATINE|LEUCOVORIN|5-FLOUROURACIL|@BMS@IMCLONE@MERCK SERONO@@@BMS|IMCLONE|MERCK SERONO||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ERBITUX@FOLFOX4@@@@ERBITUX|FOLFOX4|||@mAb@Chimeric@TK Inhibitor@EGFR@@mAb|Chimeric|TK Inhibitor|EGFR|@@@@@@@@@@@METASTATIC@@@@@@@@@@1.75@m²@38023.08408@@@12@month@12 month@38023.08@38023.08@104.18@1@1.1511@823.92@@@@@@@@@@@@1.65@7@1@mg/m²@400@1@7@@mg/m²@250@1@@@@@@8/2/2017@823.92@823.92@9301111T@SOLUTION FOR PERFUSION 100 ML@EURO@@@@@@@@500@MG@5 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@85@France
16384830@Onco@@@@@300f1018ntsdm@@@@@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384830@Indicated for the adjuvant treatment of adult patients who are at significant risk of relapse followingresection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrenceshould not receive adjuvant treatment.@@NO@@@@@@@100%@@@@@The recommended dose of Glivec is 400 mg/day for the adjuvant treatment of adult patients followingresection of GIST. Optimal treatment duration is not yet established. Length of treatment in theclinical trial supporting this indication was 36 months@@@@Yes@@@@@No@@@@@@APPROVED@@@PBS@@@@@@ADJUVANT@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Sarcoma@GIST@@@@Sarcoma|GIST||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@@@@@@@@@@@1@1@105816.2907@@@36@month@36 month@105816.29@105816.29@96.64@30@0.779@2899.14@3047.02@2969.08@@@@@@@@@@0.24@1@@mg@400@1@@@@@@@@@@@8/1/2017@96.64@96.64@1632-1271-GE-AF@TABLET@A$@@@@@@@@400@MG@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14920800@Onco@@@@@300f1020ntsdm@@@@@@Kytril Injection at a dose of 40 mcg/kg was administered for 2, 4 or at least 6 cycles of chemotherapy@@A04AA02@A04A@NO@BASEL, SWITZERLAND@@@Granisetron is a potent anti-emetic and highly selective antagonist of 5-hydroxytryptamine (5-HT3) receptors. Radioligand binding studies have demonstrated that Granisetron has negligible affinity for other receptor types including 5-HT and dopamine D2 binding sites. Granisetron is effective orally prophylactically in abolishing the retching and vomiting evoked by cytostatic therapy.@@14920800@Kytril Injection is indicated for a) the prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin and b) the prevention and treatment of postoperative nausea and vomiting. Kytril Injection is recommended even where the incidence of postoperative nausea and/or vomiting is low.@@NO@-@@NO REVIEW@@@@100%@-@-@-@512@Adults The dose of Kytril is 1mg twice a day or 2mg once a day during cytostatic therapy. The first dose of Kytril should be administered within one hour before the start of cytostatic therapy. Concomitant use of dexamethasone: The efficacy of Kytril may be enhanced by the addition of dexamethasone. Maximum Dose and Duration of Treatment: Kytril is also available as ampoules for intravenous administration. The maximum dose of Kytril administered orally and/or intravenously over 24 hours should not exceed 9mg.@N/A@@@-@@@Hypersensitivity reactions may occur in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.@-@No@-@512 CANCER PATIENTS RECEIVED KYTRIL INJECTION, PROPHYLACTICALLY, FOR TWO CYCLES OF CHEMOTHERAPY, 224 PATIENTS RECEIVED IT FOR AT LEAST FOUR CYCLES, AND 108 PATIENTS RECEIVED IT FOR AT LEAST SIX CYCLES.@@@CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING / REPEAT-CYCLE CHEMOTHERAPY@APPROVED@@@SSN@Kytril Injection efficacy remained relatively constant over the first six repeat cycles, with complete response rates (no vomiting and no moderate or severe nausea in 24 hours) of 60% to 69%.@-@@@@MONO@GRANISETRON HYDROCHLORIDE@@@@@GRANISETRON HYDROCHLORIDE||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@KYTRIL@@@@@KYTRIL||||@5-HT3 Receptor Antagonist@@@@@5-HT3 Receptor Antagonist||||@RESPONSE RATE@@@@@@@@@@-@@@@@UNCONTROLLED@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@5@1.1229@35.4@58.43@37@@@@@@@@@@3.54@@@@@@@@@@@@@@@@6/7/2017@7.08@7.08@28093084@FILM-COATED TABLET@EURO@@@@@@@@2@MG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14919098@Onco@@@@@300f1015ntsdm@@@@@@Patients are randomised to doxycycline 100mg po daily or no preventative treatment whilst on Tarceva 150mg/kg/po daily.@@L01XE03@L01X@-@BASEL, SWITZERLAND@@@The mechanism of clinical antitumor action of erlotinib is not fully characterized. Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR). Specificity of inhibition with regard to other tyrosine kinase receptors has not been fully characterized. EGFR is expressed on the cell surface of normal cells and cancer cells.@@14919098@Cancer rash secondary to Tarceva in advanced NSCLC@@-@-@@NO REVIEW@@@@-@">> Roche announces US$43.7 billion proposal to assume full control of Genentech. [Roche, 21 July 2008]      >> To meet FTC requirements for its merger with Warner Lambert, Pfizer was was forced to divest its stake in erlotinib in June 2000 back to OSI. In January 2001, Genentech and Roche licensed global co-development and commercialisation. [OSI, January 2001]       >> Pfizer acquired major stake in Oncogene (now OSI) to form a collaborative research programme. [Oncogene, 8.07.1986]"@-@NCT00531934@100-500 @-@-@@@-@@9/1/2007@-@ML20829  @@-@-@@@II@II@@-@-@RESULTS PENDING (recruiting).@-@@@@-@ERLOTINIB HYDROCHLORIDE@@@@@ERLOTINIB HYDROCHLORIDE||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Supportive Care@@@@@Supportive Care|||||||||@TARCEVA@@@@@TARCEVA||||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@INCIDENCE OF RASH@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TABLET@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14916225@Onco@@@@@300f1012ntsdm@@@@@@Actiq for breakthrough cancer pain@@N02AB03@N02A@YES@FRAZER, PENNSYLVANIA@@@Fentanyl is a pure opioid agonist whose principal therapeutic action is analgesia. Other members of the class known as opioid agonists include substances such as morphine, oxycodone, hydromorphone, codeine, and hydrocodone.@@14916225@Indicated only for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Patients considered opioid tolerant are those who are taking at least 60 mg of oral morphine/day, at least 25 mcg of transdermal fentanyl/hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer. This product must not be used in opioid non-tolerant patients because life-threatening hypoventilation could occur at any dose in patients not on a chronic regimen of opiates. September 2007: Dear Healthcare Professional letter issued to emphasise that it is not generic Actiq and ensure non-use in opioid non-tolerant patients or non-labelled indications.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@130@The initial dose of Actiq used should be 200 micrograms, titrating upwards as necessary through the range of available dosage strengths (200, 400, 600, 800, 1200 and 1600 micrograms). Patients should be carefully monitored until a dose is reached that provides adequate analgesia with acceptable side effects using a single dosage unit per episode of breakthrough pain. This is defined as the successful dose.@@@@@@@Must not be used in opioid non-tolerant patients; fentanyl is a Schedule II controlled substance; life-threatening hypoventilation can occur at any dose; contraindicated in acute or post-operative pain@LABEL@No@@@@@III@APPROVED@@@GKV@92 of 130 patients (71% achieved a successful dose during titration. The most successful doses were 400mcg (21%) and 800mcg (20%).@@@@@MONO@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@CEPHALON@@@@@CEPHALON||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@ACTIQ@@@@@ACTIQ||||@Opioid Analgesic@@@@@Opioid Analgesic||||@RESPONSE RATE@MAXIMUM TOLERATED DOSE@@@@@@@@@@@@@@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@30@1.1807@257.89@337.04@266.72@@@@@@@@@@@@@@@@@@@@@@@@@@8/15/2017@8.6@8.6@1526046@LOZENGE@EURO@@@@@@@@1600@MCG@1600 MCG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14916235@Onco@@@@@300f1010ntsdm@@@@@@Actiq for breakthrough cancer pain@@N02AB03@N02A@YES@FRAZER, PENNSYLVANIA@@@Fentanyl is a pure opioid agonist whose principal therapeutic action is analgesia. Other members of the class known as opioid agonists include substances such as morphine, oxycodone, hydromorphone, codeine, and hydrocodone.@@14916235@Indicated for the management of breakthrough pain in patients already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.@@NO@@@NO REVIEW@@@@100%@Licensed from Kyowa Hakko; supplied by Abbott. Acquired through US$444 mil. takeover of Anesta Corp in 2000.@@@130@The initial dose of Actiq used should be 200 micrograms, titrating upwards as necessary through the range of available dosage strengths (200, 400, 600, 800, 1200 and 1600 micrograms). Patients should be carefully monitored until a dose is reached that provides adequate analgesia with acceptable side effects using a single dosage unit per episode of breakthrough pain. This is defined as the successful dose.@EMA, August 2002@@@@@@Must not be used in opioid non-tolerant patients; fentanyl is a Schedule II controlled substance; life-threatening hypoventilation can occur at any dose; contraindicated in acute or post-operative pain@LABEL@No@@@@@III@APPROVED@@NO NICE REVIEW@NHS@92 of 130 patients (71% achieved a successful dose during titration. The most successful doses were 400mcg (21%) and 800mcg (20%).@@@@@MONO@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@CEPHALON@@@@@CEPHALON||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@ACTIQ@@@@@ACTIQ||||@Opioid Analgesic@@@@@Opioid Analgesic||||@RESPONSE RATE@MAXIMUM TOLERATED DOSE@@@@@@@@@@@@@@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@30@1.2961@210.41@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/21/2017@7.01@7.01@2.69E+15@LOZENGE@GB£@@@@@@@@200@MCG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14924251@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@TOKYO, JAPAN@@@Dacogen was approved by the U.S. Food and Drug Administration on May 2, 2006 and is indicated for the treatment of patients with MDS, including previously treated and untreated, de novo and secondary MDS of all French-American-British (FAB) subtypes (refractory anemia, refractory anemia with rings sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, chronic myelomonocytic leukemia), and Intermediate-1, Intermediate-2, and High-Risk International Prognostic Scoring System (IPSS) groups.@@14924251@-@@-@-@@NO REVIEW@@@@-@Dacogen for Injection was developed through a pivotal Phase 3 study by SuperGen and partnered to MGI  (acquired by Eisai Co., Ltd.). MGI subsequently sublicensed all Dacogen rights outside of North America to Janssen-Cilag, a Johnson & Johnson Company.@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@-@DECITABINE@@@@@DECITABINE||||@EISAI@MGI PHARMA@SUPERGEN@@@EISAI|MGI PHARMA|SUPERGEN||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@DACOGEN@@@@@DACOGEN||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921692@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Nasalfent monotherapy@@N02AB03@N02A@-@READING, UNITED KINGDOM@@@Fentanyl is a synthetic opiate with a clinical potency of 50 to 100 times that of morphine. Its onset of action is rapid and its duration of action is short. In man, a single iv dose of 0.5-1 mg/70 kg body weight immediately produces a pronounced state of surgical analgesia, respiratory depression, bradycardia and other typical morphine-like effects. The duration of action of the peak effects is about 30 minutes. All potent morphine-like drugs produce relief from pain, ventilatory depression, emesis, constipation, physical dependence, certain vagal effects and varying degrees of sedation. Fentanyl, however, differs from morphine not only by its short duration of action but also by its lack of emetic effect and minimal hypotensive activity in animals. @@14921692@Long-term safety study@@-@-@@NO REVIEW@@@@-@All rights@-@NCT00459277@180@-@-@@@-@@12/1/2006@-@CPO4306FCNS@@-@-@@@III@III@@-@-@Completion due in February 2008.@-@@@@MONO@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@ARCHIMEDES PHARMA@@@@@ARCHIMEDES PHARMA||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@NASALFENT@@@@@NASALFENT||||@Opioid Analgesic@@@@@Opioid Analgesic||||@PAIN RELIEF@SAFETY@@@@@@@@@-@@@@@RANDOMISED@PLACEBO-CONTROLLED@CROSSOVER@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRANASAL@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916020@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Treatment is given every 2 weeks for 4 doses. Patients with CR/PR/SD may continue until PD or a max of 8 doses. All patients will complete 3 months of follow-up. Administration of XmAb2513 (0.3, 1.0, 3.0, 6.0, 9.0 , 12.0 mg/kg) IV over 2 hours. Initial dosing will occur using an accelerated dose escalation design. Dose escalation will be divided into two segments: the initial accelerated escalation phase and the standard escalation phase. During the initial accelerated dose escalation phase, dose escalation may occur after treatment of one patient per cohort provided that there is no DLT and no Grade 2 or greater, treatment-related toxicity. Treatment-related is defined as probably or possibly related to study drug. The dose escalation safety assessment period will include data from the first 4 weeks of treatment (2 doses or one cycle). SOURCE: clinicaltrials.gov@@-@-@-@-@2/1/2009@@@@14916020@Hodgkin's lymphoma and anaplastic large cell lymphoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00606645@48@-@-@@@-@@12/1/2007@-@XmAb2513-01@@-@-@@@I@I@@-@-@Endpoint over 1 year.@-@@@@MONO@-@@@@@-||||@XENCOR@@@@@XENCOR||||@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@@@@Haematological Malignancy|Hodgkin's Lymphoma||||||||@XMAB-2513@@@@@XMAB-2513||||@mAb@Humanised@CD30@@@mAb|Humanised|CD30||@MAXIMUM TOLERATED DOSE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924409@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NO LABELLED TRIAL@@@@YES@PETACH TIKVA, ISRAEL@@@@@14924409@Zanosar is indicated in the treatment of metastatic islet cell carcinoma of the pancreas. Responses have been obtained with both functional and nonfunctional carcinomas. Because of its inherent renal toxicity, therapy with this drug should be limited to patients with symptomatic or progressive metastatic disease.@@NO@@@NO REVIEW@@@@@Acquired through takeover of Sicor@@@@Daily Schedule—The recommended dose for daily intravenous administration is 500 mg/m2 of body surface area for five consecutive days every six weeks until maximum benefit or until treatment-limiting toxicity is observed. Dose escalation on this schedule is not recommended.@FDA, 7 May 1982@5/7/1982@@@@@Zanosar should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. A patient need not be hospitalized but should haveaccess to a facility with laboratory and supportive resources sufficient to monitor drug tolerance and to protect and maintain a patient compromised by drug toxicity. Renal toxicity is dose-related and cumulative and may be severe or fatal. Other major toxicities are nausea and vomiting which may be severe and at times treatment-limiting. In addition, liver dysfunction, diarrhea, and haematological changes have been observed in some patients. Streptozocin is mutagenic. When administered parenterally, it has been found to be tumourigenic or carcinogenic in some rodents.@NO LABELLED TRIAL@No@N/A@@@@@APPROVED@@@MEDICARE@NO LABELLED TRIAL@@@@@@STREPTOZOCIN@@@@@STREPTOZOCIN||||@TEVA PHARMACEUTICAL@@@@@TEVA PHARMACEUTICAL||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@ZANOSAR@@@@@ZANOSAR||||@Alkylating Agent@Nitrosourea@@@@Alkylating Agent|Nitrosourea|||@@@@@@@@@@@METASTATIC@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@US$@@@@@@@@1@G@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922616@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Gleevec 400MG PO twice daily with letrozole 2.5MG PO once daily@@L02BG04@L02B@-@BASEL, SWITZERLAND@2/1/2008@@The elimination of oestrogen-mediated stimulatory effects is a prerequisite for tumour response in cases where the growth of tumour tissue depends on the presence of oestrogens. In postmenopausal women, oestrogens are mainly derived from the action of the aromatase enzyme, which converts adrenal androgens - primarily androstenedione and testosterone - to oestrone (E1) and oestradiol (E2). The suppression of oestrogen biosynthesis in peripheral tissues and the cancer tissue itself can therefore be achieved by specifically inhibiting the aromatase enzyme. Letrozole is a non-steroidal aromatase inhibitor. It inhibits the aromatase enzyme by competitively binding to the haem of the cytochrome P450 subunit of the enzyme, resulting in a reduction of oestrogen biosynthesis in all tissues.@@14922616@Letrozole (Femara) Plus Imatinib Mesylate (Gleevec) for Postmenopausal Patients With ER and/or PR Positive Metastatic Breast Cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00338728@45@-@-@@@-@@10/1/2003@-@2003-0384@@-@-@@@II@II@@-@-@Trial registered. [Novartis, 16.06.2006]@-@@@@COMBO@LETROZOLE@IMATINIB MESYLATE@@@@LETROZOLE|IMATINIB MESYLATE|||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@FEMARA@GLEEVEC@GLIVEC@@@FEMARA|GLEEVEC|GLIVEC||@Hormone Antagonist@Aromatase Inhibitor@@@@Hormone Antagonist|Aromatase Inhibitor|||@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924546@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@L02AE02@L02A@-@-@@@This is a synthetic nonapeptide analogue of naturally occurring gonadotrophin releasing hormone (GnRH) which possesses greater potency than the natural hormone. It is a peptide and therefore unrelated to the steroids. Chronic administration results in an inhibition of gonadotrophin production and subsequent suppression of ovarian and testicular steroid secretion. This effect is reversible on discontinuation of therapy. Administration of leuprorelin acetate results in an initial increase in circulating levels of gonadotrophins which leads to a transient increase in gonadal steroid levels in both men and women. Continued administration of leuprorelin acetate results in a decrease of gonadotrophin and sex steroid levels. In men serum testosterone levels, initially raised in response to early luteinising hormone (LH) release, fall to castrate levels in about 2-4 weeks. Oestradiol levels will decrease to postmenopausal levels in premenopausal women within one month of initiating treatment.@@14924546@Multiple myeloma; enhance immune function following bone marrow transplant@@-@-@@NO REVIEW@@@@-@Abbott/Takeda joint venture TAP Pharmaceuticals dissolved. Abbott received rights to Lupron franchise; Takeda received the remaining organisation and pipeline - though Abbott receives payments based on TAP's current and future products. SOURCE: Takeda, 19@-@NCT00275262@80@-@-@@@-@@2/1/2006@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING; expected completion in January 2010.@-@@@@-@LEUPROLIDE ACETATE@@@@@LEUPROLIDE ACETATE||||@ABBOTT@TAP PHARAMACEUTICALS@@@@ABBOTT|TAP PHARAMACEUTICALS|||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@LUPRON DEPOT@@@@@LUPRON DEPOT||||@LH-RH Analog@@@@@LH-RH Analog||||@RESPONSE RATE@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14923892@Onco@@@@@300f1010ntsdm@@@@@@142 urinary bladder carcinoma patients (69 CIS and 73 non-CIS) received doxorubicin and 143 with Theracys (70 CIS and 73 non-CIS).@@@@YES@PARIS, FRANCE@@@@@14923892@Indicated for intravesical use in the treatment of carcinoma in situ (CIS) in the absence of an associated invasive cancer of the bladder in the following situations: 1) primary treatment of CIS with or without papillary tumors after TUR, 2) secondary treatment of CIS in patients failing to respond or relapsing after intravesical therapy with other agents, 3) primary or secondary treatment of CIS for patients with medical contraindications to radical surgery. It is not indicated for the prevention of papillary tumors after TUR or for the treatment of papillary tumors occurring alone.@@@@@NO REVIEW@@@@100%@Sanofi Pasteur is a subsidiary of sanofi-aventis.@SECOND-LINE@@285@One dose consists of the intravesical instillation of 81 mg (dry weight) BCG. This dose is prepared by reconstituting the vial containing freeze-dried BCG with the contents of the vial containing diluent. The vial of reconstituted BCG is further diluted in 50 mL of sterile, preservative-free saline, for a total of 53 mL instillation volume.@@@@@@@TheraCys contains live, attenuated mycobacteria. Because of the potential risk for transmission, it should be prepared, handled, and disposed of as a biohazard material. BCG infections have been reported in health-care workers, primarily from exposures resulting from accidental needle sticks or skin lacerations during the preparation of BCG for administration. Nosocomial infections have been reported in immunosuppressed patients receiving parenteral drugs which were prepared in areas in which BCG was prepared. BCG is capable of dissemination when administered by the intravesical route, and serious infections, including fatal infections, have been reported in patients receiving intravesical BCG.@LABEL@No@@@@@III@APPROVED@@@NHS@Complete RR within 6 months was 33% and 71% with doxorubicin and Theracys respectively in the CIS population. DFS at 2 years was 23% and 51% respectively. Median DFS was 4.9 and 30 months respectively.@@@@@MONO@BACILLUS CALMETTE-GUERIN@@@@@BACILLUS CALMETTE-GUERIN||||@SANOFI-AVENTIS@SANOFI PASTEUR@@@@SANOFI-AVENTIS|SANOFI PASTEUR|||@@@@@@|||||||||@Bladder Cancer@@@@@Bladder Cancer|||||||||@THERACYS@@@@@THERACYS||||@Immunotherapy@@@@@Immunotherapy||||@RESPONSE RATE@DISEASE-FREE SURVIVAL@@@@@@@@@@@@@@RANDOMISED@MULTI-CENTRE@@@@@@Invalid Factory Price@@@@@@@@@1@1.299@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@GB£@@@@@@@@81@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14921526@Onco@@@@@300f1037ntsdm@@@@@@NO LABELLED TRIAL@@L01CA04@L01C@YES@CASTRES, FRANCE@@@Navelbine is an antineoplastic drug of the vinca alkaloid family but unlike all the other vinca alkaloids, the catharantine moiety of vinorelbine has been structurally modified. At the molecular level, it acts on the dynamic equilibrium of tubulin in the microtubular apparatus of the cell. It inhibits tubulin polymerization and binds preferentially to mitotic microtubules, affecting axonal microtubules at high concentrations only. The induction of tubulin spiralization is less than that produced by vincristine. Navelbine blocks mitosis at G2-M, causing cell death in interphase or at the following mitosis.@@14921526@As a single agent or in combination for the first line treatment of stage 3 or 4 non small cell lung cancer. - Treatment of advanced breast cancer stage 3 and 4 relapsing after or refractory to an anthracycline containing regimen.@@YES@@@NO REVIEW@@@@@@@@@As a single agent: The recommended regimen is :First three administrations: 60mg/m² of body surface area, administered once weekly. Subsequent administrations: Beyond the third administration, it is recommended to increase the dose of Navelbine soft capsules to 80mg/m² once weekly except in those patients for whom the neutrophil count dropped once below 500/mm3 or more than once between 500 and 1000/mm3 during the first three administrations at 60mg/m².@1-Apr-04@4/1/2004@@@@@Vinorelbine should be administered in carefully adjusted doses by or under the supervision of a chemo-experienced physician. Patients treated with vinorelbine should be frequently monitored for myelosuppression both during and after therapy. Granulocytopaenia is dose-limiting. Granulocyte nadirs occur between 7 and 10 days after dosing with granulocyte count recovery usually within the following 7 to 14 days. Complete blood counts with differentials should be performed and results reviewed prior to administering each dose of vinorelthose@NO LABELLED TRIAL@No@EXPIRED@@@@@APPROVED@@NO REVIEW@SNS@NO LABELLED TRIAL@@@@@BOTH@VINORELBINE TARTRATE@CISPLATIN@@@@VINORELBINE TARTRATE|CISPLATIN|||@PIERRE FABRE@@@@@PIERRE FABRE||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@NAVELBINE@@@@@NAVELBINE||||@Plant Alkaloid@Vinca Alkaloids@@@@Plant Alkaloid|Vinca Alkaloids|||@@@@@@@@@@@ADVANCED@REFRACTORY@@@@@@@@@@@Invalid Dosage Value Phase 1@@@1@year@1 year@33701.12@33701.12@92.33@1@1.1511@67.8@105.84@73.36@@@@@@@@@@2.26@@@@@@@@@@@@@@@@8/4/2017@67.8@67.8@843797@CAPSULE@EURO@@@@@@@@30@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
16384764@Onco@@@@@300f1008ntsdm@@@@@@Patients were treated with Gleevec 340 mg/m2/day, with no interruptions in the absence of dose limiting toxicity.@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384764@Pediatric patients with newly diagnosed, Philadelphia-chromosome-positive, chronic myeloid leukemia (CML) in chronic phase.@@NA@@@@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@FIRST-LINE@@51@Pediatric Patients with Ph+ CML: The recommended dose of Gleevec for children with newly diagnosed Ph+ CML is 340 mg/m2/day (not to exceed 600 mg).@@@@@@@Women of childbearing potential should be advised to avoid becoming pregnant.@@No@@PAEDIATRIC PATIENTS WITH NEWLY DIAGNOSED AND UNTREATED CML IN CHRONIC PHASE WERE TREATED WITH GLEEVEC@PAEDIATRIC@@II; STUDY 2108@APPROVED@@@NHI@@@@@@MONO@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@RESPONSE RATE@@@@@@@@@@CHRONIC PHASE@@@@@OPEN-LABEL@MULTI-CENTRE@SINGLE-ARM@@@1.2@m²@1748727.692@@@6.74@month@6.74 month@1748727.69@1748727.69@8530.22@1@0.0091@2090.74@2465.5@@@@@@@@@@@20.91@1@@mg/m²@340@1@@@@@@@@@@@8/30/2017@2090.74@2090.74@4291011F1028@TABLET@YEN@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
16382367@Onco@@@@@300f1014ntsdm@@@@@@@@M05BX04@M05B@@THOUSAND OAKS, CALIFORNIA@@@Denosumab is a fully human monoclonal antibody that specifically targets the receptor activator of nuclear factor kappa B ligand (“RANKL”), a key mediator of the cells responsible for bone breakdown. Denosumab is being studied across a range of conditions, including osteoporosis, treatment-induced bone loss, bone metastases, rheumatoid arthritis, and multiple myeloma.@@16382367@XGEVA is indicated for the treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity@@NO@@@NO REVIEW@@@@@Japanese rights licensed to Daiichi Sankyo for US$20 mil upfront and royalties in July 2007, and Daiichi Sankyo will pay US$150 mil of expected worldwide development costs through 2009.@@@@The recommended dose of Xgeva for the treatment of giant cell tumour of bone and hypercalcaemia of malignancy is 120 mg administered as a single subcutaneous injection once every 4 weeks into the thigh, abdomen or upper arm with a loading dose of 120 mg on days 8 and 15 of the initial 4-week treatment period.@Health Canada@@3/16/2012@@@@@@No@@@@@@APPROVED@@@RAMQ@@@@@@MONO@DENOSUMAB@@@@@DENOSUMAB||||@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Bone Metastases@@@@@Bone Metastases|||||||||@XGEVA@@@@@XGEVA||||@mAb@Human@RANK Ligand@@@mAb|Human|RANK Ligand||@@@@@@@@@@@RELAPSED@@@@@@@@@@1@1@4586.363257@@@6@month@6 month@4586.36@4586.36@25.13@1@0.7881@538.45@@@@@@@@@@@@4.49@28@1@mg@120@3@28@@mg@120@1@@@@@@7/19/2017@538.45@538.45@23681531@SOLUTION FOR INJECTION@C$@@@@@@@@120@MG@120 MG/1.7 ML@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
16617145@Onco@@@@@300f1010ntsdm@@@@@@Ibrutinib will be supplied as hard gelatin 140-mg capsules for oral (PO) administration. Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis. Ibrutinib will be dispensed to patients in bottles at each visit.Chlorambucil will be supplied as 2-mg tablets for PO administration. Chlorambucil is administered orally on Days 1 and 15 of each 28-day cycle. The starting dosage (Cycle 1) is 0.5 mg/kg. If well tolerated, the Chlorambucil dose can be increased starting at Cycle 2, with increments of 0.1 mg/kg on Day 1 of each cycle to a maximum of 0.8 mg/kg.@@L01XE27@L01X@@BEERSE, BELGIUM@5/1/2015@@Ibrutinib was designed to specifically target and selectively inhibit an enzyme called Bruton's tyrosine kinase (BTK). BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel – regulating apoptosis, adhesion, and cell migration and homing. Through these multiple actions, BTK helps to direct malignant B-cells to lymphoid tissues, thus allowing access to a microenvironment necessary for survival.@@16617145@IMBRUVICA as a single agent is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia@Both@NO@@@NO REVIEW@@@@100%@@FIRST-LINE@NCT01722487@269@420 mg taken orally once daily (three 140 mg capsules once daily); Treatment should continue until disease progression or no longer tolerated by the patient.@EMA, 26 May 2016@5/26/2016@12/29/2014@Yes@@3/1/2013@@PCYC-1115-CA@No@@@@ADULTS@III@APPROVED@@@NHS@@@@@@MONO@IBRUTINIB@@@@@IBRUTINIB||||@JANSSEN PHARMACEUTICAL@@@@@JANSSEN PHARMACEUTICAL||||@@@@@@|||||||||@Chronic Lymphocytic Leukaemia@@@@@Chronic Lymphocytic Leukaemia|||||||||@IMBRUVICA@@@@@IMBRUVICA||||@TK Inhibitor@@@@@TK Inhibitor||||@PROGRESSION FREE SURVIVAL@@@@@OVERALL SURVIVAL@OVERALL RESPONSE RATE@@@@@@@@@RANDOMISED@PARALLEL ASSIGNMENT@OPEN LABEL@@@1@1@Invalid Average Duration of Use@@@@@@@@@90@1.299@4599@@@@@@@@@@@@0.37@1@@mg@420@1@@@@@@@@@@@7/28/2017@51.1@51.1@2.83E+16@CAPSULE@GB£@@@@@@@@140@MG@140 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14921434@Onco@@@@@300f1020ntsdm@@@@@@N/A@@L01A@L01A@YES@BRENTFORD, UNITED KINGDOM@@@@@14921434@Myleran is indicated as conditioning treatment prior to haematopoietic progenitor cell transplantation in patients when the combination of high dose busulfan and cyclophosphamide is considered the best available option. Myleran is indicated for the palliative treatment of the chronic phase of chronic granulocytic leukaemia. Myleran is effective in producing prolonged remission in polycythaemia vera, particularly in cases with marked thrombocytosis. Myleran may be useful in selected cases of essential thrombocythaemia and myelofibrosis.@@NO@-@@NO REVIEW@@@@0%@-@-@-@N/A@• Adults: The recommended dose of busulfan in adult patients is 1 mg/kg every 6 hours for four days, starting seven days prior to transplantation. 60 mg/kg per day of cyclophosphamide is usually given for two days commencing 24 h after the final dose of Busulfan@N/A@@@-@@@Myleran is an active cytotoxic agent for use only under the direction of physicians experienced in the administration of such agents. Immunisation using a live organism vaccine has the potential to cause infection in immunocompromised hosts. Therefore, immunisations with live organism vaccines are not recommended. Myleran should be discontinued if lung toxicity develops.@LABEL@No@-@-@@@N/A@APPROVED@@@@Approximately 90% of adults with previously untreated chronic myelogenous leukemia will obtain haematologic remission with regression or stabilization of organomegaly following the use of busulfan. It has been shown to be superior to splenic irradiation with respect to survival times and maintenance of haemoglobin levels, and to be equivalent to irradiation at controlling splenomegaly. It is not clear whether busulfan unequivocally prolongs the survival of responding patients beyond the 31 months experienced by an untreated group of historical controls. Median survival figures of 31 to 42 months have been reported for several groups of patients treated with busulfan, but concurrent control groups of comparable, untreated patients are not available.@-@@@@MONO@BUSULFAN@@@@@BUSULFAN||||@GSK@@@@@GSK||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@Supportive Care@@@Haematological Malignancy|Chronic Myeloid Leukaemia|Supportive Care|||||||@MYLERAN@@@@@MYLERAN||||@Alkylating Agent@Alkylsulfonates@@@@Alkylating Agent|Alkylsulfonates|||@HAEMATOLOGIC RESPONSE@OVERALL SURVIVAL@@@@@@@@@-@@@@@N/A@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@100@1.1229@236.23@387.84@246.81@@@@@@@@@@1.18@@@@@@@@@@@@@@@@6/7/2017@2.36@2.36@24787018@FILM-COATED TABLET@EURO@@@@@@@@2@MG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14916287@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@NO LABELLED TRIAL@@M04AA01@M04A@NO@WOODCLIFF LAKE, NEW JERSEY@@@@@14916287@Indicated in the management of patients with signs and symptomas of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephroptahy; the management of patients with leukaemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment should be discontinued when the potential for overproduction of uric acid is no longer presents; and, the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800mg/day in male patients and 750mg/day in female patients. This is not an innocuous drug. It is not recommended for the treatment of asymptomatic hyperuricemia.@@NO@@@NO REVIEW@@@@@@@@@For the prevention of uric acid nephropathy during the vigorous therapy of neoplastic disease, treatment with 600 to 800 mg daily for two or three days is advisable together with a high fluid intake. Otherwise similar considerations to the above recommendations for treating patients with gout govern the regulation of dosage for maintenance purposes in secondary hyperuricemia.@@@@@@@Should be discontinued at the first appearance of skin rash or other signs which may indicate an allergic rection. Dose should be adjusted if co-administered with Purinethol or Imuran.@NO LABELLED TRIAL@No@@@@@@APPROVED@@Covered; preferred@MEDICARE@NO LABELLED TRIAL@@@@@@ALLOPURINOL@@@@@ALLOPURINOL||||@PAR PHARMACEUTICAL@@@@@PAR PHARMACEUTICAL||||@@@@@@|||||||||@Supportive Care@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Non-Hodgkin's Lymphoma@Supportive Care|Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Non-Hodgkin's Lymphoma|||||@GENERIC@@@@@GENERIC||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@100@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@49884-0603-01@TABLET@US$@@@@@@@@300@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920969@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Ixempra + Xeloda: IV/Tablet, IV/oral, 40mg/m2 or 32mg/m2; 1000mg/m2, D1/2xd 1-14, up to 48 weeks versus Taxotere/Xeloda: IV/Tablet, IV/oral, 75mg/m2/1000mg/m2, D1/2xd 1-14, up to 48 weeks @@L01C@L01C@-@NEW YORK, NEW YORK@9/1/2010@@Ixabepilone is a microtubule inhibitor belonging to a class of antineoplastic agents, the epothilones and their analogs. The epothilones are isolated from the myxobacterium Sorangium cellulosum. Ixabepilone is a semisynthetic analog of epothilone B, a 16-membered polyketide macrolide, with a chemically modified lactam substitution for the naturally existing lactone. Ixabepilone is a semi-synthetic analog of epothilone B. Ixabepilone binds directly to ß-tubulin subunits on microtubules, leading to suppression of microtubule dynamics. Ixabepilone suppresses the dynamic instability of  ß-II and  ß-III microtubules. Ixabepilone possesses low in vitro susceptibility to multiple tumor resistance mechanisms including efflux transporters, such as MRP-1 and P-glycoprotein (P-gp). Ixabepilone blocks cells in the mitotic phase of the cell division cycle, leading to cell death.@@14920969@Combination of IXabepilone Plus CapeciTabine or CapEcitabiNe Plus Docetaxel in the Treatment of Metastatic Breast Cancer@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00546364@150@-@-@@@-@@12/1/2007@-@IXTEND@@-@-@@@II@II@@-@-@Trial registered [BMS, 17.10.2007]@-@@@@COMBO@IXABEPILONE@CETUXIMAB@DOCETAXEL@@@IXABEPILONE|CETUXIMAB|DOCETAXEL||@BMS@@@@@BMS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@IXEMPRA@BMS-247550@XELODA@TAXOTERE@@IXEMPRA|BMS-247550|XELODA|TAXOTERE|@Epothilone@@@@@Epothilone||||@RECIST@@@@@TIME TO PROGRESSION@DURATION OF RESPONSE@SAFETY@@@METASTATIC@TRIPLE NEGATIVE@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920847@Onco@@@@@300f1020ntsdm@@@@@@NO LABELLED TRIAL@@-@-@YES@NEW YORK, NEW YORK@@@Etoposide is a semisynthetic derivative of podophyllotoxin used in the treatment of certain neoplastic diseases. Podophyllotoxins inhibit mitosis by blocking microtubular assembly. Etoposide inhibits cell cycle progression at a premitotic phase (late S and G2). It does not interfere with the synthesis of nucleinic acids.@@14920847@Etoposide is indicated for the management of - testicular tumours in combination with other chemotherapeutic agents - small cell lung cancer, in combination with other chemotherapeutic agents - monoblastic leukaemia (AML M5) and acute myelomonoblastic leukaemia (AML M4) when standard therapy has failed (in combination with other chemotherapeutic agents).@@NO@-@@NO REVIEW@@@@0%@-@-@-@-@Eposin, concentrate for solution for infusion 20 mg/ml must be diluted immediately prior to use with either 5 % dextrose in water, or 0.9 % sodium chloride solution to give a final concentration of 0.2 to 0.4 mg/ml. At higher concentrations precipitation of etoposide may occur. The usual dose of etoposide, in combination with other approved chemotherapeutic agents, ranges from 100-120 mg/m²/day via continuous infusion over 30 minutes for 3-5 days, followed by a resting period of 10-20 days. Generally 3 to 4 chemotherapy cycles are administered.@N/A@@@-@@@Patients being treated with VePesid must be frequently observed for myelosuppression both during and after therapy. Myelosuppression resulting in death has been reported. Dose-limiting bone marrow suppression is the most significant toxicity associated with VePesid therapy. Therefore, the following studies should be obtained at the start of therapy and prior to each subsequent cycle of VePesid: platelet count, haemoglobin, white blood cell count, and differential. The occurrence of a platelet count below 50,000/mm3 or an absolute neutrophil count below 500/mm3 is an indication to withhold further therapy until the blood counts have sufficiently recovered.@NO LABELLED TRIAL@@-@-@@@-@APPROVED@@@@NO LABELLED TRIAL@-@@@@-@ETOPOSIDE PHOSPHATE@@@@@ETOPOSIDE PHOSPHATE||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Testicular Cancer@SCLC@Haematological Malignancy@Acute Myeloid Leukaemia@@Testicular Cancer|SCLC|Haematological Malignancy|Acute Myeloid Leukaemia||||||@LASTET@@@@@LASTET||||@Plant Alkaloid@Topoisomerase II Inhibitor@@@@Plant Alkaloid|Topoisomerase II Inhibitor|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@@@@@500@1.1229@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@CAPSULE@EURO@@@@@@@@100@MG@100 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
16626379@Onco@@@@@300f1012ntsdm@@@@@@@@L01XE29@L01X@@TOKYO, JAPAN@@@@@16626379@Indicated in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy.@Both@NA@16-Mar-17@3/16/2017@NO REVIEW@@@@0%@@SECOND-LINE@@153@The recommended daily dose of lenvatinib is 18 mg (one 10 mg capsule and two 4 mg capsules) once daily in combination with 5 mg of everolimus once daily. The daily doses of lenvatinib and, if necessary, everolimus are to be modified as needed according to the dose/toxicity management plan.Treatment should continue as long as there is clinical benefit or until unacceptable toxicity occurs@EMA, 25 August 2016@8/25/2016@@@@@@@No@@@@ADULTS@@APPROVED@@16 March 2017: Low added benefit, [https://www.g-ba.de/downloads/39-261-2878/2017-03-16_AM-RL-XII_Lenvatinib_D-257_BAnz.pdf]@@@@@@@COMBO@LENVATINIB@EVEROLIMUS@@@@LENVATINIB|EVEROLIMUS|||@EISAI@@@@@EISAI||||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@KISPLYX@AFINITOR@@@@KISPLYX|AFINITOR|||@TK Inhibitor@@@@@TK Inhibitor||||@@@@@@@@@@@ADVANCED@@@@@MULTICENTER@RANDOMIZED@Open Label@@@1@1@35331.22493@@@11@month@11 month@35331.22@35331.22@105.6@30@1.1511@1760@2214.55@1798.5@@@@@@@@@@5.87@1@@mg@18@1@@@@@@@@@@@8/1/2017@58.67@58.67@12448131@HARD CAPSULE@EURO@@@@@@@@10@MG@10 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14924140@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@UNITED STATES@@@ABT-263 is a small molecule that is designed to restore apoptosis, also known as programmed cell death, by blocking the function of pro-survival Bcl-2 family proteins. Apoptosis is a natural process by which damaged or unwanted cells, including those that are cancerous, die and are cleared from the body. The Bcl-2 family proteins, which are expressed at high levels in many tumors, play a central role in regulating apoptosis and, consequently, are thought to impact tumor formation, tumor growth and resistance to treatment.@@14924140@-@@-@-@@NO REVIEW@@@@-@Roche announces US$43.7 billion proposal to assume full control of Genentech. SOURCE: Roche, 21 July 2008Part of a partnership signed in June 2007 with Genentech which also includes ABT-869. They will co-develop the drugs and co-promote in the U.S., with Abbott holding overseas rights.@-@NCT00406809@80@-@-@@@-@@11/1/2006@-@-@@-@80 PATIENTS WITH RELAPSED OR REFRACTORY LYMPHOID MALIGNANCIES@@@I/II@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@ABBOTT@GENENTECH@@@@ABBOTT|GENENTECH|||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@ABT-263@@@@@ABT-263||||@Bcl-2 Inhibitor@@@@@Bcl-2 Inhibitor||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16669279@Onco@@@@@300f1018ntsdm@@@@@@Experimental: Eribulin MesylateActive Comparator: Capecitabine@@L01XX41@L01X@@TOKYO, JAPAN@3/1/2012@@The mesylate salt of a synthetic analogue of halichondrin B, a substance derived from a marine sponge (Lissodendoryx sp.) with antineoplastic activity. Eribulin binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at G2/M phase, and, potentially, tumor regression@@16669279@Treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless these are contraindicated.@Female@YES@@@NO REVIEW@@@@0%@Acquired through takeover of Morphotek in April 2007; Ludwig Institute@SECOND-LINE@NCT00337103@1102@The recommended dose of eribulin as the ready to use solution is 1.23 mg/m2 which should be administered intravenously over 2 to 5 minutes on Days 1 and 8 of every 21-day cycle.@@@@No@@6/1/2006@@E7389-G000-301@No@@Patients with locally advanced or metastatic breast cancer to investigate the efficacy of HALAVEN monotherapy compared to capecitabine monotherapy in terms of OS and PFS as co-primary endpoint. Patients had previously received up to three prior chemotherapy regimens, including both an anthracycline and a taxane and a maximum of two for advanced disease, with the percentage who had received 0, 1 or 2 prior chemotherapy treatments for metastatic breast cancer being 20.0%, 52.0% or 27.2% respectively.@@ADULTS@III@APPROVED@@@@@@@@@MONO@ERIBULIN MESYLATE@@@@@ERIBULIN MESYLATE||||@EISAI@@@@@EISAI||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@HALAVEN@@@@@HALAVEN||||@Plant Alkaloid@Vinca Alkaloids@@@@Plant Alkaloid|Vinca Alkaloids|||@OVERALL SURVIVAL@@@@@PROGRESSION FREE SURVIVAL@PROGRESSION FREE RATE@@@@ADVANCED@METASTATIC@@@@RANDOMISED@PARALLEL ASSIGNMENT@OPEN LABEL@@@1.6@m²@46426.9824@@@15.9@month@15.9 month@46426.98@46426.98@96@1@0.779@450@@@@@@@@@@@@450@21@@mg/m²@1.4@2@@@@@@@@@@@8/1/2017@450@450@1658-1200-IN-EI@SOLUTION FOR INJECTION, 2 ML@A$@@@@@@@@1@MG@1 MG/2 ML@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14918809@Onco@@@@@@@@@@@Weekly and biweekly schedules of 1D09C3@@-@-@-@MUNICH, GERMANY@@@@@14918809@Patients with relapsed or refractory B-cell lymphomas, such as Hodgkin's and non-Hodgkin's lymphomas, in whom prior standard therapy has failed.@@-@-@@NO REVIEW@@@N/A@-@-@-@-@25@-@EMEA COMP recommended for orphan drug status for multiple myeloma; early granted orphan drug designation for CLL and Hodgkin's lymphoma. SOURCE: GPC Biotech, 14 February 2006@2/14/2006@@EMEA COMP recommended for orphan drug status for multiple myeloma; early granted orphan drug designation for CLL and Hodgkin's lymphoma. SOURCE: GPC Biotech, 14 February 2006@@@-@N/A@@-@-@@@I@DISCONTINUED@@-@-@"Candidate discontinued after data on IgG4 antibodies published by Genmab indcated that they are rone to swapping resulting in new molecules with unknown properties. The results to date ""are not definitive, but GPC has decided to not put further intenrla resources into developing 1D09C3"". SOURCE: GPC, 25 february 2008Preliminary data from 25 patients suggest that 1D09C3 is well tolerated in this heavily pre-treated patient population.  A maximum tolerated dose had not yet been reached.  ""Hints"" of antitumor activity were observed in two patients. SOURCE: GPC Biotech, ASH, 11 December 2006"@-@@@@-@-@@@@@-||||@GPC BIOTECH@@@@@GPC BIOTECH||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@Hodgkin's Lymphoma@B-Cell Lymphoma@@Haematological Malignancy|Non-Hodgkin's Lymphoma|Hodgkin's Lymphoma|B-Cell Lymphoma||||||@1D09C3@@@@@1D09C3||||@mAb@Human@@@@mAb|Human|||@MAXIMUM TOLERATED DOSE@@@@@@@@@@RELAPSED@REFRACTORY@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916008@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Patients receive oral ZD 1839 twice daily on day 1 and once daily on days 2-28 of the first course and then once daily on days 1-28 of subsequent courses. Courses repeat every 28 days for 6 months in the absence of disease progression or unacceptable toxicity.@@L01XE02@L01X@-@LONDON, UNITED KINGDOM@@@The mechanism of the clinical antitumor action of gefitinib is not fully characterized. Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinasesassociated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor (EGFR-TK). EGFR isexpressed on the cell surface of many normal cells and cancer cells. No clinical studies have been performed that demonstrate a correlation between EGFRreceptor expression and response to gefitinib@@14916008@Recurrent prostate cancer who have rising serum PSA@@-@-@@NO REVIEW@@@@-@-@-@NCT00033579@45@-@-@@@-@@@-@ZENECA-1839US0040@@-@-@@@II@II@@-@-@None of the 40 patients evaluable for PSA decline were PSA responders; there was no evidence of anti-tumor activity in this patient population. The mean change from baseline serum PSA concentration at the withdrawal/completion visit was 43 ng/mL, the mean change ranging at any visit from 5 ng/mL at months 5 and 6 to 44 ng/mL at month 3. The duration of PSA decline could not be determined because none of the patients experienced a PSA decline as defined in the study.@-@@@@MONO@GEFITINIB@@@@@GEFITINIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@IRESSA@ZD-1839@@@@IRESSA|ZD-1839|||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@PSA@@@@@@@@@@RELAPSED@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TABLET@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921423@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@L01XX11@L01X@NO@OSAKA, JAPAN@@@Estramustine is a chemical compound of oestradiol and nitrogen mustard. It is effective in the treatment of advanced prostatic carcinoma. Estramustine has a dual mode of action. The intact molecule acts as an anti-miotic agent; after hydrolysis of the carbamate ester, the metabolites act to bridge the released oestrogens and exert an anti-gonadotrophic effect. The low level of clinical side effects may be due to the fact that estramustine binds to a protein present in the tumour tissue, so resulting in accumulation of the drug at the target site. Estracyt also has weak oestrogenic and anti-gonadotrophic properties. Estramustine causes little or no bone marrow depression at usual therapeutic dosage. Estramustine is effective in patients who have not previously received drug therapy, as well as in those who have shown no response to conventional hormone treatment.@@14921423@Carcinoma of the prostate, especially in cases unresponsive to, or relapsing after, treatment by conventional oestrogens (stilboestrol, polyestradiol phosphate etc.) or by orchidectomy.@@@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@Dosage range may be from 1 to 10 capsules a day by mouth. The capsules should be taken not less than 1 hour before or 2 hours after meals. The capsules should not be taken with milk or milk products. Standard starting dosage is 4-6 capsules a day in divided doses with later adjustment according to response and gastrointestinal tolerance.@@@@@@@Use with caution in patients with moderate to severe bone marrow depression, thrombophlebitis, thrombosis, thromboembolic disorders, cardiovascular disease, coronary artery disease and congestive heart failure.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@ESTRAMUSTINE PHOSPHATE SODIUM@@@@@ESTRAMUSTINE PHOSPHATE SODIUM||||@TAKEDA PHARMACEUTICAL@@@@@TAKEDA PHARMACEUTICAL||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@MULTOSIN@@@@@MULTOSIN||||@Oestrogen@Nitrogen Mustard Analogue@@@@Oestrogen|Nitrogen Mustard Analogue|||@@@@@@@@@@@REFRACTORY@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@100@1.1511@239.93@314.33@248.19@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@2.4@2.4@7428379@CAPSULE@EURO@@@@@@@@280@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14918282@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@L01DC01@L01D@YES@BASEL, SWITZERLAND@@@@@14918282@a. Squamous cell carcinoma affecting the mouth, nasopharynx and paranasal sinuses, larynx, oesophagus, external genitalia, cervix or skin. Well differentiated tumours usually respond better than anaplastic ones. b. Hodgkin's disease and other malignant lymphomas, including mycosis fungoides. c. Testicular teratoma d. Malignant effusions of serous cavities. e. Secondary indications in which Bleomycin has been shown to be of some value (alone or in combination with other drugs) include metastatic malignant melanoma, carcinoma of the thyroid, lung and bladder@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Acquired through takeover of Hexal@@@@Malignant lymphomas: Used alone the recommended dosage regime is 15 x 10³ IU (1 vial) once or twice a week, intramuscularly, to a total dose of 225 x 10³ IU (15 vials). Dosage should be reduced in the elderly. The dose may need to be adjusted when bleomycin is used in combination chemotherapy.@@@@@@@Patients undergoing treatment with bleomycin should have chest X-rays weekly. These should continue to be taken for up to 4 weeks after completion of the course. If breathlessness or infiltrates appear, not obviously attributable to tumour or to co-existent lung disease, administration of the drug must be stopped immediately and patients should be treated with a corticosteriod and a broad spectrum antibiotic. High oxygen concentrations should be used with caution in these cases. Lung function tests which use 100% oxygen should not be used in patients who have been treated with Bleomycin. Lung function tests using less than 21% oxygen are recommended as an alternative.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@BLEOMYCIN@@@@@BLEOMYCIN||||@HEXAL@NOVARTIS@@@@HEXAL|NOVARTIS|||@@@@@@|||||||||@Head & Neck Cancer@Cervical Cancer@Oesophageal Cancer@Melanoma / Skin Cancer@Testicular Cancer@Head & Neck Cancer|Cervical Cancer|Oesophageal Cancer|Melanoma / Skin Cancer|Testicular Cancer|||||@GENERIC@@@@@GENERIC||||@Cytotoxic Antibiotic@@@@@Cytotoxic Antibiotic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@46.98@70.38@49.16@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@46.98@46.98@573285@POWDER AND SOLVANT FOR INJECTION@EURO@@@@@@@@15000@IU@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14924781@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients receive Velcade, Adriamycin and dexamethasone followed by thalidomide with dexamethasone.@@L04AX02@L04A@-@SUMMIT, NEW JERSEY@9/1/2008@@The mechanism of action is not fully understood. It possesses immunomodulatory, anti-inflammatory and anti-angiogenic properties; the immunologic effects vary substantially under different conditions, but may be related to the suppression of excessive TNF-alpha production and down-modulation of selcted cell surface adhesion molecules involved in leukocyte migration.@@14924781@-@@-@-@@NO REVIEW@@@@-@In November 2001, Celgene sold Pharmion exclusive licenses for thalidomide and S.T.E.P.S. in exchange for royalties. Celgene retained the rights for North America, China, Japan, Korea, and Taiwan. After revision of agreement in December 2004, Pharmion pay@MULTIPLE@NCT00319865@47@-@-@@@-@@11/1/2005@-@-@@-@47 PATIENTS WHO RELAPSED AFTER AT LEAST 1 LINE OF THERAPY@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@THALIDOMIDE@ADRIAMYCIN@DEXAMETHASONE@@@THALIDOMIDE|ADRIAMYCIN|DEXAMETHASONE||@CELGENE@PHARMION@@@@CELGENE|PHARMION|||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@THALOMID@@@@@THALOMID||||@Immunotherapy@@@@@Immunotherapy||||@RESPONSE RATE@@@@@@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@CAPSULE@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920069@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Ifosfamide dosed at 2-4G/M2 d x 3-5@@@@YES@PETACH TIKVA, ISRAEL@@@@@14920069@Used in combination with certain other approved antineoplastic agents, Ifex is indicated for third line chemotherapy of germ cell testicular cancer. It should ordinarily be used in combination with a prophylactic agent for haemorrhagic cystitis, such as mesna. Mesnex is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced haemorrhagic cystitis.@@@@@NO REVIEW@@@@@@@@46@For IV, Ifosfamide should be given at 1.2G/M2 at 0 hours, with Mesnex given at 240MG/M2 at 0, 4 and 8 hours.@@@@@@@Ifex should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Urotoxic side effects, especially haemorrhagic cystitis, as well as CNS toxicities such as confusion and coma have been associated with the use of Ifex When they occur, they may require cessation of Ifex therapy. Severe myelosuppression has been reported.@LABEL@No@@@@@III FUKUOKA@APPROVED@@@MEDICARE@31% (14/46) versus 6% (3/46) developed haematuria in the conventional versus standard Mesnex IV groups respectively.@@@@@COMBO@IFOSFAMIDE/MESNA@@@@@IFOSFAMIDE/MESNA||||@TEVA PHARMACEUTICAL@@@@@TEVA PHARMACEUTICAL||||@@@@@@|||||||||@Testicular Cancer@Supportive Care@@@@Testicular Cancer|Supportive Care||||||||@GENERIC@@@@@GENERIC||||@Detoxifying Agent@@@@@Detoxifying Agent||||@HAEMATURIA@@@@@@@@@@@@@@@RANDOMISED@CONTROLLED@@@@@@Invalid Factory Price@@@@@@@@@1@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@US$@@@@@@@@@@5 G|1 G@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921006@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@L01DB01@L01D@-@-@5/1/2009@@Although not completely elucidated, the mechanism of action of doxorubicin is related to its ability to bind to DNA and inhibit nucleic acid synthesis. Cell culture studies have demonstrated rapid cell penetration and perinucleolar chromatin binding, rapid inhibition of mitotic activity and nucleic acid synthesis, mutagenesis and chromosomal aberrations. The specificity of doxorubicin toxicity appears to be related primarily to proliferative activity of normal tissue. Thus, bone marrow, gastro-intestinal tract and gonads are the main normal tissues damaged.@@14921006@Treating patients refractory to platinum-based chemotherapy@@-@-@@NO REVIEW@@@@-@>> Takeover is complete. [CytRx, 22.09.2008]>> CytRx acquires Innovive in US$25 million deal, mainly paid in future milestones. [CytRx, 10 June 2008]@-@NCT00472771@40@-@-@@@-@@5/1/2008@-@INNO-206-P2@@-@>> Have a histologically or cytologically confirmed diagnosis of recurrent extensive small cell lung cancer (SCLC) at the time of enrollment into the study. >> Have responded to first-line platinum-based chemotherapy, but progressed or relapsed =60 days after completion of first-line therapy.@@@II@II@@-@-@Trial registered. [Innovive, 11.05.2007]@-@@@@-@DOXORUBICIN@@@@@DOXORUBICIN||||@INNOVIVE PHARMACEUTICAL@CYTRX CORP.@@@@INNOVIVE PHARMACEUTICAL|CYTRX CORP.|||@@@@@@|||||||||@SCLC@@@@@SCLC|||||||||@INNO-206@@@@@INNO-206||||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@RESPONSE RATE@TIME TO PROGRESSION@PROGRESSION-FREE SURVIVAL@SAFETY@@PROGRESSION-FREE SURVIVAL@SAFETY@@@@REFRACTORY@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916671@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Pixantrone will be administered for three consecutive days on days 1, 2 and 3 of each 21-day cycle, for up to two cycles.@@-@-@-@SEATTLE, WASHINGTON@3/1/2007@@Pixantrone is an investigational agent under development for the potential treatment of various hematological malignancies, solid tumors and immunological disorders. It was developed to improve the activity and safety of the anthracycline family of anti-cancer agents. Anthracyclines have been shown to be very active clinically in a number of tumor types. However, they are usually associated with cumulative heart damage that prevents them from being used in a large proportion of patients. Pixantrone has been designed to reduce the potential for these severe cardiotoxicities, as well as to potentially increase activity and simplified administration compared to the currently marketed anthracyclines.@@14916671@Refractory AML@@-@-@@NO REVIEW@@@@-@Novartis holds an option to develop and commercialise pixantrone based on agreed terms from the Xyotax deal. If Novartis exercises its option on pixantrone under certain conditions, Novartis would pay CTI a US$7.5M fee and up to US$104M in registration an@-@NCT00106600@119@-@FDA FAST-TRACK DESIGNATION FOR RELAPSED OR REFRACTORY INDOELENT NHL GRANTED IN MAY 2007.@@@-@@3/1/2005@-@PIX109@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@PIXANTRONE@@@@@PIXANTRONE||||@CELL THERAPEUTICS@@@@@CELL THERAPEUTICS||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@PIXUVRI@@@@@PIXUVRI||||@Anthracycline@Topoisomerase II Inhibitor@@@@Anthracycline|Topoisomerase II Inhibitor|||@MAXIMUM TOLERATED DOSE@RESPONSE RATE@@@@@@@@@REFRACTORY@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918858@Onco@@@@@300f1008ntsdm@@@@@@Matuzumab in combination with Camptosar@@-@-@-@OSAKA, JAPAN@@@A monoclonal antibody that is being studied in the treatment of some types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to cancer cells. Matuzumab binds to the epithelial growth factor receptor (EGFR) on tumor cells and blocks growth signals.@@14918858@mCRC with irinotecan@@-@-@@NO REVIEW@@@@-@Takeda licensed co-development rights from Merck KGaA in September 2005. Merck and ImClone amended their Erbitux and EGFR antibody licensing agreement in May 2007 to accommodate this deal.@MULTIPLE@-@N/A@N/A@-@@@-@@@-@N/A@@-@-@@@II@II@@-@@"Merck Serono and Takeda discontinued development of the drug in all indications ""based on clinical findings to date"". SOURCE: Merck Serono/Takeda, 18 February 2008Merck Serono/Takeda August 2007; matuzumab did not meet predefined endpoint in the trial, and are now ""reconsidering"" further development in this area- although trials for other indications are proceeding. SOURCE: Merck, Takeda August 2007"@-@@@@COMBO@MATUZUMAB@IRINOTECAN@@@@MATUZUMAB|IRINOTECAN|||@TAKEDA PHARMACEUTICAL@MERCK SERONO@@@@TAKEDA PHARMACEUTICAL|MERCK SERONO|||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@EMD-72000@CAMPTOSAR@@@@EMD-72000|CAMPTOSAR|||@mAb@Humanised@EGFR@@@mAb|Humanised|EGFR||@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14921775@Onco@@@@@300f1012ntsdm@@@@@@Patients receive rituximab on day 0 in course 1 and on day 1 in courses 2-6. Patients also receive bendamustine on days 1 and 2 in courses 1-6. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. SOURCE: clinicaltrials.gov/German CLL Group@@-@-@-@BASEL, SWITZERLAND@3/1/2008@@Bendamustine is an alkylating that is a bifunctional mechlorethamine derivative. Mechlorethamine and its derivatives dissociate into electrophilic alkyl groups. These groups form covalent bonds with electron-rich nucleophilic moieties. The bifunctional covalent linkage can lead to cell death via several pathways. The exact mechanism of action of bendamustine remains unknown. Bendamustine is active against both quiescent and dividing cells.@@14921775@Treanda/Rituxan in relapsed CLL@@-@-@@NO REVIEW@@@@-@Cephalon acquired U.S. rights through takeover of Salmedix, which licensed it from Fujisawa (Astellas. It is marketed by MundiPharma as Ribomustin in Germany as a single or combination agent for indolent NHL, MM and CLL under the name Ribomustin. SymBio h@-@NCT00274989@61@-@-@@@-@@11/1/2005@-@CLL2M@@-@-@@@GCLLSG-CLL2M, EU-20552, EUDRACT-2005-001596-34, @II@@-@-@Trial registered. [Mundipharma, 10.01.2006]@-@@@@COMBO@BENDAMUSTINE@RITUXIMAB@@@@BENDAMUSTINE|RITUXIMAB|||@MUNDIPHARMA@RIBOSEPHARM@@@@MUNDIPHARMA|RIBOSEPHARM|||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@TREANDA@RIBOMUSTIN@@@@TREANDA|RIBOMUSTIN|||@Alkylating Agent@Nitrogen Mustard Analogue@@@@Alkylating Agent|Nitrogen Mustard Analogue|||@RESPONSE RATE@@@@@@@@@@RELAPSED@@@@@NON-RANDOMISED@OPEN-LABEL@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14917416@Onco@@@@@300f1037ntsdm@@@@@@NO LABELLED TRIAL@@L01AX04@L01A@YES@@@@Dacarbazine is a cytostatic agent. The antineoplastic effect is due to an inhibition of cell growth which is independent of the cell cycle and due to an inhibition of DNA synthesis. An alkylating effect has also been shown and other cytostatic mechanisms may also be influenced by dacarbazine. Dacarbazine is considered not to show an antineoplastic effect by itself. However by microsomal N-demethylation it is quickly converted to 5-amino-imidazole-4-carboxamide and a methyl cation, which is responsible for the alkylating effect of the drug.@@14917416@Dacarbazine is indicated for the treatment of patients with metastatic malignant melanoma. Further indications for dacarbazine as part of combination chemotherapy are: • Hodgkin's disease • Advanced adult soft tissue sarcomas (except mesothelioma, Kaposi sarcoma)@@YES@@@NO REVIEW@@@@90%@@@@@Adult soft tissue sarcoma: For adult soft tissue sarcomas dacarbazine is given in daily doses of 250 mg/m2 body surface area i.v. (days 1-5) in combination with doxorubicin every 3 weeks (ADIC regimen). Restriction of food intake for 4-6 hours prior to treatment may reduce the severity of the nausea and vomiting which occurs in most patients particularly during the first two days of treatment. Because severe gastrointestinal and haematological disturbances can occur an extremely careful benefit-risk analysis has to be made before every course of therapy with dacarbazine.@10-Jul-07@7/10/2007@@@@@It is recommended that DTIC-Dome (dacarbazine) be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Hemopoietic depression is the most common toxicity with DTIC-Dome (See WARNINGS). Hepatic necrosis has been reported. Studies have demonstrated this agent to have a carcinogenic and teratogenic effect when used in animals. In treatment of each patient, the physician must weigh carefully the possibility of achieving therapeutic benefit against the risk of toxicity.@NO LABELLED TRIAL@No@@@@@@APPROVED@@NO REVIEW@SNS@NO LABELLED TRIAL@@@@@@DACARBAZINE@@@@@DACARBAZINE||||@MADAUS@@@@@MADAUS||||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@DTIC-DOME@@@@@DTIC-DOME||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@METASTATIC@MALIGNANT@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.1807@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@EURO@@@@@@@@500@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
15356217@Onco@@@@@300f1012ntsdm@@@@@@@@L01XE28@L01X@@BASEL, SWITZERLAND@@@Zykadia (ceritinib) is an oral, selective inhibitor of ALK.@@15356217@Indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.@Both@NA@17-Dec-15@12/17/2015@@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@SECOND-LINE@@163@The recommended dose of Zykadia is 750 mg taken orally once daily at the same time each day. The maximum recommended dose is 750 mg daily. Treatment should continue as long as clinical benefit is observed.@EMA, 6 May 2015@5/6/2015@7/1/2015@No@@@@@No@@@(ALK)-positive@ADULTS@I@APPROVED@@No added benefit [G-BA, https://www.g-ba.de/downloads/39-261-2414/2015-12-17_AM-RL-XII_Ceritinib_2015-07-01-D-171_BAnz.pdf]@GKV@@@@@@MONO@CERITINIB@@@@@CERITINIB||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@ZYKADIA@@@@@ZYKADIA||||@TK Inhibitor@@@@@TK Inhibitor||||@OVERALL RESPONSE RATE@DURATION OF RESPONSE@PROGRESSION-FREE SURVIVAL@@@@@@@@METASTATIC@@@@@MULTICENTER@SINGLE-ARM@OPEN-LABEL@@@1@1@30988.91578@@@7@month@7 month@30988.92@30988.92@145.55@150@1.1511@4366.44@5409.26@4404.94@@@@@@@@@@0.19@1@@mg@750@1@@@@@@@@@@@8/1/2017@29.11@29.11@11095759@HARD CAPSULE@EURO@@@@@@@@150@MG@150 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14922557@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Eligible patients will receive six to eight cycles of R-Chemo, and after a six-month rest period, will receive a series of 24 immunizations with MyVax personalised immunotherapy over a 92-week period.@@-@-@-@FREMONT, CALIFORNIA@@@@@14922557@Follicular NHL following primary Rituxan-chemo treatment@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00510471@100@-@-@@@-@@5/1/2007@-@2007-12@@-@-@@@II@CLINICAL HOLD@@-@-@After a review of the data from the pivotal Phase III trial, the FDA has communicated to Genitope that, in light of the Phase 3 clinical trial's failure to meet its primary endpoint, one or more additional Phase 3 clinical trials for MyVax personalized immunotherapy would be required before the FDA would accept a Biologics License Application for FDA review. Genitope has determined that it is not feasible at this time to pursue further clinical trials of MyVax personalized immunotherapy prior to receipt of FDA approval. Genitope is evaluating its alternatives with respect to the MyVax personalized immunotherapy program. SOURCE: Genitope press release, 10 March 2008@-@@@@COMBO@-@@@@@-||||@GENITOPE@@@@@GENITOPE||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@MYVAX@GTOP-99@@@@MYVAX|GTOP-99|||@Immunotherapy@Vaccine@@@@Immunotherapy|Vaccine|||@SAFETY@@@@@@@@@@-@@@@@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924617@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@BEMA fentanyl versus placebo in doses from 200mcg to 12mcg@@N02AB03@N02A@-@RALEIGH, NORTH CAROLINA@@@Fentanyl is a synthetic opiate with a clinical potency of 50 to 100 times that of morphine. Its onset of action is rapid and its duration of action is short. In man, a single iv dose of 0.5-1 mg/70 kg body weight immediately produces a pronounced state of surgical analgesia, respiratory depression, bradycardia and other typical morphine-like effects. The duration of action of the peak effects is about 30 minutes. All potent morphine-like drugs produce relief from pain, ventilatory depression, emesis, constipation, physical dependence, certain vagal effects and varying degrees of sedation. Fentanyl, however, differs from morphine not only by its short duration of action but also by its lack of emetic effect and minimal hypotensive activity in animals. @@14924617@Breakthrough cancer pain@@-@-@@NO REVIEW@@@@-@Meda licensed European rights in August 2006. In September 2007, a licensing agreement was signed for the U.S. distribution rights.@-@-@300@-@>FDA completed its review; requests Risk Evaluation and Mitigation Strategy (REMS) to be included in Onsolis' marketing application; Meda anticipates that the drug will clear U.S. regulatory evaluation in H1 of 2009. [BioDelivery, 29.08.2008]>NDA accepted for review; action expected 31 August 2008 [BioDelivery, January 2008]>NDA filed. [BioDelivery, October 2008]@8/31/2008@@-@@@-@-@@-@-@@@III@FILED@@-@-@BEMA met primary endpoint at 30 mins and secondary endpoint at 15 mins. BEMA Fentanyl was associated with a low incidence of application site reactions, with 1.3% considered probably or possibly related to the drug. Most cases were mild and none led to discontinuation.@-@@@@MONO@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@BIODELIVERY SCIENCES@MEDA AB@@@@BIODELIVERY SCIENCES|MEDA AB|||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@ONSOLIS@BEMA@@@@ONSOLIS|BEMA|||@Opioid Analgesic@@@@@Opioid Analgesic||||@SPID@@@@@@@@@@-@@@@@PIVOTAL@PLACEBO-CONTROLLED@OPEN-LABEL@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16396594@Onco@@@@@300f1012ntsdm@@@@@@10 mg once daily or 10 mg once daily for 21 days every 28 days. Sequential dose reductions to 5 mg daily and 5 mg every other day, as well as dose delays, were allowed for toxicity.@@L04AX04@L04A@@SUMMIT, NEW JERSEY@@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16396594@Indicated for the treatment of patients with transfusiondependent anaemia due to low or intermediate1risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@148@The recommended starting dose of lenalidomide is 10 mg orally once daily on days 121 of repeated 28day cycles. Dosing is continued or modified based upon clinical and laboratory findings.@EMA, 25 April 2013@4/25/2013@@Yes@@@@MDS003@No@@148 PATIENTS WHO HAD RBC TRANSFUSION DEPENDENT ANEMIA. RBCTRANSFUSION DEPENDENCE WAS DEFINED AS HAVING RECEIVED = 2 UNITS OF RBCS WITHIN 8 WEEKS PRIOR TO STUDY TREATMENT. THE STUDY ENROLLED PATIENTS WITH ABSOLUTE NEUTROPHIL COUNTS (ANC) = 500 CELLS/MM3,@@@III@APPROVED@@@GKV@@@@@@MONO@LENALIDOMIDE@@@@@LENALIDOMIDE||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myelodysplastic Syndrome@@@@Haematological Malignancy|Myelodysplastic Syndrome||||||||@REVLIMID@@@@@REVLIMID||||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@@@@@@@@@@@@@@@@OPEN-LABEL@SINGLE-ARM@MULTI-CENTRE@@@1@1@11094.99997@@@56@day@56 day@11095@11095@198.13@21@1.1511@5547.5@6856.89@5586@@@@@@@@@@26.42@28@@mg@10@21@@@@@@@@@@@8/1/2017@264.17@264.17@1875261@HARD CAPSULE@EURO@@@@@@@@10@MG@10 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14921011@Onco@@@@@300f1014ntsdm@@@@@@Patients receive oral AZD2281 twice a day on days -7 to 21 in course 1 and on days 1-21 in all subsequent courses. Patients also receive irinotecan hydrochloride IV over 90 minutes on day 1. Courses repeat every 21 days (course 1 is 28 days) in the absence of disease progression or unacceptable toxicity. Patients undergo cheek swabs, tumor tissue, and blood sample collection periodically for pharmacokinetic, pharmacodynamic, and correlative studies. [clinicaltrials.gov]@@-@-@-@LONDON, UNITED KINGDOM@10/1/2009@@A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. PARP inhibitor AZD2281 selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.@@14921011@Locally advanced or metastatic colorectal cancer@@-@-@@NO REVIEW@@@@-@Acquired through takeover of KuDOS in January 2007@-@NCT00535353@30@-@-@@@-@@8/1/2007@-@IND187@@-@>Histologically or cytologically confirmed colorectal cancerLocally advanced and/or metastatic disease Disease considered incurable > Suitable for treatment with single agent irinotecan hydrochloride as a palliative intervention, as determined by the investigator > Must have clinically and/or radiologically documented disease. Patients whose only evidence of disease progression is tumor marker elevation are not eligible > Must have received one prior oxaliplatin-based chemotherapy regimen given either with adjuvant, neoadjuvant, or palliative intent. One adjuvant fluoropyrimidine (fluorouracil or capecitabine) regimen may have been given for relapsed or metastatic disease@@@I@I@@-@-@Trial registered. [AstraZeneca, 25.09.2007]@-@@@@COMBO@-@IRINOTECAN@@@@-|IRINOTECAN|||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@AZD-2281@CAMPTOSAR@@@@AZD-2281|CAMPTOSAR|||@PARP Inhibitor@@@@@PARP Inhibitor||||@MAXIMUM TOLERATED DOSE@SAFETY@@@@-@@@@@LOCALLY ADVANCED@METASTATIC@@@@NON-RANDOMISED@MULTI-CENTRE@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@CAPSULE@C$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14918232@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01XA03@L01X@YES@@@@Eloxatin is an antineoplastic agent which is an organoplatinum complex in which the platinum atom is complexed with 1,2-DACH and with an oxalate ligand as a leaving group. It undergoes non-enzymatic conversion in physiologic solutions to active derivatives via displacement of the labil oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.@@14918232@Oxaliplatin in combination with 5-fluorouracil (5-FU) and folinic acid (FA) is indicated for: • Adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of primary tumor. • Treatment of metastatic colorectal cancer.@@YES@@@No ASMR rating.@@@@@@@@@The recommended dose for oxaliplatin in treatment of metastatic colorectal cancer is 85 mg/m² intravenously repeated every 2 weeks.@@@12/1/2008@@@@Hypersensitivity and anaphylactic / anaphylactoid reactions to Eloxatin have been reported. Eloxatin may cause fetal harm when administered to a pregnant woman.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@OXALIPLATIN@@@@@OXALIPLATIN||||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@GENERIC@@@@@GENERIC||||@Platinum@@@@@Platinum||||@@@@@@@@@@@METASTATIC@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@306@@@@@@@@@@@@3.06@@@@@@@@@@@@@@@@8/2/2017@306@306@9312801R@CONCENTRATE FOR SOLUTION FOR INFUSION (ONCO-TAIN VIAL), 20 ML@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14925076@Onco@@@@@@@@@@@Aflibercept once every 2 weeks versus placebo together with irinotecan/5-FU (FOLFIRI) combination@@-@-@-@PARIS, FRANCE@6/1/2012@@Aflibercept (VEGF Trap) is a unique fusion protein that binds all forms of Vascular Endothelial Growth Factor-A (called VEGF-A). VEGF-A is required for the growth of new blood vessels that are needed for tumors to grow and is a potent regulator of vascular permeability and leakage. In addition, aflibercept binds Placental Growth Factor (PLGF), which has also been implicated in tumor angiogenesis. @@14925076@A Multicenter, Randomized, Double Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated With Docetaxel/ Prednisone for Metastatic Androgen-independent Prostate Cancer@@-@-@@NO REVIEW@@@@-@sanofi-aventis holds worldwide licensed including (since January 2006) Japan. Bayer Schering holds eye disease rights.@@NCT00519285@1200@-@FDA grants priority review; PDUFA data: 4 August 2012[Sanofi, 5 April 2012 http://en.sanofi.com/Images/30138_20120405_ZALTRAP_BLA_VENICE_en.pdf ]@8/4/2012@@-@@8/1/2007@-@VENICE@@-@Histologically- or cytologically-confirmed prostate adenocarcinomaMetastatic diseaseProgressive disease while receiving hormonal therapy or after surgical castrationEffective castration@@@III@III@@-@-@>> Trial did not meet primary endpoint of OS [Sanofi, 5 April 2012 http://en.sanofi.com/Images/30138_20120405_ZALTRAP_BLA_VENICE_en.pdf ]>>Trial registered [Sanofi, Regeneron 21 August 2007]@The most frequent adverse events reported with ZALTRAP in combination with FOLFIRI werediarrhea, asthenia/fatigue, stomatitis and ulceration, nausea, infection, hypertension,gastrointestinal and abdominal pains, vomiting, decreased appetite, decreased weight,epistaxis, alopecia, and dysphonia.@@@@COMBO@AFLIBERCEPT@DOCETAXEL@@@@AFLIBERCEPT|DOCETAXEL|||@SANOFI-AVENTIS@REGENERON PHARMACEUTICALS@@@@SANOFI-AVENTIS|REGENERON PHARMACEUTICALS|||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@VEGF-TRAP@TAXOTERE@@@@VEGF-TRAP|TAXOTERE|||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@OVERALL SURVIVAL@PSA MEASUREMENT@@@@@@@@@METASTATIC@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
15039118@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Daily V. weekly dosing@@-@-@-@CAMBRIDGE, UNITED KINGDOM@12/1/2013@@SGI-110 is a small molecule, DNA-hypomethyating agent with demonstrated activity in restoring silenced tumor suppressor gene expression in cancer cells by reversal of DNA methylation.@@15039118@A Phase 1-2, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects With Intermediate or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)@@@@@NO REVIEW@@@@-@-@-@NCT01261312@300@-@@@@@@12/1/2010@-@SGI-110-01@@@Eastern ECOG performance status of 0 to 2.Adequate organ function.Prior allogeneic stem cell transplant, no evidence of active graft-versus host disease (GVHD) and must be = 2 weeks off immunosuppressive therapy.@@@I/II@II@@-@@As of end of June 2013, 67 AML patients had a minimum follow up of 3 months (50 patients representing the complete cohort of relapsed/refractory AML, and 17 patients in the treatment-naive elderly AML not suitable for induction chemotherapy cohort). There were 8 remissions in relapsed/refractory AML and 9 remissions in treatment-naive elderly AML for an overall complete remission rate (CR, CRi/CRp) of 17/67 or 25%. The detailed results to be presented at ASH meeting in December. [Astex, 28 August 2013,  http://files.shareholder.com/downloads/AMDA-FFK19/2689042778x0x687363/2d0a74e8-310c-4a12-b2da-615b08905491/ASTX_News_2013_8_28_General_Releases.pdf]@@@@@MONO@-@@@@@-||||@ASTEX THERAPEUTICS@@@@@ASTEX THERAPEUTICS||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@SGI-110@@@@@SGI-110||||@-@@@@@-||||@OPTIMAL DOSING@OVERALL SURVIVAL@@@@REMISSION DURATION@@@@@@@@@@OPEN-LABEL@RANDOMISED@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918146@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01CB01@L01C@YES@PETACH TIKVA, ISRAEL@@@Etoposide is a semisynthetic derivative of podophyllotoxin used in the treatment of certain neoplastic diseases. Podophyllotoxins inhibit mitosis by blocking microtubular assembly. Etoposide inhibits cell cycle progression at a premitotic phase (late S and G2). It does not interfere with the synthesis of nucleinic acids.@@14918146@Used in combination therapy with other approved chemotherapeutics in patients with refractory testicular tumors who have already received appropriate surgical, chemotherapeutic, and radiotherapeutic therapy; used in combination with other approved chemotherapeutic agents as first-line treatment in patients with small cell lung cancer.@@YES@@@NO REVIEW@@@@@@@@@The usual dose in testicular cancer in combination with other approved chemotherapeutic agents ranges from 50 to 100 mg/m2/day on days 1 through 5 to 100 mg/m2/day on days 1, 3, and 5. In small cell lung cancer, the dose in combination with other approved chemotherapeutic drugs ranges from 35 mg/m2/day for 4 days to 50 mg/m2/day for 5 days.@@@5/1/2000@@@@Patients being treated with VePesid must be frequently observed for myelosuppression both during and after therapy. Myelosuppression resulting in death has been reported. Dose-limiting bone marrow suppression is the most significant toxicity associated with VePesid therapy. Therefore, the following studies should be obtained at the start of therapy and prior to each subsequent cycle of VePesid: platelet count, haemoglobin, white blood cell count, and differential. The occurrence of a platelet count below 50,000/mm3 or an absolute neutrophil count below 500/mm3 is an indication to withhold further therapy until the blood counts have sufficiently recovered.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@ETOPOSIDE PHOSPHATE@@@@@ETOPOSIDE PHOSPHATE||||@TEVA PHARMACEUTICAL@@@@@TEVA PHARMACEUTICAL||||@@@@@@|||||||||@Testicular Cancer@SCLC@@@@Testicular Cancer|SCLC||||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Topoisomerase II Inhibitor@@@@Plant Alkaloid|Topoisomerase II Inhibitor|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@23@@@@@@@@@@@@0.02@@@@@@@@@@@@@@@@8/2/2017@23@23@9208297R@SOLUTION TO DILUTE FOR PERFUSION, 50 ML@EURO@@@@@@@@1000@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14919356@Onco@@@@@300f1012ntsdm@@@@@@Patients received either Kytril Injection, 40 mcg/kg or the combination of chlorpromazine and dexamethasone. They were all treated with ifosfamide =3 g/m2/day for two or three days.@@A04AA02@A04A@NO@HOLZKIRCHEN, GERMANY@@@Granisetron is a potent anti-emetic and highly selective antagonist of 5-hydroxytryptamine (5-HT3) receptors. Radioligand binding studies have demonstrated that Granisetron has negligible affinity for other receptor types including 5-HT and dopamine D2 binding sites. Granisetron is effective orally prophylactically in abolishing the retching and vomiting evoked by cytostatic therapy.@@14919356@Kytril tablets are indicated for the prevention of nausea and vomiting induced by cytostatic therapy@@NO@-@@NO REVIEW@@@@0%@Novartis purchases Hexal and Eon Labs in a 5.65 billion euro deal. [Novartis, 21.02.2005]@-@-@88@Adults The dose of Kytril is 1mg twice a day or 2mg once a day during cytostatic therapy. The first dose of Kytril should be administered within one hour before the start of cytostatic therapy. Concomitant use of dexamethasone: The efficacy of Kytril may be enhanced by the addition of dexamethasone. Maximum Dose and Duration of Treatment: Kytril is also available as ampoules for intravenous administration. The maximum dose of Kytril administered orally and/or intravenously over 24 hours should not exceed 9mg.@N/A@@@-@@@Hypersensitivity reactions may occur in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.@-@@-@88 PEDIATRIC PATIENTS RECEIVED EITHER KYTRIL INJECTION 20 MCG/KG OR CHLORPROMAZINE PLUS DEXAMETHASONE@PAEDIATRIC@@CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING / PEDIATRIC STUDIES@DISCONTINUED@@-@GKV@22% of Kytril Injection patients achieved complete response (no vomiting and no moderate or severe nausea in 24 hours) compared with 10% on the chlorpromazine regimen. The median number of vomiting episodes with Kytril Injection was 1.5; with chlorpromazine it was 7.0.@-@@@@MONO@GRANISETRON HYDROCHLORIDE@@@@@GRANISETRON HYDROCHLORIDE||||@HEXAL@NOVARTIS@@@@HEXAL|NOVARTIS|||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@GENERIC@@@@@GENERIC||||@5-HT3 Receptor Antagonist@@@@@5-HT3 Receptor Antagonist||||@RESPONSE RATE@EMETIC EPISODES@@@@@@@@@-@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@1@1.3598@@@@@@@@@@@@@@@@@@@@@@@@@@@@@1/16/2015@@@6326197@FILM-COATED TABLET@EURO@@@@@@@@2@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16384821@Onco@@@@@300f1037ntsdm@@@@@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384821@Indicated for the treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.@@YES@@@NO REVIEW@@@@90%@@FIRST-LINE@@@Dosing for children should be on the basis of body surface area (mg/m2). The dose of 340 mg/m2 daily is recommended for children with Ph+ ALL (@@@@Yes@@@@@No@@@PAEDIATRIC@@@APPROVED@@@SNS@@@@@@BOTH@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@@@@Haematological Malignancy|Acute Lymphocytic Leukaemia||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@@@@@@@@@@@1.2@m²@29383.7775@@@1@year@1 year@29383.78@29383.78@80.5@30@1.1511@2367.75@2520.61@2375.29@@@@@@@@@@0.2@1@@mg/m²@340@1@@@@@@@@@@@8/4/2017@78.93@78.93@779660@TABLET@EURO@@@@@@@@400@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14920902@Onco@@@@@300f1018ntsdm@@@@@@NO LABELLED TRIAL@@L01AA02@L01A@YES@BRENTFORD, UNITED KINGDOM@@@Leukeran is a bifunctional alkylating agent of the nitrogen mustard type that has been found active against selected human neoplastic diseases.@@14920902@Indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin's disease. It is not curative in any of these disorders but may produce clinically useful palliation.@@NO@@@@@@@@@@@@The usual oral dosage is 0.1 to 0.2 mg/kg body weight daily for 3 to 6 weeks as required. This usually amounts to 4 to 10 mg per day for the average patient. The entire daily dose may be given at one time. These dosages are for initiation of therapy or for short courses of treatment. The dosage must be carefully adjusted according to the response of the patient and must be reduced as soon as there is an abrupt fall in the white blood cell count. Patients with Hodgkin's disease usually require 0.2 mg/kg daily, whereas patients with other lymphomas or chronic lymphocytic leukemia usually require only 0.1 mg/kg daily.@TGA, 1 May 1957@5/1/1957@@@@@Can severely suppress bone marrow function. Chlorambucil is a carcinogen in humans. Chlorambucil is probably mutagenic and teratogenic in humans. Chlorambucil produces human infertility@NO LABELLED TRIAL@No@NOT AVAILABLE@@@@@APPROVED@@Unrestricted reimbursement.@PBS@NO LABELLED TRIAL@@@@@@CHLORAMBUCIL@@@@@CHLORAMBUCIL||||@GSK@@@@@GSK||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@Hodgkin's Lymphoma@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia|Hodgkin's Lymphoma|||||||@LEUKERAN@@@@@LEUKERAN||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@26.76@26.76@@25@0.779@29.59@@31.82@@@@@@@@@@0.59@@@@@@@@@@@@@@@@8/1/2017@1.18@1.18@1976-0486-GE-AS@TABLET@A$@@@@@@@@2@MG@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14916220@Onco@@@@@300f1010ntsdm@@@@@@Actiq for breakthrough cancer pain@@N02AB03@N02A@YES@FRAZER, PENNSYLVANIA@@@Fentanyl is a pure opioid agonist whose principal therapeutic action is analgesia. Other members of the class known as opioid agonists include substances such as morphine, oxycodone, hydromorphone, codeine, and hydrocodone.@@14916220@Indicated for the management of breakthrough pain in patients already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.@@NO@@@NO REVIEW@@@@100%@Licensed from Kyowa Hakko; supplied by Abbott. Acquired through US$444 mil. takeover of Anesta Corp in 2000.@@@130@The initial dose of Actiq used should be 200 micrograms, titrating upwards as necessary through the range of available dosage strengths (200, 400, 600, 800, 1200 and 1600 micrograms). Patients should be carefully monitored until a dose is reached that provides adequate analgesia with acceptable side effects using a single dosage unit per episode of breakthrough pain. This is defined as the successful dose.@EMA, August 2002@@@@@@Must not be used in opioid non-tolerant patients; fentanyl is a Schedule II controlled substance; life-threatening hypoventilation can occur at any dose; contraindicated in acute or post-operative pain@LABEL@No@@@@@III@APPROVED@@NO NICE REVIEW@NHS@92 of 130 patients (71% achieved a successful dose during titration. The most successful doses were 400mcg (21%) and 800mcg (20%).@@@@@MONO@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@CEPHALON@@@@@CEPHALON||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@ACTIQ@@@@@ACTIQ||||@Opioid Analgesic@@@@@Opioid Analgesic||||@RESPONSE RATE@MAXIMUM TOLERATED DOSE@@@@@@@@@@@@@@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@3@1.2961@21.05@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/21/2017@7.02@7.02@2.69E+15@LOZENGE@GB£@@@@@@@@800@MCG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
16159403@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01XC06@L01X@YES@NEW YORK, NEW YORK@@@Erbitux is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Cetuximab is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions and has an approximate molecular weight of 152 kDa. Cetuximab is produced in mammalian (murine myeloma) cell culture.@@16159403@Erbitux, as a single agent, is indicated for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck for whom prior platinum-based therapy has failed.@@NA@@@NO REVIEW@@@@@>> Acquisition completed. [Lilly, 24.11.2008]          >> Lilly acquires ImClone for US$6.5 billion. [Lilly, 7.10.2008]        >> BMS Offers US$4.3Billion for ImClone or US$60.0 per share in cash. [BMS, 1 August 2008]      >> ImClone licensed co-development and co-promotion rights to BMS in North America and Japan, and to Merck KGaA in Europe.@@@@@FDA, 2 October 2007@10/2/2007@@No@@@Infusion reactions such as airway obstruction (bronchospasm, stridor, hoarseness), urticaria, hypotension, cardiac arrest ; Cardiopulmonary arrest and/or sudden death ; pulmonary toxicity leading to interstitial lung disease ; dermatologic toxicity including acneform rash, skin drying and fissuring, and inflammatory and infectious sequelae@@No@@@@@@APPROVED@@@@@@@@@MONO@CETUXIMAB@@@@@CETUXIMAB||||@BMS@IMCLONE@MERCK SERONO@@@BMS|IMCLONE|MERCK SERONO||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@ERBITUX@@@@@ERBITUX||||@mAb@Chimeric@TK Inhibitor@EGFR@@mAb|Chimeric|TK Inhibitor|EGFR|@@@@@@@@@@@RECURRENT@METASTATIC@@@@@@@@@1.75@m²@66535.49786@@@5.8@month@5.8 month@66535.5@66535.5@377.16@1@1@589.42@@@@@@@@@@@@5.89@7@1@mg/m²@400@1@7@@mg/m²@250@1@@@@@@8/2/2017@589.42@589.42@66733-0948-23@IV INFUSION - 50 ML@US$@@@@@@@@100@MG@2 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918154@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01BC02@L01B@YES@CANONSBURG, PENNSYLVANIA@@@Fluorouracil is an analogue of uracil, a component of ribonucleic acid. The drug is believed to function as an antimetabolite. After intracellular conversion to the active deoxynucleotide, it interferes with the synthesis of DNA by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase. Fluorouracil may also interfere with RNA synthesis.@@14918154@Fluorouracil may be used alone, or in combination, for the management of common malignancies particularly cancer of the colon and breast.@@YES@5-Dec@@NO REVIEW@@@@@Acquired through takeover of generics unit of Merck KGaA@@@@Intravenous infusion: 15mg/kg bodyweight but not more than 1g per infusion, diluted in 300 - 500ml of 5% glucose or 0.9% NaCl injection and given over 4 hours. Alternatively the daily dose may be infused over 30 - 60 minutes or may be given as a continuous infusion over 24 hours. The infusion may be repeated daily until there is evidence of toxicity or a total dose of 12 - 15g has been reached. Intravenousi Injection: l2mg/kg bodyweight may be given daily for 3 days and then, if there is no evidence of toxicity, 6mg/kg on alternate days for 3 further doses. An alternative regimen is 15mg/kg as a single intravenous injection once a week throughout the course. Intra-arterial infusion: 5/7.5mg/kg bodyweight daily may be given by 24 hour continuous intra-arterial infusion.@1-Nov-00@11/1/2000@6/1/2001@@@@Intravenous infusion: 15mg/kg bodyweight but not more than 1g per infusion, diluted in 300 - 500ml of 5% glucose or 0.9% NaCl injection and given over 4 hours. Alternatively the daily dose may be infused over 30 - 60 minutes or may be given as a continuous infusion over 24 hours. The infusion may be repeated daily until there is evidence of toxicity or a total dose of 12 - 15g has been reached. Intravenousi Injection: l2mg/kg bodyweight may be given daily for 3 days and then, if there is no evidence of toxicity, 6mg/kg on alternate days for 3 further doses. An alternative regimen is 15mg/kg as a single intravenous injection once a week throughout the course. Intra-arterial infusion: 5/7.5mg/kg bodyweight daily may be given by 24 hour continuous intra-arterial infusion.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@FLUOROURACIL@@@@@FLUOROURACIL||||@MYLAN@@@@@MYLAN||||@@@@@@|||||||||@Colorectal Cancer@Breast Cancer@@@@Colorectal Cancer|Breast Cancer||||||||@GENERIC@@@@@GENERIC||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@3.66@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/2/2017@3.66@3.66@9227716R@SOLUTION FOR PERFUSION (VIAL, 20 ML)@EURO@@@@@@@@1000@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
16396601@Onco@@@@@300f1010ntsdm@@@@@@Experimental: Lenalidomide / Dexamethasone until disease progression Experimental: Lenalidomide / Dexamethasone for 18 cycles Active Comparator: Melphalan, Prednisone, and Thalidomide (MPT) for 12 cycles@@L04AX04@L04A@@SUMMIT, NEW JERSEY@6/1/2016@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16396601@Treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant@Both@NO@@@NO REVIEW@@@@100%@@FIRST-LINE@NCT00689936@1623@The recommended starting dose of lenalidomide is 25 mg orally once daily on days 121 of repeated 28day cycles.@EMA, 11 February 2015@2/11/2015@@Yes@@8/1/2008@@CC5013MM020, 200700482339@No@@Must understand and voluntarily sign informed consent form. Age ≥ 18 years at the time of signing consent. Previously untreated. ECOG performance status of 0, 1, or 2. Able to adhere to the study visit schedule and other protocol requirements. Females of childbearing potential (FCBP)^2@@ADULTS@III@APPROVED@@@NHS@@@@@@COMBO@LENALIDOMIDE@DEXAMETHASONE@@@@LENALIDOMIDE|DEXAMETHASONE|||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@REVLIMID@GENERIC@@@@REVLIMID|GENERIC|||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@PROGRESSION FREE SURVIVAL@@@@@OVERALL SURVIVAL@DURATION OF RESPONSE@@@@@@@@@RANDOMISED@PARALLEL ASSIGNMENT@OPEN LABEL@@@1@1@846667.38@@@26@month@26 month@846667.38@846667.38@1070.63@21@1.299@2997.75@@3426@@@@@@@@@@57.1@28@@mg@25@21@@@@@@@@@@@7/28/2017@142.75@142.75@2.33E+16@CAPSULE@GB£@@@@@@@@2.5@MG@2.5 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14917466@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@NO LABELLED TRIAL@@L01BC02@L01B@NO@ALISO VIEJO, CALIFORNIA@@@Fluorouracil is an analogue of uracil, a component of ribonucleic acid. The drug is believed to function as an antimetabolite. After intracellular conversion to the active deoxynucleotide, it interferes with the synthesis of DNA by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase. Fluorouracil may also interfere with RNA synthesis.@@14917466@Efudex is recommended for the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas whenconventional methods are impractical, such as with multiple lesions or difficult treatment sites.@@YES@@@NO REVIEW@@@@@@@@@When Efudex is applied to a lesion, a response occurs with the following sequence: erythema, usually followed by vesiculation, desquamation, erosion and reepithelialization. Efudex should be applied preferably with a nonmetal applicator or suitable glove. If Efudex is applied with the fingers, the hands should be washed immediately afterward. Actinic or Solar Keratosis: Apply cream or solution twice daily in an amount sufficient to cover the lesions. Medication should be continued until the inflammatory response reaches the erosion stage, at which time use of the drug should be terminated. The usual duration of therapy is from 2 to 4 weeks. Complete healing of the lesions may not be evident for 1 to 2 months following cessation of Efudex therapy. Superficial Basal Cell Carcinomas: Only the 5% strength is recommended. Apply cream or solution twice daily in an amount sufficient to cover the lesions. Treatment should be continued for at least 3 to 6 weeks. Therapy may be required for as long as 10 to 12 weeks before the lesions are obliterated.@FDA, 29 July 1970@7/29/1970@@@@@Application to mucous membranes should be avoided due to the possibility of local inflammation and ulceration. Additionally, cases of miscarriage and a birth defect (ventricular septal defect) have been reported when Efudex was applied to mucous membrane areas during pregnancy.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@MEDICARE@NO LABELLED TRIAL@@@@@@FLUOROURACIL@@@@@FLUOROURACIL||||@VALEANT PHARMACEUTICALS@@@@@VALEANT PHARMACEUTICALS||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@EFUDEX@@@@@EFUDEX||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@SOLUTION, TOPICAL@US$@@@@@@@@5@%@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921625@Onco@@@@@300f1014ntsdm@@@@@@N/A@@-@-@-@LONDON, UNITED KINGDOM@@@A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. PARP inhibitor AZD2281 selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.@@14921625@Known BRCA or Recurrent High Grade Ovarian Cancer or Known BRCA/ Triple Neg Breast Cancer@@-@-@@NO REVIEW@@@@-@Acquired through takeover of KuDOS in January 2007@-@NCT00679783@90@-@-@@@-@@@-@D0810C00020@@-@Histologically confirmed high grade serous and/or undifferentiated carcinoma of ovary, fallopian tube or peritoneum Oestrogen, progesterone and HER2 negative advanced adenocarcinoma of the breast Known BRCA positive breast cancer or ovarian cancer, that is not high grade serous or undifferentiated tubo-ovarian carcinoma. Performance status of no more than 2.@@@II@II@@-@-@Completion due in August 2009. SOURCE: AstraZeneca, 15 May 2008@-@@@@MONO@-@@@@@-||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Breast Cancer@Ovarian Cancer@HER2-@@@Breast Cancer|Ovarian Cancer|HER2-|||||||@AZD-2281@@@@@AZD-2281||||@PARP Inhibitor@@@@@PARP Inhibitor||||@RECIST@@@@@TIME TO PROGRESSION@OVERALL SURVIVAL@@@@RELAPSED@TRIPLE NEGATIVE@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@CAPSULE@C$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14918227@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01XA03@L01X@YES@CANONSBURG, PENNSYLVANIA@@@Eloxatin is an antineoplastic agent which is an organoplatinum complex in which the platinum atom is complexed with 1,2-DACH and with an oxalate ligand as a leaving group. It undergoes non-enzymatic conversion in physiologic solutions to active derivatives via displacement of the labil oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.@@14918227@Oxaliplatin in combination with 5-fluorouracil (5-FU) and folinic acid (FA) is indicated for: • Adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of primary tumor. • Treatment of metastatic colorectal cancer.@@YES@@@No ASMR rating.@@@@@@@@@The recommended dose for oxaliplatin in treatment of metastatic colorectal cancer is 85 mg/m² intravenously repeated every 2 weeks.@@@7/1/2007@@@@Hypersensitivity and anaphylactic / anaphylactoid reactions to Eloxatin have been reported. Eloxatin may cause fetal harm when administered to a pregnant woman.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@OXALIPLATIN@@@@@OXALIPLATIN||||@MYLAN@@@@@MYLAN||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@GENERIC@@@@@GENERIC||||@Platinum@@@@@Platinum||||@@@@@@@@@@@METASTATIC@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@9297355T@POWDER FOR SOLUTION FOR PERFUSION, 10 ML@EURO@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14924006@Onco@@@@@300f1012ntsdm@@@@@@@@V03AF01@V03A@NO@DEERFIELD, ILLINOIS@@@@@14924006@Indicated as a prophylactic agent in reducing the incidence of ifosfamide-inducing haemorrhagic cystitis.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@@@@@@@@Allergic reactions to mesna ranging from mild hypersensitivity to systemic anaphylactic reactions have been reported. Patients with autoimmune disorders who were treated with cyclophosphamide and mesna appeared to have a higher incidence of allergic reactions. The majority of these patients received mesna orally. Mesnex has been developed as an agent to reduce the risk of ifosfamide induced haemorrhagic cystitis. It will not prevent or alleviate any of the other adverse reactions or toxicities associated with ifosfamide therapy. Mesnex does not prevent haemorrhagic cystitis in all patients. Up to 6% of patients treated with mesna have developed haematuria (>50 RBC/hpf or WHO grade 2 and above). As a result, a morning specimen of urine should be examined for the presence of haematuria (microscopic evidence of red blood cells) each day prior to ifosfamide therapy. If haematuria develops when Mesnex is given with ifosfamide according to the recommended dosage schedule, depending on the severity of the hematuria, dosage reductions or discontinuation of ifosfamide therapy may be initiated. In order to reduce the risk of hematuria, Mesnex must be administered with each dose of ifosfamide as outlined in@@No@@@@@@APPROVED@@@GKV@RESULTS PENDING@@@@@@MESNA@@@@@MESNA||||@BAXTER HEALTHCARE@@@@@BAXTER HEALTHCARE||||@@@@@@|||||||||@Supportive Care@@@@@Supportive Care|||||||||@UROMITEXAN@@@@@UROMITEXAN||||@Detoxifying Agent@@@@@Detoxifying Agent||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@10@1.1511@52.68@77.59@55.04@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@5.27@5.27@7713861@FILM-COATED TABLET@EURO@@@@@@@@600@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14922483@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Subjects receive decitabine 20 mg/m2 IV over one hour for days1-5 of each cycle, and arsenic trioxide 0.25 mg/kg IV for days 1-5 of cycle 1 followed by 0.25 mg/kg twice weekly (Mon-Thurs or Tues-Fri) for all remaining cycles. Patients will have transfusion and supportive care therapy administered per the treating physician's discretion. Patients with a response after 4 cycles of therapy may choose to continue on two more cycles of decitabine with arsenic and ascorbic acid given only during the first week of those two additional cycles. SOURCE: clinicaltrials.gov@@-@-@-@TOKYO, JAPAN@12/1/2010@@Dacogen was approved by the U.S. Food and Drug Administration on May 2, 2006 and is indicated for the treatment of patients with MDS, including previously treated and untreated, de novo and secondary MDS of all French-American-British (FAB) subtypes (refractory anemia, refractory anemia with rings sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, chronic myelomonocytic leukemia), and Intermediate-1, Intermediate-2, and High-Risk International Prognostic Scoring System (IPSS) groups.@@14922483@Combo of Dacogen, Trisenox and ascorbic acid@@-@-@@NO REVIEW@@@@-@Dacogen for Injection was developed through a pivotal Phase 3 study by SuperGen and partnered to MGI  (acquired by Eisai Co., Ltd.). MGI subsequently sublicensed all Dacogen rights outside of North America to Janssen-Cilag, a Johnson & Johnson Company.@-@NCT00621023@20@-@-@@@-@@11/1/2007@-@9193, 7667A@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@DECITABINE@ARSENIC TRIOXIDE@@@@DECITABINE|ARSENIC TRIOXIDE|||@EISAI@MGI PHARMA@SUPERGEN@CEPHALON@@EISAI|MGI PHARMA|SUPERGEN|CEPHALON|@@@@@@|||||||||@Haematological Malignancy@Myelodysplastic Syndrome@@@@Haematological Malignancy|Myelodysplastic Syndrome||||||||@DACOGEN@TRISENOX@@@@DACOGEN|TRISENOX|||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16061298@Onco@@@@@300f1008ntsdm@@@@@@@@L01XX17@L01X@@@@@Topoisomerase I relieves torsional strain in DNA by inducing reversible single strand breaks. Topotecan binds to the topoisomerase I-DNA complex and prevents religation of these single strand breaks. The cytotoxicity of topotecan is thought to be due to double strand DNA damage produced during DNA synthesis, when replication enzymes interact with the ternary complex formed by topotecan, topoisomerase I, and DNA. Mammalian cells cannot efficiently repair these double strand breaks.@@16061298@ovarian cancer that has progressed after cancer chemotherapy.@@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@SECOND-LINE@@@1.5mg / m2 (body surface area) was dispensed daily drip infusion for 5 days, with a 3 week interval between the start of each course@MHLW, 1 June 2007@6/1/2007@@@@@@@No@@@@@@APPROVED@@@NHI@@@@@@MONO@TOPOTECAN HYDROCHLORIDE@@@@@TOPOTECAN HYDROCHLORIDE||||@NIPPON KAYAKU@@@@@NIPPON KAYAKU||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@HYCAMTIN@@@@@HYCAMTIN||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@@@@@@@@@@@@@@@@@@@@@1.6@m²@504452.0727@@@19@week@19 week@504452.07@504452.07@3792.87@1@0.0091@7301.28@8610@@@@@@@@@@@6637.53@21@@mg/m²@1.5@5@@@@@@@@@@@8/30/2017@7301.28@7301.28@4240408D1037@POWDER FOR INJECTION@YEN@@@@@@@@1.1@MG@1.1 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
16162120@Onco@@@@@@@@@@@Napabucasin plus Weekly Paclitaxel, Experimental, Patients randomized to this arm will receive napabucasin administered orally, twice daily in combination with paclitaxel administered intravenously, once weekly, on 3 of every 4 weeks.Weekly Paclitaxel, Active Comparator, Patients randomized to this arm will receive weekly paclitaxel alone administered intravenously, once weekly, on 3 of every 4 weeks.@@@@@CAMBRIDGE, MASSACHUSSETTS@10/1/2019@@@@16162120@A Phase III Randomized, Open-Label Clinical Trial of BBI-608 Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer@Both@@@@@Napabucasin will be administered in continuous 28-day cycles. The starting dose of napabucasin is 240 mg twice daily (480 mg total daily dose) with approximately 12 hours between each dose. Napabucasin should be taken with fluids either 1 hour prior to a meal or 2 hours after a meal.@@@@@SECOND-LINE@NCT02826161@870@@@@@@@10/1/2017@@CanStem43L@@@-  Must have histologically or cytologically confirmed non-squamous NSCLC.  -  Must have progressed following treatment with platinum-based combination chemotherapy for metastatic disease, and patients with an EGFR or ALK/ROS1 genetic aberration must have@@ADULTS@Phase 3@III@@@@@@@@@COMBO@NAPABUCASIN@PACLITAXEL@@@@NAPABUCASIN|PACLITAXEL|||@BOSTON BIOMEDICAL, INC@@@@@BOSTON BIOMEDICAL, INC||||@World@@@@@World|||||||||@NSCLC@@@@@NSCLC|||||||||@BBI-608@GENERIC@@@@BBI-608|GENERIC|||@Other@@@@@Other||||@OVERALL SURVIVAL@@@@@Overall Survival in biomarker positive patients@PROGRESSION FREE SURVIVAL@@@@ADVANCED@@@@@RANDOMIZED@SAFETY/EFFICACY STUDY@PARALLEL ASSIGNMENT@OPEN LABEL@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
15413593@Onco@@@@@@@@@@@Experimental: Abemaciclib + Trastuzumab + Fulvestrant; Abemaciclib given orally every 12 hours (Q12H) of a 21-day cycle; plus trastuzumab intravenous (IV) infusion on Day 1 of the cycle then a maintenance dose IV infusion on Day 1 of each subsequent cycle; plus fulvestrant intramuscularly (IM) on day 1, 15 and 29 and then once every 4 weeks thereafter.Experimental: Abemaciclib + Trastuzumab; Abemaciclib given orally Q12H of a 21-day cycle; plus trastuzumab IV infusion on Day 1 of the cycle then a maintenance dose IV infusion on Day 1 of each subsequent cycle.Active Comparator: Trastuzumab + Standard of Care Chemotherapy. Trastuzumab IV infusion on Day 1 of a 21-day cycle then a maintenance dose IV infusion on Day 1 of each subsequent cycle plus standard of care single agent chemotherapy of physician's choice administered according to product label.@@@@@INDIANAPOLIS, INDIANA@6/1/2018@@@@15413593@A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib Plus Trastuzumab With or Without Fulvestrant to Standard-of-Care Chemotherapy of Physician's Choice Plus Trastuzumab in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer@Female@@@@@@@791@@@@NCT02675231@225@@@@@@@4/1/2016@@15804, I3Y-MC-JPBZ, 2015-003400-24@@@diagnosis of HR+, HER2+ breast cancer (BC)unresectable locally advanced recurrent BC or metastatic BCadequate tumor tissue available and collected prior to randomizationmeasurable and/or non-measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1previously received: ◦at least 2 HER2-directed therapies for advanced disease◦participant must have received trastuzumab emtansine (T-DM1) in any disease settingmust have received a taxane in any disease settingmay have received any endocrine therapy (excluding fulvestrant)have postmenopausal statusperformance status (PS) of 0 to 1 on the Eastern Cooperative Oncology Group scaleleft ventricular ejection fraction (LVEF) of 50% or higher at baselineadequate organ function@HR+, HER2+@ADULTS@Phase 2@II@@@@@@@@@COMBO@ABEMACICLIB@TRASTUZUMAB@FULVESTRANT@@@ABEMACICLIB|TRASTUZUMAB|FULVESTRANT||@LILLY@@@@@LILLY||||@World@@@@@World|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@LY2835219@HERCEPTIN@FASLODEX@@@LY2835219|HERCEPTIN|FASLODEX||@Other@@@@@Other||||@PROGRESSION-FREE SURVIVAL@@@@@OVERALL SURVIVAL@COMPLETE RESPONSE@DURATION OF RESPONSE@@@ADVANCED@METASTATIC@@@@RANDOMIZED@PARALLEL ASSIGNMENT@OPEN LABEL@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14920598@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Ifosfamide dosed at 2-4G/M2 d x 3-5@@L01AA06@L01A@YES@NEW YORK, NEW YORK@@@@@14920598@Used in combination with certain other approved antineoplastic agents, Ifex is indicated for third line chemotherapy of germ cell testicular cancer. It should ordinarily be used in combination with a prophylactic agent for haemorrhagic cystitis, such as mesna. Mesnex is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced haemorrhagic cystitis.@@@@@NO REVIEW@@@@@@@@46@For IV, Ifosfamide should be given at 1.2G/M2 at 0 hours, with Mesnex given at 240MG/M2 at 0, 4 and 8 hours.@@@@@@@Ifex should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Urotoxic side effects, especially haemorrhagic cystitis, as well as CNS toxicities such as confusion and coma have been associated with the use of Ifex When they occur, they may require cessation of Ifex therapy. Severe myelosuppression has been reported.@LABEL (MESNA):@No@@@@@III FUKUOKA@APPROVED@@@MEDICARE@31% (14/46) versus 6% (3/46) developed haematuria in the conventional versus standard Mesnex IV groups respectively.@@@@@COMBO@IFOSFAMIDE/MESNA@@@@@IFOSFAMIDE/MESNA||||@BMS@@@@@BMS||||@@@@@@|||||||||@Testicular Cancer@Supportive Care@@@@Testicular Cancer|Supportive Care||||||||@IFEX/MESNEX@@@@@IFEX/MESNEX||||@Detoxifying Agent@@@@@Detoxifying Agent||||@HAEMATURIA@@@@@@@@@@@@@@@RANDOMISED@CONTROLLED@@@@@@Invalid Factory Price@@@@@@@@@1@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@US$@@@@@@@@@@1 G| 1G@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16159505@Onco@@@@@300f1018ntsdm@@@@@@Drug: treatment crizotinib 250mg orally continuous twice daily dosingDrug: treatment pemetrexed 500mg/m2 IV day 1 plus cisplatin 75mg/m2 IV day 1 every 21 days OR pemetrexed 500mg/m2 IV day 1 plus carboplatin AUC 5 or 6 day 1 every 21 days investigator's choice@@L01XE16@L01X@@NEW YORK, NEW YORK@11/1/2013@@@@16159505@XALKORI is indicated for the first-line treatment of adults with anaplastic lymphoma kinase(ALK)-positive advanced non-small cell lung cancer (NSCLC).@@NO@14-Nov@@NO REVIEW@@@@100%@Acquired through takeover of Pharmacia Corp., which acquired it from Sugen@FIRST-LINE@NCT01154140@343@The recommended dose schedule of XALKORI is 250 mg taken orally twice daily. Continue treatment as long as the patient is deriving clinical benefit from therapy.@TGA, 27 September 2013@9/27/2013@7/1/2015@Yes@@1/1/2011@@A8081014, 2010-021336-33, XALCORI@No@@Proven diagnosis of locally advanced not suitable for local treatment, recurrent and metastatic non-squamous cell carcinoma of the lung - Positive for translocation or inversion events involving the ALK gene locus- No prior systemic treatment for locally advanced or metastatic disease; Patients with brain metastases only if treated and neurologically stable with no ongoing requirement for corticosteroids - Evidence of a personally signed and dated informed consent document and willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures including completion of patient reported outcome [PRO] measures - 18 years of age or older with the exception of India which has an upper age limit of 65 years old@(ALK)-positive@@@APPROVED@@@PBS@@@@@@MONO@CRIZOTINIB@@@@@CRIZOTINIB||||@PFIZER@@@@@PFIZER||||@World@@@@@World|||||||||@NSCLC@@@@@NSCLC|||||||||@XALKORI@@@@@XALKORI||||@PDGF@@@@@PDGF||||@OVERALL SURVIVAL@Objective response rate@DURATION OF RESPONSE@@@OBJECTIVE RESPONSE RATE@@@@@ADVANCED@@@@@RANDOMIZED@PARALLEL ASSIGNMENT@OPEN LABEL@@@1@1@78775.88878@@@10.9@month@10.9 month@78775.89@78775.89@237.61@60@0.779@7128.3@7275.17@7198.24@@@@@@@@@@0.48@1@@mg@500@1@@@@@@@@@@@8/1/2017@118.81@118.81@3616-0553-GE-PF@HARD CAPSULE@A$@@@@@@@@250@MG@250 MG@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
16384794@Onco@@@@@300f1012ntsdm@@@@@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384794@Indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@FIRST-LINE@@@The recommended dose of Glivec is 600 mg/day for adult patients with Ph+ ALL.@@@@Yes@@@@@No@@@ADULT@@@APPROVED@@@GKV@@@@@@BOTH@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@@@@Haematological Malignancy|Acute Lymphocytic Leukaemia||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@@@@@@@@@@@1@1@52389.18@@@1@year@1 year@52389.18@52389.18@143.53@60@1.1511@1435.32@1816.59@1473.82@@@@@@@@@@0.24@1@@mg@600@1@@@@@@@@@@@8/1/2017@23.92@23.92@1755166@FILM-COATED TABLET@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
15409692@Onco@@@@@300f1020ntsdm@@@@@@Ibrutinib: 420 mg daily or 840 mg daily@@L01XE27@L01X@@BEERSE, BELGIUM@6/1/2013@@Ibrutinib was designed to specifically target and selectively inhibit an enzyme called Bruton's tyrosine kinase (BTK). BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel – regulating apoptosis, adhesion, and cell migration and homing. Through these multiple actions, BTK helps to direct malignant B-cells to lymphoid tissues, thus allowing access to a microenvironment necessary for survival.@@15409692@Indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy,@@YES@26-Nov-15@11/26/2015@NO REVIEW@@@@@@SECOND-LINE@NCT01105247@133@420 mg taken orally once daily (three 140 mg capsules once daily)@EMA, 21 October 2014@10/21/2014@@YES@@4/1/2010@@PCYC-1102-CA@No@@@@@II@APPROVED@@@SSN@@@@@@MONO@IBRUTINIB@@@@@IBRUTINIB||||@JANSSEN PHARMACEUTICAL@PHARMACYCLICS@@@@JANSSEN PHARMACEUTICAL|PHARMACYCLICS|||@@@@@@|||||||||@Chronic Lymphocytic Leukaemia@@@@@Chronic Lymphocytic Leukaemia|||||||||@IMBRUVICA@@@@@IMBRUVICA||||@TK Inhibitor@@@@@TK Inhibitor||||@SAFETY@@@@@PROGRESSION-FREE SURVIVAL@RESPONSE RATE@@@@@@@@@OPEN-LABEL@NON-RANDOMISED@SINGLE GROUP ASSIGNMENT@@@1@1@55352.40497@@@9@month@9 month@55352.4@55352.4@202.2@90@1.1229@6066.15@10011.57@6339.19@@@@@@@@@@0.48@1@@mg@420@1@@@@@@@@@@@6/7/2017@67.4@67.4@43693011@CAPSULE@EURO@@@@@@@@140@MG@140 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14922552@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@15mg/kg volociximab once-weekly@@-@-@-@REDWOOD, CALIFORNIA@2/1/2009@@Volociximab is a chimeric monoclonal antibody that inhibits the functional activity of a5ß1 integrin, a protein found on activated endothelial cells that are involved in the formation of blood vessels. Volociximab is currently being investigated in Phase 2 clinical trials in patients with advanced solid tumors. PDL BioPharma and Biogen Idec have a broad collaboration for the joint development, manufacture and commercialization of volociximab.@@14922552@Platinum-resistant, advanced epithelial ovarian cancer or primary peritoneal cancer@@-@-@@NO REVIEW@@@@-@Biogen Idec and PDL announced a broad collaboration for the joint development, manufacture and commercialization of three Phase II antibody products. The agreement provides for shared development and commercialization of daclizumab in multiple sclerosis and indications other than transplant and respiratory diseases, and for shared development and commercialization of M200 (volociximab) and HuZAF(TM) (fontolizumab) in all indications. Under terms of the agreement, PDL will receive an upfront payment of $40 million, and Biogen Idec will purchase $100 million of common stock from PDL. If multiple products were developed successfully in multiple indications and all milestones were achieved, PDL could receive certain development and commercialization milestone payments totaling up to $660 million. Of these, $560 million are related to development and $100 million are related to commercialization of collaboration products. Biogen Idec and PDL will share equally the costs of all development activities and all operating profits from each collaboration product within the United States and Europe. The companies will jointly oversee development, manufacturing and commercialization plans for collaboration products and intend to divide implementation responsibilities to leverage each company's capabilities and expertise. Each party will have co-promotion rights in the United States and Europe. Outside the United States and Europe, Biogen Idec will fund all incremental development and commercialization costs and pay a royalty to PDL on sales of collaboration products. [Biogen, 2.08.2005]@-@NCT00516841@56@-@-@@@-@@8/1/2007@-@206OC201@@-@-@@@II@II@@-@-@PHASE II BEGAN AUGUST 2007; DATA DUE 2008@-@@@@MONO@VOLOCIXIMAB@@@@@VOLOCIXIMAB||||@PDL BIOPHARMA@BIOGEN IDEC@@@@PDL BIOPHARMA|BIOGEN IDEC|||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@M-200@@@@@M-200||||@mAb@Chimeric@Angiogenesis Inhibitor@@@mAb|Chimeric|Angiogenesis Inhibitor||@RECIST@@@@@@@@@@ADVANCED@@@@@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15045785@Onco@@@@@300f1037ntsdm@@@@@@@@L03AA02@L03A@@BERLIN, GERMANY@@@Human G-CSF is a glycoprotein which regulates the production and release of functional neutrophils from the bone marrow. NEUPOGEN containing rmetHuGCSF (filgrastim) causes marked increases in peripheral blood neutrophil counts within twenty-four hours, with minor increases in monocytes. In some severe chronic neutropenia patients filgrastim can also induce a minor increase in the number of circulating eosinophils and basophils relative to baseline; some of these patients may present with eosinophilia or basophilia already prior to treatment. Elevations of neutrophil counts are dosedependent at recommended doses. Neutrophils produced in response to filgrastim show normal or enhanced function as demonstrated by tests of chemotactic and phagocytic function. Following termination of filgrastim therapy, circulating neutrophil counts decrease by 50% within 1 to 2 days, and to normal levels within 1 to 7 days.@@15045785@Indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. The safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy. It is indicated for the mobilisation of peripheral blood progenitor cells (PBPC). In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of 0.5 x 109/l, and a history of severe or recurrent infections, long term administration of Biograstim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events. It is indicated for the treatment of persistent neutropenia (ANC less than or equal to 1.0 x 109/l) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.@@YES@@@NO REVIEW@@@@@@@@@@EMA, 24 July 2008@7/24/2008@@@@@@@No@@@@@@APPROVED@@@SNS@@@@@@@FILGRASTIM@@@@@FILGRASTIM||||@RATIOPHARM@@@@@RATIOPHARM||||@@@@@@|||||||||@Supportive Care@Neutropaenia@@@@Supportive Care|Neutropaenia||||||||@RATIOGRASTIM@BIOSIMILAR@@@@RATIOGRASTIM|BIOSIMILAR|||@Immunotherapy@G-CSF@@@@Immunotherapy|G-CSF|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@34.12@53.26@36.89@@@@@@@@@@@@@@@@@@@@@@@@@@8/4/2017@34.12@34.12@660726@PREFILLED SYRINGE 0.5 ML@EURO@@@@@@@@300@MCG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14921195@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Cisplatin 50 mg/m2 IV day 1 of a 21 day cycle; Topotecan 0.75 mg/m2 IV Days 1, 2, 3 of a 21 day cycle; Bevacizumab 15 mg/kg day 1 of a 21 day cycle. [clinicaltrials.gov]@@L01X X17@L01X@-@BRENTFORD, UNITED KINGDOM@9/1/2009@@Topoisomerase I relieves torsional strain in DNA by inducing reversible single strand breaks. Topotecan binds to the topoisomerase I-DNA complex and prevents religation of these single strand breaks. The cytotoxicity of topotecan is thought to be due to double strand DNA damage produced during DNA synthesis, when replication enzymes interact with the ternary complex formed by topotecan, topoisomerase I, and DNA. Mammalian cells cannot efficiently repair these double strand breaks.@@14921195@Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer @@-@-@@NO REVIEW@@@@-@Merck KGaA licensed marketing and sales rights from SmithKline Beecham in June 2000 for the U.K. only.@-@NCT00548418@30@-@-@@@-@@9/1/2007@-@GSK-107278@@-@>> Recurrent or persistent squamous, adenosquamous or adenocarcinoma of the uterine cervix not amenable to curative treatment with surgery and/or radiotherapy >> No prior therapy (radiation, chemotherapy, hormonal therapy or immunotherapy) for recurrence or persistence. May have received platinum in combination with radiation as part of up-front treatment or adjuvant treatment@@@II@II@@-@-@Trial registered [GSK, 23.10.2007]@-@@@@COMBO@TOPOTECAN HYDROCHLORIDE@BEVACIZUMAB@CISPLATIN@@@TOPOTECAN HYDROCHLORIDE|BEVACIZUMAB|CISPLATIN||@GSK@GENENTECH@@@@GSK|GENENTECH|||@@@@@@|||||||||@Cervical Cancer@@@@@Cervical Cancer|||||||||@HYCAMTIN@AVASTIN@@@@HYCAMTIN|AVASTIN|||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@PROGRESSION-FREE SURVIVAL@@@@@OVERALL SURVIVAL@RECIST@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@CAPSULE@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16639031@Onco@@@@@300f1015ntsdm@@@@@@@@L01XE23@L01X@@LONDON, UNITED KINGDOM@7/1/2011@@Dabrafenib is an  orally bioavailable inhibitor of the BRAF protein.  Dabrafenib was discovered and developed at GSK.@@16639031@Dabrafenib is indicated in monotherapy for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.@Both@No@7-May-14@5/7/2014@@@@@100%@@@NCT01153763@92@The recommended dose of dabrafenib, either used as monotherapy or in combination with trametinib, is 150 mg (two 75 mg capsules) twice daily (corresponding to a total daily dose of 300 mg).@EMA, 26 August 2013@8/26/2013@10/7/2013@No@@8/1/2010@@BRF113710@No@@Must be at least 18 years of age; Must have histologically confirmed cutaneous metastatic melanoma (Stage IV) that is BRAF mutation-positive (V600 E/K) as determined via central testing with a BRAF mutation assay; Is treatment naive or has received prior treatment for metastatic melanoma; Must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1); Women of child-bearing potential must have a negative pregnancy test within 14 days prior to the first dose of study treatment; Women with reproductive potential must be willing to practice acceptable methods of birth control during the study and for up to 4 weeks after the last dose of study medication; Men with reproductive potential must be willing to practice acceptable methods of birth control during the study and for up to 16 weeks after the last dose of study medication; Must have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1; Adequate organ function.@BRAF V600 mutation@ADULTS@II@APPROVED@@ASMR V [http://www.has-sante.fr/portail/upload/docs/application/pdf/2015-10/tafinlar_summary_ct13242.pdf]@HAUTE AUTORITÉ DE SANTÉ@@@@@@MONO@DABRAFENIB@@@@@DABRAFENIB||||@GSK@@@@@GSK||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@TAFINLAR@@@@@TAFINLAR||||@Other@@@@@Other||||@OVERALL RESPONSE RATE@@@@@PROGRESSION FREE SURVIVAL@@@@@UNRESECTABLE@METASTATIC@@@@SINGLE GROUP@OPEN LABEL@@@@1@1@38476.17004@@@6.9@month@6.9 month@38476.17@38476.17@183.33@120@1.1511@3666.66@3873.55@3696.66@@@@@@@@@@0.61@1@@mg@300@1@@@@@@@@@@@8/1/2017@30.56@30.56@3.40E+12@CAPSULE@EURO@@@@@@@@50@MG@50 MG@@@@@@@@@@@@@@@@@@@@@@@@85@France
14916071@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@NO LABELLED TRIAL@@M04AA01@M04A@NO@@@@@@14916071@Indicated in the management of patients with signs and symptomas of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephroptahy; the management of patients with leukaemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment should be discontinued when the potential for overproduction of uric acid is no longer presents; and, the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800mg/day in male patients and 750mg/day in female patients. This is not an innocuous drug. It is not recommended for the treatment of asymptomatic hyperuricemia.@@NO@@@NO REVIEW@@@@@@@@@For the prevention of uric acid nephropathy during the vigorous therapy of neoplastic disease, treatment with 600 to 800 mg daily for two or three days is advisable together with a high fluid intake. Otherwise similar considerations to the above recommendations for treating patients with gout govern the regulation of dosage for maintenance purposes in secondary hyperuricemia.@@@@@@@Should be discontinued at the first appearance of skin rash or other signs which may indicate an allergic rection. Dose should be adjusted if co-administered with Purinethol or Imuran.@NO LABELLED TRIAL@No@@@@@@APPROVED@@Covered; preferred@MEDICARE@NO LABELLED TRIAL@@@@@@ALLOPURINOL@@@@@ALLOPURINOL||||@QUALITEST@@@@@QUALITEST||||@@@@@@|||||||||@Supportive Care@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Non-Hodgkin's Lymphoma@Supportive Care|Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Non-Hodgkin's Lymphoma|||||@GENERIC@@@@@GENERIC||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@100@1@76.96@@@@@@@@@@@@@@@@@@@@@@@@@@@@9/1/2017@0.77@0.77@00603-2116-21@TABLET@US$@@@@@@@@300@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15322743@Onco@@@@@300f1010ntsdm@@@@@@150 mg once daily until disease progression or unacceptable toxicity@@L01XX43@L01X@@BASEL, SWITZERLAND@8/1/2013@@@@15322743@Indicated for the treatment of adult patients with: symptomatic metastatic basal cell carcinoma or locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy@Both@YES@@@NO REVIEW@@@@100%@@@NCT01367665@150@The recommended dose is one 150 mg capsule taken once daily. In clinical trials, treatment with Erivedge was continued until disease progression or until unacceptable toxicity.@EMA, 12 July 2013@7/12/2013@@No@@6/1/2011@@MO25616, 2011-000195-34@No@@Metastatic or locally advanced basal cell carcinoma considered inoperable or that surgery is contraindicated and radiotherapy is contraindicated or inappropriateEastern Cooperative Oncology Group (ECOG) Performance Status 0-2@@ADULTS@II@APPROVED@@@NHS@The study showed Erivedge shrank lesions (objective response rate, or ORR) in 43 percent (27/63) of patients with locally advanced BCC and 30 percent of patients (10/33) with metastatic BCC, as assessed by independent review, the primary endpoint of the study. The median duration of response was 7.6 months.[Roche, 30 January 2012 http://www.roche.com/media/media_releases/med-cor-2012-01-30.htm]>>Trial registered [Roche 30 May 2011]@The most common side effects of Erivedge are muscle spasms, hair loss, change in how things taste or loss of taste, weight loss, tiredness, nausea, diarrhoea, decreased appetite, constipation, vomitting and joint aches. Other side effects may include missed monthly periods in females who can become pregnant, low levels of sodium in the blood, low potassium levels, and a higher than normal blood level of urea or other nitrogen containing compounds in the blood.@@@@@VISMODEGIB@@@@@VISMODEGIB||||@ROCHE@CURIS@@@@ROCHE|CURIS|||@@@@@@|||||||||@Other@@@@@Other|||||||||@ERIVEDGE@@@@@ERIVEDGE||||@Hedgehog Pathway Inhibitor@@@@@Hedgehog Pathway Inhibitor||||@SAFETY@@@@@RESPONSE@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@@ADVANCED@METASTATIC@@@@SINGLE-ARM@OPEN-LABEL@@@@1@1@64859.40408@@@9.5@month@9.5 month@64859.4@64859.4@224.46@28@1.299@6285@@@@@@@@@@@@1.5@1@@mg@150@1@@@@@@@@@@@7/28/2017@224.46@224.46@2.28E+16@HARD CAPSULE@GB£@@@@@@@@150@MG@150 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14921507@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Induction: EC145 1.0 mg intravenous injection, Monday through Friday, for the first 3 weeks of each 4 week cycle.Maintenance: EC145 2.5 mg intravenous injection, Monday, Wednesday, and Friday, weeks 1 and 3 of each 4 week cycle.At the investigator's discretion, patients may receive EC145 via an ambulatory pump after the first week of therapy has been administered in the clinic setting. [clinicaltrials.gov]@@-@-@-@WEST LAFAYETTE, INDIANA@3/1/2011@@EC145 links a very potent anticancer drug to the vitamin folate, which is requiredfor cell division. Rapidly dividing cancer cells over-express folate receptors tocapture enough folate to support cell division. By combining a chemotherapy drugwith folate, EC145 targets cancer cells while avoiding normal cells. This targetedapproach is designed to provide treatment with more potent drugs with lowertoxicity.@@14921507@Adenocarcinoma of the lung@@-@-@@NO REVIEW@@@@-@-@-@NCT00511485@41@-@-@@@-@@8/1/2007@-@EC-FV-03@@-@Previously received at least 2 cytotoxic containing chemotherapeutic regimens (can include an EGFR inhibitor). There is no upper limit to the number of prior chemotherapeutic regimens.@@@II@II@@-@-@>> At the planned interim analysis, 35 percent (6/17) of patients achieved clinical benefit (CR+PR+SD), sixty-seven percent (4/6) of patients had a duration of response of six months or longer, and one patient had significant tumor reduction (>30 percent). All of these patients had previously failed two to eight prior therapies. Analysis of the safety data indicates that EC145 was generally well tolerated. Based on the positive results from the interim analysis, the two-stage clinical trial will continue on to full enrollment. [Endocyte, 24 March 2009]>> Trial registered [Endocyte, 2 August 2007]@-@@@@MONO@-@@@@@-||||@ENDOCYTE@@@@@ENDOCYTE||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@EC-145@@@@@EC-145||||@Other@@@@@Other||||@RESPONSE RATE@@@@@PROGRESSION-FREE SURVIVAL@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16062570@Onco@@@@@@@@@@@TAK-580 + nivolumab, Experimental, TAK-580 orally, once weekly along with nivolumab, intravenous, twice weekly.TAK-202 (plozalizumab) + nivolumab, Experimental, TAK-202 (plozalizumab) 2 mg, intravenous, once in Week 1, 3, 5, 9, and every 4 weeks thereafter with nivolumab infusion, intravenous, twice weekly.vedolizumab + nivolumab + ipilimumab, Experimental, Vedolizumab intravenous, once in Week 1, 3, 5, and 13 along with nivolumab infusion, intravenous, once in Week 3, 6, 9, and 12 and every 2 weeks thereafter, along with ipilimumab intravenous, once in Week 3, 6, 9, and 12.@@@@@CAMBRIDGE, MASSACHUSSETTS@9/1/2018@@@@16062570@An Open-Label, Phase 1b, Multi-Arm Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Patients With Advanced Melanoma@Both@@@@@TAK-580 tablets@@@@@@NCT02723006@156@@@@@@@3/1/2016@@C28003@@@1. Is a male or female participant of 18 years or older.  2. Has histologically confirmed, unresectable Stage III or Stage IV melanoma per the American Joint Committee on Cancer (AJCC) staging system.  3. Has an eastern cooperative oncology group (ECOG) performance status of 0-1.  4. Adequate bone marrow reserve and renal and hepatic function within 28 days before the first dose of study drug on the basis of the defined laboratory parameters.  5. Had disease accessible for repeat biopsy and willingness to undergo serial tumor biopsies.  6. Additional Inclusion Requirements for arm 1 only (nivolumab + TAK-580)  a) BRAF (gene) V600 mutation-positive or NRAS (gene) mutation-positive disease previously untreated with RAF, MEK, or other inhibitors of the mitogen-activated protein kinase (MAPK) pathway. Participants who have progressed on these agents can still be enrolled in Arms 2 or 3.  7. Additional Inclusion Requirements for expansion cohorts only a) Measurable disease per RECIST guidelines (v 1.1) and at least 1 non-target lesion accessible for biopsy per the guidelines above.@@ADULTS@Phase 1@I@@@@@@@@@COMBO@-@NIVOLUMAB@@@@-|NIVOLUMAB|||@MILLENNIUM PHARMACEUTICALS@@@@@MILLENNIUM PHARMACEUTICALS||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@TAK-580@OPDIVO@@@@TAK-580|OPDIVO|||@Other@@@@@Other||||@Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE's)@@@@@Overall Response Rate (ORR)@Duration of response (DOR)@@@@ADVANCED@@@@@NON-RANDOMIZED@Safety Study@PARALLEL ASSIGNMENT@OPEN LABEL@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
15318124@Onco@@@@@300f1010ntsdm@@@@@@120 mg administered as a single subcutaneous injection once every 4 weeks into the thigh, abdomen or upper arm.@@M05BX04@M05B@-@THOUSAND OAKS, CALIFORNIA@@@Denosumab is a fully human monoclonal antibody that specifically targets the receptor activator of nuclear factor kappa B ligand (“RANKL”), a key mediator of the cells responsible for bone breakdown. Denosumab is being studied across a range of conditions, including osteoporosis, treatment-induced bone loss, bone metastases, rheumatoid arthritis, and multiple myeloma.@@15318124@Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumours.@@NO@@@NO REVIEW@@@@100%@Japanese rights licensed to Daiichi Sankyo for US$20 mil upfront and royalties in July 2007, and Daiichi Sankyo will pay US$150 mil of expected worldwide development costs through 2009.@@@2862@The recommended dose of XGEVA for the prevention of skeletal related events is 120 mg administered as a single subcutaneous injection once every 4 weeks into the thigh, abdomen or upper arm.@EMA, 15 July 2011@7/15/2011@@No@@@@@No@@@@@III@APPROVED@@@NHS@Denosumab treatment produced statistically significantly greater increases in bone mineral density (BMD) at the lumbar spine (primary endpoint) and non-vertebral sites compared with placebo at multiple time points. These improvements in BMD were consistent with those seen in other denosumab studies evaluating BMD in women with breast cancer receiving aromatase inhibitor therapy, and in post-menopausal women with low bone mass. [Amgen, 14 July 2008]          Trial registered. [Amgen, 02.02.2006]@@@@@MONO@DENOSUMAB@@@@@DENOSUMAB||||@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Supportive Care@Bone Loss@@@@Supportive Care|Bone Loss||||||||@XGEVA@@@@@XGEVA||||@mAb@Human@RANK Ligand@@@mAb|Human|RANK Ligand||@@@@@@@@@@@@@@@@@@@@@1@1@9290.063163@@@27.6@month@27.6 month@9290.06@9290.06@11.07@1@1.299@309.86@@@@@@@@@@@@2.58@28@@mg@120@1@@@@@@@@@@@7/28/2017@309.86@309.86@1.94E+16@SOLUTION FOR INJECTION, 1.7 ML@GB£@@@@@@@@120@MG@120 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14916619@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Talabostat with Alimta versus Alimta with placebo.@@-@-@-@BOSTON, MASSACHUSSETTS@@@This is a substance being studied in the treatment of cancer, including certain types of lung, pancreas, and brain cancer. Talabostat may help the immune system block the growth of cancer cells. It may also increase the growth of new blood cells. It is a type of enzyme inhibitor. @@14916619@Stage IIIb/IV NSCLC combo with pemetrexed after failure of platinum-based chemo@@-@-@@NO REVIEW@@@@-@DARA and Point to merge; DARA will become wholly-owned subsidiary, whilst Point will change its name to DARA BiosSciences. SOURCE: Point, 10 October 2007@SECOND-LINE@NCT00290017@360@-@-@@@-@@2/1/2006@-@PTH-305@@-@-@@@III@CLINICAL HOLD@@-@-@IDMC recommended stopping both Phase III NSCLC studies due to neither the primary endpoint of median PFS nor the secondary endpoint of OS demonstrating improvement over the placebo groups. The talabostat combination trial with docetaxal, the talabostat arm had significantly lower overall survival than the placebo arm.@-@@@@COMBO@TALABOSTAT@PEMETREXED@@@@TALABOSTAT|PEMETREXED|||@DARA BIOSCIENCES@@@@@DARA BIOSCIENCES||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@PT-100@ALIMTA@@@@PT-100|ALIMTA|||@Immunotherapy@@@@@Immunotherapy||||@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@@@@@@@@METASTATIC@@@@@RANDOMISED@PLACEBO-CONTROLLED@DOUBLE-BLIND@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924177@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@CO-FACTOR PLUS 5-FLOUROURACIL@@-@-@-@SAN DIEGO, CALIFORNIA@@@CoFactor is a folate-based biomodulator designed to replace leucovorin as the preferred method to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapeutic agent 5-FU. Compared to leucovorin, CoFactor creates more stable binding between the active form of 5-FU and the target enzyme, thymidylate synthase, or TS. CoFactor bypasses the metabolic pathway required by leucovorin to deliver the active form of folate, potentially allowing 5-FU to work more effectively. Inhibiting TS is a well-established and effective method of killing rapidly dividing cells, such as tumor cells. Inhibition of TS is most frequently accomplished through use of 5-FU, the metabolite of which binds to TS and disrupts cell replication. Binding between TS and the metabolite of 5-FU requires the action of a specific folate: 5,10-methylenetetrahydrofolate, or MTHF.@@14924177@-@@-@-@@NO REVIEW@@@@-@"Adventrx is ""exploring strategic alternatives"", including the potential sale of its key oncology assets ANX-514 and ANX-530. The company has already reduced its size by 27% to 24 in October. [Adventrx, 22.12.2008]"@-@-@300@-@-@@@-@@@-@-@@-@-@@@IIB@DISCONTINUED@@-@-@In Phase IIb trials, CoFactor plus flourouracil missed the primary endpoint of a lower proportion of patients reporting >1 hematological or gastrointestinal adverse event of grade 3 or higer compared with leucovarin plus 5-flourouracil. There were 23 such events in the CoFactor arm versus 10 events in the control arm (p<0.05). Objective response rates were 10.7% in the CoFactor group compared with 13.3% in the control arm. Median PROGRESSION-FREE SURVIVAL and median survival were 6.3 and 14.7 months in CoFactor patients compared with 6.1 and 14.3 months in patients receiving leucovorin plus 5-flourouracil.@-@@@@COMBO@THYMIDYLATE SYNTHASE@FLUOROURACIL@@@@THYMIDYLATE SYNTHASE|FLUOROURACIL|||@ADVENTRX PHARMACEUTICAL@@@@@ADVENTRX PHARMACEUTICAL||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ANX-510@COFACTOR@@@@ANX-510|COFACTOR|||@Folic Acid Analogue@@@@@Folic Acid Analogue||||@RESPONSE RATE@TIME TO PROGRESSION@QUALITY OF LIFE@@@QUALITY OF LIFE@@@@@METASTATIC@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922617@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Photofrin PDT versus Nd:YAG laser therapy@@L01XD01@L01X@NO@QUEBEC, CANADA@@@@@14922617@Photodynamic therapy with Photofrin is indicated for: - Palliation of patients with completely obstructing esophageal cancer, or of patients with partially obstructing esophageal cancer who, in the opinion of their physician, cannot be satisfactorily treated with Nd:YAG laser therapy. - Reduction of obstruction and palliation of symptoms in patients with completely or partially obstructing endobronchial non-small-cell lung cancer (NSCLC). - Treatment of microinvasive endobronchial NSCLC in patients for whom surgery and radiotherapy are not indicated. - Ablation of high-grade dysplasia in Barrett's esophagus patients who do not undergo esophagectomy.@@NO@@@NO REVIEW@@@@@Licensed from QLT@@@211@Photodynamic therapy with Photofrin is a two-stage process requiring administration of both drug and light. The first stage of PDT is the intravenous injection at 2 mg/kg. Illumination with laser light 40–50 hours following injection constitutes the second stage of therapy. A second laser light application may be given 96-120 hours after injection, preceded by gentle debridement of residual tumor@@@@@@@Endobronchial Cancer: Patients should be assessed for the possibility that a tumor may be eroding into a pulmonary blood vessel. Patients at high risk for fatal massive hemoptysis (FMH) include those with large, centrally located tumors, those with cavitating tumors or those with extensive tumor extrinsic to the bronchus.@LABEL@No@N/A@@@@III TWO TRIALS [ENDOBRONCHIAL CANCER]@APPROVED@@@MEDICARE@Objective tumour response rates (CR + PR), which demonstrate reduction of obstruction, were 59% for PDT and 58% for Nd:YAG at Week 1. The response rate at 1 month or later was 60% for PDT and 41% for Nd:YAG.@@@@@MONO@PORFIRMER SODIUM@@@@@PORFIRMER SODIUM||||@PINNACLE BIOLOGICS@@@@@PINNACLE BIOLOGICS||||@@@@@@|||||||||@NSCLC@Oesophageal Cancer@@@@NSCLC|Oesophageal Cancer||||||||@PHOTOFRIN@@@@@PHOTOFRIN||||@Other@@@@@Other||||@RESPONSE RATE@@@@@@@@@@@@@@@RANDOMISED@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1@20427@@@@@@@@@@@@272.36@@@@@@@@@@@@@@@@8/2/2017@20427@20427@76128-0155-75@POWDER FOR SOLUTION FOR INJECTION (VIAL)@US$@@@@@@@@75@MG@75 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918092@Onco@@@@@300f1014ntsdm@@@@@@404 patients received Casodex 50mg once-daily, 409 received flutamide 250mg three-times daily, each in combination with goserelin acetate implant or leuprolide acetate depot.@@L02BB03@L02B@NO@LONDON, UNITED KINGDOM@@@Casodex is a non-steroidal antiandrogen, devoid of other endocrine activity. It binds to androgen receptors without activating gene expression, and thus inhibits the androgen stimulus. Regression of prostatic tumours results from this inhibition. Clinically, discontinuation of Casodex can result in antiandrogen withdrawal syndrome in a subset of patients. Casodex is a racemate with its antiandrogenic activity being almost exclusively in the (R)-enantiomer.@@14918092@Indicated for use in combination therapy with an LH-RH analogue for the treatment of Stage D2 metastatic carcinoma of the prostate.@@NO@@@NO REVIEW@@@@100%@@FIRST-LINE@@813@Adult males including the elderly: one tablet (50mg) once a day. Treatment with 'Casodex' should be started at least 3 days before commencing treatment with an LHRH analogue, or at the same time as surgical castration.@@@@@@@Rare cases of death or hospitalisation due to severe liver injury have been reported in post-marketing in association with Casdoex use.@N/A@No@@813 PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED PROSTATE CANCER@@@III@APPROVED@@Unrestricted reimbursement.@RAMQ@Overall survival was not statistically significant; 52.7% of the Casodex/LHRH group had died, and 57.5% of the flutamide/LHRH group had died.@@@@@COMBO@BICALUTAMIDE@@@@@BICALUTAMIDE||||@GENPHARM@@@@@GENPHARM||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@GEN-BICALUTAMIDE@GENERIC@@@@GEN-BICALUTAMIDE|GENERIC|||@Hormone Antagonist@Anti-androgen@@@@Hormone Antagonist|Anti-androgen|||@OVERALL SURVIVAL@@@@@@@@@@METASTATIC@@@@@MULTI-CENTRE@DOUBLE-BLIND@CONTROLLED@@@@@Invalid Factory Price@@@@@@@@@100@0.7881@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@C$@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
16384687@Onco@@@@@300f1020ntsdm@@@@@@@@L01CD02@L01C@@PARIS, FRANCE@@@Docetaxel is an antineoplastic agent which acts by promoting the assembly of tubulin into stable microtubules and inhibits their disassembly which leads to a marked decrease of free tubulin. The binding of docetaxel to microtubules does not alter the number of protofilaments. Docetaxel has been shown in vitro to disrupt the microtubular network in cells which is essential for vital mitotic and interphase cellular functions. Docetaxel was found to be cytotoxic in vitro against various murine and human tumour cell lines and against freshly excised human tumour cells in clonogenic assays. Docetaxel achieves high intracellular concentrations with a long cell residence time. In addition, docetaxel was found to be active on some but not all cell lines over expressing the p-glycoprotein which is encoded by the multidrug resistance gene. In vivo, docetaxel is schedule independent and has a broad spectrum of experimental antitumour activity against advanced murine and human grafted tumours.@@16384687@TAXOTERE is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy.@@YES@8-Oct-10@10/8/2010@NO REVIEW@@@@100%@@SECOND-LINE@@@For treatment after failure of prior platinum-based chemotherapy, the recommended dose is 75 mg/m² as a single agent. Docetaxel is administered as a one-hour infusion every three weeks.@N/A@@@@@@@@No@@@@@@APPROVED@@@SSN@@@@@@MONO@DOCETAXEL@@@@@DOCETAXEL||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@TAXOTERE@@@@@TAXOTERE||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@@@@@@@@@@@LOCALLY ADVANCED@UNRESECTABLE@@@@@@@@@1.75@m²@3209.713827@@@12.3@week@12.3 week@3209.71@3209.71@37.28@1@1.1229@477.17@787.52@498.64@@@@@@@@@@5.96@21@@mg/m²@75@1@@@@@@@@@@@6/7/2017@477.17@477.17@32391029@CONCENTRATE AND SOLVENT FOR SOLUTION FOR INFUSION, 2 ML@EURO@@@@@@@@80@MG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14924661@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@KVISTGARD, DENMARK@@@@@14924661@Androgen-independent prostate cancer (AIPC) treated with PROSTVAC-VF + immune modulating agents@@-@-@@NO REVIEW@@@@-@The drug was initially developed by Therion Biologics, but after failing to meet its primary endpoint in June 2006, the firm was liquidated, and Prostvac was returned to the US government. Bavarian Nordic and the NCI are currently co-developing the drug.@-@NCT00078585@125@-@-@@@-@@11/1/2003@-@-@@-@ABOUT 125 MALE PATIENTS@@@II@II@@-@-@Prostvac had a statistically significantly longer median overall survival by 8.5 months (p=0.015) compared to the control group. Currently the only approved treatment for advanced prostate cancer extends median overall survival by an average of approximately 2 months. Based on these results, Bavarian Nordic expects to initiate confirmatory Phase III studies together with NCI in the first half of 2010 that will form the basis of approval for this therapy. [Bavarian Nordic, 7.10.2008]@-@@@@COMBO@-@@@@@-||||@BAVARIAN NORDIC@@@@@BAVARIAN NORDIC||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@PROSTVAC@@@@@PROSTVAC||||@Vaccine@@@@@Vaccine||||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@METASTATIC@@@@@MULTI-CENTRE@DOUBLE-BLIND@RANDOMISED@PLACEBO-CONTROLLED@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16511654@Onco@@@@@@@@@@@Phase 1, Experimental, Ramucirumab: 8 mg/kg, every two week Nivolumab: 3.0 mg/kg or 1.0 mg/kg (optional), every two weeksPhase 2, Experimental, Ramucirumab: 8 mg/kg, every two week Nivolumab: recommended dose established in the phase 1, every two weeks@@L01XC21@L01X@@OSAKA, JAPAN@6/1/2019@@IMC-1121B is a fully human IgG1 monoclonal antibody designed to bind to the extracellular domain of VEGFR-2 found on tumor vasculature, thereby inhibiting certain ligands known as vascular endothelial growth factors from binding to and activating the rece@@16511654@A Multicenter, Phase 1/2 Study of Ramucirumab Plus Nivolumab as Second-line Therapy in Participants With Gastric or GEJ Cancer@Both@@@@@Ramucirumab (8 mg/kg) is administered.@@@@@FIRST-LINE@NCT02999295@44@@@@@@@1/1/2017@@NCCH-1611@@@Advanced or recurrent unresectable gastric or GEJ cancer  -  Histologically confirmed adenocarcinoma (papillary adenocarcinoma, tubular adenocarcinoma or poorly differentiated adenocarcinoma), signet-ring cell carcinoma, mucinous adenocarcinoma or hepatoid adnocarcinoma  -  Patients with normal oral intake  -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1  -  Patients who have measurable target lesion  -  Patients has a refractory or intolerant pretreatment by pyrimidine fluoride anticancer agent and platinum-based anticancer agent  -  Patients with adequate organ function  -  Patients with no pretreatment history including ramucirumab, nivolumab or other therapies targeting control of T cells  -  Patients with written informed consent@@ADULTS@Phase 1/Phase 2@I/II@@@@@@@@@COMBO@RAMUCIRUMAB@NIVOLUMAB@@@@RAMUCIRUMAB|NIVOLUMAB|||@ONO PHARMACEUTICALS@@@@@ONO PHARMACEUTICALS||||@@@@@@|||||||||@GIST@@@@@GIST|||||||||@CYRAMZA@OPDIVO@@@@CYRAMZA|OPDIVO|||@TK Inhibitor@Angiogenesis Inhibitor@VEGF@mAb@Human@TK Inhibitor|Angiogenesis Inhibitor|VEGF|mAb|Human@Number of participants with dose limiting toxicities (DLTs)@Progression free survival rate after 6 months@@@@Number of participants with adverse events@Objective response rate (ORR): percentage of participants with with a best response of complete response (CR) or partial response (PR)@@@@ADVANCED@UNRESECTABLE@@@@Non-Randomized@Safety/Efficacy Study@Parallel Assignment@Open Label@Treatment@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916706@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@"Up to 5 cohorts will receive PCI-24781 orally at doses starting at 30 mg/m2 three times a day approximately 4 hours apart (""TID""), up to 150 mg/m2 TID, administered 5 days per week during the first 21 days of each 28 day cycle until MTD is reached. An additional cohort (Dose Expansion Cohort) will receive PCI-24781 orally TID 5 days per week for 28 days of each 28 day cycle at the MTD determined from the 21 day administration schedule cohorts. SOURCE: clinicaltrials.gov"@@-@-@-@SUNNYVALE, CALIFORNIA@12/1/2008@@@@14916706@Advanced cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00562224@36@-@-@@@-@@11/1/2007@-@PCYC-0402@@-@-@@@I@I@@-@-@The company plans to initiate a Phase 1/2 trial evaluating PCI-24781 in haematologic malignancies in the second quarter of 2008. This trial will utilize a novel proprietary biomarker, RAD51, to confirm pre-clinical data demonstrating that high RAD51 levels in tumors make the tumor more sensitive to PCI-24781. SOURCE: Pharmacyclics, 28 February 2008@-@@@@MONO@-@@@@@-||||@PHARMACYCLICS@@@@@PHARMACYCLICS||||@@@@@@|||||||||@Solid Tumours@Haematological Malignancy@@@@Solid Tumours|Haematological Malignancy||||||||@PCI-24781@@@@@PCI-24781||||@HDAC@@@@@HDAC||||@DOSE-LIMITING TOXICITY@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15361149@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@DASISION@Patients were randomized to receive either SPRYCEL 100 mg once daily or imatinib 400 mg once daily@@L01XE06@L01X@@NEW YORK, NEW YORK@12/1/2013@@Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRß. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.@@15361149@Indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.@Both@NA@@@@@@@@@FIRST-LINE@NCT00481247@519@@FDA, 28 October 2010@10/28/2010@@Yes@@8/1/2007@@CA180-056/2006-005712-27@No@@Male & Female ≥18 years/Chronic Phase Ph+ CML/Eastern Cooperative Oncology Group Performance Status (ECOG PS) score 0-2@@ADULTS@III@APPROVED@@@@@@@@@MONO@DASATINIB@@@@@DASATINIB||||@BMS@@@@@BMS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@SPRYCEL@@@@@SPRYCEL||||@TK Inhibitor@bcr-abl@PDGF@@@TK Inhibitor|bcr-abl|PDGF||@RATE OF CONFIRMED COMPLETE CYTOGENETIC RESPONSE@@@@@@@@@@CHRONIC PHASE@PH+@@@@OPEN-LABEL@MULTICENTER@RANDOMISED@@@1@1@214307.283@@@14@month@14 month@214307.28@214307.28@503.28@30@1@12078.64@@@@@@@@@@@@5.03@1@@mg@100@1@@@@@@@@@@@8/2/2017@402.62@402.62@00003-0855-22@TABLET@US$@@@@@@@@80@MG@80 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924622@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@ONTAK versus placebo@@L01XX29@L01X@-@TOKYO, JAPAN@@@Ontak is indicated for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor. ONTAK is a genetically-engineered cytotoxic fusion protein consisting of the amino acid sequences for the enzymatically-active portion of diphtheria toxin fused to the sequence of human interleukin-2, resulting in a molecule that is cytotoxic for cells bearing the target IL-2 receptor. Ontak was granted approval in February 1999 under Subpart E, an FDA regulation that allows the accelerated approval of a biologic agent based on a surrogate endpoint or an effect on a clinical endpoint other than survival. The process by which Ontak received accelerated approval requires a confirmatory, placebo-controlled Phase III trial. Accelerated approval is most commonly granted in serious diseases or for medications that fill an unmet medical need. @@14924622@Previously treated, indolent NHL@@-@-@@NO REVIEW@@@@-@Global rights licensed from Ligand in September 2006@-@NCT0051025@64@-@-@@@-@@5/1/2000@-@-@@2014@-@@@II@II@@-@-@RESULTS PENDING (recruiting).@-@@@@MONO@DENILEUKIN DIFTITOX@@@@@DENILEUKIN DIFTITOX||||@EISAI@@@@@EISAI||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@B-Cell Lymphoma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|B-Cell Lymphoma|||||||@ONTAK@@@@@ONTAK||||@Interleukin@@@@@Interleukin||||@COMPLETE RESPONSE@PARTIAL RESPONSE@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16431998@Onco@@@@@300f1008ntsdm@@@@@@@@@@@NEW YORK, NEW YORK@@@Elotuzumab is a humanized IgG1 monoclonal antibody that specifically targets the SLAMF7 (Signaling Lymphocytic Activation Molecule Family member 7) protein. SLAMF7 is expressed on myeloma cells independent of cytogenetic abnormalities. SLAMF7 is also expressed on Natural Killer cells, plasma cells, and at lower levels on specific immune cell subsets of differentiated cells within the hematopoietic lineage.@@16431998@@@NA@18-Nov-16@11/18/2016@@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@@@@@MHLW, 28 September 2016@9/28/2016@@Yes@@@@@No@@@@@@APPROVED@@@NHI@@@@@@COMBO@ELOTUZUMAB@LENALIDOMIDE@DEXAMETHASONE@@@ELOTUZUMAB|LENALIDOMIDE|DEXAMETHASONE||@BRISTOL MYERS SQUIBB@@@@@BRISTOL MYERS SQUIBB||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@EMPLICITI@REVLIMID@GENERIC@@@EMPLICITI|REVLIMID|GENERIC||@mAb@Humanised@@@@mAb|Humanised|||@@@@@@@@@@@REFRACTORY@RELAPSED@@@@@@@@@76.5@kg@15686044.96@@@19.4@month@19.4 month@15686044.96@15686044.96@26583.34@1@0.0091@177729.78@209587@@@@@@@@@@@444.32@28@2@mg/kg@10@4@28@@mg/kg@10@2@@@@@@8/30/2017@177729.78@177729.78@4291434D2027@IV DRIP INFUSION@YEN@@@@@@@@400@MG@400 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
15400324@Onco@@@@@300f1008ntsdm@@@@@@@@L01CX01@L01C@@@@@Yondelis (trabectedin, ET-743) was originally isolated from the marine tunicate Ecteinascidia turbinata. Yondelis has a novel mechanism of action. It is a unique anti cancer agent that binds into the minor groove of the DNA and interacts with DNA repair enzymes and transcription factors, interfering with different cell cycle processes. In addition to STS, Yondelis is being developed in a pivotal Phase III trial in ovarian cancer and in Phase II in prostate and breast cancers. Yondelis was designated Orphan Drug for STS by the European Commission (E.C.) in 2001 and by the U.S. FDA in 2004 and for ovarian cancer by the E.C. in 2003 and by the U.S. FDA in 2005.@@15400324@Malignant soft tissue tumors@@NA@1-Nov-15@11/1/2015@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@@@73@he recommended dose is 1.5 mg/m2 body surface area, administered as an intravenous infusion over 24 hours with a three-week interval between cycles@MHLW, 1 November 2015@11/1/2015@@@@@@@No@@@@@II@APPROVED@@@NHI@@@@@@MONO@TRABECTEDIN@@@@@TRABECTEDIN||||@TAIHO@@@@@TAIHO||||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@YONDELIS@@@@@YONDELIS||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@PROGRESSION FREE SURVIVAL@@@@@@@@@@ADVANCED@@@@@@@@@@1.75@m²@3524612.741@@@5.6@month@5.6 month@3524612.74@3524612.74@20692.9@1@0.0091@165543.17@195216@@@@@@@@@@@165543.17@21@@mg/m²@1.5@1@@@@@@@@@@@8/30/2017@165543.17@165543.17@4291431D2023@INTRAVENOUS INFUSION@YEN@@@@@@@@1@MG@1 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14924206@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Oral AV-951 once daily vs placebo@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@@@AV-951 is a novel, highly potent and specific inhibitor of VEGF receptors 1, 2 and 3. Angiogenesis inhibition has demonstrated benefit for patients with a wide range of cancer types, including renal cell carcinoma, metastatic breast cancer, colorectal cancer, and non-small cell lung cancer.  Due to its specificity, AVEO believes AV-951 may be more readily combined with standard chemotherapy as well as other targeted therapies, potentially increasing the breadth of its clinical utility.  AVEO's translational research effort, comprising its Human Response Platform (HRP), offers an opportunity to exploit AV-951's unique characteristics and will provide further insight into potential clinical settings, combinability with other anti-cancer agents, tumor subtypes and responsive patient populations.@@14924206@Renal cell carcinoma@@-@-@@NO REVIEW@@@@-@-@-@-@200@-@-@@@-@@11/1/2007@-@-@@-@-@@@II@II@@-@-@>>The median progression-free survival achieved by patients was 11.8 months.[AVEO 29 May 2009 http://www.aveopharma.com/content/media-news/news-detail.jsp/q/news-id/137 ]>>Trial registered. [AVEO, 16.07.2007]@Adverse events included mucositis/stomatitis (4.4%, no Grades 3/4), hand-foot syndrome (3.0%, no Grades 3/4) and fatigue (9.9%; 1.5% Grade 3, no Grade 4). The most common treatment-related adverse events seen in the trial were hypertension and dysphonia (hoarseness of voice. [AVEO 29 May 2009 http://www.aveopharma.com/content/media-news/news-detail.jsp/q/news-id/137 ]>>Trial registered. [AVEO, 16.07.2007]@@@@MONO@-@@@@@-||||@AVEO PHARMACEUTICALS@@@@@AVEO PHARMACEUTICALS||||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@AV-951@@@@@AV-951||||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@RESPONSE RATE@PROGRESSION-FREE SURVIVAL@@@@@@@@@-@@@@@DOUBLE-BLIND@MULTI-CENTRE@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16063865@Onco@@@@@300f1018ntsdm@@@@@@@@L01XC06@L01X@@@@@Erbitux is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Cetuximab is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions and has an approximate molecular weight of 152 kDa. Cetuximab is produced in mammalian (murine myeloma) cell culture.@@16063865@Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer in first-line in combination with FOLFOX@@YES@@@@@@@@>> Acquisition completed. [Lilly, 24.11.2008]          >> Lilly acquires ImClone for US$6.5 billion. [Lilly, 7.10.2008]        >> BMS Offers US$4.3Billion for ImClone or US$60.0 per share in cash. [BMS, 1 August 2008]      >> ImClone licensed co-development and co-promotion rights to BMS in North America and Japan, and to Merck KGaA in Europe.@FIRST-LINE@@254@In all indications, Erbitux is administered once a week. The initial dose is 400 mg cetuximab per m2 body surface area. All subsequent weekly doses are 250 mg cetuximab per m2 each.@@@@No@@@@EMR 62 202-013@No@@@(EGFR)-expressing, KRAS WILD-TYPE@@@APPROVED@@@PBS@@@@@@COMBO@CETUXIMAB@FLUOROURACIL@LEUCOVORIN@OXALIPLATIN@@CETUXIMAB|FLUOROURACIL|LEUCOVORIN|OXALIPLATIN|@MERCK SERONO@@@@@MERCK SERONO||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ERBITUX@FOLFOX@@@@ERBITUX|FOLFOX|||@mAb@Chimeric@TK Inhibitor@EGFR@@mAb|Chimeric|TK Inhibitor|EGFR|@@@@@@@@@@@METASTATIC@@@@@RANDOMISED@@@@@1.75@m²@74749.84275@@@12@month@12 month@74749.84@74749.84@204.8@1@0.779@323.95@@@@@@@@@@@@3.24@7@1@mg/m²@400@1@7@@mg/m²@250@1@@@@@@8/1/2017@323.95@323.95@1352-0901-IN-SG@SOLUTION FOR IV INFUSION - 20 ML@A$@@@@@@@@100@MG@100 MG/20 ML@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14916261@Onco@@@@@@@@@@@INGN-201 combined with cisplatin and 5-FU compared to cisplatin and 5-FU.@@-@-@-@AUSTIN, TEXAS@@@Advexin therapy combines the p53 tumor suppressor with a non-replicating, non-integrating adenoviral delivery system we have developed and extensively tested. The p53 gene is one of the most potent members of a group of naturally-occurring tumor suppressors, which act to kill cancer cells, arrest cancer cell growth and protect cells from becoming cancerous. Introgen's clinical trial strategy for Advexin is to test it in a variety of life-threatening cancers for which there are no effective treatments. Introgen is seeking to register Advexin for the treatment of head and neck cancer and Li-Fraumeni Syndrome. Additional late stage clinical trials in breast and lung cancers will enable Introgen to add follow-on indications. @@14916261@Squamous cell carcinoma of the head and neck.@@-@-@@NO REVIEW@@@@-@Introgen forms Gendux as a gene therapy subsidiary in the UK. [Introgen, 28.09.1998]@-@NCT00041626@-@-@The company expects to announce top-line Phase 3 data and submit its BLA and MAA for ADVEXIN for head and neck cancer in the first half of 2008. SOURCE: Intogen, 20 December 2007@12/20/2007@@-@@@-@T302@@-@PATIENTS WHO HAVE FAILED SURGERY AND RADIOTHERAPY.@@@III@III@@-@-@Tumor response was correlated with a statistically significant increased survival. Importantly, p53 profiles favorable for Advexin efficacy demonstrated a highly statistically significant correlation between Advexin efficacy and tumor response. An analysis from recurrent SCCHN patients treated with monotherapy in phase I, II and III trials showed tumor response in 79 percent of patients with p53 biomarkers favorable for ADVEXIN efficacy compared to 25 percent of patients with unfavorable p53 biomarkers (p=0.004 by Fisher's Exact Test). SOURCE: Introgen/AACR, 13 April 2008Preliminary results indicating statistically significant increase survival to be presented at AACR April 12-16 2008. SOURCE: Introgen, 17 March 2008@-@@@@COMBO@CONTUSUGENE LADENOVEC@CISPLATIN@FLUOROURACIL@@@CONTUSUGENE LADENOVEC|CISPLATIN|FLUOROURACIL||@INTROGEN THERAPEUTICS@GENDUX@@@@INTROGEN THERAPEUTICS|GENDUX|||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@ADVEXIN@5-FU@@@@ADVEXIN|5-FU|||@Gene Therapy@@@@@Gene Therapy||||@SAFETY@RESPONSE RATE@@@@@@@@@RELAPSED@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924160@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients randomised to 3mcg/kg or 10mcg/kg with a maximum total dose of 0.25mg and 0.75mg respectively, prior to moderately (n=21) or highly (n=39) emetogenic chemo.@@-@-@-@-@@@Palonosetron is a 5-HT3 receptor antagonist with a strong binding affinity for this receptor and little or no affinity for other receptors. Cancer chemotherapy may be associated with a high incidence of nausea and vomiting, particularly when certain agents, such as cisplatin, are used. 5-HT3 receptors are located on the nerve terminals of the vagus in the periphery and centrally in the chemoreceptor trigger zone of the area postrema. It is thought that chemotherapeutic agents produce nausea and vomiting by releasing serotonin from the enterochromaffin cells of the small intestine and that the released serotonin then activates 5-HT3 receptors located on vagal afferents to initiate the vomiting reflex.@@14924160@Paediatric.@@-@-@@NO REVIEW@@@@-@Riemser Arzneimittel licensed German licensing rights for Aloxi and Gelclair. SOURCE: Helsinn, 13 February 2008MGI Pharma licensed Aloxi for the U.S. market in 2003@FIRST-LINE@-@60@-@-@@@-@@@-@-@@-@60 PAEDIATRIC PATIENTS (2-17 YEARS OF AGE).@PAEDIATRIC@@III@III@@-@-@ASCO June 2007; Day 1 CR rates of 7.1% and 54.1% in 3mcg/kg (n=35) and 10mcg/kg (n=37) groups respectively.@-@@@@MONO@PALONOSETRON HYDROCHLORIDE@@@@@PALONOSETRON HYDROCHLORIDE||||@HELSINN@@@@@HELSINN||||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@ALOXI@@@@@ALOXI||||@5-HT3 Receptor Antagonist@@@@@5-HT3 Receptor Antagonist||||@COMPLETE RESPONSE@EMETIC EPISODES@@@@@@@@@-@@@@@MULTI-CENTRE@RANDOMISED@DOUBLE-BLIND@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922607@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Subjects receive low dose decitabine by vein over one hour, once a day, for 5 days (1 course). If this is not possible due to complications, they will receive the drug as an injection under the skin twice a day for 5 days (1 course). Treatment will be given every 4 to 8 weeks depending on how well the blood counts recover. After completing 8-12 weeks of therapy, response will be evaluated. If the response to treatment is good, treatment with decitabine will continue. Decitabine treatment may be continued for up to 12 courses, or as long as it is judged best to control the leukaemia.@@-@-@-@TOKYO, JAPAN@@@Dacogen was approved by the U.S. Food and Drug Administration on May 2, 2006 and is indicated for the treatment of patients with MDS, including previously treated and untreated, de novo and secondary MDS of all French-American-British (FAB) subtypes (refractory anemia, refractory anemia with rings sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, chronic myelomonocytic leukemia), and Intermediate-1, Intermediate-2, and High-Risk International Prognostic Scoring System (IPSS) groups.@@14922607@Post-azacytidine failure@@-@-@@NO REVIEW@@@@-@Dacogen for Injection was developed through a pivotal Phase 3 study by SuperGen and partnered to MGI  (acquired by Eisai Co., Ltd.). MGI subsequently sublicensed all Dacogen rights outside of North America to Janssen-Cilag, a Johnson & Johnson Company.@SECOND-LINE@NCT00113321@40@-@-@@@-@@3/1/2005@-@2004-0468@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@DECITABINE@@@@@DECITABINE||||@EISAI@MGI PHARMA@SUPERGEN@@@EISAI|MGI PHARMA|SUPERGEN||@@@@@@|||||||||@Haematological Malignancy@Myelodysplastic Syndrome@@@@Haematological Malignancy|Myelodysplastic Syndrome||||||||@DACOGEN@@@@@DACOGEN||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@RESPONSE RATE@@@@@@@@@@REFRACTORY@@@@@NON-RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16078276@Onco@@@@@@@@@@@LY3039478 + Taladegib, Experimental, LY3039478 given orally 3 times per week (TIW) in combination with taladegib given orally daily on a 28 day cycle. A single dose of taladegib will also be given on day 1 during a 3-day lead-in period.LY3039478 + LY3023414, Experimental, LY3039478 given orally TIW in combination with LY3023414 given orally every 12 hours on a 28-day cycle. A single dose of LY3023414 will also be given on day 1 during a 3-day lead-in period.LY3039478 + Abemaciclib, Experimental, LY3039478 given orally TIW in combination with abemaciclib given orally every 12 hours on a 28-day cycle. A single dose of abemaciclib will also be given on day 1 during a 3-day lead-in period.LY3039478 + Cisplatin/Gemcitabine, Experimental, LY3039478 given orally TIW in combination with cisplatin and gemcitabine given as intravenous (IV) infusions on days 1 and 8 of a 21 day cycle.LY3039478 + Gemcitabine/Carboplatin, Experimental, LY3039478 given orally TIW in combination with gemcitabine and carboplatin given as IV infusions on days 1 and 8 of a 21 day cycle.@@@@@INDIANAPOLIS, INDIANA@7/1/2018@@@@16078276@A Phase 1b Study of LY3039478 in Combination With Other Anticancer Agents in Patients With Advanced or Metastatic Solid Tumors@Both@@@@@Administered orally@@@@@@NCT02784795@163@@@@@@@6/1/2016@@16209@@@For all parts: The participant must be, in the judgment of the investigator, an appropriate candidate for experimental therapy after available standard therapies have failed to provide clinical benefit for their advanced or metastatic cancer.  -  For dose escalation for all combinations: The participant must have histological or cytological evidence of cancer, either a solid tumor or a lymphoma, which is advanced or metastatic.  -  For Part A dose confirmation: All participants must have histological evidence of advanced or metastatic soft tissue sarcoma or breast cancer. Breast cancer participants must have prescreened mutations, amplification, or gene/protein expression alterations related to Notch pathway.  -  For Part B dose confirmation: All participants must have histological evidence of advanced or metastatic colon cancer or soft tissue sarcoma. Colon cancer participants must have prescreened mutations, amplification, or gene/protein expression alterations related to Notch pathway.  -  For Part C dose confirmation: All participants must have histological evidence of advanced or metastatic breast cancer and prescreened mutations, amplification, or gene/protein expression alterations related to Notch pathway.  -  For Part D dose confirmation: All participants must have histological evidence of cholangiocarcinoma and prescreened mutations, amplification, or gene/protein expression alterations related to Notch pathway. Participants must not have received >1 line of prior systemic therapy for metastatic or resectable disease (that is, participants may have received adjuvant gemcitabine and then later gemcitabine/cisplatin for recurrent metastatic disease).  -  For Part E dose confirmation: All participants must have histological evidence of locally advanced or metastatic triple negative breast cancer (TNBC) and prescreened mutations, amplification, or gene/protein expression alterations related to Notch pathway. Participants must not have received >2 lines of systemic treatment for advanced or metastatic TNBC.  -  Have adequate organ function.  -  Have a performance status of ≤1 on the Eastern Cooperative Oncology Group (ECOG) scale.  -  Have discontinued all previous therapies for cancer.@COMBO@Adult@Phase 1@I@@@@@@@@@@-@-@@@@-|-|||@LILLY@@@@@LILLY||||@@@@@@|||||||||@Solid Tumours@Breast Cancer@Colorectal Cancer@Sarcoma@@Solid Tumours|Breast Cancer|Colorectal Cancer|Sarcoma||||||@LY3039478@-@@@@LY3039478|-|||@Other@@@@@Other||||@MAXIMUM TOLERATED DOSE@@@@@PHARMACOKINETICS@PHARMACOKINETICS@@@@ADVANCED@METASTATIC@@@@NON-RANDOMIZED@Safety Study@PARALLEL ASSIGNMENT@OPEN LABEL@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922070@Onco@@@@@@@@@@@MLN8237 will be given daily for 7 to 21 consecutive days followed by a 14-day recovery period (cycle length = 21 to 35 days). Patients will continue to receive repeated cycles of MLN8237 as long as their disease has not progressed and they have not experienced unacceptable MLN8237-related toxicity. The dose of MLN8237 will be increased in successive cohorts of 3 to 6 patients until a maximum tolerated dose of MLN8237 has been identified. Once a maximum tolerated dose has been identified for 7 consecutive days of treatment, a total of 9 to 12 patients will be treated at that dose to better define its safety, PK, and pharmacodynamics. Longer periods of dosing with MLN8237 then will be evaluated, with an increase from 7 to 14 days, and, if feasible, to 21 days. Intermediate lengths of dosing may also be evaluated. A 14-day recovery period will follow each dosing period regardless of its duration. [clinicaltrials.gov]@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@@@Based on the early clinical experience with MLN8054, Millennium engineered a second-generation Aurora A kinase inhibitor, MLN8237. Inhibition of the Aurora A kinase represents a novel approach to treating cancer. Aurora A kinases are required for cancer cells to divide and create tumors. In preclinical models, the inhibition of Aurora A kinases has been shown to stop the proliferation of the cells and reduce tumor growth. Aurora A kinases have been shown to be over-expressed in a variety of cancers. @@14922070@A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Solid Tumors@@-@-@@NO REVIEW@@@May 2007-November 2008@-@>> Takeda acquisition of Millennium completed. [Millennium, 14 May 2008]       >> Takeda acquired Millennium Pharma on 10 April 2008 in a US$8.8 bil. deal. Millennium Pharma will continue to operate as a standalone unit. [Takeda, 10 April 2008]@SECOND-LINE@NCT00500903@60@-@-@@@-@@@-@C14001@@-@Histologically or cytologically confirmed metastatic and/or advanced solid tumors (including lymphomas) for which no effective standard treatment is available @@@I@I@@-@-@>> Trial design updated [Millennium, 1.04.2008]        >> Trial registered. [Millennium, 12.07.2007]@-@@@@MONO@-@@@@@-||||@MILLENNIUM PHARMACEUTICALS@TAKEDA PHARMACEUTICAL@@@@MILLENNIUM PHARMACEUTICALS|TAKEDA PHARMACEUTICAL|||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@MLN-8237@@@@@MLN-8237||||@Aurora Kinase Inhibitor@@@@@Aurora Kinase Inhibitor||||@DOSE-LIMITING TOXICITY@MAXIMUM TOLERATED DOSE@@@@PHARMACOKINETICS@@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14919600@Onco@@@@@300f1015ntsdm@@@@@@@@L01XX19@L01X@YES@PETACH TIKVA, ISRAEL@@@Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks.@@14919600@CAMPTO is indicated for the treatment of patients with advanced colorectal cancer as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen.@@YES@@@NO REVIEW@@@@@@SECOND-LINE@@@The recommended dosage of CAMPTO is 350 mg/m² administered as an intravenous infusion over a 30- to 90- minute period every three weeks.Treatment with CAMPTO should be continued until there is an objective progression of the disease or an unacceptable toxicity.@@@5/19/2009@@@@Can induce both early and late forms of diarrhea. Both forms of diarrhea may be severe. Early diarrhea (occurring during or shortly after infusion may be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping. Late diarrhea (generally occurring more than 24 hours after administration) can be life threatening since it may be prolonged and may lead to dehydration, electrolyte imbalance, or sepsis. Patients with diarrhea should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated or antibiotic therapy if they develop ileus, fever, or severe neutropenia. Severe myelosuppression may also occur.@@No@@@@@@APPROVED@@No ASMR/SMR rating@HAUTE AUTORITÉ DE SANTÉ@@@@@@MONO@IRINOTECAN@@@@@IRINOTECAN||||@TEVA PHARMACEUTICAL@@@@@TEVA PHARMACEUTICAL||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@@@@@@@@@@@ADVANCED@@@@@@@@@@1.75@m²@Invalid Factory Price@@@3.9@month@3.9 month@@@@1@1.1511@@@@@@@@@@@@@@21@@mg/m²@350@1@@@@@@@@@@@@@@9330207T@DILUTED SOLUTION FOR PERFUSION, 2 ML@EURO@@@@@@@@40@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14923497@Onco@@@@@@@@@@@All patients will receive MabThera (375mg/m² iv) every 3 weeks for 8 cycles, in combination with standard chemotherapy@@L01XC02@L01X@-@BASEL, SWITZERLAND@@@Rituximab binds specifically to the antigen CD20 (human B-lymphocyte-restricted differentiation antigen, Bp35), a hydrophobic transmembrane protein with a molecular weight of approximately 35 kD located on pre-B and mature B lymphocytes. The antigen is expressed on >90% of B-cell non-Hodgkin's lymphomas (NHL), but the antigen is not found on hematopoietic stem cells, pro-B-cells, normal plasma cells or other normal tissues. CD20 regulates an early step(s) in the activation process for cell cycle initiation and differentiation, and possibly functions as a calcium ion channel. CD20 is not shed from the cell surface and does not internalize upon antibody binding. Free CD20 antigen is not found in the circulation. B cells are believed to play a role in the pathogenesis of rheumatoid arthritis (RA) and associated chronic synovitis. In this setting, B cells may be acting at multiple sites in the autoimmune/inflammatory process, including through production of rheumatoid factor (RF) and other autoantibodies, antigen presentation, T-cell activation, and/or proinflammatory cytokine production. Mechanism of Action: The Fab domain of rituximab binds to the CD20 antigen on B lymphocytes, and the Fc domain recruits immune effector functions to mediate B-cell lysis in vitro. Possible mechanisms of cell lysis include complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). The antibody has been shown to induce apoptosis in the DHL-4 human B-cell lymphoma line. Normal Tissue Cross-reactivity: Rituximab binding was observed on lymphoid cells in the thymus, the white pulp of the spleen, and a majority of B lymphocytes in peripheral blood and lymph nodes. Little or no binding was observed in the non-lymphoid tissues examined.@@14923497@Patients with newly diagnosed and untreated mantle cell lymphoma at stage II, III and IV.@@-@-@@NO REVIEW@@@@-@-@-@NCT00472420 @<100@-@-@@@-@@6/1/2007@-@-@@-@<100 patients with previously untreated mantle cell lymphoma@@@II@II@@-@-@Trial registered. SOURCE: Roche, 10 May 2007@-@@@@MONO@RITUXIMAB@@@@@RITUXIMAB||||@ROCHE@@@@@ROCHE||||@Hungary@@@@@Hungary|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@Mantle Cell Lymphoma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma|||||||@RITUXAN@@@@@RITUXAN||||@mAb@Chimeric@CD20@@@mAb|Chimeric|CD20||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922062@Onco@@@@@@@@@@@Myocet 60 mg/m2) and cyclophosphamide (600 mg/m2) and trastuzumab (8 mg/kg loading dose followed by 6 mg/kg once every 3 weeks) once every 3 weeks for 4 cycles followed by docetaxel (100 mg/m2) and trastuzumab (6 mg/kg) once every 3 weeks for 4 cycles (MCH?TH) versus the same treatment without Myocet [clinicaltrials.gov]@@L01DB01@L01D@-@-@6/1/2010@@The active substance in Myocet is doxorubicin HCl. Doxorubicin may exert its antitumour and toxic effects by a number of mechanisms including inhibition of topoisomerase II, intercalation with DNA and RNA polymerases, free radical formation and membrane binding. Liposomal-encapsulated compared with conventional doxorubicin was not found more active in doxorubicin resistant cell lines in vitro. In animals, liposome-encapsulated doxorubicin reduced the distribution to heart and gastrointestinal mucosa compared with conventional doxorubicin, while antitumoural efficacy in experimental tumours was maintained. @@14922062@Myocet Plus Cyclophosphamide and Trastuzumab Versus Free Doxorubicin Plus Cyclophosphamide Alone, Each Followed by Docetaxel and Trastuzumab, in Neoadjuvant Setting in Treatment-Naive Patients With HER2-Positive Breast Cancer@@-@-@@NO REVIEW@@@@-@Licensed future commercialisation in North America from Zeneus Pharma in October 2004@-@NCT00712881@120@-@-@@@-@@10/1/2008@-@C19562@@-@Treatment-naive patients with stage II or III invasive breast cancer (proven histologically/cytologically) and with tests showing an overexpressing of human epidermal growth factor receptor 2 (HER2). @@@II@II@@-@-@Trial registered. [Cephalon, 8.07.2008]@-@@@@COMBO@DOXORUBICIN, PEGYLATED LIPOSOMAL @TRASTUZUMAB@CYCLOPHOSPHAMIDE@@@DOXORUBICIN, PEGYLATED LIPOSOMAL |TRASTUZUMAB|CYCLOPHOSPHAMIDE||@CEPHALON@@@@@CEPHALON||||@Belgium@@@@@Belgium|||||||||@Breast Cancer@HER2+@@@@Breast Cancer|HER2+||||||||@MYOCET@HERCEPTIN@@@@MYOCET|HERCEPTIN|||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921313@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Obatoclax administered in 2-week cycles to patients with previously-untreated Myelodysplastic Syndromes with anemia and/or thrombocytopenia. Treatment may be administered on an outpatient basis. @@-@-@-@-@12/1/2007@@Obatoclax (GX15-070) is a small molecule indole bipyrrole drug compound that was discovered and is being developed at Gemin X. The attractive safety profile and mechanism of action of obatoclax offers the opportunity to treat many forms of cancer as both a single agent and in combination with current treatments. Obatoclax  is a pan-inhibitor of the pro-survival members of the Bcl-2 family of apoptosis regulators. Many of the cellular events that initiate malignant transformation of a normal cell (e.g., activation of oncogenes) also activate oncogenic stress pathways that usually cause the cell to self destruct by a process called apoptosis [3]. In order for these cells to survive and cause cancer, they typically must have acquired changes in other cellular pathways to prevent apoptosis. The Bcl-2 family of proteins are important regulators and executioners of the cellular decision to live or die. Moreover, this family of proteins also dictates whether or not many current cancer therapies are effective, because most of these treatments result in stress signals that ultimately must activate the cancer cell's apoptosis machinery.@@14921313@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00413114@55@-@-@@@-@@12/1/2006@-@GEM013@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@OBATOCLAX MESYLATE@@@@@OBATOCLAX MESYLATE||||@GEMIN X@@@@@GEMIN X||||@@@@@@|||||||||@Haematological Malignancy@Myelodysplastic Syndrome@@@@Haematological Malignancy|Myelodysplastic Syndrome||||||||@GX15-070@@@@@GX15-070||||@Bcl-2 Inhibitor@@@@@Bcl-2 Inhibitor||||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRAVENOUS@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918777@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01BA01@L01B@YES@LAKE FOREST, ILLINOIS@@@Methotrexate is an antimetabolite which acts principally by competitively inhibiting the enzyme, dihydrofolate reductase. In the process of DNA synthesis and cellular replication, folic acid must be reduced to tetrahydrofolic acid by this enzyme, and inhibition by methotrexate interferes with tissue cell reproduction. Actively proliferating tissues such as malignant cells are generally more sensitive to this effect of methotrexate. It also inhibits antibody synthesis.@@14918777@Methotrexate is indicated in the treatment of neoplastic disease, such as trophoblastic neoplasms and leukaemia, and the symptomatic treatment of severe recalcitrant disabling psoriasis which is not adequately responsive to other forms of therapy.@@NO@@@NO REVIEW@@@@100%@Via takeover of Mayne Pharma@@@@Choriocarcinoma and Similar Trophoblastic Diseases: Methotrexate is administered intramuscularly in doses of 15-30mg daily for a five day course. Such courses may be repeated 3-5 times as required, with rest periods of one or more weeks interposed between courses until any manifesting toxic symptoms subside.@@@@@@@Methotrexate should be used with extreme caution in patients with haematological depression, renal impairment, diarrhoea, ulcerative disorders of the GI tract and psychiatric disorders. Hepatic toxicity has been observed, usually associated with chronic hepatic disease. Renal lesions may develop if the urinary flow is impeded and urinary pH is low, especially if large doses have been administered. The administration of low doses of methotrexate for prolonged periods may give rise, in particular, to hepatic toxicity. Particular care and possible cessation of treatment are indicated if stomatitis or GI toxicity occurs as haemorrhagic enteritis and intestinal perforation may result.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@METHOTREXATE@@@@@METHOTREXATE||||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@Endometrial Cancer@@@@@Endometrial Cancer|||||||||@GENERIC@@@@@GENERIC||||@Anti-metabolite@Folic Acid Analogue@@@@Anti-metabolite|Folic Acid Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.299@48@@@@@@@@@@@@0.1@@@@@@@@@@@@@@@@7/28/2017@48@48@3.62E+15@INJECTION 20 ML@GB£@@@@@@@@500@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14917269@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@M04AA01@M04A@NO@@@@@@14917269@Indicated in the management of patients with signs and symptomas of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephroptahy; the management of patients with leukaemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment should be discontinued when the potential for overproduction of uric acid is no longer presents; and, the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800mg/day in male patients and 750mg/day in female patients. This is not an innocuous drug. It is not recommended for the treatment of asymptomatic hyperuricemia.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@Dosage in Adults: should be introduced at low dosage e.g. 100mg/day to reduce the risk of adverse reactions and increased only if the serum urate response is unsatisfactory. Extra caution should be exercised if renal function is poor. The following dosage schedules are suggested: 100 to 200 mg daily in mild conditions, 300 to 600 mg daily in moderately severe conditions, 700 to 900 mg daily in severe conditions. If dosage on a mg/kg bodyweight basis is required, 2 to 10 mg/kg bodyweight/day should be used. Dosage in children: Children under 15 years: 10 to 20 mg/kg bodyweight/day up to a maximum of 400 mg daily. Use in children is rarely indicated, except in malignant conditions (especially leukaemia) and certain enzyme disorders such as Lesch-Nyhan syndrome.@@@@@@@Should be discontinued at the first appearance of skin rash or other signs which may indicate an allergic rection. Dose should be adjusted if co-administered with Purinethol or Imuran.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@ALLOPURINOL@@@@@ALLOPURINOL||||@HENNIG@@@@@HENNIG||||@@@@@@|||||||||@Supportive Care@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Non-Hodgkin's Lymphoma@Supportive Care|Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Non-Hodgkin's Lymphoma|||||@CELLIDRIN@@@@@CELLIDRIN||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@100@1.1807@3.4@15.28@4.2@@@@@@@@@@@@@@@@@@@@@@@@@@8/15/2017@0.03@0.03@2046561@TABLET@EURO@@@@@@@@300@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14919557@Onco@@@@@300f1015ntsdm@@@@@@Tamoxifen compared to ovarian ablation@@L02BA01@L02B@YES@@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14919557@@@NO@2-Jul@@NO REVIEW@@@@@@@@N/A@Adjuvant treatment of breast cancer, Adults (including elderly): The recommended dose is 20mg, given either in divided doses twice daily or as a single dose once daily. The current recommended treatment duration is five years; however the optimum duration has not been established. Treatment of locally advanced or metastatic breast cancer: The recommended dose is 20mg to 40mg, given either in divided doses twice daily or as a single dose once daily.@2-Apr@@4/24/2003@@@@Women should be informed of the potential risks to the foetus, should they become pregnant whilst taking tamoxifen; or within two months of cessation of therapy. A number of secondary primary tumours, occurring at sites other than the endometrium and the opposite breast, have been reported in clinical trials, following the treatment of breast cancer patients with tamoxifen. No causal link has been established and the clinical significance of these observations remains unclear.@LABEL@No@@@@@III; METASTATIC BREAST CANCER@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@The objective RR, time to treatment failure, and survival were similar with both treatments. In an overview analysis of survival data from the 3 studies, the hazard ratio for death (tamoxifen/ovarian ablation) was 1.00. Elevated serum and plasma oestrogens have been observed in premenopausal women receiving tamoxifen, but the data from the randomized studies do not suggest an adverse effect of this increase. A limited number of premenopausal patients with disease progression during tamoxifen therapy responded to subsequent ovarian ablation.@@@@@MONO@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@EUROGENERICS@@@@@EUROGENERICS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GENERIC@@@@@GENERIC||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RESPONSE RATE@@@@@@@@@@@@@@@PROSPECTIVE@RANDOMISED@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@30@1.1511@2.63@3.69@2.93@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@0.09@0.09@3.40E+12@TABLET@EURO@@@@@@@@10@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14921221@Onco@@@@@300f1014ntsdm@@@@@@The first cohort will receive Gleevec at 300 mg daily on days 1-10 and chlorambucil 8mg/m2/d from day 3-7. This will be repeated every 28 days. Cohort 2 will receive 400 mg Gleevec and Cohort 3 will receive 600 mg Gleevec. Each dose level may be expanded up to 6 patients if 1 of 3 patients experiences any dose limiting toxicities. @@L01XE01@L01X@-@BASEL, SWITZERLAND@4/1/2009@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@14921221@-@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00558961@34@-@-@@@-@@10/1/2005@-@GL-CLB-001@@-@-@@@I/II; CR0506PI, REC:05-054; @II@@-@-@Endpoint over 1 month.@-@@@@COMBO@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@GLEEVEC@GLIVEC@@@@GLEEVEC|GLIVEC|||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@MAXIMUM TOLERATED DOSE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TABLET@C$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14918260@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@M04AA01@M04A@NO@GERMANY@@@@@14918260@Indicated in the management of patients with signs and symptomas of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephroptahy; the management of patients with leukaemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment should be discontinued when the potential for overproduction of uric acid is no longer presents; and, the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800mg/day in male patients and 750mg/day in female patients. This is not an innocuous drug. It is not recommended for the treatment of asymptomatic hyperuricemia.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@Dosage in Adults: should be introduced at low dosage e.g. 100mg/day to reduce the risk of adverse reactions and increased only if the serum urate response is unsatisfactory. Extra caution should be exercised if renal function is poor. The following dosage schedules are suggested: 100 to 200 mg daily in mild conditions, 300 to 600 mg daily in moderately severe conditions, 700 to 900 mg daily in severe conditions. If dosage on a mg/kg bodyweight basis is required, 2 to 10 mg/kg bodyweight/day should be used. Dosage in children: Children under 15 years: 10 to 20 mg/kg bodyweight/day up to a maximum of 400 mg daily. Use in children is rarely indicated, except in malignant conditions (especially leukaemia) and certain enzyme disorders such as Lesch-Nyhan syndrome.@@@@@@@Should be discontinued at the first appearance of skin rash or other signs which may indicate an allergic rection. Dose should be adjusted if co-administered with Purinethol or Imuran.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@ALLOPURINOL@@@@@ALLOPURINOL||||@ACIS@@@@@ACIS||||@@@@@@|||||||||@Supportive Care@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Non-Hodgkin's Lymphoma@Supportive Care|Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Non-Hodgkin's Lymphoma|||||@GENERIC@@@@@GENERIC||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@50@1.1511@1.8@13.26@2.56@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@0.04@0.04@108938@TABLET@EURO@@@@@@@@300@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14918278@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@M04AA01@M04A@NO@BAD VILBEL, GERMANY@@@@@14918278@Indicated in the management of patients with signs and symptomas of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephroptahy; the management of patients with leukaemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment should be discontinued when the potential for overproduction of uric acid is no longer presents; and, the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800mg/day in male patients and 750mg/day in female patients. This is not an innocuous drug. It is not recommended for the treatment of asymptomatic hyperuricemia.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@Dosage in Adults: should be introduced at low dosage e.g. 100mg/day to reduce the risk of adverse reactions and increased only if the serum urate response is unsatisfactory. Extra caution should be exercised if renal function is poor. The following dosage schedules are suggested: 100 to 200 mg daily in mild conditions, 300 to 600 mg daily in moderately severe conditions, 700 to 900 mg daily in severe conditions. If dosage on a mg/kg bodyweight basis is required, 2 to 10 mg/kg bodyweight/day should be used. Dosage in children: Children under 15 years: 10 to 20 mg/kg bodyweight/day up to a maximum of 400 mg daily. Use in children is rarely indicated, except in malignant conditions (especially leukaemia) and certain enzyme disorders such as Lesch-Nyhan syndrome.@@@@@@@Should be discontinued at the first appearance of skin rash or other signs which may indicate an allergic rection. Dose should be adjusted if co-administered with Purinethol or Imuran.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@ALLOPURINOL@@@@@ALLOPURINOL||||@STADA ARZNEIMITTEL@@@@@STADA ARZNEIMITTEL||||@@@@@@|||||||||@Supportive Care@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Non-Hodgkin's Lymphoma@Supportive Care|Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Non-Hodgkin's Lymphoma|||||@GENERIC@@@@@GENERIC||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@50@1.1511@1.78@13.23@2.53@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@0.04@0.04@106388@TABLET@EURO@@@@@@@@300@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14922461@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@ARM1; CP-675,206 administered intravenously every 3 months. Escalating doses from 6mg/kg to 15mg/kg will be tested; Sutent administered at a dose of 37.5mg/day every day. ARM2: CP-675,206 administered intravenously every 3 months. Escalating doses from 6mg/kg to 15mg/kg will be tested; Sutent administered at a dose of 50mg/day for 4 weeks followed by 2 weeks off, repeated every 6 weeks. SOURCE: clinicaltrials.gov@@-@-@-@NEW YORK, NEW YORK@1/1/2010@@Tremelimumab is a fully human anti-CTLA4 (cytotoxic T-lymphocyte antigen 4) IgG2 monoclonal antibody developed by Pfizer for its potential therapeutic application in melanoma, non-small cell lung cancer (NSCLC) and colorectal cancer. CTLA4 is a CD28-family receptor expressed mainly on T-lymphocyte that acts to inhibit T-lymphocyte function.@@14922461@Combo with Sutent@@-@-@@NO REVIEW@@@@-@Medarex entitled to royalties@-@NCT00372853@48@-@-@@@-@@11/1/2006@-@A3671025@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@COMBO@TREMELIMUMAB@TICILIMUMAB@SUNITINIB@@@TREMELIMUMAB|TICILIMUMAB|SUNITINIB||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@CP-675206@SUTENT@@@@CP-675206|SUTENT|||@mAb@CTLA4 Receptor Antagonist@@@@mAb|CTLA4 Receptor Antagonist|||@MAXIMUM TOLERATED DOSE@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921549@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01CA04@L01C@YES@CASTRES, FRANCE@@@Navelbine is an antineoplastic drug of the vinca alkaloid family but unlike all the other vinca alkaloids, the catharantine moiety of vinorelbine has been structurally modified. At the molecular level, it acts on the dynamic equilibrium of tubulin in the microtubular apparatus of the cell. It inhibits tubulin polymerization and binds preferentially to mitotic microtubules, affecting axonal microtubules at high concentrations only. The induction of tubulin spiralization is less than that produced by vincristine. Navelbine blocks mitosis at G2-M, causing cell death in interphase or at the following mitosis.@@14921549@As a single agent or in combination for the first line treatment of stage 3 or 4 non small cell lung cancer. - Treatment of advanced breast cancer stage 3 and 4 relapsing after or refractory to an anthracycline containing regimen.@@NO@6-Mar@@NO REVIEW@@@@@@@@@As a single agent: The recommended regimen is :First three administrations: 60mg/m² of body surface area, administered once weekly. Subsequent administrations: Beyond the third administration, it is recommended to increase the dose of Navelbine soft capsules to 80mg/m² once weekly except in those patients for whom the neutrophil count dropped once below 500/mm3 or more than once between 500 and 1000/mm3 during the first three administrations at 60mg/m².@1-Feb@@1/26/2006@@@@Vinorelbine should be administered in carefully adjusted doses by or under the supervision of a chemo-experienced physician. Patients treated with vinorelbine should be frequently monitored for myelosuppression both during and after therapy. Granulocytopaenia is dose-limiting. Granulocyte nadirs occur between 7 and 10 days after dosing with granulocyte count recovery usually within the following 7 to 14 days. Complete blood counts with differentials should be performed and results reviewed prior to administering each dose of vinorelthose@NO LABELLED TRIAL@No@EXPIRED@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@BOTH@VINORELBINE TARTRATE@CISPLATIN@@@@VINORELBINE TARTRATE|CISPLATIN|||@PIERRE FABRE@@@@@PIERRE FABRE||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@NAVELBINE@@@@@NAVELBINE||||@Plant Alkaloid@Vinca Alkaloids@@@@Plant Alkaloid|Vinca Alkaloids|||@@@@@@@@@@@ADVANCED@REFRACTORY@@@@@@@@@@@Invalid Dosage Value Phase 1@@@1@year@1 year@25285.25@25285.25@69.27@1@1.1511@49@61.38@52.27@@@@@@@@@@2.45@@@@@@@@@@@@@@@@8/1/2017@49@49@3.40E+12@SOFT CAPSULE@EURO@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14923397@Onco@@@@@300f1012ntsdm@@@@@@Tamoxifen compared to ovarian ablation@@L02BA01@L02B@YES@PETACH TIKVA, ISRAEL@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14923397@@@NO@@@NO REVIEW@@@@@@@@N/A@Adjuvant treatment of breast cancer, Adults (including elderly): The recommended dose is 20mg, given either in divided doses twice daily or as a single dose once daily. The current recommended treatment duration is five years; however the optimum duration has not been established. Treatment of locally advanced or metastatic breast cancer: The recommended dose is 20mg to 40mg, given either in divided doses twice daily or as a single dose once daily.@@@@@@@Women should be informed of the potential risks to the foetus, should they become pregnant whilst taking tamoxifen; or within two months of cessation of therapy. A number of secondary primary tumours, occurring at sites other than the endometrium and the opposite breast, have been reported in clinical trials, following the treatment of breast cancer patients with tamoxifen. No causal link has been established and the clinical significance of these observations remains unclear.@LABEL@No@@@@@III METASTATIC BREAST CANCER@APPROVED@@@GKV@The objective RR, time to treatment failure, and survival were similar with both treatments. In an overview analysis of survival data from the 3 studies, the hazard ratio for death (tamoxifen/ovarian ablation) was 1.00. Elevated serum and plasma oestrogens have been observed in premenopausal women receiving tamoxifen, but the data from the randomized studies do not suggest an adverse effect of this increase. A limited number of premenopausal patients with disease progression during tamoxifen therapy responded to subsequent ovarian ablation.@@@@@ADJUVANT@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@TEVA PHARMACEUTICAL@@@@@TEVA PHARMACEUTICAL||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@TAMOX-TEVA@@@@@TAMOX-TEVA||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RESPONSE RATE@@@@@@@@@@@@@@@PROSPECTIVE@RANDOMISED@@@@@@Invalid Factory Price@@@@@@@@@100@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@EURO@@@@@@@@30@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14921317@Onco@@@@@300f1037ntsdm@@@@@@Four Rituximab – CHOP courses will be given. The courses will be given every 21 days Drug Dose Day Rituximab (Mabthera?) 500mg/m2; Cyclophosphamide 750mg/m2 1 Adriamycin 50mg/m2 1 Vincristine 1,4 mg/m2 1 Prednisone 60mg/m2 1 to 5. SOURCE: clinicaltrials.gov/CABYC@@L01XC04@L01X@-@LEVERKUSEN, GERMANY@6/1/2012@@"Alemtuzumab binds to CD52, an antigen present on the surface of B andT lymphocytes, a majority of monocytes, macrophages, NK cells, anda subpopulation of granulocytes. A proportion of bone marrow cells,including some CD34+ cells, express variable levels of CD52. The proposedmechanism of action is antibody-dependent cellular-mediatedlysis following cell surface binding of alemtuzumab to the leukemic cells."@@14921317@R-CHOP-A versus R-CHOP in refractory or recidivant patients with CLL after purine analogous treatment@@-@-@@NO REVIEW@@@@-@ILEX Oncology (acquired by Genzyme) and LeukoSite (acquired by Millennium Pharma) entered into a distribution and development agreement with Schering AG (now Bayer Schering) in August 1999. The agreement grants Schering AG exclusive marketing and distribution rights to Campath in the United States, Europe and the rest of the world except Japan and East Asia, where LeukoSite and ILEX have retained these rights. Millenniusm sold Campath rights to ILEX in 2001 for US$140 million plus royalties. Initial rights licensed by LeukoSite from BTG.@SECOND-LINE@NCT00504491@60@-@-@@@-@@7/1/2007@-@GELLC-2@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@ALEMTUZUMAB@RITUXIMAB@@@@ALEMTUZUMAB|RITUXIMAB|||@BAYER HEALTHCARE@GENZYME@@@@BAYER HEALTHCARE|GENZYME|||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@CAMPATH@MABCAMPATH@RITUXAN@R-CHOP@@CAMPATH|MABCAMPATH|RITUXAN|R-CHOP|@mAb@Humanised@CD52@@@mAb|Humanised|CD52||@RESPONSE RATE@@@@@@@@@@REFRACTORY@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@15659.64@15659.64@42.9@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain15413590@Onco@@@@@300f1037ntsdm@@@@@@"Procedure: DNX2401 and Temozolomide Virus injection in the brain parenchyma after pathology confirmation of recurrent glioblastoma.Temozolomide oral 14 days after virus injection."@@@@@@12/1/2015@@@@15413590@Phase I Trial of Combination of DNX-2401 (Formerly Named Delta-24-RGD) Oncolytic Adenovirus With a Short Course of Temozolomide for Treatment of Glioblastoma at First Recurrent@Both@@@@@@@821@@@@NCT01956734@31@@@@@@@9/1/2013@@D24GBM EudraCT: 2011-005935-21@@@"Patients willing and able to give informed consent and willing to comply with all the protocol procedures.Patient must be, in the investigator opinion, able to comply with all the protocol procedures.Age 18-75 years.Negative pregnant test in case of fertile women.Patient diagnosed GBM in first recurrence after radiotherapy and TMZ. Must have completed at least radiotherapy and one TMZ cycle afterwards.Intraoperative histological verification of recurrence is needed to confirm inclusion.Karnofsky Performance Status ≥ 70 before inclusionLesion considered by the investigator to be resectable or accessible for stereotactic biopsy. Lesion location will allow injection without entrance of virus in the ventricular system.Last TMZ cycle must have been finished at least 4 weeks before entry in the study.Must have adequate renal, bone marrow and liver function."@COMBO@ADULTS@Phase 1@I@@@@@@@@@@-@TEMOZOLOMIDE@@@@-|TEMOZOLOMIDE|||@DNATRIX THERAPEUTICS @@@@@DNATRIX THERAPEUTICS ||||@Spain@@@@@Spain|||||||||@Brain Cancer@@@@@Brain Cancer|||||||||@DNX-2401@TEMODAL@@@@DNX-2401|TEMODAL|||@Other@@@@@Other||||@NUMBER OF PARTICIPANS WITH ADVERSE EVENTS@@@@@EFFICACY OF THE COMBINATION@Tumor Response@QUALITY OF LIFE@@@@@@@@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14916410@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Patients receive SCH-58500 by intraperitoneal instillation on days 1-5 (depending on dose level). Patients undergo ascites fluid and tumor sampling before and after intraperitoneal instillation. The ascitic fluid or tumor and normal tissue are then submitted for cytologic or histopathologic examination and biological activity analysis. Cohorts of 3-6 patients receive escalating doses of SCH-58500 until 3 patients experience dose limiting toxicity or until the highest planned dose is reached. Patients are followed at 2 months, every 3 months for 1 year, and then yearly thereafter.@@-@-@-@KENILWORTH, NEW JERSEY@@@@@14916410@Primary ovarian, fallopian tube or peritoneal cancer@@-@-@@NO REVIEW@@@@-@Merck & Co and Schering-Plough have announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. Based on the closing price of Merck stock on March 6, 2009, the consideration to be received by Schering-Plough shareholders is valued at $23.61 per share, or $41.1 billion in the aggregate. [Merck & Co, 9 March 2009]@-@NCT00002960@Jun-60@-@-@@@-@@9/1/2006@-@SPRI-IC95-084@@-@-@@@I@DISCONTINUED@@-@-@RESULTS PENDING (recruiting).@-@@@@MONO@-@@@@@-||||@SCHERING-PLOUGH@MERCK & CO@@@@SCHERING-PLOUGH|MERCK & CO|||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@SCH-58500@@@@@SCH-58500||||@Gene Therapy@@@@@Gene Therapy||||@SAFETY@@@@@@@@@@-@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14923996@Onco@@@@@300f1015ntsdm@@@@@@@@V03AF01@V03A@NO@DEERFIELD, ILLINOIS@@@@@14923996@Indicated as a prophylactic agent in reducing the incidence of ifosfamide-inducing haemorrhagic cystitis.@@YES@6-Sep@@NO REVIEW@@@@65%@@@@@@1-Jun-96@6/1/1996@@@@@Allergic reactions to mesna ranging from mild hypersensitivity to systemic anaphylactic reactions have been reported. Patients with autoimmune disorders who were treated with cyclophosphamide and mesna appeared to have a higher incidence of allergic reactions. The majority of these patients received mesna orally. Mesnex has been developed as an agent to reduce the risk of ifosfamide induced haemorrhagic cystitis. It will not prevent or alleviate any of the other adverse reactions or toxicities associated with ifosfamide therapy. Mesnex does not prevent haemorrhagic cystitis in all patients. Up to 6% of patients treated with mesna have developed haematuria (>50 RBC/hpf or WHO grade 2 and above). As a result, a morning specimen of urine should be examined for the presence of haematuria (microscopic evidence of red blood cells) each day prior to ifosfamide therapy. If haematuria develops when Mesnex is given with ifosfamide according to the recommended dosage schedule, depending on the severity of the hematuria, dosage reductions or discontinuation of ifosfamide therapy may be initiated. In order to reduce the risk of hematuria, Mesnex must be administered with each dose of ifosfamide as outlined in@@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@RESULTS PENDING@@@@@@MESNA@@@@@MESNA||||@BAXTER HEALTHCARE@@@@@BAXTER HEALTHCARE||||@@@@@@|||||||||@Supportive Care@@@@@Supportive Care|||||||||@UROMITEXAN@@@@@UROMITEXAN||||@Detoxifying Agent@@@@@Detoxifying Agent||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@4@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/2/2017@4@4@9194804R@SCORED TABLET@EURO@@@@@@@@600@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14919601@Onco@@@@@300f1015ntsdm@@@@@@@@L01XX19@L01X@YES@PETACH TIKVA, ISRAEL@@@Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks.@@14919601@CAMPTO is indicated for the treatment of patients with advanced colorectal cancer as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen.@@YES@@@NO REVIEW@@@@@@SECOND-LINE@@@The recommended dosage of CAMPTO is 350 mg/m² administered as an intravenous infusion over a 30- to 90- minute period every three weeks.Treatment with CAMPTO should be continued until there is an objective progression of the disease or an unacceptable toxicity.@@@5/19/2009@@@@Can induce both early and late forms of diarrhea. Both forms of diarrhea may be severe. Early diarrhea (occurring during or shortly after infusion may be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping. Late diarrhea (generally occurring more than 24 hours after administration) can be life threatening since it may be prolonged and may lead to dehydration, electrolyte imbalance, or sepsis. Patients with diarrhea should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated or antibiotic therapy if they develop ileus, fever, or severe neutropenia. Severe myelosuppression may also occur.@@No@@@@@@APPROVED@@No ASMR/SMR rating@HAUTE AUTORITÉ DE SANTÉ@@@@@@MONO@IRINOTECAN@@@@@IRINOTECAN||||@TEVA PHARMACEUTICAL@@@@@TEVA PHARMACEUTICAL||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@@@@@@@@@@@ADVANCED@@@@@@@@@@1.75@m²@Invalid Factory Price@@@3.9@month@3.9 month@@@@1@1.1511@@@@@@@@@@@@@@21@@mg/m²@350@1@@@@@@@@@@@@@@9326393T@CONCENTRATE FOR PERFUSION (VIAL), 25 ML@EURO@@@@@@@@500@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
16829136@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01XC05@L01X@@MADISON, NEW JERSEY@@@Gemtuzumab ozogamicin (marketed as Mylotarg) is a monoclonal antibody used to treat acute myelogenous leukaemia. It is a monoclonal antibody to CD33 linked to a cytotoxic agent, calicheamicin. CD33 is expressed in most leukaemic blast cells but is not found on normal hematopoietic stem cells. When given to patients in first relapse, 15% of patients achieve a complete remission. In the United States, it was approved by the FDA for use in patients over the age of 60 with relapsed AML who are not considered candidates for standard chemotherapy. A notable complication of therapy with gemtuzumab is the increased risk of veno-occlusive disease in the absence of bone marrow transplantation. The onset of VOD can also be delayed and can occur at increased frequency following bone marrow transplantation.@@16829136@Treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older.@@NA@@@NO REVIEW@@@@@Pfizer acquired Wyeth on 26 January 2009 in a deal worth U.S $68 billion [Pfizer 26.01.2009]@@@57@3 mg/m2 (up to one 4.5 mg vial) on Days 1, 4, and 7@FDA, 1 September 2017@9/1/2017@@Yes@@@@MyloFrance-1@No@@@ADULTS CD33-positive@@II@APPROVED@@@@@@@@@MONO@GEMTUZUMAB OZOGAMICIN@@@@@GEMTUZUMAB OZOGAMICIN||||@WYETH@@@@@WYETH||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@MYLOTARG@@@@@MYLOTARG||||@mAb@Humanised@CD33@@@mAb|Humanised|CD33||@@@@@@@@@@@REMAPSED@REFRACTORY@@@@SINGLE-ARM@OPEN-LABEL@@@@1.5@m²@Invalid Factory Price@@@7@day@7 day@@@@1@1@@@@@@@@@@@@@@7@@mg/m²@3@3@@@@@@@@@@@@@@00008-4510-01@POWDER FOR SOLUTION FOR INFUSION (VIAL)@US$@@@@@@@@5@MG@5 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917257@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@404 patients received Casodex 50mg once-daily, 409 received flutamide 250mg three-times daily, each in combination with goserelin acetate implant or leuprolide acetate depot.@@L02BB03@L02B@NO@LONDON, UNITED KINGDOM@@@Casodex is a non-steroidal antiandrogen, devoid of other endocrine activity. It binds to androgen receptors without activating gene expression, and thus inhibits the androgen stimulus. Regression of prostatic tumours results from this inhibition. Clinically, discontinuation of Casodex can result in antiandrogen withdrawal syndrome in a subset of patients. Casodex is a racemate with its antiandrogenic activity being almost exclusively in the (R)-enantiomer.@@14917257@Indicated for use in combination therapy with an LH-RH analogue for the treatment of Stage D2 metastatic carcinoma of the prostate.@@NO@@@NO REVIEW@@@@Co-pay tier 2. SOURCE: Aetna Preferred Drug Guide 2008@@FIRST-LINE@@813@The recommended dose is 50mg tablet once-daily with or without food.@FDA, 4 October 1995@10/4/1995@@@@@Rare cases of death or hospitalisation due to severe liver injury have been reported in post-marketing in association with Casdoex use.@N/A@No@Paediatric extension for 6 months in prostate cancer. [AstraZeneca, 23.09.2008]@813 PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED PROSTATE CANCER@@@III@APPROVED@@Covered; preferred brand; quantity limit 30 for 30 days@MEDICARE@Overall survival was not statistically significant; 52.7% of the Casodex/LHRH group had died, and 57.5% of the flutamide/LHRH group had died.@@@@@COMBO@BICALUTAMIDE@@@@@BICALUTAMIDE||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@CASODEX@@@@@CASODEX||||@Hormone Antagonist@Anti-androgen@@@@Hormone Antagonist|Anti-androgen|||@OVERALL SURVIVAL@@@@@@@@@@METASTATIC@@@@@MULTI-CENTRE@DOUBLE-BLIND@CONTROLLED@@@1@1@19602.61296@@@160@week@160 week@19602.61@19602.61@17.5@30@1@525.07@@@@@@@@@@@@0.35@1@@mg@50@1@@@@@@@@@@@9/1/2017@17.5@17.5@00310-0705-30@FILM-COATED TABLET@US$@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918265@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@M04AA01@M04A@NO@@@@@@14918265@Indicated in the management of patients with signs and symptomas of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephroptahy; the management of patients with leukaemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment should be discontinued when the potential for overproduction of uric acid is no longer presents; and, the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800mg/day in male patients and 750mg/day in female patients. This is not an innocuous drug. It is not recommended for the treatment of asymptomatic hyperuricemia.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@Dosage in Adults: should be introduced at low dosage e.g. 100mg/day to reduce the risk of adverse reactions and increased only if the serum urate response is unsatisfactory. Extra caution should be exercised if renal function is poor. The following dosage schedules are suggested: 100 to 200 mg daily in mild conditions, 300 to 600 mg daily in moderately severe conditions, 700 to 900 mg daily in severe conditions. If dosage on a mg/kg bodyweight basis is required, 2 to 10 mg/kg bodyweight/day should be used. Dosage in children: Children under 15 years: 10 to 20 mg/kg bodyweight/day up to a maximum of 400 mg daily. Use in children is rarely indicated, except in malignant conditions (especially leukaemia) and certain enzyme disorders such as Lesch-Nyhan syndrome.@@@@@@@Should be discontinued at the first appearance of skin rash or other signs which may indicate an allergic rection. Dose should be adjusted if co-administered with Purinethol or Imuran.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@ALLOPURINOL@@@@@ALLOPURINOL||||@HEUMANN@@@@@HEUMANN||||@@@@@@|||||||||@Supportive Care@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Non-Hodgkin's Lymphoma@Supportive Care|Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Non-Hodgkin's Lymphoma|||||@GENERIC@@@@@GENERIC||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@30@1.1511@1.09@12.36@1.82@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@0.04@0.04@1564911@TABLET@EURO@@@@@@@@300@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14924946@Onco@@@@@@@@@@@Subjects will be assigned to a set of treatment groups depending on their eligibility to receive bevacizumab. Subjects with squamous NSCLC and/or CNS metastases will not be eligible to receive bevacizumab and will be assigned to either cohort A or B (provided all other eligibility criteria are met). Subjects who are eligible to receive bevacizumab will be assigned to cohort C, D or E. Cohorts are defined as follows: Subjects with squamous NSCLC or CNS mets: Cohort A: Chemotherapy alone Cohort B: Chemotherapy plus 8 mg/kg AMG 951 for 5 days Subjects without squamous NSCLC and without CNS mets: Cohort C: Chemotherapy and bevacizumab Cohort D: Chemotherapy, bevacizumab plus 8 mg/kg AMG 951 for 5 days Cohort E: Chemotherapy, bevacizumab plus up to 20 mg/kg AMG 951 for 2 days Approximately forty subjects will be recruited to each cohort.@@-@-@-@THOUSAND OAKS, CALIFORNIA@@@rhApo2L/TRAIL is a soluble recombinant human protein that targets the pro-apoptotic death receptors DR4 and DR5, which are involved in the regulation of apoptosis (programmed cell death). rhApo2L/TRAIL is being evaluated as a potential cancer therapeutic. A phase 1b study of CRC initiated in 2006 is ongoing. Phase 2 studies were initiated in 2007 for the treatment of NSCLC in combination with chemotherapy both with and without bevacizumab and non-Hodgkin's lymphoma (“NHL”) as a monotherapy and in combination with rituximab.@@14924946@Previously untreated Stage IIIb/IV NSCLC treated with chemo with or without Avastin@@-@-@@NO REVIEW@@@NOVEMBER 2007-@-@Roche announces US$43.7 billion proposal to assume full control of Genentech. SOURCE: Roche, 21 July 2008@-@NCT00508625@200@-@-@@@-@@@-@20050190@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@BEVACIZUMAB@@@@-|BEVACIZUMAB|||@AMGEN@GENENTECH@@@@AMGEN|GENENTECH|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@AMG-951@RH-APO2L/TRAIL@AVASTIN@@@AMG-951|RH-APO2L/TRAIL|AVASTIN||@Other@@@@@Other||||@COMPLETE RESPONSE@PARTIAL RESPONSE@RECIST@@@RECIST@@@@@-@@@@@RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
16384775@Onco@@@@@300f1010ntsdm@@@@@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384775@Indicated for the treatment of adult with Ph+ CML in blast crisis.@@NO@@@NO REVIEW@@@@100%@@@@260@The recommended dose of Glivec is 600 mg/day for adult patients in blast crisis.@@@@Yes@@@@Study 0102@No@@@ADULT@@@APPROVED@@@NHS@@@@@@MONO@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@BLAST PHASE@@@@@@@@@@1@1@17910.72318@@@6.05@month@6.05 month@17910.72@17910.72@97.33@60@1.299@973.32@@@@@@@@@@@@0.16@1@@mg@600@1@@@@@@@@@@@7/28/2017@16.22@16.22@8.09E+15@FILM-COATED TABLET@GB£@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
16384814@Onco@@@@@300f1012ntsdm@@@@@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384814@Indicated for the treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@FIRST-LINE@@@Dosing for children should be on the basis of body surface area (mg/m2). The dose of 340 mg/m2 daily is recommended for children with Ph+ ALL (@@@@Yes@@@@@No@@@PAEDIATRIC@@@APPROVED@@@GKV@@@@@@BOTH@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@@@@Haematological Malignancy|Acute Lymphocytic Leukaemia||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@@@@@@@@@@@1.2@m²@35624.6424@@@1@year@1 year@35624.64@35624.64@97.6@60@1.1511@1435.32@1816.59@1473.82@@@@@@@@@@0.24@1@@mg/m²@340@1@@@@@@@@@@@8/1/2017@23.92@23.92@1755166@FILM-COATED TABLET@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14919103@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Oral capsules, 30mg and 100 mg capsule strengths; administered twice daily for 14 days in a 28 day cycle @@-@-@-@ROCKVILLE, MARYLAND@4/1/2008@@MKC-1 is an orally-active, small molecule, cell cycle inhibitor with in vitro and in vivo efficacy against a broad range of human solid tumor cell lines, including multi-drug resistant cell lines. MKC-1 acts through multiple mechanisms of action (MOA), arresting cellular mitosis and inducing cell death (apoptosis) by binding to tubulin and to members of the importin ß family, which are proteins involved in nuclear transport, spindle formation, and mitotic progression. MKC-1 also inhibits activation of the oncogenic kinase Akt and the mTOR pathway through a mechanism that is a subject of intensive investigation by EntreMed scientists. MKC-1 has demonstrated broad antitumor effects in multiple preclinical models, including paclitaxel-resistant models, and was evaluated in several Phase 1 and 2 clinical studies involving nearly 270 patients prior to the licensing of the drug from Roche. These studies resulted in extensive pharmacokinetic and safety data.@@14919103@-@@-@-@@NO REVIEW@@@@-@>> Entremed announces restructuring plan, including the loss of 60% of staff and core focus on development of ENMD-2076. [EntreMed, 19.12.2008]        >> Acquired through takeover of Miikana Therapeutics in December 2005; originally developed by Roche, but EntreMed has exclusive worldwide license.@-@NCT00306631@65@-@-@@@-@@1/1/2006@-@MKC-101@@-@Must have failed both a taxane and an anthracycline, given sequentially or in combination, either in an adjuvant or metastatic setting @@@II@II@@-@-@Results did not meet primary endpoint. 55 patients were evaluable for tumor response; the antitumor activity observed with MKC-1 included 3 patients who had responses and 5 patients with stable disease lasting more than four months. SOURCE: Entremed/ASCO, 3 June 2008Results to be reported in Q2 08. SOURCE: Entremed press release, 13 March 2008Interim results from 35 evaluable patients: oral MKC-1 produced 1 complete response, 2 partial responses and 3 cases of stable diseases lasting >4 months. SOURCE: Entremed@-@@@@MONO@-@@@@@-||||@ENTREMED@@@@@ENTREMED||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@MKC-1@@@@@MKC-1||||@mTOR Inhibitor@@@@@mTOR Inhibitor||||@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@SINGLE-ARM@OPEN-LABEL@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@CAPSULE@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919177@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Dose Level -1: Dasatinib 40 mg; DTIC 600 mg/m2 Dose Level 1: Dasatinib 50 mg; DTIC 800 mg/m2 Dose Level 2: Dasatinib 70 mg; DTIC 800 mg/m2 Dose Level 3: Dasatinib 70 mg; DTIC 1000 mg/m2Level MTD: Dasatinib 70 mg; DTIC 1000 mg/m2@@L01XE06@L01X@-@NEW YORK, NEW YORK@2/1/2009@@Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRß. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.@@14919177@Sprycel and dacarbazine@@NO@-@@NO REVIEW@@@@-@-@-@NCT00597038@47@-@-@@@-@@11/1/2007@-@MCC-15256@@APRIL 2020 ('746); PATENT EXTENSION FILED.@-@@@I/II; CA180-092; @II@@-@-@RESULTS PENDING@-@@@@COMBO@DASATINIB@@@@@DASATINIB||||@BMS@@@@@BMS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@SPRYCEL@DTIC@@@@SPRYCEL|DTIC|||@TK Inhibitor@bcr-abl@PDGF@@@TK Inhibitor|bcr-abl|PDGF||@TOXICITY@OVERALL SURVIVAL@TIME TO PROGRESSION@@@TIME TO PROGRESSION@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@CROSSOVER@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16384281@Onco@@@@@300f1008ntsdm@@@@@@@@L01XC08@L01X@@THOUSAND OAKS, CALIFORNIA@@@Panitumumab binds specifically to EGFR on both normal and tumor cells, and competitively inhibits the binding of ligands for EGFR. Nonclinical studies show that binding of panitumumab to the EGFR prevents ligand-induced receptor autophosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, decreased proinflammatory cytokine and vascular growth factor production, and internalization of the EGFR. In vitro assays and in vivo animal studies demonstrate that panitumumab inhibits the growth and survival of selected human tumor cell lines expressing EGFR.@@16384281@Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC) in first-line in combination with FOLFOX or FOLFIRI.@@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@Acquired through takeover of Abgenix, with which it was co-developing the drug, in December 2005. Takeda and Amgen signed a deal in February 2008 through which, in its first part, Takeda acquired Japanese rights for up to 13 molecules in Amgen's pipeline,@FIRST-LINE@@@@MHLW, 16 April 2010@4/16/2010@@No@@@@PRIME@No@@@@@@APPROVED@@@NHI@@@@@@COMBO@PANITUMUMAB@OXALIPLATIN@LEUCOVORIN@FLUOURACIL@@PANITUMUMAB|OXALIPLATIN|LEUCOVORIN|FLUOURACIL|@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@VECTIBIX@FOLFOX@@@@VECTIBIX|FOLFOX|||@mAb@Human@TK Inhibitor@EGFR@@mAb|Human|TK Inhibitor|EGFR|@@@@@@@@@@@METASTATIC@@@@@@@@@@76.5@kg@6382740.046@@@10.2@month@10.2 month@6382740.05@6382740.05@20573.34@1@0.0091@251003.76@295995@@@@@@@@@@@627.51@14@@mg/kg@6@1@@@@@@@@@@@8/30/2017@251003.76@251003.76@4291417A2027@IV INFUSION - 20 ML@YEN@@@@@@@@400@MG@20 MG/ML@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14917115@Onco@@@@@300f1037ntsdm@@@@@@Busulfex (16 doses of 0.8mg/kg every 6 hours as a 2-hour infusion for 4 days) followed by cyclophosphamide 60mg/kg once per day for two days.@@L01A@L01A@YES@CASTRES, FRANCE@@@@@14917115@Busilvex followed by cyclophosphamide (BuCy2) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation (HPCT) in adult patients when the combination is considered the best available option. Busilvex followed by cyclophosphamide (BuCy4) or melphalan (BuMel) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation in paediatric patients.@@YES@@@NO REVIEW@@@@@@@@61@Dosage in adults: When followed by 2 cycles of 60 mg/kg body weight (BW) cyclophosphamide the recommended dosage and schedule of administration is 0.8 mg/kg BW of busulfan as a two-hour infusion every 6 hours over 4 consecutive days for a total of 16 doses prior to cyclophosphamide and conventional haematopoietic progenitor cell transplantation (HPCT)@EMA, 22 April 2004@4/22/2004@@@@@The consequence of treatment with Busilvex at the recommended dose and schedule is profound myelosuppression, occurring in all patients. Severe granulocytopenia, thrombocytopenia, anaemia, or any combination thereof may develop. Frequent complete blood counts, including differential white blood cell counts, and platelet counts should be monitored during the treatment and until recovery is achieved. Prophylactic or empiric use of anti-infectives (bacterial, fungal, viral) should be considered for the prevention and management of infections during the neutropenic period. Platelet and red blood cell support, as well as the use of growth factors such as G-CSF, should be employed as medically indicated.@LABEL@No@@@@@III@APPROVED@@NO REVIEW@SNS@38% relapsed at a median of 183 days post-transplant. 62% were disease-free at median follow-up of 269 days.@@@@@COMBO@BUSULFAN@CYCLOPHOSPHAMIDE@@@@BUSULFAN|CYCLOPHOSPHAMIDE|||@PIERRE FABRE@@@@@PIERRE FABRE||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@Supportive Care@@@Haematological Malignancy|Chronic Myeloid Leukaemia|Supportive Care|||||||@BUSILVEX@@@@@BUSILVEX||||@Alkylating Agent@Alkylsulfonates@@@@Alkylating Agent|Alkylsulfonates|||@RATE OF RELAPSE@DISEASE-FREE SURVIVAL@@@@@@@@@@@@@@SINGLE-ARM@OPEN-LABEL@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@8@1.1807@1284.78@1394.32@1292.32@@@@@@@@@@2.68@@@@@@@@@@@@@@@@8/23/2017@160.6@160.6@660371@CONCENTRATE FOR SOLUTION FOR PERFUSION, 10 ML@EURO@@@@@@@@60@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14918177@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01BC02@L01B@YES@PETACH TIKVA, ISRAEL@@@Fluorouracil is an analogue of uracil, a component of ribonucleic acid. The drug is believed to function as an antimetabolite. After intracellular conversion to the active deoxynucleotide, it interferes with the synthesis of DNA by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase. Fluorouracil may also interfere with RNA synthesis.@@14918177@Fluorouracil may be used alone, or in combination, for the management of common malignancies particularly cancer of the colon and breast.@@YES@5-May@@NO REVIEW@@@@@@@@@Intravenous infusion: 15mg/kg bodyweight but not more than 1g per infusion, diluted in 300 - 500ml of 5% glucose or 0.9% NaCl injection and given over 4 hours. Alternatively the daily dose may be infused over 30 - 60 minutes or may be given as a continuous infusion over 24 hours. The infusion may be repeated daily until there is evidence of toxicity or a total dose of 12 - 15g has been reached. Intravenousi Injection: l2mg/kg bodyweight may be given daily for 3 days and then, if there is no evidence of toxicity, 6mg/kg on alternate days for 3 further doses. An alternative regimen is 15mg/kg as a single intravenous injection once a week throughout the course. Intra-arterial infusion: 5/7.5mg/kg bodyweight daily may be given by 24 hour continuous intra-arterial infusion.@Apr-97@@@@@@Intravenous infusion: 15mg/kg bodyweight but not more than 1g per infusion, diluted in 300 - 500ml of 5% glucose or 0.9% NaCl injection and given over 4 hours. Alternatively the daily dose may be infused over 30 - 60 minutes or may be given as a continuous infusion over 24 hours. The infusion may be repeated daily until there is evidence of toxicity or a total dose of 12 - 15g has been reached. Intravenousi Injection: l2mg/kg bodyweight may be given daily for 3 days and then, if there is no evidence of toxicity, 6mg/kg on alternate days for 3 further doses. An alternative regimen is 15mg/kg as a single intravenous injection once a week throughout the course. Intra-arterial infusion: 5/7.5mg/kg bodyweight daily may be given by 24 hour continuous intra-arterial infusion.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@FLUOROURACIL@@@@@FLUOROURACIL||||@TEVA PHARMACEUTICAL@@@@@TEVA PHARMACEUTICAL||||@@@@@@|||||||||@Colorectal Cancer@Breast Cancer@@@@Colorectal Cancer|Breast Cancer||||||||@GENERIC@@@@@GENERIC||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@1.15@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/2/2017@1.15@1.15@9268276R@SOLUTION FOR PERFUSION (VIAL 5 ML)@EURO@@@@@@@@250@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14918674@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01AX04@L01A@YES@@@@Dacarbazine is a cytostatic agent. The antineoplastic effect is due to an inhibition of cell growth which is independent of the cell cycle and due to an inhibition of DNA synthesis. An alkylating effect has also been shown and other cytostatic mechanisms may also be influenced by dacarbazine. Dacarbazine is considered not to show an antineoplastic effect by itself. However by microsomal N-demethylation it is quickly converted to 5-amino-imidazole-4-carboxamide and a methyl cation, which is responsible for the alkylating effect of the drug.@@14918674@Dacarbazine is indicated for the treatment of patients with metastatic malignant melanoma. Further indications for dacarbazine as part of combination chemotherapy are: • Hodgkin's disease • Advanced adult soft tissue sarcomas (except mesothelioma, Kaposi sarcoma)@@NO@@@NO REVIEW@@@@100%@@@@@Hodgkin's Disease: Dacarbazine is administered in a daily dose of 375 mg/m2 body surface area i.v. on day 1 and day 15 in combination with doxorubicin, bleomycin and vinblastine for each cycle of ABVD regimen.@EMA, November 1997@@@@@@It is recommended that dacarbazine be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. 1. Hemopoietic depression is the most common toxicity with dacarbazine. 2. Hepatic necrosis has been reported. 3. Studies have demonstrated this agent to have a carcinogenic and teratogenic effect when used in animals. 4. In treatment of each patient, the physician must weigh carefully the possibility of achieving therapeutic benefit against the risk of toxicity.@NO LABELLED TRIAL@No@@@@@@APPROVED@@NO NICE REVIEW@NHS@NO LABELLED TRIAL@@@@@@DACARBAZINE@@@@@DACARBAZINE||||@MEDAC@@@@@MEDAC||||@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@@@@Haematological Malignancy|Hodgkin's Lymphoma||||||||@GENERIC@@@@@GENERIC||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.299@37.5@@@@@@@@@@@@0.08@@@@@@@@@@@@@@@@7/28/2017@37.5@37.5@7.32E+15@POWDER FOR SOLUTION FOR INFUSION VIAL@GB£@@@@@@@@500@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14922371@Onco@@@@@@@@@@@ARM1: Xeloda 1250 mg/m2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles EXPERIMENTAL: Sutent 37.5 mg daily, continuous dosing@@L01XE04@L01X@-@NEW YORK, NEW YORK@9/1/2009@@Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFR? and PDGFRß), vascular endothelial growth factor receptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays. Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFRß, VEGFR2, KIT) in tumor xenografts expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit PDGFRß- and VEGFR2-dependent tumor angiogenesis in vivo.@@14922371@Sutent versus Xeloda in breast cancer patients who failed both a taxane and an anthracycline thearpy or failed a taxane where further anthracycline is not indicated@@-@-@@NO REVIEW@@@@-@Acquired through takeover of Pharmacia Corp., which acquired it from Sugen@-@NCT00373113@700@-@-@@@-@@11/1/2006@-@A6181107@@JANUARY 2011 (NCE EXCLUSIVITY); FEBRUARY 2021 (GIST PATENT)@-@@@III@III@@-@-@RESULTS PENDING@-@@@@MONO@SUNITINIB MALEATE@@@@@SUNITINIB MALEATE||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@SUTENT@@@@@SUTENT||||@TK Inhibitor@VEGF@PDGF@SCF@@TK Inhibitor|VEGF|PDGF|SCF|@PROGRESSION-FREE SURVIVAL@@@@@@@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
16384796@Onco@@@@@300f1012ntsdm@@@@@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384796@Indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@FIRST-LINE@@@The recommended dose of Glivec is 600 mg/day for adult patients with Ph+ ALL.@@@@Yes@@@@@No@@@ADULT@@@APPROVED@@NO REVIEW@GKV@@@@@@BOTH@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@@@@Haematological Malignancy|Acute Lymphocytic Leukaemia||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@@@@@@@@@@@1@1@49889.11214@@@1@year@1 year@49889.11@49889.11@136.68@30@1.1511@2733.65@3407.95@2772.15@@@@@@@@@@0.23@1@@mg@600@1@@@@@@@@@@@8/1/2017@91.12@91.12@1755195@FILM-COATED TABLET@EURO@@@@@@@@400@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16384842@Onco@@@@@300f1037ntsdm@@@@@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384842@Indicated for the adjuvant treatment of adult patients who are at significant risk of relapse followingresection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrenceshould not receive adjuvant treatment.@@YES@@@@@@@90%@@@@@The recommended dose of Glivec is 400 mg/day for the adjuvant treatment of adult patients followingresection of GIST. Optimal treatment duration is not yet established. Length of treatment in theclinical trial supporting this indication was 36 months@@@@Yes@@@@@No@@@@@@APPROVED@@@SNS@@@@@@ADJUVANT@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Sarcoma@GIST@@@@Sarcoma|GIST||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@@@@@@@@@@@1@1@82791.49889@@@36@month@36 month@82791.5@82791.5@75.61@120@1.1511@2268.31@2417.19@2275.85@@@@@@@@@@0.19@1@@mg@400@1@@@@@@@@@@@8/4/2017@18.9@18.9@741975@CAPSULE@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14923283@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L02AE01@L02A@NO@PARIS, FRANCE@@@@@14923283@For the treatment of advanced prostatic carcinoma (stage C or stage D) in which suppression of testosterone is indicated. Buserelin acts by blockade and subsequent down-regulation of pituitary LHRH receptor synthesis. Gonadotrophin release is consequently inhibited. As a result of this inhibition there is reduced stimulation of testosterone secretion and serum testosterone levels fall to castration range. Before inhibition occurs there is a brief stimulatory phase during which testosterone levels may rise.@@NO@@@NO REVIEW@@@@100%@@@@@Initiation of therapy: is most conveniently carried out in hospital; 0.5 ml Suprefact injection should be injected subcutaneously at 8 hourly intervals for 7 days. Maintenance therapy: on the 8th day of treatment the patient is changed to intranasal administration of Suprefact. One spray dose is introduced into each nostril 6 times a day@EMA, June 2006@@@@@@For the treatment of advanced prostatic carcinoma (stage C or stage D) in which suppression of testosterone is indicated. Buserelin acts by blockade and subsequent down-regulation of pituitary LHRH receptor synthesis. Gonadotrophin release is consequently inhibited. As a result of this inhibition there is reduced stimulation of testosterone secretion and serum testosterone levels fall to the castration range. Before inhibition occurs there is a brief stimulatory phase during which testosterone levels may rise.@NO LABELLED TRIAL@No@@@@@@APPROVED@@1@NHS@NO LABELLED TRIAL@@@@@@BUSERELIN ACETATE@@@@@BUSERELIN ACETATE||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@SUPREFACT NASAL SPRAY@@@@@SUPREFACT NASAL SPRAY||||@LH-RH Analog@@@@@LH-RH Analog||||@@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.299@106.96@@122.24@@@@@@@@@@3.18@@@@@@@@@@@@@@@@7/28/2017@106.96@106.96@4.26E+15@NASAL SPRAY, 336 DOSES@GB£@@@@@@@@33.6@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14917414@Onco@@@@@300f1037ntsdm@@@@@@NO LABELLED TRIAL@@L01AX04@L01A@YES@@@@Dacarbazine is a cytostatic agent. The antineoplastic effect is due to an inhibition of cell growth which is independent of the cell cycle and due to an inhibition of DNA synthesis. An alkylating effect has also been shown and other cytostatic mechanisms may also be influenced by dacarbazine. Dacarbazine is considered not to show an antineoplastic effect by itself. However by microsomal N-demethylation it is quickly converted to 5-amino-imidazole-4-carboxamide and a methyl cation, which is responsible for the alkylating effect of the drug.@@14917414@Dacarbazine is indicated for the treatment of patients with metastatic malignant melanoma. Further indications for dacarbazine as part of combination chemotherapy are: • Hodgkin's disease • Advanced adult soft tissue sarcomas (except mesothelioma, Kaposi sarcoma)@@YES@@@NO REVIEW@@@@90%@Teva acquires Barr. SOURCE: Teva, 21 July 2008@@@@Adult soft tissue sarcoma: For adult soft tissue sarcomas dacarbazine is given in daily doses of 250 mg/m2 body surface area i.v. (days 1-5) in combination with doxorubicin every 3 weeks (ADIC regimen). Restriction of food intake for 4-6 hours prior to treatment may reduce the severity of the nausea and vomiting which occurs in most patients particularly during the first two days of treatment. Because severe gastrointestinal and haematological disturbances can occur an extremely careful benefit-risk analysis has to be made before every course of therapy with dacarbazine.@13-Dec-06@12/13/2006@@@@@It is recommended that DTIC-Dome (dacarbazine) be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Hemopoietic depression is the most common toxicity with DTIC-Dome (See WARNINGS). Hepatic necrosis has been reported. Studies have demonstrated this agent to have a carcinogenic and teratogenic effect when used in animals. In treatment of each patient, the physician must weigh carefully the possibility of achieving therapeutic benefit against the risk of toxicity.@NO LABELLED TRIAL@No@@@@@@APPROVED@@NO REVIEW@SNS@NO LABELLED TRIAL@@@@@@DACARBAZINE@@@@@DACARBAZINE||||@PLIVA@BARR PHARMACEUTICALS@TEVA PHARMACEUTICAL@@@PLIVA|BARR PHARMACEUTICALS|TEVA PHARMACEUTICAL||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@DTIC-DOME@@@@@DTIC-DOME||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@METASTATIC@MALIGNANT@@@@@@@@@@@Invalid Factory Price@@@@@@@@@10@1.1807@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@EURO@@@@@@@@100@MG@100 MG@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14917560@Onco@@@@@300f1010ntsdm@@@@@@Patients receiving cisplatin over 50mg/m2 (mean dose of 80.2mg/m2) were given aprepitant 125mg, dexamethasone 12mg and ondansetraon 32mg IV on day 1, and aprepitant 80mg and dexamethasone 8mg for days 2-3.@@A04AD12@A04A@NO@WHITEHOUSE STATION, NEW JERSEY@@@@@14917560@Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy. Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.Emend is given as part of combination therapy@@NO@NO NICE REVIEW@@NO REVIEW@@@@100%@Japanese rights with Ono.@@@1105@Emend is given for 3 days as part of a regimen that includes a corticosteroid and a 5-HT3 antagonist. The recommended dose is 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) and 80 mg once daily in the morning on Days 2 and 3. Dosing is the same for Days 1-3 for highly and moderately emetogenic cancer chemotherapy.@EMA, November 2003@@@@@@Emend should be used with caution in patients receiving concomitant orally administered medicinal products, including chemotherapy agents that are primarily metabolised through CYP3A4. Moderate inhibition of CYP3A4 by aprepitant, 125 mg/80 mg regimen, could result in elevated plasma concentrations of these concomitant medicinal products. Weak inhibition of CYP3A4 by a single 40 mg dose of aprepitant is not expected to alter the plasma concentrations of concomitant medicinal products that are primarily metabolised through CYP3A4 to a clinically significant degree.@@No@@@@@III; HIGHLY EMETOGENIC CHEMOTHERAPY; 2 RANDOMISED, PARALLEL ASSIGNMENT, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS.@APPROVED@@NO NICE REVIEW@NHS@Complete response was seen in 89% and 78% for the aprepitant and standard groups respectively for the acute phase, and 75% and 56% for the delayed phase.@@@@@COMBO@APREPITANT@@@@@APREPITANT||||@MERCK & CO@@@@@MERCK & CO||||@@@@@@|||||||||@Supportive Care@CINV@PONV@@@Supportive Care|CINV|PONV|||||||@EMEND@@@@@EMEND||||@NK1 Antagonist@@@@@NK1 Antagonist||||@COMPLETE RESPONSE@@@@@@@@@@@@@@@RANDOMISED@PARALLEL ASSIGNMENT@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@Invalid Dosage Value Phase 1@@@@@@31.56@31.56@@5@1.2961@69.15@@79.03@@@@@@@@@@0.11@@@@@@@@@@@@@@@@8/21/2017@13.83@13.83@7.53E+15@HARD CAPSULE@GB£@@@@@@@@125@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14916496@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@N/A@@-@-@-@BASEL, SWITZERLAND@1/1/2010@@The active substance in Afinitor, everolimus, is an anticancer medicine, which acts by blocking a protein called ‘mammalian target of rapamycin' (mTOR). In the body, everolimus attaches to a protein that is found inside cells to make a ‘complex'. This complex then blocks mTOR. Since mTOR is involved in the control of cell division and the growth of blood vessels, Afinitor prevents the division of cancer cells and reduces their blood supply. This slows down the growth and spread of kidney cancer.@@14916496@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00392821@81@-@-@@@EMEA issued positive opinion to grant Orphan Drug status for everolimus to treat neuroendocrine gastroenteropancreatic tumours@@1/1/2007@-@SCRI GU 44,@@-@-@@@I/II; CRAD001C2480;@II@@-@-@RESULTS PENDING@-@@@@COMBO@EVEROLIMUS@SORAFENIB@@@@EVEROLIMUS|SORAFENIB|||@NOVARTIS@BAYER HEALTHCARE@@@@NOVARTIS|BAYER HEALTHCARE|||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@AFINITOR@RAD-001@NEXAVAR@@@AFINITOR|RAD-001|NEXAVAR||@Immunotherapy@Immunosuppressive@mTOR Inhibitor@@@Immunotherapy|Immunosuppressive|mTOR Inhibitor||@OPTIMAL DOSE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922450@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Figitumumab: IGF-1R antibody, 20 mg/kg, IV every 3 weeks for up to 1 year Pegvisomant: growth hormone antagonist, 10, 20 or 30 mg per day via subcutaneous injection for up to 1 year  [clinicaltrials.gov]@@-@-@-@NEW YORK, NEW YORK@5/1/2010@@CP-751,871, a fully human monoclonal antibody, is a highly specific inhibitor of the IGF-1R pathway. The IGF-1R pathway is one of the key signaling pathways in cancer cells that lead to uncontrolled growth and survival of tumour cells. @@14922450@Phase 1 Safety And Tolerability Study Of Figitumumab Combined With Pegvisomant In Patients With Advanced Solid Tumors@@-@-@@NO REVIEW@@@@-@Acquired through takeover of Pharmacia Corp.@-@NCT00976508@42@-@-@@@-@@11/1/2009@-@A4021040@@-@>>Patients =18 years of age with advanced solid tumors for which the combination of figitumumab and pegvisomant are reasonable treatment options. >>Patients between the ages of 10 and 18 years with advanced sarcomas for which there is no available curative therapy or therapy proven to prolong survival with an acceptable quality of life will be included in the Sarcoma Expansion Cohort.@@@I@I@@-@-@Trial registered. [Pfizer, 30.07.2007]@Trial registered [Pfizer 10 September 2009]@@@@COMBO@FIGITUMUMAB@PEGVISOMANT@@@@FIGITUMUMAB|PEGVISOMANT|||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@CP-751,871@PEGVISOMANT@@@@CP-751,871|PEGVISOMANT|||@mAb@Human@@@@mAb|Human|||@SAFETY AND TOLERABILITY@@@@@EFFICACY@PHARMACOKINETICS@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919117@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NO LABELLED TRIAL@@J06BB04@J06B@YES@DEERFIELD, ILLINOIS@@@@@14919117@Indicated for prevention of bacterial infections in patients with hypogammaglobulinemia and/or recurrent bacterial infections associated with B-cell Chronic Lymphocytic Leukemia (CCL), for the prevention of coronary artery aneurysms associated with Kawasaki Syndrome and to induce rapid rise in platelet count when needed to prevent and/or to control bleeding in a patient with Idiopathic Thrombocytopenic Purpura (ITP).@@@@@NO REVIEW@@@@@@@@@B-cell CLL: For patients with hypogammaglobulinemia and/or recurrent bacterial infections due to B-cell CLL, a dose of 400 mg/kg every 3 to 4 weeks is recommended.@FDA, May 2005@@@@@@Immune Globulin Intravenous (Human) products have been reported to be associated with renal dysfunction, acute renal failure, osmotic nephrosis, and death.18 Patients predisposed to acute renal failure include patients with any degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Especially in such patients, IGIV products should be administered at the minimum concentration available and the minimum rate of infusion practicable. While these reports of renal dysfunction and acute renal failure have been associated with the use of many of the licensed IGIV products, those containing sucrose as a stabilizer accounted for a disproportionate share of the total number.@NO LABELLED TRIAL@No@N/A@@@@@APPROVED@@@MEDICARE@NO LABELLED TRIAL@@@@@@IMMUNOGLOBULIN (HUMAN)@@@@@IMMUNOGLOBULIN (HUMAN)||||@BAXTER HEALTHCARE@@@@@BAXTER HEALTHCARE||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@B-Cell Lymphoma@Supportive Care@@Haematological Malignancy|Chronic Lymphocytic Leukaemia|B-Cell Lymphoma|Supportive Care||||||@GAMMAGARD S/D@@@@@GAMMAGARD S/D||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1@2799.4@@@@@@@@@@@@0.14@@@@@@@@@@@@@@@@8/2/2017@2799.4@2799.4@00944-2700-06@INJECTION (VIAL)@US$@@@@@@@@20000@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916181@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@TH-302 is administered as a 30-minute intravenous infusion weekly for three weeks followed by one week off therapy. Patients who have received one or more regimens of chemotherapy, or for whom no effective therapy is available, are eligible for the trial. Patients will not receive any additional chemotherapy while receiving TH-302. Patients who successfully complete a four week treatment cycle without evidence of significant treatment-related toxicity or progressive disease will continue to receive treatment for up to six cycles. Tumor response will be measured at the end of cycles 2, 4 and 6. The weekly dose has been escalated from the initial dose of 7.5 mg/m2 to 670 mg/m2. 20 patients enrolled to date. The clinical trial was designed with an initial accelerated titration design followed by a standard dose escalation schema. SOURCE: Threshold@@-@-@-@RIDGEFIELD PARK, NEW JERSEY@@@TH-302 consists of two distinct parts, a toxic portion and an attached molecular trigger. To prevent general toxicity, the molecular trigger keeps the toxin inactive until the prodrug is in the hypoxic region of the tumor, where it is then activated by low oxygen concentration. Once activated, the toxin kills cells in its vicinity.@@14916181@-@@-@-@@NO REVIEW@@@@-@-@-@-@50@-@-@@@-@@@-@TH-CR-401@@-@Patients with advanced solid tumours. Histologically confirmed, locally advanced or metastatic solid malignancy; Previously treated with at least one chemotherapy regimen for advanced or metastatic disease OR no curative standard treatment is available@@@I@I@@-@-@One patient with refractory small cell lung cancer metastatic to the liver had a partial response at their initial response assessment with a greater than 45% reduction in target lesion diameters. The patient, who has received two cycles of TH-302 at 480 mg/m2, is being followed by RECIST (Response Evaluation Criteria In Solid Tumors) criteria. Additionally, this patient experienced a marked improvement in liver function tests. Other anti-tumor activity observed include one patient with non-small cell lung cancer with tumor shrinkage lasting over 6 months. SOURCE: Threshold, 22 July 2008@-@@@@MONO@-@@@@@-||||@THRESHOLD PHARMACEUTICALS@@@@@THRESHOLD PHARMACEUTICALS||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@TH-302@@@@@TH-302||||@Other@@@@@Other||||@SAFETY@@@@@@@@@@-@@@@@DOSE ESCALATION@RANDOMISED@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916006@Onco@@@@@300f1014ntsdm@300f1813ntsdm@@@@@Phase I: Patients receive oral AZD0530 once daily on days 1-28 and gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients receive 2 additional courses after achieving complete response or stable partial response. Patients with ongoing stable disease receive up to 6 courses. Patients who discontinue gemcitabine due to unacceptable toxicity or who complete 6 courses of therapy may continue to receive AZD0530 alone in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of AZD0530 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD. Phase II: Patients receive AZD0530 at the MTD determined in phase I and gemcitabine as in phase I. SOURCE: clinicaltrials.gov@@-@-@-@LONDON, UNITED KINGDOM@6/1/2009@@AZD0530 is an orally available, dual-specific, Src/Abl kinase inhibitor that is being evaluated to determine its effects as an anti-invasive agent. AZD0530 is being studied in a variety of clinical settings in solid tumors and leukemias.@@14916006@Locally advanced or metastatic pancreatic cancer that cannot be removed by surgery@@-@-@@NO REVIEW@@@@-@-@-@NCT00265876@60@-@-@@@-@@9/1/2005@-@ZENECA-CAN-NCIC-IND173@@-@-@@@I/II; CAN-NCIC-IND173, @II@@-@-@RESULTS PENDING@-@@@@COMBO@-@GEMCITABINE@@@@-|GEMCITABINE|||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@AZD-0530@GEMZAR@@@@AZD-0530|GEMZAR|||@TK Inhibitor@@@@@TK Inhibitor||||@RESPONSE RATE@@@@@@@@@@METASTATIC@LOCALLY ADVANCED@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@C$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14918238@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01XA03@L01X@YES@@@@Eloxatin is an antineoplastic agent which is an organoplatinum complex in which the platinum atom is complexed with 1,2-DACH and with an oxalate ligand as a leaving group. It undergoes non-enzymatic conversion in physiologic solutions to active derivatives via displacement of the labil oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.@@14918238@Oxaliplatin in combination with 5-fluorouracil (5-FU) and folinic acid (FA) is indicated for: • Adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of primary tumor. • Treatment of metastatic colorectal cancer.@@YES@@@No ASMR rating.@@@@@@@@@The recommended dose for oxaliplatin in adjuvant setting is 85 mg/m² intravenously repeated every two weeks for 12 cycles (6 months).@@@2/1/2008@@@@Hypersensitivity and anaphylactic / anaphylactoid reactions to Eloxatin have been reported. Eloxatin may cause fetal harm when administered to a pregnant woman.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@ADJUVANT@OXALIPLATIN@@@@@OXALIPLATIN||||@EBEWE PHARMA@@@@@EBEWE PHARMA||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@GENERIC@@@@@GENERIC||||@Platinum@@@@@Platinum||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@9301401T@POWDER FOR SOLUTION FOR PERFUSION, 10 ML@EURO@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14924518@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Ixabepilone plus Erbitux@@L01C@L01C@-@NEW YORK, NEW YORK@@@Ixabepilone is a microtubule inhibitor belonging to a class of antineoplastic agents, the epothilones and their analogs. The epothilones are isolated from the myxobacterium Sorangium cellulosum. Ixabepilone is a semisynthetic analog of epothilone B, a 16-membered polyketide macrolide, with a chemically modified lactam substitution for the naturally existing lactone. Ixabepilone is a semi-synthetic analog of epothilone B. Ixabepilone binds directly to ß-tubulin subunits on microtubules, leading to suppression of microtubule dynamics. Ixabepilone suppresses the dynamic instability of  ß-II and  ß-III microtubules. Ixabepilone possesses low in vitro susceptibility to multiple tumor resistance mechanisms including efflux transporters, such as MRP-1 and P-glycoprotein (P-gp). Ixabepilone blocks cells in the mitotic phase of the cell division cycle, leading to cell death.@@14924518@-@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00383149@52@-@-@@@-@@1/1/2007@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING (recruiting).@-@@@@COMBO@IXABEPILONE@CETUXIMAB@@@@IXABEPILONE|CETUXIMAB|||@BMS@@@@@BMS||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@IXEMPRA@BMS-247550@ERBITUX@@@IXEMPRA|BMS-247550|ERBITUX||@Epothilone@@@@@Epothilone||||@OVERALL SURVIVAL@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-GROUP@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16384847@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384847@Indicated for the adjuvant treatment of adult patients who are at significant risk of relapse followingresection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrenceshould not receive adjuvant treatment.@@NO@@@@@@@Co-pay tier 2. SOURCE: Aetna Preferred Drug Guide 2008@@@@@The recommended dose of Glivec is 400 mg/day for the adjuvant treatment of adult patients followingresection of GIST. Optimal treatment duration is not yet established. Length of treatment in theclinical trial supporting this indication was 36 months@@@@Yes@@@@@No@@@@@@APPROVED@@@MEDICARE@@@@@@ADJUVANT@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Sarcoma@GIST@@@@Sarcoma|GIST||||||||@GLEEVEC@@@@@GLEEVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@@@@@@@@@@@1@1@410126.4231@@@36@month@36 month@410126.42@410126.42@374.55@90@1@8427.44@@@@@@@@@@@@0.94@1@@mg@400@1@@@@@@@@@@@8/2/2017@93.64@93.64@00078-0401-34@TABLET@US$@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920924@Onco@@@@@300f1012ntsdm@@@@@@Capsules of 50, 25 or 12,5 mg. Dosage 50 mg, 37.5 mg or 25 mg once daily until progression of disease or untolerable side effects @@L01XE04@L01X@-@NEW YORK, NEW YORK@12/1/2009@@Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFR? and PDGFRß), vascular endothelial growth factor receptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays. Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFRß, VEGFR2, KIT) in tumor xenografts expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit PDGFRß- and VEGFR2-dependent tumor angiogenesis in vivo.@@14920924@Gastric cancer@@-@-@@NO REVIEW@@@@-@Acquired through takeover of Pharmacia Corp., which acquired it from Sugen@SECOND-LINE@NCT00411151@50@-@-@@@-@@12/1/2006@-@KKS 2005-015@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@SUNITINIB MALEATE@@@@@SUNITINIB MALEATE||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Stomach Cancer@@@@@Stomach Cancer|||||||||@SUTENT@@@@@SUTENT||||@TK Inhibitor@VEGF@PDGF@SCF@@TK Inhibitor|VEGF|PDGF|SCF|@COMPLETE RESPONSE@PARTIAL RESPONSE@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
